<SEC-DOCUMENT>0001285819-14-000012.txt : 20141110
<SEC-HEADER>0001285819-14-000012.hdr.sgml : 20141110
<ACCEPTANCE-DATETIME>20141110160519
ACCESSION NUMBER:		0001285819-14-000012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20140930
FILED AS OF DATE:		20141110
DATE AS OF CHANGE:		20141110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		141208655

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>omer-2014930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>OMER-2014.9.30-10Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sBA0AA8B96B59D70FB1AC0F27FA3E8A47"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: 001-34475</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="3%"></td><td width="48%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91-1663741</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification Number)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">201 Elliott Avenue West</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Seattle, Washington</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98119</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(206)&#160;676-5000</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;padding-bottom:4px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="16%"></td><td width="3%"></td><td width="53%"></td><td width="3%"></td><td width="19%"></td><td width="3%"></td><td width="3%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168; </font><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:12pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">November&#160;6, 2014</font><font style="font-family:inherit;font-size:10pt;">, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.01 per share, was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">34,075,924</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s161D483348CD219A95DB0F280BCB76D3"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections for such statements. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical fact are &#8220;forward-looking statements.&#8221; Terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions and variations thereof are intended to identify forward-looking statements, but these terms are not the exclusive means of identifying such statements. Examples of these statements include, but are not limited to, statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our anticipation that we will begin U.S. commercial sales of Omidria</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;in early 2015;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to receive regulatory approval for our Marketing Authorisation Application, or MAA, for OMS302, or Omidria, in the European Union, or EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectation of receiving an opinion on the MAA from the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, in the fourth quarter of 2014;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to partner in Europe and our anticipation that we will initiate marketing and sales of Omidria in the EU in the first half of 2015, assuming approval of our MAA for Omidria and partnering in Europe;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our plans for sales, marketing and distribution of Omidria in the U.S. and for partnering, sales, marketing and distribution in the EU and other international territories;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectation that additional sales representatives will be hired, trained and in the field by the end of January 2015;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to successfully complete our Phase 2 clinical trials for OMS824 and OMS721;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to recommence active enrollment in our Phase 2 clinical trial of OMS824 in Huntington&#8217;s disease or initiate further clinical studies in either our OMS824 Huntington&#8217;s or schizophrenia programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to initiate post-marketing studies for Omidria and additional clinical trials for OMS103, should they be necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">whether there may be an opportunity to have OMS103 produced and commercialized by a registered outsourcing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectations regarding the clinical, therapeutic and competitive benefits of Omidria and our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our anticipated future sales from Omidria and our estimate regarding how long our existing cash, cash equivalents and short-term investments will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our anticipation that we will rely on contract manufacturers to develop and manufacture our product candidates and to manufacture Omidria for commercial sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to enter into acceptable arrangements with potential corporate partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">whether pediatric studies may afford Omidria an additional six months of exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectations about the commercial competition that Omidria and our product candidates may face; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expected financial position, performance, growth, expenses, magnitude of net losses and availability of resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the extent of protection that our patents provide and that our pending patent applications will provide, if patents issue from such applications, for our technologies, programs, products and product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our estimates regarding our future net losses, revenues, research and development expenses and selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks, uncertainties and other factors described in Item IA of Part II of this Quarterly Report on Form 10-Q under the heading &#8220;Risk Factors&#8221; and in our other filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, actual results or developments anticipated may not be realized or, even if substantially realized, may not have the expected consequences to or effects on our company, business or operations. Accordingly, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of the filing of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual results in subsequent periods may materially differ from current expectations. Except as required by law, we assume no obligation to update these forward-looking statements, or to </font></div><br><div></div><hr style="page-break-after:always"><a name="s161D483348CD219A95DB0F280BCB76D3"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sC862CEFCE297C7BE8F140F280BEA3526"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-Q FOR THE QUARTER ENDED </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="94%"></td><td width="6%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s6336C68F3238D02DA68D0F280C285716"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">Part I &#8212; Financial Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s6336C68F3238D02DA68D0F280C285716">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sD7B6E69C66E36204CF080F280C38A5E3"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;1. Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sD7B6E69C66E36204CF080F280C38A5E3">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s32B82667CCD12C700A230F27FA4E001B"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Consolidated Balance Sheets as of September 30, 2014 (unaudited) and December&#160;31, 201</font></a><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s32B82667CCD12C700A230F27FA4E001B">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s04351B23B0D4E577EB590F27FA5DC1B9"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss for the Three </font></a><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">and Nine </font><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s04351B23B0D4E577EB590F27FA5DC1B9"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Months Ended </font></a><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">September 30, 2014</font><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s04351B23B0D4E577EB590F27FA5DC1B9"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">&#160;and 2013 (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s04351B23B0D4E577EB590F27FA5DC1B9">4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s1824EA51B82EFB94F59B0F27FA6D77A2"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013 (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s1824EA51B82EFB94F59B0F27FA6D77A2">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7DBBA404A01B2EB4B3B90F280D1219C4"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Notes to Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7DBBA404A01B2EB4B3B90F280D1219C4">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s20D4AE93F222DBAF3E540F280F25B3ED"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s20D4AE93F222DBAF3E540F280F25B3ED">13</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s894ED42F58F37468B2F40F28105DF47F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s894ED42F58F37468B2F40F28105DF47F">22</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7A565E58A93D86D5105B0F28107C2C20"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7A565E58A93D86D5105B0F28107C2C20">22</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s0ECDFEBBC0CA5A8E08D30F2810ABD4ED"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">Part II &#8212; Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s0ECDFEBBC0CA5A8E08D30F2810ABD4ED">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s41B8C21830BEAC6A72250F2810CA86C6"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s41B8C21830BEAC6A72250F2810CA86C6">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s51627ca1ed2847deaa69c36a709b06a3"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 2. Unregistered Sales of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s51627ca1ed2847deaa69c36a709b06a3">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA042E9D40415DECACB500F2810F9D213"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;6. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA042E9D40415DECACB500F2810F9D213">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s077D6671E25A471529970F281128E348"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s077D6671E25A471529970F281128E348">44</a></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s6336C68F3238D02DA68D0F280C285716"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I&#8212;FINANCIAL INFORMATION</font></div><a name="sD7B6E69C66E36204CF080F280C38A5E3"></a><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. FINANCIAL STATEMENTS</font></div><a name="s32B82667CCD12C700A230F27FA4E001B"></a><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="76%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,361</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of notes payable, net of discount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable, net of current portion and discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,148</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 8)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, par value $0.01 per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares&#8212;20,000,000 at September 30, 2014 (unaudited) and December&#160;31, 2013;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued and outstanding shares&#8212;none</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, par value $0.01 per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares&#8212;150,000,000 at September 30, 2014 (unaudited) and December&#160;31, 2013;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued and outstanding shares&#8212;34,022,145 and 30,359,508 at September 30, 2014 (unaudited) and December&#160;31, 2013, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(254,373</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total shareholders&#8217; deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to consolidated financial statements</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s04351B23B0D4E577EB590F27FA5DC1B9"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,196</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,934</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,630</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,392</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,033</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,614</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(592</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,768</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(254</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,005,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,844,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,945,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,984,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to consolidated financial statements</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s1824EA51B82EFB94F59B0F27FA6D77A2"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="76%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,960</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal of assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant modification expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current and noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,399</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases and sales of property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,847</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,963</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from the sale and maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net proceeds from borrowings under notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments on notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,464</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock upon exercise of stock options &amp; warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reduction of equipment cost basis due to assets purchased with grant funding</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to consolidated financial statements</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s7DBBA404A01B2EB4B3B90F280D1219C4"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><a name="s6AD726D91DF3FC096E7B0F27FA7D3131"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1&#8212;Organization and Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derived from our proprietary PharmacoSurgery platform, our first drug product Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(phenylephrine and ketorolac injection) 1%/0.3% was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2014 for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. We began calling on ophthalmic surgeons and their staff in the U.S. in August 2014 regarding Omidria. In October 2014, we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria. Marketing and sales of Omidria in the European Union (EU) are subject to approval of our MAA and, most likely, entering into a partnership for European marketing and distribution. In addition to the EU, we plan to enter into one or more partnerships for the marketing and distribution of Omidria in other international territories.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;For Omidria and each of our product candidates and our programs, we have retained all manufacturing, marketing and distribution rights.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries.  All inter-company transactions between and among our subsidiaries have been eliminated.  The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information.  The Consolidated Balance Sheet at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;has been derived from audited financial statements but does not include all of the information and footnotes required by GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;filed with the Securities and Exchange Commission (SEC) on March 13, 2014.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future sales from Omidria and capital that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost or market. Capitalization of costs as inventory begins when the product has received regulatory approval in the U.S. or the EU. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. For Omidria, capitalization of costs as inventory began upon U.S. regulatory approval on May 30, 2014.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update, or ASU, No. 2014-15 related to disclosure of an entity&#8217;s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity&#8217;s ability to continue as a going concern at each reporting period for a period of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December&#160;15, 2016. We do not expect the adoption of this guidance to have any impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented, or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. This standard is effective for interim and annual periods beginning after December 15, 2016 and cannot be adopted before that effective date. We are currently evaluating the impact this standard may have on our financial statements once it is adopted.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s3C6CAA1E9BFBFC7B95220F27FA8C2A67"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;2&#8212;Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basic and diluted net loss per share amounts for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="74%"></td><td width="11%"></td><td width="1%"></td><td width="2%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,909,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,384,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,518,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sE700695C67ED652E5F920F27FA8C9A7B"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;3&#8212;Cash, Cash Equivalents and Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, all investments are classified as short-term and available-for-sale on the accompanying Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. Investment income consists primarily of interest income.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sE53C988BB8FBB00FAA260F27FA8C710B"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;4&#8212;Fair-Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Observable inputs for identical assets or liabilities, such as quoted prices in active markets;</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets that are either directly or indirectly observable;&#160;and</font></div><div style="line-height:120%;padding-top:6px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash held in demand deposit accounts of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is excluded from our fair-value hierarchy disclosure as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;unrealized gains and losses associated with our short-term investments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The carrying amounts reported in the accompanying Consolidated Balance Sheets for grant and other receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.</font></div><a name="sD6E7FDA617CFA6D7ECF70F27FA9C506B"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;5&#8212;Accrued Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="74%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract research</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting &amp; professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">8</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s283DF0BA7C22D98735A60F27FAABBEE8"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;6&#8212;Notes Payable</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we entered into a new Loan and Security Agreement (the Oxford/MidCap Loan Agreement) with Oxford Finance LLC (Oxford) and MidCap Financial SBIC, LP (MidCap) pursuant to which we borrowed </font><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;">. We used approximately </font><font style="font-family:inherit;font-size:10pt;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the loan proceeds to repay all of the amounts owed by us under our then outstanding loan from Oxford and, after deducting all loan initiation costs including a </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront loan initiation fee and lenders&#8217; legal costs, we received </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds. The Oxford/MidCap Loan Agreement provides for monthly interest-only payments at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">9.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. Beginning </font><font style="font-family:inherit;font-size:10pt;">April&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, monthly principal and interest payments of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;are due through the maturity date of </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Oxford/MidCap Loan Agreement requires a </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loan maturity fee upon full repayment of the loan. We may prepay the outstanding principal balance in its entirety at any time if we pay an additional fee equal to </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the then-outstanding principal balance, which prepayment fee would be waived if we refinance the indebtedness with Oxford and MidCap and pay the loan maturity fee. As security under the Oxford/MidCap Loan Agreement, we granted Oxford, as collateral agent for the lenders, a security interest in substantially all of our assets, excluding intellectual property. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Oxford/MidCap Loan Agreement contains covenants that limit or restrict our ability to incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, pledge our intellectual property or repurchase stock. Additionally, the Oxford/MidCap Loan Agreement includes events of default regarding non-payment, inaccuracy of representations and warranties, covenant breach, occurrence of a material adverse effect (MAE, as defined below), cross default to material indebtedness, bankruptcy or insolvency, material judgment defaults and a change of control. The occurrence of an event of default could result in the acceleration of the Oxford/MidCap Loan Agreement and, under certain circumstances, could increase our interest rate by </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum during the period of default.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MAE is defined as a material adverse effect upon (i)&#160;our business operations, properties, assets, results of operations or financial condition of Omeros, taken as a whole with respect to our viability, that reasonably would be expected to result in our inability to repay any portion of the loans in accordance with the terms of the Oxford/MidCap Loan Agreement, (ii)&#160;the validity, perfection, value or priority of the lenders&#8217; security interest in the collateral, (iii)&#160;the enforceability of any material provision of the Oxford/MidCap Loan Agreement or related agreements, or (iv)&#160;the ability of the lenders to enforce their rights and remedies under the Oxford/MidCap Loan Agreement or related agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We accounted for the Oxford/MidCap Loan Agreement as a debt modification and, accordingly, the remaining unamortized debt issuance costs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$103,000</font><font style="font-family:inherit;font-size:10pt;">&#32;associated with the then outstanding loan with Oxford and the debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$244,000</font><font style="font-family:inherit;font-size:10pt;">&#32;associated with the Oxford/MidCap Loan Agreement are being amortized to interest expense using the effective interest method through the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Oxford/MidCap Loan Agreement maturity date. Additionally, the </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;maturity fee, which is treated as a debt discount, is being amortized to interest expense using the effective-interest method through </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining unamortized discount and debt issuance costs associated with the debt were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$284,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sEB7769C7726E7D5884460F27FABB90E0"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;7&#8212;Revenue</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from grants and other sources is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="46%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business Innovative Research Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vulcan Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">970</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have periodically received Small Business Innovative Research (SBIR) grants from the National Institutes of Health (NIH), which are used to support the research and development of our product candidates. We recorded revenue related to these grants of </font><font style="font-family:inherit;font-size:10pt;">$214,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$196,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$359,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$461,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. We recorded cost reductions to property and equipment due to assets being purchased with grant funding of </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">9</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$785,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of potential revenue remained available under these grants, if qualifying research is performed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, we entered into a platform development funding agreement with Vulcan Inc. and its affiliate (collectively, Vulcan) pursuant to which we received </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for our G protein-coupled receptor (GPCR) program. Of the funds received, </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded as deferred revenue. The remaining deferred revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$970,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was recognized as revenue during the first quarter of 2013. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s65773196206CAB4FBEB20F27FABBF22A"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;8&#8212;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Obligations</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease our office and laboratory space in The Omeros Building under a lease agreement with BMR-201 Elliott Avenue LLC (BMR). The initial term of the lease ends in November 2027 and we have </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;options to extend the lease term, each by </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining aggregate non-cancelable rent payable under the initial term of the lease is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$59.4 million</font><font style="font-family:inherit;font-size:10pt;">. The deferred rent balance relates to rent deferrals since the inception of our lease. Deferred rent is being amortized to research and development and selling, general and administrative expense on a straight-line basis through the term of the lease.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we entered into an agreement with Ventiv Commercial Services, LLC (inVentiv) for field sales representatives and related sales operation services for the U.S. commercial launch of Omidria. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had a monthly fee of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, which began in August 2014. We can terminate the agreement upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria, or upon 90 days written notice any time subsequent to </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into an amendment to the agreement with inVentiv for additional sales representatives in the U.S. Under the terms of the amendment, our total monthly fee will increase to approximately </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon inVentiv providing additional sales representatives, which is expected in </font><font style="font-family:inherit;font-size:10pt;">January 2015</font><font style="font-family:inherit;font-size:10pt;">, and will continue through </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a non-exclusive agreement with Patheon Manufacturing Services LLC (Patheon) for commercial supply of Omidria through December 31, 2015. Pursuant to the terms of the contract, we are required to provide a monthly, non-binding production forecast covering the term of the contract. Upon submission of the monthly forecast, a portion of the forecast becomes a firm purchase commitment. In the event we do not purchase the quantities included in the firm purchase commitment, we would owe a cancellation fee. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had a firm purchase commitment requiring payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$519,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into a non-exclusive agreement with Hospira S.p.A and Hospira Worldwide, Inc. (together, &#8220;Hospira&#8221;) for commercial supply of Omidria. We have no firm purchase commitments under this agreement until, in connection with the commencement of commercial manufacturing of Omidria at Hospira, we provide monthly rolling forecasts that will be used to calculate our firm purchase commitment. We have not commenced commercial manufacturing of Omidria at Hospira and, therefore, do not currently have any firm purchase commitments under this agreement.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Development Milestones and Product Royalties</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have retained worldwide commercial rights to Omidria and all of our product candidates in our clinical and preclinical programs. We potentially owe certain development milestones and sales based royalties on commercial sales of certain product candidates within our pipeline. These are low-single-digit royalties based on net sales or net income as more fully described in our 2013 Annual Report on Form 10-K filed with the SEC on March 13, 2014.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2014, we incurred a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Helion Biotech ApS (Helion) related to the filing of an Investigational New Drug Application (IND) with the FDA for our mannan-binding lectin-associated serine protease-2 (MASP-2) program. </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2013, we recorded $</font><font style="font-family:inherit;font-size:10pt;">900,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as selling, general and administrative expense in connection with previously awarded NIH grants.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s57EB76F05753005577970F27FACBADC0"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;9&#8212;Shareholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Public Offering</font><font style="font-family:inherit;font-size:10pt;">&#32;- In March 2014, we sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock at a public offering price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$11.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. After deducting offering expenses and underwriter discounts of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, we received net proceeds from the transaction of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our total outstanding warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, which have a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$23.94</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="30%"></td><td width="4%"></td><td width="31%"></td><td width="4%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding At<br>September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;29, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.00</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April&#160;26, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 28, 2014, we extended to </font><font style="font-family:inherit;font-size:10pt;">September&#160;29, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;the expiration dates of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">197,478</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.25</font><font style="font-family:inherit;font-size:10pt;">&#32;per share that had been due to expire on March 29, 2014. We evaluated the fair value of the warrants before and after the modifications and recorded the </font><font style="font-family:inherit;font-size:10pt;">$452,000</font><font style="font-family:inherit;font-size:10pt;">&#32;change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2014.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During September 2014, warrants associated with a total of </font><font style="font-family:inherit;font-size:10pt;">4,689</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were exercised by the warrant holders resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">3,305</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. Of that amount, </font><font style="font-family:inherit;font-size:10pt;">3,088</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were issued upon cash exercise of warrants, pursuant to which we received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37,828</font><font style="font-family:inherit;font-size:10pt;">, and the remainder were issued pursuant to cashless net exercise provisions in the warrants.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 28, 2014, we extended to </font><font style="font-family:inherit;font-size:10pt;">March&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;the expiration date of the remaining warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">192,789</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock that had been due to expire on </font><font style="font-family:inherit;font-size:10pt;">September&#160;29, 2014</font><font style="font-family:inherit;font-size:10pt;">. We evaluated the fair value of the warrants before and after the modifications and recorded the </font><font style="font-family:inherit;font-size:10pt;">$411,000</font><font style="font-family:inherit;font-size:10pt;">&#32;change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Considering the extensions on March 28 and September 28, 2014, the total other expense recorded in the Consolidated Statement of Operations and Comprehensive Loss for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$863,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, in connection with the Vulcan agreement, we issued to Vulcan </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants to purchase our common stock, each exercisable for </font><font style="font-family:inherit;font-size:10pt;">133,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, with exercise prices of </font><font style="font-family:inherit;font-size:10pt;">$20</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$30</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$40</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively.</font></div><a name="sEBB950115830D3A6D11E0F27FADAB2CB"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note&#160;10&#8212;Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2008 Equity Incentive Plan (the 2008 Plan) provides for the grant of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units and performance shares to employees, directors and consultants and subsidiary corporations&#8217; employees and consultants. Options are granted with exercise prices equal to the closing fair market value of our common stock on the date of the grant. The terms of options may not exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10 years</font><font style="font-family:inherit;font-size:10pt;">&#32;and options generally vest over a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;">-year period. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2014, in accordance with provisions of the 2008 Plan, the authorized shares available for grant under the 2008 Plan were increased by </font><font style="font-family:inherit;font-size:10pt;">1,517,975</font><font style="font-family:inherit;font-size:10pt;">&#32;shares. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, a total of </font><font style="font-family:inherit;font-size:10pt;">8,741,276</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were reserved for issuance under our stock plans, of which </font><font style="font-family:inherit;font-size:10pt;">1,961,278</font><font style="font-family:inherit;font-size:10pt;">&#32;were available for future grants under the 2008 Plan.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, in connection with our annual employee review process, we granted qualified employees options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$11.58</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to stock option grants during the periods ended:</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="50%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three&#160;Months&#160;Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average assumptions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense has been reported in our Consolidated Statements of Operations and Comprehensive Loss as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="46%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity for all stock plans and related information is as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="46%"></td><td width="11%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="12%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160; Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,969,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,577,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,755,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,024,005</font><font style="font-family:inherit;font-size:10pt;">&#32;unvested options outstanding that will vest over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.0</font><font style="font-family:inherit;font-size:10pt;">&#32;years. Excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with these options is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s20D4AE93F222DBAF3E540F280F25B3ED"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q.</font></div><a name="sF3F309FDEAEA99DCDEF90F280F63EA4C"></a><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of U.S. Food and Drug Administration, or FDA, -approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies. For our first drug product Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482; </sup></font><font style="font-family:inherit;font-size:10pt;">(phenylephrine and ketorolac injection) 1%/0.3% and each of our product candidates and our programs, we have retained all manufacturing, marketing and distribution rights.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Products, Product Candidates and Development Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Products</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derived from our proprietary PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">platform, Omidria was approved by the&#160;FDA&#160;on May 30, 2014 for use during cataract surgery or intraocular lens replacement, or ILR, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Our U.S. marketing and sales leadership, including our national and regional sales managers, have been hired and our initial group of 20 contract field sales representatives, solely dedicated to Omeros, began calling on ophthalmic surgeons and their staff in August 2014. We are in the process of recruiting an additional 20 field sales representatives and expect them to be hired, trained and deployed by the end of January 2015. In October 2014 we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services, or CMS, for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost, or WAC, of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the European Union, or EU, we submitted a Marketing Authorisation Application, or MAA, to the European Medicines Agency, or EMA, in September 2013 seeking authorization to permit us to market and sell Omidria in the EU for use in patients undergoing ILR. In October 2013, the MAA for Omidria was validated by the EMA and we expect to receive an opinion on the MAA from the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, the scientific committee of the EMA, in the fourth quarter of 2014. In the EU and other international territories, we plan to enter into one or more partnerships for the marketing and distribution of Omidria. Assuming approval of our MAA for Omidria and partnering in Europe, we anticipate the initiation of EU marketing and sales of Omidria in the first half of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have discussed with the FDA and EMA the design for pediatric studies for Omidria. In 2014 we initiated a pediatric study for Omidria in the U.S., and we have begun enrolling in this study. If this study is successfully completed according to the FDA&#8217;s written request, Omidria would be eligible for an additional six months of marketing exclusivity in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Product Candidates</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our pipeline we have a series of development programs targeting pain, inflammation, coagulopathies and disorders of the central nervous system, including the following six clinical-stage programs: (1) our lead MASP-2 antibody OMS721, which is in a Phase 2 clinical program in patients with thrombotic microangiopathies, or TMAs, (2) our Phase 2 program evaluating our lead phosphodiesterase 10, or PDE10, inhibitor OMS824 for the treatment of Huntington&#8217;s disease, which is in a Phase 2 clinical trial that is currently suspended pending further evaluation of an observation from a nonclinical study in rats, (3) our Phase 2 program evaluating OMS824 for the treatment of schizophrenia, which is not in an active clinical trial, (4) our PharmacoSurgery product candidate OMS103 for reducing inflammatory pain following arthroscopic partial meniscectomy, which has completed one Phase 3 trial in patients undergoing this procedure, (5) our PPAR&#947; program, in which three Phase 2 clinical trials are being conducted by our collaborators to evaluate a PPAR&#947; agonist, alone or in combination with other agents, </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for their effects on smoking, as well as in the abuse liability of oxycodone or heroin and (6) our PharmacoSurgery product candidate OMS201 for use during urological procedures, including uroendoscopic procedures, which completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. Of these clinical programs, we currently are focused on OMS721, OMS824, and OMS103.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our IND application to evaluate OMS721 in patients with complement-mediated TMAs was cleared by the FDA in April 2014. A Phase 2 clinical program is currently in progress. OMS721 has received Orphan Drug designation for the prevention (inhibition) of complement-mediated-TMAs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we announced positive data using a Phase 2a derivative of OMS721 in a well-established animal model of stroke. Compared to control antibody-treated mice, mice treated with MASP-2 antibody in this study demonstrated significantly reduced neurological deficits 48 hours after an ischemic stroke. In addition, the infarcted area of the brain was significantly smaller in MASP-2 antibody-treated mice. A similar degree of protection was also observed in gene-targeted MASP-2-deficient mice, which showed significantly lesser neurological deficits and infarct sizes compared to wild-type control mice.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we announced the suspension of our Huntington&#8217;s clinical trial for OMS824 resulting from an observation in a nonclinical study in rats being conducted concurrently with our Huntington&#8217;s trial. Following preliminary data collection from that nonclinical study, we submitted a report on an observation in several of the rats receiving the maximum dose administered in the study to the FDA&#8217;s Division of Neurology Products and its Division of Psychiatry Products, the FDA divisions which cleared our Investigational New Drug applications for Huntington&#8217;s disease and schizophrenia, respectively. In response to a request from the FDA in follow-up communications, we suspended the ongoing Huntington&#8217;s disease trial. The FDA has requested that we further evaluate the nonclinical data from the study in rats, as well as from nonclinical studies that we conducted that did not yield the observation, to characterize the observation more fully before we can reinitiate clinical enrollment in our OMS824 clinical program, including our Phase 2 Huntington&#8217;s clinical trial or other clinical trials in our Huntington&#8217;s or schizophrenia programs. OMS824 has received Orphan Drug designation for the treatment of Huntington&#8217;s disease and Fast Track designation for the treatment of cognitive impairment in patients with Huntington&#8217;s disease. We also are seeking Fast Track designation for OMS824 for schizophrenia.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OMS103, a PharmacoSurgery product candidate, is being developed for use during arthroscopic procedures, including partial meniscectomy surgery. Our Phase 3 clinical program in arthroscopic partial meniscectomy surgery may be redesigned to include reduction of early postoperative pain as the primary endpoint. In addition, we are evaluating alternative approaches for making OMS103 commercially available, such as through a registered outsourcing facility without the need to conduct any additional clinical trials.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Development Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our preclinical programs include: (1) our PDE7 program in which we are developing proprietary compounds to treat addiction and compulsive disorders as well as movement disorders, (2) our Plasmin program in which we are advancing novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma as well as for other hyperfibrinolytic states (e.g., liver disease), (3) our proprietary </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;antibody platform and (4) our orphan GPCR platform in which we are working to complete high-throughput surrogate de-orphanization of orphan GPCRs, identifying small-molecule compounds that bind and functionally interact with the receptors and to develop product candidates that act at these new potential drug targets. To date, we have identified and confirmed sets of small-molecule compounds that interact selectively with, and modulate signaling of, each of 54 Class A orphan GPCRs, as well as two Class B GPCRs (glucagon-like peptide-1 receptor, or GLP-1R, and parathyroid hormone 1 receptor, or PTH-1R). We have initiated medicinal chemistry efforts to optimize compounds against several orphan GPCRs including GPR17, tied to re-myelination, GPR151, linked to neuropathic pain, and GPR161, which is strongly associated with triple negative breast cancer.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Summary</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our operating expenses to date have been for research and development activities. Research and development expenses consist of costs associated with research activities as well as costs associated with our product development efforts, which include clinical trial expenses and, prior to the point we receive approval in either the U.S. or the EU, third-party manufacturing services. Internal research and development costs are recognized as incurred. Third-party research and development costs are expensed when the contracted work has been performed and when milestone payments are made. Research and development expenses include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee and consultant-related expenses, which include salaries and benefits, and non-cash stock-compensation;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations prior to product approval, clinical research organizations, or CROs, clinical trial sites, and collaborators or licensors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and depreciation of leasehold improvements and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party supplier expenses including laboratory and other supplies.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$53.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$38.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. These losses have resulted principally from expenses incurred in connection with research and development activities, consisting primarily of manufacturing services, clinical trials and preclinical studies associated with our current product and product candidates. Compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, we expect our 2014 net losses to increase as we continue to add personnel for our anticipated growth and to prepare for the U.S. commercial launch of Omidria planned for early 2015, to advance our clinical trials, and to expand our research and development efforts. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, our accumulated deficit was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$307.3 million</font><font style="font-family:inherit;font-size:10pt;">, total shareholders&#8217; deficit was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$26.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sF945E9FEFF62413CCF910F27FCED5E98"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FDA approved Omidria for use during cataract surgery and we began calling on ophthalmic surgeons and their staff in the U.S. in August 2014. In October 2014 we were granted transitional pass-through reimbursement status from the CMS, which will become effective on January 1, 2015. We expect to begin selling Omidria in the U.S. in early 2015. With respect to the EU, an opinion on our MAA is expected before the end of the first quarter and we will begin marketing Omidria in the EU subsequent to approval and, most likely, entering into a partnership for European marketing and distribution. Due to the above and our lack of history of Omidria sales, we are not able to estimate future revenues from Omidria.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="51%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business Innovative Research Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vulcan Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">970</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our revenue has consisted of grant funding and revenue recognized in connection with funding from third parties. Other than these funding sources, we do not expect to receive product revenue until we begin selling Omidria in the U.S., which is currently expected in early 2015, and we do expect to receive revenue from our product candidates unless we receive regulatory approval and commercialize our product candidates or enter into collaborative agreements for the development and commercialization of our product and product candidates. We continue to pursue government and private grant funding as well as collaboration funding for our product candidates and research programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in revenue during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the prior year quarter was due to an increase in research activity on our NIH grant projects.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in revenue during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the prior year period was primarily due to lower revenue recognized from our GPCR program funding agreement with Vulcan Inc. and its affiliate, which we collectively refer to as Vulcan. We recognized the remaining deferred revenue in connection with the Vulcan agreement as revenue in the first quarter of 2013, and as of that date no further revenue remains to be recognized under the agreement. In addition, there was a decrease in revenue recognized from our NIH grants during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;due to a reduction of research activity on our NIH grant projects in the first half of the current year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development expenses can be divided into direct external expenses, which include clinical research and development and preclinical research and development activities; internal, overhead and other expenses; and stock-based compensation expense. The following table illustrates our expenses associated with these activities:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="54%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct external expenses:</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical research and development:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OMS824</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OMS721</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omidria</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other clinical programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total clinical research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">470</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total direct external expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Internal, overhead and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,791</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in total research and development expenses during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2013 was due primarily to higher manufacturing costs related to our Phase 2 clinical program evaluating OMS721 for the inhibition of complement-mediated TMAs, our Phase 2 clinical program evaluating OMS824 for the treatment of Huntington&#8217;s disease and our Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of OMS824 in healthy subjects. Additional increases in research and development expenses include costs related to Omidria, primarily expenses incurred for contract research. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the non-cash stock compensation expense decreased compared to the same period in 2013 due to the grant of stock options during the third quarter of 2013 related to annual performance reviews. In October 2014, in connection with our annual employee review process, we granted qualified employees options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$11.58</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in total research and development expenses during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in the prior year was due primarily to higher manufacturing and clinical trial expenses related to our Phase 2 clinical trial evaluating OMS721 for the inhibition of complement-mediated TMAs and for our Phase 1 and Phase 2 clinical programs evaluating OMS824 for the treatment of schizophrenia and of Huntington&#8217;s disease as well as higher clinical trial costs related to ongoing trials for Omidria. These increased expenses for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2013 were partially offset by lower preclinical activity on our PDE7 program. We expect our research and development expenses to increase in the near term as we continue to advance our clinical product candidates through development, initiate or continue pediatric and other studies for Omidria, and initiate clinical trials for our Plasmin and PDE7 programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct external clinical research and development expenses consist primarily of expenses incurred pursuant to agreements with third-party manufacturing organizations, CROs, clinical trial sites, collaborators, licensors and consultants. Direct external preclinical research and development expenses consist primarily of third-party manufacturing organizations and CROs, laboratory supplies and consulting. Costs are reported in preclinical research and development until the program enters the clinic. Internal, overhead and other expenses consist of personnel costs, overhead costs such as rent, utilities and depreciation and other miscellaneous costs. Our internal resources, employees and infrastructure are generally not directly tied to any individual research project and are deployed across multiple clinical and preclinical projects we are advancing in parallel.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At this time, due to the inherently unpredictable nature of our preclinical and clinical development activities and given the early stage of many of our preclinical development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of our product candidates. Clinical development timelines, the probability of success and development costs can differ materially as expectations change. While we currently are focused on advancing our product development programs, our future research and development expenses will depend on the preclinical or clinical success of each product candidate as well as ongoing assessments of each program&#8217;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations, financial condition and liquidity. Because of the factors above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our research and development projects.</font></div><div style="line-height:120%;padding-top:18px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative, excluding stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in selling, general and administrative expenses during the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">primari</font><font style="font-family:inherit;font-size:10pt;">ly due to sales and marketing costs related to our planned commercial launch of Omidria in the U.S. This increase was primarily due to costs related to hiring sales managers and our marketing team, contract costs for our field sales representatives, and an increase in marketing activities for Omidria in the 2014 period.</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we entered into an agreement with Ventiv Commercial Services, LLC, or inVentiv, for field sales representatives and related sales support systems for the U.S. commercial launch of Omidria. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we have a monthly fee of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">. We can terminate the agreement upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria or upon 90 days written notice any time subsequent to </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. In October, 2014, we amended the inVentiv agreement to add additional sales representatives in the U.S. Under the terms of the amendment, our total monthly fee will increase to approximately </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon inVentiv providing additional sales representatives, which is expected in </font><font style="font-family:inherit;font-size:10pt;">January 2015</font><font style="font-family:inherit;font-size:10pt;">, and will continue through </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="51%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in interest expense during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to a higher average balance on our note payable during the 2014 period due to our entry in March 2014 into a new loan agreement, or the Oxford/MidCap Loan Agreement, with Oxford Finance LLC, or Oxford, and MidCap Financial SBIC, LP, or MidCap, under which we increased the aggregate amount of our outstanding indebtedness by approximately </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense), Net</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="51%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) principally includes rental income and non-cash charges associated with warrant modifications.  The change in other income (expense) for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to a </font><font style="font-family:inherit;font-size:10pt;">$411,000</font><font style="font-family:inherit;font-size:10pt;">&#32;charge related to extending the exercise period by six months of warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">192,789</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in September 2014.  The change in other income (expense) during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to </font><font style="font-family:inherit;font-size:10pt;">$863,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of charges related to extending the exercise period of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">197,478</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock by six months in March 2014 and extending the exercise period of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">192,789</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock by an additional </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">six months in September 2014. Rental income partially offsets the non-cash warrant charges in both the three and nine month periods in 2014 and was consistent with the same periods in the prior year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s061E637872A9AF5AFC0A0F280FB12FE6"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Condition - Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments that are held principally in interest-bearing instruments, including money-market accounts. Cash in excess of our immediate requirements is invested in accordance with established guidelines intended to preserve principal and maintain liquidity. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in a public offering at a public offering price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$11.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. After deducting offering expenses and underwriter discounts, we received net proceeds from the transaction of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;">. Also in March 2014, we terminated our existing loan agreement with Oxford and entered into the Oxford/MidCap Loan Agreement, whereby we received </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional funds and deferred the repayment of principal under the new loan agreement until </font><font style="font-family:inherit;font-size:10pt;">April&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit report covering our 2013 consolidated financial statements contained a &#8220;going concern&#8221; explanatory paragraph based on our losses and financial condition as of December 31, 2013. Subsequent to the March 13, 2014 issuance of the audit report, as stated above, we received net proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the sale of our common stock in the public offering and </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in incremental borrowings under the Oxford/MidCap Loan Agreement, both in March 2014. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future product sales of Omidria, and funds that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and note payments for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="74%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Selected cash flow data</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash provided by (used in):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,845</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities.</font><font style="font-family:inherit;font-size:10pt;">&#160;Expenditures related to operating activities were primarily for research and development and selling, general and administrative expenses in support of our operations. Net cash used in operating activities increased for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, as compared to the same period in 2013 by </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to higher operating expenses relating to preparing for the U.S. commercial launch of Omidria, manufacturing of material associated with the Phase 2 clinical trials evaluating OMS824 in Huntington&#8217;s disease, and clinical costs associated with the Phase 2 clinical trial evaluating OMS721 in complement-mediated TMAs, which led to an increase in our net loss of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">. This net loss was partially offset by a </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in non-cash charges, primarily related to increases in stock compensation and warrant modification expenses and </font><font style="font-family:inherit;font-size:10pt;">$338,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash provided due to the net change in operating assets and liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#160;Investing activities, other than the purchases of property and equipment, consist primarily of purchases and sales of short-term investments. Cash flows from investing activities primarily reflect cash used to purchase short-term investments and receipts from the sale of short-term investments, thus causing a shift between our cash and cash equivalents and short-term investment balances. Because we manage our cash usage with respect to our total cash, cash equivalents and short-term investments, we do not consider these fluctuations in cash flows to be important to the understanding of our liquidity and capital resources.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the purchase of short-term investments with the proceeds we received from the sale of common stock in our public offering and borrowings under the Oxford/MidCap Loan Agreement, both of which occurred in March 2014, and is partially offset by the sale of short-term investments to provide cash for operating activities.   </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;Net cash provided by financing activities in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of net proceeds that we received from the sale of </font><font style="font-family:inherit;font-size:10pt;">3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in our public offering and the net additional borrowings of </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Oxford/MidCap Loan Agreement, both of which occurred in March 2014. During the 2013 period, cash provided by financing activities was primarily due to the </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;we received in our registered direct offering in May 2013 in which we sold 3.9 million shares of common stock. During the period, from January 2014 to March 2014, we also paid </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal on the then outstanding Oxford notes. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2013</font><font style="font-family:inherit;font-size:10pt;">, no cash was used for principal payments on the Oxford notes as we amended the notes in December 2012 to provide for interest-only payments through December&#160;31, 2013.</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with the development and commercialization of Omidria and our product candidates, and to the extent that we may or may not enter into collaborations with third parties to participate in the development and commercialization of Omidria or one or more of our product candidates, we are unable to estimate the amounts of increased capital requirements and operating expenditures required in the future. Our future operating and capital requirements will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercial success of Omidria in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to enter into a partnership for the distribution of Omidria in the EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercial success of Omidria in the EU, if and when Omidria is approved for sale and we have entered into a partnership for the marketing and distribution of Omidria in the EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the progress and results of our preclinical and clinical programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of commercialization activities, including product manufacturing, marketing, sales and distribution and related support activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost, timing and outcomes of the regulatory processes for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we raise capital by selling our stock or entering into other forms of financing including debt agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms and timing of receipts or payments related to collaborative or licensing agreements we have or may establish;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the hiring of new employees to support the commercialization of Omidria and the continued advancement of our development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to these types of transactions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of preparing, filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our continued operating losses to result in an increase in the total amount of cash used in operations until at least the time that Omidria becomes cash flow positive, which may be in several years, if at all. To meet our future capital requirements, we will need to fund our future cash needs through corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If we do not raise additional capital through equity or debt financings or collaborations and licensing arrangements, we may be required to delay, reduce the scope of or eliminate our research and development programs or reduce our planned commercialization efforts. We currently do not have any commitments for future external equity or debt funding. </font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we entered into the Oxford/MidCap Loan Agreement with Oxford and MidCap, pursuant to which we borrowed </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;">. We used approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the loan proceeds to satisfy all of the amounts owed by us under our then-outstanding loan from Oxford and, after deducting all loan initiation costs including a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$160,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront loan initiation fee and lenders&#8217; legal costs, we received </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds. Part of the costs paid included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$520,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the prorated portion of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loan maturity fee payable under our then-outstanding loan agreement with Oxford, with no further obligation for the remaining </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$880,000</font><font style="font-family:inherit;font-size:10pt;">. We have used, and intend to continue to use, the loan proceeds for general corporate purposes and working capital. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest on the amounts borrowed under the Oxford/MidCap Loan Agreement accrues at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">9.25%</font><font style="font-family:inherit;font-size:10pt;">. Payments due under the Oxford/MidCap Loan Agreement are interest-only, payable monthly, in arrears, through March&#160;1, 2015. Beginning </font><font style="font-family:inherit;font-size:10pt;">April&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, 36 payments of principal and interest are payable monthly, in arrears. All unpaid principal and accrued and unpaid interest are due and payable on </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration for the lenders agreeing to provide us with a one-year period of interest-only payments, we will be required to pay the lenders a final payment fee equal to 7.00% of the original principal amount borrowed under the Oxford/MidCap Loan Agreement (i.e., </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">), less any portion of the fee previously paid in connection with a prepayment. We may prepay all or a portion of the outstanding principal and accrued and unpaid interest at any time upon prior notice to the lenders and the payment of a fee equal to 1.00% of the prepaid principal amount in addition to the pro rata portion of the final payment fee attributable to the prepaid principal amount. As security for our obligations under the Oxford/MidCap Loan Agreement, we granted Oxford, as collateral agent for the lenders, a security interest in substantially all of our assets, excluding intellectual property.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Oxford/MidCap Loan Agreement contains covenants that limit or restrict our ability to incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, pledge our intellectual property or repurchase stock. Additionally, the Oxford/MidCap Loan Agreement includes events of default regarding non-payment, inaccuracy of representations and warranties, covenant breach, occurrence of a material adverse effect, or MAE (as defined below), cross default to material indebtedness, bankruptcy or insolvency, material judgment defaults and a change of control. The occurrence of an event of default could result in the acceleration of the Oxford/MidCap Loan Agreement and, under certain circumstances, could increase our interest rate by 5.0% per annum during the period of default.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MAE is defined as a material adverse effect upon (i)&#160;our business operations, properties, assets, results of operations or financial condition of Omeros, taken as a whole with respect to our viability, that reasonably would be expected to result in our inability to repay any portion of the loans in accordance with the terms of the Oxford/MidCap Loan Agreement, (ii)&#160;the validity, perfection, value or priority of the lenders&#8217; security interest in the collateral, (iii)&#160;the enforceability of any material provision of the Oxford/MidCap Loan Agreement or related agreements, or (iv)&#160;the ability of the lenders to enforce their rights and remedies under the Oxford/MidCap Loan Agreement or related agreements. We considered the MAE definition and believe that the MAE clause has not been triggered as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sCC670D40A66E8A0FBF960F280FD059D8"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of our contractual obligations and commitments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due Within&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1&#160;Year <br>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2-3&#160;Years <br>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">4-5&#160;Years <br>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;than<br>5&#160;Years <br>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total <br>&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases (principal and interest)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable (principal and interest)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goods &amp; services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,833</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,090</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Leases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently lease our office and laboratory space in The Omeros Building under a lease agreement with BMR-201 Elliott Avenue LLC. The initial term of the lease ends in November 2027 and we have two options to extend the lease term, each by five years. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining aggregate non-cancelable rent payable under the initial term of the lease was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$59.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goods &amp; Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we entered into an agreement with Ventiv Commercial Services, LLC, or inVentiv, for field sales representatives and related sales support systems for the U.S. commercial launch of Omidria. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had a monthly fee of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">. We can terminate the agreement  upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria, or upon 90 days written notice any time subsequent to </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. The estimated costs for this agreement through </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are included in the table above.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October, 2014, we entered into an amendment to the agreement with inVentiv to add additional sales representatives in the U.S. Under the terms of the amendment, our total monthly fee will increase to approximately </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon inVentiv providing additional sales representatives, which is expected in </font><font style="font-family:inherit;font-size:10pt;">January 2015</font><font style="font-family:inherit;font-size:10pt;">, and will continue through </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. The estimated costs for this amendment are not included in the table above as the agreement was entered into in October 2014.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a non-exclusive agreement with Patheon Manufacturing Services LLC, or Patheon, for commercial supply of Omidria through December 31, 2015. We are required to provide a monthly, non-binding production forecast covering the term of the contract. Upon submission of the monthly forecast, a portion of the forecast becomes a firm purchase commitment. In the event we do not purchase the quantities included in the firm purchase commitment, we would owe a cancellation fee. The firm purchase commitment as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;is included in the table above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into a non-exclusive agreement with Hospira S.p.A  and Hospira Worldwide, Inc. (together, &#8220;Hospira&#8221;) for commercial supply of Omidria. The agreement has an initial term of five years from the date of first commercial sale of Omidria. In connection with the commencement of commercial processing of Omidria at Hospira, we are obligated to provide Hospira with monthly rolling forecasts that will be used to calculate our firm commitment. We have not commenced commercial manufacturing of Omidria at Hospira and, therefore, do not currently have any firm purchase commitments under this agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also be required, in connection with in-licensing or asset acquisition agreements, to make certain royalty and milestone payments and we cannot, at this time, determine when or if the related milestones will be achieved or the events triggering the commencement of payment obligations will occur. See Note 8 to our consolidated financial statements in our 2013 Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 13, 2014 for a description of the agreements that include these royalty and milestone payment obligations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s610A0C60FDEFEE0B7E3B0F280FFFE5DE"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of our financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates. An accounting policy is considered critical if it is important to a company&#8217;s financial condition and results of operations and if it requires the exercise of significant judgment and the use of estimates on the part of management in its application. Although we believe that our judgments and estimates are appropriate, actual results may differ materially from our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In relation to our commercial launch of Omidria, capitalization of costs as inventory will begin on lots manufactured after the regulatory approval date for Omidria, which was May 30, 2014 in the U.S. Inventory is stated at the lower of cost or market. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a more detailed listing of our other critical accounting estimates, refer to our 2013 Annual Report on Form 10-K filed with the SEC on March 13, 2014.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s236394E7B35BC4A120F80F28102E1BBC"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not engaged in any off-balance sheet arrangements.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s894ED42F58F37468B2F40F28105DF47F"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our exposure to market risk is primarily confined to our investment securities and notes payable. The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in high-credit-quality securities. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and short-term investments of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;">. In accordance with our investment policy, we invest funds in highly liquid, investment-grade securities. These securities in our investment portfolio are not leveraged and are classified as available-for-sale. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a materially negative impact on the realized value of our investment portfolio. We actively monitor changes in interest rates and, with our current portfolio of short-term investments, we do not believe that we are exposed to potential loss due to changes in interest rates.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s7A565E58A93D86D5105B0F28107C2C20"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) under the Exchange Act that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">22</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s0ECDFEBBC0CA5A8E08D30F2810ABD4ED"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II&#8212;OTHER INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s41B8C21830BEAC6A72250F2810CA86C6"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business, prospects, financial condition or operating results could be materially adversely affected by any of the risks and uncertainties described below, as well as other risks not currently known to us or that we currently deem immaterial. You should carefully consider these risks before making an investment decision. The trading price of our common stock could decline due to any of these risks and you may lose all or part of your investment. In assessing the risks described below, you should also refer to the other information contained in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December&#160;31, 2013.</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Products, Programs and Operations</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are focusing a significant portion of our activities and resources on Omidria, and if we are unable to commercialize Omidria successfully, our inability to generate significant revenue from the sales of Omidria would adversely impact our ability to achieve profitability.  </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company with one product approved by the FDA for commercial sale in the U.S., Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or ILR. Omidria was approved by the FDA on May 30, 2014 and we anticipate beginning commercial sales of Omidria in early 2015. Consequently, we have not yet generated any revenue from any product sales to date. We may not be able to commercialize Omidria successfully for a number of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a lack of acceptance of Omidria by physicians, patients, third-party payors and other members of the medical community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our limited experience in marketing, selling and distributing Omidria or any other product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our limited experience managing third-party commercial manufacturing of Omidria or any other product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reliance on a limited number of manufacturers of Omidria and a limited number of suppliers of the product&#8217;s active pharmaceutical ingredients, excipients and packaging materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, group purchasing organizations, insurance companies, health maintenance organizations and other plan administrators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the relative price of Omidria as compared to alternative options for maintenance of pupil size and reduction of postoperative ocular pain during cataract surgery or ILR;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changed or increased regulatory restrictions in the U.S., EU and other foreign territories; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a lack of adequate financial or other resources to commercialize Omidria successfully.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not able to commercialize Omidria successfully for these or other reasons, our ability to generate revenue from product sales and achieve profitability will be adversely affected and the market price of our common stock could decline significantly.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the level of demand for Omidria;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which coverage and reimbursement for Omidria is available from government and private third-party payors such as Medicare, Medicaid, insurance companies, group purchasing organizations, health maintenance organizations and other plan administrators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the duration of transitional pass-through reimbursement status from CMS for Omidria and the continued availability of separate reimbursement once transitional pass-through reimbursement expires;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing, cost and level of investment in our sales and marketing efforts to support Omidria sales;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing, cost and level of investment in our research and development activities involving Omidria and our product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and cost of conducting required post-approval studies for Omidria and expenditures we will or may incur to acquire or develop additional technologies, products and product candidates.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">23</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, from time to time, we may enter into collaboration agreements with other companies that may include commercial arrangements, development funding and/or significant upfront and milestone payments. Amounts earned from our collaboration agreements, if any, may be an important source of our revenues. Accordingly, our revenues may also depend on commercial arrangements, development funding and the achievement of development and clinical milestones under collaboration and license agreements. These upfront and milestone payments may vary significantly from quarter to quarter and any such variance could cause a significant fluctuation in our operating results from one quarter to the next.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For these and other reasons, it is difficult for us to forecast accurately future profits or losses. As a result, it is possible that in some quarters our sales of Omidria and/or our operating results may not meet the expectations of securities analysts or investors, which could cause the trading price of our common stock to decline, perhaps substantially. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We cannot be certain that we will successfully commercialize any of our product candidates, even if we receive regulatory approval for our product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have invested a significant portion of time and financial resources in the development of our product candidates, in addition to the development and commercialization of Omidria. Our ability to generate revenues depends on the commercial success of our product candidates that may be approved, as well as Omidria, which in turn will depend on several factors, including our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">generate commercial sales through our own sales force or contract sales organizations, or collaborations with pharmaceutical companies, that we may establish;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish effective marketing programs and build brand identity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain acceptance of our product candidates, if approved, by physicians, patients and third-party payors and obtain and maintain distribution of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish and maintain agreements with distributors on commercially reasonable terms; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrate commercial manufacturing capabilities, and maintain commercial manufacturing arrangements with third-party manufacturers, necessary to meet the commercial demand for a product.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we fail to commercialize successfully product candidates in our pipeline, if approved, or if we are significantly delayed in doing so, we may be unable to generate sufficient revenues to grow our business, which would materially and adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Omidria and our product candidates, if commercialized, may never achieve market acceptance.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of Omidria and our product candidates, if commercialized, will depend on, among other things, their acceptance by physicians, patients, third-party payors and other members of the medical community. If Omidria or our product candidates, if commercialized, fail to gain market acceptance, we may be unable to earn sufficient revenue to continue our business. Market acceptance of, and demand for, Omidria or any product candidate that we may develop and commercialize will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to provide acceptable evidence of safety, efficacy and product quality;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability and relative cost and efficacy of alternative and competing treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness of our marketing and distribution strategy to, among others, hospitals, surgery centers, physicians and/or pharmacists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence of the condition for which the product is approved or commercialized or frequency of the related surgical procedure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the acceptance by physicians of each product as a safe and effective treatment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perceived advantages over alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of adequate reimbursement by Medicare and other third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the frequency and severity of adverse side effects; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">publicity concerning our products or competing products and treatments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, the number of procedures in which Omidria or any of our PharmacoSurgery product candidates, if commercialized, would be used may be significantly less than the total number of such procedures performed. If Omidria or our product candidates, if commercialized, do not receive sufficient levels of acceptance from physicians, patients, third-party payors and other members of the medical community, it is unlikely that we will ever become profitable. If we are unable to gain or increase market penetration with Omidria or our product candidates, if commercialized, our growth prospects would be significantly harmed.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we do not have adequate reimbursement from governments or other third-party payors for Omidria or any other approved product that we may develop, or if we do not establish and maintain market-acceptable pricing for Omidria or those approved products, they may not be purchased or used and, as a result, our prospects for revenue and profitability could suffer.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future revenue and profit will depend heavily on the pricing and availability of adequate reimbursement for the use of our approved products, including Omidria, from governmental and other third-party payors, both in the U.S. and in other countries. Even if we are successful in bringing one or more products to market, these products may not be considered cost-effective, and the amount reimbursed for any product may be insufficient to allow us to sell the product profitably. Reimbursement by a third-party payor may depend on a number of factors, including the third-party payor&#8217;s determination that use of a product is:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a covered benefit under its health plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">safe, effective and medically necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">appropriate for the specific patient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost-effective; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">neither experimental nor investigational.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obtaining reimbursement approval for any product from each government or third-party payor can be a time-consuming and costly process that will require the build-out of a sufficient staff or the engagement of third parties and could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our approved products to each payor. We can provide no assurances at this time regarding the cost-effectiveness of Omidria or any of our product candidates. Further, we can provide no assurance that the amounts, if any, reimbursed to surgical facilities for utilization of any of our surgery-related products, including Omidria, or product candidates or to surgeons for the administration and delivery of these products or product candidates will be considered adequate to justify the use of these products or product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There may be significant delays in obtaining reimbursement coverage for newly approved products, and we may not be able to provide data sufficient be granted reimbursement. Even when a payor determines that a product is eligible for reimbursement, coverage may be limited to the uses of a product that are either approved by the FDA or foreign regulatory agencies and/or appear in a recognized drug compendium, and other conditions may apply. Increasingly, third-party payors who reimburse healthcare costs, such as government and private payors, are requiring that companies provide them with predetermined discounts from list prices and challenging the prices charged for medical products. Moreover, eligibility for coverage does not mean that any product will be reimbursed at a rate that allows us to make a profit in all cases or at a rate that covers our costs, including research, development, manufacturing, sales and distribution. Even if we receive reimbursement for a product, the initial rate or method at which the product will be reimbursed could become unfavorable to us at the time reimbursement is initiated or in the future. In addition, pass-through reimbursement status is usually granted for a limited duration and we expect pass-through reimbursement status for Omidria to last for two to three years from the January 1, 2015 effective date.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In non-U.S. jurisdictions, we must obtain separate reimbursement approvals and comply with related foreign legal and regulatory requirements. In some countries, including those in the EU, our products may be subject to government price controls. Pricing negotiations with governmental authorities can take a considerable amount of time and expenditure of resources after the receipt of marketing approval for a product.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the reimbursement that we are able to obtain and maintain for any product that we develop, including Omidria, is inadequate in light of our development and other costs or is significantly delayed, our business could be materially harmed.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to market and sell successfully Omidria or our product candidates, if approved, we may be unable to generate product revenue.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omeros has never sold, marketed or distributed any biopharmaceutical product. Developing a sales force for any product is expensive and time-consuming, and a delay in hiring and training a sales force, or difficulties managing a contract sales force, could impact the timing or effectiveness of any product launch. We have entered into an agreement with inVentiv for a field sales force and related sales operation services for the U.S. commercial launch of Omidria but we have never operated or managed an internal or third-party sales force for any approved product. Factors that may inhibit our efforts to commercialize any approved products, including Omidria, without commercialization partners include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to recruit in a timely manner, and retain, adequate numbers of effective sales and marketing personnel, or to partner or contract with a third party to provide sales and marketing services, in the applicable region of the world;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of sales personnel to sell or promote any approved product(s) to adequate numbers of hospitals, surgery centers, physicians and/or pharmacists;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to develop and maintain, or access, adequate information systems to monitor sales by distribution channel, report pricing, maintain customer lists and track selling and marketing operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen costs and expenses associated with creating a sales and marketing organization.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unsuccessful in building and managing a sales and marketing infrastructure internally or through a third-party partner for any approved product, we will have difficulty commercializing the product, which would adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the EU, we plan to enter into partnerships for Omidria marketing and distribution with one or more third parties. Outside of the U.S. and EU, we are exploring potential regional partnerships to make Omidria available to ophthalmologists. We have not yet entered into any agreements with third parties to market Omidria outside of the U.S. Even if we obtain approvals from relevant government authorities in one or more non-U.S. territories, we would not expect to see sales of Omidria in those territories if we are unable to enter into such agreements on terms acceptable to us, if at all, which could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are subject to extensive government regulation, including the regulations associated with approval for marketing of Omidria and our product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Both before and after approval of any product, we, Omidria and our product candidates, and our suppliers, contract manufacturers and clinical investigators are subject to extensive regulation by governmental authorities in the U.S. and other countries, covering, among other things, testing, manufacturing, quality control, clinical trials, labeling, advertising, promotion, distribution, and import and export. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions: warning letters; unanticipated expenditures; delays in approval or refusal to approve a product candidate; product recall or seizure; interruption of manufacturing or clinical trials; operating or marketing restrictions; injunctions; criminal prosecution and civil or criminal penalties including fines and other monetary penalties. We, the FDA or an independent Institutional Review Board or Ethics Committee may suspend or terminate human clinical trials at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk or because of the way in which the investigators on which we rely carry out the trials.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omidria is our only product approved by the FDA, and the FDA has not approved any of our product candidates for sale in the U.S. Obtaining FDA approval requires substantial time, effort, and financial resources, and may be subject to both expected and unforeseen delays, and there can be no assurance that any approval will be granted on any of our product candidates on a timely basis, if at all.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may decide that our data are insufficient for approval of our product candidates and require additional preclinical, clinical or other studies or additional work related to chemistry, manufacturing and controls. For example, we have had to suspend clinical trials of OMS824 based on a nonclinical finding, and the FDA has required that we review and further evaluate our nonclinical data before the FDA may permit us to resume or initiate further clinical trials in our OMS824 Huntington&#8217;s and schizophrenia clinical programs. If, based on our review and evaluation of these data, the FDA concludes that there is an unwarranted safety risk to patients, the FDA may require us to run additional nonclinical studies before permitting us to resume or initiate additional clinical trials, may impose limits on such trials or may not permit us to resume or initiate clinical trials at all. As we develop our product candidates, we periodically discuss with the FDA clinical, regulatory and manufacturing matters, and our views may, at times, differ from those of the FDA. For example, the FDA regulates Omidria and our product candidates that consist of two or more active ingredients as combination drugs under its Combination Drug Policy. The Combination Drug Policy requires that we demonstrate that each active ingredient in a drug product contributes to the product&#8217;s claimed effect. The FDA has maintained questions regarding whether available data and information provided to the FDA demonstrate the contribution of each active ingredient in OMS103. If we are unable to resolve these or any other questions by the FDA, we may be required to provide additional information, which may include the results of additional preclinical studies or clinical trials.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond that which we currently contemplate for regulatory approval, if we are unable to complete successfully our clinical trials or other testing, or if the results of these and other trials or tests fail to demonstrate efficacy or raise safety concerns, we may face substantial additional expenses, be delayed in obtaining marketing approval for our product candidates or may never obtain marketing approval.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if regulatory approval of a product candidate is obtained, such as Omidria in the U.S., such approval may be subject to significant limitations on the indicated uses for which that product may be marketed, conditions of use, and/or significant </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">26</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post approval obligations, including additional post-marketing studies and clinical trials. These regulatory requirements may, among other things, limit the size of the market for the approved product. Even after approval, discovery of previously unknown problems with an approved product, manufacturer, or facility, such as previously undiscovered side effects or adverse effects, may result in restrictions on any product, manufacturer, or facility, including, among other things, a possible withdrawal of approval of the approved product. The realization of any of these risks could harm our business and operating results.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The commercialization of Omidria and our product candidates, if approved, is subject to extensive regulation and oversight under a number of different healthcare compliance laws.&#160; Compliance with these requirements requires the expenditure of substantial resources and attention, and the failure to comply with these requirements could result in substantial fines or penalties. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, the commercialization of Omidria and our product candidates, if approved, is subject to regulation and enforcement under a number of federal and state health-care compliance laws. For example, the FDA requires that we advertise and promote our approved products only for uses that FDA has approved and for which we provide appropriate information about safety risks to balance information presented about product effectiveness.&#160;The federal Anti-Kickback Law prohibits offering or paying anything of value to a person or entity to induce the use of a good or service covered by a federal health care program such as Medicare or Medicaid.&#160;The federal False Claims Act prohibits presenting or causing to be presented a false claim for payment by a federal health care program, and this law has been interpreted to include claims caused by improper drug-manufacturer product promotion or the payment of kickbacks. We are subject to a variety of governmental pricing, price reporting, and rebate requirements, including those under Medicaid and the Veterans Health Care Act.&#160;Under the so-called Sunshine Act and related provisions of the Affordable Care Act, we must report to the federal government information on financial payments we make to physicians and certain health care institutions and also on drug samples that we distribute. In addition to these federal law requirements, there are related state law requirements.&#160;Also, if we receive protected patient health information, we may be subject to federal or state privacy laws.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similar requirements apply to our operations outside the United States.&#160;United States laws such as the Foreign Corrupt Practices Act prohibit the offering or payment of bribes or inducements to foreign public officials, including potentially physicians or other medical professionals who are employees of public health care entities.&#160;In addition, many countries have their own laws similar to the health-care compliance laws that exist in the United States.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to comply with these United States and other laws, we must establish and maintain an effective healthcare compliance program.&#160;This requires the expenditure of significant time and resources.&#160;If we are found to be in violation of any of these laws, there could be considerable civil or criminal penalties.&#160;In addition, if government enforcement authorities initiate an investigation into potential violations of these laws, we would be required to expend considerable resources and face adverse publicity and the potential disruption of our business, even if we are ultimately found not to have committed a violation.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have a history of operating losses, and we may not achieve or maintain profitability.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not been profitable and have generated substantial operating losses since we were incorporated in June 1994. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$307.3 million</font><font style="font-family:inherit;font-size:10pt;">. We do not anticipate generating revenue from the sale of our first FDA-approved product, Omidria, until 2015 at the earliest and may incur additional losses depending upon the commercial success of Omidria, and we cannot be certain that we will ever achieve profitability. We will continue to incur significant and increasing costs as we support the commercial launch of Omidria in the U.S. and, if approved, in the EU and other foreign territories, as well as incurring costs associated with conducting additional research on our product candidates. As a result, our business is subject to all of the risks inherent in the development of a new business enterprise, such as the risks that we may be unable to obtain the additional capital needed to support the preclinical and clinical development and commercialization of any of our product candidates should they be approved, to develop a market for Omidria and our product candidates, if approved, to successfully transition from a company with a research and development focus to a company capable of commercializing products, and to attract and retain qualified management as well as technical and scientific staff.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to raise additional capital when needed, we may be unable to complete the development and commercialization of Omidria and our product candidates or to continue our other preclinical development programs.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the commercialization of Omidria;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the clinical development of OMS824 and OMS721;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the development of OMS103 for use in arthroscopic partial meniscectomy surgery;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">27</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue our development efforts in our GPCR program to advance this program for potential partnering and/or for internal development of product candidates targeting GPCRs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">scale-up and produce clinical and commercial supplies of Omidria and our product candidates, and conduct clinical studies for Omidria and our product candidates, including OMS103, OMS824, OMS721, and product candidates being developed in our PDE7 and Plasmin programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue research and development in all of our programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make principal and interest payments when due under the Oxford/MidCap Loan Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiate and conduct clinical trials for other product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make milestone payments to our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">undertake development activities and make the required payments to maintain our exclusive licenses to our MASP-2 program; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">launch and commercialize any product candidates for which we receive regulatory approval.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we do not raise additional capital through one or more funding avenues (e.g., corporate partnering, debt, equity financings, etc.), we may be unable to commercialize Omidria or complete all of the clinical trials in our Phase 3 clinical program for OMS103, which could prevent us from generating sales revenue for Omidria and/or OMS103, respectively. Furthermore, we may need to raise additional capital to continue the clinical development of OMS824, OMS721 and our other clinical programs and to advance one or more of our preclinical programs into clinical development. Also, our clinical trials may be delayed or we may need to conduct additional trials for many of the reasons discussed in these &#8220;Risk Factors,&#8221; which would increase our development expenses and may require us to raise additional capital to commercialize Omidria and complete the clinical development and commercialization of our product candidates and to decrease spending on our other development programs. If we are unable to raise sufficient capital to commercialize Omidria, complete the clinical development of OMS721 and/or OMS824, or advance the development of one or more of our other programs, our business and prospects could be harmed and our stock price could decline significantly.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing Omidria or our product candidates internationally.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to have Omidria and our product candidates, if approved, marketed outside the U.S. In order to market Omidria or any of our product candidates, if approved, in the EU and many other non-U.S. jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. Although we have filed for regulatory approval of Omidria in the EU, we may be unable to file for regulatory approvals in other non-U.S. geographies and may not receive necessary approvals to commercialize Omidria or any of our product candidates in any non-U.S. market. The regulatory approval procedure varies among countries and can involve additional testing and data review. The requirements governing marketing authorization, the conduct of clinical trials, pricing and reimbursement vary from country to country. The time required to obtain regulatory approval outside the U.S. may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval discussed in these &#8220;Risk Factors&#8221; and we may not obtain foreign regulatory approvals on a timely basis, or at all. Approval by the FDA or EMA does not ensure approval by regulatory agencies in other jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory agencies in other foreign countries or by the FDA or EMA. The failure to obtain regulatory approval in one or more foreign jurisdictions for Omidria or any of our product candidates could harm our business.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have submitted an MAA with the EMA for Omidria, which is currently under review. The EU regulatory process is subject to substantial agency discretion and risks, including those described elsewhere in these &#8220;Risk Factors.&#8221; The EMA may decide not to approve our application, or to require us to obtain additional data regarding Omidria and to resubmit our marketing application(s) in order to consider Omidria for approval, further delaying our ability to market and generate revenue from the sale of Omidria in the EU. If there are any negative decisions or delays in the regulatory process, the market price of our common stock could decline significantly.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We cannot be certain that OMS103 will receive regulatory approval.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Phase 3 clinical program evaluating OMS103 in patients undergoing arthroscopic partial meniscectomy may be redesigned to include postoperative pain reduction as the primary endpoint before further clinical studies are conducted, if we elect to conduct additional OMS103 trials. While OMS103 demonstrated a drug effect in the first Phase 3 clinical trial by reducing early postoperative pain, which was a secondary endpoint, we can provide no assurance that in subsequent trials, OMS103 will meet the primary endpoint of early postoperative pain reduction or that the design of our Phase 3 program will be acceptable to regulatory authorities. Also, we can provide no assurances that we will have sufficient resources to conduct any subsequent clinical trials that we or regulatory authorities may deem necessary, including any trial regulatory authorities require </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">28</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to show a contribution from each drug in the OMS103 combination. If the data from any subsequent trials are negative or if our program design, data analysis, and proposed label claims are not acceptable to regulatory authorities, we may be unable to seek, or be significantly delayed in seeking, marketing approval of OMS103, which could cause the market price of our common stock to decline significantly.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may find it difficult to prevent compounders from preparing compounded formulations of Omidria or our product candidates that may compete with Omidria or our product candidates, if and when commercialized.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, President Obama signed the Drug Quality and Security Act, which provided for the oversight of compounded human drugs. The law permits a compounding pharmacy to voluntarily register with the FDA as an outsourcing facility and create compounded products, subject to certain requirements including compliance with good manufacturing practices, or GMPs, for outsourcing facilities and FDA inspection. Registered outsourcing facilities will be permitted to compound products in large quantities instead of pursuant to individual patient prescriptions. Outsourcing facilities may not engage in wholesale selling of compounded drugs, compound a drug that is essentially a copy of a commercially available drug, or compound drugs that the FDA identifies as prohibited for compounding. Outsourcing facilities will still be subject to potential liability for patent infringement by compounding patented drugs. It is not clear how many compounding pharmacies will register with the FDA as outsourcing facilities or how aggressively the FDA will implement the new law.&#160;It is also not clear to what extent traditional compounding pharmacies that do not register as outsourcing facilities will continue to produce compounded drugs without individual patient prescriptions. We may be unable to prevent a registered outsourcing facility or traditional compounding pharmacy from preparing a compounded formulation in large quantities that is similar to Omidria or OMS103 but outside the scope of the claims of our issued patents, or we may be unsuccessful in enforcing our issued patents against outsourcing facilities or traditional compounding pharmacies that prepare compounded formulations that are within the scope of our issued patents. Because these patent violations may be sporadic and dispersed, we may not easily be able to identify the violations.&#160;Such actions may hinder our ability to generate enough revenue to achieve profitability and adversely affect our margins.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no internal capacity to manufacture clinical or commercial supplies of Omidria or our product candidates and intend to rely solely on third parties to manufacture clinical and commercial supplies of Omidria and our product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to rely on third party manufactures to produce commercial quantities of Omidria and any of our product candidates should they receive regulatory approval. Additionally, we intend to rely on third parties to produce clinical drug supplies need for clinical trials. With the exception of our agreements with Patheon and Hospira for the commercial supply of Omidria, and Hospira for the commercial supply of liquid OMS103, we have not yet entered into any agreement for the commercial supply of any of our other product candidates, and can provide no assurance that we will be able to do so on commercially reasonable terms, if at all. Our agreement with Patheon for the commercial supply of Omidria has a term extending through December 31, 2015, which term could be terminated early by either party upon the occurrence of certain specified events, including any mandate from a regulatory authority prohibiting manufacture at Patheon&#8217;s relevant facility in the absence of an agreement with Patheon to transfer the manufacture of Omidria to an alternative Patheon facility. If the Patheon agreement is terminated before we have completed manufacturing method transfer, validation and approval of Hospira as a manufacturing site for Omidria or an alternative Patheon facility as a manufacturing site for Omidria, we could have a shortage of supply of Omidria. Even if Hospira has been established as a manufacturing site for Omidria, if we elect not to transfer manufacturing of Omidria from the current Patheon facility to an alternative Patheon facility, or if Patheon is unable or unwilling to manufacture Omidria at Patheon&#8217;s planned alternative facility, or if our supply agreement with Patheon is terminated, we will have only Hospira as a source of supply of Omidria, which may be inadequate to meet product demand. The cost of transferring the Omidria manufacturing process to Hospira and potentially also to an alternate Patheon manufacturing facility or a different manufacturer, or any significant delays in the timely completion of these transfers of the Omidria manufacturing process, could materially harm our business and prospects. Any significant delays in the manufacture of clinical or commercial supplies of Omidria or our product candidates could materially harm our business and prospects.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If the contract manufacturers that we rely on experience difficulties manufacturing Omidria or our product candidates or fail FDA or other regulatory inspections, our clinical trials, regulatory submissions and ability to sell Omidria and our product candidates and generate revenue may be significantly delayed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturers that we select to manufacture Omidria or our product candidates for clinical testing or for commercial supply may encounter difficulties with the small- and large-scale formulation and manufacturing processes required for such manufacture. These difficulties could result in delays in clinical trials, regulatory submissions, or impact the  commercialization of Omidria and our product candidates. Once a product is approved and being marketed, these difficulties could also result in the recall or withdrawal of the product from the market or failure to have adequate supplies to meet market demand. Even if we are able to establish additional or replacement manufacturers, identifying these sources and entering into </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">29</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">definitive supply agreements and obtaining regulatory approvals may require a substantial amount of time and cost and such supply arrangements may not be available on commercially reasonable terms, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we and our contract manufacturers must comply with current good manufacturing practices, or GMPs, that are strictly enforced by the FDA and other regulatory authorities through facilities inspection programs. These cGMPs include quality control, quality assurance and the maintenance of records and documentation. We or our contract manufacturers may be unable to comply with cGMPs or with other FDA, state, local and foreign regulatory requirements. Although we have obligations to review their compliance, we have limited control over our current, and expect to have limited control for any future, contract manufacturers&#8217; compliance with these regulations and standards, or with their quality control and quality assurance procedures. Large-scale manufacturing processes that have been developed, or which would be developed in the future, for our product candidates, or establishing additional manufacturers for Omidria, will require validation studies, which the FDA or other regulatory authorities must review and approve. Failure to comply with these requirements by our contract manufacturers could result in the initiation of enforcement actions by the FDA and other regulatory authorities, as well as the imposition of sanctions, including fines and civil penalties, suspension of production, suspension or delay in regulatory approval, product seizure or recall or withdrawal of product approval. If the safety of Omidria or any product candidate supplied by contract manufacturers is compromised due to their failure to adhere to applicable laws or for other reasons, we may not be able to obtain or maintain regulatory approval for or successfully commercialize Omidria or one or more of our product candidates, which would harm our business and prospects significantly.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If one or more of our contract manufacturers were to encounter any of these difficulties or otherwise fail to comply with its contractual obligations, our ability to provide Omidria or product candidates to patients in our clinical trials or on a commercial scale would be jeopardized. Any delay or interruption in the supply of clinical trial materials could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial programs and, depending on the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. If we need to change to other commercial manufacturers, the FDA and comparable foreign regulators must first approve these manufacturers&#8217; facilities and processes, which could require new testing and compliance inspections, and the new manufacturers would have to be educated in or independently develop the processes necessary for the production of the applicable product(s).</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ingredients, excipients and other materials necessary to manufacture Omidria or our PharmacoSurgery product candidates may not be available on commercially reasonable terms, if at all, which may adversely affect the development and commercialization of Omidria or those PharmacoSurgery product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and our third-party manufacturers must obtain from third-party suppliers the active pharmaceutical ingredients, excipients and primary and secondary packaging materials necessary for our contract manufacturers to produce Omidria and our PharmacoSurgery product candidates for our clinical trials and, to the extent approved, for commercial distribution. Suppliers may not sell these ingredients, excipients or materials at the time they are needed or on commercially reasonable terms, if at all. Although we have or intend to enter into agreements with third-party suppliers that will guarantee the availability and timely delivery of active pharmaceutical ingredients, excipients and materials for Omidria and our PharmacoSurgery product candidates, we have not yet entered into agreements for the supply of all such ingredients, excipients or materials and we may be unable to secure all such supply agreements or guarantees. Even if we were able to secure such agreements or guarantees, our suppliers may be unable or choose not to provide us the ingredients, excipients or materials in a timely manner or in the quantities required. If we or our third-party manufacturers are unable to obtain these active pharmaceutical ingredients, excipients and materials as necessary for the manufacture of commercial supplies of Omidria, our ability to generate revenue from the sale of Omidria would be materially and adversely affected. Further, if we or our third-party manufacturers are unable to obtain active pharmaceutical ingredients, excipients and materials as necessary for our clinical trials or for the manufacture of commercial supplies of our product candidates, if approved, potential regulatory approval or commercialization would be delayed, significantly impacting our ability to develop and commercialize our product candidates, which would materially and adversely affect our ability to generate revenue from the sale of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If our clinical trials are delayed, we may be unable to develop our product candidates on a timely basis, which will increase our development costs and delay the potential commercialization of our product candidates should they receive regulatory approval.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict whether we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause regulatory agencies, Institutional Review Boards or Ethics Committees, or us to delay our clinical trials or suspend or delay the analysis of the data from those trials. Clinical trials can be delayed for a variety of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discussions with the FDA, the EMA or other foreign authorities regarding the scope or design of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays or the inability to obtain required approvals from Institutional Review Boards, Ethics Committees or other responsible entities at clinical sites selected for participation in our clinical trials;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in enrolling patients into clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lower than anticipated retention rates of patients in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to repeat or conduct additional clinical trials as a result of problems such as inconclusive or negative results, poorly executed testing, a failure of a clinical site to adhere to the clinical protocol or an unacceptable study design;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an insufficient supply of product candidate materials or other materials necessary to conduct our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to qualify new suppliers of product candidate materials for FDA and foreign regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an unfavorable FDA inspection or review of a clinical trial site or records of any clinical investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the occurrence of unacceptable drug-related side effects or adverse events experienced by participants in our clinical trials; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the placement by a regulatory agency of a trial on a clinical hold.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, a clinical trial or development program may be suspended or terminated by us, the FDA or other regulatory authorities, or Institutional Review Boards or Ethics Committees due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues or any determination that a trial presents unacceptable health risks; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of adequate funding to continue the clinical trial or development program, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies and increased expenses associated with the services of our CROs and other third parties.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, our Phase 2 clinical trial of OMS824 in Huntington&#8217;s disease has been suspended. As a result, we may need to perform additional studies, the reinitiation of a Phase 2 clinical trial may be delayed or not allowed, or the trial&#8217;s scope may be narrowed. Our OMS824 schizophrenia program may also be delayed or not allowed to initiate further clinical trials due to the current enrollment suspension in the OMS824 program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to Institutional Review Boards or Ethics Committees for re-examination, which may impact the costs, timing or successful completion of a clinical trial. If the results of our clinical trials are not available when we expect or if we encounter any delay in the analysis of data from our clinical trials, we may be unable to file for regulatory approval or conduct additional clinical trials on the schedule we currently anticipate. Any delays in completing our clinical trials may increase our development costs, would slow down our product development and regulatory submission process, could delay our receipt of product revenue and could make it difficult to raise additional capital. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. In addition, significant clinical trial delays also could allow our competitors to bring products to market before we do and impair our ability to commercialize our future products and may harm our business.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we experience delays or difficulties in enrolling patients in our clinical trials, those clinical trials could take longer than expected to complete and our receipt of regulatory approvals could be delayed or prevented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to initiate or continue clinical trials for Omidria or our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other regulatory authorities outside the U.S.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient enrollment for any of our clinical trials also may be affected by other factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the severity of the disease under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the design of the trial protocol;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the size of the patient population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of competing therapies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the eligibility criteria of the study in question;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perceived risks and benefits of the product or product candidate under study;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efforts to facilitate timely enrollment in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the patient referral practices of physicians;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to monitor patients adequately before and after treatment; and</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">31</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the proximity and availability of clinical trial sites for prospective patients.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays and could require us to abandon one or more clinical trials altogether.  Enrollment delays may result in increased development costs for our products or product candidates, and we may not have or be able to obtain sufficient cash to fund such increased cost when needed, which could result in further delay or termination of the trial.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We rely on third parties to conduct portions of our preclinical research and clinical trials. If these third parties do not perform as contractually required or otherwise expected, or if we fail to adequately supervise or monitor these parties, we may not be able to obtain regulatory approval for or commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on third parties, such as CROs and research institutions, to conduct a portion of our preclinical research. We also rely on third parties, such as medical institutions, clinical investigators and CROs, to assist us in conducting our clinical trials. Nonetheless, we are responsible for confirming that our preclinical research and clinical trials are conducted in accordance with applicable regulations, the relevant trial protocol and within the context of approvals by an Institutional Review Board or Ethics Committee, and we may not always be successful in ensuring such compliance. Our reliance on these third parties does not relieve us of responsibility for ensuring compliance with FDA and other regulations and standards for conducting, monitoring, recording and reporting the results of preclinical research and clinical trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical and clinical development processes may be extended, delayed, suspended or terminated, and we may not be able to commercialize or obtain regulatory approval for our product candidates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may need licenses for active ingredients from third parties to develop and commercialize some of our product candidates, which could increase our development costs and delay our ability to commercialize those product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should we decide to use active pharmaceutical ingredients in any of our product candidates that are proprietary to one or more third parties, we would need to obtain licenses to those active ingredients from those third parties. For example, we intend to use proprietary active ingredients that we have exclusively licensed from Daiichi Sankyo Co., Ltd. for our PDE7 program. If we are unable to access rights to these active ingredients prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate active ingredients, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to access rights to the desired active ingredients on commercially reasonable terms or develop suitable alternate active ingredients, we may not be able to commercialize product candidates from these programs.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our agreements with Vulcan and the Life Sciences Discovery Fund Authority, a granting agency of the State of Washington, or LSDF, include terms that may reduce the purchase price that a third party would be willing to pay for the GPCR program or for us in a change of control.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our GPCR funding agreement with Vulcan, if we decide to sell or assign all or substantially all of the assets in our GPCR program prior to the time that Vulcan has received $60.0 million from us under our agreement, Vulcan may require that the purchaser assume all of our rights and obligations pursuant to the agreement, including our obligation to pay tiered percentages of any net proceeds that we receive from the GPCR program. The term of the Vulcan agreement is at least 35 years. If, at our option, we elect to assign the LSDF agreement in connection with the sale of the GPCR program, a potential purchaser would also have to assume similar payment obligations to LSDF. Potential purchasers of our GPCR program may be less inclined to purchase the program because of these obligations. Further, even if they are willing to assume our rights and obligations, they may be unwilling to pay as much for our GPCR program as they would be without such requirement. In addition, if a transaction results in a change of control of Omeros, the acquiring party will be required to assume our rights and obligations under the Vulcan and LSDF agreements. As a result of these provisions, a party that wants to acquire us through a change of control may be less inclined to do so or not be willing to pay as much.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have granted Vulcan a lien on all of our GPCR assets, excluding intellectual property, which provides Vulcan a right, senior to our shareholders, to receive proceeds generated from a liquidation of our GPCR assets as well as potentially limiting our operating and financial flexibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have granted Vulcan a lien on all of our GPCR assets, excluding intellectual property, to secure our obligations under our agreement with Vulcan. This lien is, and will continue to be, junior to security interests we grant to third parties in connection with indebtedness for borrowed money. The lien will automatically be released once we have paid Vulcan or its affiliate $25.0 million out of net proceeds received from the GPCR program. If we default under our agreement with Vulcan, in </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">32</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain circumstances Vulcan may, subject to the rights of any holders of senior security interests, take control of such pledged assets. We have also agreed with Vulcan not to grant any liens on our GPCR-related intellectual property related to our cellular redistribution assay, subject to specified exceptions. If we are liquidated, Vulcan&#8217;s right to receive any payments then due under our agreement would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation of our GPCR program assets. Further, the junior lien and negative pledge on our intellectual property restrict our operating and financial flexibility, potentially limiting our ability to pursue business opportunities and making it more difficult for us to respond to changes in our business.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be successful in partnering new drug targets made accessible by our GPCR program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To fully exploit the developments arising from our GPCR program, we intend to partner or out-license our proprietary rights associated with some of the new drug targets made accessible by our GPCR program. There can be no assurance that we will enter into any such agreements and, even if we do, that the terms of any such agreements will be favorable to us. For example, potential partners may require that we first advance the development and optimization of functionally active compounds identified from our high-throughput screening of orphan GPCRs prior to entering into a licensing or other partnering arrangement, requiring us to invest substantial resources without any certainty that we will successfully optimize one or more of the compounds or recover our investment. Potential partners may also require that we obtain the issuance of patents protecting the new drug targets and compounds that interact with those targets. We may not be successful in obtaining the issuance of such patents for the targets and compounds we intend to partner or for the targets and compounds we intend to develop ourselves and, even if we do, the breadth of our patent rights may be inadequate or may be viewed as inadequate by potential partners. Further, if we are unable to secure the issuance of patents or patents of adequate breadth, we may be unable to exclude competitors from developing and commercializing compounds that interact with GPCR targets, limiting our ability to successfully commercialize these targets either independently or with a partner.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our ability to pursue the development and commercialization of product candidates from our MASP-2 program depends on the continuation of licenses from third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our MASP-2 program is based in part on intellectual property rights that we licensed on a worldwide exclusive basis from the University of Leicester, the UK Medical Research Council at Oxford University and Helion. The continued maintenance of these agreements requires us to undertake development activities and, if regulatory approval for marketing is obtained, to pay royalties to each of these organizations upon commercialization of a MASP-2 product, such as OMS721. In addition, we are obligated to pay Helion up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of certain events related to a MASP-2 product, such as the initiation of clinical trials, receipt of marketing approval and reaching specified sales milestones. Our ability to continue development and commercialization of product candidates from our MASP-2 program, including OMS721, depends on our maintaining these exclusive licenses, which cannot be assured.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our ability to pursue the development and commercialization of product candidates from our MASP-2 and Plasmin programs depends on third-party developers and manufacturers of biologic drug products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any product candidate from our MASP-2 or Plasmin programs would be a biologic drug product and we do not have the internal capability to hybridize, clone or manufacture biologics for clinical or commercial use. There are only a limited number of manufacturers of biologic drug products and we cannot be certain that we can enter into supply agreements with them on commercially reasonable terms, if at all. If we are unable to obtain clinical supplies of drug product for one of these programs, clinical trials or the development of any such product candidate for that program could be substantially delayed until we can find and qualify a manufacturer, which may increase our development costs, slow down our product development and approval process, delay receipt of product revenue and make it difficult to raise additional capital.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our preclinical programs may not produce product candidates that are suitable for clinical trials or that can be successfully commercialized or generate revenue through partnerships.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any product candidates from our preclinical programs, including our PDE7, Plasmin and GPCR programs, must successfully complete preclinical testing, which may include demonstrating efficacy and the lack of toxicity in established animal models, before entering clinical trials. Many pharmaceutical and biological products do not successfully complete preclinical testing and, even if preclinical testing is successfully completed, may fail in clinical trials. In addition, there can be no assurance that positive results from preclinical studies will be predictive of results obtained from subsequent preclinical studies or clinical trials. For example, our studies of PDE7 inhibitors in different animal models of Parkinson&#8217;s disease, which may or may not be relevant to the mechanism of action of PDE7 inhibitors in humans, have produced varying results. Further, we cannot be certain that any of our preclinical product development programs will generate product candidates that are suitable for clinical testing. For example, we have not yet generated any products or product candidates from our GPCR program. We may discover that there are fewer druggable targets among the orphan GPCRs than we currently estimate and that, for those orphan GPCRs for which we identify functionally active compounds that we elect to develop independently, we are </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">33</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unable to develop related product candidates that successfully complete preclinical or clinical testing. If we are unable to develop product candidates, potential corporate partners may be unwilling to enter into partnership agreements with us. We also cannot be certain that any product candidates that do advance into clinical trials will successfully demonstrate safety and efficacy in clinical trials. Even if we achieve positive results in early clinical trials, they may not be predictive of the results in later trials.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Because we have a number of development programs and are considering a variety of product candidates, we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited resources, we must focus on clinical and preclinical development programs and product candidates that we believe are the most promising. As a result, we may forego or delay the pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential and may not be able to progress development programs, including our GPCR program, as rapidly as otherwise possible. Our resource allocation decisions may cause us to fail to capitalize on viable potential commercial products or profitable market opportunities. Further, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product through collaboration, license or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for the use, formulation and structure of our products and product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods of treatment as well as on successfully defending these patents against potential third party challenges. Our ability to protect our products and product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Case law and policy regarding the breadth of claims allowed in biotechnology patents has continued to evolve in the U.S., and tests used for determining the patentability of patent claims in all technologies are in flux. The pharmaceutical, biotechnology and other life sciences patent situation outside the U.S. is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Further, the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. For example, in the U.S., a determination of patentability by the U.S. Patent and Trademark Office, or USPTO, or validity by a court or other trier of fact requires a determination that the claimed invention has utility and is both novel and non-obvious to those of ordinary skill in the art in view of prior known publications and public information, and that the patent specification supporting the claim adequately describes the claimed invention, discloses the best mode known to the inventors for practicing the invention, and discloses the invention in a manner that enables one of ordinary skill in the art to make and use the invention. These standards may be challenging to meet for patents directed to some of our technologies, including our target-based technologies. The ultimate determination by the USPTO or by a court or other trier of fact in the U.S., or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents and other information that may impact the patentability of claims in our various patent applications and patents, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or patent applications, our licensed patents or patent applications or in third-party patents.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot assure you that any of our patent applications will be found to be patentable, including over our own prior art patents, or will issue as patents, nor can we make assurances as to the scope of any claims that may issue from these pending and future patent applications or to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the U.S. or foreign jurisdictions, which could limit patent protection for our products and product candidates and materially harm our business.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to make the inventions covered by any of our pending U.S. patent applications filed or having priority dates prior to the U.S. having adopted a first-to-file standard on March 16, 2013, or any U.S. patents issued based on such patent applications;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">34</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to file patent applications on inventions that are the subject of pending foreign patent applications or that are the subject of pending U.S. patent applications filed or having priority dates after March 16, 2013, or any patents issued based on such foreign or U.S. patent applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may independently develop similar or alternative technologies or products or duplicate any of our technologies or products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to generate sufficient data to support fully patent applications that protect the entire breadth of developments expected to result from our development programs, including the GPCR program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">it is possible that none of our pending patent applications will result in issued patents or, if issued, that these patents will be sufficient to protect our technology or provide us with a basis for commercially viable products or provide us with any competitive advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable under U.S. or foreign laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if issued, the patents under which we hold rights may not be valid or enforceable; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may develop additional proprietary technologies or products or product candidates that are not patentable and which are unlikely to be adequately protected through trade secrets if, for example, a competitor were to develop independently duplicative, similar or alternative technologies or products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, to the extent we are unable to obtain and maintain patent protection for one of our products or product candidates or in the event such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product candidate for follow-on indications.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also may rely on trade secrets to protect our technologies or products, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we choose to go to court to stop someone else from using our inventions, that individual or company has the right to ask the court to rule that the underlying patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and other resources even if we were successful in stopping the infringement of these patents. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe the patents. It may not be feasible to detect and undertake patent enforcement action to stop infringing activity by a number of individual entities, each on a small scale, such as compounding pharmacies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, a third party may claim that we or our contract manufacturers are using inventions covered by the third party&#8217;s patent rights and may go to court to stop us from engaging in the alleged infringing activity, including making, using or selling our products and product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we, or our contract manufacturers, are infringing the third party&#8217;s patents and would order us or our partners to stop the activities covered by the patents. In addition, if we or our contract manufacturers are found to have violated a third party&#8217;s patent, we or our contract manufacturers could be ordered to pay damages to the other party. We have agreed to or may agree to indemnify our contract manufacturers against certain patent infringement claims and thus may be responsible for any of their costs associated with such claims and actions. The pharmaceutical, biotechnology and other life sciences industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our products and product candidates or methods of use either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we have conducted searches of third-party patents with respect to our programs, we have not obtained written freedom to operate opinions for our programs and may not have identified all relevant third-party patents. Consequently, we </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">35</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cannot assure you that third-party patents containing claims covering our products, product candidates, programs, technologies or methods do not exist, have not been filed, or could not be filed or issued.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, because patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our patents, our licensors&#8217; patents, our pending applications or our licensors&#8217; pending applications, or that we or our licensors were the first to invent or the first to file patent applications for inventions embodied in our technologies. Our competitors may have filed, and may in the future file, patent applications covering technologies similar to ours. Any such patent application may have priority over our or our licensors&#8217; patent applications and could further require us to obtain rights to issued patents covering such technologies. If our or our licensors&#8217; pending patent applications issue as patents, we can provide you no assurances that the patents will not be challenged in post-grant review or inter-parties review proceedings. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in interference derivation proceedings declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our U.S. patent position with respect to such inventions. Similar patent opposition proceedings in other countries and regions may also be costly and could result in the loss of patent rights in those countries and regions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the capital necessary to continue our operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The terms of our debt facility place restrictions on our operating and financial flexibility and, if we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we borrowed </font><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;pursuant to the terms of the Oxford/MidCap Loan Agreement. As collateral for this loan, we pledged substantially all of our assets other than intellectual property. The Oxford/MidCap Loan Agreement restricts our ability to incur additional indebtedness, pay dividends, pledge our intellectual property and engage in significant business transactions such as a change of control of Omeros, so long as we owe any amounts to the lenders under the Oxford/MidCap Loan Agreement. Any of these restrictions could significantly limit our operating and financial flexibility and ability to respond to changes in our business or competitive activities. In addition, if we default under the Oxford/MidCap Loan Agreement, the lenders may have the right to accelerate all of our repayment obligations under the Oxford/MidCap Loan Agreement and to take control of our pledged assets, which include our cash, cash equivalents and short-term investments, potentially requiring us to renegotiate the Oxford/MidCap Loan Agreement on terms less favorable to us. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. An event of default under the Oxford/MidCap Loan Agreement includes the occurrence of any material adverse effect upon our business operations, properties, assets, results of operations or financial condition, taken as a whole with respect to our viability, that would reasonably be expected to result in our inability to repay the loan. If either lender declares all obligations under the Oxford/MidCap Loan Agreement immediately due and payable upon the occurrence of any event that the lender interprets as constituting an event of default as defined under the Oxford/MidCap Loan Agreement, including but not limited to the lender concluding that a material adverse change has occurred as defined under the Oxford/MidCap Loan Agreement, we will be required to repay the loan immediately or to attempt to reverse the declaration through negotiation or litigation. Any declaration of an event of default could significantly harm our business and prospects and could cause our stock price to decline. If we raise any additional debt financing, the terms of such debt could further restrict our operating and financial flexibility.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research operations produce hazardous waste products, which include chemicals and radioactive and biological materials. We are subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply with applicable legal regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. We generally contract with third parties for the disposal of such substances and store our low-level radioactive waste at our facility until the materials are no longer considered radioactive. We may be required to incur further costs to comply with current or future environmental and safety regulations. In addition, although we carry insurance, in the event of accidental contamination or injury from these materials, we could be held liable for any damages that result and any such liability could exceed our insurance coverage and other resources.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">36</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The loss of members of our management team could substantially disrupt our business operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success depends to a significant degree on the continued individual and collective contributions of our management team. The members of our management team are at-will employees, and we do not maintain any key-person life insurance policies other than on the life of Gregory A. Demopulos, M.D., our president, chief executive officer and chairman of the board of directors. Losing the services of any key member of our management team, whether from death or disability, retirement, competing offers or other causes, could delay the execution of our business strategy, cause us to lose a strategic partner, or otherwise materially affect our operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We rely on highly skilled personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to maintain our operations or grow effectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our performance is largely dependent on the talents and efforts of highly skilled individuals. Our future success depends on our continuing ability to identify, hire, develop, motivate and retain highly skilled personnel for all areas of our organization. If we are unable to hire and train a sufficient number of qualified employees for any reason, we may not be able to implement our current initiatives or grow effectively. We have in the past maintained a rigorous, highly selective and time-consuming hiring process. We believe that our approach to hiring has significantly contributed to our success to date. If we do not succeed in attracting qualified personnel and retaining and motivating existing personnel, our existing operations may suffer and we may be unable to grow effectively.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may encounter difficulties managing our growth, which could delay our business plans or adversely affect our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage effectively the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. Additionally, our inability to manage growth effectively could cause our operating costs to grow even faster than we currently are anticipating.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We incur significant costs and demands on management as a result of complying with the laws and regulations affecting public companies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred, and will continue to incur, significant costs associated with compliance with public company reporting and corporate governance requirements, including under the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, as well as rules implemented by the SEC and The NASDAQ Stock Market. The requirements of applicable SEC rules and regulations may increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. We also expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage than was previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to make an assessment of the effectiveness of our internal control over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act of 2002. Further, our independent registered public accounting firm has been engaged to express an opinion on the effectiveness of our internal control over financial reporting. Section&#160;404 requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management and our independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting for each fiscal year. Our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to comply with the requirements of Section&#160;404, management may not be able to assess whether our internal control over financial reporting is effective, which may subject us to adverse regulatory consequences and could result in a negative reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we fail to maintain effective controls and procedures, we may be unable to provide the required financial information in a timely and reliable manner or otherwise comply with the standards applicable to us as a public company. Any failure by us to provide the required financial information in a timely manner could materially and adversely impact our financial condition and the market value of our securities.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">37</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Industry</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our competitors may develop products that are less expensive, safer or more effective, or which may otherwise diminish or eliminate the commercial success of any products that we may commercialize.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not achieve commercial success, particularly if our competitors market products that are safer, more effective, less expensive or faster to reach the market than Omidria or any future products that we may develop and commercialize. Our competitors also may market a product that proves to be unsafe or ineffective, which may affect the market for our competing product, or future product, regardless of the safety or efficacy of our product. For example, other pharmaceutical companies, many with significantly greater resources than we have, are developing PDE10 inhibitors similar to our product candidate OMS824, and these companies may be further along in development and have the resources to develop their product candidates at a faster rate than we can. For example, in 2012, Pfizer Inc. announced that its PDE10 inhibitor product candidate failed to demonstrate efficacy in a Phase 2 clinical trial evaluating the compound in acute exacerbation of schizophrenia. This and other potential clinical trial failures of PDE10 inhibitor product candidates may negatively reflect on the ability of OMS824 to demonstrate safety and efficacy. In addition, we believe that other companies are attempting to find compounds that functionally interact with orphan GPCRs. If any of these companies are able to achieve this for a given orphan GPCR before we do, we may be unable to establish a commercially valuable intellectual property position around that orphan GPCR. The failure of Omidria or any other future product that we may market to effectively compete with products marketed by our competitors would impair our ability to generate revenue, which would have a material adverse effect on our future business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The pharmaceutical industry is intensely competitive and many of our competitors have significantly more resources and experience, which may limit our commercial opportunities.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is intensely competitive in the markets in which we expect to compete. We expect to compete for market share against large pharmaceutical and biotechnology companies, smaller companies that are collaborating with larger pharmaceutical companies, new companies, academic institutions, government agencies and other public and private research organizations. Our competitors may:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operate larger research and development programs, possess commercial-scale manufacturing operations or have substantially greater financial resources than we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiate or withstand substantial price competition more successfully than we can;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">have greater success in recruiting skilled technical and scientific workers from the limited pool of available talent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more effectively negotiate third-party licenses and strategic relationships; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">take advantage of acquisition or other opportunities more readily than we can.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the pharmaceutical and biotechnology industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to remain current with rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our product discovery process that we believe we derive from our research approach and proprietary technologies and programs.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our products could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products if and when any of them are approved.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any product candidate for which we obtain marketing approval, such as Omidria, together with the manufacturing processes, post-approval clinical data, and advertising and promotional activities for such product, will be subject to continued regulation by the FDA and other regulatory agencies. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or the approval may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Later discovery of previously unknown problems with Omidria or any of our other approved products, or failure to comply with regulatory requirements, may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on such products or manufacturing processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of the products from the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary or mandatory recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of regulatory approvals;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizures; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we may lose marketing approval for Omidria, or for our product candidates when and if any of them are approved.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be exposed to the risk of product liability claims that is inherent in the biopharmaceutical industry. A product liability claim may damage our reputation by raising questions about our product&#8217;s safety and efficacy and could limit our ability to sell one or more products by preventing or interfering with commercialization of our products and product candidates. In addition, product liability insurance for the biopharmaceutical industry is generally expensive to the extent it is available at all. There can be no assurance that we will be able to obtain and maintain such insurance on acceptable terms or that we will be able to secure increased coverage if the commercialization of Omidria or our product candidates progresses, or that future claims against us will be covered by our product liability insurance. Further, our product liability insurance coverage may not reimburse us or may be insufficient to reimburse us for any or all expenses or losses we may suffer. A successful claim against us with respect to uninsured liabilities or in excess of insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our stock price has been and may continue to be volatile, and the value of an investment in our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the 12-month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, our stock traded as high as </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.80</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and as low as </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.92</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors could include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of Omidria or any of our product candidates, if approved, to achieve commercial success;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMA actions related to our MAA submission for Omidria;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA or foreign regulatory actions related to Omidria or any of our product candidates, including the suspension by the FDA of our OMS824 Phase 2 clinical trial in Huntington&#8217;s disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">results from our clinical development programs, including the data from our ongoing clinical development programs evaluating Omidria, OMS103, OMS824, OMS721 and PPAR&#947;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements regarding the progress of our preclinical programs, including without limitation our GPCR program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quarterly variations in our results of operations or those of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to develop and market new and enhanced products on a timely basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of acquisitions, regulatory approvals, clinical milestones, new products, significant contracts, commercial relationships or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party coverage and reimbursement policies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commencement of, our involvement in and resolution of litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to meet our repayment and other obligations under the Oxford/MidCap Loan Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of our contract manufacturers to provide us with adequate commercial supplies of Omidria and our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in governmental regulations or in the status of our regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any major change in our board or management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic conditions and slow or negative growth of our markets; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">political instability, natural disasters, war and/or events of terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we estimate the timing of the accomplishment of various commercial, scientific, clinical, regulatory and other product development goals or milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. Also, from time to time, we expect that we will publicly announce the anticipated timing of some of these milestones. All of these milestones are based on a variety of </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">39</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, our stock price may decline and the commercialization of Omidria and our product candidates may be delayed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the stock market has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of publicly traded companies. Broad market and industry factors may seriously affect the market price of companies&#8217; stock, including ours, regardless of actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We expect that we will continue to need additional capital in the future; however, such capital may not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing shareholders would experience further dilution.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we expect that we will need additional capital in the future, we cannot be certain that it will be available to us on acceptable terms, if at all, when required. Disruptions in the global equity and credit markets may limit our ability to access capital. To the extent that we raise additional funds by issuing equity securities, our shareholders would experience dilution, which may be significant and could cause the market price of our common stock to decline significantly. Any debt financing, if available, may restrict our operations similar to the Oxford/MidCap Loan Agreement, or in other ways. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the commercialization of Omidria or the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. We also could be required to seek collaborators for one or more of our current or future products at an earlier stage than otherwise would be desirable or on terms that are less favorable than otherwise might be available or to relinquish or license on unfavorable terms our rights to technologies or products that we otherwise would seek to develop or commercialize ourselves. We also may have insufficient funds or otherwise be unable to advance our preclinical programs, such as potential new drug targets developed from our GPCR program, to a point where they can generate revenue through partnerships, collaborations or other arrangements. Any of these events could significantly harm our business and prospects and could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Future sales of shares by holders of outstanding warrants and options could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock that are either subject to outstanding warrants or subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-takeover provisions in our charter documents and under Washington law could make an acquisition of us, which may be beneficial to our shareholders, difficult and prevent attempts by our shareholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions in our articles of incorporation and bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on shareholder actions by less than unanimous written consent, restrictions on the ability of shareholders to fill board vacancies and the ability of our board of directors to issue preferred stock without shareholder approval. In addition, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, restricts the ability of shareholders owning 10% or more of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some shareholders. In addition, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it difficult for shareholders to replace members of our board of directors, which is responsible for appointing the members of our management.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have never declared or paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business requires significant funding, and we have not generated any material revenue. We currently plan to invest all available funds and future earnings, if any, in the development and growth of our business. Additionally, under the Oxford/MidCap Loan Agreement, we have agreed not to pay any dividends so long as we have any outstanding obligations under the </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreement. Therefore, we currently do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, a rise in the market price of our common stock, which is uncertain and unpredictable, will be the sole source of potential gain for shareholders in the foreseeable future, and an investment in our common stock for dividend income should not be relied upon.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">41</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s51627ca1ed2847deaa69c36a709b06a3"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Unregistered Sales of Equity Securities. We issued </font><font style="font-family:inherit;font-size:10pt;">3,305</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock upon the exercise of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">4,689</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in September 2014. We received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37,828</font><font style="font-family:inherit;font-size:10pt;">&#32;from the cash exercise of </font><font style="font-family:inherit;font-size:10pt;">3,088</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants upon payment of the cash exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.25</font><font style="font-family:inherit;font-size:10pt;">&#32;per warrant. We also issued 217 shares of our common stock upon the cashless net exercise of 1,601 warrants. The warrants were issued on March 29, 2007 in connection with our Series E preferred stock financing in a transaction that was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. We deemed the issuance of common stock upon the exercise of these warrants to be exempt from registration under the Securities Act under the same provisions. No underwriters were involved in the issuance of our common stock upon the exercise of warrants and no commissions were paid in connection with such issuances.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">42</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="sA042E9D40415DECACB500F2810F9D213"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="12%"></td><td width="88%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-align:center;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice Regarding the Extension of the Expiration Date to March 29, 2015 of Warrants to Purchase up to an Aggregate of 192,789 Shares of Common Stock of the Registrant</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ratio of Earnings to Fixed Charges</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed on September&#160;29, 2014 (File No.&#160;001-34475).</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">43</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div><hr style="page-break-after:always"><a name="s077D6671E25A471529970F281128E348"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC862CEFCE297C7BE8F140F280BEA3526"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="45%"></td><td width="55%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OMEROS CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Gregory A. Demopulos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gregory A. Demopulos, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Chairman of the Board of Directors</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance, Chief Accounting Officer and Treasurer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">44</font><font style="font-family:inherit;font-size:10pt;">-</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>exhibit12120140930.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Exhibit 12.1 2014.09.30</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s476C1D9A9ADD36716B6F0F27FD2B00B5"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="42%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Omeros Corporation</font></div></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computation of Deficiency in the Coverage of Fixed Charges by Earnings Before Fixed Charges</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">nine months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2012</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2011</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2010</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">2009</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings before fixed charges:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,960</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,546</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,089</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Add fixed charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Add amortization of capitalized interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Add distributed income of equity investees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtract capitalized interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,139</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fixed Charges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt expense and loss from extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimate of interest expense within rental expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preference security dividend requirements of consolidated subsidiaries</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,072</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deficiency of earnings available to cover fixed charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,960</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,546</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,089</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>omer-ex311_20140930.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>OMER-EX31.1_2014.09.30</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s4194E1F557B8C4ACE0660F2812BDB47A"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Gregory A. Demopulos, M.D., certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Omeros Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Gregory A. Demopulos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gregory A. Demopulos, M.D.</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>omer-ex312_20140930.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>OMER-EX31.2_2014.09.30</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s5EAA859CB524C6A07BCD0F27FE25E536"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Michael A. Jacobsen, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Omeros Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Financial and Accounting Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>omer-ex321_20140930.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>OMER-EX32.1_2014.09.30</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sF2155739919827E24C630F28160817CD"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Omeros Corporation (the &#8220;Company&#8221;) for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Gregory A. Demopulos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gregory A. Demopulos, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>omer-ex322_20140930.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>OMER-EX32.2_2014.09.30</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s108507FE198F9E4A8C430F2817DC9771"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Omeros Corporation (the &#8220;Company&#8221;) for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November&#160;10, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael A. Jacobsen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Financial and Accounting Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>omer-20140930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!--p:ca5f1f8ce4174b4687fda7c646d244bf,x:19794bdfccb34a51a025d420150adecd-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:omer="http://www.omeros.com/20140930" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="omer-20140930.xsd" xlink:type="simple" />
  <xbrli:context id="D2010Q4Oct01toOct31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-10-01</xbrli:startDate>
      <xbrli:endDate>2010-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q4Oct01toOct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-10-01</xbrli:startDate>
      <xbrli:endDate>2010-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1Jan01toJan31_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">omer:EquityIncentivePlanTwentyZeroEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1OxfordLoan_us-gaap_DebtInstrumentAxis_omer_OxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">omer:OxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q3Sep01-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q3Sep01-30_us-gaap_ClassOfWarrantOrRightAxis_omer_SharesfromcashexerciseofwarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:SharesfromcashexerciseofwarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q4Oct01-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-10-01</xbrli:startDate>
      <xbrli:endDate>2014-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3QTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:SmallBusinessInnovativeResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3QTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:SmallBusinessInnovativeResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q4YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q1QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod1Q14Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:SeriesEMod1Q14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q1QTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">omer:OxfordMidcapLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:SmallBusinessInnovativeResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod3Q14MemberMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:SeriesEMod3Q14MemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_HelionBiotechApSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:HelionBiotechApSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_OxfordMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:OxfordMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:SmallBusinessInnovativeResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">omer:OxfordMidcapLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">omer:EquityIncentivePlanTwentyZeroEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">omer:EquityIncentivePlanTwentyZeroEightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2012Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">omer:NonCurrentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">omer:NonCurrentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_DSMMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:DSMMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_InVentivMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:InVentivMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_OxfordMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:OxfordMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:SmallBusinessInnovativeResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">omer:OxfordMidcapLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">omer:NonCurrentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">omer:NonCurrentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q3_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">omer:EquityIncentivePlanTwentyZeroEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2007Q1March29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-03-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">omer:VulcanIncorporatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">omer:WarrantTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1MidCap_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">omer:OxfordMidcapLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q3SharesOutstanding">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="Leases">
    <xbrli:measure>omer:Leases</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217_USD_per_Right">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>omer:Right</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="number">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="segment">
    <xbrli:measure>omer:segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usdPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="warrant">
    <xbrli:measure>omer:warrant</xbrli:measure>
  </xbrli:unit>
  <us-gaap:AccountsPayableCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-C7D231915C28068160A10F27FA2F3250" unitRef="usd">4156000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-C58DF148BFC367EED47D0F27FA00E34B" unitRef="usd">2329000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-DD024658F350693FF5960F27FA00202A" unitRef="usd">6250000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-541EAF8A9950698FDF830F27FA00C2E1" unitRef="usd">3944000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-0E5D616E8EE95CF9B35E0F27FA2F5215" unitRef="usd">649000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-F3349A3B6F9E9F7BC30E0F27FA0FC754" unitRef="usd">1536000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="FI2013Q4" decimals="-3" id="Fact-0A1CBD2D18160A090E7B0F27FA0F649B" unitRef="usd">235685000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="FI2014Q3" decimals="-3" id="Fact-8BE5EE09656A9796E32D0F27FA0F4C15" unitRef="usd">280404000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="FD2014Q3YTD" decimals="-3" id="Fact-86C1D7951C45E8EEEE520F27F9F0FD7A" unitRef="usd">863000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="FD2013Q3YTD" decimals="-3" id="Fact-A08EAF6DBF6810BBEE6E0F27F9F0ACB2" unitRef="usd">41000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-F936762E634A0D7556370F27FA1FD0DC" unitRef="usd">786000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-23B0EFE683A0006ABB5A0F27FA2F42F5" unitRef="usd">2791000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-24DF8BC7651B69B473290F27FA1F7ABC" unitRef="usd">2292000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-AE5FDC9ACD75BEDD74BA0F27FA1FAF5F" unitRef="usd">1371000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-A556062C1C31360377880F27FA1FA888" unitRef="usd">840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-C461F9A8981CD3BC78110F27FA1FF529" unitRef="usd">879000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D49FA2B9B51EC6218F070F27FA2FCB20" unitRef="usd">2518000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-4DBAA4AA8CE7BD0EB3670F27FA1FA50D" unitRef="usd">1846000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-19F6C0B77125F24558860F27FA0004EF" unitRef="shares">604327</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-30FA9349E047C61FE2D40F27F9F0C412" unitRef="shares">609016</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD" decimals="INF" id="Fact-3B69B664786D5F0512ED0F27FA008CE3" unitRef="shares">7384325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-50FB13B0AA9ACFAEDFE20F27FA0072AF" unitRef="shares">6909332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q3YTD" decimals="INF" id="Fact-6D37AF35F14B0656AC990F27FA0FADF2" unitRef="shares">7518348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-AC464871491CA6ED68550F27FA00DBF4" unitRef="shares">6779998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="FI2013Q4" decimals="-3" id="Fact-00317DB61FEE41BF9F1E0F27FA00FA90" unitRef="usd">16535000</us-gaap:Assets>
  <us-gaap:Assets contextRef="FI2014Q3" decimals="-3" id="Fact-E9F0D60891E1B754350F0F27FA1F1F35" unitRef="usd">25294000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-631FC3CED78BDD69BE2A0F27FA2FADBA" unitRef="usd">14817000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-FFD8733540C235534DC40F27F9F0E285" unitRef="usd">23361000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BAD2DBACB6D093E88EA80F27FA2F3AA6" unitRef="usd">13609000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1E4789800438BFFD194A0F27F9F00F3C" unitRef="usd">13609000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-84E73D5A379DD6E36F570F27FA00ECB9" unitRef="usd">21709000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8F9DCAB76AB02B730B750F27FA2F3D0C" unitRef="usd">21709000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1C4954169B0E7D1E94EB0F27FA1F7CB0" unitRef="usd">12717000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CCF2FE8A8E3F14855C780F27FA0F336F" unitRef="usd">12717000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="FI2014Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-59F920666A4A7227066A0F27FA00AB42" unitRef="usd">21030000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="FI2014Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6FA2E560EA540D9F0F290F27F9E1C845" unitRef="usd">21030000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-C5A298E35294147C97620F27FA2F50F5" unitRef="usd">12717000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-B164E4607F3FC6C858FF0F27F9F04CF2" unitRef="usd">21030000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2014Q3YTD" id="Fact-69B4128153FC3C4934B10F27FA2FFDCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries.  All inter-company transactions between and among our subsidiaries have been eliminated.  The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information.  The Consolidated Balance Sheet at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been derived from audited financial statements but does not include all of the information and footnotes required by GAAP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; filed with the Securities and Exchange Commission (SEC) on March 13, 2014.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:Cash contextRef="FI2013Q4" decimals="-5" id="Fact-ABF8F04F8D91EB16612B0F27F9F09616" unitRef="usd">1200000</us-gaap:Cash>
  <us-gaap:Cash contextRef="FI2014Q3" decimals="-3" id="Fact-1C9542D39131DE1F8ADD0F27F9F0B4A5" unitRef="usd">750000</us-gaap:Cash>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q3" decimals="-3" id="Fact-2990E85B56F19604E6980F27FA2F742A" unitRef="usd">750000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-49812CC18536A4BB8DAE0F27FA003D9E" unitRef="usd">1384000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q3" decimals="-3" id="Fact-2CB6659C706F91292EC00F27FA1FDF4F" unitRef="usd">1150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="-3" id="Fact-E612540B665DAF0499F90F27FA00F9D9" unitRef="usd">1520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-060745FF8B8213081CCF0F27FA00C748" unitRef="usd">213000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-027A0DA12F41C94B72F30F27F9E1B74C" unitRef="usd">213000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q3YTD" decimals="-3" id="Fact-7FD2FC05EFD81C7B195A0F27FA006B59" unitRef="usd">-634000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q3YTD" decimals="-3" id="Fact-2D7157B89361FA873C1D0F27FA0056DC" unitRef="usd">-370000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2014Q3" decimals="-5" id="Fact-FD096F5D49D6D6F2139E0F27FA1F4F63" unitRef="usd">21800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="FD2014Q3YTD" id="Fact-25C5973B541D7DA322430F27FA2F6295">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash, Cash Equivalents and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, all investments are classified as short-term and available-for-sale on the accompanying Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Investment income consists primarily of interest income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2007Q1March29" decimals="2" id="Fact-5CE0985ED8BA9B537DD01F404F21080A" unitRef="usdPerShare">12.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember" decimals="2" id="Fact-EEDFABBFC6BD52857BF40F27FA2F5E70" unitRef="usdPerShare">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember" decimals="2" id="Fact-9B210D7F163B855E18E80F27FA0FEA9A" unitRef="usdPerShare">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember" decimals="2" id="Fact-2B55E1BE58137B0AA2230F27FA1F9387" unitRef="usdPerShare">40.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember" decimals="2" id="Fact-BE5F58433242D78171610F27FA0F6F74" unitRef="usdPerShare">40.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember" decimals="2" id="Fact-01539A287A12436DE8AB0F27FA2F499E" unitRef="usdPerShare">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q3_dei_LegalEntityAxis_omer_OxfordMember" decimals="2" id="Fact-4970396911D7143F88C20F27F9F06372" unitRef="usdPerShare">9.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember" decimals="2" id="Fact-88026ADBC6807C8E6B770F27FA1F757A" unitRef="usdPerShare">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q3" decimals="2" id="Fact-6CB0321D731287141B710F27F9F0F7FF" unitRef="usdPerShare">12.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q3" decimals="INF" id="Fact-D93FDD1C108F201EE7810F27FA1FCD01" unitRef="shares">192789</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2007Q1March29" decimals="INF" id="Fact-7CECF610CA3BC8E657CA1F41B141864A" unitRef="shares">197478</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember" decimals="INF" id="Fact-40F4DA1C99F3DCA07E3C0F27FA2F99DD" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q3_dei_LegalEntityAxis_omer_OxfordMember" decimals="INF" id="Fact-FFD471E83683F47F33770F27FA1F617E" unitRef="shares">11539</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember" decimals="INF" id="Fact-2A7AB2FD6F9A5D36994F0F27F9F03E33" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember" decimals="INF" id="Fact-E468998857D3F2EF7FF40F27FA0F9521" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q3_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember" decimals="INF" id="Fact-8D5C15BE9F65833EEFA80F27FA1F51EE" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember" decimals="0" id="Fact-CB415430E8292128AB5B9B0E68C3604E" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember" decimals="0" id="Fact-1BFD871C759CE0202CBE9B0E68C3AA99" unitRef="shares">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q3" decimals="INF" id="Fact-9BB12C5937D14304102B0F27FA3EB9F4" unitRef="shares">604327</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="FI2013Q4" id="Fact-7B8FDAC891BEC18C2F5F0F27F9F022AF" unitRef="usd" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies contextRef="FI2014Q3" id="Fact-B163072C637237E74B3E0F27F9F057BC" unitRef="usd" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2014Q3YTD" id="Fact-20047DC22AE54DE18C4C0F27FA1F21A4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Real Estate Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We lease our office and laboratory space in The Omeros Building under a lease agreement with BMR-201 Elliott Avenue LLC (BMR). The initial term of the lease ends in November 2027 and we have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options to extend the lease term, each by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the remaining aggregate non-cancelable rent payable under the initial term of the lease is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$59.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The deferred rent balance relates to rent deferrals since the inception of our lease. Deferred rent is being amortized to research and development and selling, general and administrative expense on a straight-line basis through the term of the lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2014, we entered into an agreement with Ventiv Commercial Services, LLC (inVentiv) for field sales representatives and related sales operation services for the U.S. commercial launch of Omidria. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had a monthly fee of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which began in August 2014. We can terminate the agreement upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria, or upon 90 days written notice any time subsequent to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, we entered into an amendment to the agreement with inVentiv for additional sales representatives in the U.S. Under the terms of the amendment, our total monthly fee will increase to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$630,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon inVentiv providing additional sales representatives, which is expected in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and will continue through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have a non-exclusive agreement with Patheon Manufacturing Services LLC (Patheon) for commercial supply of Omidria through December 31, 2015. Pursuant to the terms of the contract, we are required to provide a monthly, non-binding production forecast covering the term of the contract. Upon submission of the monthly forecast, a portion of the forecast becomes a firm purchase commitment. In the event we do not purchase the quantities included in the firm purchase commitment, we would owe a cancellation fee. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had a firm purchase commitment requiring payment of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$519,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, we entered into a non-exclusive agreement with Hospira S.p.A and Hospira Worldwide, Inc. (together, &amp;#8220;Hospira&amp;#8221;) for commercial supply of Omidria. We have no firm purchase commitments under this agreement until, in connection with the commencement of commercial manufacturing of Omidria at Hospira, we provide monthly rolling forecasts that will be used to calculate our firm purchase commitment. We have not commenced commercial manufacturing of Omidria at Hospira and, therefore, do not currently have any firm purchase commitments under this agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Development Milestones and Product Royalties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have retained worldwide commercial rights to Omidria and all of our product candidates in our clinical and preclinical programs. We potentially owe certain development milestones and sales based royalties on commercial sales of certain product candidates within our pipeline. These are low-single-digit royalties based on net sales or net income as more fully described in our 2013 Annual Report on Form 10-K filed with the SEC on March 13, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the first quarter of 2014, we incurred a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Helion Biotech ApS (Helion) related to the filing of an Investigational New Drug Application (IND) with the FDA for our mannan-binding lectin-associated serine protease-2 (MASP-2) program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of 2013, we recorded $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;900,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as selling, general and administrative expense in connection with previously awarded NIH grants.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q3" decimals="INF" id="Fact-F9F2A94534B2255FC3690F27FA0FAF6A" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2013Q4" decimals="INF" id="Fact-85D781AA630524036D9C0F27FA00EE64" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="FI2013Q4" decimals="INF" id="Fact-7D7C27B802F6575F31380F27FA0FCE15" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q3" decimals="INF" id="Fact-B7A431AACDFD1B71D5800F27FA00C985" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="FI2014Q3" decimals="INF" id="Fact-D500B5FFB31B6ADCAAB60F27FA000BD1" unitRef="shares">34022145</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="FI2013Q4" decimals="INF" id="Fact-95BFE7B9CFF11EB5F5E60F27FA1F8780" unitRef="shares">30359508</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q3" decimals="INF" id="Fact-336470909F5D8CE91BC30F27FA2F69F9" unitRef="shares">34022145</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4" decimals="INF" id="Fact-7A7738C35FA832FC78B00F27FA0FF729" unitRef="shares">30359508</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="FI2014Q3" decimals="-3" id="Fact-D364E0900D803AA10B9C0F27FA1FC3C7" unitRef="usd">340000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="FI2013Q4" decimals="-3" id="Fact-C2E938C5436BB0D8CA550F27FA2FE777" unitRef="usd">304000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-6911D0DA7520AD53DE950F27FA0FCA2F" unitRef="usd">-52960000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q3QTD" decimals="-3" id="Fact-7D87CE04224D2A5B791B0F27FA1F5AFF" unitRef="usd">-13870000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q3YTD" decimals="-3" id="Fact-CD175E8FB11A883B17F00F27FA003218" unitRef="usd">-37951000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-FDA4EED81D282D8F40B00F27FA0FE2A7" unitRef="usd">-18327000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DebtDisclosureTextBlock contextRef="FD2014Q3YTD" id="Fact-BB400AC7FC54FA1EBC640F27FA00F888">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Notes Payable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2014, we entered into a new Loan and Security Agreement (the Oxford/MidCap Loan Agreement) with Oxford Finance LLC (Oxford) and MidCap Financial SBIC, LP (MidCap) pursuant to which we borrowed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We used approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the loan proceeds to repay all of the amounts owed by us under our then outstanding loan from Oxford and, after deducting all loan initiation costs including a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront loan initiation fee and lenders&amp;#8217; legal costs, we received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net proceeds. The Oxford/MidCap Loan Agreement provides for monthly interest-only payments at an annual rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;March&amp;#160;1, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April&amp;#160;1, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, monthly principal and interest payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are due through the maturity date of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, the Oxford/MidCap Loan Agreement requires a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; loan maturity fee upon full repayment of the loan. We may prepay the outstanding principal balance in its entirety at any time if we pay an additional fee equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the then-outstanding principal balance, which prepayment fee would be waived if we refinance the indebtedness with Oxford and MidCap and pay the loan maturity fee. As security under the Oxford/MidCap Loan Agreement, we granted Oxford, as collateral agent for the lenders, a security interest in substantially all of our assets, excluding intellectual property. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Oxford/MidCap Loan Agreement contains covenants that limit or restrict our ability to incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, pledge our intellectual property or repurchase stock. Additionally, the Oxford/MidCap Loan Agreement includes events of default regarding non-payment, inaccuracy of representations and warranties, covenant breach, occurrence of a material adverse effect (MAE, as defined below), cross default to material indebtedness, bankruptcy or insolvency, material judgment defaults and a change of control. The occurrence of an event of default could result in the acceleration of the Oxford/MidCap Loan Agreement and, under certain circumstances, could increase our interest rate by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum during the period of default.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;MAE is defined as a material adverse effect upon (i)&amp;#160;our business operations, properties, assets, results of operations or financial condition of Omeros, taken as a whole with respect to our viability, that reasonably would be expected to result in our inability to repay any portion of the loans in accordance with the terms of the Oxford/MidCap Loan Agreement, (ii)&amp;#160;the validity, perfection, value or priority of the lenders&amp;#8217; security interest in the collateral, (iii)&amp;#160;the enforceability of any material provision of the Oxford/MidCap Loan Agreement or related agreements, or (iv)&amp;#160;the ability of the lenders to enforce their rights and remedies under the Oxford/MidCap Loan Agreement or related agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We accounted for the Oxford/MidCap Loan Agreement as a debt modification and, accordingly, the remaining unamortized debt issuance costs of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;$103,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; associated with the then outstanding loan with Oxford and the debt issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$244,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; associated with the Oxford/MidCap Loan Agreement are being amortized to interest expense using the effective interest method through the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;March&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Oxford/MidCap Loan Agreement maturity date. Additionally, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; maturity fee, which is treated as a debt discount, is being amortized to interest expense using the effective-interest method through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the remaining unamortized discount and debt issuance costs associated with the debt were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$284,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="I2014Q1MidCap_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-5" id="Fact-F15EC6BD90A3DD2B32620F27F9E1E646" unitRef="usd">32000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="FD2014Q3YTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" id="Fact-3EE7F1B7A888B9E27F570F27FA008407">2015-04-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentFeeAmount contextRef="FI2014Q3_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-5" id="Fact-FA95AFDF18AE7C958AAF0F27FA3E2C14" unitRef="usd">2200000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2014Q3_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="INF" id="Fact-41C6B0A59E9DF945C2F80F27FA009F3C" unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="FD2014Q3YTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="INF" id="Fact-5CE85FE1E8E6B28C4F2C0F27FA0FC0C9" unitRef="usd">1021000</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2014Q3_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-3" id="Fact-B280FB82BCA6A5D647BF0F27FA0F2D69" unitRef="usd">1851000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtIssuanceCosts contextRef="FD2014Q1QTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="0" id="Fact-6FC0778CD58BBFA9EDEA0F27FA0F0311" unitRef="usd">244000</us-gaap:DebtIssuanceCosts>
  <us-gaap:DebtIssuanceCosts contextRef="D2014Q1OxfordLoan_us-gaap_DebtInstrumentAxis_omer_OxfordLoanAgreementMember" decimals="0" id="Fact-864BE3C2CA2D20EB86E50F27FA2F1586" unitRef="usd">103000</us-gaap:DebtIssuanceCosts>
  <us-gaap:DeferredFinanceCostsNet contextRef="FI2014Q3_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-3" id="Fact-BFEC334162C1D674A67D0F27FA008104" unitRef="usd">284000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="FI2014Q3" decimals="-3" id="Fact-D07629E0D53F509FF73A0F27FA00FF40" unitRef="usd">8935000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-59C7A8F51381DE4750EC0F27FA2F4627" unitRef="usd">8148000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenue contextRef="I2010Q4Oct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-5" id="Fact-B113BB8D7006C48D15030F27FA0F65B0" unitRef="usd">8200000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="FD2013Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-3" id="Fact-0AB0CE5F70E019BD179E0F27FA003516" unitRef="usd">970000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="FD2014Q3QTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-3" id="Fact-C602BC5F912F5D3A65C50F27FA3E5B4C" unitRef="usd">0</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-3" id="Fact-6669CB938DA4168FCEE70F27FA1F22AF" unitRef="usd">0</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="FD2013Q3QTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-3" id="Fact-A1971924F36D393F91CD0F27FA1FB0E1" unitRef="usd">0</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DepreciationAndAmortization contextRef="FD2013Q3YTD" decimals="-3" id="Fact-9744A5E2B81968B10E840F27FA0F192F" unitRef="usd">222000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="FD2014Q3YTD" decimals="-3" id="Fact-A58E187AA760AEB535B30F27FA3EE419" unitRef="usd">246000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2014Q3YTD" id="Fact-7B8307EAF434E7E016D50F27F9E16C3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our 2008 Equity Incentive Plan (the 2008 Plan) provides for the grant of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units and performance shares to employees, directors and consultants and subsidiary corporations&amp;#8217; employees and consultants. Options are granted with exercise prices equal to the closing fair market value of our common stock on the date of the grant. The terms of options may not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and options generally vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2014, in accordance with provisions of the 2008 Plan, the authorized shares available for grant under the 2008 Plan were increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,517,975&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,741,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were reserved for issuance under our stock plans, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,961,278&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were available for future grants under the 2008 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, in connection with our annual employee review process, we granted qualified employees options to purchase approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock with an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.58&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to stock option grants during the periods ended:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months&amp;#160;Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated weighted-average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-average assumptions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term, in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense has been reported in our Consolidated Statements of Operations and Comprehensive Loss as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;840&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock option activity for all stock plans and related information is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160; Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,969,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(159,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(214,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,779,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,577,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,755,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2,024,005&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unvested options outstanding that will vest over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. Excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with these options is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q3QTD" decimals="2" id="Fact-6CD041C89E456F426F380F27FA0FF3A8" unitRef="usdPerShare">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q3YTD" decimals="2" id="Fact-443852400C6D25F448DF0F27F9F0C9CB" unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q3YTD" decimals="2" id="Fact-14B78A0B68CC4EABEEED0F27FA2FD002" unitRef="usdPerShare">-1.61</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q3QTD" decimals="2" id="Fact-8AED9B7F6F44D26B552E0F27FA2F5539" unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="FD2014Q3YTD" id="Fact-8C457A52C468E79F86F50F27FA0FC376">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The basic and diluted net loss per share amounts for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,779,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,909,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;604,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;609,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,384,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,518,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-5282162F20C81B8BF93F0F27F9F0FCA5" unitRef="usd">1346000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-11F5DF8B6B1C3B7BBBCA0F27FA00CAEB" unitRef="usd">1403000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2014Q3" decimals="-5" id="Fact-11AF6BB4F1EA88F36C090F27FA00AC6B" unitRef="usd">11100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2014Q3YTD" id="Fact-99C60A2740620E180D0A0F27F9E128B5">P2Y0M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod3Q14MemberMember" decimals="0" id="Fact-6EC48114C5292C4FBBEF2007C399F24D" unitRef="usd">-411000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2014Q3YTD" decimals="0" id="Fact-6F73127D3EE42804E32C205A66030CD5" unitRef="usd">-863000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2014Q1QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod1Q14Member" decimals="0" id="Fact-A0EC0F663B8167E1D5A90F27FA0F1AA2" unitRef="usd">-452000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2014Q3YTD" id="Fact-B64C4A3F72EF8DB28FAA0F27FA1F4E08">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as non-current restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as non-current restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2013Q3YTD" decimals="INF" id="Fact-D2042AF9AE431DB621920F27FA2FB7A5" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2014Q3YTD" decimals="INF" id="Fact-F520FDECE210974BA02E0F27FA00C7AD" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2013Q3QTD" decimals="INF" id="Fact-9E12AABB22AFD4A44CD10F27FA0038F7" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2014Q3QTD" decimals="INF" id="Fact-5EACC3E7E5D7428525720F27FA004032" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="FD2014Q3YTD" id="Fact-B649EC22CF333212B9130F27FA3EC1F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair-Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1&amp;#8212;Observable inputs for identical assets or liabilities, such as quoted prices in active markets;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2&amp;#8212;Inputs other than quoted prices in active markets that are either directly or indirectly observable;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as non-current restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as non-current restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money-market funds classified as short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash held in demand deposit accounts of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is excluded from our fair-value hierarchy disclosure as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrealized gains and losses associated with our short-term investments as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The carrying amounts reported in the accompanying Consolidated Balance Sheets for grant and other receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="FD2013Q3YTD" decimals="-3" id="Fact-5E2B48CCA625D757DB7A0F27F9E1C9BA" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D7246C4AD56D2922017C0F27FA00FC5B" unitRef="usd">9000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-5ADC969209A58A96627C0F27FA1FB23B" unitRef="usd">14196000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-0580A6FAD2F4CFA94F5E0F27F9F09CDD" unitRef="usd">5574000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q3YTD" decimals="-3" id="Fact-D45496B546718B04F2620F27F9F05675" unitRef="usd">11934000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q3QTD" decimals="-3" id="Fact-CD61F02AE52ACE063AC00F27FA0F0B9D" unitRef="usd">4210000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-2AA5A106BC25DC3078EA0F27F9F0B009" unitRef="usd">3949000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-6E03FDB24A6015272AE10F27FA0F4ACF" unitRef="usd">453000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2014Q3YTD" decimals="-3" id="Fact-57301DEB0537CF2A1A0F0F27FA1FCA18" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2013Q3YTD" decimals="-3" id="Fact-466146FD38BB027DD6750F27FA1F376D" unitRef="usd">-970000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-CB60D51D1831DD4409CF0F27FA1F5AB2" unitRef="usd">787000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-F35CD8BEF735DE3FBB2B0F27FA1FC8E2" unitRef="usd">2987000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q3YTD" decimals="-3" id="Fact-E7DB24CF28796725EC190F27FA1F9506" unitRef="usd">842000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2013Q3YTD" decimals="-3" id="Fact-11EAE6C9370C85A0F4220F27FA1F22A3" unitRef="usd">-31000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F873FA6EA1A16DBC27F50F27FA1FF751" unitRef="usd">2000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="FD2013Q3YTD" decimals="-3" id="Fact-9AE8FAE4686BAE0BDD490F27FA000C1F" unitRef="usd">-1053000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:InterestExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-E02CA56FA8E1AE2F68CF0F27FA2F371C" unitRef="usd">944000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2013Q3YTD" decimals="-3" id="Fact-869A8107D985A6692DA20F27FA0F57D0" unitRef="usd">1768000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0BC249BD01031ED4D37B0F27FA0050F7" unitRef="usd">2555000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2013Q3QTD" decimals="-3" id="Fact-CC9C63BE29FBFCBCBD150F27FA1FAA89" unitRef="usd">592000</us-gaap:InterestExpense>
  <us-gaap:InterestPaid contextRef="FD2014Q3YTD" decimals="-3" id="Fact-6842D03F7837C2FDB72E0F27FA2F6CF0" unitRef="usd">1931000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="FD2013Q3YTD" decimals="-3" id="Fact-D5E3C03149B46F8C84300F27FA0F7E73" unitRef="usd">1243000</us-gaap:InterestPaid>
  <us-gaap:InventoryPolicyTextBlock contextRef="FD2014Q3YTD" id="Fact-02B58B3F154D843BC1820F27FA3E2DFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost or market. Capitalization of costs as inventory begins when the product has received regulatory approval in the U.S. or the EU. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. For Omidria, capitalization of costs as inventory began upon U.S. regulatory approval on May 30, 2014.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InvestmentIncomeNet contextRef="FD2013Q3QTD" decimals="-3" id="Fact-CB644CE8E1984A2BCA050F27F9F0CF71" unitRef="usd">2000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet contextRef="FD2013Q3YTD" decimals="-3" id="Fact-7A77270D3BE9B075E2390F27FA1F87C5" unitRef="usd">10000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-640390F86F5B659F47270F27FA0F820D" unitRef="usd">10000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-E9868CB27907FF64C13E0F27F9F0DC6C" unitRef="usd">3000</us-gaap:InvestmentIncomeNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-6F185849D4C1613FEB8C0F27FA00B644" unitRef="usd">16535000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q3" decimals="-3" id="Fact-2DCBCFAC809CA6C827F80F27FA00D9E3" unitRef="usd">25294000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-7671A3F47D95AA9A03B60F27F9F0AF5B" unitRef="usd">14397000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-4E42D81E757C47DE13F30F27FA00C1FE" unitRef="usd">11873000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiquidityDisclosureTextBlock contextRef="FD2014Q3YTD" id="Fact-BBDFB64AD1EFDA20D08E0F27F9F07228">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:174%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future sales from Omidria and capital that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <us-gaap:LongTermDebtCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-E3A60D012F5D8B8428F60F27FA2F6200" unitRef="usd">5600000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-66D2AD6E3005A25C2F190F27FA1F7C58" unitRef="usd">3991000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-C91E4A9D8C6D144B98B70F27FA0F1C53" unitRef="usd">14898000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="FI2014Q3" decimals="-3" id="Fact-6C8489C3722AAE5289160F27FA2FEA6D" unitRef="usd">28551000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NatureOfOperations contextRef="FD2014Q3YTD" id="Fact-C396B974E17B1A3A11BE0F27FA2F8D03">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Organization&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derived from our proprietary PharmacoSurgery platform, our first drug product Omidria&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#8482;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (phenylephrine and ketorolac injection) 1%/0.3% was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2014 for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. We began calling on ophthalmic surgeons and their staff in the U.S. in August 2014 regarding Omidria. In October 2014, we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria. Marketing and sales of Omidria in the European Union (EU) are subject to approval of our MAA and, most likely, entering into a partnership for European marketing and distribution. In addition to the EU, we plan to enter into one or more partnerships for the marketing and distribution of Omidria in other international territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-3C3B70915CCF766CEBCE0F27FA002C5B" unitRef="usd">50044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-53B85B1766062DADDAEF0F27FA00405F" unitRef="usd">16184000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-827B72FC45D0FD3734C70F27F9F0723E" unitRef="usd">12845000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-E4A842938BAE6D4E0E570F27FA3E75FA" unitRef="usd">-8325000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-CF3B195D5B652B43E6D80F27FA0055B6" unitRef="usd">-29399000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-143BE82169AD17AB4F6E0F27FA1FC0BE" unitRef="usd">-42353000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D26464286B2BA68EC36D0F27FA2F6557" unitRef="usd">-52960000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2013Q3YTD" decimals="-3" id="Fact-C9591D9A397DA852A1A10F27FA1F8C1C" unitRef="usd">-37951000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2013Q3QTD" decimals="-3" id="Fact-305AF4ED6A4814B38AF00F27FA2FE6C6" unitRef="usd">-13870000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-33EEB9189F48D36B1C590F27FA0F67AA" unitRef="usd">-18327000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2014Q3YTD" id="Fact-63000F313CB4BF8035660F27FA1F42BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update, or ASU, No. 2014-15 related to disclosure of an entity&amp;#8217;s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity&amp;#8217;s ability to continue as a going concern at each reporting period for a period of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December&amp;#160;15, 2016. We do not expect the adoption of this guidance to have any impact on our financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented, or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. This standard is effective for interim and annual periods beginning after December 15, 2016 and cannot be adopted before that effective date. We are currently evaluating the impact this standard may have on our financial statements once it is adopted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="FD2014Q3YTD" decimals="INF" id="Fact-7EE2781B55A67C2BABF40F27FA1FEF87" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingExpenses contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8FF3159E93066BDE24C20F27FA2FAB26" unitRef="usd">50392000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="FD2013Q3YTD" decimals="-3" id="Fact-3CFD04B2D3D02DEDE0430F27FA2FAFFB" unitRef="usd">38045000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="FD2013Q3QTD" decimals="-3" id="Fact-43564E3219DC219E7B020F27FA2FFC0C" unitRef="usd">13630000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="FD2014Q3QTD" decimals="-3" id="Fact-417EE96D8A95E904D9A30F27FA1F74FE" unitRef="usd">17346000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="FD2013Q3QTD" decimals="-3" id="Fact-8C1ECD88D8E78543B10C0F27FA2F7B14" unitRef="usd">-13434000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2013Q3YTD" decimals="-3" id="Fact-D3846D3C26D3BE89C9440F27FA2F2E03" unitRef="usd">-36614000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-9BA3DBC42BEA195C8B5C0F27FA00CD15" unitRef="usd">-17132000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-4DC7384406B12B0314E10F27FA2FB972" unitRef="usd">-50033000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2014Q3" decimals="-5" id="Fact-1187B2CF178AB30674760F27FA0F24E2" unitRef="usd">59400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="FD2014Q3YTD" id="Fact-57CBE2C91A674DE139040F27FA000C09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Organization&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derived from our proprietary PharmacoSurgery platform, our first drug product Omidria&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#8482;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (phenylephrine and ketorolac injection) 1%/0.3% was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2014 for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. We began calling on ophthalmic surgeons and their staff in the U.S. in August 2014 regarding Omidria. In October 2014, we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria. Marketing and sales of Omidria in the European Union (EU) are subject to approval of our MAA and, most likely, entering into a partnership for European marketing and distribution. In addition to the EU, we plan to enter into one or more partnerships for the marketing and distribution of Omidria in other international territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; For Omidria and each of our product candidates and our programs, we have retained all manufacturing, marketing and distribution rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries.  All inter-company transactions between and among our subsidiaries have been eliminated.  The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information.  The Consolidated Balance Sheet at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been derived from audited financial statements but does not include all of the information and footnotes required by GAAP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; filed with the Securities and Exchange Commission (SEC) on March 13, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future sales from Omidria and capital that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost or market. Capitalization of costs as inventory begins when the product has received regulatory approval in the U.S. or the EU. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. For Omidria, capitalization of costs as inventory began upon U.S. regulatory approval on May 30, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update, or ASU, No. 2014-15 related to disclosure of an entity&amp;#8217;s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity&amp;#8217;s ability to continue as a going concern at each reporting period for a period of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December&amp;#160;15, 2016. We do not expect the adoption of this guidance to have any impact on our financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented, or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. This standard is effective for interim and annual periods beginning after December 15, 2016 and cannot be adopted before that effective date. We are currently evaluating the impact this standard may have on our financial statements once it is adopted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-0C69CF8407297369B6990F27FA1F968C" unitRef="usd">495000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-82CBB4B8AEADDA56F7FC0F27F9F0DC1E" unitRef="usd">616000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-E0C2CC274DC1BDA62C380F27FA0F53D9" unitRef="usd">148000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-55AA6B530306B73E6C650F27FA1F0FE4" unitRef="usd">86000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="FI2014Q3" decimals="-3" id="Fact-992FE16EF764AB7F8F360F27F9F09D07" unitRef="usd">408000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-BE0CB978DD0F07389F170F27FA0F81FF" unitRef="usd">100000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-BE556E68EFBDDAEE788C0F27FA2F824E" unitRef="usd">-254000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q3YTD" decimals="-3" id="Fact-9CC2F1CD4B376D7139970F27FA1F31EB" unitRef="usd">421000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-B78351CD7876F6AB27120F27FA2FAECD" unitRef="usd">-382000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q3QTD" decimals="-3" id="Fact-24FCCBA62F1FDEAB600B0F27FA0F57E7" unitRef="usd">154000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaidInKindInterest contextRef="FD2014Q3YTD" decimals="-3" id="Fact-928724A9FE0B9A562A510F27FA1FA56A" unitRef="usd">532000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest contextRef="FD2013Q3YTD" decimals="-3" id="Fact-C112019CC9F8557ECCE80F27FA1FEE9A" unitRef="usd">371000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsOfDebtRestructuringCosts contextRef="FD2014Q1QTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-3" id="Fact-D47AE924C635DF1A2F470F27F9F041CF" unitRef="usd">160000</us-gaap:PaymentsOfDebtRestructuringCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2014Q3YTD" decimals="-5" id="Fact-86A7386C0927AC2304A30F27F9F0AAF6" unitRef="usd">2500000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-B0F97F9525C6A7EED3AF0F27FA1F42AD" unitRef="usd">58847000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-A9639CB82FCC78095E7E0F27FA3E54D6" unitRef="usd">22963000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0FD12CBD393C29D379330F27FA2F11CF" unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2013Q3YTD" decimals="-3" id="Fact-833BC02C1D31556FB0C20F27FA1FCB53" unitRef="usd">137000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q3" decimals="INF" id="Fact-BD81CD062A3824310F240F27FA2F6A80" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2013Q4" decimals="INF" id="Fact-2E4D74A016256302D4F20F27F9F094E7" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="FI2014Q3" decimals="INF" id="Fact-12AD11A90DB3A43521BF0F27F9F02625" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="FI2013Q4" decimals="INF" id="Fact-379630E40C5D364087F50F27F9F01DEE" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="FI2013Q4" decimals="INF" id="Fact-2360947471ED292E43ED0F27FA00E5FD" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="FI2014Q3" decimals="INF" id="Fact-D430C45F1811E5481A190F27FA009F3C" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="FI2014Q3" decimals="INF" id="Fact-6AF683B14552C353706D0F27FA0FA8EC" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="FI2013Q4" decimals="INF" id="Fact-1CFC58C611241AD73C7C0F27FA1F8B17" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="FI2014Q3" id="Fact-68E5C34C535F5F1990010F27FA0F9665" unitRef="usd" xsi:nil="true" />
  <us-gaap:PreferredStockValue contextRef="FI2013Q4" id="Fact-1AC2EC4603DEC7314E430F27FA1F1354" unitRef="usd" xsi:nil="true" />
  <us-gaap:PrepaidExpenseCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-59FF7BE875F5795133430F27FA00B35D" unitRef="usd">1052000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-31149530C20EF5096AF90F27F9E18C87" unitRef="usd">251000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:ProceedsFromGrantors contextRef="D2010Q4Oct01toOct31_dei_LegalEntityAxis_omer_VulcanIncorporatedMember" decimals="-5" id="Fact-271A1F6E8C93C7FA52650F27FA0F9EAD" unitRef="usd">20000000</us-gaap:ProceedsFromGrantors>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q3YTD" decimals="-3" id="Fact-69331FE3DB67F77AF5D30F27FA1F8F9E" unitRef="usd">37754000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2013Q3YTD" decimals="-3" id="Fact-8FEBD5BC115BEFC705010F27FA2F3452" unitRef="usd">16120000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2014Q3YTD" decimals="-3" id="Fact-FF649FE76C84DFA3C1BE0F27FA0F56BD" unitRef="usd">12699000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2013Q3YTD" decimals="-3" id="Fact-5F1566E5DAB8C2A012B80F27FA0F4425" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2014Q1QTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-3" id="Fact-2FD3B22E04D4B17649C60F27F9E1E3B5" unitRef="usd">12699000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2013Q3YTD" decimals="-3" id="Fact-C2A51D7982CBB0A882C70F27FA1F7465" unitRef="usd">35945000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-9CA6956400295E3CB7770F27FA2FF772" unitRef="usd">50534000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2013Q3YTD" decimals="-3" id="Fact-62B40CCD2F90A5540E060F27FA3E5321" unitRef="usd">64000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="FD2014Q3QTD" decimals="0" id="Fact-142DB2CD32A359330BE1536BE0262BE0" unitRef="usd">37828</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2013Q4" decimals="-3" id="Fact-C916BB7D3944B8D4E8230F27FA0FA8C7" unitRef="usd">939000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q3" decimals="-3" id="Fact-8B0CB514658F986C13FE0F27FA00D096" unitRef="usd">846000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="FI2014Q3" decimals="-3" id="Fact-9177818EE41BF521ABD40F27F9F01551" unitRef="usd">381000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-13207CAFD2CE16448D7A0F27F9F08C85" unitRef="usd">379000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear contextRef="FI2014Q3_dei_LegalEntityAxis_omer_InVentivMember" decimals="-3" id="Fact-E99CA738CC510C0E74DE0F27FA00A0CB" unitRef="usd">300000</us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear>
  <us-gaap:RepaymentsOfDebt contextRef="FD2014Q1QTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="-5" id="Fact-1808EFA9F9EAF3B6B9FF0F27FA2FA26E" unitRef="usd">19100000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfNotesPayable contextRef="FD2014Q3YTD" decimals="-3" id="Fact-C660ECDACE69DFAADA560F27FA0F7D73" unitRef="usd">1464000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable contextRef="FD2013Q3YTD" decimals="-3" id="Fact-98D62E70FE2E350BEA900F27F9F0951B" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-303892F4725162BEAF060F27FA2FA423" unitRef="usd">11772000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-50FF5C33692CF0CF6DE60F27FA1F214F" unitRef="usd">36196000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q3YTD" decimals="-3" id="Fact-84EBDDFA253237C61F860F27F9F0BBB3" unitRef="usd">26111000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q3QTD" decimals="-3" id="Fact-FCFA3D0945D5788FCADD0F27FA1F631A" unitRef="usd">9420000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_HelionBiotechApSMember" decimals="0" id="Fact-F264FF276C7C8017AF170F27F9F066E4" unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2014Q3" decimals="-3" id="Fact-CCD9E4B2827A962E1B470F27FA0F866D" unitRef="usd">679000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-7D39D4C262CDC186D0500F27FA2F32ED" unitRef="usd">679000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2013Q4" decimals="-3" id="Fact-9CC11368761E42C366750F27FA1FD50F" unitRef="usd">-254373000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q3" decimals="-3" id="Fact-4B265CDD462F543162D10F27FA1F66DD" unitRef="usd">-307333000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromGrants contextRef="FD2014Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-E9C4CF37A9A93FBCD0D40F27FA2F5021" unitRef="usd">214000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="FD2013Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-007FEFB0681E6AA937E20F27FA0087D8" unitRef="usd">196000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="FD2013Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-619599389E7FB5F249770F27FA0F2633" unitRef="usd">461000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-EE5D6F4C6C5AF21035940F27F9E12FE3" unitRef="usd">359000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueRecognitionMultipleElementArrangements contextRef="FD2014Q3YTD" id="Fact-7D323E6B9B33721621DB0F27FA0F573A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from grants and other sources is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:4pt;"&gt;&lt;font style="font-family:inherit;font-size:4pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Small Business Innovative Research Grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vulcan Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionMultipleElementArrangements>
  <us-gaap:Revenues contextRef="FD2013Q3QTD" decimals="-3" id="Fact-C02362D09B6AE62065EB0F27F9E14F10" unitRef="usd">196000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="FD2014Q3YTD" decimals="-3" id="Fact-9FB74B6EE14FF17190B90F27FA3E6EA0" unitRef="usd">359000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="FD2013Q3YTD" decimals="-3" id="Fact-5BB0A4BE5030F55CA0310F27FA0F88F1" unitRef="usd">1431000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="FD2014Q3QTD" decimals="-3" id="Fact-B20C7A4703A175FE585C0F27FA1F016B" unitRef="usd">214000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="FD2013Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-2BBC333284809CBB0FE40F792BEAF596" unitRef="usd">461000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-BD6B1DE749AA6ED8214C9B1C31FE74E1" unitRef="usd">359000</us-gaap:Revenues>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2014Q3YTD" id="Fact-D0B4BAE5892A1B0CFBD90F27FA1FBA94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract research&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consulting &amp;amp; professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;616&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2014Q3YTD" id="Fact-6CA8D26E8875704FF01E0F27FA0F62FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,779,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,909,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;604,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;609,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,384,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,518,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2014Q3YTD" id="Fact-5A98C3909D72FFC79C1A0F27F9F0EBD9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense has been reported in our Consolidated Statements of Operations and Comprehensive Loss as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;840&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="FD2014Q3YTD" id="Fact-08016F9FB41DE50508050F27FA1F057E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock option activity for all stock plans and related information is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160; Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,969,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(159,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(214,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,779,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,577,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,755,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2014Q3YTD" id="Fact-4A08CA537DE5849114C4768DC4764C03">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to stock option grants during the periods ended:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months&amp;#160;Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated weighted-average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-average assumptions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term, in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2014Q3YTD" id="Fact-0EA7E7074A9DD5D11F1C0F27FA0F4F2B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our total outstanding warrants as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which have a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.94&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="30%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding At&lt;br clear="none"/&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;29, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,539&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April&amp;#160;26, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;604,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2014Q3YTD" id="Fact-EBDB0B5B02C915BBA3390F27FA2F36AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="FD2014Q3YTD" decimals="-3" id="Fact-66AE7D882A373F5FD4AA0F27F9F01104" unitRef="usd">5083000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="FD2013Q3YTD" decimals="-3" id="Fact-7F98FB31A70C5671A1AA0F27FA1F315F" unitRef="usd">4364000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="FD2014Q3QTD" decimals="-3" id="Fact-DD228B68040B5ACA93470F27FA0F35F4" unitRef="usd">1665000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="FD2013Q3QTD" decimals="-3" id="Fact-C849C3471F69471FC81D0F27FA1FE15F" unitRef="usd">2211000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember" id="Fact-05F9DBA8F4280EEB3AAD0F27FA1F1F84">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q3YTD" decimals="2" id="Fact-CCE887121BA0BC5C63ED0F27FA0043C2" unitRef="number">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q3QTD" decimals="2" id="Fact-068B7BA8C1CD8134A1EE0F27FA009D12" unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2013Q3QTD" decimals="2" id="Fact-036764E1786BCA1C487F0F27F9E11A92" unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2013Q3YTD" decimals="2" id="Fact-E903BC338D80AC4A46170F27F9F090E7" unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q3YTD" decimals="4" id="Fact-0DE55DA39DF1DA8018B70F27FA0083CB" unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2013Q3QTD" decimals="4" id="Fact-4056E978964C5FAB50160F27FA2F67ED" unitRef="number">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2013Q3YTD" decimals="4" id="Fact-542D9CDFBE99AB8EA2660F27F9F0EDE4" unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q3QTD" decimals="4" id="Fact-89D71A2330C073A1A9C60F27FA00CAA0" unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2014Q3_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember" decimals="INF" id="Fact-61231F2FF4609952643F0F27FA00DA9C" unitRef="shares">8741276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2014Q3_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember" decimals="INF" id="Fact-614D29B48073AC65C81F0F27F9F0FF5C" unitRef="shares">1961278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2014Q3" decimals="INF" id="Fact-5928B25B82A03DC568200F27F9F0EA22" unitRef="shares">4755993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2014Q3" decimals="2" id="Fact-D774761BA9B4AE6593890F27F9E1F348" unitRef="usdPerShare">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2014Q3YTD" decimals="INF" id="Fact-556702245756E62607270F27F9F00CF8" unitRef="shares">214223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q3YTD" decimals="2" id="Fact-210F93DD24006A548BB70F27FA00BB43" unitRef="usdPerShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2014Q3YTD" decimals="INF" id="Fact-FD7A15D98FE64EC7E7AE0F27FA0085BE" unitRef="shares">184250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="D2014Q4Oct01-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-14A78E5C475EBE0CB21786A79B0050BB" unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q3YTD" decimals="2" id="Fact-F850CAAA12FF1B8461EA0F27FA2F66F8" unitRef="usdPerShare">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q3QTD" decimals="2" id="Fact-966FAF30317E96E2B0530F27F9F05AA7" unitRef="usdPerShare">10.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q3YTD" decimals="2" id="Fact-572AAFA2C4BE1064E1770F27FA007130" unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q3QTD" decimals="2" id="Fact-89E0CCF54BB201D532B80F27F9E176B5" unitRef="usdPerShare">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q3" decimals="-3" id="Fact-732AAA60D14D12DDA9400F27FA2F2B16" unitRef="usd">42797000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q3" decimals="INF" id="Fact-3422BE8F23FD1CBF6A1C0F27F9F05822" unitRef="shares">6779998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4" decimals="INF" id="Fact-5742ADE0B5892A05AEC60F27FA008190" unitRef="shares">6969303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q3" decimals="2" id="Fact-6A0B330E371F6408C10F0F27FA0FC59B" unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4" decimals="2" id="Fact-ACB2A38BEADD2419C3490F27FA2FE8BD" unitRef="usdPerShare">6.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2014Q3" decimals="-3" id="Fact-CF40EE4C6ADB70CFC3930F27F9F0C348" unitRef="usd">42141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2014Q3" decimals="INF" id="Fact-2D3A22DDE7CEDB24C79E0F27FA2FD5A9" unitRef="shares">6577603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2014Q3" decimals="2" id="Fact-524062F5C4B34D6565700F27F9F0BCC9" unitRef="usdPerShare">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q3YTD" decimals="2" id="Fact-F4072066AD49DAF352C70F27F9E112DD" unitRef="usdPerShare">6.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q3YTD" decimals="2" id="Fact-4887A282D386D45E69AD0F27FA1F522A" unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2014Q4Oct01-31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-7560B3790C15C1F6142B86A7CF2F3A4E" unitRef="usdPerShare">11.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="FI2014Q3" decimals="2" id="Fact-951933CC2D72D3B2C3EB0F27FA2F3999" unitRef="usdPerShare">11.50</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q3QTD" id="Fact-E09B0B8130837A53464C0F27F9F0325A">P6Y0M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2013Q3YTD" id="Fact-96AB304E585F91D574260F27FA1F6FDC">P5Y9M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2013Q3QTD" id="Fact-B8173118AD691CE50CD70F27FA2F9D6B">P5Y9M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q3YTD" id="Fact-C9E5B5A081DCED482D820F27FA0FAF09">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-5B5659125672B1095AFD0F27FA2FAFEB">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2014Q3" decimals="-3" id="Fact-07958A7F563D307DB5C70F27FA2F6D0B" unitRef="usd">36147000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2014Q3YTD" id="Fact-C451502757C3BB1F80840F27FA1FBCF0">P5Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2014Q3YTD" id="Fact-479E897A19C7C148832E0F27FA0FA97A">P6Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2014Q3YTD" id="Fact-88BCC27294E04C5AF1480F27FA2F8C69">P6Y4M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q3YTD" decimals="-5" id="Fact-37C3E0A6E28B938BB1CE0F27FA1F9AAA" unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="D2014Q3Sep01-30_us-gaap_ClassOfWarrantOrRightAxis_omer_SharesfromcashexerciseofwarrantsMember" decimals="0" id="Fact-7485FC3F8AEE13FBE99261A3F71259C0" unitRef="shares">3088</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="D2014Q3Sep01-30" decimals="0" id="Fact-452E368ABF46623AACC4205BD43D2248" unitRef="shares">3305</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q3YTD" decimals="INF" id="Fact-66DC51C1E50929EEBB6F0F27FA2FA574" unitRef="shares">159332</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-2C43CDD748218E81D9250F27FA0F9098" unitRef="usd">-18384000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="FI2014Q3" decimals="-3" id="Fact-996E443381A0F9DBF3AB0F27FA003E71" unitRef="usd">-26589000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2014Q3YTD" id="Fact-A67B409479CD87F70FDF0F27FA3E68E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shareholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Public Offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - In March 2014, we sold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock at a public offering price of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$11.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. After deducting offering expenses and underwriter discounts of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we received net proceeds from the transaction of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$37.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our total outstanding warrants as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which have a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.94&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="30%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding At&lt;br clear="none"/&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;29, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October&amp;#160;21, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,539&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April&amp;#160;26, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;604,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 28, 2014, we extended to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;29, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the expiration dates of warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,478&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share that had been due to expire on March 29, 2014. We evaluated the fair value of the warrants before and after the modifications and recorded the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$452,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During September 2014, warrants associated with a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,689&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were exercised by the warrant holders resulting in the issuance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,305&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. Of that amount, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,088&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were issued upon cash exercise of warrants, pursuant to which we received proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37,828&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the remainder were issued pursuant to cashless net exercise provisions in the warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 28, 2014, we extended to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;29, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the expiration date of the remaining warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,789&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock that had been due to expire on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;29, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We evaluated the fair value of the warrants before and after the modifications and recorded the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$411,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Considering the extensions on March 28 and September 28, 2014, the total other expense recorded in the Consolidated Statement of Operations and Comprehensive Loss for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$863,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2010, in connection with the Vulcan agreement, we issued to Vulcan &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants to purchase our common stock, each exercisable for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, with exercise prices of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2014Q3YTD" id="Fact-F0E3CE14CC10E0F6D5950F27FA0FCDB0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accrued Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract research&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consulting &amp;amp; professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;616&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2014Q3YTD" decimals="INF" id="Fact-F07980A04D1967688CC20F27FA1FBC8E" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2013Q4YTD" decimals="INF" id="Fact-0346CFC7F6DB6456190B0F27FA2FD9C4" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="FI2014Q3_dei_LegalEntityAxis_omer_DSMMember" decimals="0" id="Fact-478ED399A4D89F904AC861A1DD6B487F" unitRef="usd">519000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
  <us-gaap:UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents contextRef="FI2014Q3_dei_LegalEntityAxis_omer_InVentivMember" decimals="0" id="Fact-D5EAB568CD75775A2BB352E6C11ADFA5" unitRef="usd">630000</us-gaap:UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents>
  <us-gaap:UseOfEstimates contextRef="FD2014Q3YTD" id="Fact-131B67ACBEB56FFBE8E20F27FA3ED39B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q3YTD" decimals="0" id="Fact-E01AF44A55C6940248390F27FA1FA683" unitRef="shares">27984133</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q3YTD" decimals="0" id="Fact-C4FC86EB7F1DC1EEBCA30F27FA0F77B3" unitRef="shares">32945346</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q3QTD" decimals="0" id="Fact-30609474B2E137B0B9FC0F27FA005FF6" unitRef="shares">29844507</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q3QTD" decimals="0" id="Fact-C0A3652FCAC9A8B2CF6D0F27F9F03697" unitRef="shares">34005642</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <omer:AccruedClinicalTrialCosts contextRef="FI2013Q4" decimals="-3" id="Fact-721FB6FBA6DE44A9415A0F27FA1F9A97" unitRef="usd">596000</omer:AccruedClinicalTrialCosts>
  <omer:AccruedClinicalTrialCosts contextRef="FI2014Q3" decimals="-3" id="Fact-AB9671F0C85E3DA688B00F27FA0FB6BD" unitRef="usd">949000</omer:AccruedClinicalTrialCosts>
  <omer:AccruedContractResearchCosts contextRef="FI2014Q3" decimals="-3" id="Fact-E142CDB4E28334D713980F27FA00910A" unitRef="usd">1746000</omer:AccruedContractResearchCosts>
  <omer:AccruedContractResearchCosts contextRef="FI2013Q4" decimals="-3" id="Fact-2F507F80454FDD8A3FEA0F27FA003752" unitRef="usd">858000</omer:AccruedContractResearchCosts>
  <omer:AdditionalDefaultInterestRate contextRef="FD2014Q3YTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="INF" id="Fact-92A2E1F0B6703D0BB3990F27FA0F4180" unitRef="number">0.05</omer:AdditionalDefaultInterestRate>
  <omer:ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice contextRef="FI2014Q3" decimals="2" id="Fact-B6B45F3A8D39B49CBAB90F27FA2FD2B2" unitRef="iso4217_USD_per_Right">23.94</omer:ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice>
  <omer:ClassofWarrantorRightExercisedDuringPeriod contextRef="D2014Q3Sep01-30" decimals="INF" id="Fact-FB63202E90714813F63C205BA3BC0AB6" unitRef="shares">4689</omer:ClassofWarrantorRightExercisedDuringPeriod>
  <omer:ClassofWarrantorRightNumberofWarrantsIssued contextRef="D2010Q4Oct01toOct31" decimals="0" id="Fact-AC278DF0D36945B1C24F0F27FA0F7566" unitRef="warrant">3</omer:ClassofWarrantorRightNumberofWarrantsIssued>
  <omer:DebtPrepaymentPenaltyRate contextRef="FD2014Q3YTD_us-gaap_DebtInstrumentAxis_omer_OxfordMidcapLoanMember" decimals="INF" id="Fact-2F2F7C71AFDAA3D8ABD10F27FA2FC958" unitRef="number">0.01</omer:DebtPrepaymentPenaltyRate>
  <omer:GovernmentGrantsUnderReview contextRef="FD2013Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="0" id="Fact-829E72F78277CD9A8ACB0F27FA1F7E4C" unitRef="usd">900000</omer:GovernmentGrantsUnderReview>
  <omer:LeaseExtensionPeriod contextRef="FD2014Q3YTD" id="Fact-4B42993FA4E531B8BD0B0F27FA0F0EB6">P5Y</omer:LeaseExtensionPeriod>
  <omer:OperatingLeaseNumberOfAdditionalRenewalOption contextRef="FD2014Q3YTD" decimals="INF" id="Fact-FF9DF70FD918F29628D40F27FA0FEC1F" unitRef="Leases">2</omer:OperatingLeaseNumberOfAdditionalRenewalOption>
  <omer:ProceedsfromStockOptionsandWarrantsExercised contextRef="FD2014Q3YTD" decimals="-3" id="Fact-5A42ECDB00488164532D0F27FA2F2412" unitRef="usd">1055000</omer:ProceedsfromStockOptionsandWarrantsExercised>
  <omer:Reductionofequipmentcostbasispurchasedwithgrantfunding contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-799BE2DF3BEAF01953D152D9EAFDF0F9" unitRef="usd">40000</omer:Reductionofequipmentcostbasispurchasedwithgrantfunding>
  <omer:Reductionofequipmentcostbasispurchasedwithgrantfunding contextRef="FD2013Q3YTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-E9A97F810F2C4D2BD35652DA87799F45" unitRef="usd">0</omer:Reductionofequipmentcostbasispurchasedwithgrantfunding>
  <omer:Reductionofequipmentcostbasispurchasedwithgrantfunding contextRef="FD2014Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="0" id="Fact-4D66156588F30FE46F78536633EE880B" unitRef="usd">40000</omer:Reductionofequipmentcostbasispurchasedwithgrantfunding>
  <omer:Reductionofequipmentcostbasispurchasedwithgrantfunding contextRef="FD2013Q3QTD_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="0" id="Fact-3904894F358AB3855C81536660C75EB6" unitRef="usd">0</omer:Reductionofequipmentcostbasispurchasedwithgrantfunding>
  <omer:RemainingGrantFunding contextRef="FI2014Q3_dei_LegalEntityAxis_omer_SmallBusinessInnovativeResearchMember" decimals="-3" id="Fact-98EF9619343F9D38BA640F27FA1FA604" unitRef="usd">785000</omer:RemainingGrantFunding>
  <omer:RestrictedCashFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-ABCCEEE5D4DC8E4E93720F27FA0F9E9E" unitRef="usd">679000</omer:RestrictedCashFairValueDisclosure>
  <omer:RestrictedCashFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-19C747779D1124E647DB0F27FA00A0C9" unitRef="usd">679000</omer:RestrictedCashFairValueDisclosure>
  <omer:RestrictedCashFairValueDisclosure contextRef="FI2014Q3_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9F28FFF03AADE1EFA4D80F27FA001E8F" unitRef="usd">679000</omer:RestrictedCashFairValueDisclosure>
  <omer:RestrictedCashFairValueDisclosure contextRef="FI2014Q3_us-gaap_FairValueByAssetClassAxis_omer_NonCurrentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C2CE859BBC9D2C815AC80F27FA2F6721" unitRef="usd">679000</omer:RestrictedCashFairValueDisclosure>
  <omer:RevenueRecognitionTextBlock contextRef="FD2014Q3YTD" id="Fact-BACA8F4F8922CB4F3B200F27FA0F95FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from grants and other sources is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:4pt;"&gt;&lt;font style="font-family:inherit;font-size:4pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Small Business Innovative Research Grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vulcan Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have periodically received Small Business Innovative Research (SBIR) grants from the National Institutes of Health (NIH), which are used to support the research and development of our product candidates. We recorded revenue related to these grants of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$214,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$196,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three months ended September 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$359,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$461,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. We recorded cost reductions to property and equipment due to assets being purchased with grant funding of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$785,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of potential revenue remained available under these grants, if qualifying research is performed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2010, we entered into a platform development funding agreement with Vulcan Inc. and its affiliate (collectively, Vulcan) pursuant to which we received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for our G protein-coupled receptor (GPCR) program. Of the funds received, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded as deferred revenue. The remaining deferred revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$970,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recognized as revenue during the first quarter of 2013.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</omer:RevenueRecognitionTextBlock>
  <omer:ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized contextRef="D2014Q1Jan01toJan31_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_omer_EquityIncentivePlanTwentyZeroEightMember" decimals="INF" id="Fact-DBD29976AFDF7B8C98FC0F27F9E107B2" unitRef="shares">1517975</omer:ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized>
  <omer:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber contextRef="FI2014Q3" decimals="INF" id="Fact-746DB4F58EC2F456B98C0F27FA2FCFCE" unitRef="shares">2024005</omer:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber>
  <omer:WarrantExpirationDate contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod3Q14MemberMember" id="Fact-93451CCBA92EEE3C3A290F27FA0FCC53">2015-03-29</omer:WarrantExpirationDate>
  <omer:WarrantExpirationDate contextRef="FD2014Q1QTD_us-gaap_ClassOfWarrantOrRightAxis_omer_SeriesEMod1Q14Member" id="Fact-B0152DD998AABC19E0C10F8B3ACF07F5">2014-09-29</omer:WarrantExpirationDate>
  <omer:WarrantExpirationDate contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantOneMember" id="Fact-98521668111502F5F8FB0F27FA000C83">2015-10-21</omer:WarrantExpirationDate>
  <omer:WarrantExpirationDate contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantTwoMember" id="Fact-11B63C04DFCCC59D063C0F27FA0F3826">2015-10-21</omer:WarrantExpirationDate>
  <omer:WarrantExpirationDate contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_VulcanIncorporatedMember_us-gaap_ClassOfWarrantOrRightAxis_omer_WarrantThreeMember" id="Fact-9E625A318C5C8253A6270F27FA2F2E2D">2015-10-21</omer:WarrantExpirationDate>
  <omer:WarrantExpirationDate contextRef="FD2014Q3YTD_dei_LegalEntityAxis_omer_OxfordMember" id="Fact-B54A14874CF00A2E50730F27FA0F04B7">2015-04-26</omer:WarrantExpirationDate>
  <dei:AmendmentFlag contextRef="FD2014Q3YTD" id="Fact-ACC79A502CA00529A1700F27FA0F5A82">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="FD2014Q3YTD" id="Fact-B16A64F90BCD8366EE860F27FA2FA02A">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="FD2014Q3YTD" id="Fact-77A84E59A5B227FB123E0F27FA0F7DC7">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="FD2014Q3YTD" id="Fact-2DF8494A9A078E8EF1830F27F9F04570">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="FD2014Q3YTD" id="Fact-30ACC759C46FC8A6D6130F27FA2F1D89">2014-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="FD2014Q3YTD" id="Fact-1DF558C323FD8C070A880F27FA2F415B">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="FD2014Q3YTD" id="Fact-D84FBADC4AE6495CD39C0F27FA0F7346">0001285819</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="I2014Q3SharesOutstanding" decimals="INF" id="Fact-A661879685D8D360F79D0F27FA0FBEBC" unitRef="shares">34075924</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="FD2014Q3YTD" id="Fact-F273CB040CBFA2674FE30F27F9F0A779">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="FD2014Q3YTD" id="Fact-091B4D7C916BC51050EF0F27FA1FBFCF">OMEROS CORP</dei:EntityRegistrantName>
  <dei:TradingSymbol contextRef="FD2014Q3YTD" id="Fact-ED34415867C4823D62480F27FA1FF3A6">OMER</dei:TradingSymbol>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>omer-20140930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.omeros.com/20140930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:omer="http://www.omeros.com/20140930" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="omer-20140930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="omer-20140930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="omer-20140930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="omer-20140930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedLiabilities" roleURI="http://www.omeros.com/role/AccruedLiabilities">
        <link:definition>2108100 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesAccruedLiabilitiesDetail" roleURI="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail">
        <link:definition>2408402 - Disclosure - Accrued Liabilities - Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.omeros.com/role/AccruedLiabilitiesTables">
        <link:definition>2308301 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsAndInvestments" roleURI="http://www.omeros.com/role/CashCashEquivalentsAndInvestments">
        <link:definition>2104100 - Disclosure - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.omeros.com/role/CommitmentsAndContingencies">
        <link:definition>2112100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetail" roleURI="http://www.omeros.com/role/CommitmentsAndContingenciesDetail">
        <link:definition>2412401 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.omeros.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.omeros.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair-Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>2406402 - Disclosure - Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetail" roleURI="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail">
        <link:definition>2406403 - Disclosure - Fair-Value Measurements - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.omeros.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair-Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.omeros.com/role/NetLossPerShare">
        <link:definition>2102100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" roleURI="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail">
        <link:definition>2402402 - Disclosure - Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.omeros.com/role/NetLossPerShareTables">
        <link:definition>2302301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.omeros.com/role/NotesPayable">
        <link:definition>2110100 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableDetail" roleURI="http://www.omeros.com/role/NotesPayableDetail">
        <link:definition>2410401 - Disclosure - Notes Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSignificantAccountingPolicies" roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSignificantAccountingPoliciesDetail" roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail">
        <link:definition>2401402 - Disclosure - Organization and Significant Accounting Policies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.omeros.com/role/Revenue">
        <link:definition>2111100 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetail" roleURI="http://www.omeros.com/role/RevenueDetail">
        <link:definition>2411402 - Disclosure - Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenueByAgreementTables" roleURI="http://www.omeros.com/role/RevenueRevenueByAgreementTables">
        <link:definition>2311301 - Disclosure - Revenue Revenue by Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.omeros.com/role/ShareholdersEquity">
        <link:definition>2113100 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetail" roleURI="http://www.omeros.com/role/ShareholdersEquityDetail">
        <link:definition>2413402 - Disclosure - Shareholders' Equity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.omeros.com/role/ShareholdersEquityTables">
        <link:definition>2313301 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.omeros.com/role/StockBasedCompensation">
        <link:definition>2115100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" roleURI="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails">
        <link:definition>2415403 - Disclosure - Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetail" roleURI="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail">
        <link:definition>2415402 - Disclosure - Stock-Based Compensation - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2415404 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" roleURI="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail">
        <link:definition>2415405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.omeros.com/role/StockBasedCompensationTables">
        <link:definition>2315301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="omer_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="omer_AccruedContractResearchCosts" name="AccruedContractResearchCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="omer_AdditionalDefaultInterestRate" name="AdditionalDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice" name="ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant" />
  <xsd:element id="omer_ClassofWarrantorRightExercisedDuringPeriod" name="ClassofWarrantorRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_ClassofWarrantorRightNumberofWarrantsIssued" name="ClassofWarrantorRightNumberofWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_DSMMember" name="DSMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_DebtPrepaymentPenaltyRate" name="DebtPrepaymentPenaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_DocumentDocumentandEntityInformationAbstract" name="DocumentDocumentandEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_EquityIncentivePlanTwentyZeroEightMember" name="EquityIncentivePlanTwentyZeroEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_GovernmentGrantsUnderReview" name="GovernmentGrantsUnderReview" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_HelionBiotechApSMember" name="HelionBiotechApSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_InVentivMember" name="InVentivMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_LeaseExtensionPeriod" name="LeaseExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_NonCurrentMember" name="NonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_OperatingLeaseNumberOfAdditionalRenewalOption" name="OperatingLeaseNumberOfAdditionalRenewalOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_OxfordLoanAgreementMember" name="OxfordLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_OxfordMember" name="OxfordMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_OxfordMidcapLoanMember" name="OxfordMidcapLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_ProceedsfromStockOptionsandWarrantsExercised" name="ProceedsfromStockOptionsandWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" name="Reductionofequipmentcostbasispurchasedwithgrantfunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="omer_RemainingGrantFunding" name="RemainingGrantFunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="omer_RestrictedCashFairValueDisclosure" name="RestrictedCashFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="omer_RevenueLineItems" name="RevenueLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_RevenueRecognitionTextBlock" name="RevenueRecognitionTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_RevenueRecognitionbyArrangementAbstract" name="RevenueRecognitionbyArrangementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_RevenueTable" name="RevenueTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_SeriesEMod1Q14Member" name="SeriesEMod1Q14Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_SeriesEMod3Q14MemberMember" name="SeriesEMod3Q14MemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized" name="ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="omer_SharesfromcashexerciseofwarrantsMember" name="SharesfromcashexerciseofwarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_SmallBusinessInnovativeResearchMember" name="SmallBusinessInnovativeResearchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_VulcanIncorporatedMember" name="VulcanIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="omer_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_WarrantOneMember" name="WarrantOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_WarrantThreeMember" name="WarrantThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="omer_WarrantTwoMember" name="WarrantTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>omer-20140930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilities" xlink:href="omer-20140930.xsd#AccruedLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:href="omer-20140930.xsd#AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:href="omer-20140930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:href="omer-20140930.xsd#CashCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:href="omer-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:href="omer-20140930.xsd#CommitmentsAndContingenciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:href="omer-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurements" xlink:href="omer-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:href="omer-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShare" xlink:href="omer-20140930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:href="omer-20140930.xsd#NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareTables" xlink:href="omer-20140930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayable" xlink:href="omer-20140930.xsd#NotesPayable" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayableDetail" xlink:href="omer-20140930.xsd#NotesPayableDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/Revenue" xlink:href="omer-20140930.xsd#Revenue" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueDetail" xlink:href="omer-20140930.xsd#RevenueDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:href="omer-20140930.xsd#RevenueRevenueByAgreementTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquity" xlink:href="omer-20140930.xsd#ShareholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:href="omer-20140930.xsd#ShareholdersEquityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityTables" xlink:href="omer-20140930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensation" xlink:href="omer-20140930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:href="omer-20140930.xsd#StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationTables" xlink:href="omer-20140930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <calculationLink xlink:role="http://www.omeros.com/role/AccruedLiabilities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_AccruedContractResearchCosts" xlink:label="loc_omer_AccruedContractResearchCosts_abe39319-c477-53c8-08ff-cac4a1b3aa95" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_omer_AccruedContractResearchCosts_abe39319-c477-53c8-08ff-cac4a1b3aa95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_AccruedClinicalTrialCosts" xlink:label="loc_omer_AccruedClinicalTrialCosts_ace22087-9ccf-f3ea-f1a9-cac4a1a921b1" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_omer_AccruedClinicalTrialCosts_ace22087-9ccf-f3ea-f1a9-cac4a1a921b1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_bb524fdc-8c17-f026-dd5a-c2f49f6280d7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_bb524fdc-8c17-f026-dd5a-c2f49f6280d7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1a174c70-bae7-a93c-896e-3bca354d2c55" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1a174c70-bae7-a93c-896e-3bca354d2c55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d8efa5f9-d69a-54ac-efc6-6e7e03d11640" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d8efa5f9-d69a-54ac-efc6-6e7e03d11640" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_913601c5-bb02-9f7f-1683-87bdfa12cca4" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_913601c5-bb02-9f7f-1683-87bdfa12cca4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4599c23a-11f0-4277-ea32-9886d26f8792" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4599c23a-11f0-4277-ea32-9886d26f8792" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_55393c1a-fc24-e579-ffe3-04ec8ee0f328" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_55393c1a-fc24-e579-ffe3-04ec8ee0f328" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_2ce8accf-e09c-efa1-9d09-9b291f4dca51" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_2ce8accf-e09c-efa1-9d09-9b291f4dca51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_7572aa3e-fb67-19c4-4e10-d8c3ceded4e5" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_DepreciationAndAmortization_7572aa3e-fb67-19c4-4e10-d8c3ceded4e5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6cdee630-2249-6482-0a7c-a21e2870c956" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_PaidInKindInterest_6cdee630-2249-6482-0a7c-a21e2870c956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_e0ab572e-7b53-0acb-ea2e-6b264f09e687" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_e0ab572e-7b53-0acb-ea2e-6b264f09e687" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_b7b4b1a7-b864-5660-8468-21c7409fee96" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_b7b4b1a7-b864-5660-8468-21c7409fee96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_af8dcf28-5bbb-ce71-1ed2-41689425cc96" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_af8dcf28-5bbb-ce71-1ed2-41689425cc96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a785e250-46dd-9933-9ebc-e8177d277129" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a785e250-46dd-9933-9ebc-e8177d277129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_379ac631-1b1e-c2fc-f458-cc9c7958568f" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_379ac631-1b1e-c2fc-f458-cc9c7958568f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_a0029051-5e45-07b3-aa2a-67a017f85138" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_a0029051-5e45-07b3-aa2a-67a017f85138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_77fb0894-8e98-8acd-7d89-0f52e26449e8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_77fb0894-8e98-8acd-7d89-0f52e26449e8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9ecf34e1-f694-ca92-232e-8e07eeacecc0" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9ecf34e1-f694-ca92-232e-8e07eeacecc0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ProceedsfromStockOptionsandWarrantsExercised" xlink:label="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_72765238-6384-11e4-a349-22000a1e8102" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_72765238-6384-11e4-a349-22000a1e8102" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_efa02f76-7356-78e3-0d79-a026176a2602" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_InvestmentIncomeNet_efa02f76-7356-78e3-0d79-a026176a2602" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_cefe1779-647b-11ee-28a9-2740d86c056b" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_InterestExpense_cefe1779-647b-11ee-28a9-2740d86c056b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/NetLossPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/NetLossPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/NotesPayable" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/NotesPayableDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/Revenue" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/RevenueDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/ShareholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/ShareholdersEquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>omer-20140930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilities" xlink:href="omer-20140930.xsd#AccruedLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:href="omer-20140930.xsd#AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:href="omer-20140930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:href="omer-20140930.xsd#CashCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:href="omer-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:href="omer-20140930.xsd#CommitmentsAndContingenciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:href="omer-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurements" xlink:href="omer-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:href="omer-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShare" xlink:href="omer-20140930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:href="omer-20140930.xsd#NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareTables" xlink:href="omer-20140930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayable" xlink:href="omer-20140930.xsd#NotesPayable" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayableDetail" xlink:href="omer-20140930.xsd#NotesPayableDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/Revenue" xlink:href="omer-20140930.xsd#Revenue" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueDetail" xlink:href="omer-20140930.xsd#RevenueDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:href="omer-20140930.xsd#RevenueRevenueByAgreementTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquity" xlink:href="omer-20140930.xsd#ShareholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:href="omer-20140930.xsd#ShareholdersEquityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityTables" xlink:href="omer-20140930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensation" xlink:href="omer-20140930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:href="omer-20140930.xsd#StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationTables" xlink:href="omer-20140930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.omeros.com/role/AccruedLiabilities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:type="extended">
    <loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8E6ED53671C0F57FC6599ACAD589B148" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8E6ED53671C0F57FC6599ACAD589B148" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:to="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:to="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_InVentivMember" xlink:label="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_DSMMember" xlink:label="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_HelionBiotechApSMember" xlink:label="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OperatingLeaseNumberOfAdditionalRenewalOption" xlink:label="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_LeaseExtensionPeriod" xlink:label="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_GovernmentGrantsUnderReview" xlink:label="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:to="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:to="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:to="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:to="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:to="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:to="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:to="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:to="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:to="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:to="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:to="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SmallBusinessInnovativeResearchMember" xlink:label="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:to="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A60B71B4F4444A63E45277A48E60033F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A60B71B4F4444A63E45277A48E60033F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ProceedsfromStockOptionsandWarrantsExercised" xlink:label="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:to="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" xlink:label="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:to="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:to="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:to="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:to="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7E475CB638F0002371889B0BCD49AFDD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_Revenues_7E475CB638F0002371889B0BCD49AFDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:to="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:to="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:to="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:to="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:to="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_NonCurrentMember" xlink:label="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:to="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_RestrictedCashFairValueDisclosure" xlink:label="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:to="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:to="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:to="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/NetLossPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:to="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/NetLossPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/NotesPayable" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/NotesPayableDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:to="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordMidcapLoanMember" xlink:label="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:to="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordLoanAgreementMember" xlink:label="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:to="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ACAA318F22E06E9164E10F27FB28C358" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ACAA318F22E06E9164E10F27FB28C358" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_DebtPrepaymentPenaltyRate" xlink:label="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_AdditionalDefaultInterestRate" xlink:label="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:to="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:to="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:to="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:to="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:to="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_80B05CB363533F0F13AB62295B78CBD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_80B05CB363533F0F13AB62295B78CBD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2865F98512ACBBA7C20062295B787F89_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80B05CB363533F0F13AB62295B78CBD2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2865F98512ACBBA7C20062295B787F89_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2865F98512ACBBA7C20062295B787F89" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80B05CB363533F0F13AB62295B78CBD2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2865F98512ACBBA7C20062295B787F89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5E39CC6B39724584016E62295B78660A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2865F98512ACBBA7C20062295B787F89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5E39CC6B39724584016E62295B78660A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:to="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:to="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:to="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/Revenue" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/RevenueDetail" xlink:type="extended">
    <loc xlink:href="omer-20140930.xsd#omer_RevenueLineItems" xlink:label="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_RevenueTable" xlink:label="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:to="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:to="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:to="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SmallBusinessInnovativeResearchMember" xlink:label="loc_omer_SmallBusinessInnovativeResearchMember_60C92B71DD3D4967D6579B1C4DAB9DA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:to="loc_omer_SmallBusinessInnovativeResearchMember_60C92B71DD3D4967D6579B1C4DAB9DA9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_VulcanIncorporatedMember" xlink:label="loc_omer_VulcanIncorporatedMember_CB33A7EC96C67A4511519B1C4DAB1101" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:to="loc_omer_VulcanIncorporatedMember_CB33A7EC96C67A4511519B1C4DAB1101" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" xlink:label="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_73D07D26F2ABAB8A794E9B1C4DABE895" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_73D07D26F2ABAB8A794E9B1C4DABE895" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_RemainingGrantFunding" xlink:label="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/ShareholdersEquity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SharesfromcashexerciseofwarrantsMember" xlink:label="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SeriesEMod1Q14Member" xlink:label="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SeriesEMod3Q14MemberMember" xlink:label="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantOneMember" xlink:label="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantTwoMember" xlink:label="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantThreeMember" xlink:label="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:to="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:to="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_VulcanIncorporatedMember" xlink:label="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:to="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordMember" xlink:label="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:to="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantExpirationDate" xlink:label="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisedDuringPeriod" xlink:label="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice" xlink:label="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/ShareholdersEquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:to="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:to="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:to="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_EquityIncentivePlanTwentyZeroEightMember" xlink:label="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:to="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:to="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:to="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:to="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:to="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized" xlink:label="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber" xlink:label="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.omeros.com/role/StockBasedCompensationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>omer-20140930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:to="lab_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:type="arc" />
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3_terseLabel_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Table]</link:label>
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3_label_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3_documentation_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Table]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812_label_en-US" xlink:label="lab_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:to="lab_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1_label_en-US" xlink:label="lab_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:to="lab_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:to="lab_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="arc" />
    <link:label id="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0_terseLabel_en-US" xlink:label="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Current</link:label>
    <link:label id="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0_label_en-US" xlink:label="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current [Member]</link:label>
    <link:label id="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0_documentation_en-US" xlink:label="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_NonCurrentMember" xlink:label="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:to="lab_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="arc" />
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E_terseLabel_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E_label_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E_documentation_en-US" xlink:label="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="lab_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money-market funds classified as cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="arc" />
    <link:label id="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE_terseLabel_en-US" xlink:label="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money-market funds classified as restricted cash</link:label>
    <link:label id="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE_label_en-US" xlink:label="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE_documentation_en-US" xlink:label="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RestrictedCashFairValueDisclosure" xlink:label="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:to="lab_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money-market funds classified as short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:to="lab_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:to="lab_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592_label_en-US" xlink:label="lab_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:to="lab_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:to="lab_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:to="lab_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair-Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:to="lab_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="arc" />
    <link:label id="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1_terseLabel_en-US" xlink:label="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant-Series E</link:label>
    <link:label id="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1_label_en-US" xlink:label="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares from cash exercise of warrants [Member]</link:label>
    <link:label id="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1_documentation_en-US" xlink:label="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares from cash exercise of warrants [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_SharesfromcashexerciseofwarrantsMember" xlink:label="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:to="lab_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="arc" />
    <link:label id="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274_terseLabel_en-US" xlink:label="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Mod 1Q14</link:label>
    <link:label id="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274_label_en-US" xlink:label="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Mod 1Q14 [Member]</link:label>
    <link:label id="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274_documentation_en-US" xlink:label="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Mod 1Q14 [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_SeriesEMod1Q14Member" xlink:label="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:to="lab_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="arc" />
    <link:label id="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27_terseLabel_en-US" xlink:label="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Mod 3Q14</link:label>
    <link:label id="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27_label_en-US" xlink:label="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Mod 3Q14 [Member] [Member]</link:label>
    <link:label id="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27_documentation_en-US" xlink:label="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Mod 3Q14 [Member] [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_SeriesEMod3Q14MemberMember" xlink:label="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:to="lab_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="arc" />
    <link:label id="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42_terseLabel_en-US" xlink:label="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant One</link:label>
    <link:label id="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42_label_en-US" xlink:label="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant One [Member]</link:label>
    <link:label id="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42_documentation_en-US" xlink:label="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 1 [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_WarrantOneMember" xlink:label="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:to="lab_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="arc" />
    <link:label id="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506_terseLabel_en-US" xlink:label="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Two</link:label>
    <link:label id="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506_label_en-US" xlink:label="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Two [Member]</link:label>
    <link:label id="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506_documentation_en-US" xlink:label="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 2 [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_WarrantTwoMember" xlink:label="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:to="lab_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="arc" />
    <link:label id="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C_terseLabel_en-US" xlink:label="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Three</link:label>
    <link:label id="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C_label_en-US" xlink:label="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Three [Member]</link:label>
    <link:label id="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C_documentation_en-US" xlink:label="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 3 [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_WarrantThreeMember" xlink:label="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:to="lab_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="arc" />
    <link:label id="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5_terseLabel_en-US" xlink:label="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vulcan Incorporated</link:label>
    <link:label id="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5_label_en-US" xlink:label="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vulcan Incorporated [Member]</link:label>
    <link:label id="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5_documentation_en-US" xlink:label="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vulcan Incorporated [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_VulcanIncorporatedMember" xlink:label="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:to="lab_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="arc" />
    <link:label id="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C_terseLabel_en-US" xlink:label="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford</link:label>
    <link:label id="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C_label_en-US" xlink:label="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford [Member]</link:label>
    <link:label id="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C_documentation_en-US" xlink:label="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_OxfordMember" xlink:label="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:to="lab_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="lab_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9_label_en-US" xlink:label="lab_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:to="lab_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock to purchase by warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="arc" />
    <link:label id="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829_terseLabel_en-US" xlink:label="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration date</link:label>
    <link:label id="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829_label_en-US" xlink:label="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Date</link:label>
    <link:label id="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829_documentation_en-US" xlink:label="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant expiration date</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_WarrantExpirationDate" xlink:label="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:to="lab_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="arc" />
    <link:label id="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF_terseLabel_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF_label_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF_documentation_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisedDuringPeriod" xlink:label="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:to="lab_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="arc" />
    <link:label id="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC_terseLabel_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Weighted Average Price</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC_label_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Weighted Average Price</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC_documentation_en-US" xlink:label="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Weighted Average Price</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice" xlink:label="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:to="lab_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="arc" />
    <link:label id="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2_terseLabel_en-US" xlink:label="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2_label_en-US" xlink:label="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Issued</link:label>
    <link:label id="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2_documentation_en-US" xlink:label="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Issued</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:to="lab_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:type="arc" />
    <link:label id="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644_terseLabel_en-US" xlink:label="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Small Business Innovative Research</link:label>
    <link:label id="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644_label_en-US" xlink:label="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Small Business Innovative Research [Member]</link:label>
    <link:label id="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644_documentation_en-US" xlink:label="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Small Business Innovative Research [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_SmallBusinessInnovativeResearchMember" xlink:label="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:to="lab_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:to="lab_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:to="lab_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:to="lab_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:to="lab_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant modification expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74_label_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment of Warrants Granted for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current and noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases and sales of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="arc" />
    <link:label id="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A_terseLabel_en-US" xlink:label="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A_label_en-US" xlink:label="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A_documentation_en-US" xlink:label="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options and Warrants Exercised</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ProceedsfromStockOptionsandWarrantsExercised" xlink:label="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:to="lab_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9_label_en-US" xlink:label="lab_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:to="lab_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="arc" />
    <link:label id="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65_terseLabel_en-US" xlink:label="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of equipment cost basis purchased with grant funding</link:label>
    <link:label id="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65_label_en-US" xlink:label="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of equipment cost basis purchased with grant funding</link:label>
    <link:label id="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65_documentation_en-US" xlink:label="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction of equipment cost basis purchased with grant funding</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" xlink:label="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:to="lab_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, Issued shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:to="lab_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, Issued shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:to="lab_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="arc" />
    <link:label id="lab_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574_label_en-US" xlink:label="lab_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition by Arrangement [Abstract]</link:label>
    <link:label id="lab_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574_documentation_en-US" xlink:label="lab_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition by Arrangement [Abstract]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RevenueRecognitionbyArrangementAbstract" xlink:label="loc_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:to="lab_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:type="arc" />
    <link:label id="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8_terseLabel_en-US" xlink:label="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [Table]</link:label>
    <link:label id="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8_label_en-US" xlink:label="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Table]</link:label>
    <link:label id="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8_documentation_en-US" xlink:label="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue [Table]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RevenueTable" xlink:label="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:to="lab_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="arc" />
    <link:label id="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1_terseLabel_en-US" xlink:label="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [Line Items]</link:label>
    <link:label id="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1_label_en-US" xlink:label="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Line Items]</link:label>
    <link:label id="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1_documentation_en-US" xlink:label="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue [Line Items]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RevenueLineItems" xlink:label="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="lab_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:to="lab_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="arc" />
    <link:label id="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370_terseLabel_en-US" xlink:label="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining available amount under grant</link:label>
    <link:label id="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370_label_en-US" xlink:label="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Grant Funding</link:label>
    <link:label id="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370_documentation_en-US" xlink:label="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total available remaining grant funding.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RemainingGrantFunding" xlink:label="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:to="lab_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464_label_en-US" xlink:label="lab_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Grantors</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:to="lab_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:to="lab_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1_label_en-US" xlink:label="lab_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:to="lab_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="arc" />
    <link:label id="lab_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7_label_en-US" xlink:label="lab_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Documentand Entity Information [Abstract]</link:label>
    <link:label id="lab_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7_documentation_en-US" xlink:label="lab_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Documentand Entity Information [Abstract]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_DocumentDocumentandEntityInformationAbstract" xlink:label="loc_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:to="lab_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:type="arc" />
    <link:label id="lab_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE_label_en-US" xlink:label="lab_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:to="lab_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="lab_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB_terseLabel_en-US" xlink:label="lab_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB_label_en-US" xlink:label="lab_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:to="lab_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58_label_en-US" xlink:label="lab_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:to="lab_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:to="lab_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:to="lab_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:to="lab_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D_label_en-US" xlink:label="lab_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:to="lab_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD_label_en-US" xlink:label="lab_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:to="lab_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:to="lab_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:to="lab_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683_label_en-US" xlink:label="lab_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:to="lab_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:to="lab_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:to="lab_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Description</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:label="loc_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:to="lab_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:to="lab_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="lab_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:to="lab_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:to="lab_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:to="lab_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2_label_en-US" xlink:label="lab_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:to="lab_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:to="lab_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute basic and diluted net loss per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="arc" />
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82_terseLabel_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82_label_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82_documentation_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="lab_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="arc" />
    <link:label id="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544_terseLabel_en-US" xlink:label="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InVentiv [Member]</link:label>
    <link:label id="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544_label_en-US" xlink:label="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InVentiv [Member]</link:label>
    <link:label id="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544_documentation_en-US" xlink:label="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InVentiv [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_InVentivMember" xlink:label="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:to="lab_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="arc" />
    <link:label id="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034_terseLabel_en-US" xlink:label="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DSM [Member]</link:label>
    <link:label id="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034_label_en-US" xlink:label="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DSM [Member]</link:label>
    <link:label id="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034_documentation_en-US" xlink:label="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DSM [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_DSMMember" xlink:label="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:to="lab_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="arc" />
    <link:label id="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04_terseLabel_en-US" xlink:label="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Helion Biotech ApS</link:label>
    <link:label id="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04_label_en-US" xlink:label="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Helion Biotech Ap S [Member]</link:label>
    <link:label id="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04_documentation_en-US" xlink:label="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Helion Biotech ApS [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_HelionBiotechApSMember" xlink:label="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:to="lab_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="arc" />
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E_terseLabel_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E_label_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E_documentation_en-US" xlink:label="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="lab_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:type="arc" />
    <link:label id="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18_terseLabel_en-US" xlink:label="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options to extend the lease term</link:label>
    <link:label id="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18_label_en-US" xlink:label="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Number Of Additional Renewal Option</link:label>
    <link:label id="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18_documentation_en-US" xlink:label="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Number Of Additional Renewal Option</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_OperatingLeaseNumberOfAdditionalRenewalOption" xlink:label="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:to="lab_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="arc" />
    <link:label id="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466_terseLabel_en-US" xlink:label="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to extend the lease term, number of options</link:label>
    <link:label id="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466_label_en-US" xlink:label="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Extension Period</link:label>
    <link:label id="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466_documentation_en-US" xlink:label="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Extension Period</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_LeaseExtensionPeriod" xlink:label="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:to="lab_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining aggregate rent payable</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recorded Unconditional Purchase Obligation, Due in Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recorded Unconditional Purchase Obligation, Due in Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Change of Amount as Result of Variable Components</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Change of Amount as Result of Variable Components</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="arc" />
    <link:label id="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD_terseLabel_en-US" xlink:label="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Grants Under Review</link:label>
    <link:label id="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD_label_en-US" xlink:label="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants Under Review</link:label>
    <link:label id="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD_documentation_en-US" xlink:label="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grants received by entity between 2004 and 2007 under administrative review.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_GovernmentGrantsUnderReview" xlink:label="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:to="lab_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="lab_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Equity Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant and other receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:to="lab_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:to="lab_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:to="lab_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29_label_en-US" xlink:label="lab_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:to="lab_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:to="lab_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:to="lab_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:to="lab_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, net of current portion and discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:to="lab_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="lab_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.01 per share: Authorized shares - 20,000,000 at September 30, 2014 (unaudited) and December 31, 2013; Issued and outstanding shares&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:to="lab_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.01 per share: Authorized shares - 150,000,000 at September 30, 2014 (unaudited) and December 31, 2013; Issued and outstanding shares&#8212;34,022,145 and 30,359,508 at September 30, 2014 (unaudited) and December 31, 2013, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:to="lab_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:to="lab_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:to="lab_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="arc" />
    <link:label id="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660_terseLabel_en-US" xlink:label="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract research</link:label>
    <link:label id="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660_label_en-US" xlink:label="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Contract Research Costs</link:label>
    <link:label id="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660_documentation_en-US" xlink:label="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued preclinical research and development contract costs.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_AccruedContractResearchCosts" xlink:label="loc_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:to="lab_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting &amp; professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:type="arc" />
    <link:label id="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0_terseLabel_en-US" xlink:label="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0_label_en-US" xlink:label="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Costs</link:label>
    <link:label id="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0_documentation_en-US" xlink:label="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued clinical trial costs.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_AccruedClinicalTrialCosts" xlink:label="loc_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:to="lab_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:type="arc" />
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B_terseLabel_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Life</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B_label_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B_documentation_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:to="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:type="arc" />
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156_terseLabel_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156_label_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156_documentation_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:to="lab_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:to="lab_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:to="lab_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="arc" />
    <link:label id="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714_terseLabel_en-US" xlink:label="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Midcap Loan [Member]</link:label>
    <link:label id="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714_label_en-US" xlink:label="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Midcap Loan [Member]</link:label>
    <link:label id="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714_documentation_en-US" xlink:label="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Midcap Loan [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_OxfordMidcapLoanMember" xlink:label="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:to="lab_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="arc" />
    <link:label id="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD_terseLabel_en-US" xlink:label="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Loan Agreement [Member]</link:label>
    <link:label id="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD_label_en-US" xlink:label="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Loan Agreement [Member]</link:label>
    <link:label id="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD_documentation_en-US" xlink:label="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_OxfordLoanAgreementMember" xlink:label="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:to="lab_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="lab_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan and security agreement, existing outstanding indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:to="lab_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Date of First Required Payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Date of First Required Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:to="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="arc" />
    <link:label id="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2_terseLabel_en-US" xlink:label="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Penalty Rate</link:label>
    <link:label id="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2_label_en-US" xlink:label="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Penalty Rate</link:label>
    <link:label id="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2_documentation_en-US" xlink:label="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Penalty Rate</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_DebtPrepaymentPenaltyRate" xlink:label="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:to="lab_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="arc" />
    <link:label id="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75_terseLabel_en-US" xlink:label="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Default Interest Rate</link:label>
    <link:label id="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75_label_en-US" xlink:label="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Default Interest Rate</link:label>
    <link:label id="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75_documentation_en-US" xlink:label="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Default Interest Rate</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_AdditionalDefaultInterestRate" xlink:label="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:to="lab_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:to="lab_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized balance of debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized balance of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Finance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:to="lab_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:to="lab_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D_terseLabel_en-US" xlink:label="lab_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D_label_en-US" xlink:label="lab_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:to="lab_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:to="lab_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B_label_en-US" xlink:label="lab_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:to="lab_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding dilutive securities not included in diluted loss per share calculation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:type="arc" />
    <link:label id="lab_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E_terseLabel_en-US" xlink:label="lab_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash excluded from fair value hierarchy disclosure</link:label>
    <link:label id="lab_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E_label_en-US" xlink:label="lab_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:to="lab_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:to="lab_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:type="arc" />
    <link:label id="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B_terseLabel_en-US" xlink:label="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B_label_en-US" xlink:label="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Text Block]</link:label>
    <link:label id="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B_documentation_en-US" xlink:label="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for revenue recognition.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_RevenueRecognitionTextBlock" xlink:label="loc_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:to="lab_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:to="lab_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:to="lab_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:to="lab_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="arc" />
    <link:label id="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197_terseLabel_en-US" xlink:label="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2008</link:label>
    <link:label id="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197_label_en-US" xlink:label="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan Twenty Zero Eight [Member]</link:label>
    <link:label id="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197_documentation_en-US" xlink:label="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan Twenty Zero Eight [Member]</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_EquityIncentivePlanTwentyZeroEightMember" xlink:label="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:to="lab_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B_label_en-US" xlink:label="lab_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:to="lab_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2_label_en-US" xlink:label="lab_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:to="lab_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767_label_en-US" xlink:label="lab_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:to="lab_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:to="lab_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options, maximum term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, average vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="arc" />
    <link:label id="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610_terseLabel_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in authorized shares</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610_label_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement Share Based Payment Award Additional Shares Authorized</link:label>
    <link:label id="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610_documentation_en-US" xlink:label="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation, Arrangement Share Based Payment Award, Additional Shares Authorized</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized" xlink:label="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:to="lab_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, number of shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="arc" />
    <link:label id="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B_terseLabel_en-US" xlink:label="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested options outstanding</link:label>
    <link:label id="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B_label_en-US" xlink:label="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number</link:label>
    <link:label id="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B_documentation_en-US" xlink:label="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of non-vested employee stock options as of the balance sheet date.</link:label>
    <link:loc xlink:href="omer-20140930.xsd#omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber" xlink:label="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:to="lab_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested options outstanding, vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted in period (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted in period (USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>omer-20140930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilities" xlink:href="omer-20140930.xsd#AccruedLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:href="omer-20140930.xsd#AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:href="omer-20140930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:href="omer-20140930.xsd#CashCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:href="omer-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:href="omer-20140930.xsd#CommitmentsAndContingenciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="omer-20140930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="omer-20140930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:href="omer-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurements" xlink:href="omer-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:href="omer-20140930.xsd#FairValueMeasurementsNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:href="omer-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShare" xlink:href="omer-20140930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:href="omer-20140930.xsd#NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NetLossPerShareTables" xlink:href="omer-20140930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayable" xlink:href="omer-20140930.xsd#NotesPayable" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/NotesPayableDetail" xlink:href="omer-20140930.xsd#NotesPayableDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="omer-20140930.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/Revenue" xlink:href="omer-20140930.xsd#Revenue" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueDetail" xlink:href="omer-20140930.xsd#RevenueDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:href="omer-20140930.xsd#RevenueRevenueByAgreementTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquity" xlink:href="omer-20140930.xsd#ShareholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:href="omer-20140930.xsd#ShareholdersEquityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/ShareholdersEquityTables" xlink:href="omer-20140930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensation" xlink:href="omer-20140930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:href="omer-20140930.xsd#StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationNarrativeDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:href="omer-20140930.xsd#StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.omeros.com/role/StockBasedCompensationTables" xlink:href="omer-20140930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.omeros.com/role/AccruedLiabilities" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F674E02B48C7A96E367F0F27FB577B7F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F674E02B48C7A96E367F0F27FB577B7F" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_AE3FF400E7174AA4E2000F27FB575F61" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_AccruedContractResearchCosts" xlink:label="loc_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_omer_AccruedContractResearchCosts_A5095BDF34EF3313F95E535E00207660" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2FF7252FF2DF1AF3FE57535E0020E558" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5F80FBA1FA88D10EFEFD535E00202348" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_AccruedClinicalTrialCosts" xlink:label="loc_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_omer_AccruedClinicalTrialCosts_7C76E6911A8E417DFD4E535E002016C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB68CF16434F4F7553B7535E0020B41C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ED13E3BD37A7ED6840B7535E00200FB5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_BBEC315786F0AD6E643A535E00206B78" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_517C8D2BDBB1D49DCF9E0F27FB28C35C" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D230AA340F7847C484C70F27FB2811B6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/CashCashEquivalentsAndInvestments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_00A7CC124865942554FB0F27FC60BDC0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_6FC1920D3289C6285DAF0F27FC6044C6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0C9F04B1CD4C9D1F1650F27FB19ED0A" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A21F555BB2351FD3C0C00F27FB191C7F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/CommitmentsAndContingenciesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65ECC34685B3F5C7BA719ACAD5891A07" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65ECC34685B3F5C7BA719ACAD5891A07" xlink:to="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71AAB10AA78110EB6A959ACAD58906CE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8E6ED53671C0F57FC6599ACAD589B148" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E2A8DE9EF661D213268E9ACAD589F621" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8E6ED53671C0F57FC6599ACAD589B148" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_98A5A82AE5EEE38BBC949ACAD5899268" xlink:to="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_InVentivMember" xlink:label="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_InVentivMember_0A78F20B49416EF58C0F9ACAD5895544" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_DSMMember" xlink:label="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_DSMMember_F0957F6C74D91E98F6749ACAD589A034" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_HelionBiotechApSMember" xlink:label="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AA282630D8760F18D5489ACAD5892B65" xlink:to="loc_omer_HelionBiotechApSMember_5FAB517FFFDF69C3BC6A9ACAD589EB04" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureTable_0835FF51DA41504652B69ACAD589BB82" xlink:to="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OperatingLeaseNumberOfAdditionalRenewalOption" xlink:label="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_OperatingLeaseNumberOfAdditionalRenewalOption_0C49C17E59B2AF2DE3BF9ACAD589EE18" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_LeaseExtensionPeriod" xlink:label="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_LeaseExtensionPeriod_47B29B8B1368982340AE9ACAD5892466" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_576DCF3AD268780FEEE09ACAD58933AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_22AA82A58FE5A46551589ACAD589AB42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents_ACBD433753BE8C49FA3D9ACAD589DD49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_EE3572E1E4690FD2BB579B0976093129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7B380D545D04E01788F19ACAD589EA46" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_GovernmentGrantsUnderReview" xlink:label="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_CommitmentsAndContingenciesDisclosureLineItems_EA736FAFF8B6CA3C798B9ACAD589603E" xlink:to="loc_omer_GovernmentGrantsUnderReview_081157DC2170907784819ACAD589DAAD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_DB2BC8C1634097E66BDE9A93929B542C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DB2BC8C1634097E66BDE9A93929B542C" xlink:to="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:to="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5C98FE80C950D2DEB5AD9A93929BE6CE" xlink:to="loc_dei_EntityDomain_09EE2F4761C68A49925D9A93929B4A3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1B983F711A19052D6DBC9A93929B046F" xlink:to="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:to="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2F1894207987FFA06109A93929D6A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_968E93638A1C22E608159A93929D388A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_CD3B3D42D8A1D366FFC19A93929D4416" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_E2A91AEF643AA62091119A93929DD45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_OtherAssetsCurrent_1CDE211C2D8D35C696769A93929D3924" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D373C314F1CDF6A0DCD9A93929CBFC6" xlink:to="loc_us-gaap_AssetsCurrent_3FDE429749FA807454709A93929DCCF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_496066ABD650059A31449A93929D24A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1DB3E55D15B0B97BFE319A93929DDFC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A9A8936696EB386DADFD9A93929DD749" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EDA4D8FDABB7C2CCFB3F9A93929B49E6" xlink:to="loc_us-gaap_Assets_B7166C08E4FD48CE49599A93929ECE29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFF77ECB71986CB9C1E69A93929B4241" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_AccountsPayableCurrent_BF9146AB2D8154A290F59A93929E7E46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28564E7295EFC0B59C7D9A93929E6E5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_LongTermDebtCurrent_F0465FB7A1D5A56167149A93929E2487" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DBD3CAC040D948290EF59A93929EF4DC" xlink:to="loc_us-gaap_LiabilitiesCurrent_26900F1BA24A717A3D149A93929E137D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_BAEEE1E3352EA255C6ED9A93929E5E89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_BA38F2E0F131E5980AD09A93929E216D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_CommitmentsAndContingencies_097B721D7CF446B2B0C99A93929EAA37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_PreferredStockValue_8360B053D228E659E1E89A93929EC0EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_CommonStockValue_6FA6D5E94F7C79A399009A93929E4A3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_525E410EE050F15477BF9A93929E8E16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AEEB494D0635A01665099A93929E85A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B16396211D081926A85A9A93929EC2E2" xlink:to="loc_us-gaap_StockholdersEquity_291075435D372215A9D29A93929ED947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A470042DD89B05BEBFAC9A93929E538B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_17647BD672C31D9653979A93929E1F00" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F06D28BE2F5FFC0466880F27FB38D5D1" xlink:to="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:to="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_E159C5E4C0E59CB848BD0F27FB3832AA" xlink:to="loc_dei_EntityDomain_686AB6EAD2F65B63697A0F27FB38C329" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FA256B2EF5FE7EAF7D1E0F27FB3812DF" xlink:to="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E398D961BFD5086E50640F27FB38DB01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_AA376CE9940CC7C0C5C40F27FB38CE0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_F746A1144D1F1430E34D0F27FB3870F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_FB43A5E3068350EE6CA90F27FB38522A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B10E45F2293F899E32360F27FB38E9CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CD76364709155ABEA8F90F27FB382AEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesIssued_F03725EF2202DAF9A1230F27FB38132C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C4F7A8667CA70243C0980F27FB3864E3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_818FD72C93DB5910BF7F0F27FB380712" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1473B96C0DC03A5626FD77A48E5C33D4" xlink:to="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:to="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0944D4C1A71A5235FB2E77A48E5CB4F5" xlink:to="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SmallBusinessInnovativeResearchMember" xlink:label="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_EE6AABD81D008C0A527F77A48E5CE282" xlink:to="loc_omer_SmallBusinessInnovativeResearchMember_01A2775149232134C14B77A48E5C0644" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EF47F6DA0EE30C05614577A48E5C3A75" xlink:to="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_NetIncomeLoss_32CA889F74C59A48968C77A48E5E9DA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_BA56CD173F7438488F1A77A48E5EE8C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_DepreciationAndAmortization_8FC6C8202D20824EBC7677A48E5EB1B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_ShareBasedCompensation_A813526D1DB85E2415C877A48E5E1ECB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_PaidInKindInterest_F7E308140ED9F59354DA77A48E5E769A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8DBE1FD1E61F268018C477A48E5E1A74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D53244CC081A053E209377A48E5EB01F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_EDAC57B04DBF609C4C4777A48E5EF07C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6838AE69A58BF250F0EE77A48E5E5994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89537D286F262A7AF31577A48E5EAD43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D9FD63E58E906447A1E377A48E5E223D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81612139317C208B7D1577A48E5E708D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_A73D030F176750FB83C377A48E5F8620" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3BAD7AA6723A5C61B06C77A48E5DB8F7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DA7402221F5962C24A2877A48E5F25CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F85F351C72BE28A0BF7377A48E5F768C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_30D4848439881ACFEB2377A48E5F5F5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_443651A0B86F1830D71B77A48E5FF0D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2379057EFBB442D464AA77A48E5F19DE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31F9CDD462B21EBE46E677A48E5F0287" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A60B71B4F4444A63E45277A48E60033F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A60B71B4F4444A63E45277A48E60033F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A9B8EEF2B3022AFEC81677A48E60D9C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_D3A6AAAA8359235C26BE77A48E60FC80" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ProceedsfromStockOptionsandWarrantsExercised" xlink:label="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_omer_ProceedsfromStockOptionsandWarrantsExercised_ED9D8C84CB48B3D6B8D977A48E60910A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_B3B3DB5C6634885DDA5F77A48E6062E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8294090F561853D0691F77A48E5FC478" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DF580859C333DFBF5B1977A48E600B67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_183EFFC55FBD62AFA45077A48E6040BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15B8A0779E12FEDDAA7F77A48E6068F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19E0E387468E7EEE3C6C77A48E610083" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B6A138A43A125280219D77A48E5C6BFF" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:to="loc_us-gaap_InterestPaid_69DE8CA2A9A3AFA1EFA477A48E6181E9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" xlink:label="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_43C6327D160915C2684B77A48E616A3B" xlink:to="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_EDA65EE158138A1DD8B677A48E61CC65" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_235580B69EE3CCD670069B0BCD39143E" xlink:to="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:to="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9D2F185AE70B3C2199489B0BCD49572C" xlink:to="loc_dei_EntityDomain_A11A13EDA77CF81D14759B0BCD49E1FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FB0147565449DC599D529B0BCD49699F" xlink:to="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7E475CB638F0002371889B0BCD49AFDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_Revenues_7E475CB638F0002371889B0BCD49AFDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3C53F5B2034BDD3754369B0BCD4ACE34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7DDF9A7718B534B4ED3B9B0BCD4A6328" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41238F285D0BBE2D08D39B0BCD49F1A6" xlink:to="loc_us-gaap_OperatingExpenses_B2702CFB7AAA7F4830319B0BCD4AA770" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OperatingIncomeLoss_5FBB92C57292F3CAF34D9B0BCD4B4A44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_InvestmentIncomeNet_A979CA2B157A514461989B0BCD4B8D61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_InterestExpense_52F9A93ACF136CAE14C49B0BCD4B5BA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_70211FC9BEEEEBA861089B0BCD4BBEAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_NetIncomeLoss_217909ED74AC6DF14D9B9B0BCD4BE96E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_D434B7161F3014026FBA9B0BCD4BA22D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A217A1939B5B99A2419B9B0BCD4B5995" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A9FD6F135C11817F64E99B0BCD49C52E" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_137C1E9DEC5095B8266A9B0BCD4B5F99" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="omer-20140930.xsd#omer_DocumentDocumentandEntityInformationAbstract" xlink:label="loc_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_DocumentDocumentandEntityInformationAbstract_C3976F6DC33A80CADDD89B30FC038DF7" xlink:to="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:to="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_55E5BE37F16CE858CD909B30FC03508A" xlink:to="loc_dei_EntityDomain_96902B87974D1985C2E79B30FC032688" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_27AA2677AFA7CE50533F9B30FC03DFAE" xlink:to="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentType_2583538E2A158E0FE1229B30FC033FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_AmendmentFlag_A57440793DF4A9AF47839B30FC03AF58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentPeriodEndDate_AAD4A170520EC39965139B30FC036908" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentFiscalYearFocus_761FDD6985B65DE4C4599B30FC03F56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_DocumentFiscalPeriodFocus_EA2E6CC5150C2B3DFC539B30FC034374" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_TradingSymbol_BD26CBD1A6434B1FD6569B30FC03C29D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityRegistrantName_25D3E3720FB9118BF70E9B30FC036FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityCentralIndexKey_A0F174B3B5DD252755BA9B30FC035702" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_CurrentFiscalYearEndDate_FA7A3352839C632AB8F59B30FC03F110" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityFilerCategory_F87F789D6A8B860FE16E9B30FC036683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2059F1B13D27A7F580D49B30FC032900" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6DBE4FB8D51E54AF0F489B30FC03504E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C87F98409477F7C4A2340F27FC709727" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C87F98409477F7C4A2340F27FC709727" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_FBE0E8A87DC5A0CA09AB0F27FC70DC5D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54ABB10BE7F1712F0C790F27FB281C9A" xlink:to="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8A49210F3D87210546B00F27FB287812" xlink:to="loc_dei_EntityDomain_077E5ED321FA2E479C800F27FB288BB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6CAE25916FE9AC93EF990F27FB285572" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_149A5B629E35E3BE91E80F27FB28F995" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_EF58EE58D90C64C44F650F27FB2847FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1DDECABF3FB35DEDE12B0F27FB28BCD7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_131432EFC8F909AD33100F27FB28949B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B0BCE5DD9C2E373ACD890F27FB280112" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E60E1352A77A4364D6D10F27FB28DD8A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8A141616CA06E162E36D0F27FB286412" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_NonCurrentMember" xlink:label="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91496D511F9C2946A46E0F27FB28B9E9" xlink:to="loc_omer_NonCurrentMember_00AC4117B2D89F5482250F27FB28DED0" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92FFC728E3FB3CFA049B0F27FB28BAE3" xlink:to="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DB6B421050109C05268B0F27FB28EB32" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_RestrictedCashFairValueDisclosure" xlink:label="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_omer_RestrictedCashFairValueDisclosure_08A7DA9F67D5E11841200F27FB280FBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9DA86BE27E9BCD4279F00F27FB28D193" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8130C1D7DCB4109D0C610F27FB286B0E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9BB19E2B52C5CD8DEF5E0F27FB289B09" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77D8DC78C16D4342FD310F27FB388EFA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77D8DC78C16D4342FD310F27FB388EFA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:to="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4F6C206A48A8B3A601670F27FB384067" xlink:to="loc_dei_EntityDomain_81CC008A164ADFE3A5AB0F27FB387BBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CE8B9B11BD25FCB072BD0F27FB3848CD" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="loc_us-gaap_Cash_43D227082A6FACCFAD720F27FB38C18E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4A0698E42E837CAEB60C0F27FB384A60" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_F568593F07DC866245D70F27FB38359B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8504F25A640C306037120F27FB47CF0B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8504F25A640C306037120F27FB47CF0B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_D3F3DBB235A6A58F58280F27FB47BC7B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DFD322D65CA3D68A314B0F27FB09D752" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DFD322D65CA3D68A314B0F27FB09D752" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1FFFC9FEBDDEBEFD6CE70F27FB09BD13" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9BECA435C9E1171E60590F27FC7068C1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9BECA435C9E1171E60590F27FC7068C1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_36FE41CE1D8DC8812C860F27FC706C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_125E86F1C20B242FBC270F27FC70A851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72C82F05F6A504B485360F27FC7041A8" xlink:to="loc_us-gaap_WarrantMember_30B3E06CFFC30626A1F80F27FC70854B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_209D2AD566E15850829A0F27FC70E17C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_AC80894E835FDDF2958E0F27FC70E161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9D0EB2D0216C4B6E2D770F27FC70747F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4BF6F891854C00877EA90F27FB575F30" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_078216BF40DED28B25650F27FB57A3E6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/NotesPayable" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E2C09D2A57FF78CEDE010F27FB57219C" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_A3AC7598CC34E0A68CAF0F27FB57055C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/NotesPayableDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1E4CF85EC9E85E27AD640F27FB28500B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1E4CF85EC9E85E27AD640F27FB28500B" xlink:to="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:to="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F05ED28D6945AB4C4E130F27FB2888C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordMidcapLoanMember" xlink:label="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:to="loc_omer_OxfordMidcapLoanMember_710176638FC5ED7D55C50F27FB288714" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordLoanAgreementMember" xlink:label="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6859ADF793EB6DD108E20F27FB2877E7" xlink:to="loc_omer_OxfordLoanAgreementMember_47BCEC167B88D25691300F27FB28F4AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10A15560C97DDD96DBF10F27FB289E3D" xlink:to="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2E8C55A61341E5E6B3570F27FB28EBF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_RepaymentsOfDebt_02E1ADA1BBE6F4F853430F27FB2856FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_6AF04998E252135B32450F27FB2838D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ACAA318F22E06E9164E10F27FB28C358" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ACAA318F22E06E9164E10F27FB28C358" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8EC74744DE957C22C1DB0F27FB2847CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_DC781B06056266D4AA4F0F27FB2819D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_22D9E6CD83E21D82E9A70F27FB2889AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_FA58886CB5B8234F5AEB0F27FB28FF31" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_DebtPrepaymentPenaltyRate" xlink:label="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_omer_DebtPrepaymentPenaltyRate_5489884F34FA857334220F27FB285FA2" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_AdditionalDefaultInterestRate" xlink:label="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_omer_AdditionalDefaultInterestRate_7D2ACDC8D8CB98AD5DB70F27FB281D75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtIssuanceCosts_6CA1DE2996AB3BA9978D0F27FB28487E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0BD0E00D04E0E4DAA7220F27FB28913E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46771FAEF84D1A54FE550F27FB28E8CE" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_73E4F0A0F37DA7B7A69A0F27FB285301" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2071C5A46991D6F3C3B30F27FB38BE30" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2071C5A46991D6F3C3B30F27FB38BE30" xlink:to="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:to="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_36E596AECC2E1A63AE9F0F27FB38B654" xlink:to="loc_dei_EntityDomain_009578881032577E438F0F27FB3829FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77A4AAA71A58CB7F3D700F27FB38D568" xlink:to="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6B70D1E4CC0FDFC9CF530F27FB382AFF" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7AA3ED6D9CC508850B410F27FB380A7A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:to="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B0309697C34E28DDCD2261ED664C18B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B0309697C34E28DDCD2261ED664C18B0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9E9377C68E89E97FE54861ED664C89BF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B0309697C34E28DDCD2261ED664C18B0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9E9377C68E89E97FE54861ED664C89BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0D95B0FBF8B95ACA636461ED664CB836" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9E9377C68E89E97FE54861ED664C89BF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0D95B0FBF8B95ACA636461ED664CB836" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438FE292B56F6BE7EAAC623864205592" xlink:to="loc_us-gaap_StatementLineItems_09E1069BC39FD9AA46BB62393ECEEE55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_28A6D09D79A91801154361ED664C2D74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71518FFA0E01114F57CA61ED664C3444" xlink:to="loc_us-gaap_NumberOfOperatingSegments_F2A37DF94AD1DB095F5B61ED664C2FC3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75DA6559F1B302B7871A0F27FB479F60" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75DA6559F1B302B7871A0F27FB479F60" xlink:to="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:to="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_DF5527D305769A89386A0F27FB47AF12" xlink:to="loc_dei_EntityDomain_F58F8650A1F45021BB440F27FB473E53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_064DF4755575CF0894260F27FB47A980" xlink:to="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_NatureOfOperations_2B1AC43C679A2308962F0F27FB47CD95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D8C4FC16CDF744C120310F27FB4727E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_UseOfEstimates_21CF1272A8177160B69C0F27FB47E6EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_LiquidityDisclosureTextBlock_92703C2CDCCA1E1660AC0F27FB47CB1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_AE9FC6B3D78DB45CE2DF0F27FB47559C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8D159D7F7F6F9D6E8AC50F27FB4750ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_594F13A144BE9472A3DC0F27FB474095" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FD92B87BB07D7822CCDD0F27FB471166" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/Revenue" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_RevenueRecognitionTextBlock" xlink:label="loc_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_7124BEE931AC327FC7FD0F27FB385534" xlink:to="loc_omer_RevenueRecognitionTextBlock_D7C83AE2435A8DB24C490F27FB383A0B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/RevenueDetail" xlink:type="extended">
    <loc xlink:href="omer-20140930.xsd#omer_RevenueRecognitionbyArrangementAbstract" xlink:label="loc_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:type="locator" />
    <loc xlink:href="omer-20140930.xsd#omer_RevenueTable" xlink:label="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueRecognitionbyArrangementAbstract_13F5E7D77119DA2EC1199B1C4DA84574" xlink:to="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:to="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_11722B7FF21612703A559B1C4DAA8EF0" xlink:to="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SmallBusinessInnovativeResearchMember" xlink:label="loc_omer_SmallBusinessInnovativeResearchMember_60C92B71DD3D4967D6579B1C4DAB9DA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:to="loc_omer_SmallBusinessInnovativeResearchMember_60C92B71DD3D4967D6579B1C4DAB9DA9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_VulcanIncorporatedMember" xlink:label="loc_omer_VulcanIncorporatedMember_CB33A7EC96C67A4511519B1C4DAB1101" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F7476A7D449F9DC8CE939B1C4DAA0008" xlink:to="loc_omer_VulcanIncorporatedMember_CB33A7EC96C67A4511519B1C4DAB1101" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_RevenueLineItems" xlink:label="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueTable_76946F3FA0B186FBE6709B1C4DAA2CF8" xlink:to="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_RevenueFromGrants_E649994D7473B5CA1ED39B1C4DABA567" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_Reductionofequipmentcostbasispurchasedwithgrantfunding" xlink:label="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_73D07D26F2ABAB8A794E9B1C4DABE895" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding_73D07D26F2ABAB8A794E9B1C4DABE895" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_RemainingGrantFunding" xlink:label="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_omer_RemainingGrantFunding_2362293296B85FF4F0E69B1C4DABC370" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_ProceedsFromGrantors_A51C5A2421E20AEBB62A9B1C4DAB5464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_DeferredRevenue_63D03A3AB8D56DF864C79B1C4DAB2F46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized_8AD162F53F47B11B1E729B1C4DAB0777" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_RevenueLineItems_2C7CEC5820BABC8704319B1C4DABBBD1" xlink:to="loc_us-gaap_Revenues_42E4AAF828DE463A07C39B1C4DABF0D1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/RevenueRevenueByAgreementTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleElementArrangements" xlink:label="loc_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_978AEAA434E46C2CBEFD0F27FB476B4C" xlink:to="loc_us-gaap_RevenueRecognitionMultipleElementArrangements_0DA7781232D3A955F1890F27FB479ECC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_172C3442C3B39270703E0F27FB477055" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_172C3442C3B39270703E0F27FB477055" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918184E2FBF08FBFEB3A0F27FB47B19E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ShareholdersEquityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2EC6CE50988B976B4A229ACAD579FA76" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2EC6CE50988B976B4A229ACAD579FA76" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7EC12265B3A3042750109ACAD579510B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SharesfromcashexerciseofwarrantsMember" xlink:label="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SharesfromcashexerciseofwarrantsMember_21F95939E4D3D6F57DAC9ACAD5794DF1" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SeriesEMod1Q14Member" xlink:label="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SeriesEMod1Q14Member_E0B8679B8D78AC8D214F9ACAD579E274" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SeriesEMod3Q14MemberMember" xlink:label="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_SeriesEMod3Q14MemberMember_7DDC42354320BA2670549ACAD5798E27" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantOneMember" xlink:label="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantOneMember_DCD6EE2D55F9B9D50DC49ACAD5790F42" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantTwoMember" xlink:label="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantTwoMember_3D2FC05AED3ACBD83D829ACAD5793506" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantThreeMember" xlink:label="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_D86EE37A99FE2F3756319ACAD57969F5" xlink:to="loc_omer_WarrantThreeMember_2BDC59F62CFCD9F1CDC49ACAD579505C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9516209FE62396F2810C9ACAD5792EB5" xlink:to="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_VulcanIncorporatedMember" xlink:label="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:to="loc_omer_VulcanIncorporatedMember_5725424744A1861C81849ACAD579D6B5" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_OxfordMember" xlink:label="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6207938EE1C810DE0AF79ACAD579C112" xlink:to="loc_omer_OxfordMember_E273B8DF58ED820B07929ACAD579C28C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A9FA07EE10216634F6F39ACAD579A0AB" xlink:to="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8BDF1BFE5B925719E68D9ACAD579E1C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_SharePrice_5DDF17E0C6773237CA399ACAD5793EE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_A2B3CD0CE354303BA42F9ACAD579CF61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86965C80761CA0003D3E9ACAD579CC15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03B231169C8B8634EAED9ACAD57925B8" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_WarrantExpirationDate" xlink:label="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_WarrantExpirationDate_5520CB4BF08DB6E00C6F9ACAD579B829" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CC9202671589534D37F89ACAD5792193" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E1F1212EEE947598C1919ACAD579630F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3CF69E799431C64A7CC99ACAD5798AC7" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisedDuringPeriod" xlink:label="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightExercisedDuringPeriod_F0A1050D28D7396CCDA49ACAD579DBAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_0D7350F142F6584961A79ACAD5798999" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_401490534E726BC12DAF9ACAD579A883" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice" xlink:label="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice_B662DA5B2379B77776A89ACAD579C4FC" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00588A5E49D11216A1869ACAD57939CA" xlink:to="loc_omer_ClassofWarrantorRightNumberofWarrantsIssued_226A8E27051D4ECC68D59ACAD579C3D2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/ShareholdersEquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7FFFF1E578E9588BD7F10F27FB19AFB9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7171FA6E949E6A16DFC70F27FB19172D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B902147A5534DC3FD808779F06179F61" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B902147A5534DC3FD808779F06179F61" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16D73474A84610ADAC91779F06185059" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6BB599A0BFA6278CEDC9779F07DB3AA2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6BB599A0BFA6278CEDC9779F07DB3AA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64C547D3ED4DD3A20C5B779F07DCA502" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6BB599A0BFA6278CEDC9779F07DB3AA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15C4F6E28277D5DDE9C1779F07DCFCA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_58191D1E9F2D4F5044C6779F07DD494F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77FFD579CCDF72B705AC779F07DD6A0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_FCBFD9E992707F4A8F2F779F07DC4E49" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_E5360C98A4DF77A14E47779F07DDCBF5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationNarrativeDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD0DAE2FB121650F0D0D86A8656A8493" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD0DAE2FB121650F0D0D86A8656A8493" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CD4844AD55C862E327EA86A891038065" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_72EF0F0333CF66E719A286A8920E5F8A" xlink:to="loc_us-gaap_SubsequentEventMember_545194ADD076CCC90C6386A8B1FF9C14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D974E6153A036752D5FA86A8656A6736" xlink:to="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_EquityIncentivePlanTwentyZeroEightMember" xlink:label="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7408E9B56E35BCF7F30186A8656A8FFB" xlink:to="loc_omer_EquityIncentivePlanTwentyZeroEightMember_F1BB7609224F1DFEB32486A8656AD197" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_798BDD9EFA8544ECC75D86A8656AB73B" xlink:to="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F8722E914A063A39D6EF86A8656A5FE2" xlink:to="loc_us-gaap_MaximumMember_7A2590A7D6EE77AC175586A8656A3767" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_586893E152C9657A8EF386A8656AE4CD" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_AFCA4272E2220069B9C386A8656A6E37" xlink:to="loc_us-gaap_StockOptionMember_B10A8159CCEE77E042CE86A8656A2CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3E5501BEB99156F57FA486A8656A9E6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E5970FCB1EC5CC5BE44E86A8656ADDA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363635037405B346C3B386A8656A4ABB" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized" xlink:label="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized_A9F92EC7F31C64456B2886A8656BA610" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28D8096573C95550273D86A8656B2CAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_632013B638D1E658A38F86A8656BE5E9" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber" xlink:label="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber_179BDDF0CE3786CC628B86A8656B871B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F9F8DBCB80F4D56A9A9486A8656B4463" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7EDE0B0F3781A4AC3BE986A8656B382F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_142B78F4FA1701B140DC86A875146C1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EBF8365DFF1F5A85612586A8656AF804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_057331A85DA67B2018FA86A875B40403" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E386EAF1F62F614C0C816226C2B4033C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC0136CED44FA30818926226C2B41110" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6BF382DBC9DF188F86246226C2B48BF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1AA49973DCD67577DE16226C2B4E894" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5B20D78D865B6841FCDE6226C2B490DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07BD5C8FFA48D0504B5C6226C2B447C1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C6485F531F7A9E87EAF36226C2B4B0C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D5970B24503D15AD60C6226C2B42CC9" xlink:to="loc_us-gaap_ShareBasedCompensation_A10D3C8C5E4CDAE590496226C2B4D58F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_810AB09FC2091E7ED47586A854EDBD7E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_810AB09FC2091E7ED47586A854EDBD7E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51FE4E00CFF9442A528286A854EF151C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D454FCC4104A511A74B586A854EF5D3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49323AD294DF8153A16C86A854EFE251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74B128CE74C1DCDF9D6986A854EFCEE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3885146C7217152CE0F286A854EF538E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_413764A5A7C9B195611386A854EFD5EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_16A6DB1FD1CD7243160086A854EE92D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6C5667C3C5979EEE3F3486A854EFB4EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_810AB09FC2091E7ED47586A854EDBD7E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F0FF7CCC74218FE4C40B86A854EF8006" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8FF6E78A4831AFE1901A86A854EFECB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_426AE143CB65003BB5C786A854EF7DE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_E64D92FB51412C9CAECA86A854EFE170" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B5F74AAC190ABB7FA6F86A854EF7441" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1A8A4A56D9C2C80CA72286A854EFB0D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_845E7DBE1D0F88A759D086A854EF438B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_D23073A9E886284FD1EA86A854F0CC48" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_810AB09FC2091E7ED47586A854EDBD7E" xlink:to="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_375FE1C0827EF1C41F2786A854F0ADB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8656436326C1FC6A263486A854F08552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0E5383D32DD919AA128386A854F0FA5B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_C146AF90FB8081779A0786A854F0A4A1" xlink:type="arc" />
    <loc xlink:href="omer-20140930.xsd#omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_810AB09FC2091E7ED47586A854EDBD7E" xlink:to="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_DE491C2F3E4CC01951D886A854F0458A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_214ABEF8E6F129BCA88186A854F0AB9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1B7AB0B8971DED4B747586A854F0A156" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CBA2A0EA67AFD34E53A386A854F0206A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.omeros.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9CC1A4EF30FF71B9933C779F0724BB34" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9CC1A4EF30FF71B9933C779F0724BB34" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1AD8954937266A38A112779F0725988F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9CC1A4EF30FF71B9933C779F0724BB34" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_886FAB6D14BC25C66A98779F072592A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9CC1A4EF30FF71B9933C779F0724BB34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4B5BDB2056DE23726FF3779F072540ED" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`=?[]DX`$``+H6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-UNVC`8AL\G[1XBGT[$
MV-FZMB+T8#^'&]+8!;CQ!XE(;,MV.[C[.8&B"E$J5*2^)T00^WL?K.B1\D[N
MUEV;/9(/C34E$_F8960JJQNS+-G?^<_1-<M"5$:KUAHJV88"NYM^_#"9;QR%
M+.TVH61UC.Z6\U#5U*F06T<FW5E8WZF8OOHE=ZI:J25Q.1Y?\<J:2":.8C^#
M32??::$>VIC]6*>?MR2>VL"R;]N%?5;)E'-M4ZF82/FCT0<IHUU"GG8.:T+=
MN/`I83!^-*&_\W+`;M_O=#2^T93-E(^_5)<P^+KE_ZQ?W5N[RD\/.4)I%XNF
M(FVKARZ=0!Z<)Z5#312[-A^N>:<:\\1](G]8'/AP$1<&Z?_?,/A,#@G"48!P
M?`;A^`+"<07"\16$XQJ$XP:$0XQ10%",*E"4*E"<*E"D*E"L*E"T*E"\*E#$
M*E#,*E',*E',*E',*E',*E',*E',*E',*E',*E',*E',6J"8M4`Q:X%BU@+%
MK`6*68OW,FM,S2#QX?/MC^DPYI5J*L1-2^'"KY/;H:\EU\J3_A-]ZE`O#O!\
M]BF.U##.O'4A=:V>SC^%IS*UWSUR:1#YV-"^3CU62^X34T][?N!!+TI]$ZQ)
M'\GF0_,\_0\``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?
M<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````",DL].PS`,QN](
MO$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4
M'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR
MBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'
MJC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB
M8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%
M#U1?````__\#`%!+`P04``8`"````"$`Z,')Y]\!``"K%0``&@`(`7AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````O)C+3L,P$$7W2/Q#Y#UU9P;*0Z1L$!);'A]@)6Y3
MT2:1;1[]>ZP*4BK!91/-)I(=U;FZ,[TGD^N;C\VZ>/,AKKJV-#29FL*W55>O
MVF5IGI_N3BY,$9-K:[?N6E^:K8_F9GY\=/W@UR[E'\5FU<<BG]+&TC0I]5?6
MQJKQ&Q<G7>_;?&?1A8U+>1F6MG?5BUMZR]/IS(:?9YCYP9G%?5V:<%^3F.)I
MV^='_W]XMUBL*G_;5:\;WZ9?GF'?N_`2&^]3/M2%I4^E&;:BW=TAF63-QOXA
M)_NA*^<"R>&9LAR>03FD+8>0'#E5EB.G2,ZYLIIS)(9860TQE*-M#D%W^$S9
M'3Y#[HAV"`H,01DU!&/C@J\?4\C,B=GVKUP^V$;F:#<R[F/M0"8<R)GGJKCB
M*2S5I;:<2R1'FU805MJ-`_N&U*V!WK`VR!F"7+0C1V#FR*CLC&F[SB_Y^QS>
MK='?2)N5$)6DK8:@'-8F-T-R\ZCD'D:G?;<,6U_3%,/Q148-O92G3K^7LEO:
MW16&"VDSDB`C29N1!!DIVB006"QM$$`.:%<*%HJTK2'H#6LSDB$C>51&#BFW
M3YMAZSOXX'PIVIDC,'-$&YH"H:D-*<RH7&/-[X\#O^W!)];Y)P```/__`P!0
M2P,$%``&``@````A`*Q>T6*&`P``)PL```\```!X;"]W;W)K8F]O:RYX;6R4
MEE%OFS`0Q]\G[3L@WC<"A&ZMFDYI2K5(75(M6?MHN>`$JV!GMFF:??H=SI(<
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M549#'!(D?I^5I*LR54LJ^!_+F,WOC"\%!PZI,&2(O,1?D(RE`H<T88;<2:W)
M/5-D5E#%\%9HL[V#+UT'(ZH+8O^DOVO^0DM@7ULK8_'2DCE',E^[,K>4JP=:
MUHS\8%37"D@&'>2B#XCN79QWMP^S3-4L)W></O&2&PZCX`!6OT56K[MY(@V#
MT.F&/I78<3]"KPP=(G^R%R;JUH88;W#QDU7%C0W,)F@DH1G$$F9:QRX&)W3X
ML_4I9)G#'"%-TLT&QYI@#PYV,R.SYVNJ(5<C6<$@U)8=+(!;*/Q/XB#1^W;N
M8^3"=S!'YDT!6H7#Z(4.>\>A.2*#T0L=]H[`XVHDF+_0`?`?#&1W?=J0X5(Q
MBS&9HZPDF$68NYTQ=Z2X1[Q@,",'S!,U/J*#>8T<7M\>+N!A7^H$$QLYQ+KC
M!29&F=7;;R/2B5HZ#KPGZGW+!84>0CH);H+(8?B$SH0J!=V`=.#[>1@ZVX\I
M'IO'P#G<0SI)2\?AN#6`R`TSE,.1X)!=W$B1@^\..6=?A+&'10<UZ/_3XXC@
M]^,NC-^%K.,EP5[B=R.[+0GR<H;;,':0/85^4W'R@'1BC#XL.KDYI;.]CW4P
ML;%#[$F=NJJHPCJ86#B`@9_``@"'J0QZ!4YYS:4Y)MD"!+LS[M5?````__\#
M`%!+`P04``8`"````"$`(%*8S7T$``#K#@``&````'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;(Q7VV[C-A!]+]!_$/1N2Q1U-6POHDO:!;9`4?3R+,NT+<02
M#4F)LW_?(2E;Y,C9[(L3<0Z'Y\P,.>3ZRWMSMMY8U]>\W=ADZ=H6:RN^K]OC
MQO[G[^=%;%O]4+;[\LQ;MK&_L][^LOWUE_65=R_]B;'!`@]MO[%/PW!9.4Y?
MG5A3]DM^82U8#KQKR@$^NZ/37SI6[N6DYNQXKALZ35FWMO*PZG[&!S\<ZHKE
MO'IM6#LH)QT[EP/P[T_UI;]Y:ZJ?<=>4W<OK95'QY@(N=O6Y'KY+I[;55*NO
MQY9WY>X,NM^)7U8WW_)CYKZIJX[W_#`LP9VCB,XU)T[B@*?M>E^#`A%VJV.'
MC?U$5@4);&>[E@'ZMV;77OO?ZD_\^EM7[[_5+8-H0YY$!G:<OPCHU[T8@LG.
M;/:SS,"?G;5GA_+U//S%K[^S^G@:(-URO8J?827XM9I:U`!(+]_EWVN]'TX;
MFX;+('(I\0+;VK%^>*[%7-NJ7ON!-_\I$!&KWYUXHQ.8,3HAWM*+`Q*$GWMQ
M%".I)"^'<KON^-6"\H`U^TLIBHVLP/,H8>1Q%P6QK03Z2<#E)*#;P^C;-@S6
MSAL$J1HAJ8)$MC5!(A.2W2!"GG";WP:F.<2<4MP0(A]`_<X?HH+Y4_=.5U@1
MW=!TG,XAGHG(YH@P-B'Y'(*<%'.$YL101`U%M\"+T8T-7J:H)B:)5$%BF16/
M^*8UTZTD05'(=2L-D.="MQ*?3KDQB/L/B8M1J'>->.2:U%(%@=^[-E13V:>(
M_%-$\2.$H0.V@592MP2(43,!T10'6<6I@H0R`81$$:J!3+<GOH?"D.MF&LYR
M5.AV+R1D6MZ@'SZD+T81?40O51!%/P@B7$"ZV?<(9J^;B3]G;]A)0B?W!GLX
M-QX$7XPB]A05D8*,P8^HCRH\,^PTI)B_;@]<FJ#H%+J=QJX_E:C!7_3VZ3R]
M%8\81?PG_:IX%$3Q7Y"(4$0@,P'4UR*H#E$#$+@N12$J#``-0^V,,#0D#S6(
M4:1ABH'2H""^W`!H\4RW(6FY;L.%57Q@-!@3Z-T/PBZ'$6=4%^F(4:07B8_R
MDIGV`-=%/MK'Q'E!@()2F``2?73N$]'BYJ4CAY$&U$_3$3-J\(*9!M4]E9U@
M<VY.IS%*3V'88>O?=YZ9`]'B'O!7G4_O7!%JGRE1F%OQQ]1#"C.$H#%N(KF)
M"+PD1#N\,!$T2H*/E(A^]T"):H.&$M0I4Z*WR@5YI,1$/%)B(!XJ,1`_4B*:
MWJ1$7N^TZQ%1/5%7%*.HI2,FD9MZX2YQ]608@$_>W`2093B%71X;!0;0:8^:
M%28Z(%+C!T!,NGF"JS<^H6*T5#IB5*51WW6#T$?EGAD8+XE]/W!1/>8&AGJ)
M'\PZCGAZ"#YJ+2\"1T0[DI4R];90-_*&=4>6L?.YMRK^VL)ER`-M]U'UIDG)
M"J[/<`M&X[EXZ\C7RMT`+Y!+>61_E-VQ;GOKS`[@TEU&0*M3CQ7U,?"+O"/O
M^`!O#_GO"1Z5#"[FD&[;.G`^W#[$]?O^3-W^#P``__\#`%!+`P04``8`"```
M`"$`4A/.4\H$``!^%```&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R,
MF%V/JS80AN\K]3\@[D^((9!-E.1HP6Q[I%:JJGY<$^(D:`%'0#9[_GUG,%\V
MJ7WV(AN&A_&\GL'C>/?UL\BM#U;5&2_W-EDL;8N5*3]EY65O__W7VY<7VZJ;
MI#PE.2_9WO[.:OOKX>>?=@]>O==7QAH+/)3UWKXVS6WK.'5Z9452+_B-E7#G
MS*LB:>"RNCCUK6+)J7VHR!UWN0R<(LE*6WC85C_B@Y_/6<HH3^\%*QOAI&)Y
MTD#\]36[U;VW(OT1=T52O=]O7U)>W,#%,<NSYGOKU+:*=/OM4O(J.>:@^Y.L
MDK3WW5[,W!=96O&:GYL%N'-$H'/-&V?C@*?#[I2!`IQVJV+GO?U*MK%+;.>P
M:R?HGXP]ZLEWJ[[RQR]5=OHM*QG,-N0),W#D_!W1;R<TP</.[.FW-@-_5-:)
MG9-[WOS)'[^R[')M(-T^/I+R'$:"3ZO(L`9`>O+9_G]DI^:ZM[U@X:^7'G%]
MVSJRNGG+\%G;2N]UPXM_!=2&/CAQ.R?P1.>$N`OWQ2=^8/;BB(A:)31IDL.N
MX@\+R@/&K&\)%AO9@N=.0A?'(`KF-D7Z%?&]O;8M"+<&Z\?!\X*=\P&SE'9,
M.&>"M8Q$/8)3A7YI;QC]$OF1N"<P(1#[(`"F92*@CQ.M&&<_0-@;Q@%<>8!H
M3@0O,D(%`I$,ZA4GL=:)%+?W-&ZT2G&KAD@U4&&8!N5YRGS'DX>D(%92$&WV
MO>60;+P+I3J1ZWG*E(2"@<]A2GQYTB(C08U$K",D05#"DVI0!>'=O0TY&H+U
MO(T<;B@8G2`C07L"WP^U0OI[8PSCA$E2`JT4O*M(62T5*8+123$2=$YX*_75
MG#/_(PG6C4EV^G<5K:H49=9"P;RT*XZ_62WQ3U8;"42CEIJ=Q#HG4G:PAX_K
M9B\%K:H43XXS%$S02B%DO8:FK4J9(IL5`@I!IX07D$TP0^(IX@:$D"DB:=D\
MU8)65<M*T2(8S9Q'1H(:B5A'2$((M/!)5M37O[UM6M`Z2*?)C%`S$FL161;V
MOK'86EDK?UBFB6B-TK*V&M_`ML&&'23*SL.*4DHJZ@B-<&IT$FN=R**P56I$
MB4XJBYKM-`0D1`6M*KE`(R((K2B3DUCK1!:%C784U2\+1/1?68S2H\,.TH0:
MF1%J1F(M(LN!8"9R9N\3WC:^3P+2RC(BE!B16(O(LK`'CUF:R1(M6LZ6NN^!
M?3YJ%Z7GD\V3]TG7Z;M=K\E)W`WS?/9D4=B%1U%#Z8GF+(M1]SQ$U\';4",S
M0LU(K$5D.=B)1SFS'(E&K=^;$ETW[V09$6KV$FL1619VY5'6D"71K.4LJ1L'
M(J#GM=#),2*T\R(*M]U:*(T@UHXCJ\'./*J9)4DT;DF5KXP6$EUW[U09$6KV
M$FL129:KWT:TMTW+7@?IDF5&J!F)M8@L2]Y&]+7G/MD^^,H6/^P@K1SA1X-0
MLQ<\K\%U5>ST<56=[%.$&G$<(PXQ"E9=6,3RO+92?B_A9QW6]6`=CH%>/3P)
M4.PAV<)!Q-Q.X=CHF3UTM^$S/Y&[A5_E<S^QNX4?WF!WAH'A4.B67-CO277)
MRMK*V1E"7B[6T`<J<7XD+AI^:X]FCKR!XZ#VZQ7.^1@<E2P7`)\Y;_H+'&`X
M.3S\!P``__\#`%!+`P04``8`"````"$`$-;8<T\$``"%$0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6R4F%V/HS84AN\K]3\@[C=@',B'0E:3`.U*
MK515N^TU(4Z"!G"$R63VW_<8`X,-:V_G(A,.#Z_]^AS\D=WG][*PWDC-<EJ%
M-EJXMD6JC)[SZAK:W[XFG]:VQ9JT.J<%K4AH?R?,_KS_]9?=D]:O[$9(8X%"
MQ4+[UC3WK>.P[$;*E"WHG51PYT+K,FW@LKXZ[%Z3]-P^5!:.Y[J!4Z9Y90N%
M;?TS&O1RR3,2T>Q1DJH1(C4IT@;ZSV[YG?5J9?8S<F5:OS[NGS):WD'BE!=Y
M\[T5M:TRVWZY5K1.3P7X?D?+-.NUVXN)?)EG-67TTBQ`SA$=G7K>.!L'E/:[
M<PX.^+!;-;F$]@O:)LBWG?VN':!_<O)DH^\6N]'G;W5^_B.O"(PVY(EGX$3I
M*T>_G'D('G8F3R=M!OZJK3.YI(^B^9L^?R?Y]=9`NMOV,EI`2_!IE3FO`;">
MOK?_G_FYN84V#A;^RL7(\VWK1%B3Y/Q9V\H>K*'EOP)"O/5!Q.M$X'\G@OS%
MTO-7Z_^C@CN5X$/%6WAK'_F!N2^.\-6.1Y0VZ7Y7TZ<%108]9_>4ERS:@G(W
M$)V;86@@0QFG7S@>VBO;`M,,HF][[*UVSAN,==8Q!\'`YXA9R\QQJA,H,E&/
M\)'D;<=]X$,7R:I)3_#4@[_!)`S\R&3OA4>YE[Z!@PB`R*CC&[F)XY3Q9"*:
M$H'B/IXBBD@R)48BDC<HBQEO/`JU.K:"7;FC!\$L1XPO$T<C$1F)V$@D.D*R
M"EV=L<JCH0T#-F0M4))V$(C.J2#6;45[:.FZRF!%8P!M@@D0CP'L;R9`,@;0
M$J,Q(=F$B67&)H_*-A%2JN8@&&AH&`HUHT8B,A*QD4ATA&059IP9JSQJ*E[!
MZ*P:B<A(Q$8BT1&259@S9ZSRJ)Q5C)59[2`8G55!!#^NWC$P6[UC8+9ZQ\`R
M^''Q\AV2LIY@=U@^^%W9+D)8GG0.@M'9%82PRU]5]5WM%?CRI-R+#<\F\\]*
MF=QH+?*[LD6,U?=4,#J+@A`65VM_ZM$H$9LD$IV$9!C!_FJ4U'[];,.RU<G,
MVS$ZJV8D,B-QAX@1FZU@B="5,.+;B(\:'NR*W<5XH<%8+=[VV=#6^A4Z&B0R
MJ\1F)-$B<H+Y=F/&L=B%P/H\K"=XLHM``M+8.9J1R(S$9B31(K)CONF8<2SV
M(G*.E\H$A0343;=\_H$_F3EVC&94(C,2FY%$B\B6H3-SEGE8?HLWDZH6C'"\
MAK/JC&&!P.=0*\K>(T)&)#8CB1:1#?-MR$>.V[/-:"V"\YYJ'&.ESX<.TM@Z
M=HC8.RIU$.ENQKJ;_/C+NR=D-RMIR(5-<;H5I[F2U%=R)$7!K(P^*L@!AD5W
MB`ZGZA>/'W>4^!%MX;0UC<?\%,[CSO``G(WOZ97\F=;7O&)602[0E+M806=K
M<8P6%PV]MV?+$VW@5-Q^O<'/'03.<>X"X`NE37_!&QA^0-G_!P``__\#`%!+
M`P04``8`"````"$`S:;VX`L%```B%@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6R4F%V3HC@4AN^W:O\#Q7T#`46QU*E&/G:J9JNVMO;CFL:H5`.Q
M@&YG_OV>D(`F,(G;%[;&AS><-R?A>+9?OE>E\8F;MB#USD268QJXSLFQJ,\[
M\^^_DI>U:;1=5A^SDM1X9_[`K?EE_^LOVQMIWML+QIT!"G6[,R]==]W8=IM?
M<)6U%KGB&KXYD:;*.OC8G.WVVN#LV%]4E;;K.+Y=945M,H5-\XP&.9V*'$<D
M_ZAPW3&1!I=9!_??7HIK.ZA5^3-R5=:\?UQ?<E)=0>*M*(ON1R]J&E6^^7JN
M29.]E1#W=[3(\D&[_S"1KXJ\(2TY=1;(V>Q&IS$'=F"#TGY[+"`":KO1X-/.
M?$6;%*U,>[_M#?JGP+?VX;W17L@M;8KCMZ+&X#:L$UV!-T+>*?KU2(?@8GMR
M==*OP!^-<<2G[*/L_B2WWW!QOG2PW$MZ24Y*F`E>C:J@.0"A9]_[_[?BV%UV
MIN=;RY7C(7=I&F^X[9*"7FL:^4?;D>I?!B$NQ41<+N+!;?+O7<M=+]'2_Q\J
M"Z[BCRKNVEHOEPM_O7K^7E9<!?X/`;G6PEVNUD]$9#-W>E>CK,OVVX;<#$A5
MB+^]9C3QT0:4N9W<D]%@6.><TJ\4WYD`@G4MC'[N/6>]M3]AQ7+.A%,&B<1A
M(.BJ4=F(#<#K*.NOQ&OB*2*I)@,QJ*;#P%W5<X)1U@8'1AM@H1]L&**EHS3:
M03$<!NZ*[JC71W*8$K[D3\20QV`]Y(@R\921)DJF!&2VJ)*J&<$`R/`9`^BH
M8(`\<)`'(C8@1B>M5/P$DSS!I'.,-WH@Q`=[<"8^.@H'PT/>>6@Q"O0K&C(&
M7L?<7(K$04M$6B+6$HF62%6$8`8<.@]F])O><\8]3K_=F9`[8\`>DD(.&0,3
MCHQ$'+1$I"5B+9$P8LU.(G@4TS]Q=5*5B.`*',\/K@QG`!V5W?#%*4+&J-S0
M$A$C_#X2%*"92&*M2*(E4A4AN`%G_(P;=%1V0SJI0\:HW-`2$2.X&_YT56.M
M1*(E4A4A>$&+1^DA^;!?Z+>B)\B13N*0,3P>UP^"29X>&++H$T#*X4A_>3Q<
M_M,=F6B)5$4(A@2"(<-6H:.B$1Z2'GXA8U3)H24B+1$S(F!^!Y:["(2_^$5:
MGT0KF:H(P1L$-:TB6_JO99?N50E[YG!(99,>B?1(S)%EGW4+UPFD8SS1:Z1*
M1+2&5F3WC33D#6*%FO#$<:4M$')(:0G342"17B7F"-^KCDN/8O&\3_0JJ1(1
M3:%5VHPIK'@339$*J1`Q2!'Q08]$>B3F"#/%90]:V13MO:3*B413:&DW8PJK
M^$13I+T<(@8I3=$BD5XEY@@_9AS+D98GT6ND2D2T!`*:LX0.2^>)>R^"^7G"
M(*4E6B1"6B3FR-V2R7FBU4B5TXB6T-IN)DM8R2=FB5S60].`^J:T1(M$7(7O
MB\5B<E;$^GD2/9(*\R#'>YQ'M(06>#.6L+I/M$1:FQ"IBD/V\U:/1'HDY@@_
M8J&=\AA./U&B5TF5B&@*K?3NIL@_>*!?-=U"<HW/(66^J`K*/JQ(KQ)SA/VF
M<=?3E$KT(K0%]_/L9MZP%AMK!E6X.>,#+LO6R,E'#3_J:!TZCHZMO5>/]D*D
M\1!MH*,S,^YNPCG^X&Z@;0"\/0I!X^Z:G?'O67,NZM8H\0ENP;%H=ZQA/3[V
MH2/7OF7U1CIHV?5O+]"+Q=!#<BR`3X1TPP<ZP=C=W?\'``#__P,`4$L#!!0`
M!@`(````(0"PCS^9]@(``-4'```9````>&PO=V]R:W-H965T<R]S:&5E=#(W
M+GAM;(Q576_:,!1]G[3_8/F]Y#L0!%0E5;=)FS1-^W@VB4.L)G%DF]+^^UW;
M$!*7=7T!<N_Q.?=<WUQ6M\]M@YZHD(QW:QS,?(QH5_"2=?LU_O7SX6:!D52D
M*TG#.[K&+U3BV\W'#ZLC%X^RIE0A8.CD&M=*]4O/DT5-6R)GO*<=9"HN6J+@
M4>P]V0M*2G.H;;S0]U.O):S#EF$IWL/!JXH5])X7AY9VRI((VA`%]<N:]?+,
MUA;OH6N)>#ST-P5O>Z#8L8:I%T.*45LLO^P[+LBN`=_/04R*,[=Y>$7?LD)P
MR2LU`SK/%OK:<^9E'C!M5B4#![KM2-!JC>^"99YA;[,R_?G-Z%&.?B-9\^,G
MP<JOK*/0;+@F?0$[SA\U]$NI0W#8>W7ZP5S`=X%*6I%#HW[PXV?*]K6"VT[T
MD8(WH`2?J&5Z!,`Y>3;?1U:J>HVC=);,_2@($XQV5*H'IL]B5!RDXNT?"PI.
M5)8D/)%$4.8I'\["11(DZ?]9/%N1<7)/%-FL!#\BF`[0E#W1LQ8L@5E;B'SH
M9*&3=SIK,!"6$'W:1'ZZ\IZ@*<4)L[68.48#)IPB\BN(Q0#QH)"A&O#X1C4Z
M.ZTFG`\\IN"MA<Q-X[2#?!28*('7D=+9KXY"`T9>@C1Q)"PF'F$<1/X68E($
MD%PI0D?7&`H?&AJDF5.$Q2S,E03SV+F3?)Q>)/]H-HS>%74===3GOJ-N,:E5
M3R)7W:9CDT[C2^D3[^E5=1UUU0-'W6).ZK$?3=/Y)!V-6C.1AWF]8EY'77EG
MFK<68]UE(W=F`/-Q-LDNG9F(Z_U_>>G.PZ>CKKAC;FLQI]8&%WHK/L[&V64L
M)^+957$=G8I'OOMR68P=.M@YSE3`IM44-AUE<3S<BY6W:]0NGY:*/<UITTA4
M\$,'@Q["M`Q1N[VWP1+>9]BF3CR'K6[BWI"`9=N3/?U&Q)YU$C6T`DI_-H=)
M%'8OVP?%>[-`=ES!FC4_:_C[I+`I_!F`*\[5^4%O_N$/>?,7``#__P,`4$L#
M!!0`!@`(````(0!\B2TKD`(``#<&```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;)146V_;(!1^G[3_@'BO+W'<I)'MJDG5K=(F3=,NSP1C&]48"TC3
M_OL=(&%.4DV='VQS^/C.=VX4MR^B1\],:2Z'$J=1@A$;J*SYT);XYX^'JR5&
MVI"A)KT<6(E?F<:WU<</Q5ZJ)]TQ9A`P#+K$G3'C*HXU[9@@.I(C&V"GD4H0
M`TO5QGI4C-3ND.CC69)<QX+P`7N&E7H/AVP:3MF]I#O!!N-)%.N)`?VZXZ,^
ML@GZ'CI!U--NO*)2C$"QY3TWKXX4(T%7C^T@%=GV$/=+.B?TR.T6%_2"4R6U
M;$P$=+$7>AGS37P3`U-5U!PBL&E'BC4EODM7FQS'5>'R\XNSO9[\(]W)_2?%
MZR]\8)!L*),MP%;*)PM]K*T)#L<7IQ]<`;XI5+.&['KS7>X_,]YV!JKM_%'9
M@R=X(\%M"T#DY,5]][PV78FSZRA?)%DZRS':,FT>N#V+$=UI(\5O#TJM]T`R
M.Y#`]T"2YM%\EB^6_\.2'5C@>V2Y?C=+[.-R^;@GAE2%DGL$/0;*]4ALQZ8K
M8#XDXA!-2`T4B%KTG867>($1!*W!^EQE25K$SY!K>L"L/0;>`7.&V%PBLF06
M6&*0%O1!SB;ZCC*LU<JP6;:ZUMXP]?F7SR$V;R"6;[N$-$Q<NI3,\Y`!NPM=
M,(DN2[)`Y-5XS'R"R4\1FW\A3N('DG,Q61+$V-T20V@AU5DR/W6U]IBE*]8B
M3^`Y!6RF@!3NH2GB1`MT_$3+L1;6>J[A+-RUQW@-Y^[?WO.._0#[AA5,M6S#
M^EXC*G>#F[JJ"-9P;]S-W.B'#1CGD;3L*U$M'S3J60-'DV@!?I6??+\P<G3C
ML)4&!MG]=G!!,VBO)`)P(Z4Y+NS=$J[\Z@\```#__P,`4$L#!!0`!@`(````
M(0`@_N1\]@,``+0.```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(Q7
MVX[B.!!]7VG_(?)[DSA`Z"#"J)-1[XZT(ZU6<WDVP4#421S%INGY^RW;2;`3
MQO`"Q'52/G7QP;7Y]%&5WCMM><'J!.%9@#Q:YVQ?U,<$??_V^O2,/"Y(O2<E
MJVF"?E&./FW__&-S8>T;/U$J//!0\P2=A&C6OL_S$ZT(G[&&UF`YL+8B`A[;
MH\^;EI*]>JDJ_3`((K\B18VTAW7[B`]V.!0Y_<SR<T5KH9VTM"0"^/-3T?#>
M6Y4_XJXB[=NY><I9U8"+75$6XI=RBKPJ7W\YUJPENQ+B_L`+DO>^U</$?57D
M+>/L(&;@SM=$IS''?NR#I^UF7T`$,NU>2P\)>L'K+,3(WVY4@GX4],*-WQX_
ML<M?;;'_IZ@I9!OJ)"NP8^Q-0K_LY1*\[$_>?E45^+?U]O1`SJ7XCUW^IL7Q
M)*#<2_E*SDK8"3Z]JI`]`*&3#_5]*?;BE*!Y-%NN@CD.E\C;42Y>"_DN\O(S
M%ZSZJ4&*^N`D[)S,@69G#V?A\Q(OH_M>?,U(1?*9"++=M.SB07O`GKPALMGP
M&CS+$%9+2&4NC2_2JC"PS&'U?1O&\XW_#DG).TRJ,2OD73$V(KN!>!X@/A`9
MV$",8S;S8&`CK2,VJ\&/(IQJR$K50$:0&0O63A#K>*?%-6YIA2*9,<6+T58:
MLS`P2QN1N1`6&7!BD.F3+U<3!`$,B<4+;&^1:LRS+@U>!;%MSTP[GD>&W2(`
M77B#@%RU"83Q*,948V";@>0(D;D0%HG((J%:T2B)M-XKB<:XR+@0%AGH9R,C
MBHS1B=)J9P9'H9WZ5&-<9'J$.E?X>JXL(O+/8G1`#2+2.B8R[A&-B;H>">:!
M330S[3A<X>N9LHC$%I&^2>6J32",(WN#5&-<F7`A+!(81'J<#J-)E/E>EW0@
M%Q\GQ"9T0T"-^F"M?>8A#N-K@K5H=:"%JE"T&I_AWYIM(E+IKHW2UP=K`;0)
M7-6W(Z!!SHRX(#81*7M7(N-SC+4JPN>@&.%$6SN0D]##ZHK!C4%HR(Q<MEMW
MJJ_JW03UAV<JL!;`H;!P+S!)C`5%F6TR83QJA+0#.;/RL-IBM]PJ\]V3Y))3
MU5I9Y^<V9[MOW)*+']'<#G1[MX[00ZJ+W;*KS':Y<#36W0[4]\Y4>"V`0WFQ
M+;V3WIEJ\#P8B7RJ?"3(F9F'53ATJ[`RW^N=#N0BY(18O1.Z55B9[7)-5;@#
MZ;O45(5_:]9$])"@K]85;8\THV7)O9R=:]"Y$*1]6-7#28K7<%N%66&TGLFA
M18T=@P%&B88<Z5?2'HN:>R4]@,M@!O=TK]53AWX0K%'7XQT3,$2HGR>8#BG<
M@X,9@`^,B?Y!SC7#O+G]'P``__\#`%!+`P04``8`"````"$`U`U+I1(#``#'
M"```&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R,5MMNHS`0?5]I_P'Y
MO>&6D!"%5$VK[E;:E5:KO3P[8()5P,AVFO;O=P8'$H.6]B4!S_&9,Q=[V-R^
M5J7SPJ3BHDZ(/_.(P^I49+P^).3WK\>;%7&4IG5&2U&SA+PQ16ZWGS]M3D(^
MJX(Q[0!#K1)2:-VL75>E!:NHFHF&U6#)A:RHAE=Y<%4C&<W:357I!IX7N17E
M-3$,:_D1#I'G/&4/(CU6K-:&1+*2:M"O"MZHCJU*/T)74?E\;&Y2435`L><E
MUV\M*7&J=/UTJ(6D^Q+B?O7G-.VXVY<1?<53*93(]0SH7"-T''/LQBXP;3<9
MAP@P[8YD>4+N_/6][Q%WNVD3](>SD[IZ=E0A3E\DS[[QFD&VH4Y8@;T0SPA]
MRG`)-KNCW8]M!7Y()V,Y/9;ZISA]9?Q0:"CW`K>DH@1/\.M4''L`0J>O[?^)
M9[I(2!C-%DLO](,%<?9,Z4>.>XF3'I46U5\#\L]4AB0XDX0@\VP/9L%JX2^B
M]UE<HZB-Y(%JNMU(<7*@/<"G:B@VF[\&9@QA#IJ,CCXHR&V*Z#N$)V1)',`I
M6'W9!K&W<5\@2^D9LQMC?!MQWR$PN:"C%P,A7HGI?.(J^L2\HHB=60"2BXB!
M@S$B6O40RR7$?.6RB[]SC58HUK6G>!#,SF#F5YA%[ZK5>S^%L,0`R808M"8$
M0KN$'0>VJYW!1&UEEN%J'@9#,19BX:_"^7\R`UTP%!-Z?2.@U1;CA_%`C,&`
MPU[P4,P4PLI,-!8#;=J5":WOE<E@IL1,(2PQT/[#S%R)0:N=F6!4)H,Q98J6
MRSB.+T4P/6,A8B\.PTNI+3$X3"X'N,L(KMHB_/GPG!K,5$:F$):(V!(Q/$5H
M?:\\!C,E9@IAB8$K_SHE0S6MV<[-N$!GT+E"'IRCI=W<.%@PJ@X1>W[4(XP<
M,S?,;5LQ>6#WK"R5DXIC#0<B@.[M5_MY=1?@-3=8W^$<PW6W-\!T:>B!?:?R
MP&OEE"P'2F^VA`,ES2`R+UHT[1V_%QKF2OM8P`<#@VO4FP$X%T)W+^B@_P39
M_@,``/__`P!02P,$%``&``@````A`%<=K;\L"```H#(``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULG)M;<^(Z%H7?IVK^`\5[`[:Y5Y)3;7R_>^J<
MF6="G(1JP"GL=/K\^Y$LFUC;Q(L^>8"P_6E)LI9U0]S]\>MX&/S,SL4^/]T/
ME=%D.,A.N_QI?WJY'_[UI_5M.1P4Y?;TM#WDI^Q^^'=6#/]X^/>_[C[R\X_B
M-<O*`5,X%??#U[)\6X_'Q>XU.VZ+4?Z6G=B5Y_Q\W);LX_EE7+R=L^U3E>AX
M&*N3R7Q\W.Y/0Z&P/M^BD3\_[W>9D>_>C]FI%"+G[+`M6?F+U_U;T:@==[?(
M';?G'^]OWW;Y\8U)/.X/^_+O2G0X..[6[LLI/V\?#ZS>OY3I=M=H5Q\Z\L?]
M[IP7^7,Y8G)C4=!NG5?CU9@I/=P][5D-^&T?G+/G^^%W99TJJ^'XX:ZZ0?_=
M9Q]%Z_]!\9I_V.?]4[`_9>QNLW;B+?"8YS\XZC[Q$$L\[J2VJA9(SH.G['G[
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M2=*&8$G&S`07)S![M9W0-#@/\P9O<M";P&<.I/TW@F#Y7)I24U=R2QE0Q82$
MU27FQ&9V%]%F4[DHCF#:Q245<B'A=0E-F<CY^%V&Y!-`(NP2G5L;=1F23]PE
M.BI)ER$J:9=HJTC>8F/1-6_QL.0M&MB(0+MMM)DFWU>#)C)IP*(!FP8<$9#S
MF<GYN->8N<QXUQC2C?G7&.+;X!I#'J'P!B:ZPLR)+^,;F.0:0_JBM)^1_,"F
M%]?\P,.2'VA@(P)BVE0-&Y0P:<"B`9L&'!'X%'5IP*,!GP:")M#J\S1BU/`&
M)KJ!B6]@DAN8M)^1&HS-Z*XU&`^SJ6Z[IY^3;D(7#,OK,AJ0!VL#"0,2)B0L
M2-B0<"#A0L*#A`^)`!(A)")(Q)!(()'V$9+#V'RZ[;!J(JI-+O-.?OE^R(:<
MBXNT.7F^=,'T.0T2!B1,0<SKN>^$_\F#@`4U;$@XD'`AX4'"AT0`B1`2$21B
M2"202/L(R6EL\=)V6C/1Y6'J,#)5U`6SJMI>44:T(Q.7>PQH]`N8_9<MJ&]#
MPH&$"PD/$CXD`DB$D(@@$4,B@43:1TC&XKM^K;5T8RP>IL8BSM$%T^.<#20,
M2)B"6%;V56?7NBZH84/"@80+"0\2/B0"2(20B"`10R*!1-I'2`YC^T]MA]%!
MDE^6G:9,R"Q=%TR?TR!A0,(41#U(+A:S:7>4;"/*7&$[VW0@M6$^#B1<2'B0
M\"$10"*$1`2)&!())-(^0O(:W[;L,UMU77:;-B?K8;V&A!&4E;I8DE7LIB9Z
M#&E`$1,2%L[&)B*+Z8*LRAV94&8:J8R+<_$PXF,DD$NB\3]Y$AI"(H)$#(D$
M$FD?(?N-[;ZT_=8,GPJ/4Y^1/16]AGI<M,&(@1$3(Q9&;(PX-3*K!NNIROI'
MN8%=K.')&LI*(8.!+P/J9$46[P$!U!5Y)$)<B@AIQ%@C01IIKX;L,[YO>66:
MQK]?Z?B,5%>OH7H%P+[4(A.Y30WT&-%`&B8"+)R)C30<"6!?(VG5=+!Y(?5V
M<8X>1GR,!#52SU&)Y\/>JY%T52-IX]ZKB71U2M*F7UV5C<4W0*\92VR,RGL7
M9.30%0&)@7(^F6HJZ>(V-='K+"1BPFPLG(V-$0<C+D8\C/@8"3`28B3"2(R1
M!"-I+R(;CGGAJN%XG(R8"V)I71%0CYTV&#$P8M:(</:WY9QW-/)09F$5&R,.
M1ER,>#52%W<ZX^L2N;@^012E@P0XHQ`C$49BC"0827L1V7-\0[?5R=$E*#L=
MT_4>F7;H-23N\73>71/T[1K7QP4@8M:Y]#C<PHB-$0<C+D8\C/@8"3`28B3"
M2(R1!"-I+R(;C^_O]AE/[/]*H^R"3&=U14#">)HVZ<S>^C:1:^-!Q*QSZ34>
M5+&QBH,15Z[Q9$DF=AZ6\#$28"3$2(21&",)1M)>1'8=W_QMN>ZR*!6;PK+;
MR!)<Y^>IV#C<XX,-1HP:$3-B;;&DAY%,K&%AQ,:(@Q$7(QY&?(P$&`DQ$F$D
MQDB"D;07D1W'-X-;CJL&V"G?!J@/X(G-8MEY]'LJI=E1Y@?T5&VT(L#F`GQ^
MGTKZ0N."?*%A(L"Z`%]F8F/$P8B+$0\C/D8"C(08B3`28R3!2-J+R*[CV\(M
MUUW<)K:+9;<1I^CL!#;LYQJD.C$JSZ<-G-[$B(41&R,.1ER,>!CQ,1)@),1(
MA)$8(PE&^$'\KVT@W"8.VHL#R,?L_))MLL.A&.SR]Q,[U\%WU2[1RP'_[U-^
M]I3$=67-CA!WXZ:R9H>`NW%/6;,3N=VXKJ[U:_J&NC:NQ4UUS4Z8=74L=<T.
MFG7CMKIFY\U8?'RI`/O9P-OV)0NWYY?]J1@<LF=6]<EHP18T9_$+`_&AS-^J
MX]F/><E^,%#]^\I^"9*QP]*3$8.?\[QL/O`,+K\M>?@_````__\#`%!+`P04
M``8`"````"$`6B_J,#,%``"A%P``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6R4F-N.HS@0AN]7VG=`W$\(D`02)1D-9Z19:;7:PS5-2((Z0`1T]\S;
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MI+37O($_2^F27*.W1_U7\1$DZ>U>P^MNZHN+!]0$GU*6LC$`78]^-/\_TDM]
M/\GZ;K4UUKJJ;67I):EJ+V5E92E^J^HB^X]#*JN]%]%:$2C1BFCZ:J-M#?-7
M5':M"HS!3F7SZRK[5@7^MRJJL=+,K;K=T3U2N#N-JTY41^=C67Q(,%2A_]4S
M8@-?/8!R:V?K26\PO.>8T=\8WA0"ZRJ(OI]U8W=4WN&-Q2UC<<:0I9[9&2)B
M=PCSFNDZ76`HHXI%W([HBG@XX/,`?/;UZIHIJ@13!M433HFQB@*V]=[!Z,#>
MZ>O>*O846X5\L#@SMDH3&VQ/B1WJDS-%D(@[);"(QY&Q>4C$GQ*ZL1=;&TP9
MI!)."=T<&,%>7;"W&X$LRFSMQH'%`T8?L''`P0$7!SP>&/=>-Y#-_B>8X!-,
M.,.8>N^CX,!FU@$6%1S@@9$#..#@@(L#'@\,MOI=8#2;S'7?S&;6!G,,GD\=
M`^]+Z!LLJ7CR;+;]Y&%/8<4>SV5S(]9N<0;T^_F^%0F;)!R2<$G"(PF?)`*2
M")<(P5C8;4;&=M.&14\RS+[>+-U$=EF<&1NJFVAQM^<8M*HY<PR:3>X<@W2\
M*8-:[)-$,"5T$ZU:X909ZA&LA85ZQEH61=;NT4RQ.#.V=JBBF4LV23@DX9*$
M-R7T/9JQ_I1!;0U((EPB!$M97C[D']UH95%LZ;!+-(99G%FRE"0<DG!)PB,)
MGQ.[)EU2MZJQ-["AI$:X1`B&0A(W,K1)Z$9)"7N*C1TV'VXL9Y:,)0F')%R2
M\#C!;3.-C:KA3-,G-0*2")<(P5@5SBK8V=V0[C6/L;5XRVJA)6]IQ*$1ET:\
M%FF'Y7X'_J)%VJ=5`AH)%Q'18I9\3U<#E>?DPN:U1U/(:B'>'6VM;=9KA-@M
MLN"^0ZNXM(I'(SZ-!#02+B*BM2SQ'JS%ZX+*\W+18K3W6RVTX)]-(\X,HN_1
MUN_.0.AM>C3BTTA`(^$B(IK,<OO!Y&XW4WG*+YJ+YIK50GN^2Z@KM"O;[?,%
M\QU"PJ4E/!KQ:22@D7`1$4V%+L^9RL)XO469G:5R:,$TFT:<%FE72A/N?U!Z
MY](B'HWX-!+02-@B;6OA>A+^^G.1Z"P[4\P,5W[4&`]76$Q["9XDP)T;LW_1
M61)Q6A63#WJ4X;ET'1Z-^#02T`B[TV3][:?G=IB_W%-^8\GOUK*DO"5V\GA4
M4ER\Y7#D8F^CC_*;4DL]P#T8'(M1W%$/<+<UC5O:P=K,Q&WM8,_%'>T`Y_ZI
MCJL=X/C/CN-]Q7!O^HQNR1]1>4OS2GHD5VCR>F5`GTM^Q<I_U,6SN=%Z*6JX
M,6V^WN$J/($;O/4*X&M1U-T/5D%_N7[^'P``__\#`%!+`P04``8`"````"$`
M8GFXC6T#``!]"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R,5EV/
MHC`4?=]D_P/I^_"I*$:=C,+L;K*;;#;[\5RA:#-`25O'F7^_MU00BM'Q0>7>
MT]-[[FEIEX]O96&]$BXHJU;(LUUDD2IE&:WV*_3G]_/#'%E"XBK#!:O("KT3
M@1[7GS\M3XR_B`,AT@*&2JS00<IZX3@B/9`2"YO5I(),SGB))3SRO2-J3G#6
M#"H+QW?=T"DQK9!F6/"/<+`\IRF)67HL224U"2<%EE"_.-!:M&QE^A&Z$O.7
M8_V0LK(&BATMJ'QO2)%5IHMO^XIQO"M`]YLWP6G+W3R,Z$N:<B98+FV@<W2A
M8\V1$SG`M%YF%!2HMEN<Y"OTY"V2"#GK9=.?OY2<1.^_)0[L](73[#NM"#0;
M;%(&[!A[4=!OF0K!8&<T^KDQX">W,I+C8R%_L=-70O<'"6Y/U9"4%3`3?%LE
M54L`E..WYO=$,WE8H2"TIS,W\/PILG9$R&>JQB(K/0K)RG\:Y)VI-(E_)H$1
M9Q(_L"?^=#;_`(NC*VJ4Q%CB]9*SDP6K`^84-59KS5L`LY(00"-T'9TH:&VJ
MT$\*OD(S9`%.0/1U/7&]I?,*74K/F,T8$\Z&D&T+4:U2O'$;N/`:K$F+4(9`
M[9T`:$M/0%NGBJHZVPDV.@`D7>&^4=,8$<Z'D'@,,4B2,:)',J@[&-3=-'XR
M[?JLLN!$OUQ_,JQFHS&3'F8Z1&SO(N*[B.068B`("ND9T0B:702I[`I!>[K^
M3URC>1N-B9IEY;FV9[1_V\^']LQ85'$_/;>#:-B,I)^&T4&7'JB`/6"J"-W.
M%I4=VC)Q+T3-4MYH#,S6*35MN8N([R*26XB!H'`@J-T?*CJTPP],(1H3A8T?
MKFVT>VNDYX9;L9DWW$[,_(5_4#^\:WJ&M/6KJ%F_T>:-QO2-".9AYWICUO8:
MYE*(?C==PQABDVN8"\]`D#K\+V_<5I"*FH*,8C<:<S;$LZ-I\F`T=6M`PG`$
MB0U(-$(D!B*<NOV/UQ\P4!9=5::BIK)+:_2>T9AVJ1D>W4K&MY)P]JNI1[2Z
M:'VLZ\.P)'Q/MJ0HA)6R8P4[-X!5WT6[V\23KTX4([[Q%G"@C>,QW#Z:N-,-
M@$M!C??D!^9[6@FK(#E,!5L+=C/7]P?](%G=',T[)N$ZT/P]P#6/P%'IV@#.
M&9/M@SH03^W%<?T?``#__P,`4$L#!!0`!@`(````(0#84IBD%`4``-(1```8
M````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC%A;CZLV$'ZOU/^`>-^`S240
M)3E:.-KV2*U45;T\L\1)T`8<`7LY_[YCCX,OD.UYR6YF/F:^&8\_XVR_?+07
M[XWU0\.[G4]6H>^QKN:'ICOM_+__>GK(?&\8J^Y077C'=OYW-OA?]C__M'WG
M_<MP9FST($(W[/SS.%XW03#49]96PXI?60>>(^_;:H2O_2D8KCVK#O*A]A+0
M,$R#MFHZ'R-L^A^)P8_'IF9?>?W:LF[$(#V[5"/P'\[-=;A%:^L?"==6_<OK
M]:'F[15"/#>79OPN@_I>6V^^G3K>5\\7J/N#Q%5]BRV_S,*W3=WS@1_'%80+
MD.B\YCS(`XBTWQX:J$"TW>O9<><_DDU),S_8;V6#_FG8^V#\[PUG_OY+WQQ^
M:SH&W89U$BOPS/F+@'X["!,\',R>?I(K\$?O'=BQ>KV,?_+W7UES.H^PW(EX
MI.87R`2?7MN(&8#2JP_Y][TYC.>='Z6K9!U&A":^]\R&\:D1S_I>_3J,O/T7
M042%PB!4!8F`IO+3%<T2DJ3_'R5`1K*2K]58[;<]?_=@/"#G<*W$L)$-1!8E
M1"&TLA;.1^&5&#`/8'W;TW0;O$%/:@4I$++V/0VQ$>4"(IL@`?"8R$")GY`1
M7H?,>HHC^18(6<N^B0)*PV!E@E*-3+=RA17J-VO)G0P(B0U(8B/*SQ`6!PBR
MP$%8=S[PGOH9A7:&`B&97(]UXGA+TTNB+)X>MI+#W"TD%U8G.9F>QQ8C),5A
M(*%+KC3]A*Z)7B(K?[J87UB=_-3)CY!8YH\RAUUI>==Z\:S<,*P+M0NKDSMR
M<B,$:R=AXE`KT8W4:**I6<F%^.L-=YL\8762ZX7#QB,$HY-8[R#I+4UOIO>H
ME3I?3"VL3FIGI`N$J#6/HE27ALE-/U"[M^8$%':A=FEV&.@*L'B%P>JSV'&7
MECN/[JP[L<7NUGMI=O+KJ57Y4<0P?VH,%C9`A9B[K?X3H4;SM9=F)[^SO(7"
M8((X=-REY2:AE@0[OY"FA?RH6);DZ`ZJ^A&C1B"AN3.=)3$!)$TB/4,VAV75
M(ZA:$&22O5A7H3@@!CXGC$ZBUN$SB,UC60#A^'9W0^Q,>Z$PV(L8CE];)4K+
M3R.J>VDS6)9`,M?`V!&:0F&0`9S^3J=*RQ_EL5XLFX$MA+/#?ZZ(L:N(Q)3$
M*,^=7I66/TGO3N:R*I*Y+!JUJ*E`#/:"Q%'N;-U2!5$`DJUU#78W;'F<=6.N
MD[$S?@4QA1!>S8PS0,VG"0"ES/5&MKC09:649ELI7"DL%`;+S7)C'R(%VV\>
M)#8#6RO=;E#40U,S8J?QA<*8^W5V;'V.L1DMJR<59ONE+=8[#F=$84PFSM*5
MGT)L'D+IM(K*SJP3>!^1N1XI"J'9&7=_%@IC\IEW!N/<P=B,`.0R(K#.$R7A
MM\?&G<R"(@8/F,C5WM)VAW<$1=Q##")3_KFHNN].A7QTY^/8TBR,C1QJ<#&*
M0D1)FNDUM-NQ+*QT+JR)E@(U*(C!'`]1N(XB!U*J,`I"DSBZ)RC4EM>I&W-9
M370_%0]35A]HFF3.2)<R^*U?#R2[^Z(/%V!S368;>2ZQB>ZK8H,8O'#0A<-?
MYMCY"%@Z_/$*C1?/EO4G5K++9?!J_MK!64YA4B<K7MT+LBFHN,8Y]E)<Z84]
MF!QPT;Y6)_9[U9^:;O`N[`@APQ5L2:_'.SE^&?E5WAZ?^0A7;/GO&7X[87!-
M#%<`/G(^WKZ(!-.O,?O_````__\#`%!+`P04``8`"````"$`0&UGP+,"``"T
M!P``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;(Q5VXZ;,!!]K]1_0'Y?
MKH&$*&2U9+7M2JU45;T\.V""%<#(=C:[?]^QG<N:D'3S0&#F^,R9"\/B_K5M
MG!?"!65=A@+71P[I"E;2;I.AW[^>[F;($1)W)6Y81S+T1@2Z7W[^M-@SOA4U
M(=(!ADYDJ):RGWN>*&K28N&RGG3@J1AOL81'OO%$SPDN]:&V\4+?3[P6TPX9
MACG_"`>K*EJ01U;L6M))0\))@R7H%S7MQ9&M+3Y"UV*^W?5W!6M[H%C3ALHW
M38J<MI@_;SK&\;J!O%^#"2Z.W/KA@KZE!6>"5=(%.L\(O<PY]5(/F):+DD(&
MJNP.)U6&'H+Y*D7><J'K\X>2O7AW[XB:[;]P6GZC'8%B0YM4`]:,;17TN50F
M..Q=G'[2#?C!G9)4>-?(GVS_E=!-+:';L3I2L`8BP=5IJ1H!R!R_ZO\]+66=
MH2AQXZD?!6&,G#41\HFJL\@I=D*R]J\!!0<J0Q(>2"*0>?"';CB+@SCY/XMG
M%.E,'K'$RP5G>P>F`V**'JM9"^;`K%*(?*ADH9P/RJLQ8!9@?5G&R<)[@9H4
M!TA^"0EMQ&H$,3M!/-!Q$@,IWA"CO!F"ZUG,],2C]>8&DFJEONL'MGMUU6VI
M@#*\4W$LA;(.HI^S,-$-)-'1X4W4OX&"FQ!+Q614A;(.5*1VB-Q`)J8&MF\U
M[K/BPD".9*^L=MS$M[ES`QF/.^ZSXB96W.$@*N\@_J"YN8%<[?U5MZ5B:JDX
M]EY9!]$'0YX;B.E]$(\W_S;&TJ&^$.?7\JA#60<ZHD$7#,3HB"9^&`:3V(:L
M+(@?Q6GLGR?94I&.JE#6@8J)'2(WD)LJ+,BX"K-XS;KJ\89\QWQ#.^$TI((5
MX+M3&"MNUJYYD*S7VVK-)&Q1?5O#UY'`*O-=`%>,R>.#6NRG[^WR'P```/__
M`P!02P,$%``&``@````A`-9"?/]W.@``:,P``!0```!X;"]S:&%R9613=')I
M;F=S+GAM;.R=VVX<V9*>[PWX'1("MYL"2#8/H@Z]NSF@**J;,Y+($:5N#QJ^
M2%8ER=I=K*I=626*&[[8,/P(OC'@`1IS;?@AY#?I)_'W1ZR5F96952RV#F-O
MCSUCMUB9ZQ`KCG_$BOSV[]Y?]9-WV3CO#0??W=O:V+R79(/.L-L;7'QW[^V;
MY^N/[R7Y)!UTT_YPD'UW[R;+[_W=WK__=]_F^23AW4'^W;W+R63TS==?YYW+
M["K--X:C;,`OY\/Q53KAG^.+K_/1.$N[^6663:[Z7V]O;C[\^BKM#>XEG>%T
M,&'>W0=/[B730>_/T^S`__1@9_?>WK=Y;^_;R=ZS86=ZE0TF">M(#@>3WN0F
M.1KX!*S[VZ\G>]]^K4?]\2?)R^%@<IGS:#?KUG\]S48;R<[F6K*]N?6@_N.K
MX;N-9/-A^X_%,BIS)S^_Z`VRY&B27>7_J3[:5_4_%".\N1EE]1^_VMI<_\?Z
M'_?9=]?V_KR?7M1__>H\[>>-@8I93K)Q;RB*=9-GZ63^<\][>2?M)_^4I>/D
M.;3.&_.TT:J8)KP>9FL?X!]WZF.^&:?BLN3TYNILV*__^M7QR\/7]3^&HW^=
M7?3RR3B%(5ZE5XUMV:O'I\G!\>N3.2,<P$QC=GP$@[Q/_B&[J3_WU>;FYM;V
MX]W'6T_J/QU,QV/Q8I5H\RC\U?KZUO;ZSE9]C+"1Y[U^-DX..)J+X;BYAOU.
M)^,!?NXR&_\U9YB#X=75<)"<3H:=7]:2T\MTG.7)\71B<@N)ZZ\='+\Z/7YQ
M]&S_S>&SY.G^B_U7!X?)Z0^'AV].D]6WI\^2E?OU5XX&R9O+X31'`/,U!+6?
MY7DRG%QFX^M>GB7Y*.OTSGM-87N6=1"V+9.G!@=$2J9YGDWR;^IS'J3YI4E\
M1_^1_7G:>Y?VH7R#.T\OA^/)^B0;7R6]P;LLGTA>&D]];PPC#6+K3L99)V/$
M,[92G_EDG(W27C?)WJ/*\N;OQ]IXT@F,X,NOC_%F.('!%C]S,D97CE%F6I4V
M.-+*UY)!-JD/]YIMC7L=L8+(4?_95[1H)>V_Q2/H]]*S7K\WZ67-<X`-I9+S
M9)3>B%SUN?E]/&5=\Z@5YQAQ2FCK9'B>#(836#2,9_O57[NH(<U4GV"6E)6E
MUA]\U3IL/(,XOX@];ZIGV7F&>'?ACN8Z)&<]9R[G2ZP,XH6]A&S)JF9/'C=$
MYZL/OW[XM;Y2$]++8;^+Y?W?__+;?_F?O_W7?S$.F-PTY`!N#(O*7<)'J&E$
M89HE*YL;FUL)/)3DDOIODOWI!&'H_84=V%_R9!T[MX8VT_\FZ23!_&&KSG@E
MVL!D=3I(I]T>O'7?]H70AB>"X/XQ.<IS';%)3ZE8PAR^@;_^\P`/H;[1H)M^
MW\JW=K_4TG<>K&UN;Z]M/=BU/4*:G=TG:[N;CW\OR=;@(&G%2>]=UF^H]OTN
MY$86T!!2-.N]`5(]ZJ$QZO1#N*97T[[9@&YVWNOTYHB''7>=HQ:^41$DVW3K
M"-)*D\;Z%UJ0$S@1]RN;]'`J[L^S*`NXVFQ0P=0-@6J\F=:9OD[$QAN!G5U$
M;GUZV.#X^BOSN/R6G<R^=NLV9A]?N(?91Y?80-4E.'V#9_#R\!7NP/'SY/CD
M\/7^FR,>2/9?/<.K>GGR^O"'PU>G1S\>)B^.3Y?T&;+W'32/>R=)-YVD=W$C
M=I;VZ!M.QNOL73:8-O32,?R52GL79JNA=S&Y.,0=]T&Z#-,?FGVN'_YIUN\S
MT%J")6#0O@E3VKWJ#<Q+E0:HO^(63<9_=@WUYUX,<;/.Q\.K)#P['#2<E:/"
MY<'[Z0R;_O#1`-<(]R'NM#Z)^P[^;K(:K/C]5B_D539)^JRI/@3L-AIGESA+
M;+;UB:=IWNL89;J]_E1N#$Z./5F:+U<5\P7_IZQW<<FKZRD!:WJ!V^FN[C1G
MN,F08/)JQ-#)V5)S^<L-[3*CVF8EX6#_](?D^8OCG^:R?,E5J33_''^J^Z=I
M\%&U:OS0(1Y$/RLIPE]%'?-[;7/8AY)9%@S]/4%U@HN%>S,:YK`B7E6[X_<L
MX\`Z/=B/QV76TRNY9W^Q/]2/UR*+=<@*G45DSME?#,Q2?_[5<+!NB^_=PGH_
MI6/SRJ\`'+!M"P<]N$SQM7*8O$H+"QUL`Q5SUA!E#,",0V\O>!@0O4/1``>F
M^*<-7-]8W15VRMWB_U9\RE95)*&Z]:CK*W&IE_Y:P`XG4]07IY;;.N$'_@N.
M&"T?=I0C\-Z"X(I(II-EW:"L,/Z)9K-I`8&F8Y,$S;U@C((.JX'G[VNE[WI=
MN.[L)KPYN^,Z59[W!BFR=`M59M;:P[/EG4R+@[<52`=G52+('X?G>-\:LC/,
MFU'E[,9ED^-@+X:#"P]*GV5G#:?M)+VQ*%72.JB&+?4MS4Y@DI@<CR2V?JI!
MA`"[WF?C#L%X]RXCS'VI.(SJ$9RWD+<^FU[L9AWP/G`!\VN7C.(/YH7[<L'/
M@'P&`YT")X*%`-:J3[SP?4"T^6^>3D>C?J;C4,2N99SWA]<L?B[":'.91N$1
M'G0#6U_1Z57:[R=/ISD((7;\:#`8OD/%82&C:U%_XW76G6(XX`FV60`"QGEF
MU8B9@TAWD^O>Y#*Y,/5Y/AT(2JN/=CR^2`=!I9LHGO8N!J9G@:^"*A-)3X9]
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MWD1__=I>G>Q]^%]._);QMC9_QX""[;_)1YS6=_=P`G+VD]W;2T8$F6)XG4T.
MH_BA]7#LAG!L!Q=7\5Q"+,%A!4,"^:!*#B`(I2Z&.CE887*9]CFZX85>6(-)
M)I?C(=#.J-?!Z1_'7XS,;H1SZ&:C,UD'&6!5:TDO%\^S#,0!>5SO#M$HS'V&
M%G+]Q\D\?[:_GHYLC3!9R1H)_J%6ULWZ")P0G6X/AV?2OQ$KZCR+.7.0#_XR
M'DXO@#@G]B-+L#GBX1?KTMN]P67OK#?!.F79%:I8$;ZT1<%0E9WQ(I#958Y>
M,:N&(2LFAIVF5ZD]S*C:`[:NI/09X<1YCSV<0:2$%45A2<_1-S8,O+:1((>7
M>,1)WGM?O+P.]HN#7(E:-#[:@I7(@8)G1[T1M!ED:\GU94]13C_7UCK]*>>/
M5'=%-RA^`6%&ICRA7^2"8K"*O$VNATE:`38"/^7?<(!L*QT)/-1`P,<@U=K-
M(+M.OM?*)-GK@'_H86%O"A61D=7O3PY>WT^ZX^E%$%V731V?,X[1%.)YZ,4Y
MDA3HG>%-9OE&(35%:@@)(IF$?+UC%@^K1`C<H7$O0S?<U`6Y(A0BV7EO3!AE
MR^$EJ>KD^*K7'??28JY/(O&`@7,'_)0BOSHB9+OI9Z-+>,N]-73H$`E-.[#"
MGP1?#0?WDZT_?+VYL?.'Y)K3+H0-3M8YO-TXW2!I1)I)6O.9CFJ_$OLBNZO(
MZ'T)\<OTI@0=I;DYO<C7^/[I&%<VLC7:FQ4@(:2C4/`)P'\.8Z"DP":1[&3U
MZ`6LP=$KD3A1W#.:CGI]I.`O1(`WG*H"_Z#K-8X'V\C)56^8HUM6_7F"+T?6
M;:?:`V.B+Z:=+"&&FI3OA95@]@<F=/@DF!=4G*)_[2^J/@)=R7@6733(U$->
M)^FY_-^2:OSW_O2"6-!2D4QZD8YEQR-3;>`R),>=R5!HK3)PB&K&_V!TS>[#
MQ&R,F%NGA&H>$>JM!T7&:+VKLRD";-1B\@DVRWA>IZ8$F&R;3N%E)@,I2\[F
M_1_D/DXQ"[T.FF#UX.7I?7LP\/I:DN$2&[*9_'TZF$IN'"C>W4A.JFL(LT*A
MX;7/E1.'*:$E[-\6I@5("TBH7+A=L*]L4?UDDG4N!V8Q6`J&99)<D42.":=.
MJ?`<$-<6Y*>S?8#+L6T^M]-2J`I[S=#(3EK\HV/Q3=E&T^!BFO9'J_$<9,VR
MY`9`J$+%VNXK=`'@0K&ZHG;U.NE=0?:7I_AMN"=7Z2_RG+3SV8/J9IP+T)%9
MGXINGYZ1>I`C)8*%@V"`:Q#?S$.M#AMV5G`*H&A7'CS<=7@%KNIGZY*W=_A8
M58*P-W.ND]QAK&)P2%+(M\B3CK%R<.%NBV*=[!V1?RPR"SRU8[R:%\M.D7XY
M:&+OD*0(&,(^SC?\)QY.5E_NHRJ,W%ERB*LPRA`QXTGYT,F^DBTWR>KA2QZK
M4&*C,KI80!0QQRU2*FRF&/+MP*8[?$O&`\YGG5)VFMGU&]($_:3S69$$8RVY
M$EOU>[]@[)$`B8_V@N[A'=AJ/,$QS"][(UM7,9&[I7I2Z\*I)(MWAI<\1(=`
MLV@OBSV_-;JAYJ#^T*?Q.61#.7I0&@E/,9N+E0YJ_DS:2H40+F`6M#B;L5EV
M@]=)YJBPFV4YQ?,JQ[&)+,5;"-2)9K##[GIB^B##;E;-W[`-F8,RQL9RC%@*
MDX#!]!R%;VX-U"VXHTZG9"S4+YKS<EE"%.V,3^3#8@)$5#>;\2'9^W9O5TZ[
M-#^1CU:-6'EH"RFDM%QO0'CSADP.R@>P"J9Q[429>]K'1Q,]W,)(ZQO!,YS>
MY(`H9!A\R=5C8IQA[DDV\9:D%Z$:7HLH\&#>Z_92.X-D'Q+9$>$578T42YFJ
M%]BC"<ZRR766%<@=[*7QJD.X3WBFAW#S3*-DW0VR^.@=$KHVIMBRR/TM00\[
M11MR)$!-7C6"I>'&78,]+"8UCR!@X>R.GZ48.'6>F[I%QM\"IL'9P[Q\O[]_
MXL)L^^U=5<ZB$H(;M6U\,7M/1GL:B(&@P*-7B>IG[+'7BAGY%[E13N)U1FSG
M^N5T_3\Z"68&MO-:RN$:7YQ]=^_Y<U*I_)_;([="(W[X-29;EYJ&'2X7&[8S
MM]%`VE&46FK".^[+C:$$%4@F)#<^<W0*+J>*+G`<..ES[.E?\ZP^QWYD@Y<:
M]V.9K0P945EIF=M`[UM<&97H0/6`?=R=#G4S9A"KSPZ(^?)<KB32C':11D_.
MTYZ<#JFVA;K!9?J@JL^?IIA07/A3U1P*05R*%HODX`T.7)Z\PF-[/;Q*!Y+^
M\_2JQ_H,VC$@)T(VL8("N9^I??K,0@+6CV5`XW>K,6ZH[:BHU8J)PQ=)ND,V
M-AA.(++;.]EG%*<K6A2)PV1!K0PG/,H+P<,V;%XZO,4MG&]_WWR,&3+%8VN`
M5VZWXCFH3I]E9BPY-8O%.W^:#LQZ.(RJG48RW3Z@YA]GF!14D=."]W%N%"7`
M:7(H`R5M-K'O_H`XJ8\IPAD@JS`H#-8_F+NH^15;?$;]]J_$DN<D-@-6K4V>
M2OH]&20J'KXG/T56#S>)TJI<1<C)ZNGA08`+E'Q7)*'8MX6])GMO"6A@U,.<
MZ$K.IPMY=/\F>V^8$F6"J^+VGV=+/ZXB!7@Q'+LX7:7%YF6(I2./Y[BG`_`T
MBU@Y9HO>R*C[I"87A+U388%RSIP++$8V&2*UBM]C\`6G#SE"--*Z%)%EQD$S
M#MM(JM@]@"4X7B5HR:=0JEQ0E&.#0"@30^<.0?ZUNC53JL'=#E5D4*62EEOS
M_->"=*]O6%E/,$/CWP(7)+K1W[0)"*IHSZOC'#`!S35E7JZ4\[XD)B+P`$>Q
M`@7<7^EMC<"/[W"'!;9[S*)X84@`;@0&"CG#LP7E,8E3P@D41!"CH=%&^4YO
M3/D4!\V0^1^3R^$UCX\)S(D[S!:Y\XY?BH(@!7V>`?*IW`)>9:W%.@/SE8SU
M@DIUG/50NGG@M5N(=XZP,]4L'\Y7@_M_:ZYG"/8^CXNVLKVU\1CX#L`M1GJ?
MV:!*+Y`/)$&DK*`@)6P]GHES.(:EI>[863UPIG&J#$#V'C:7UW/G\=;PB$A:
M86%<,0GA)G;RJ'5*_.RY]@!+Q3C?)#"P9127*_!7K*#)"%ILG*IT.^*%57R!
M>,Z"UEFD`=0#`L#R,2.>*U5TAIL6T\+\@>16/ST+$2__!MI159#P#Y5ZN`Z%
MZ\=DZ*CZ=J0&KA$HQMKRZ;EJ'.7\L4+E-4UA5/<<PFQ&C`7'.AXKGO2_()80
MQ8_(W$;$V/1)B#H1_(`^L@[/A50+Y-RB*WS"EO?1*BP%,S+(WD^2K6T`&`4B
M&T5@7Z?1:'K&GK5!IB/=BQ9QJADFA>HI,R0MQ(MTGR&C+7XI0J+7;\R3TS&_
M2WL<A5(N8$F`BM$PP3`>DT=&F')./0J%H%)?^3I9(`"'\RF).[@NK+\XY>0Z
MJ$O5<1EM!&`X]H4IF>%V*[(*5:D`7N<"L.4?@3IH9047Q@-4@H'IK\E+0/&,
M8`]S).-&*-`7J_O<!D2D8/UE/GL`>FZY=3*6J/=XLJ6-Q1YYT6VK)Z%Z&J"\
MF+LM-7WQ@_*1YC)`'6<)4&W(PY8-<>;$'<2"-YP=8^H]/,'6E'P+\\#ME#20
MK=96Q6`12I,3KPR8):G("0B[8%TE,!F\!X-9F%3O'KXM(%WN*U0FL9H5AG-G
M%7+'6:J`G>9K+W4L1$S,K+F4&IF[(D8)%<\%GDAZ\CGO!:U4".JME`'^G([@
M6]MDVY3\5DTG-0ST:78A;VUI2_P38F+XG16MN/V^Q;@L"A9;TOA%<?PMPW*>
M'P7^Y+YS0>*%SSK-T8=FPZRR!0YSCL.!A;.N4'*2+4[7_5R3X;-8MR*!+$+$
M,/KL$U*6IFF5A<+=5B4A^IF_4@E$4H)R0%QF_M0J>J]A=O3]?@D/GHR'`UQF
MS_35CM!2#96T&>81`7A>P+>584[MWN*XFR=/AV36$&"[Q-#ZQ-N1<.`UK7G_
M%!#^U7##PH[UK=VJ^*B&A0)840NIADM9.2;QM[_^=Z3;;M`8@.&^+YZW]%GB
MA1'\K9.-@?W?X/%*DW"GDD6%,+H>8F3*9\EZH!_8H&.[O#/!O^8TIIA=<RDD
MNS%M*$+<>3U29H;HE^?F]57FV%<S8?(0+$CUM)9F$\V,_J6:-15IHF>*/M`<
MLI;V"#X[0\SL-$0.S'ZD!J8:P]#CIBC\RM4HY>8*H*$D/GKTW-#N-HK4*7PU
MQ80S(9D=PH6N5&#44X*GX6[.HTQI%LP,$JT?4P_=G2C"5V(EFI.AC*NW=BU2
M?6BJN$L)+XA*R#J*5FEW:/&A&(<RHSRY(((PC`IZN$'#Z,ZS7C'I8/=*VC(.
MY#-BY5HS5W+DVE)Q].^0E].WI3AL/JF*@_95"2ZUM1ASFM.93R$;)3R<9N$`
MQVW7CZE#FE]W"`O=%#,$.I`PB=6&Q1G(HH5JL107]%U&S4LVTND*2:R/7F<"
MX)KQ4-D4*][A!$P&W,HU)&$D^TC&#V?$UL*K%0XJDA+AI@Y#QF2R=`1<=R-M
M*%H5?![W4X(!0>B,2SQ14]42GX)#D\B@QM8X`&)0R848DX6<95!:XBR-4&3X
M)>+&T7+;!-U"",0FZ*>XL<"VQM?%)N6,&F,'+[M524@K)A13L<.X=[>^I0NF
MDE*["7&"'CQ5S7_]B<-TK.+0/"F>2'[>/R-%Q`G7;V6WYTR43>S@<C;N)+`N
MH`D5H1B-;E071>0?#K1XX0R]SP%?UZ\H#*9VUPY&(.=FQ<5^9Z$:<8C!];*S
MP$;R;/X-":W&;SEP7I]J+6;@-:<XM[K,F8AW_HH5!BK`L-RNO`9G]HD@F>GX
M!KFDW`LO@ZN)9"!GSVX^-O(&BE#_=_NMD0BO13+Z!+=X67=TWOXMX_7I"DW%
M;I_CC+Y8QLLJL$HQ!-4TK-(4?)#N4MR-]ZNR$PHY]70E8'+9QVR=D-@P+P\E
M:U>E))1Y"9MSCTX5FE0L!)S2G^(/NICEU3Y:1*&U\+[-$\,5/0><H1(K7(]!
M0HK*R,E>D?]4B=ZLC$[VCBLW(-V+P4H33(9B]$)I:+/U=XL+"LN^8)?CZJ,<
M&`RG_S<YK,%PBM#GW/FWY\5OC1?GF8?Y^FC_;PVK-3?@<PABZ1)_R>PGP!48
MHO"5>+G.I*`/SFBM*12+51!;<^TC1+:.[5@70&=8&9()0%:6R!S,32PCKP`'
M5#Z9LP\,!DTI\"ZEU7S#Z0!+B*M:R&@H(#)`",_@<YQ!(<Y?N/0$5^9S;.=S
ML]2>JO$BY\!$G+Y<(9!K[GP)_`(H4:J?TRH@97^J%=)X3N'"^H_6HN&E@RLM
M8-1D3X\E_MBS`EC(Y[NN]D(8M_)"75<>PX:*F$*=A9PH$%Z0UPCTQ,BZ=,@-
MC(<?O>;"\X)`=UJ?@`A%ZSAY/`\/(T<R7A@BS]U"'5QX3S*4F?8`8,HI`R9Q
ML)__MDM36`*K9E.Z+25%$)`30<^*$W6S@B$!I2,R"JG)>%"4H`)(H?G==T`A
M9&25&W34M<BC%U,5XVH<1K;K/)QAI9".F,?KZ,(8(PHK+;FB%`]V4_L,1+/<
MKP=#;X*"F&*G\76+>*<*7A"2EL3C4M%8-\D5(T#B`O+1=@T_<NCM/65Z%*]K
M4@`[\=KP+*<,VZ#RWH"[S3I&E1J48(KBW"P8=EO,E$M-:@#BA^1^:U^7K<Q\
M^2AQ!=W&1=D7>O+#KUN__?6_'=?G-@IS0X45*UD;6(8CB80F=@]H/2SRYRF.
MC,`6*R+7"5BP'4XK_V.=:</,V\Q\9%L-.5\H-KAM,">KU'W&I3B8JKCKP^IT
M_PMA4-!:DO./'W[%`,Q9PPYK>#LH'V8(T5YLY"5--,J9R%90NB[(U"Z>P1JI
M@QP008OP:#K<P($2'AC!(W.J!LHG">R4DO&Y&(=+<$HXZ/J3\4\:YZRP:TB,
MP#<-*/QX2E);"LDEN61&R::R-4TU@,=4.=0H`I;XJ+"U',NZGFEW-<M8WHXY
M:33$BJ<_[T3J?U\]DG`B_9QBWKC#O]_>4.HE".9-O"BHW"+!](Q[P/WO]0!Q
ML"^_%L+)=?`ZZPM8J?\!GJG_Z=;Y*NY(Q6^Y\S!:7S54GQU@OD=K3O%E1ND#
MG-VE=Q_'W@6]I[S9'"#TVZ?Q>>]2.K?RR)O^^"9NB>*1LX_*E6C'*UL;9'6]
MJ,"0X)D`R^2C37A*,%H&\6_,BQ-=ECJ`.\(HG]N-:\?V9GLQF<7$5%@4C_ZN
M>.<7I!MP@J3]B*4QH=BXH9IDH`3,DQ<WM`OMWR`38!W^7^0!7'FY1-QH&QON
M'N%!1_4Y290=>F/I$,_<'K]G+\[P2C0<BM@\$*_5,Y=%0SOC('\N6A.07[]@
M&KPFX[&RYYXG]_'_E$^K6-BSS*X-2[UHR3TNR7-#A&<XFPH?\IJJ*BT\X3G\
MA-*D^TT)"S]:0Q6RH=:][T6YFEG[,=FC5X5<4)<,>UXU?O,0E,E>'++J0H18
M"O*'O3@6A<O:\$%G0]?Z8F942/U'(G7#_&6]*:?M-,RV0GFR9_*4_T-Z-?JC
MTD7GI(L`R7!IS[-ZZ=YD[_!JU!_></=/@$!L?-.8-]Z+]OK'^L_''`J13JB8
MK/^J_H#E__764/8LQ*J0L/[:*ZN`#F=3__&9ZK+*$''N8<UW#G"P7EKW*T\:
M$CWB^./52GZ(W_SNXHLASKEX.=3UWG!#CWN2%BNMBF./W^-D=K]^V>M2$T,2
MA\>+)^Z[3O5'0@8_2UZ\.$A6_6]^42J\^[S(\)\^/3I82UZ<<%O0AJ5-S'2L
MOBM6,^9>,\NE"&U,@0X&?F=[8S-:>`-L\)+Q94><O8L<H<'*UI.-K?A0Y-&^
MUFL)1;6V8=?H$'):E?+XJ%QL(O/;0_6I+`4$4'E9T8<5J\)XAMN&34,ZU(==
MYP?2U7TF&%/#VY-T7"#=KZI=F$\XA-?UVC,L^*'W=)R.&)&]UU^!F=V4Z<[,
M.*=$@6JV"[C<QC(\P+682+2UO?&HV#T*4GFMN''7IXM.4H^J=X$7`Z/K)I>0
M-`(EZ\,!_RI*[@B`C6FL(-[N`J,1GFQL[_X!@ED3AH\W.W=Q.(W+"7DM>;_K
M@O1YW<Z-Y&E11+!/@*R`VV?7+5,G'G\.F(?$*Y*RI"(TPW$MV-K"KBXX322A
MA*\P"U:FP1LS6WT\<P'5RP(6'G()6R0KVQ6?V1BOF$ML9Z5;YU/XV`3&U$%0
M^WK89%#)X9'+D]9:%9-R[V?A%@\<J488@AY(W".!XB'0%-VIIA($:3>Y1!>5
MU95:"*6+,#R""ZG^$*5:8KF^<+X8>_OZ;/D:S6L/S_B/E*0,IV(S$Z";:G+@
M!K0!U9MUK>./^8REJ"=!E>E$M5[MNT&\C60?G-H19'``R:X]N.AH3)AC2P!_
M$+6B5#'%N"AM:`!6AHY0Q&^SND[@H7*J@L<@MBZ2AM(:1#?H.ZDT=U^H!+8@
M29I(K_6%4(C2Z`$261.J_@HYJJ28WMQB$%BO=7+0PJF21*$+Q.*L=7^5BDZ5
M@7A0;K!%I=X*66%Q5=K3C=%:(U'Q,\@1*]K3F-<D/R1<^B5M;6WR^#ME&@89
MZ!XR%_,KP7CX2UK>KF<TLX3:.=>/0I%2!52DIE.MF>CV0'T*Y.<%G;;5#4!W
M@D55BC(-TQ>WP?40-V6T2-M)"U&=`$7.S;+J<$O!\;J7KL-=Q"DL.C1X`>@+
MX3VX;HI/!'%C(9EPD*"O!<+BC-`.AWOWT`F)E6\5KEN[2WCM7?P,_HLGEYR1
M\^A0.3_4RQ2-`!&+S%)*7$Y+X<BN]Y<)?1>X^G]H3!MA9BYW#*]I0]FAV,;`
M9ULD)"]&F#WOLW3PRW@ZFFB=X@6.F2UV($KQPI^F7:L*%92MT7SY:1*`;-8G
M#J3]B9N\VM(!:T4S;2.2S"^.0!#1#[D1^:&6=VV7W>;96X_$G``7],A-,_=6
M(('!ZAR=*BI*#I$T4,5/.(#GL2L-A_"A&*DYB6U5-+FGEBO+;B"$D+X&\,\_
M)]/MJ[W['WX5HQ9%HN7E=QC9M8#Q0Y0KIY$!)>6C.J@R4H'V7J"MI?I5>1@:
M04&M<U+@H?2Z<-EB-.OF`3=H%?2T\-I+"8`![.$N$'>Y8D;"*_'0VKQ3'I@+
M6T63!`\/XS)2%6MYA%+4!@%SOC/7W45B6)KR^B4.>RU9[8EV>@DXUJX00;!L
M;`U5=#W+05H(@Q7D6E01U.&\%7Y<81ZJ.EM#E@K?)HHS9;K:ULGB-EFGK&<A
M%N:]V=V[)7;@6DAF!1<Z.OMH+U:\VGL7ME:92<L*2Q?IPU(D%>26O+4#JU$=
MK&);7$B7!+VV4)$Q7RQK+Y=1X^SYT<U/'O]/5=176,6%\QD+RK;CHE6:E9KP
M.DM@#:,*9C-`23*/7'3PQJK,8V^K[-6J/MVEA^*%J9376>T65VWUM`AHNXNW
MN[*UN:-6\$M-RB%\'+Q:@\]TJ/QO2U!4]Y3TY!QRK6P_H%F[FMFWC+[X"$']
MSF@T1HA5G`DL60A1N$\4,C5:0ED&63SD96QLPT,5/;44+3_5`<[Z\$M-S1H_
MZA@7$A4MXMB3YT:;[LA,K%`\C3\=O6Q2RRH5-(4B/6_G+GA=MV;Q/U1S_;L.
M;7W>H<W2L`46FZ\X<,X_A<BVW`^9A;WL\L&7.%WW&><HK'`(IJ#;Q+%-!.TY
M`]>76OXBN6BA$D'ODPA4+#7^QS*_;--2$]UU(]N/38TM-?;2F]BKY3J*T:MA
MF&XR/E4+QKFPX&3OM7Q=\`0@(ET=5^V2`5<65;G?[`AWN/$L,<5$SE88EFG?
M-]8^[:7`C?!9KJ3Y490/OQ8RT%:$^(KJDZ0Z1'.$VSON)M\K+&S<*?IQVJ<@
MGAJ@3LV%H(>`?<@G7#IP>L9]S5<3^!=6^>Z^M^HEB*,+N&V)9:Z"<M+?,)"[
MJ/5\97`@T=,1#9"XYTIT*7WT`_5EA)RKKXY^(&)R"%3E$`9T8N*XAR%W5L:7
M5<RYZ\<X<H?Q!JVS97E#T/`:,0+]<.6H1<YP)Y#A&9:P)*R58;BH'4STYQ*>
MK2</OY@7$T&30I9^KY_6HLYP(P"6#/2+S8UF9."+F0%3\9]CAU^J*GM6\8$D
MP'HK^HB/N8KZQX.'6_:/>)[J774;Z?_&R#(KR8I`$&?+.P"+*3R+`)[M6Q>_
M1X9^&K),TL=`LN".12"JK1.Y=-+*@_#-*=%^LPBRG.-U.O]?TO]OT'_\'%IC
MY='CW2^FX&'64;QU43%O"N&Q=^6]U0*9*(P=T<DYQ8D`.>=6:U#85KPA@3HT
M%.(N7T&@P@F;[S@<S73\Y2NEUXW$:VS43J!$L:9_D\A:95B0%"$9!\HJ?HV)
MM+(H!3"=K`HO`KHGFR'DPA^>DTXMG)>5;3XZ%UUP$VMY#;=W\4:UX"%<T3#?
M,5$OP(O#KB4KCRLY)76:+CP._AO`-0O?Y3/OPP':,FJI__ZY@K25)X],JQ5'
MNL@76-IK;R];LG;;(D+POXTD[GM5[A!Y3W)XD,Y2UHQ"!K>%Y29[!^JQ5?E\
MX0'>."P#1@[LYAN*CNTM#R]36:`0`C_UD#P2`/4QE[K5GP,S,SO3?$G`A5;W
M%8>[:3FC(G.9C=!>1BTQ[",&PMW?X-<Z8LSG-GK]KB3!I97R<ANDP`A=+IZ^
M?+T.H9)#]1*:T'S`Z6K%!_QVW_G+$_!]@W?%47*??3BP6`.#^5ZP?RIQ>W/[
MD2T/>37/7]WP*U>EB+EXIS*"(&,R2>JE"WJO^\O>7=KR?\RU%(?=,>8L7,LO
M>RFD#C&D%R@IN(&F.O:A*')#WJA&=XN5*[."]T+;<L"J@V@[!@6=(Q1+4<;Q
M.:BVLOMDXT%4>$M-L+3@AUJUBO:"`#'I[?!VJ#OA[_Z42J^X8HLPB!OU'T57
M`>EA8T^N$)?ZDC?;(;3"6$FJJK9$_P[=P!=]U(XD\(CD*@*J.G!=ME:CYG5]
M4R)\K*8*DHK?9V1HCH[R`JZ:EIC3Q1EC^?=39IM3HL2R:M80_NJ]LV:#_K$9
MZI:\RSWU1*H[Z@U^M$>\'S'-"*B-UK4P&:.1Z&5Y3^X)F:C'_(,_4:2UH%UH
MG1\C#>MB0_U8^,0-*HSF)M9#.S3&B4+?(J#F`5S2MY*4G.`3<`35(J`A9CE_
M9<>_\1K#?_I4`&B@&RN]4LS]%\ZAPR"OBP2*B4HJ67)O9Y.^'C=DL<D^H;1T
MM4VZ%T\G-A>#GP38=\<I-]X*;.+*+T)HTTHO*5>I]!G_XK_+ID$R.-04=/!$
M+.`(257EQ%D6<FY(2<CS:WDBK_9;-!%B2%OHD_:%%I4AJF(@AI%28:;8K!]F
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M-7*<*2K,.-%&\E9=L6#LV"V57>CAXOS#4!Q`/8%=S'*&2ZE6QNJ:@DZ.<3RS
M1__0*L,TK,LF7-_U=C;%L_H1GY.CY0M0L3"18"GP[[R!C5">DJ=BDA6@C##^
M`(G*M*/7EE.$\X8/]#?RAN^+-/7D[I9A0@V<]W9A7\R2/]`3IC=.D].-T89]
M,B*)?_EI..YWKZF/7#.`.5F-#1W7DM_^^C_"4[_]]9]OYU13X"8?7%R81X4R
MA8Z$EG(SY;#H[L<)P4VTVS:2FS#I,$T^.(M8JU>1%^X%562L(C946H3%V[FZ
M!BEYD3H:^S).9#STO8HS8JO'B$UW8G<54V?S-E7=N00%6\IJU66VL*I+K%-J
MR;Q1OYU'!9CS=2C31RNX\L%\S5M(.W4;W/2L$IN_I`<RU5KZ@(G4XDD`V%\/
M;T#M6V*OJ`,I=70(XCHR4'6[H78"31/-L@:OU.H%#2,9B]_FX/!E,XIVO7IC
MA/*)Y>N\HA@]-VH7F(B4)=(:BY.JKB+WIJI;<Z/&A6/E">+VY!]6CLF?@8WB
M>"WK%%N&M<;/E%E$AK,I-4MAV+K:S/!)FV[O@M+`<BZ?FQE5P1RFTA>&5)[%
M(GB?"\,H20`3.1K4+'?X((MK+I%&T?/";MVU?M:'!]J>)93KK:IO<2Z>D3;'
M#DCXX#6T_VP,[]X&BU;UG'E_D=2*D**8`L:X,8<-?J#G+&MY2D#+1Y.2_=%I
MLNI_NX]B1,<R#(_YA":94HY*>NGB>PC/";/4XMZ_XZ6&:?'+/$>OGH6"?0W`
M)[T*Z`>YHU:S,&P&*`W6*ZEA_&'%!)SS1+'X^K:^\W-ZLKX-U!1!H9H_MF=7
M)NI_1$7/(]>.J2"A)9:D6GD2Z,)QWR64:=&.R,<[]:"&6U(J'94"(\T6LET-
MN;?V5*'AZ5?6JF1R4]^&&IA0US7_`DUU$-7M^PNU8=I=U@/T(4QP:FUG9M\0
MU+)WXNUIC]7J&O;S)P1B+:@]@N8?53^R#HO5+Y-0G?D)\NIWJ7S:V=C]/$%\
M^T'$CY,C8Z9R_5R\%196$/<L-`H.)X$H*,KB\:7.9!'R<Q>JK&QM;>QN+C7E
MQ[(!@+@3!2>O=N4E=I2.D((;2D.`%(7R8JP'^C3E-W>BT/:799RHR+P!</4B
M3AEJ5ZK-OSS'[#SZLEW88[".BBH2*'Q]V(O.EP.*WLC(XHX.K\WD&K[(]QI`
M+*Q31AE'5Z^%A+)V>-&8KAV;L4_<A(@U-O\C9<2=BPO"I_>"F7!:"ME>V=[9
M>/+@FSK\,--@:W\RJ[>Y@_A>D84Y[,\PX\V?PS0G4B'U7T.QV_:3Z@6GPC?9
M"]^7_/#K]LP-J/*!<$-I^^&<]PO5_M@>""B)P=WN<%0(%Q;QP,PXX$'<E6H'
MC<@%S7%4BF!SZ\FCM0>/'M^F4:G/;]*;BVW;NU87GUM7-`M!!*?Y=W*$2U"4
MK)48CNF.7%RFN<&Q$Z^#]Y7+N:AJ>2/%DL^\XX=YX:;?]&NU6-BU6N&CZ.>5
M![O;!L:$*PCX'Y49Q'@\I:\'.-+*SWI+]<;%!]P.RALMW,-4MB4ZA\=H7,^Y
M6-R!:X`O0_FM`2K64%-8G09L*4-Q2H0&7O'K*R57!.^U.-N(P0:I5*G`S,WY
M-`!5$.W!VL/'3^)A6J%@/#?K::GU!)KRP8Y^E[N+N*_QUFZ@0%%%S7@[:SN;
MNW$\_ETWMR'C**-K'V)9XXW-QP4[V0I"FV*#Q+R=1F0E!HPG3*%^!0TJ+IIR
MH*ZK<68[]*PW1E[9>;3V>!N1$#MH2YZK9#>`B/!:F+`ZH.8EFN)33$0KD23R
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M$-H?Z(KX6F*Q8_AXTXD#!?-[-2@D;`]?CJ?"0C8?A]A3P"5Y%&6I3_1M6KO<
M;[_KGQ;'EQ?`Q7-6#*JU@F"$%Z4)A8"K(F!JG[3P:"ADR8U2W(?L"*>P7\*7
MJ"Q_P7<$W`%RV,OO3.G+=`Q/JM_J6@1F>=&-_=4,OB69LM##`?)X+S!]1$K+
M@;=D6.RFJ?ZMC)%]@_6&GXH/M]K=^6*,^HN8E_#=+T%3MF\VT,HI)*/`5V!0
M44C?$9!0F[V_\MQ9N/S5M&&2=;TD1REJ9YO*"Q6(D#Q!%"L.XG=@2*!@D3X^
MI&PI7=W:](*%+Q([ZG#BWD@@ZDHS>(QPJT0Y$\+II9:Q*&INV>(Y:F*I<3F:
MCT%(UNVS"O!NKVR078UV%HAIF7=S]QWW&YU9OZ-8<2(023%2(;M>G)%.Z::F
M8`@9\!;&9=F;%*&+<UF24;P>O)EP-=4<N*VUW:U':T\>19\LYG26HN0=3Z@P
M>9^KHH4+%177]?':HP=;:]N/'D8JF2^GPH"Q&@*(4H5GZL22H7$U-T)1HH"@
MOWN.6VM/*$C>)JZQ06;I?>X?]C*REQF'RK$%2U+EDCF:?-:F.G_4;:I6&;YS
M$?4<#NN['DBP.;4Y"R<#$)6;U)CWU(U/8P6#$JPZB+.)YVJ?M<!D$$-3$\T(
MM'0ZF>;$Q,R:6='-L"K:5C@CE;'(&_BY$C7QI)55^8H"ZRI9#<BM&@,TR:PR
M#<Q=-*Y_VD\[OZR?=G3?.&YL72&\U#4!71;NAY>(`M'.-'[]T4]3T#DS08VJ
MD?/%4,XX+?PYE_I0_-_HA?1&]P,^_/I2E1_YAU\/*0EH=*VLW(N9\\1AL?,(
M4:Q'B**D6YVJ/]4_95#99/W90^)3L]OOALKETA^S`7K_8>X[,EZFM:0%ZWC.
MWNM>_LOZN6Y)%+?Y=.5][FBQS4)RH^J=^F.GPL47?=JR^(0N!3_<F.$(4:?B
MT78'V;R_V^-L?-YY-Z-L14%Z5!7#UR7(#4B3*)7GS&.JP_R.F,>I?K]<6=[Y
MXQ^[7-8)<5RV):K_5!Q\_0>*)`5KU?]\&$+E^M\-C9)'5O_!7-3Z'U_'*]/U
M'R"\%5F@<S[\FKSHG3<6H&:@QCO-1J"QTK`^Z!%CTB*BUZG_\*.Z'=?_R`0?
M?IW?;O1IZ%)#J!LK2#!';H]WZF-]K_MG32&.1&QP[.H6=UAV=K;KXS3V^GQ(
M$P&P\N8(V]S&VMYNK*2R[,*,%H%G?;H?T9X(@_PP@5$F["@W\\#8]^T#A`U:
M:+7$"_-=GOW)9_'UBAU\+D^B/<X*U0CN`SC1V;K^Y_=T`FCQ88$7MW49;W>I
MP3_2D242$T?(Q`9WH`JHE^4?5<>]89+<(LK@+[7D.WJ,]();:MB/I80II`U]
MX9K/=<AQ4.@;W:49IP#?2AZY%_*53@I.40$'F,RIU!:1.YNYE(MUJCMS#,:3
M\0"P#DOM]XYDE"^V]7GRJ7MMONW>\9AZUOC=2*FAZ@>Q][T#I\A\0G<G76A(
M5N-_-31E^?'F"JSRLSU^D[PI;D?7/QRUIT()^T;HFL]""O_VEU1-45W>S*<-
M39\>6!M]@W=G'@0YZ8WD@?Z\8$VOP(H-RC_)QH[])*MOI&2;7;$/0J&5BD00
MKA_*[VY7G`'_^)1PGM#24:1\Q8?"`(#\NS-P7/Q`E4V,N/K$SF:E6WX2[U2I
MSB9^7BJTKM&HWD,,75%4$-M3_`%DY$Y?LBGG?*Y6S6;#D^J'%^;2I.PJN>]W
M&\59E5:H<10LW\0_A^"#0\+7Q0<6@.]Z#;^5HZSW59V[BM>JLR05%?]_+H3L
M%Y7K\XXS/LPZXL?=%Y24M#R]EKP$^Q*+K1/2<.1C,\[[E>\TK^'0J$#*E'G]
M?,V-JY6ZS-TBT1073;V0VUS>^HOP&/61/\7\$?[O:UTG:-#5/?@F8KK<S,(V
M9L'19!^`N`MN:A4SP5OF+AQ^H`..,$81V_ULHK5(1\Q=GD(D-'B#B)5IT1/!
M_1<71ESW2,V;B%L1V_K+=]>)SU12V+^?K+X]?9:L-#0CCC3%BBHCPRA-!Y:-
MLKS!M;+8ZKEE87]]'>&CL/4_5[59U,KSBYX.2'^M-3[4Y`FTT_)+ZUZMIA1G
M@S5>%=_:"W<Q,`=A:<UGFWISG<G]0W^?6$-65'.@?X-20.N%BJPH7O<>HHH4
M[#\%/`_+:_OHX0L5VAV1`LX;UJNJY(NY*NIX@)+'Y!1*_G9E7-_%/.6[7OT\
M[T>JV62U8&%-9W**WJ@J^[52-:\E[7Q>??4VQ=]4]<G/"\@,5)/=J-KM%SCL
M.2!@D_48\<!Z(D[J%+27%WVA`J@QIDB4+JZ_7]V7?T6%BTVJ1&Y^<6/!H\E_
M5IN56W:Q^/U7\_>H%]M,]'KR2LK?<DSE(;>?W];V3".8162XT_%*[[)TDJ.<
MC[Q),^T+SUMJJ^;*G(LQW]EGD\J/K:B`#;]FVOQXZ=OR\V#?IWA7JW*K[@ND
M7*#KVMR+=3F:3:>C$)AV6OZ^AN,5.6P?=O$)(1\;\9;-@_KQ>;\Q=<OMQ*;A
M/[^T:[8-I6;C;`)J*]L]9YP7ZKI=^E/SAGJFWGYJJS.>6@'-(B&W(<4L07]2
M&AS]-?7&Q;,6\U1CWVJOTOHZ7ZNKN%DT^>5:1_V)(I$;?D?#:9TTW34NM=1O
M_9W("PMAT]JF\??`5K6*YU:2_IJ,)951W%GP!=;G:+R.J2.'Q3=;EWWA.<#N
MOI7EM(Y]8OTX[3Q.Z`C<!QI]W8+^EEWG=//5&L6"\%%G0WZP[7E?=^S$*/+5
M9W];Z=MX%O`]R-(5D\1:U+N\4Z2%U'2E81*B=WZKWENH]BCE*X0J@!QE9!2G
M6,36\1D+R`RH;%EI[&Q9)JQ2.[]PX=Z2*77*A((,8LB056^BE#X=62<OIJJ/
M4%QH#FN4D8]!4^R04'\'?VE^PX-;%=@+W55H['_QF%4\88&/4#JJ(=X0KM/:
M(:"^I=N>YXYAQ0F6I]C8P5>[U;Q]E4&*DXVH.:?!W5F4DP+#^E)00?:)#<,P
MJG>"A`^W1#I'X6YU,D\!*Y"UZQ5O89/0"CCMZP9FAZQ,M8<$:HIH&5/I20.J
MHUQEY1V>_R=655^K3.SR@SL@HR%=,RF]PF[5XYF__4C1L`7*<L=QDUH"D6>G
M+^?N\BY+J6^C><.G_L0IERDQ/6O)]UXD88>SW^6RMWJ-NW,5(M$&8WRO2HJ!
MZ=H@C&_M!C*"1B*X,9-"Z7H0?YO^"K58];',BGL!X.:C^H_N#=3_&H""]5,,
M#EC28?WW^'<49C?9^L>F<S#SP$[+`V&&Y'C08/WXTYOK87W>XB<E;NL_'NAK
M<^(A!QL6J6)_X@@3A?4-Q;9N7$.)%P&ZH$5[HG&4!LUPT;"E'+SJ2I236,%4
MJQMA0]FB.]4L/0JKJ`,%KKIVW*:^X4@-5$*UU+O^6$Q^E77R8;S&Q@H*QI$C
M3K265.+;^OAEK$*[_#]-_?O`.H<PREVFB6NMG4I]RI*T\\^O]8[;22PB-B,<
MMQEG_3TK=3ZH;E=-&1Q=`W$+:7ZUP+%+"ZU<4UJL>#*A@KEUWRT%C<E=PKL9
M&$HE;",RC%:^3_U;>A=D*ERUP_%`3Q?5BZI>JB^<M@2%\]2()/PTW?C67WR9
MTGUF>E7_<]49:XY7=J8X5$ZA_K)M-N"4,C.Q+#2I@+-J&U1]+@BVXYD+0U;?
MS=`S=/H\@FW`6AO4%_+50W<6$CI^60U*PFT*=0=I/!B\BH3NO/[@UJ/%#VZ1
M/O(G'[<_.%M@6#HJM>7'2A;E%!5UD8\@!&FL[T&[UP-G^$<5\"8:17#U06HS
MEZY6[C5SQ!O-0K#&(!4,^G>=+8J_\/&,`7)D%U37G!(5CICUKD_[=D%F]B[/
M\H6"Q83>KG/,5OOYNB,4>IMA6THFG^-`VK;0IIR4GW&RZG1OP-@M3PJDX"VO
MVVN\8`?;KK4JM@.#<1B_!N>ZP$FM)F=E95F,H&T1,<H`SYD#N5=%^'>R0P@*
M</JLM[$(%%V%AG;W5=D:RYW5S_\3K*D<G.\9E0D4828O,TIINL/^\&+A'6BK
MU&K)\ZR[]]1V6L&SC42?2_/B%'$"W^G6[;P-KR7[7!H,5^`Y?H4H@6.=PI2%
MZ<-LBSRYF3BIVA8BK+9!_`4;MRN+UKK&55'@PMOR1K<2)'#0(A_JZ?\A[`IR
M&`9AV(NF:6C:<5(_T1?T!^S_6D)PVD)BKB5-@PO&HA;U7Y9A.V0U^[)V:)DC
MG;]N94HCQ`BI7+\J91>J$L;04:>D<G,M+<IK;)K%8%H]()K0IZZUE&G:F!I?
M;H`B9R9066./G,#P?,&4Y[M`RP-'A'DT!9K?VDLWO'FHP^YBU5V#ZL^$33`T
M"<+M)F>\V0(U+0*N=>2<@"YA8JU#.[M.+V<)6OI20N%S`R1/!\'U0;K7.TRW
M^6Z.FQ[MJ]DT-FV;<[Q,>CN&7BH_FYZU_KY_````__\#`%!+`P04``8`"```
M`"$`;5-Q4VP-``"-@0``#0```'AL+W-T>6QE<RYX;6SD76UOX\81_EZ@_X'@
MM44#U*9>*$MR+`=GV6P/N%Z#G(L6:(J"HBB;.;ZH)'6Q4_2_=W;Y-BN*Y))<
M:G-IC)PE6IQ]9N:9V=DAM;SYYL5SE<]V&#F!OU+'ER-5L7TKV#K^TTK]ZZ-Q
ML5"5*#;]K>D&OKU27^U(_>;VU[^ZB>)7U_[X;-NQ`B+\:*4^Q_'^6M,BZ]GV
MS.@RV-L^_&47A)X9P]OP28OVH6UN(W*2YVJ3T>A*\TS'5Q,)UY[%(\0SPT^'
M_845>'LS=C:.Z\2O5):J>-;UNR<_",V-"U!?QKII9;+IFY)XS['"(`IV\26(
MTX+=SK'L,LJEMM1`TNV-?_`,+XX4*SCX\4J=Y(>4Y"_OMBOU2E42E=?!%D#\
M[M^'(/[Z-\FO-W]X\V;TKZ^^_L=W]O:?W_^^_+?OOU*U;!@D$WQ0+_-R5"L6
M_IQ(UE(-;F]V@5\H,AV!)N3([4WTD_+9=($)8X+$"MP@5&)P**A"C_BF9R>?
M6)NNLPD=\K&=Z3GN:W)X0@Y0#J2?\QSP"#FH)2.<=YP-09/IM"`P&)VFY`C6
MR0.53'*P7B?SAQ,Z,6/-FL?J8S]F+*I%O5["QBKSHF3#/F/EOD+CA$^;E6H8
MD"[&HQ$Q*W;80(,MUR,8[VR#7<W.IMG4F!ISH9HQ7"S[C0PX-42:LF%`X^W\
M_FSF%#]8E79I&CY7!)"`$VM%!T*W)K[G!ODY!T_./*$-XS$JE4GZ-/2*W/CH
M>':D?+!_5+X+/-,GAL63&OTT,R<SQ&L4_\Y_MD,G)F(9*8R7.TO)>=);PIP@
MK+-3E2*G(.1343DV!(EI[;4,9KFX.>)#%4#L]LY",A3+OM;6NPHXX.S2@364
MQ!'$B..Z>8D_U4EE#$=N;V"U$=NA;\`;)7W]^+J'NMB'A1$!K26?:_CT4VB^
MCB>T.N0[(0I<9TM0/*UI-9Y2<'WU8*P?Z+@(&2^*"J&&L9X/(/3A;KD6CW2]
MI&33!*H_,>!',-*W,_(C6*@!_ZV%V32=#VGHB3!G+D^)';)0'EW.E\OE8GRU
M6"R6^G2LZ]3(FY31CK^U7VRR=A9FIC*"&2!83A?+JPD`&>D+.M19$4P!P'PV
M6\S&RXD._]/T/#P"T3:=J;*]BA!(\BI"(,FK=`$G,%:A;24Y5A$"25Y%""1Y
ME=:J`KTZE^Y5A$"25Q$"25ZE1;5`KT([6'*L(@22O(H02/*JL.(SK566TKV*
M$$CR*D)P;J]FRZKUPX-!FU#ERJRZ/J8K.5@[;H)P"]?2L@M$XQFLVY)CMS>N
MO8MAE1@Z3\_D=QSLX=]-$,=PY>GV9NN83X%ONO!2R\[(?M><"=?FX#+<2HV?
M'>L3#,;T.1*\R1!#C9!G(IU4^/I<'\WUV>0J640)&MJSM\[!*VN7CWV2*V!&
M8MMFQ9$-_7R0E`Y%3U(C7DC=QWD&=37U-.<)P(F,$IQGB-"QZ,_SZHC.X-,1
MG<"I(SJ#5T<(G5/!E5ER&QS@LO"Q@PUC,1HEK5#><>H%(N`G&',:!#JG;,_&
M4TY8M/&<MKI"?BG%QMV$_-#&Q@E-&\XHZ]EPP@DM&\[@U9'E3>9=1GC>3B#I
M^022(WLS'^\&`P9*3LSP'"7!-#^1-G1RD88[W9U6MU$\TAHD])RNCNPE4YDS
MV;=1XV;[IG4!E!F6[;H?R<3_]UU>:T!+[?;F98?N&H%;><B]%N2F%/(2^M;I
MRZ2N2-Z`+ZM.FE2>I)C[O?OZX>!M[-"@]_?0(>A1TA\OWMW1@JAX_]9UGGS/
MIDU!-1'S;1C$MA73^X]HV[X*S[0"SS@5Q(.GS_AZQ?A@)VY[]!D?FDXGG0AV
MD3H^D(M[?)%\('=:I:0&%V!2U^$1B0!:"QD"<((,!.3.L-0&0$\9"&#)EB$`
M@A8(`$X-*_K$P1AE,^!`,22,/]20D&,R+9DA!]2R*OW"^#5:&DSZ[65FE&^!
MZ(69X4T-@%Y#5J5862D&N1TBK3`!O*DQ@0&SKI@I#QH(.>_`!@4`:09!29<!
M!&F@SB+B6(ER+HS):Y$[@74((@5)1;(A`!PI$)`CQI+FWS'&(&D&QFR0-`5C
M",P<7)\EA,8$]@0S0TK"`'BD1$61K\?,C'%&,R`(LC(D8L-$5HK$&&3ER,(5
M$UDI$D&0E2&Q)V2E2(Q!5HY$KI"5(A$$L(B4#(D](2M%8@RR<F3A"OCZE1Q7
M(`BR,B3RQ'3@%*GAMFG21$7]T^6\4_]4>=DU-E+'58LF\'MV>K)Z2E:.X`NZ
MED)+Z3&`,[/>J?(<A,Y/L,@D7]2SH)EJARKY#F?L6/C(CZ&Y?[1?8"F:7-]Z
MV57W>@%)UM\X)B.+L!)3,3YTLE6ES>#"[=,#2W]#-&I.%_6-C?DC9K#-[4:&
M-((@S1W9&(BM4PS"*2`H1$CDRC833)+2,6!7P83)ERL,L!Q)/@W9K)&K:'"R
MFI`W.*CRRQD<1PBY?M\N9PMW1#\XW+089/XB$9I>A0$@3%7-SIY#1$1-B[C3
MX/T<,3E'K=,J8Z"@G1ZO@.L,9-">=6/V*INK1_4Q&1AL&\.1_I4\5E?1B'3<
MZ[R6-35;^2VKH=N8IY+H8R#98`@+;G7"/#"]^L<"*DM;Q,+IXIA-MAW"F=ZC
MQC$M<H&&#56.:-$>=2=R\VI!IM"TU&UA^DY&;A5GE9PM6[0.#+?MNH(3,O,/
M%D'UZ'BH6%DY8<R\9*L(&09E.=7SP.3V<Q?8%3'"P(8W=>F_THQ">%>V&1L3
MW-;IBD9ZB:60;Q.3=2?=ED@K-;TJF,?B)A>T62?R4(^=8KA-+9"(35JP9.B(
MMPTU2,!PK8R$A,7X[*T)W,NKK@A+*8&'39WXPUT5?K'`":.R,J5RD0!!SH8O
M2_QA3<N#L,0(%F!E-.!<P>UK#`A54W!X0V^+2F\+K[,8%Z`.7:0AX?2L18YR
M:<EC/#'<,<-B+_-J4>'D)BU8WG7$VV9&&'IM\:793B!>)J";5D>=<J#`""^7
M6"P5A\1740,VV(\GX#NAY@UQ+MB=*M=!85=DI@9K=V1#UU3$HBD942J:4N>H
M(YK!4HTH<PD$R,Y[X-VZZH:=]LY=ZPA;L__?F(]U;M-,QWJW4ZKK-^\=P6V(
MEI\;W(;L(P`N[_Q7,9&<W;P]\3)334-FZIB+\B98LJ%4J0F&+8GNP!."K-4,
M+/H:(TZ!'8+V"[F6WI3Q.N4X[G9"11EZ%(:EM,%3/@M()MQJX!A`;8@F-=C:
MZYR`T7U@U8OH,C5^;G:OH$]][N%1@BM7]J5'/4R6'&(!5=B-Y2O`8PM='L.Q
M)!:+FBO*2JA9.PZ)C\NJY0J]O5FEY&2&K>6."X\6P^+&]""ON:X5L>RHY&NK
M0D3TE:-^A8CP"UG]X%1/-ZTBMQ.5.E1QE;/Y\&A[+@T:DCE+?#8M<ANW35A4
MA60Y(?YBAN>:$$I$XLFD'?V%0[<GO0#V)K_B5_8A2R]NCV*`G-%:8606'WQ5
MM'TMTPFU4+.68'<T:YLXQ0FZP8@=T71P,@#995?J44H>'A^O.RM8R";A<<F?
M7T:L-VG!\J!C;NK*T;.`$T?9L\/E93#)X5F,D9=<Y?-I_K8JH^E7:>'+LV@K
M0G8CPORKM@IY'A4\*G/T6^5">6N1Y7?>&2)5[N;@N+"9.;D%A7P-VCI$L&?O
M77(P_>)JG:R\ESZ!8,:R(&K;R@()R7PS@98HE@6-E[:R\J0Q!6V1+-BEL;4L
M:$HFN*9DXX+"7CK<_M06%YR2RF)M/^.TO7[*CW2+CP(749D'%Y95^!$LAW0D
M*K>55?@1'(=E@<IM915^!(1(E@Z#M)55^!&\@&4!W=K*ROVH@^.0K!FG[:].
M^I'E*OD^/@\N+*OP(\O5*2=7L:S"CRQ7B<IM<15^!*G(7CK\H:VLPH]LGM`Y
M\P36L?`C:_L9I^V/,RK+^`DGXQ,IA>_@%;(1F?UX;)1(*;S&LGS*R?)$2N$O
MEM\Z)[\3*86G0![22(<_\&N4^VC*6E?GM.Z=N<VR+DL8,L_PP(`G+5L'%QYV
M'9!'9=/])DB;'RE$=A?BDO1L6Y^4-6P?G`MBXX%,HSR"'E[VKNF;<1"^*F2/
MB5P<Z_09I[@_!D%N(U8"N:F:!]"?X,'B\,QR!>R23N*,@<C^`FW$Y+'`FH=L
M.-=&#)R=H&'Y1[Y:V48,G)V(89,JJ9]XQ+SS]X?<0VPN)5,WCXCWCO_)WK+,
M8;/$!$#R2/I@'^+0S/G'AM2$TS`?R*;3N0PV122/?LQVR$[KSP^PQW1F1'+K
M.XH=4D/S`/_+(49F)&<A(60!SB/DT8GA&019$#,B""PN$0'L^Y*+.,HHG#+^
M9H8^B18F=(\X6J%1L8L.5/_;EV(#<FKWV(1G+-"MR?/U`!AJ:^_,@QL_YG]<
MJ<7K/].G>P"9TD]]ZWP.8BIBI1:OWY/'ID`4PW[ED&[>1_`H#OBM'$)GI?[G
MX6Z^O'\P)A>+T=WB0I_:LXOE[.[^8J:O[^[OC>5H,EK_%TSFN7YT_3+65^IS
M'.^O-8T^I]Z,+CW'"H,HV,67%CR-)=CM',O6HGT(225ZMNW8<[7):+34EIIG
MT@<A@)#KR(5/A:FR*?B/Q;&5BMXD\.FS$@`V/$0@4T*+R#[N'\D@M_\#``#_
M_P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE
M;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`
MTDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B
M?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>
MG$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"
M'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[
MGM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\
MTG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:M
MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4W
MEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:
MPA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ
M0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM
M9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV
M[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)
MZ9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S
M*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?X
ME)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X
M*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`8
M1[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L
M8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<
MB=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\
MB_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?D
MIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`
MIJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC
M=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T0
M6+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ
M['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:
M'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P
M4P<2(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/B
MJZ*S"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46
MYS3IBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\
M/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4
MYK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@R
ML6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N
M?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3A
MG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&
M80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['S
MYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E
M33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`(:/3P'N
M`P``8@T``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULC)==CYLZ$(;O
M*YW_@+A?P.8K1$FJKJH]IU(K54?GXYH0)T$;<`3L9OOO._88C(TCY2:;#"_S
M,)YYC7?S^:.Y>.^LZVO>;GT21+['VHH?ZO:T]?_]Y^5IY7O]4+:'\L);MO5_
ML=[_O/OCT^;&N]?^S-C@08:VW_KG8;BNP["OSJPI^X!?60M7CKQKR@%^=J>P
MOW:L/,B;FDM(HR@+F[)N?<RP[A[)P8_'NF)?>?76L';`)!V[E`,\?W^NK_V8
MK:D>2=>4W>O;]:GBS152[.M+/?R227VOJ=;?3BWOROT%ZOX@25F-N>6/1?JF
MKCK>\^,00+H0'W19<Q$6(63:;0XU5""6W>O8<>M_(>MGFOGA;B,7Z+^:W?K9
M=Z\_\]N?77WX7K<,5AOZ)#JPY_Q52+\=1`AN#A=WO\@._.R\`SN6;Y?A;W[[
MB]6G\P#M3L4M%;\`"3Z]IA8S`*67'_+OK3X,YZT?9T&:1S&AJ>_M63^\U.)>
MWZO>^H$W_Z.(J%28A*HD\%<EH7&0T#1?/9`EQ">2E7PMAW*WZ?C-@_$`9G\M
MQ;"1-606)20I+&4E+GX15Z4&PCU$WW=)E&_"=UB42FF>EQHR*4*@3"A(;Z/B
M:$*)JR8JRZ8\\FF>EQ(Z*0Q2;)#&8D045M[W9L6LI@2(0$TRTZ23PD"`9%;,
MB!#1K0_/.4,44P)$H":3JYD561%'\:0P$#`:#H2(6@@230D0@1I$D!7,B!88
MA,Q)$%&;H%N*!-0@X8FD11S?:47N1(BHC=`)$($:A:`DH?3..HGM5(_PV`H1
MM1$Z`2)0HUJ1YT51Z'DP%JIP(D341B16*U"C$&F>9_>Z36#[<90APS9$SR36
MH41(2?(T+0I=JE$(<?A]9D)YV?((L6VH1`^8A)B6'ULCPW9-BVT%W5Z@3X+X
M3F>(V^LR;"-T"K5LZ/:51!`]?^:*N9U.'%8GMM65:*I!7S<1;J?#JV0Q7U0[
M6=6`(D04P>I>%6ZK$X?7J>UU)1JK2.XA3*O+5\E\M!R>ISJ5J@9%(^K>ID+<
MEI=AJ^FS34,AT/2(2(.[;3<MOZ@&?6V\3*CM?8*B!XQ"W>:78;L@V_Q*-*<D
M5'O6F#1JVG\TI`S;'-N02F1RM*5,CMOX%#T-G_K]2+4IL$%*9'!B/?8FQ^U^
MBL8VNA/;8ZU$<XY>6I,"&L?63$786K79Q*IJ4(1[3$+S0B^KR7#O`>)\N&#H
MO5TQ4*2V?WA5ZE)-AGL3@"/RDF'/LA)A'7%&$KL./"7CV?):GMB/LCO5;>]=
MV!&:'04Y/&2'9V3\,?"K/._M^0!'7OGU#/_+,#AW1@&(CYP/XP]Q"I_^.]K]
M!@``__\#`%!+`P04``8`"````"$`&-'37&D#```]"P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6R,EEUOFS`4AN\G[3\@WS=\$Q(EJ9I`MTF;-$W[
MN':(2:P"1K;3M/]^QSA0#%7H31M\'K^<U^=@>W7_4A;6,^&"LFJ-W)F#+%)E
M[$"KXQK]^?UX%R-+2%P=<,$JLD:O1*#[S>=/JPOC3^)$B+1`H1)K=)*R7MJV
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M72QH#WBGJ+%J-G<)RE<+USPZ4["VF:(?%-Y,@G0%C#YO`B=8V<^P2MF5V6IF
MCJR.B>8FLFL1M51*-VD'WN:XYI2T)51!(/?.`"S+T(#O=/FJJ)FO-\AE^PYB
MOGHW)J+81)(QXIE$.B9Z(H8C?^PH"#M'*@K]TUO=P`G-=VTU$_28`;&;))))
M(KU%&(8@D5Z)VE92HVL$R]*UB1L,BK[53-PTFAM%0Q?]L.>Y@]E)/QPZL6^N
M4MH/!W[TUL9&\O!1O).\&C63#YS(U-]J!M[2&1SF/TDDDT1ZBS",1(:1YDOO
MM96*3K659FX9FB2222*]11B&8(=YIS)JU*Q,//SB-1(T717/%V;9=CH:Z9[S
MY\.FZH>]^6(03HUPZ+[M$T;JZ@8PV'5[FY:*FA;\T#&SW&KF5BTFB6222&\1
MAJ'%V%"ON51TJKDT<\O0))%,$NDMPC`$]X9^B=I-JQDV:S-JKRNC=ZUY/-@6
M=D8X#@:%38RPYRV&YX@1=^/@35[GKV\K^HPO"3^2'2D*867L7,$^Y$%;=Z/Z
MEK1UEW`>P[$Z&$_4[:FY_W0!N-/4^$A^8'ZDE;`*DH.D,YO#'L3U]4<_2%8W
MA^Z>2;C--#]/<$TE<-([,X!SQF3[H,[S[N*[^0\``/__`P!02P,$%``&``@`
M```A`"?%B-5P`P``^0H``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R4
MEEUOFS`4AN\G[3\@WS=@\M5$(55#U:W2)DW[O';`!*N`F>TTW;_?,28$&S)U
M-PD<7I_S^/C%>'/W6A;>"Q62\2I">!(@CU8)3UEUB-"/[X\WM\B3BE0I*7A%
M(_2'2G2W??]N<^+B6>:4*@\R5#)"N5+UVO=EDM.2R`FO:05/,BY*HN!6''Q9
M"TK29E!9^&$0+/R2L`J9#&OQEAP\RUA"'WAR+&FE3!)!"Z*`7^:LEN=L9?*6
M="41S\?Z)N%E#2GVK&#J3Y,4>66R?CI47)!]`?-^Q3.2G',W-X/T)4L$ESQ3
M$TCG&]#AG%?^RH=,VTW*8`:Z[9Z@683N\3K&,^1O-TV#?C)ZDKUK3^;\]$&P
M]!.K*'0;UDF1_3=:T$31%%8.>7I%]IP_ZZ%/$`J@B&P$NHC\?2YS'^HJ?E>F
M?WTN^=@LVQ?AI30CQT)]Y:>/E!UR!97F>GC""]#"KU<R;1SH%WDU&"Q5>82F
MB\E\&4QQ.$?>GDKUR/18Y"5'J7CYRXAPF\HD"=LD\']JG_]_DFF;!/[/2<*W
MDOAF5DUG'H@BVXW@)P]\"=RR)MKE>#V%MB8Z>*^C$5K"2D1(0O1E&VS\%VAG
MTBIV1@&_G0+;BOBLT"L"Q;J*T(.1BCJJ*^H%T`@[$^@7")T"0\6T4U@5H6$C
M%744%K,W@UDWW"`8Q:RGF-N*^%\*"P&2C"#H:(1@'ET3%W:!G5'T$9:V(AXJ
M+I`6`KAU!$%';81;N\#.*/H(*UL1#Q57$!:C"#IJ(V#7;48R;YPXPROL6L$\
M[S->(0!+CS1!1QT"Q\T[(^E7&$`,)5<@](=G^,[IJ`-Q\;,QI)%8$(YGXZ'D
M"L1J%$)''8C+>`-A)!:$X]IX*+DDL3R)8;,?:443=C`<W^]:C<7A6#<>T5P#
MT;O5<$VPV<3Z;RAVW+]K-7V0T/%O/**Y!J)WM1$0L]GU04+7HMAH+!#W11G1
M7`/1>]L(B-GR+!#7IGBX+8:N3T<TUT!@0CT03W^II_H$T-CQ'DX6KF7#2R9C
MV5;3[XPCT0<4G6;1;#'36;"<KWK,QK3F8&$^GR45!QK3HI!>PH\5,&$8VD6[
MDT][).D>P-&B)@?ZF8@#JZ17T`R&!I,E[*'"G$+,C>)U\W'><P6'BN8RAR,F
MA4]C,`%QQKDZW^@O;'=HW?X%``#__P,`4$L#!!0`!@`(````(0`QLJTD2P(`
M`%D%```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(R4RX[;(!2&]Y7Z
M#HC]&#OW1+9'$XW2CM1*HZJ7-<$X1C'&`G*9M^\!$D_B9)&-;0Z'[S\WG#X?
M98WV7!NAF@PG48P1;Y@J1+/)\)_?JZ<91L;2IJ"U:GB&/[C!S_G7+^E!Z:VI
M.+<("(W)<&5MNR#$L(I+:B+5\@9V2J4EM;#4&V):S6GA#\F:#.)X0B05#0Z$
MA7Z$H<I2,/ZJV$[RQ@:(YC6U$+^I1&O.-,D>P4FJM[OVB2G9`F(M:F$_/!0C
MR19OFT9INJXA[V,RHNS,]HL;O!1,*Z-*&P&.A$!O<YZ3.0%2GA8",G!E1YJ7
M&7Y)%LL))GGJZ_-7\(.Y^$:F4H=O6A0_1,.AV-`FUX"U4EOG^E8X$QPF-Z=7
MO@'O&A6\I+O:_E*'[UQL*@O='KLC3-6@!$\DA1L!R)P>_?L@"EME>#B)QM-X
MF`S&&*VYL2OASF+$=L8J^2\X)2=4@`Q.$'B?(,DX&@W&T]D#%!(B\IF\4DOS
M5*L#@ND`3=-2-VO)`L@NA6$,E61N\\7M>A\P&[#N\\%LE)(]%(6=?):W/DGG
M04"EDP+\A=19PEG[$N,.X,-8WO'I/*XDAG<EG-5)N,:XM)9G`[I(:W*?.+I+
M=%8H%+X$3#M`$`D^\.Q$/M.Z"AI&X*(N_1:XW0Q#!3K,8#;K206?>6A0$GUN
M7^E,KG3.]7?6/G_>XP>?D>?WFQMN1YBIEF[X3ZHWHC&HYB5$'$=3"$Z'NQ$6
M5K6^WVME8=3]9P6_,`Z-B2-P+I6RYX6[?=U/,?\/``#__P,`4$L#!!0`!@`(
M````(0"=6='PKP0``.8/```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;)17VXZC.!!]7VG_`?$^@+D&E&34(;`[TJRT6NWEF29.@AIP!'1GYN^W"AMB
MXW1F.@_MY'1=3EWLLM>?OS6U\4:[OF+MQB268QJT+=FA:D\;\Y^_\T\KT^B'
MHCT4-6OIQOQ.>_/S]M=?UE?6O?1G2@<#++3]QCP/PR6Q[;X\TZ;H+7:A+?SG
MR+JF&.!G=[+[2T>+PZC4U+;K.*'=%%5K<@M)]S,VV/%8E73/RM>&M@,WTM&Z
M&(!_?ZXN_62M*7_&7%-T+Z^73R5K+F#BN:JKX?MHU#2:,OER:EE7/-<0]S?B
M%^5D>_RAF6^JLF,].PX6F+,Y43WFV(YML+1='RJ(`--N=/2X,9](DI/`M+?K
M,4'_5O3:2]^-_LRNOW75X6O54L@VU`DK\,S8"XI^.2`$RK:FG8\5^+,S#O18
MO-;#7^SZ.ZU.YP'*/?HK60V>X*_15-@#$'KQ;5ROU6$X;TPOM(+(\8@;F,8S
M[8>\0EW3*%_[@37_<2&"WF<CKC`"JS#BAM8J"/QP%8&5!YJ>T(15:)+8<E<!
M"4+T_T#3%YJP3L1=*R).[/W`)9@=(X;U@RY#H0GK%&;PR*7-<SW6:%\,Q7;=
ML:L!C0_9["\%;B.2@#%1'!'M7"[HFA*EGU!\8T:F`87H`7W;NM%J;;]!_4LA
ML]-EB"J13A)8.#2[7P+9$L@EP`;J,W^H\T?XHSCRGSSO)D`*:$%VDIA4]DL@
M6P*Y!"ADH;4^0A;%81/(R78BE=U.R,@5"521=!:9(]"03$-R&5&"@"[_2!`H
M#LT%+2ZU3*Q2W'$A[U$4L\@<A89D&I++B!(%\)&BF-H;T9'LY&3'$1^R<:-/
M7)5^.@M-:GL-R30DEQ&%&^S#.]P05;EQQ.4'(.ZC5$/V&I)I2"XC"A&HQQTB
MB*I$!!+.VRK5D+V&9!J2RXA"!.\"MU-JJA:B*A&!P")5RUM4BPMY[LQVSQ$?
MMJVDYJMJF::6WU6[[3XE@EB)0)RS%LZ'X5R5+SL&GLE\S**T&AE'O'@\<WT2
M:STH!*2H..+>D$R3R649A2^!.7\GY2.L,A-0R*F1&`;"8GNG0L0=+PKBQ$?[
M<!+#(N4\7.1<5\P%%&&RWK;$M=QW,DYP9.A-,\*+",1P<;E)#S\JD732NB5S
M+Z!(/1H6YW.F*^8WQ7%^.K,KM0`X1.[0Y[-%7*!PT^^(&#?^`_I<1"F`T,(.
MG&<YT>AKBOGD+AC=>>_1Q_EQASX?*PI]#D6/LB^TY.P++5@>T=<4<S(K8O;]
M]^CCX+C1_]%^)7S.*&%Q*`IY54C@:;N"2RA%$4IJ4187K$QXDQ1S`<%Y@E'%
M%O$<^7.SH/88CJ`/1(GBBZW#H2@:_8:.[[F+%DIQ]*.67#P-RG0I?)3<%#EO
M_LC@%]B&=B>:TKKNC9*]MGA^8@O-,'_=[/P$+@$PEY=XD,``OH.'"<Q#'4]7
M21K?P?>K9'\/SU8)'+>ZG7R5P*&KX_`*>QHSM.2)K[,[\CLW@6NF;F?G)7!U
MT_$G/WGB[6G/'N#Q=2E.](^B.U5M;]3T"$ETQJ'4\7<:_S&P"R07GF!L@&?7
M^/4,[VD*AX]C09&.C`W3#_!LSR_T[?\```#__P,`4$L#!!0`!@`(````(0`^
M]N$%P`(``!0'```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;(R576^;
M,!2&[R?M/UB^+P;R01*%5.FJ;I4V:9KV<>T8`U8Q1K;3M/]^QY@0:+C(#1\O
MQ\][?&P?MO=OLD*O7!NAZA1'08@1KYG*1%VD^,_OI[L51L;2.J.5JGF*W[G!
M][O/G[8GI5],R;E%0*A-BDMKFPTAAI5<4A.HAM?P)5=:4@NONB"FT9QF[2!9
MD3@,ET1246-/V.A;&"K/!>./BATEKZV':%Y1"_F;4C3F3)/L%IRD^N78W#$E
M&T`<1"7L>PO%2++-<U$K30\5S/LMFE-V9K<O5W@IF%9&Y38`'/&)7L]Y3=8$
M2+MM)F`&KNQ(\SS%^VCS$(68[+9M@?X*?C*#9V1*=?JJ1?9=U!RJ#>OD5N"@
MU(L+?<Z<!(/)U>BG=@5^:I3QG!XK^TN=OG%1E!:6>^&&,%6!$UR1%&X/P-3I
M6WL_B<R6*8[GP3Q>)*LH7F!TX,8^"3<8(W8T5LE_/BKJ6)X2=Q2X=Y39,E@D
MX>P&"/$9M3-YI);NMEJ=$&P/L#0-=9LMVL100N;$O5-3G&`$21E07W=1LMB2
M5R@&ZV(>?`Q<+S%]!`%Z;P'Y3E@XU5FX:CG/!R\,>?$T;S;)<VJ*X7I))UGV
M`&_A8^:#F,ND1BE#R$3*3H4ZP8H-/"X$[^&#;O``S(2'4UN/OBZ=`KMSTG64
M]W+$1&Y#SL-UL.P7U@6,\9TR+ES2%VZ$APTQ2+G%S\)ED"QZOHL8\SL%5G>0
M_FJ:[QKC93.V_'@6!G!&SAO318SYG3+.?SW-7T_PHR2XX%W`&-\I(_PJG,9#
MK[G*?Q$-R]-&C`W.TM@A^N#@>Y`_N9+K@G_A56404\<:RNH.;J_VO6\?N\/U
M49]O]KXGDOX+M*J&%OP'U86H#:IX#LS0Y8VT[VK^Q:H&<H=^I2STJ/:QA+\/
MA],;0A%1KI0]OX`SZ?]GN_\```#__P,`4$L#!!0`!@`(````(0!3?W]]J`<`
M`'0>```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)29W6[C-A"%[POT
M'03=;VS9LAT+21;1OX`6*(IM>ZW8<BS$M@Q)V6S?OH<B*8H<-IO<;#;?#(<\
M)(<<*G=??YQ/SO>J[>KF<N]Z-W/7J2Z[9E]?GN_=O[ZE7VY=I^O+R[X\-9?J
MWOVWZMRO#[_^<O?6M"_=L:IZ!Q$NW;U[[/MK,)MUNV-U+KN;YEI=8#DT[;GL
M\6O[/.NN;57NAT;GTVPQGZ]GY[*^N#Q"T'XD1G,XU+LJ;G:OY^K2\R!M=2I[
MC+\[UM=.1COO/A+N7+8OK]<ON^9\18BG^E3W_PY!7>>\"XKG2].63R?H_N'Y
MY4[&'GXAX<_UKFVZYM#?(-R,#Y1JWLZV,T1ZN-O74,"FW6FKP[W[Z`7%PG=G
M#W?#!/U=5V_=Y/].=VS>LK;>_U9?*LPVUHFMP%/3O##78L\0&L](ZW18@3]:
M9U\=RM=3_V?SEE?U\[''<J]8DUUS0D_XUSG7;`]`>OEC^/E6[_OCO;N<WWC^
M?+U8N<Y3U?5IS9JZSNZUZYOS/]S'$Y%XC(6(@9\BQF)]L]K,E]XG@BQ%$/R4
M0=[MU!?^^"G\5ZK/=P:[$>WP\T/](".&"<+/C_0SX_,[K$M<]N7#7=N\.=CL
MF,+N6K+4\8*MZX@%$=,Z+A%VRHYY/S+W>Q>#Q.QWH-\?O+5_-_N.-=\)G]#B
MHWM$TH.M.PL;FR`Q06J"S`2Y"8H)F$'M*!G[X3.2F3N3+`<;2J#F8&'HDQZR
M26R"Q`2I"3(3Y"8H)D#3AZWZ&7W,'>FE+>E*%Q0*G^FZ&R[1Z#**)B0A)"4D
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M1;TPY^NW6AKK%WNC@QQ=(I$Z`%**,H%\?XB\]HV=DRN[#%QH4739K`BPR.:U
M@2:;(\B682.8V1FV'-Z>XD%!4"*]IJJ$ET*9\((J&3ZGJ-!BZ4+8W6\1PDL"
MM)-A0X\C/4LWGKE^W$OFGS\WSL=8A-%VJFBC-EPJO13*)!*9O30S.U<.<LR%
M1$,873<K&BRZ>2VAZ>9(2T!1<:C9B3V"$HF4AI2B3"(5*Z>HD,@BA)4/%B&B
MJE!A0X\C(P'-MZ#TXFFR-=,D5G8YRXE`DPLXI2A3#=G)O-H:B9TKNPQ<:%'T
MY6/UA$4U+S.TY1.5QS3_!%(Y$WL$)0)IJKC7!&6T84Y1H<72A"ST\D?6J`/6
MRQR!C/PSTBL27N)*6GO&+,?*+F<Y$6AR*Z049:HA6SY_:[RG<V67@0LMBJY:
MKWM^5O3A86$6?0)-LU(@_W8\LV**$HE4L9\*-)F`3'JI6#E%A41#+%V@O?A!
M04J$<&1DI5&O1J*ACPVH+D]2_`BO%2N7OS_@VZ-QNR;2025#*M!T3W^HLUS&
MXITMM[XQYD(Z#)WIL\/J$)6]/UU^7K9,LWK!T?16%6@UN54E4O=E(I'*_50@
M;09X^$FL7#94L0J)AEBZ0%:DO"/P6W-ECQID"O_TS#]QGJOVN8JJTZES=LWK
M!0N]6F,E1\R_>6/B`S8:-#8LF'%\#K=9\)W\<1BXT2+$]_-A&"9G@2P]A,L`
M'[-HSX\^XML,H1_@"Q!M$*X"?$>Q\'6`KQ$6#FFAM0>D1A!9+3$LL=6"/`C8
M3J#](!T"MB&H)8,ELUK"Q1QCLTTC3F.,P&;!H8L1V"PX>S$"FP5',!;>9L%)
MB_6R67#I!R%N'ZHG@H5=>]2"^SQ@MQ^UX%H/4JL%MWO`+C[:!I<X]IC-@HH2
M8QLJ&F/[1;"PBHI&2V!AA16UH&3$V&P65(X8F\V"^A!CLUE"S\?8;#LT@B6V
M6O`.P=AL;?`<P=AL%KQ*,#:;!8\/C,UFP<,?%OMJ(TOP5J.S@]=SP-Z-U((7
M,_38+'@J0X_-@A<S]-@L>#@'[$U)^\%C&4IM%CR3H<=F"3<!/N[16.$6,H=S
MWMPXVR"Q;;7(0[I96Z1;*+&%RK8!/EK1OO$%"*,=6LS&WO&GP&OY7/U>ML_U
MI7-.U0&']WSXB-7ROQKR7WI^[CM/38^_`K(KP#GBK[L5OO#,;_"X.S1-+W]!
MU[/Q[\4/_P$``/__`P!02P,$%``&``@````A`-^IE@?^#P``;DX``!@```!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6R4G%U3&SL2AN^W:O\#Q?T"XP\(4PFG
M8GN^O[?.[EX[8((K@"G;2<[Y]_MJ9MH:Z14&;@)YNM62NR6-NJWA\Q]_/3V>
M_%IM=^O-\Y=3[^SB]&3U?+NY6S]__W+ZGS_#?WTZ/=GME\]WR\?-\^K+Z=^K
MW>D?-__\Q^??F^V/W<-JM3^!A>?=E].'_?[%/S_?W3ZLGI:[L\W+ZAF2^\WV
M:;G'?[??SW<OV]7RKFWT]'@^NKBX/']:KI]/.PO^]CTV-O?WZ]O58G/[\VGU
MO.^,;%>/RSW&OWM8O^S$VM/M>\P]+;<_?K[\ZW;S]`(3W]:/Z_W?K='3DZ=;
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M0WR\]H-?'AJ.1V=7WL7U^`JB(PVO^H;X^9&!8F6U_>%GW\S3CC[2W77?SE-S
MH(_0^P;J'6*+7SXR5$\"JG[YT&`]B:*GX_%.MV)V]C,1OWQHM(A@-X5U*-\Y
M!SR)I?KE7<X][Y9/N^P6R_WRYO-V\_L$>QE<O'M9JIW1\Y6U?L'U$^FP!+$3
MW"KUKTK_RRD4L;IVH+]NO,GT\_DOK.G;7F?FT#$UYJ*AUK4RN[!!8(/0!I$-
M8ALD-DAMD-D@MT%A@](&E0UJ&S0#<`ZW'WR/6?HAWRM]Y7OQVDR`#L;(<K1H
M2).%#0(;A#:(;!#;(+%!:H/,!KD-"AN4-JAL4-N@&0##T5C='W*TTL<#Q9CD
MEZ9G9[W.<"58ZV!^4#EXGTA`)"02$8F))$12(AF1G$A!I"12$:F)-$-BQ`(;
M[(=BH?2Q.6%S'>PX5U8P.J7QL6`<5`[!(!(0"8E$1&(B"9&42$8D)U(0*8E4
M1&HBS9`8P8!7A\&035[AUN?BJUE'</(;1L&>[P<E:;8@$A`)B41$8B()D91(
M1B0G4A`IB51$:B+-D!@NQL-]Z.+V`3N:GD&_.SSQ(U:U,+W?D3&VM\$:^&2N
M@?E!Z>!](@&1D$A$)":2$$F)9$1R(@61DDA%I";2#(GA?>P(0^_+!%?8='%'
M+!=?6RX^*!U<3"0@$A*)B,1$$B(ID8Q(3J0@4A*IB-1$FB$Q7*Q2[\$)4ERL
ML.GBCI@NGEY8+CXH'5Q,)"`2$HF(Q$02(BF1C$A.I"!2$JF(U$2:(3%<C%S*
MY6*%31=WY!+[O=XHII[EXH/2P<5$`B(AD8A(3"0ADA+)B.1$"B(ED8I(3:09
M$L/%*DUU^;CEII-[9$UD^^2MM0YN9A0P"AE%C&)&":.44<8H9U0P*AE5C&I&
MC8%,IZO,R+%WJ`J`-;-[-.HJ."IGG#-:,`H8A8PB1C&CA%'**&.4,RH8E8PJ
M1C6CQD"FAU5*Y/)PERKUI37ESIDJFBBG7Q[RRSFC!:.`4<@H8A0S2ABEC#)&
M.:."4<FH8E0S:@QD>EAE.@,/]Q64,U6-VS^L;W_,-MB+/5U`Z3(CP_,]TIG]
M7!6D$(S)15MBF7C7GK6_++2&["\!HY!1Q"AFE#!*&66,<D8%HY)1Q:AFU!C(
M#(3*<CX2B"XK,@+1HV$@.C3!CC1XI([-1^I"E0U5N/3N%#`*>X2Y)"&+M-;0
M_,0T'VLM:9@P2ME\IK6&YJV\+==:8KY@5++Y2FL-S$^L\T:MM<1\8R`SBBJ1
M&D11CI,($ST2>C2,5H<F1J8TM4HWB]X6M&1``:.04<0H9I0P2AEEC')&!:.2
M4<6H9M08R'2ZRI]<3N_R*C041\WP>&CC@(/48#U8]9AYKS72H5DP"AB%@MIO
MB=K2<"1(VXH9)8Q20=I6)DC;RAD5C$I!VE8E2-NJ&34&,IVN,BJ7T[M,RW!Z
MAT:FT^T"@"K?JTT(CXY!:*P<=B%:D_;)<GEER8->CM.MQ#QD%(F5HWW%HH7=
M48_HTDKY$C:?,LK$UM$><]$ZVF/!YDM&E=@ZVF,M6J_XLS$,FQ-`Y7NN"=#E
M@<8$Z!`F@`1E[G4(T1:T$#0YH*!'1C2[A@,424-M*Q:D;25L*V6424-M*Q>D
M;17<L&1424-MJQ:D;35&0]/#*MUS>;A+`PT/=VAD3ASK43;W>JUINWA&WL78
MFLP+K2%A"03IC2)D%/5H@D7\^EJ)M9:83]A6RBC3#8^8S[66F"_85LFH$O2J
M8VJM(:8;0:UCC,"-K&S\K4-UJV]FZ3U"0*6_>8\F^G&V8!0(TGE0*+9T!"/1
M:N]"M`^JF%$B2-M*V58F6MI6SJ@0I&V5;*L2+?T9:T:-H-:6Z?E74G(DWO;Y
MJT?F4\D^_<U[K0E6CI[74^NIL^BUIBI/^G4S\JXN+(U`-/1>$/9HN).]J[=8
M;.&TJ,=$SR71TCVFW&/VKAYSL76TQT*T=(\E]UB]J\=:;+WJT48TVM[,26!5
M#=Y<?EQ-&'5H^,3JT52?H1:"]&$C$*37;=@C(\Z=^8&M6!KJ]9$(TK92MI6)
MEAY7+DC;*@1I6R7;JD1+VZH%Z<_8"&IMF9['86/XQ"+/_[EY&5831DK?VO@Z
M=*EW@'FO-4`+1@&CD%'$*&:4,$H998QR1@6CDE'%J&;4&,CTO$KA'6<%=2*P
M/=PAK!_]:"&TZ!L.M`)&(:.(4<PH890RRACEC`I&):.*4<VH,9#I896<NSS<
M)>W#TYBZ?Z><KM??G-&"4<`H9!0QBADEC%)&&:.<4<&H9%0QJADU!C(];.7Q
MM'M8M<@1Y_>"]%%GWJ-#+?)R;#V;%UI#%D3`*&04,8H9)8Q21AFCG%'!J&14
M,:H9-08R`Z%2\<%4?S,07>IN+($>#0/1H3=JD2BZJ+4SK$4R"GLTK$5JK<&I
M:&K7(K66Q#IAE++Y3&L-S=NU2*TEY@M&)9NOM-;`O'T:K;66F&\,9$919<J#
M*$HM<M1ET$:T>C2,5H?>J$7VMH:U2$8AHXA1S"AAE#+*&.6,"D8EHXI1S:@Q
MD.ETE6*[G-ZEWH;3>V2F%G8M4N4G6`\(LX1\P2A@%`K29[E(D+85,TH8I8*T
MK4R0MI4S*AB5@K2M2I"V53-J#&0X?6SEVS+36VX>+WND;`UR)^O;J7FO]48M
M4K2ZVMG(L[Y6"7KYX.`?,HK$RM$Z72Q:.*@-QFV5;Q(VGS+*Q-;1'G/1.MIC
MP>9+1I78.MIC+5JO^+,Q#)L3X)6T?\QI?X\P`60]S7LTK$4*TNE2T",CFIWY
M`8JDH<Z!8T':5L*V4D:9--2V<D':5L$-2T:5--2V:D':5F,T-#ULY=2')<:Y
M,]S1[EC&Q)G:Y?Y>"P5#53*A0OY"RR5.@1C6VT3(*-(-CZR46&N)^81MI8PR
MW?"(^5QKB?F";96,*MW0Z99:R\5P8U@Q@Z9R:<?#:*RXM2]V".F/V)WW6HB0
MH`6CH$>#YU/(*.*&,:.$&Z:,,FZ8,RJX8<FHXH8UH\9H:'I8)<XN#RMN>;A#
MUI/'+M&/.RUL=>W+*:,KSSH0++2&A"40I&LT(:.H1Q/T\/HC)-9:8CYA6RFC
M3#<\8C[76F*^8%LEHTK0JXZIM8:8;@2UCC$#9V7S;Z4X8\[R>V0\23HM;*,R
MA$6O-4"!(+T7AX)T!*,>3759/6:42$-M*Q6D;67<,&=42$-MJQ2D;56"]&>L
M&36"6ENFYZTL__`DX6Q^W"%5D]$SUDZ*YKW6)0Z!6HM*]&+KLEM8XTLJT8N&
M=G@H2&^!T;MZBT4+CT(])BK1BWG=8RI(]YB)K:.?+Q>MHST68E[W6`K2/59B
MZVB/M31\U:.-:+2]F9-`9?F#??/-Y=>7$W15>*9>EU&)T?")U:%+/347O1:F
MHZS(0)"NSH5B2_L@ZM'`5BQ(KX^$;:5L*Y.&>ERY(&VK8%LEVZJDH;952T/]
M&1M![6<T/6]5!5K/N]_HZ"X`6B5[]1*-_63KD#J'#":[E0W-^X;0DD@L&`6,
M0D81HYA1PBAEE#'*&16,2D85HYJ1>@-=N;#S1!><[HWR[M76I]7V^VJ^>GS<
MG=QN?C[#I1X6TLWG`^_>99^-/\G+[+;DTF_:P-O\RF_:&6YS&&J7J,VO_:9-
MDVSN7?CJ6C3B:$M&8U]]2<$2["F^FKLLP3[BJRG,$NP?^(0N"=[C_]K.([M_
MO-_?+@R;CS`L1P\S#-<UVJ\3_RNBQ$.:3?RFW7#L#J9^TRX_BR?X"&J38$O8
MZ7VU5[`$&[ZOM@R68)/WU<[!$FSLOMI`6(+]W5?[B$LR@<0U:ARV$!*7!"<J
M>,PEF:$?M2=S/WA`^W.G9`&)VJ&Y30")VJA9@F>RK_9KEN#1[*MMFR5X'/MJ
M]V8)DB=\'M<4F.&3SIR?=`Z).M:Q-1S$,6J7!.=QC-HEP;$<8W-)<.[&W'%)
M</S&W'%)<`K'#'%)<,S&#'%)D/BB'Y</D/^B'Y<$:3#Z<4F0YZ(?EP3I+N:;
M2X*L%_/-)4%]"=9<2QIE)EAS25!MPE;CDJ#"A'Y<$M26,`]<DAG&-G..;0Z)
MRHA=\V"$>>"2H&"!>>"2H&Z!>>"67&!>N\:&JB#:N"2H!"*F+@D*@HBI2X*Z
M(/8=EP2U0$3;)9F/\.Q`-9Q],!]=^ZHLS1*4H7U59&8)BLJ^*AFS!"5B]..2
MS#"VF7MLD*C:'EM;0+)P2E"S1>1<;5"Z1>1<$MQ$P=B<CY<1=LON@&H]%_"M
M)"2NA_1\=`6_N?:J"!+U915_'GPY!;^Y)/A>"?VX)+CYXZN[(VP-MWU\=86$
M);CA@WY<$EST\=6%$FZ#^SZ^NE?"$MSQ\=7U$I;@:AU&[3Y@>/[,V08WM?RY
M4X+;6;ZZJL/]X%86?.V2X'*6KR[N<)L(DL@IP;TL7UWCX38)).HV#TMP)<M7
MEWI8@HN1:./R`>Y'HHU+@FN2B)Q+@GN0B)Q+@NN0B)Q+@EN1B(]+@AO(OKH#
MRZ/&161?785E">XC^^I&+$MP!]E7%V-9@MO'.,^Y)#.,;>8<&RZY(MJN4>,F
M*Z+MDN!"*Z+MDN!>*V+JEESYZN8QCQKWQGUU`9DEN"ONJWO(+,&5<5]=1V8)
M;H[[ZE8R2W!;W%>7DUDR]W`<[;YJM/<=#^>J[EZ*)<&+"AB;:T?":P>(MDN"
MEPC0CTLRP]AFKXSMRE>WOWG4N-OOJTO@+,&M?HS:)<'E?C]T2F:>R@5<^S7>
M3H/$]:2=>SB_X>4>'@'>=()W7!*\I`3ON"1XOPC]M)+S@[/Q1\!>EM]7Q7+[
M??V\.WE<W2._NVA?M]MV?R^L^\^^NRAW\FVSQ]__0@J(OVV$O^NVPJN.%^JO
M+]QO-GOY#X9[?OA+<3?_!P``__\#`%!+`P04``8`"````"$`<^.'^%L"``!6
M!0``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(Q4RXZ;,!3=5^H_6-X/
M#H1D.BADE'24=J2.5%5]K!UCP`JVD>T\YN][C1-")EED@_#AW'/NR\R>#[)!
M.VZLT"K'<33"B"NF"Z&J'/_YO7KX@I%U5!6TT8KG^)U;_#S__&FVUV9C:\X=
M`@5E<UP[UV:$6%9S26VD6Z[@2ZF-I`Z.IB*V-9P679!L2#(:38FD0N&@D)E[
M-'19"L9?--M*KEP0,;RA#O*WM6CM24VR>^0D-9MM^\"T;$%B+1KAWCM1C"3+
M7BNE#5TW4/<A3BD[:7>'*WDIF-%6ERX".1(2O:[YB3P14)K/"@$5^+8CP\L<
M+^)L.<5D/NOZ\U?PO1V\(UOK_3<CBA]"<6@VC,D/8*WUQE-?"P]!,+F*7G4#
M^&E0P4NZ;=POO?_.154[F/;$AS#=@!,\D11^!:!R>LAQ`@ZB<'6.Q]-H\C@:
MQ\D$HS6W;B5\+$9L:YV6_P(I[MR#5I?#"W5T/C-ZCV"NP+8M]5L29PG4SCRX
M\&B.'S$"/0OH;AZGR8SLH`QVY"P#!YYG3L\@H-Y;0+XW+#SJ+7R=WG,9@*'>
MV?%";WQ3SZ/0D6$ZZ;A/*%@$3CK@3'K&A050;J3L4>@3-/M<\E5;`ND.#Y`9
M>"`_]F0:P2A/0_"$SJYOT1&!%;N9P$4)TVOY.)Y$9WE/N)0_(C"(@7SZH4-A
MC\,.26XJ_I4WC45,;Y6O`++OT?[Z+!(_YH]XFBVZ:T7Z#[#M+:WX&S654!8U
MO`3)4?0(=9MP,<+!Z18RAYW7#O:\>ZWA_\5AC490(2JU=J<#&)/^CSC_#P``
M__\#`%!+`P04``8`"````"$`3?62<8L%``"C$P``&````'AL+W=O<FMS:&5E
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M^NG,$)P=PSOI5^#/QCH7E^SUWOU%WWXKRNNMPW*OF$M.[W@2_EI5R6H`TK.O
M_>=;>>YN!]O;V-9ST79)R7QL*W]M.UK]RP>)",&=/>&,3^'LKQ>KC>L3;_7N
M(+X(@L>*(&2U($MWS6*8#W>X@%YXE'79<=_0-PO5A%3;1\9JDP2()12+",,<
M8"ER9OW$S`\V#*&R!?UR)/YR[WS!I.;"YC1CHUN$TH)-+`L;34$\!<D4I"/@
M0,L@"+/Z,X*8.1,D4SE)H!1ZD^REA72)IB">@F0*TA'0LL>R_DSVS/Q@X^]H
M.59ZNB=A,UZSB4DXF`R2#!(;)#%(.B::K.7/R6+F*$A4\DC7M,RXD?\]78/)
MH,L@L4$2@Z1CHNE"AJ/EDIN$T3Y]^=@3)S[ZQ/\+"@<CZ189)#9(8I!T3+1L
MUUJV_5[WMPMU8)C;G7GH2CCQ4;\C)6N]Y,+!:%!BD-@@B4'2,=&48-%'\_X>
M)<Q#5\+)1,EFHF0P&I08)#9(8I!T3#0E[.J@SE]908SJV7+B\4["SLS0()%!
M8H,D!DG'1$MM-YL:HWIJ@JR',S0T2&20V"")0=(QT5(C:.VC:1-M:[%!Z7>W
M,G\Y450G45V+F>M)]Q&`U,D?"N3IM;W5*R)25K(D8A,E)DHUI*MAO4P5P0_5
M\-8G+B:L%DY$H+$:CCR_[]*>2R;G9R1\8*"$B##>@!)EQ9H]POCZ?*3*`&%T
M6:S)*5FRM@GO?5KZ''DX9T>GRDY_4B@<O76O:+W9['8[8W5$I/Z2V-\M8NFF
MYB:12$3:N3O?GW3Y5-KTD71=K,W-Z.+=3]/%$73)*0Z)0/Q6R2\_`JD$8VFE
M4"*1<DPEZJWT%%G'FDF1-S(M18X\;#4U]4MW.O7<RG?YU+M+WYN<E!$1)JIV
M8A,E$LE`.Y=,FD<J3?I`NBK6V92J'^X3W@@UM1Q!K5H0CGQULD;P8,>%/]X9
M`BEUB;12CJE$O:.>.FME*O5A+_`.IZ4HFAZF<[0@9+H@W$KLA8V_Q8I,;G41
M$3;CO2#0N*[T2"NR]9>3795JD71=K+$I73]<$MX'-;VB-8[WB$"JU".<T_V2
MJ"83"X0?7G(M$VFE'%.)>D<]==;XOI/Z9_I@/82=:J.?35717(NPN-];*Z>O
M-98(E7/<#WCXH?K4E\J$G]@/6!9RRKT`/PEFN!_@4FWRIV7P!&7FP&D9X+8Z
MPU<![H4S?!W@EC7#-P'N+#.<K(/3[)-#C(2S(RC$@"V@&2W&"%M'<R3!"%M.
M<P3%B#F<&SF1)7*;4QEB))P=P;&%W.9\<'HAM[D1'&+(;6X$9Q=RFQLY;0-<
MM$PUN'3`HW\K,2F)D!!D-E<LZ,GPF1LY$0\S,%<P:)Z8@;F1""/1[`@Z)V9@
MS@<-%#,P-X*VB=SZ$6<0A#<GC^Q:_)$UU[)NK7MQP;9Q^]M:PU^R\"\=WW'6
M,^WP[H1M/NN&EV$%;CCN`@?PA=).?L%4.L/KM>-_````__\#`%!+`P04``8`
M"````"$`TSTX4)4#``"0"P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;(Q6RV[;,!"\%^@_$+S'$B4_8L-VD#1(6Z`%BJ*/,RU3%A%)%$@Z3OZ^2^I%
M6A*:BV&-EC/#)4?8[=UKD:,7)A47Y0Z368@1*Q-QY.5IAW__>KJYQ4AI6AYI
M+DJVPV],X;O]QP_;BY#/*F-,(V`HU0YG6E>;(%!)Q@JJ9J)B);Q)A2RHAD=Y
M"E0E&3W:144>1&&X#`K*2UPS;.1[.$2:\H0]BN1<L%+7))+E5(-_E?%*M6Q%
M\AZZ@LKG<W63B*("B@//N7ZSI!@5R>;KJ122'G+8]RN9TZ3EM@\#^H(G4BB1
MZAG0!;71X9[7P3H`IOWVR&$'INU(LG2'[\GF(8IQL-_:!OWA[**<_TAEXO)9
M\N,W7C+H-IR3.8&#$,^F].O10+`X&*Q^LB?P0Z(C2^DYUS_%Y0OCITS#<2_,
MDD3DH`2_J.#F#L#6Z>L.1Z#`CSK;X7@Y6ZS"F$0+C`Y,Z2=NUF*4G)46Q=^Z
MB%CUFLMZ>*2:[K=27!`<+%2KBIIK0C9`W(@W#)T=Z$IBJN]-^0ZO,`(A!>C+
MGI#Y-GB!_25-S4-=`[]]35<1@&RG#7J.=BMA4"-A&F`T'VK`Y8O&^>)1/H/"
M[J!%O9^!Y[IH[M0LQC6@Q/%L^Q4M9W``K7U38.4Z_PT"%V/4@-<2<.G0MYP&
M]3D;Q&T*(1.6EQZGM1S/>\/FM4_>(-!WQ_!RO!]P%1S#-?EZV77#O/;)&P0:
M[I"OQLG-)VYP.>/9JC=O*GS^!O'Y;\?YUT/^!7'I38%/WR`^_7J<GL"1._[;
MT[2PS]I"WGE&X00M5#FT=<_)>M9WA9B**X4&\@XU(A,*)G+7C9^3[E1)$\GZ
M*V5#VD(^_T10B8E;S]\UQL!7MAO(;TP\87LLG.'</5`RC&<+^<[[CYJ73_,9
M&7,^3*BMA,V`8'_1HXF(DO]DU+Z_ZLQ82J.)E!(_IEW#A_&TE:#D-WPBGV0L
MH.X]&<;3+@%^O]L3^21^0#O;PUC:RH'MB5Q&?BYM@)9S)S^VP&]W"WF^XXF$
M1B9LP_MMX2O:)I9>N^.)6$8@[M!:W]'RUC5N*JX4&L@W/A%,F'.&"F3E*@PS
M:A>!J*]PG=%Z_JEGCX+)$_O$\ERA1)Q+R$<$WY8.[>:N^\A,`==XO+FOY[&@
M>P-C4D5/[#N5)UXJE+,4.$,3?"3KB:I^T*("HS`L"0T#DOV;P>3+8,P(89,H
M%4*W#Z`<=+/T_A\```#__P,`4$L#!!0`!@`(````(0!-Y*]JZ@4``$D7```8
M````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC%C;;J-($'U?:?\!\6Y#=W.-
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M4&Y?/I)65_`$OZTBEST`H2<_NK_W_-A>MK8(UG[H"L9]VWK-FO8EE\_:5OK>
MM%7Q'X*8,H5&N#(B@*;:YY\UXB"A+I"O29OL-G5UMZ`[P&5S2V2OL2<PK")0
M-(:8(+6I1#]+^-8.;0O8-K#ZL8OXQOF`'*4*LI]#&$4<>H1,+=`8N$"`$RZ]
M2[DJ7<JL2@Y[7``C`P>-PF&."**!`W$)(1M<RE4HT<1#)(;GD01"O`G$IXC#
M$H)P`",&#G)U:T,D0Y3A&`-R0$C4E6'E\SAPX4=C03`BC'TVQ1`>T(D3'ETK
M"'>HO-S5<N)17WN$@,>!LIZ3)03A$A`N?2O(59J32/.P1TB`.8FGL78Y.^"^
MU^V/N2*^H;LG>>A]RU7-=Z#%CQ#TS3U9#0HX$``'L1X!A(&<#^.A[!G(58U!
M2!WL$8(,?#<24P\8_Q3AB<";(@B'V,A!KFH<]*Y$B.(@2)!(80H0X>-^9*#'
MAC1TRQJ'6,N#PB")*##D@2"\!1)2K,9:Z*>"H99-I2(>BXK'5&&6SL4BA)2%
M26T;^?2]T2W3I`A-%?<*@TE9&0I#`,SU2=HH"REN(XM95E#[IN(5:T-@SQ"C
MV$2>B<\4(A9J)$5N@0UJ(&$SRPUBD(V(/8-RL"G$6TH.%=*A1"A^A(8^5>#E
M09XO79[PW*A-E;$XA*,[MAHMCUD^V5P_/5W#%`:=A)%T0L_6@2!X3"&4AEE)
MV5Q*8WV4*(R*U>."YELE9*JG*QZ+F)2-<C%K*D,]A$8;9E:LCQ2%@?(/&`UR
M6(10'E179R=G+K#QK$13`5TQT\&A"$&J2.APL\9VRU1.8GW6*(PJD1]%'G&#
M):(@#N\HCT6%+TMMMZUQTF>/PB`G'Q2,S#=%"24;,<*//7_:XS0[5&SU8G&Y
MK3'2)Y'"J"Q%@A-OBA':00SCT1(C*8FCU/7:PE$IIVT,<DD/[EZ!EOIX$4)3
M(]5P)#)+#8KE5.R8JX\`CB!5B3#T3=6:8EC0=?L8&*5$=7=&::Z_S-7G@/QW
M#$K:ER*@BJ+*919IRL6LP'RNP,S5AX`"J99A'GU)4QS0D#XH*`<JO[-\S&68
MN;H.\ZG$PBN!J7L1`G4RR",E9-9@CAI,>T53V+T"F;VHG*`=S!M-&J6Q+,%\
M+L',U358@=`7),4SM>Y4A:%U(X(AE.#_K*73U&U3H6&NKL<*I-HF,$D?A71C
MX<%9$LM:W&WKA'0Q5B`DQ`0-'TM&(;X<98\(28U\K#<")93VD*[%"H2$0MG*
MHS/%!\THRHQ":,7,0BP,0LPT+WL%6NKE10@E(@5R3$P_$81<UBK$=`%6(!5N
M3%^Q54;0CH)P[_'X%E1^!R(&V66Z[';/RO=>DX8H(KWJFB`T(V;M%2B99$;.
M2]/KJLF+(K($H426!1AN)N<ETH>!`N$ECQ00K9GD_::T@H!Q$XG@S25>^!59
M?<X.V?7:6&GU7H)8<[@%&5:'&]-G+J_:M/4]W*1VMY'.L`'WF[?DG'U/ZG->
M-M8U.X%)=QU"G6J\"L4O;77KKAE?JQ9N-KN/%[BRSN`JSUT#^%15;?]%W@@.
ME^"[_P$``/__`P!02P,$%``&``@````A`.,P>WX*&```7W(``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&ULE)U;4QP[DL??-V*_`\'[`'VEJ;`]X>ZZ
MW[I[8W;WF8/;-G$,[0#..3/??OXJ*3M+^@O,O!C\RU1*E;J44B6)#W__Y\./
MLS\/3\_WQ\>/YY.+J_.SP^/=\<O]X[>/Y__[C_QOJ_.SYY?;QR^W/XZ/AX_G
M_SH\G__]TW__UX>_CD^_/W\_'%[.8.'Q^>/Y]Y>7G\GEY?/=]\/#[?/%\>?A
M$9*OQZ>'VQ?\]^G;Y?//I\/MER'1PX_+Z=75\O+A]O[QW%I(GMYCX_CUZ_W=
M(3W>_?%P>'RQ1IX./VY?4/[G[_<_G\7:P]U[S#W</OW^Q\^_W1T??L+$;_<_
M[E_^-1@]/WNX2ZIOC\>GV]]^X+G_.9G?WHGMX3]D_N'^[NGX?/SZ<@%SE[:@
M_,PWES>7L/3IPY=[/(%Q^]G3X>O'\\^39+]8G5]^^C`XZ/_N#W\]CWX_>_Y^
M_*MXNO_2WC\>X&W4DZF!WX['WXUJ]<4@)+ZDU/E0`[NGLR^'K[=__'CYG^-?
MY>'^V_<75/?")+D[_D!.^/?LX=ZT`3SZ[3\_GD^1P_V7E^\?SV?+B\7UU6PR
M79R?_79X?LGO3=KSL[L_GE^.#_]OE2;.E#4R<T;PTQF9S"[FT\7U:K#R1LJY
M2XF?+N7JXGIR=3.[1NYOI(-T*#9^NG2P\(;^TNGCI].?7JP6B_ER]8N,KEU"
M_'0)KR^FJ\5DL33^>2-']*2AA/AY>K+)_.I7R6Y<,OQ\UX--T#2&?,PO\FA7
M6H-OE'`B=6]^D:3O\\H$S<7FJNUF=?&.QYM(4S&_N#QOWE=::2H3;2OO;65H
M^:ZXVE[>6?\3:3GF%U?@]SVIM)R)-IUH&[VT/7+HR>GMR^VG#T_'O\XP/*)6
MGG_>FL%VDA@CK@^[1G?JU1A<[HSZ9Z/_\1R*Z*_/H']^FJZN/ES^B6'BSNFL
M66?B:VQ$PPP5QFP:@BP$>0B*$)0AJ$)0AZ`)01N"+@1]"+8AV(5@/P*7</O)
M]VC6_Y'OC;[QO7AM+6!4&8&C14.2I"'(0I"'H`A!&8(J!'4(FA"T(>A"T(=@
M&X)="/8CX#D:PP`Y>KXXM6DCQBMIW*:G<]^1:Z<S;O@+7V5S4CDYFTA&)"=2
M$"F)5$1J(@V1EDA'I">R);(CLA\3S_48C<CU9J2TKPP>7XP^QB)HC`:88/A8
M6Z796Y5Q4CE5!I&,2$ZD(%(2J8C41!HB+9&.2$]D2V1'9#\F7F7`JU09T\7%
M&]5A4@S5(6Y<6S)#5],*FJZ"KG!2DF0ID8Q(3J0@4A*IB-1$&B(MD8Y(3V1+
M9$=D/R:>]_%N'WM?WJ@&^RZV9&JGO^;UN"&2$LF(Y$0*(B61BDA-I"'2$NF(
M]$2V1'9$]F/B^1/=/^9/@WU_.K(\O3@W1%(B&9&<2$&D)%(1J8DT1%HB'9&>
MR);(CLA^3#Q_FK!\-!64]FFP[T]+YC/UIR/^H'#C#PKI24D&A8Q(3J0@4A*I
MB-268)22O)J3SFC<F@4SU_:D),DZ(CV1+9$=D?V8>%Y'##;VNIN`7YB(\>7[
M_=WOZ^,0&4MM&'6_-BP9UX8ETW%M3&;!$)V>E.11,R(YD8)(2:0B4ELRKHV3
MCM8&%;$]*4D1.R(]D2V1'9']F'BU80+<_Z0Z!GV_/@2-NH=#\XD-F*XFP>PR
M505YU(Q1+I:U51>J-81B5Y.9W^E*51#+%:.:+3>JY2P'96Y502QWC'JVO%6M
M>)EWJB"6]Q[R:\Q$5Y%ARZPW!#W%H05J7^<NLV!RN7%:2[2$D]9D$0YFHC4=
MJG1R=3$).ECF-*;#`MP0Y>:"-(0KQ,Z;N96B97-;7EQ?^]5<B67-K!:DF35B
MYLW,6M&RF:TN9L&S=V)9,^L%:69;,?-F9CO1.CU9T(#W8GG(S*]Y$^[%:M[P
MH$]:A)J7%K4QJTO06NDL*Q6D_2L3I)TY=VBJCUHX-#)?.C17K8H3UHP:AT;E
M:@5IN3I!6JZ>;6U%2Y]Q)TAM[04-MGP/F[`NYF$;[B%*$W>NS5*;<>>XMJ>S
MJ=],-TYK]"9(&66,<H=05,FQ8*V24<6H9EL-:[6,.D8]V]JRUH[1WD.^TTWX
M%G.Z#>L\IUNTP)3N-%1-9T$/VIBU3%0-FJ(9;Z^#.4^J8G%MYE!@-W@!Y$YK
M.GPD&`:X0FV9K%;!D%BJ6+*JWI55S5DU:FO(*FAIK8HEJ^Y=6?6<U59M#5D%
M8^].Q9+5_E=9^15N(L98A=M(TJMPBS#9&U=XN!"%%$.%SX<*7UX$;[A4Y5+@
MS*%1Q\P9%9K0.&)Q0?5[RE@,5VRE9M2$AH,W3JMR,=RQE9[15A-&2[Q3N1C>
M>U;\BC*A:*RB;(B*A&)D;1;R39_3\7DC:'[22AEE#GD586V-4,$)2T85VZH9
M-9RP9=1QPI[1EA/N&.V]A+Z'37`:\[`+6L<>MB@8HY;A"\=JN;%O<G$3])74
M?/.P@Z/47>908)E&/YO0&_U.MDQCFUPL@]*4G%GUKLQJIS7*K%%;-C/J,J?"
MR(-U[\JKY[RV85[+P(L[59#,]K_*S*]W$Q['ZMV&S5[/<L@?`H,Q>3-Q\39>
M?:<WXV1)K[Z3EA0[<PG-Z_F4<#JCRG>%&$]'3K8T(>58:KDDQ^I=.=:BI3DV
M:NN-'%O5DAP[L?7F,_:BI3ENU=8;.>Y42W+<BZW7<O0;@XG.1XWAU]\D;3AO
M!FZMLU4P(UA/K-:;7PU41XJ>,LH8Y8P*1B6CBE'-J&'4,NH8]8RVC':,]A[R
MJ@>#D%<]LC(U<#_L<@AOKE'%A"M1&]4Z.9U1QBAG5#`J&56,:D8-HY91QZAG
MM&6T8[3WD._T5U8Y\)'`O+[&`Z1#2WU7;ABEC#)&.:."4<FH8E0S:ABUC#I&
M/:,MHQVCO8=\#YOU@-&H<VK6=IW`\[!%L"4-=F,66U$/(Y0RRACEC`I&):.*
M4<VH8=0RZACUC+:,=HSV'O(]C-$_ZF'#@S;LT.B3S910RBACE#,J&)6,*D8U
MHX91RZACU#/:,MHQVGO(][")]&-MV*X`>&W8HJ6N3VVF%LW1E$^OT<DJF/JD
MJB6-/V.4,RH8E8PJ1K5#H_BG4:UQ48/I=JM:4M2.4<]HRVC':.\AOQY,'#RJ
MAU]]U#&[_,(>8)%7/Q:9#C:JGV`JGCI;T)*'SACEC`I&):.*4>V05S_O*6K+
MMCI&/:,MHQVCO8?\^@D"^5_6#P?X4X?&_<>BU[_RN#10T*HYI1&4BV6MP$(3
MFEAORE]Y5$',5(QJMMRHEK,<=/=6%<1RQZAGRUO5BI=YIPIB>>\AO\9,-#OJ
M4:>WLXURO9'-H7'-N%C8ZSF+8+A(L:)O>B'&/RE0QBAG5#`J&56,:H=&J]J-
M:HTZ>5C45K6DJ!VCGM&6T8[1WD-^/9@H-U8/+B#62><:'[Z&*1'>*J?AZCI8
MBMPX)>^3'']L<UIN%6=U':QU9)*55GG.J'A77J4D--L#L8@S"XM<B8)F5C-J
MWI59*PEM9M/KF\`_G2AH9CVC[;LRVTE"E]DB_&*Y%X4A,[_:@Y#\U/U.D;>T
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M_X_C3XQMZ!G#F/79=#C;%?7=-`V;U=IIO;D4KSKBY)11QBAG5#`J&56,:D8-
MHY91QZAGM&6T8[3WD%\[)LP>U<ZI%FSX/8Z*9A:9/G::-$S#G5T;U5*GGQ(*
MRE@K9U0P*AE5C&I&#:.64<>H9[1EM&.T]Y#O=!.RQYSN5@2T7ZUG%HV7XAFE
MC#)&.:."4<FH8E0S:ABUC#I&/:,MHQVCO8=\#YM`/.9A%]F//6S1:-U]8T85
M#$$CE#+*&.6,"D8EHXI1S:AAU#+J&/4>\AWU2C0^XVA<D+XN-HQ21AFCG%'!
MJ&14,:H9-8Q:1AVCWD.^HUZ)7V<<OSJ$@5+&NXU#WL+X-`Q\4M62A!G;RE5K
M-`[/@U"G4"VQ53*JV'SMD/G>KL/\/-@=T7#"5LV/$BZ"X*Y3+2E7[R'/Z?-7
M0MJ!^P&10V.G.Q0X/9@-IZHE!<K85JY:HX>;!Y/=0K7$5LFH8O.U0X'3@\UQ
M#2=LU?RH7(O@&3O5DG+U'O*='D2G,B7`HG,8(SGD.=UJ8<21K%+14I0)TBZ2
M.Q345C##+U1+S)>,*C9?.Q1X.%@&;#AAJ^;''@ZZ6Z=:4J[>0[Z'7XE"S;,'
M4:A#GH>MEN=A0ADGS!TR/T8]._CZ4ZB6/$G)J')H5*Y:M$X5W[!2*TI>&19!
M/^I42\K0>\CWYG\8VIFMKZ&7+1H]S<9IK72FD#+*'!HES!WROK%-P_6B0K7D
M"4M&%9NO'5II%-JP5BM:6OJ.4>\AWZ=!T'8:`T[!F11[C?7!8;*$']JJ%D&_
MW8B6#=V7-\N;V550ZZGHZ%)!)DB'CMRAMU=<"M&20R'AEJ%2+&MFE2#-K!:D
M6HT@U6H%J5;'J/>0[^U7@C!<,$`MU:+QVKC36NF\+!6DBVF90Z,5AURT=/6B
M$*3C<BE(;55LJV:MAK5:UNH8]1[R'?5*X#3GP,DA;XE[N@@&NXW3PE+ML#"W
MPF5`P80E%15U2<8H=PAU/!@*7@^%BJ7?E&RD8E0S:ABUC#I&O8=\O[X2+N'C
M"C5`%QN-%IZ=%IPH#Y<*&CO-)O2&2HO@-$E8N(0C5+*MBE'-J&'4,NH8]1[R
M'?5*N#3G<,DAL\5C-"X&WPTV3LOD.-(*9MNIT_*^<4X7P?0PDQQU9,K5O&F6
M2SJ(5ZB"5$')9BI&-:.&4<NH8]1[R/>W%W69SF47"><<=3GDC8Q6"\Z5ATN=
MUNA#8B8)52MW:)2P8%1RPHI1S:AAU#+J&/4>\ARU\"(E==3`_4C)H6!D#&;"
M&Z=E7EK:,&G[NVAA_J1:U#"=UKCK2T([7MY<A'NM"U60NBO93,6H9M0P:AEU
MC'H/^?[V@B0XR=YZ]>JA^P4'3PZ-/^$Y-/Z$Y]!*6V?FD.=.:WZ4L&!;I20<
MO<H%Z4!=,VH8M8PZ1KV'?`>:D.6T0C=JL#:4&2\\+RSR1])E$.-N1,O-,*^O
M;VYN@A$R%1V=J&6"U+^Y0[^888J6S###%9A2+&MFE2#-K'8(0XT=H<-(H>$T
MK4/>ZX"VO'22T&[6F&-K2/!:Z45C*(Y?.UY,]8[FS3'5PJ+Q>.P0%L:E3Z>"
M=/*:24)U4N[0Z#M;(4C;<LFV*K95<\*&M5K1TKEQY]"H]+T@_NJU@,_&S9O&
MA^"KUZ`?C-/&!%:A\1+3L749S"PW+N%J9=O/XOIZ28&5Z.B<+7/(&T-L?C=X
MDYSRHU95N(0W]B(*S"B"`I6<6<69U60F>/\TG*:5-&\6L'-:SB'S*7VS[T5C
M<(??[+U`[!W-G@.TA0O0U-<;A]#;M-E;+91$4.:TO!IQ6CJQ+L26]I=2D-JJ
MV%8M6IJP8:U6M#3'3I"6OA<TY.@[T`O0(@X,FST';@N+@M$^6"O8.*T;._K.
MKQ>+FYM`)Q4='2(R,3X>6VQ^-RCL6\W>:=G!='$QH6;O%#2SBC.KI4AB)EPG
M:3A-*VG>+&`G6M8AL^4D7++O16,HH5]K)@X;O8MIL`IN$#+G6H,5-(>\T=YJ
MC<;+U&GANYTV>ZLU7I=P6MYH;[66ZMV2;552"*W=6FQIPH:U6M$:C_94^MYI
MV=+[#O3"PM>;/9[:7H5L+U!].#Q].VP./WX\G]T=_WA$\YO"#Y\^G+B]A!GG
M#A-SF@ZI0\GT*C%'OF(2W-QL/V`&:;#!(OF,1XFD@<1L%8A)%I`,K^W`&CY0
M0S+49R!!BTRZ:#YHB8EQ)N>#ZZ8_#^-,8&N-AQGJ)N13/&3$SGJ&0D7X9SPZ
MO@!PQFL\>?3!\=RQQ_Z,*OF,/2]LJ<##%=&'*R$QK9;38*1(3.-E"0:,Q+1A
MEF"D2$Q39@D&C,2T:);@K0MKL>?!ZQ;68A*\=6$M)L&;%A4<D^`-BPJ.2=8H
MVSI:-HSHR28JP3B>F)&#GP?#>9)%)3DD>52":3%*':LY3(=1ZIADC>=91Y\'
MTR^4.O:D*21I5(*Y%TH=2Y-#DD<EF':A5<728+Z%5A638-J%5A63%'A2,X%F
MCR)H@;68!+$+K,4D"&'0JF(2Q"YH53$)0ABTJI@$43Y*$.OL"/91@I@$,3]*
M$),@]$<)8A*L`*"V8Y(URK:.E@TQ)FH[5FI$EJCMF`0!)FH[)D&<B=J.2;`$
MEYC5):X?K,0E9I&))5B02\Q:$TNP+I>8)2>68'DN,6M*+%G#.^NH=[`P!!_$
M_)9"DD8E&21FU8+SR2$Q*Q4LP?HX?!#K]5@FAP]B$JR6PP<Q"1;-X8.8!&OG
M\$%,LH9WUE'O8-4VV40E6*E-S!HC/P]69Q.SU,@2+-(F9GF1)?A(!1_$>C"^
M5<$',0D^6<$',0F^7,$',0D^8,$',<D:WEE'O8-/)_!!S&_X8@(?Q"3X<`(?
MQ"3X?@(?Q"3XOH@2Q,J&;XHH04R"+XDH04R"#XHH04R"[XJ)^2+&M8!OB2A;
M3(+M,ZB%6`_&_ACX.B;!-IG$['CA?+"7`[40F\QA#P(DL5Z"[^F0Q*9`^`0,
M2:P$^+0-[\0DV&T$[\0DV'24F/U#7&KLC$$;C94:.SH@B94:.Q$@B94:7\\A
MB94`N\;AMY@$F\<3LTN9RX8-XXG9K,P2[!3'##$F6<^ND4^T)<('ZVC9L+TK
M,9NW.)\-O&-V&,4D$TABWMG`.VG4.]C:CUJ(E1I[^A.S-YSSP=;^Q&P19PEV
M^"=FISA+L*L_,1O&68+M_(G9-\Z2-23KJ`1G)))-5))"8C;,LS4<B$C,OGF6
MX%Q$8K;/LP3'(Q*SBYXE."L$'\1\C2-#>-*8!`>#\*0Q"<X'H87$)#@FA/86
MD^`P$-I;3(+#>(DY#<:EQIF\Q!P*8PG.X27F;!A+<``/$5%,LD8)UM$2X*`7
M:B%6-ISG0BW$)#C6A5J(27"Z"VTT)L$A+K31F`0G)A-S!H^?!T<E$W,4CR4X
M,9F8$WDLP<')Q!S,8PD.2R;F?!Y+<$HR,<?T6()#J(DYD<@2G#Q-S,%$EJ20
MF/.)+,$YT\0<4V0)CILFYK0B2W#J-#&'%EFRF>)]BD-%+,%Y;_@M)L%Y;3QI
M3(+SUF@[,<EF>@UKL3$1AXV1)B993TUL'AOCUU.\T7&RGDN-^R.03RP.WTP7
MD,32X&X'M(.8!%<\H`0Q:PVLF;/]D1),KA-SH1M+"DC,[6LLP3UJ21N5X-:S
MQ%QLQFEPNQCRB:U$%)"8.[XX#6[K0CXQ"6[50CXQ"6Y*3,R-?3%K"UB+27`O
M8F(NZ^,TN!XQ,7?VL02W)*($,0DN0\3:34R"6T7A@UC]X!)0^"`FP9V=*'5,
M@BLV48*89(T2F-L4N=0;2,P-BBS!;9:)N4B1);C4,LFC$MQMB5+'TN`*R\1<
MI<C6<.LQ/!KK);C\.#&W[W(:7'B,)XU)<-,Q?!V3X-I</$_LW8A+<%&VF`17
MVJ(=Q"2XH!;YQ"2X9AH^B)6@@J2*2G#---IH+`UNFT[,;<;L`]PPC780D^!J
M:90Z)ME,\#;#+>!L#7>@HVPQ">XPA[68!'>0PP<QR1HE6+]2@DEB;HWF$J1(
M8RZ/9@DN`4>I8Q+<!8Z6&)/@2O#$W"C-UM88XF/M<(V77/0-@]=O;%S9(/")
MZ==X*<=X@VE)S$Z#E>U!__*TLHN_^O?S]MNANWWZ=O_X?/;C\!7KXE?#QHHG
M^P<"[7]>[+'!L]^.+_A[?^8$X=EW_"''`_[8"?ZNW/G9U^/Q1?X#1UR>_C3D
MIW\+````__\#`%!+`P04``8`"````"$`\0K7^(8)``!;*P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6R4FEMSXK@2Q]^W:K\#Q?L&S"W!E61K`-_O
MI_:<\TR($Z@!G`(RF?WVV[(LR])?FR$O@?SZ(KE;:EWP_9\_#_O>C_)TWE7'
MA[YU,^SWRN.F>MX=7Q_Z__W+_>.NWSM?UL?G];XZE@_]O\MS_\_'WW^[_ZA.
MW\_;LKSTR,/Q_-#?7BYO]F!PWFS+P_I\4[V51Y*\5*?#^D+_GEX'Y[=3N7ZN
MC0[[P6@XG`T.Z]VQSSW8IVM\5"\ONTVYJC;OA_)XX4Y.Y7Y]H?Z?M[NWL_!V
MV%SC[K`^?7]_^V-3'=[(Q=-NO[O\73OM]PX;.W@]5J?UTYZ>^Z<U66^$[_H?
M<'_8;4[5N7JYW)"[`>\H/O-\,!^0I\?[YQT]`0M[[U2^//2_678Q&O8'C_=U
M@/ZW*S_.G>^]\[;Z\$Z[YWAW+"G:E">6@:>J^LY4@V>&R'@`UFZ=@?S4>RY?
MUN_[RW^J#[_<O6XOE.XI,]E4>VJ)_O8..S8&Z-'7/^O/C]WS94O?YC>3T?3V
MSAI-^[VG\GQQ=\RXW]N\GR_5X?^-5N.+>QDU7NBS\3*>W4QOA^.O.!DW3NBS
M<7)[8TV&,]:/3]J>-&;T*9Y@TGF"3RS);_WLL]9R/+ZFQ=O&CCZ_TE&:6W5S
M]/G%CLX;2XN-`Q[_ZWIJM>FE+U_IJR4RRKY\L;>62*0E4W)E=T5&:*B*5J\:
M`Q:ED`]CF<O1\)I<6B*9[,LUL1WP"51/O-7ZLGZ\/U4?/:IF%.'SVYK51LMF
MSIHIUPS==A)2+=@P]6],_Z%/BC2[SD1_/,[F]X,?-*DWC<H"52Q58RDTV,1F
M7E<Z<'3@ZL#3@:^#0`>A#B(=Q#I(=)#J(--!KH.B`P84]3;T-$:_%'JFST(O
MHK800.9BI`5::`B3E0X<';@Z\'3@ZR#00:B#2`>Q#A(=I#K(=)#KH.@`)=`T
ML[\4:*;_T*>_[1BW[K3(+AJ=[D28:L%O5=KH`W&`N$`\(#Z0`$@()`(2`TF`
MI$`R(#F0HDN47%!Q_5(NF#[5)JJL;3*@X'"=\6>Y:%7:7`!Q@+A`/"`^D`!(
M""0"$@-)@*1`,B`YD*)+E%Q04+NY$"6>X3KD(E8+3L:T!?C7)"Q;'6&U`N(`
M<8%X0'P@`9`02`0D!I(`28%D0'(@19<H$:9UW11AAM4(<S*A:=-&V+H;:P6E
M56I##,0!X@+Q@/A``B`AD`A(#"0!D@+)@.1`BBY10DRSWA1BAM40<S*RVO5S
M"60%Q`'B`O&`^$`"("&0"$@,)`&2`LF`Y$"*+E'BR<[2G0VA*`H,J_%LR$S&
M$\@*B`/$!>(!\8$$0$(@$9`82`(D!9(!R8$47:+$DTY!IG@RK,:3DYG<WRTY
MF="VIE,4)FI16+5*HB@X0%P@'A`?2``DY&0\:E,>M3K=+L[4+L:MDNAB`B0%
MD@')@11=HD2=G3F[86_.-3>W5*HOV]WF^Z*BF%KR6,/TU7S4+A[ZW80T:*1F
M1-OWK:26>%X'D8O(0^0C"A"%#>HF1FIU,Z-U-99:HJL)HA11ABA'5"A(S0\[
M%'7*S"_SPP]1S640.S,NV"T!2YD<C<L&35A>?SR.AI8^6:2">%X'D8N>/:G5
M>-;69E\J",\!HA`]1U++W.=8*@C/":(4/6=2R]SG7"H(SX6"U(RQTU4G8V)A
M8%<M^LSA:-99&AHMM99-M4*QDEJB0PXB%Y&'R$<4(`H;1!^BQ:A!,ZKHLNSJ
M78VEEC!,$*6(,D0YHD)!:A[8T<J4!W[D4F8(1U.JDO))[F[5ZKQD%U^40%5K
MJEWJK!JMR2V?6OK,<AKY2"Y?+B+OJK9\M2UKK@V3`!V'B**KVHK5ML;Z<R?H
M.$647=56KK8UF6G78H7B6$TZ.\.9DL[/=DK2.:)TBH&Y9#>:/,,"K1I$Z13(
M:9"206[801[Z\M%7@+Y"1!'ZBM%7@H8IH@Q]Y>BK4`S5"+,SG"G"_&RG1)@C
M[;!VIT^K1HM"*"??;*AJK<@O2\UDTLD#1YW%W&VT.LB3AI^X]Z662'.`OD)$
MD33\Q'TLM83[!'VEB#)IR):F^:T6EES*A>-"\:*FCIT-.ZG[Y5Z"GR7)H7"^
M8#?Q+`WC%BT;-+UKT0J1TZ"Q-'0%DDN*AX8^HD`82E^A0-)7A(8QHD082E^I
M0-)7AH8YHD(8UK[4R+-39"?R[9Z`GRZ5"'.DKC)WVBJS9+]`4!YFM!N7DT:O
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MM1FXE%IMT!$YB%Q$'B(?48`H1!0ABA$EB%)$&:(<$7OGA"T+?/_#@\[?(>$_
M91_*TVNY+/?[<V]3O1]IY:!+F\?[%O.75Q93NZAGF<YG=E%/-9U;<YNEFX*O
M2T9#\1Z,)J%Z;+.)CS94EFTV_U%"I=AF90`E!4E8-4`)O8CSK5['M?87]().
M75QT/J(.&_PLQG915S%-_]N$_-?OZFB"Q<0NZKVJQFF=M%F-Q:X&)&&E%B6T
M4-JLXJ*$UDN;%5Z4T!IIL_J+DH0DK`RC9$&2A5%"^PU[:930'L-FZP]Z<TC"
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M%E15ZWL/K88MYA1.4]%;SFWZ,02'VM(:4N,FBW!.(\`DB&A-,;F*R!6[+J=&
M!FVWZ(W'M_5KF:Q/K[OCN;<O7VAI&]:_89SXRY'\GPO?Y?6>J@N]ZL@V?+TM
MO<1:TBWYD.T-7ZKJ(OYA#;2OQ3[^`P``__\#`%!+`P04``8`"````"$`"M%1
M7OX%``!D%@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R46-^/HT8,
M?J_4_P'Q?B$#(20HR>F2,.U)K515U_:9)21!&R`"=O?NOZ_G!S`><[G;?5B2
M#]OSV9ZQG=E\_%K>G->\:8NZVKIL-G>=O,KJ4U%=MNX_7_B'E>NT75J=TEM=
MY5OW6]ZZ'W>__K)YJYOG]IKGG0,6JG;K7KON'GM>FUWS,FUG]3VOX,VY;LJT
M@Z_-Q6OO39Z>I%)Y\_SY?.F5:5&YRD+<_(R-^GPNLOQ89R]E7G7*2)/?T@[X
MM]?BWO;6RNQGS)5I\_QR_Y#5Y1U,/!6WHOLFC;I.F<6?+U7=I$\W\/LK6Z19
M;UM^(>;+(FOJMCYW,S#G*:+4Y[6W]L#2;G,JP`,1=J?)SUOW$XNY'[C>;B,#
M]&^1O[7&9Z>]UF^_-<7ICZ+*(=J0)Y&!I[I^%J*?3P("98]H<YF!OQKGE)_3
MEUOW=_WV>UY<KAVD.Q0J67V#E>"_4Q9B#X#KZ5?Y?"M.W14^K6=A-`^8'[K.
M4]YVO!"ZKI.]M%U=_J>%M"EEQ-=&X*F-^,O9*@P7RU4$5AYH!EH3GN/R_BID
MX5*L_T!SH37AJ34#?Q:Q^3KXP9)@5GH,SW<NN=2:\.S=#!\MZ:E8RQP=TR[=
M;9KZS8&-#]%L[ZDX1BP&8SHYVMLA7;!K,B']28AOW<AU(!$MH*\[?[[<>*^0
M_TS+[*D,PQ*'7D+L`6'V:`.)#7`#\(#ZP!_R_![^0ESP[U?>]X#AD$6VE^A5
MCC:0V``W`$06MM9[R`KQK0O_C6!'F-U>RY@9";'(81`9/"!(0A!N(L@)V.7O
M<4*(P^:"+6YX86\9)10\\F(0&;P@2$(0;B+("^!C>-%O;X%*LOTB>X4$T(P,
M^BLKPH-0KW8D2$(0;B*(&YS#"6X"Q=P4$F%N:XO;(#1P(TA"$&XBB!NDR.`F
MZX4?SL`551]IQ1`*F+9"HK494C:W:`]"`VV")`3A)H)HBV%B+'-]N@6*N2D$
MAY39Y6L0&K@1)"$(-Q'$#0(QP4V@F)M"%G`PQZW(?"MN@]#`C2`)0;B)(&X,
MVOT$.0EC=AKRV5!;#Q0Z4BBA$$<0YB/Z`$TD4^U!CQ6BI>Q[:&GPT5(C=*12
M"84X@C`?4>HG^*@.@/AH"+:!D;[`2A]34H$_L#YJ:`%O#,4%5DRH(I]6'+L#
M=D34^]$1/0C,Q`#378OL>5_#XFR<`U1[0`[JCK&68\&"K<G>9%K"=$Y!_@@E
M5(IK2$EAVJ+`C[3[@\U4W4?T%+14]-C:CU9VJ=1:OIQG]6"BM"(X!D;PK?:5
M4$6NH4B$['7'_)G_O<"+-C#A@>H.R`,%1;XR&8@_O`L.("ZKQAC.HX8B"+3A
M@35&)%21CXIJS!N6P@D0G6*"OFH@8*.O0WNF>\KB`7TE@A*@M<"Q1_2)(N^7
M"^5RP=A?,'W1,2;HJT:"Z.O>\BCZ6LN,OM;Z0?2)(F>#HHC^XGOT15,9Z?_P
MU*H>A-S2;6FILL+"@)P*)8&2HI5P4JRI*&%$D6L(JHKP:CUCP=S\&RW@)(GV
M]`XO53=#7BHHBN2ZR_DB\*T3<&!:RTP>@1(JQ1&$>$/(".\0>I`]*JD*^Z6^
MFQ56*N,6JR%H#N99L/,U2O5'[TBAA$(<0=@1W'7E-@M64-*H+WT%ACG`GE\T
MA.G[X\Z6%?<P2HWTE2VC*294BB,(TQ=-U=H_RT#V-CL5`WW5A\T]!-U'>&31
MMV?#46JD/RCV4$*E.((P?=$C+?J/9VZXSB'!5Y#%WIX>M:(1Z2.%$@J)"R0=
M'/!1L5<70NJRH<R;2W[(;[?6R>J7"BHY;+;=9H#53=3>G\-5E.R^Y(VXI)*C
M)7GCPQMY:,F;H+_8LM\L8OAA"$1M/(SA1]D$OHSA!]$$'L7PBV,"7\4P[4_@
MZQ@F[0F<@=\P\](W!^;'!YA^Z!L8"^/CY!L8!6,Q1%$=F`AAG:DW<`?X:3*&
M$/;IJ$-H)U;80\@G[2_`OGSA#3&'J[][>LG_3)M+4;7.+3_#MIC+4]FH6T+U
MI5-UT7FJ.[CT$R72N<)M;@Y#_ES\\#S7===_`9^]X7YX]S\```#__P,`4$L#
M!!0`!@`(````(0`\E/+2B`@``%(E```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;)2:6W/BN!+'WT_5^0X4[QMB;B&N)%OA8C!W;^W9?2;$"=0`3F%G
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M]Z_S_2F&MQ$G$8&7)/DF5,-7@="X0:V#/`+K<^TU?MM\'K(_DJ])O'_?90AW
M1S39)@?TA']KQ[W(`4Q]\^.QWD0/^]=L]UAO=6\Z=[<MK]FIUU[B-`OVHFV]
MMOU,L^3XMU3R"E/22*LP@K^%$9B[H-\N]/&WT,>G"_IWA3[^7F4?69Q/"G^O
MLN\I+X@/5_7@88)Y%^+#=7W`G;(%/ES71U>UP(>B14?'AOW5D+'-<V*XR39/
M#^?DJX:%AEFE'QNQ;#W?@Q.+;"A<7N8'TG0KU)^%_F,=BHA\"OK]J7G7>6A\
M1\)M"YT^ZWBFQD!IB*039H<V&-D@L,'8!A,;A#:8VF!F@[D-%C98VF!E@[4-
MH@IHP.VE[Y$?O^1[H2]\K[S65Z`2#,O12D,U&=I@9(/`!F,;3&P0VF!J@YD-
MYC98V&!I@Y4-UC:(*L!P-#:?7W*TT,=N9R1YU_1LO]"IK@1K'0Q*E=+[1$9$
M`B)C(A,B(9$ID1F1.9$%D261%9$UD:A*C%A@._^E6`A];$[8&2L[SIT5#*G4
MNA2,4J4,!I$1D8#(F,B$2$AD2F1&9$YD061)9$5D322J$B,8\&HU&&J3%SCW
MN?)57Y(VHEI&P>NUS"@,2B75;$AD1"0@,B8R(1(2F1*9$9D361!9$ED161.)
MJL1P,0YHEXL%-ETL25->G\2A."`R)#(B$A`9$YD0"8E,B<R(S(DLB"R)K(BL
MB4158O@3:]SE3X%-?Q:D6QZ7`R)#(B,B`9$QD0F1D,B4R(S(G,B"R)+(BLB:
M2%0EAC]%65>Y`*HM0&#3GY)T]?5C($D;IVYE4VB;F\*P5%*;PHA(0&1,9$(D
M)#*5I-4L0SXK=:I#M([R>:FDAK@@LB2R(K(F$E6)X?5[T^O%M?OF#MM(MMMO
MO_43N-0K;]U"W8R&)-5H2-(THV%=28:EDIKJB$A`9$QD0B0D,I6D&HU2IQH-
M:XCS4DD-<4%D261%9$TDJA(C&AZ*Z.HB^%DX<GTS'@KIW!L4J"W"B#+IUK.7
MAE904QTQ"MCR6&L5EJV3>*(5E.60T90MS[26>\QSK:`L+Q@MV?)*:[G'O-8*
MRG)D(#-BHJ9R;%NB2K=62H&ZE8.@0.;.U;&VA:'64@,:,0H8C1E-&(6,I@7"
MPX'J<5:@+G82O<G:0YUK+=5PP6C):,5HS2@RD!D'47*YXB!+L>)=2=QF^N(Y
M!*'I8!7JF?2LF_S`J=6YMPZ50JM])Y>6O;)&A;RI#ZN`T?BJOB9F7]Z]E28A
M&YXRFEW5U]SLJV7/>\&&EXQ65_6U-OMJ=ZTWFL@P;`9=%'>NH,NBSPBZ1`BZ
M2LR!1VA8((13:8T*9$10-JR@,=N:L*V0;4T9S=C6G&TMN.&2T8IMK=E69#0T
M/2PJ-I>'925G>%@BJS3KF0MFX!5:^*,77_?6U!IJ+1T'V;!RB@>%5@6-=<,+
MYB=:2YD/V=:4T4PWO&!^KK64^07;6C):Z8;B:+J_L]RRUG)E.#*LF*$3E6`E
M=#^]2\C*T0AIM9C,WT<'$.>;9_Z]0/%D2FA4:+5:Y3H*%-)'RIAM31B%JJ&V
M-55(VYIQPSFCA6JH;2T5TK96W'#-*%(-<UNFYT7-6/&\*F4\64NBH0I?OT#6
M662=,H-"JXO;H5XT]IX\5%K-_W<6%:6L#EU0-#%V,JEUN:^)V9?C+**^IMS7
M3%FY.*^YTI+S<IQ%U->2^UHI*Q?[6JN&W=R'7KM%AU&U,S/JHK*M1/VGZZVH
MA*O9()%Q2$G4U:\Q0_'M".XO79W$HP*U]-4R*)`16K(U85LAVYJRK9EJJ,<U
M5TB/:\&VEFQKI1IJ6VO54#LG4BB?H^EY4=U>\OR?R8<H8K'JY)>1\HNG8WQ^
MCP?QX9#6MLGG"2NKVT;82RR_!>UW_"@?A<618[Z8#(Q:$J2:+^;$$J27+Z;&
MD@@2,4.6X%O8YWQOLGKIBV]G'?K]IA\Y]5M^E$?&LO/<]I^='??;?M1V=("U
M[XN\X:&&D(CT80D6OR^RB"78`WR13"S!NO=%3K%D`8E(+99@/_7[3@GV4'_@
ME&#?],6:8FLC2,328@DV3E^L,):,(1D[);A/P`>N5,*U`C-U27!OP$Q=$EP?
MD'XN"6X12#*7!)<%Y(Q+@LL[K+G2`W=X)+-+@GL[^G%)<&-'/RY)'R/H.T>`
MBR&BX!K;"!)QH6!?XP*(*+@DN`<B1UT27/20HRX)ZBNT<8T:E17:N"0HL!!3
MEP1U%O+:)4%MA6B[)*BJ$&V7!#4K_.:2H$Y%7KLD0TA$0<-^0U4*C[HD*$[A
M49<$-2KRVB7!\Q*LY3_UL+86/`_!;RX)GG<P4Y<$SS/('9=DX'FPYMKR\#:!
M-BY)'[MJ?EY8(^OW_'Y>"5I\T//QFLL>&]S[>%=D/NWY>%UD/NOY>')U\'L?
MCW_@C;)C_-#E8_,>+S;G]_TIK1WB-QQ$M_D#[%G^)D;^)Y-G6.TER?`3%W&<
MU7;X[5*,%XW;&]S`WY(D4_\1'92_AGKZ%P``__\#`%!+`P04``8`"````"$`
M#U\AL8$'``!Z'0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R4F=MN
MVS@0AN\7V'<0?-_8LB4[%I(4U5G`+K!8='>O%4>)A=J6(2E-^_;[4R3%PQ!M
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M(31>DM;Y-`-_]=Y3\UR_GL:_N[>R:5^.(Z8[9$T.W0EOPK_>N64Y`.GUM^GY
MUCZ-Q_O%9G7C!ZOM.EQXC\TPYBUKNO`.K\/8G?_C/KZ(Q&.L10P\18SU]B;<
MK3;^+P39B"!XRB`_?&D@_/$4_J%ZYP\ZNQ/M\'S7>[`BI@'"\SWO6?+QG>8E
MK<?ZX:[OWCPD.X9PN-9LZ?C1?N&)"1'#.D\1,N7`O#\Q]_L%.HG1'T"_/JQW
MP=WR*^;\('QBZN.;'HGT8//.PJ8VR&R0VZ"P06F#2@-+J)TE(Q]^13)S9Y)E
M9V,)M#&P]$D/V22U06:#W`:%#4H;5!HP]"%5?T4?<\?RTJ;4WX:FH%CXZ/-N
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M3=@4)Y$Z^Q*!S+D-K=TC55ZR.QE%.44%125%E8%,;>S,ITGK\U)`5)ILAX@%
M"C%,VC:X-X<U<7J%EE<JO%!5LMGQ=X$U'IET4`.94U2\ZV6E\`IVT\MN0ROY
M*R.P.3BL8'`,#J\CC,'A"(,CYR_Q"4H%@FSIE4FD"^4-UPH5-%8I$%3)6)41
MRQ3"SG^'$%X6&$(X"O!0L[Q;V;/,O38K/G_AQIJ_U)\=9.\RB=2VEU-4"!0$
M4^1M8&5.J>PR<&5$,66SH]\AFU<$AFR.(%N&37Q1-TSW,U%T$Y1)+UV5\%*H
M$%Y0)<.7%%5&+%,(._$=0G@A8`CAR%RE.W*=X%YR_04K:W=,$9)MW$:F"J02
M+I=>"A42B96]L5=VJ1SD4%0236%,W:Q4<.CF%03:R1BQSY&Q`$6=H;Q2X67(
M$EY*0RZ]%"HD4K%*BBJ)'$)8T>`0(FH)%3;V.;(6X-I>@,*++Y.]O4Q2&44E
M7":0=O+F%!6J(=N9P[VUL$MEET-?&5',Z6-5A$,U+RZ,Z1/UAK[^!%(24I^@
M3"!#%??24$$;EA151BQ3"*L-'$)XR6`(X<A:?];R2GSN)8ZDK6^-<JKL<I0S
M@;13(:>H4`W9]`5[Z\Y9*KL,7!E1#-5KL^[Y6:TWN9OUD$#ZJA0HN)W7;DI1
M)I$J\7.!M`$HI)>*55)4233%,@6ZBQ_<B^RJ52!K55J5:B*],+OJ\"3%C_`*
M?7[$K4/K=,VD@UH,N4!Z3K_K9:6,Q5^VV0=6GROI,+W,'!U6AZBD_^GT\[)%
M7PRHZ=E`ZJ>J0*%VJDJDSLM,(K7V<X&,$>#AM5BE;*AB51)-L4R!K$CY@<#/
MW17IS/*4?Y[EGP'/3?_2),WI-'B'[O6"B0[983=C_ET8`Q^QWJ"Q9<&(XY.Q
MRX)OR9]</$:#J1M6I'B-0(XWQ)L('WSHFS\%B.]L$$3X2D(;Q&&$;PT.#@FQ
M,Q*60)0X+2DLJ=."?(_8C-/W(.TC-O'44L!2."VQOT??IO2RA@N[+GK@LF!S
M10]<%NRQZ('+@JT6$^RR8$?%O+@L.-RC&*<,U9/`PHXW:L&Y';%3CEIP?$>Y
MTX)3/&(''&V#PQJYY++$?HB^37LD&;<0?7-9,K3)G!:4ANB;JPTJ1/3-94$=
MB+ZY++&_0=]<&9K`DCHMN&^@;ZXVN':@;RX+;A_HF\N"2P;ZYK+@@@^+>[:Q
M2G`GH[.`6W+$[H?4@ILQ]+@LN!)#C\N"FS'TN"RX($?L[DC?@TLQE+HLN`Y#
MC\L2;R-\NJ.QXMLHGNZ]=M[<1OA"1?T3+#:7?WX;X3L.]2]N(WR.<G`LL\E_
M.;\8/XA=ZY?FS[I_:2^#=VJ>L3VOIJ]3/?_MC/\Q\IW=>^Q&_!;&-GGOB-\X
M&WSG6-W@GO/<=:/\`R]>SK^:/OP/``#__P,`4$L#!!0`!@`(````(0#S*T!7
M,`,``&()```9````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(Q676^;,!1]
MG[3_8/F]`9.O$H54[:INE39IFO;Q[(`)5@$CVVG:?[]KFQ`,1.I+%`[7YQS?
MZ^O+]NZM*M$KDXJ+.L%D%F+$ZE1DO#XD^,_OIYM;C)2F=49+4;,$OS.%[W:?
M/VU/0KZH@C&-@*%6"2ZT;C9!H-*"553-1,-J>),+65$-C_(0J$8RFME%51E$
M8;@**LIK[!@V\B,<(L]YRAY%>JQ8K1V)9"75X%\5O%%GMBK]"%U%Y<NQN4E%
MU0#%GI=<OUM2C*IT\WRHA:3[$O;]1A8T/7/;AQ%]Q5,IE,CU#.@"9W2\YSB(
M`V#:;3,..S!I1Y+E";XGFP>RQL%N:Q/TE[.3ZOU'JA"GKY)GWWG-(-M0)U.!
MO1`O)O0Y,Q`L#D:KGVP%?DJ4L9P>2_U+G+XQ?B@TE'MIEJ2B!"7X114W9P"V
M3M\2'($"SW21X/EJMER'<Q(M,=HSI9^X68M1>E1:5/]<$+'JCLMZ>*2:[K92
MG!`4%J)50\TQ(9L(-I\:\-Z@"5YC!'P*T-<=B:-M\`K;2-N8!Q<#OY>8+B(`
M]DX"_$Y(&-1(F'T:S0<']/DNBA[?W.-#)E_SL+-NW@+0MQ7/.V-.RL4L>C'+
M+L*3@I`)ZP:%?$'2+UL?I<<%?4`#:"8T#&HUNORT")RO257/]VJ2TZ`^9XOT
MDT[BQ70NX#3T?-JT1V0]6W:9-P$^?8M`97N6KZ3:7&?C@VA0G[-%?,NK:<NQ
MQ^DLAXO9^N+91/C\+>)[7D_S$RA&S[05(-'M#/JQZR03XBO850#Y$K=7)&"C
M0PD_[<1$#!1:R%>(KRA`U$C!SY*Q.I1HH;X$#(XK$A,M&ZV\-+F6;.\]>Q^0
M%NI7.@K)%06_4UTEEO-^J4G7MEU+G2%_$U>N'=/OPSS%EWO'OAZ4H6U9G_YR
M&7DM2Z9[UL(#VHFNC<(K70N3:^1Z2;R\C/O6+AJ<T"@<-JZ;:&Z:5$P>V!=6
ME@JEXEA#NYMATJ'=)+V/S(4_Q!>;>S=A@^X-#+Z&'M@/*@^\5JAD.7"&QC>2
M;D:Z!RT:,`KC3V@8>?9O`=\R#"9*"'<3RH70YP=0#KJOH]U_````__\#`%!+
M`P04``8`"````"$`G=#:MG`.``"I0P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6R4G$ES&SD2A>\3,?^!P?N8XBJ[PG*'N=2^3O3,G&F*LA@MB0J2
M;G?_^WFHJBP4\"#:OGCY,O$`)M8$(7W\[:_GI\&?^]/Y<'RY&X[?W0P'^Y?=
M\?[P\O5N^)_?_7^]'P[.E^W+_?;I^+*_&_Z]/P]_^_3/?WS\?CS]<7[<[R\#
M*+R<[X:/E\NK-QJ==X_[Y^WYW?%U_P++P_'TO+W@OZ>OH_/K:;^]KPL]/XTF
M-S>+T?/V\#)L%+S3SV@<'QX.N_WZN/OVO'^Y-"*G_=/V@O:?'P^O9U%[WOV,
MW//V],>WUW_MCL^OD/AR>#I<_JY%AX/GG1=]?3F>ME^>\+G_&L^V.]&N_T/R
MSX?=Z7@^/ES>06[4-)0_\X?1AQ&4/GV\/^`3J+`/3ON'N^'GL5=-I\/1IX]U
M@/Y[V'\_]_X].#\>OP>GPWUZ>-DCVN@GU0-?CL<_E&MTKQ`*CZBT7_=`>1K<
M[Q^VWYXN_SY^#_>'KX\7=/=<%=D=GU`3_AP\']08P$??_G4WG*"&P_WE\6XX
M7;R;W]Y,QY/Y</!E?[[X!U5V.-A].U^.S_]KG,:M5",R;47P=RL"N2O^L]8?
M?[?^O3JOE+MMR^'OGZH'H[G^</A;_-^]G\]GB_>W^'!7*AI+6-0_I.CU$OC$
M=5UC'<G)3U:&MC1%\8^?JVPA)?"/ML35"(Z:7J]'RWI[V7[Z>#I^'V`*XN.=
M7[=J0H^],<+:CI,V-MW(P0#>*??/RO]N"$>,B3/HGY\FMY./HS\Q%'>MSY)]
MQJ;'2CS4<%2R:QML;.#;(+!!:(/(!K$-$AND-LALD-N@L$%I@ZH'1@A[%WL,
ME%^*O?)7L9>H+07T.L,*M'A(D;4--C;P;1#8(+1!9(/8!HD-4AMD-LAM4-B@
MM$'5`T:@L2S]4J"5/];!WB`?SQ9F9)>M3W\FS$V75>?219_(AHA/)"`2$HF(
MQ$02(BF1C$A.I"!2$JGZQ.@++/F_U!?*'XL35L;>BC,U([ULG*;7.J-SZ3J#
MR(:(3R0@$A*)B,1$$B(ID8Q(3J0@4A*I^L3H#$2UWQFRR"M<QUQBM6S(%!.L
MZX7QW%KW5YV3%%L3V1#QB01$0B(1D9A(0B0EDA')B11$2B)5GQ@AQ@;M"K'"
M9H@;,FD.5FI37!%9$]D0\8D$1$(B$9&82$(D)9(1R8D41$HB59\8\<0<=\53
M83.>+5ETV^6*R)K(AHA/)"`2$HF(Q$02(BF1C$A.I"!2$JGZQ(BG2OCX`/A.
MG8\OCX?='\MC??J7I4&YFW%NB3Z6K!HRNZF/A[/QA[&U4*P[!UDH-D1\(@&1
MD$A$)":2$$F)9$1R(@61DDC5)T;8/_Q:V)6[&?:6],+>D!E.F[TUVMHIUYU3
M%WHB?BL]Z69.T/GTI6?F)AQV3B(=$8E).NE\^M+622KMG$0Z(Y*3=-'Y]*1G
M5BI2=DXB7?6)T6=C9.']N2)SHN9F[PCJ=4^+9N8>:ATKU]I+VK-AY#,*&(6,
M(D8QHX11RBACE#,J&)6,*@.905?94V^!ZH+>9%7MG8;:+Y<J5U>S!!W8FP&W
MYC!=M5X3W35K1AM&OJ#ZXJ5.6P-!6BMD%#&*!6FM1)#62AEEC')!6JL0I+5*
M1I6!S*"K3,H5]";#,H+>H(D9]/=VT!NO&=*"7M=\,+W6ZNH$'3B;U3O'XM:R
M;UH[CJ$R.7Q&@:A<K2L4+YR-=8L6-V:+(I:/&26B=;7&5+RNUIBQ?,ZH$*VK
M-9;B]48\*T/8'``0=@X`Q:VEKD$8`-(IJW&#T-N"UH)F'=JTR.C-IF`/!5)0
M:X6"M%;$6C&C1`IJK520ULJX8,ZHD():JQ2DM2JCH!EAE92YIEB3K!E3K$$3
M<^!8&]EJW'K-FUNY\<W4&LQK[2'=LA&D%PJ?4="B&0Z1;\^54'N)?,1:,:-$
M%[PBGVHOD<]8*V=4"'HS,*7V$.E*4!T8L^-4JM?KN/;*],T3,WJ2IDR#T*%2
MWZKUFC57],V=:./50QOQTDF-WZ+>=A:(U_M./F04"=):,6LEXJ6U4D:9(*V5
MLU8A7OHSEHPJ0;66&7F5%/8BWQT%FF01!26<RW&;/QJ[DGWV6[5>,\-K;NTZ
MZ]9K/FXGUNV-Y;$1#[T6^"TR5K*F3==K"T4+G?_V7(O$2]<8<XU)BZ[7F(K6
MU1HS\=(UYEQC\5,UEJ+U9D0K\:AK,P>!RF1[@^"'TZ_-?/N#HT'&CM6@N3Y#
MK=6W(=CJYOJPL1&DYZW?(J.?22N4@GI^1(*T5LQ:B7CI=J6"M%8F2&OEK%6(
ME]8J!>G/6`FJM<S(JV3V6N1_/[[B:(!9TGY5U"2_QK1LT$)WQFI,:,UHP\AG
M%#`*&46,8D8)HY11QBAG5#`J&54&,B./!:H?^2["BENGL0;UKQ%5/@2O'EHS
MVC#R&06,0D81HYA1PBAEE#'*&16,2D:5@8P(3]Y([6MN1EB0GG\K1FM&&T8^
MHX!1R"AB%#-*&*6,,D8YHX)1R:@RD!EA*X__T;J-X6J/;4'ZL+IJ47?7N)A:
M>_-:>\CA8,/(9Q0P"AE%C&)&":.44<8H9U0P*AE5!C([0B79UY9QZ\9WTB3E
M_65<4+\CVM0=O::/+7/[]K$MB#M*W1E=04&^R.M=*=`%^_+V#:3V$JV(4<SR
MB?;JR]NWD-I+Y#-&.<L7VJLG;Y]&2^TE\I6!S%Y4F7*O%V5+F#09M-%;+>KW
M5H-^<!?9:L%+&K1AY#,*&(6,(D8QHX11RBACE#,J&)6,*@.905<IMBOH3>IM
M!+U%V'M[\\&^BU0IO=J:==>L&6T8^8+T62X0I+5"1A&C6)#62@1IK911QB@7
MI+4*05JK9%09R`RZ2H-=06_28R/H#3+O(A?6MT\K]:X-0?_!7:1X-7=GD[&U
ME&U:>^_@[S,*1`7SK3<,K#TJ%"^,!NU%=Y$L'S-*1.MJC:EX7:TQ8_F<42%:
M5VLLQ>N->%:&L#D`WDC[)YSVMZB?V;6H?Q<I2*=+FQ89O=G(]U`@!74.'`K2
M6A%KQ8P2*:BU4D%:*^.".:-""FJM4I#6JHR"9H15QNJ:8DTF:TRQ!JGIJH?J
MW+[NQX)63[%;]T7^6MOUSM(*ZV7";[UZJV.@"_:JMV=*J+U$/F*MF%&B"UZ1
M3[67R&>LE3,J=$'U<)*^WRBU780K0\7L-"L=[TX`G'9/&H1.$]U5BW"E*VC-
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M7=`5O7CH@/N"].(6_%1MH7@A<]5MLC>A2.1UC;$@76,B6E<_7RI>5VO,1%[7
MF`O2-1:B=;7&4@J^&=%*/.K:S$&@4OK>NOG#Z==<`1B#HT']'0L',36$%GIH
MKELTU=?)&T'Z=LYO$792F<H!:X6"]/R(6"MFK40*ZG:E@K16QEHY:Q524&N5
M4E!_QDI0_1G-R.,,WOP$A_XZLKV5QV=O?EBH^?&/Y_WIZWZU?WHZ#W;';R\8
MQV/,ZD\?.][\F!)&BZ=:A=*6!2/$4XUC"T8&?K;)9<$//7UV\24*U!_9JF,Y
M\2JG_Q05.&K^//,^.RM>SKRJ/OS8%<R]J@ZLQ3%Y/=7]_.$PASTU"MB"J>RI
MP<`63%]/C0FV8,IZ:FBP!3/74R/$89E\@*5.L*U68QM%E[@LV"L1,9=EB7J6
MSGJP]'HKIP7+K:?F'K=M`XN:@FS!:NNIF<@6++J>FI!LP4+KJ7G)%AR+,3+J
ME<>*P1*?=.G\I"M8U(;-:CABH=4N"TY::+7+@@,7VN:RX$2%L>.RX&"%L>.R
MX'R%$>*RX`"%$>*R(*7QU*&:/P\R&T^=K=F"!,=3YVFV((/QU+&:+4AD/'6Z
M9@OR&4^=J-F"FP.HU>N3U3^X0(":RX)[!$]ELJR&NP/4X[+@U@#CP&59HFU+
M9]M6L*A<A^O9P*)2'K8@%?54YL,69*2>RG9<EKFG;@S8@OL>E'%9(EC4_0&7
MP54/^M1EP8V/IVX3N`QN>=#;+LMJ@A44]YQ<9C69(0:NM1(7C&B;RX+K0O2V
MRX++/]3CLBS1MN4;;9M[*Z=EC3)KIP6W<6BUZY/B4@X]Y[+@C0%VG?I08(W1
MY1BK);XK=$4'.Q6^6G%9)FB!:ZW"=Q>(F\N"KQT0-Y<%WQB@'I=E.7Z/MKG&
M&UY[>.J]`+<-+SP\]6R`+7C5X:G7`VS!XPY//2)@"]YX>.HM`5OPKL-33PK8
M@N=4:+5KI\5+'6_I+(/7.=[*:<&+'$\]S^!Z\!+'4Z\TV(('.9YZK,&6`);`
M:<%;'$\]W>`R>'_CJ1<<;,$S'$\]Y&`+'L.AC"L&>!.',BX+GL:AYUP6O'U#
MS[DL>`*'GG-9\!(._>.RX-4IU%SK`1Z?0LUEP1M4C`.7!>].48_+@A>G&`<N
MRQ)M6SK;AH>-Z&U7J_%Z$;WMLN`1(WK;9<%;1O2IVS+!.'"U#6^%4<9EB6!1
M;T^YM_%,&'WJLN"U,.:IRX(7PNAMEV4UOD'<7*<`/&='#%PK$AZGHVTN"YZ:
MH[==%CP<1STNRQ)M6[[1M@GFJ:O5>,^-GG-9\)(;K799\*`;/>>R++%<N];Q
M%19$UWJXPJ'.M88'.)ZY>(*#EHL7V`QJ/NJV"?S^A-?MUWVV/7T]O)P'3_L'
MY$\W=<IU:G[50O.?2_,@:O#E>,%O3D"*A>P,OQ)CCQ]6N'F';Z$>CL>+_`=#
M:-3]DHU/_P<``/__`P!02P,$%``&``@````A`*.:Z6H7!```T`T``!D```!X
M;"]W;W)K<VAE971S+W-H965T,38N>&ULC%=-CZ,X$+VO-/\!<9\0&T(^E*25
MWE'OCK0CC58[,V>:.`EJP`@[G9Y_OU4V&!L<*9<HE,OOE5_Y&;-]^JC*X)VU
MHN#U+B2S>1BP.N?'HC[OPA__O7Q>A8&067W,2EZS7?B;B?!I_^F/[8VW;^+"
MF`P`H1:[\")ELXDBD5]8E8D9;U@-(R?>5IF$Q_8<B:9EV5%-JLJ(SN=I5&5%
M'6J$3?L(!C^=BIQ]X?FU8K74("TK,PGUBTO1B!ZMRA^!J[+V[=I\SGG5`,1K
M41;RMP(-@RK??#W7O,U>2UCW!TFRO,=6#Q/XJLA;+OA)S@`NTH5.U[R.UA$@
M[;?'`E:`L@<M.^W"`]D\TV48[;=*H)\%NPGK?R`N_/976QS_*6H&:D.?L`.O
MG+]AZM<CAF!R-)G]HCKPO0V.[)1=2_DOO_W-BO-%0KL7."7G)3#!;U`5N`=@
MZ=G'+J3`4!SE91?&Z6RQG,>$+L+@E0GY4N#<,,BO0O+JETXBBEUCJ1J^9#+;
M;UM^"Z"QD"V:#+<)V0!P1]XAF')`E1RS#YB^"Y=A`$0"HN][FBZVT3NL+^]R
MGG4._)H<8C(BH#7<P&=Q]Q0810H4`#F?=<#&HWZ\V(N'45@=2#340\8UZZ3$
MRADRG)HAQ5,S1A6'*;J+V%43B]7!A-(L3-6#.%D8S7'8!>\B((RUI-0O2NH!
M7Z<&'(==\"X"BEC@2S\X;(1QY601SY9#\9CAXG<1%W_EQ\<S;MB=_0[!J,*T
M*J1S@Z!WC4YZH*-K+P=&W;J[B--1B]7I*(%3P"I<MY2L9X,N*L,EZ$-.6^D=
M[Q"H8\Q`$F+ZJL9'^#@%0B[^'2]AEH7?2Z_""M;6/AYIWV4](#Y!XTT[K,*C
MZK5%<5W#OJ0#LZL_VF^`5?K3>6)O3-(Y5)^TZJ#I0ZY`B5F<2^&ZU@ADW#J4
M2=/!FWISXFD$K7A$(->_AF;J6]*%;%!X,]RIWN-<^\PA4]_V(5>=866N.G[G
M$H]U:3H<+ITZ#WN7^,VKPJ/MX[7OP.Q43SWVM<VEQEW\/N2J<^=8HZYY^Z:J
M\,1<:]/![G6H;6RW^4Z3J=_#*CRJ'C,AY)IK8';5<3VKS)4FUME&.ZM:UNI#
MCCSQ<&:[!&C-P;U&'@R/Y*'I('$GC\YZ1!Z_@_$RI6G,R[P/.?+$=TYFZCI6
MGSWIRM9G:EXU"=;FZG/G;(;;J*V/9B!+FV%J7S5IPC`^/_4M5=\0*]:>V9^L
M+$60\VL-I^X*7B\FVMV.*=D<H+N@U60D@1%UCQN/X!3?C'AS\.:O-@?8FAX*
M0F$D\8XL8,0+1@`-W`IHD:D+KME-=F;?LO9<U"(HV0E6.\?71=#J&[E^D+P!
M">&RS25<L-7?"WPY,;BFSD'^X,2Y[!^0P'R+[?\'``#__P,`4$L#!!0`!@`(
M````(0"9R0;@;!@``)1V```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;)2=VW(;.9*&[S=BWT&A^Y'$XD%DA>V))NM\(KDQNWNMEF5;T9;HD-2'>?OY
M02"9!?R0K+ZQY"\3"53B4$@`!7WXYU\/W\_^N'MZOC\\?CR?7%R=G]T]WAX^
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M1%J,^46<,GN?.R?2:,PO\HSO:V[H`:ZDVF[>^8S2;";:;G[VC-)B)J,F\W8]
M7MK.>>S4V<W+S:</3X<_SS!2PIO//V[,N#M)C3G7G5T[/W5PC#.W1OT7H__Q
M'(KHNL^@?WQ*DNF'RS\P8MPZG37K3'R-C6B84<.8S4*0AZ`(01F"*@1U")H0
MM"'H0M"'8`C!-@2[$.Q'X!)N/_D>C?IO^=[H&]^+U]8"1I41.%HT)$D6@CP$
M10C*$%0AJ$/0A*`-01>"/@1#"+8AV(5@/P*>HS$4D*-G\U.;-F*\G;PV/?,=
MN78ZXX8_]U4V)Y63LXGD1`HB)9&*2$VD(=(2Z8CT1`8B6R([(OLQ\5R/D91<
M;P9+^[[@\<7H8RR"QAL#C%6:OE49)Y5391#)B11$2B(5D9I(0Z0ETA'IB0Q$
MMD1V1/9CXE4&O#JN#!G3#3[Z7'RUMF2*><7KM;`Y*4FRC$A.I"!2$JF(U$0:
M(BV1CDA/9""R);(CLA\3S\5XB8]=?'R?)O,+Z+_6XDT*W_N63#&:C;P?CC8G
MI9/WB>1$"B(ED8I(3:0ATA+IB/1$!B);(CLB^S'QO(\18>Q]:>`&^RZV)'#Q
M(AC03THG%Q/)B11$2B(5D9I(0Z0ETA'IB0Q$MD1V1/9CXKG8Q/&C":.XV&#?
MQ98$+KX.7'Q2.KF82$ZD(%(2J8C41!HB+9&.2$]D(+(ELB.R'Q//Q8C.8BXV
MV'>Q)8&+EX&+3THG%Q/)B11$2B(5D9I(0Z0ETA'IB0Q$MD1V1/9CXKG81+$Q
M'Q^Y[V2'$).)`S>,,D8YHX)1R:AB5#-J&+6,.D8]HX'1EM&.T=Y#OH=-U!,9
M*,PB0-",!2U&'G9:BC+6RAD5C$I&%:.:4<.H9=0QZAD-C+:,=HSV'O(];,*=
MF(=M&(0YM#38M5E(@=-GTQ/:"/)G&2M_\,A42VSEC`I&):.*4<VH<0B#FN38
MJM9H0C2]\HO:J98D[!D-C+:,=HSV'O+KP00_HWIP:R@79O'NY=O][6_K`^9Q
MDU.X:5:FPAY@D5<_%B7C^IE,@\$]<[:@)0^=,RH8E8PJ1C6CQB&O?MY3U(YM
M]8P&1EM&.T9[#_GU8^*AOU,_-G[R^H]#X_YCT<S4*Q;!KB;!BD%F%A%-G]/W
M1LZH<`BM2RJP5"UG.5A?JU1!TM2,&K;<JE:\S)TJB.6>T<"6MZH5+_-.%<3R
MWD-^C9GP:E1C,LDTRP)AS[%HCC>]!DM36F^T6M@74:W)G`8[IY4<JQ3+_I.@
MN^6N`,GR5%N%(%V6*QUZ.[=*M&QNBXOK8&Y<BV7-K!&DF;5BYLU'ZT3+9K:\
MF`;/WHMES6P0I)EMQ<R;F>U$Z_1D00/>B^5C9G[-F]`N5O,VY$-":3YKLUZ.
MQH":%[1Q:*E=+A.D_2L7I)VY<"C11RT=&IFO')JI5LT)&T:M0Z-R=8*T7+T@
M+=?`MK:BI<^X$Z2V]H*.MGP/F\@NYF$;\7D>MF@YKNUDFOCOW8W9-4`]C%X(
M&:.<4>&0-_21K8H3UHP:MM6R5L>H9S2PK2UK[1CM/>0[W<1Z,:?;&-!SND5S
M>&(TH`4]:#.Q6FB*9KR]#N9"F8JE;^0.!7:#EU;AM)+C'O!Q:Z946R:K93`D
M5BJ6K.IW9=5P5JW:.F85M+1.Q9)5_ZZL!LYJJ[:.605C[T[%DM7^9UGY%6XB
MSUB%VXC4JW"+,/<;5WBXW#=Q6K-CA2\N@C=<IG(I<.[0J&,6C$I-:!PQOZ#Z
M/64LAFNVTC!J0\/!&Z=3N1CNV<K`:*L)HR7>J5P,[STK7D6AI4<KZLC]A0"'
MQI-T0;/3.RACE#LTK@A&)2>L&-6<L&'4<L*.4<\)!T9;3KACM/<2^AY^92$`
M"RKA9,ZA8(P*EV6=EAO[)A>KH*]DJB`-((];#D<_IX5GD82EVC*-;7*Q"$I3
MJ8*DJ=^56<.9M6K+9A9V&95+7OV[\AHXKZW:<@\6>'&G"I+9_F>9^?5NUAPB
M0Z"):(-)O"!_"`S&Y(W3FB&N.KT9)XOPU:=:4NP\;IXJWY5+9U&EVGHCQTJU
M),?Z73DVHJ4YMFKKC1P[U9(<>['ENS!XQD&T-,>MVGHCQYUJ28Y[L?5:CGYC
M@%:T,1@>#+,68;34`B7APL<F.6E)@3)&.:."4<FH8E0S:ABUC#I&/:.!T9;1
MCM'>0[[3S0I$K`?:E8GQ)"2Q:*'QU891QBAG5#`J&56,:D8-HY91QZAG-##:
M,MHQVGO(][!9,8AYV*XD>!ZV"$.H--B-.4^(QC]"&:.<4<&H9%0QJADUC%I&
M':.>T<!HRVC':.\AW\.O+`@DO"`@2/<,-HPR1CFC@E')J&)4,VH8M8PZ1CVC
M@=&6T8[1WD.^ATW,'6O#-A;WVK!%"UT`V6#)Q+3AV7BTGBR#]TZF6M+X<T8%
MHY)1Q:AFU#@TFG.WJJ4OELDRF,]UJB5%[1D-C+:,=HSV'O+K(5@C^-DV`A8A
MZ=5ID5<_%IF7M4Z:EL%<+W.VH"4/G3,J&)6,*D8UH\8AKW[>4]2.;?6,!D9;
M1CM&>P_Y]6,"X5$_^6G]V,#9ZS\.C?N/"Z]?W49(3@I:-80*IS5>2].$9H*/
M#8I@#:E2!;%<,VK8<JM:SG+0W3M5$,L]HX$M;U4K7N:=*HCEO8>\&IN^$ML?
MN3_I%#2J&8?\D6T>#!>9:DF!<D8%HY)1Q:AFU#@TJNI6M4:=/"QJIUI2U)[1
MP&C+:,=H[R&_'EY9`9CR"H!#9L9U&JZN@[6NC5/R]GQX-\=IN66"Y7403.>2
ME59YP:A\5UZ5)#1GBK%*,`V+7(N"9M8P:M^562<);6;)]2KP3R\*FMG`:/NN
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MU-8@2&UM!:FM':.](-[OG+X2HA]Y,`FP\;BQ=>HCDUDPNFY<PK=W]S.GA;#K
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MHQ7?S910QBAG5#`J&56,:D8-HY91QZAG-'C(<]3LE7C\R/U7L2`=J#:,,D8Y
MHX)1R:AB5#-J&+6,.D8]H\%#OJ->"9AQEC0<*!T:#8$;A[R%BR2<<F>J)>^C
MG&T5JC4:AV?!)+M4+;%5,:K9?..0.5JCP_PLV/AM.6&GYD<)YT%8T:N6E&OP
MD._T5\)5X\?@[>20YW2K%3@]F(=E+B%^2(%RME6HUNCA9L$TJU0ML54QJME\
MXU#@].#<3\L).S4_*M<\>,9>M:1<@X=\I[\2P9K34*'3+?*<[I#.J3*7$.]#
MR3T7I$XO'#+E&K6[8&Y9JI;8JAC5;+YQ*/!PL`#5<L).S8_*-0^Z6Z]:4J[!
M0[Z'@\A3)EWF&$7H88L\#SND[LQ<0L_#E+!P6H&'@R"H5"UYDHI1+3EJ!3:B
M=:KEEI4Z4?)J>1[THUZUI`R#AWQO!M$D36V#;SUPRP!YV469^C0;I[74V77&
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MY>$RAT9;6+DD5*V"$Y:,*DY8,VH8M8PZ1CVCP4.^HTRL$UGPF-L8:+S@X5`P
M,@8SX8W3,M,N;9ATLE>T,.E7+6Z8MA#CKB\)[7BYNEB&(Z8J2-U5#HW,U(P:
M1BVCCE'/:/"0[V\3YHS\_;-)Y]R&15X]6#0>29W6>//(H:6VSMRAD1\*3E@R
MJB3AZ%4N2`?JAE'+J&/4,QH\Y#O0Q"<C!\J<9V[C%L]1%ODCZ2*(<3<NH=O=
M65Q?KU:K8(3,1$<G:KD@]6_AT$]FF*(E,\QP!:82RYI9+4@S:QS"&&5'Z#!2
M:#E-YY#W.J##%KTDM,<$9CB4$+Q6!M$X%L>OG;\94\TYIG+(&X]=F*512>:T
ML'$AW3R7A.JDPJ'1#D\I2-MRQ;9JMM5PPI:U.M'2N7'O$':WI*B#(-YOF0<!
M%(T/P7[+43^80+C`"O,F'5L7P3BY<0F72]M^YM?7"PJL1$>WJ7.'O#'$YK?"
M%.>4'[6JTB5<V<-QF%$$!:HXLYHS:\A,\/YI.4TG:=XL8.^TG$-F">T6#Z)Q
M=(??[(-`C&HM6$HP7T4%"S8.>:.ZU<++1!I.YK30`07E#GDUXA+JQ+J4A-I?
M*D%JJV9;C6AIPI:U.M'2''M!6OI!T#%'WX%!@$8.#)L]!VYX^;D(5YMAL@C6
M"C9.:V5'W]GU?+Y:!3J9Z.@0D8OQ\=AB\UN-)SJ19N^T[&`ZOYA0LW<*FEG-
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MB^2=S"`YCJYAFBDRM\O\@00#0-JCA;(U=/S4M%V6X%[Z7X[#>F!KC?OJCUTA
MY`F*%;&SQH/$GN.76?H+ZHDS7N/YHH\W3_?'Z568\0)U$;%3XM'*Z*-5D)@A
M@O/&L)R:D8(E&)U3,V"P!,-R:L8-EF!T3LWPP1),<6`MUE`PMX&UF`13'%B+
M23"M0?7&))C.H'ICDC7*MHZ6#:_/=!.5X*69FF&:GP?OSM2,UBPI("FB$L0@
M*'6L1A%[H-0QR1K/LXX^#^:Z*'7L23-(S)R*RX:)+DH=DQ20%%$)YKAH5;$T
MF-RB5<4DF..B5<4D)9[41"M<-D2(L!:3(%"$M9@$\2):54R"0!&M*B9!O(A6
M%9-@204EB'5=K*R@!#$)%EA0@I@$ZRPH04R"Y1;4=DRR1MG6T;(AH$=MQTJ-
M,!ZU'9,@FD=MQR0(ZE';,0G6.^&#V'"'94_X(";!ZB=\$)-@$10^B$FP%@H?
MQ"1K>&<=]0Y6X>"#F-\R2+*H)(?$+!%Q>RL@,<M"+*EF&"VQZLT2[$FD9KF=
M)=B:2,VJ.TNP0Y&:Q7>68*,B-:OK+%G#.^NH=[!$#A_$_(9E<?@@)L%2.'P0
MDQ20F+5<+@%V!.&#6`_&QB!\$)-@?Q`^B$FP30@?Q"38+80/8I(UO+..>@?[
M5.DF*L'V5&IV6_AYL$N5YE$)-JM2L]'":=8HVSI:-FS@H@2Q4F/;%B6(2;![
MBQ+$)-C$3<WV(Y<`&[<H6TR"LTJHA5@/QF$D^#HFP9DD^#I6VS@X`TEL,H,#
M'Y#$>@D.+T`2F[=@OQV26`EPC@#>B4EPM`O>B4EPP@LM,59J'$.")%9J')^!
M)%9J'/N`)%9J'%6`)%8"'`Y/S2EDKA^<$4_-8626X%QX:LXDLP0'PC$_C$G6
MTQ7RB;?$"5IBK&PX2P>/QKRS@7?,<2XNP0;>,<>08A*\2Z+>P0G^U)S]YC0X
MNI^:(^`LP0G^U)P$9PD.\J?F0#A+<'@_->?"68)3^ZDY'LZ2-23KJ`2?0J3F
M0#RGP></J3D7SQ)\]Y":X_$LP></J3DESQ)\!9&:P_(LP2=!\$&LO>'+(#QI
M3(+O?_"D,0D^`T(+B4GP-1#:6TR";W[0WF(2?',':[$6@D_OT*YC$GQNAWQB
M$GQGAWQBDC5*L(Z6`-]SH19B9<-G6ZB%F`1?;Z$68A)\Q(4V&I/@6RVTT9@$
M'T8B3:S4^"(2:6(2?!B).HU)\'TDVG5,@F\B4=LQ"3Z&1&W')&M(UE$)/C!%
MNXZER2`QGR%R2\3GI/!H3(*O2N'1F`0?EZ)=QR2;9)7F=EDWB$Y+2,QGVEP"
M?):=FL^L68+/JA%+QR2;*6:=]BQ%D`^^*49[B\;3"4987-C!^:R3ZW2-E0^6
MX)H(E#KVIMTDF/-%T^`*A]1<$\#6<),#2A"SUL*:^82?TVP2U)P]=Q\\*:[X
M2LTM7IP&]W&E752"V[-2<T$6I\$M5<@G5J>X30KYQ"2X]0GYQ"2XG0GYQ"2X
M<0_>B=4/+MZ#M9@$]^NAA<0DN&8O-7>_\?/@MCV4(";!I7KP=4R"VRE3<P4E
M6\-EDJFY,9(EN/LQ-1<\L@17-:;F/D:6K%&"]2LE6*$68F7#K8CH63$)+D=,
MBZ@$=R2BYF)I<!4B6F],@MMS4W-]*Y<:E^BFYA97EN#B7#QI3((;<[%*%I/@
M^M747*[*UDI(S%6I+,'5J*FY^)0EN.@4^<0DN*X8-1<K`>XI1CXQ":XK3LUU
MN)P/;BU.S:VX+,%-Q6@',0FN*$:I8Y+-!)$X;I-F:[A+&V6+27`7-JS%)+C+
M&CZ(2=8H@;EVF//90&)N'V9)!HFYA)@EN$P:I8Y)<*=T:JXDYC2X6CHU-Q.S
M9#W!>(V_QA"3)"AU=#XZP;J+O4<B&!,W$[S1HVEP/S_J-&8-U_2C!+&QJH4U
M<S\[RG9YR@A_*O3'S=>[_N;IZ_WC\]GWNR]8-[\Z7IK_9/^JJ/W/B_U6\.S7
MPPO^2"CV,?`W"O'77^_P5P.OS)]5^G(XO,A_3`:GOR?[Z3\"````__\#`%!+
M`P04``8`"````"$`-"^E'`T%``!4$0``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6R46%VOHS80?:_4_X!XWX`A7Z`DJ\MG5]I*5;5MGPEQ$G0!1\#]
MV'_?L8T-MNEV[\MJ<^9X.,<S]L`]?'YO:NL5=WU%VJ.-5JYMX;8DEZJ]'>V_
MOF6?]K;5#T5[*6K2XJ/]'??VY].OOQS>2/?<WS$>+,C0]D?[/@R/T''Z\HZ;
MHE^1!VXA<B5=4PSPL[LY_:/#Q84M:FK'<]VMTQ15:_,,8?<S.<CU6I4X(>5+
M@]N!)^EP70R@O[]7CUYD:\J?2=<4W?/+XU-)F@>D.%=U-7QG26VK*<,OMY9T
MQ;D&W^]H790B-_MAI&^JLB,]N0XK2.=PH:;GP`D<R'0Z7"IP0+?=ZO#U:#^A
M,$=;VSD=V`;]7>&W?O9_J[^3M[RK+E^K%L-N0YUH!<Z$/%/JEPN%8+%CK,Y8
M!?[HK`N^%B_U\"=Y^PU7M_L`Y=[0)26IX4GPK]54M`?`>O%^M#UX0G49[D?;
MWZXV.]='WL:VSK@?LHJNM:WRI1](\P\G(?9TGHMI2(JA.!TZ\F9!88'=/PK:
M)BC<V=;X\#&#E`.[4E+V$Z4?;2#"@WI`7T_>-C@XK^"O'#F1R4$J(Q8,ZI&F
M370@U8%,!_(9X(`7:0AVYR.&*)T:$E(B`<P<:NH%0RQ)="#5@4P'\AF@J/<_
MII[2H0UFY4#^1I4;C9QYS31*+"G2DH&D!I(92#Y'%%OKC]FB=&A(Z.JIS7:N
MYHN3_!_YDA3IRT!2`\D,))\CBB]0.&LV<4@HRN2+QT8<\:'J,T/ZJ9`DL2PQ
MD-1`,@/)YXBB=KNHEJ*J6HYX[.)@YS,VD,1`4@/)#"2?(XHTJ.+"1E)4E38B
M[#KFT@PD,9#40#(#R>>((HW.6>.&7.U@EX=[53Y'A-VYHO:4K4H>D>F*B3GB
MS;L!^7NUO1-)$MV0&DAF(/D<45P$'W)!V:J+$9FYX(CG\RG@HK5F0,:E@3&'
M)R_;3'+8)'&1K^;(91QR*'80C-E95<3N,U@5/D(>G&%Y]I"OS:Q8L+;,S7:W
M"X)`KXC@[*7^5$#3MF0"&C,%;N#[GF9+<%@FU1<=:U.W25]\VHVO!71D1HA#
MX$OL;RP@_O+`!^O(F@2F@C5!F8"FA;F`&$N52&?7@D0^TA2)'/*@BM/6K[5[
M/$:<Y;M\Z]VU[^W4_4H$9>J<U(0R`8E$@8NV:J)<4%@BU16=79.K\47H/X\Y
MXJ-.<<LA<#L59!R(TTV:C`M]7[)2`4WN,@%-"W,!L86J=#J>)NFR9_C44B2.
M@TPY"VM]#B'.\G@'[_P]5$1[8T@$9WX6QF7SOE(S;=#>7VNG*E<RJ;[H()M\
M_6])^-Q3_(ZC<'Y&1FAJ]016T-O.GX9*.D+>W(NQ,%<6JM+IH/N!]&_D`;<4
M;0'^6<!?R1O<W7",Z[JW2O+2PIF!9CH=)"R_1YY8JVAX1+]3:$H=]T)XW5S`
M_1!>V$S\:1T^\4W4$ZU#>!,R%T2;$-XY%G"T#J/%3#%$XL4(-%9("V)F2R%"
MZV)&,HADBQ%H+MB3I341\D#;DGVXCT#;4@2N(="V%(';"+0M1>!2`FU+$;B+
M0-M2)-J&\*)D^HSW(<SW!3P($W;I:/7*@A`&J,F/D`O>EUH%QB!X7XHD$$D6
M(S`#P?O2&AB%X'TIDD.$3AC0YDC1\*G[*&[X]Z*[56UOU?@*!\!E-W#'OXKY
MCX&?'>M,!OC(I<?(NL-?+S`,17<%A_1*R"!^T`?(OX><_@4``/__`P!02P,$
M%``&``@````A`$HM\KDQ`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B
M!`$HH``!````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````)R1T4K#,!2&
M[P7?H>2^3;.)S-!FH+(K!X(3Q;N8G&W!)@TYT6YO;U:[.M$K+\/_Y\MW3JKY
MSC;9!P0TK:L)*TJ2@5.M-FY3D\?5(I^1#*-T6C:M@YKL`<E<G)]5RG/5!K@/
MK8<0#6"62`ZY\C79QN@YI:BV8"46J>%2N&Z#E3$=PX9ZJ=[D!NBD+"^IA2BU
MC)(>@+D?B61`:C4B_7MH>H!6%!JPX")25C#ZW8T0+/YYH4].FM;$O4\S#;JG
M;*V^PK&]0S,6NZXKNFFOD?P9?5[>/?2CYL8==J6`B,-^&HEQF5:Y-J"O]V+W
M&IH,<5O1WUFE56_'50`906?I/?YE=TR>IC>WJP41DY)=Y(SEK%Q-&"]GG%V]
M5/38&NZ+$6@'@7\3CP#1>__\<_$)``#__P,`4$L#!!0`!@`(````(0"B,*%8
M]@(``%<)```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````)Q6;6^;,!#^/FG_(>)[2_HV316AHH2H
ME=(D&C3[:#EP"5;!9K9!37_]#E@2LCI,V9?$^-X>/W?GL_/PGF>#"J1B@H^L
MJ\NA-0`>BX3QS<AZC287WZV!TI0G-!,<1M86E/7@?OWB+*0H0&H&:H`NN!I9
MJ=;%O6VK.(6<JDL4<Y2LA<RIQD^YL<5ZS6(8B[C,@6O[>CC\9L.[!IY`<E'L
M'5JMQ_M*_Z_31,0U/K6,M@4"=AVO*#(64XVG=%]8+(42:ST(WF/('+LK=!!=
M"'$IF=ZZ0\?N?CIA3#/PT;&[IID"QSYL.$]`:](6E$GE.I6^KR#60@X4^T#:
MKJW!BBJHX8RLBDI&N498M5K[T:RS0FGI_A3R3:4`6CDV*K2;S;*KVUVS6_?F
MKM'`U;%F[:%%@H)CC!'3&:CY>D&E-D"^N>MB;E"TB%M`NRP2K`T2<(U\D6?>
M9IN)+O+]&?SY+)Q/G\=>%(S)HS?U9GY`PJ<@B,)S]<F"_MLDC##22S"+0C*?
MD/DB.-?$]\S`YG)#.?MHRJDY?\@VG&%M8U:)9XPR`TVF0BFR`$G"E$JLGCTQ
M=1VTK/I4I:3Y"7Z5K,)RXUHU(9YY93:98,4M:58">0&J2@EU;QV5SMZ[%\>R
MA(1,&5VQC-7-:T0Q$QH0*=W2568.^@,JX*59YHL\9[I!T2#W!58'W^"U<BI>
MPT<JL@3O(5(?7&^-N$(MXK='[*.$8!"\7U23`J-N?XZNC#:?DT2BF@(S2V;B
M^RP,_/>I_R&9[/Y76^)M)#0))I'Q!`8F^R*<(+3/I)_7:R,J`Z\^S>(R.YV^
M$^1.&*=81\8H)TQF5$J,8S0Q)>2P9S0YZ@TR!DT9CI!]BQU:>9>U'I7>3B%&
MKZ8$]T0XE>"6%',$<Y.1FEZR/,NDC7Z>29GG5'9-CB;87S-KROB;>BTB,:8:
M=D/Y>--I&$MP7.WDAPWG">>QS&HG?DKQBDIV.I\%]1-BV;Z3W*O;R^'-$%\'
MG3W'/KR(W-\```#__P,`4$L!`BT`%``&``@````A`!U_OV3@`0``NA8``!,`
M`````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`
M"````"$`M54P(_4```!,`@``"P`````````````````9!```7W)E;',O+G)E
M;'-02P$"+0`4``8`"````"$`Z,')Y]\!``"K%0``&@`````````````````_
M!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`
MK%[18H8#```G"P``#P````````````````!>"@``>&PO=V]R:V)O;VLN>&UL
M4$L!`BT`%``&``@````A`"!2F,U]!```ZPX``!@`````````````````$0X`
M`'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````(0!2$\Y3
MR@0``'X4```9`````````````````,02``!X;"]W;W)K<VAE971S+W-H965T
M,S`N>&UL4$L!`BT`%``&``@````A`!#6V'-/!```A1$``!D`````````````
M````Q1<``'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"+0`4``8`"```
M`"$`S:;VX`L%```B%@``&0````````````````!+'```>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0"PCS^9]@(``-4'```9````
M`````````````(TA``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`
M%``&``@````A`'R)+2N0`@``-P8``!D`````````````````NB0``'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`(/[D?/8#``"T
M#@``&0````````````````"!)P``>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+`0(M`!0`!@`(````(0#4#4NE$@,``,<(```9`````````````````*XK
M``!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&``@````A`%<=
MK;\L"```H#(``!D`````````````````]RX``'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"+0`4``8`"````"$`6B_J,#,%``"A%P``&0``````````
M``````!:-P``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(
M````(0!B>;B-;0,``'T*```9`````````````````,0\``!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A`-A2F*04!0``TA$``!@`
M````````````````:$```'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M
M`!0`!@`(````(0!`;6?`LP(``+0'```8`````````````````+)%``!X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`UD)\_W<Z``!H
MS```%`````````````````";2```>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"
M+0`4``8`"````"$`;5-Q4VP-``"-@0``#0````````````````!$@P``>&PO
M<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3````````
M`````````-N0``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A
M`(:/3P'N`P``8@T``!D`````````````````H)<``'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`&-'37&D#```]"P``&0``````
M``````````#%FP``>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`
M!@`(````(0`GQ8C5<`,``/D*```8`````````````````&6?``!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`,;*M)$L"``!9!0``
M&0`````````````````+HP``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M`0(M`!0`!@`(````(0"=6='PKP0``.8/```9`````````````````(VE``!X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`#[VX07`
M`@``%`<``!D`````````````````<ZH``'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"+0`4``8`"````"$`4W]_?:@'``!T'@``&0``````````````
M``!JK0``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````
M(0#?J98'_@\``&Y.```8`````````````````$FU``!X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`<^.'^%L"``!6!0``&```````
M``````````!]Q0``>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&
M``@````A`$WUDG&+!0``HQ,``!@`````````````````#L@``'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0#3/3A0E0,``)`+```8
M`````````````````,_-``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M+0`4``8`"````"$`3>2O:NH%``!)%P``&`````````````````":T0``>&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`.,P>WX*&```
M7W(``!D`````````````````NM<``'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"+0`4``8`"````"$`\0K7^(8)``!;*P``&0````````````````#[
M[P``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0`*
MT5%>_@4``&06```9`````````````````+CY``!X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L!`BT`%``&``@````A`#R4\M*("```4B4``!D`````````
M````````[?\``'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`
M"````"$`#U\AL8$'``!Z'0``&0````````````````"L"`$`>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(````(0#S*T!7,`,``&()```9
M`````````````````&00`0!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!
M`BT`%``&``@````A`)W0VK9P#@``J4,``!D`````````````````RQ,!`'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`"````"$`HYKI:A<$
M``#0#0``&0````````````````!R(@$`>&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+`0(M`!0`!@`(````(0"9R0;@;!@``)1V```9````````````````
M`,`F`0!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A
M`#0OI1P-!0``5!$``!D`````````````````8S\!`'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`2BWRN3$!``!``@``$0``````
M``````````"G1`$`9&]C4')O<',O8V]R92YX;6Q02P$"+0`4``8`"````"$`
MHC"A6/8"``!7"0``$``````````````````/1P$`9&]C4')O<',O87!P+GAM
7;%!+!08`````+``L`.8+```[2P$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump">$ 10.18<span></span></td>
        <td class="nump">$ 6.77<span></span></td>
        <td class="nump">$ 8.39<span></span></td>
        <td class="nump">$ 6.73<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">70.00%<span></span></td>
        <td class="nump">88.00%<span></span></td>
        <td class="nump">82.00%<span></span></td>
        <td class="nump">87.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term, in years</a></td>
        <td class="text">6 years 0 months 25 days<span></span></td>
        <td class="text">5 years 9 months 17 days<span></span></td>
        <td class="text">5 years 11 months 8 days<span></span></td>
        <td class="text">5 years 9 months 17 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.95%<span></span></td>
        <td class="nump">1.66%<span></span></td>
        <td class="nump">1.90%<span></span></td>
        <td class="nump">1.65%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
        <td class="nump">$ 21,709<span></span></td>
        <td class="nump">$ 13,609<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money-market funds classified as cash equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">213<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Money-market funds classified as short-term investments</a></td>
        <td class="nump">21,030<span></span></td>
        <td class="nump">12,717<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non Current</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RestrictedCashFairValueDisclosure', window );">Money-market funds classified as restricted cash</a></td>
        <td class="nump">679<span></span></td>
        <td class="nump">679<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
        <td class="nump">21,709<span></span></td>
        <td class="nump">13,609<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 1 | Money Market Funds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money-market funds classified as cash equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">213<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Money-market funds classified as short-term investments</a></td>
        <td class="nump">21,030<span></span></td>
        <td class="nump">12,717<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 1 | Non Current</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RestrictedCashFairValueDisclosure', window );">Money-market funds classified as restricted cash</a></td>
        <td class="nump">$ 679<span></span></td>
        <td class="nump">$ 679<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_RestrictedCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Cash, Fair Value Disclosure</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_RestrictedCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair-Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair-Value Disclosures</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair-Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Observable inputs for identical assets or liabilities, such as quoted prices in active markets;</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets that are either directly or indirectly observable;&#160;and</font></div><div style="line-height:120%;padding-top:6px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash held in demand deposit accounts of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> is excluded from our fair-value hierarchy disclosure as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized gains and losses associated with our short-term investments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The carrying amounts reported in the accompanying Consolidated Balance Sheets for grant and other receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B
M930V,&,U8S<T,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO969E
M,F8V,#=?-6)D-U\T,C$T7SAF9#1?8F4T-C!C-6,W-#)A+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T%3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T
M:6]N7V%N9%]3:6=N:69I8V%N=%]!/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F5T7TQO<W-?4&5R7U-H87)E/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S:%]#87-H7T5Q=6EV86QE
M;G1S7V%N9%]);G9E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^1F%I<E9A;'5E7TUE87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8W)U961?3&EA8FEL:71I97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E<U]087EA
M8FQE/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5V
M96YU93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5H;VQD97)S7T5Q=6ET>3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?
M0V]M<&5N<V%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3:6=N:69I8V%N=%]!,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE=%],;W-S7U!E<E]3
M:&%R95]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y&86ER5F%L=65?365A<W5R96UE;G1S7U1A8FQE<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8W)U961?3&EA8FEL:71I
M97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4F5V96YU95]2979E;G5E7V)Y7T%G<F5E;65N=%]4/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5H;VQD97)S7T5Q=6ET
M>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ871I;VY?86YD7U-I
M9VYI9FEC86YT7T$R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F5T7TQO<W-?4&5R7U-H87)E7T-A;&-U;&%T:6]N/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E9A;'5E7TUE87-U
M<F5M96YT<U]&:6YA;F-I/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1F%I<E9A;'5E7TUE87-U<F5M96YT<U].87)R871I/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C<G5E9%],:6%B
M:6QI=&EE<U]!8V-R=65D7TQI/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3F]T97-?4&%Y86)L95]$971A:6P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2979E;G5E7T1E=&%I;#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S
M7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-H87)E:&]L9&5R<U]%<75I='E?1&5T86EL/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#
M;VUP96YS871I;VY?3F%R<F%T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?1F%I<E]6/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E
M9%]#;VUP96YS871I;VY?4W1O8VM"/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?4W5M;6%R
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(
M4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53
M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E
M/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD
M;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB
M;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*
M("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O
M9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T,C$T7SAF9#1?
M8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F
M93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7;W)K<VAE971S
M+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4R0T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#`V+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M
M96YT($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"U1/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT
M($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=F86QS93QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L
M(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R
M,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=/3452/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E
M9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)T]-15)/4R!#3U)0/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,#`P,3(X-3@Q.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E
M;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<M+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG06-C96QE<F%T960@1FEL
M97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PP-S4L.3(T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%!04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$($)!3$%.0T4@
M4TA%1513("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PS.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H;W)T+71E<FT@:6YV97-T;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#`S,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#<Q-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A
M;G0@86YD(&]T:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C,L,S8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30L.#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPU,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N
M="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#$U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(U,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.30T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M=7)R96YT('!O<G1I;VX@;V8@;F]T97,@<&%Y86)L92P@;F5T(&]F(&1I<V-O
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DY,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30L,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L.#<S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!P87EA8FQE+"!N
M970@;V8@8W5R<F5N="!P;W)T:6]N(&%N9"!D:7-C;W5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L-34Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L.#DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#DS-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,30X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R`H3F]T92`X*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4VAA<F5H;VQD97)SXH"9(&5Q=6ET>3H\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL('!A<B!V86QU92`D,"XP,2!P97(@<VAA<F4Z($%U=&AO
M<FEZ960@<VAA<F5S("T@,C`L,#`P+#`P,"!A="!397!T96UB97(@,S`L(#(P
M,30@*'5N875D:71E9"D@86YD($1E8V5M8F5R(#,Q+"`R,#$S.R!)<W-U960@
M86YD(&]U='-T86YD:6YG('-H87)E<^*`E&YO;F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,2!P97(@<VAA<F4Z($%U=&AO
M<FEZ960@<VAA<F5S("T@,34P+#`P,"PP,#`@870@4V5P=&5M8F5R(#,P+"`R
M,#$T("AU;F%U9&ET960I(&%N9"!$96-E;6)E<B`S,2P@,C`Q,SL@27-S=65D
M(&%N9"!O=71S=&%N9&EN9R!S:&%R97/B@)0S-"PP,C(L,30U(&%N9"`S,"PS
M-3DL-3`X(&%T(%-E<'1E;6)E<B`S,"P@,C`Q-"`H=6YA=61I=&5D*2!A;F0@
M1&5C96UB97(@,S$L(#(P,3,L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@
M8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@P+#0P
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S-2PV.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,P-RPS,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4T+#,W,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R
M96AO;&1E<G/B@)D@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C8L-3@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$X+#,X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@
M<VAA<F5H;VQD97)SXH"9(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R-2PR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$V+#4S-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T,C$T7SAF9#1?
M8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F
M93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7;W)K<VAE971S
M+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5#34%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H4&%R96YT:&5T
M:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E
M("A54T0@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL(&%U=&AO<FEZ960@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!)<W-U960@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D
M('-T;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H55-$
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!A=71H;W)I>F5D('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!)<W-U960@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PP,C(L,30U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,S4Y+#4P.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T+#`R,BPQ-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PS-3DL-3`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9F4R9C8P-U\U
M8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO969E,F8V,#=?-6)D-U\T,C$T7SAF9#1?8F4T-C!C-6,W
M-#)A+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A:044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.5%,@
M3T8@3U!%4D%424].4R!!3D0@0T]-4%)%2$5.4TE612!,3U-3("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,U.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PT,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW-S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#0R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,V+#$Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V+#$Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5L;&EN9RP@9V5N97)A;"!A;F0@861M:6YI
M<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PR,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-"PQ.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,2PY,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#,T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8S,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,X+#`T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPQ,S(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,L-#,T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4P+#`S,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPV
M,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G9E<W1M96YT(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Y-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3DR*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-34U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S8X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H
M97(@:6YC;VUE("AE>'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PS,C<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,L.#<P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4R+#DV,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-RPY-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$X+#,R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$S+#@W,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4R+#DV,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,W
M+#DU,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92`H
M55-$('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,"XU-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q+C8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2XS-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A
M9V4@<VAA<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E9"!N
M970@;&]S<R!P97(@<VAA<F4@*'-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,T+#`P-2PV-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PX-#0L-3`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L.30U+#,T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W
M+#DX-"PQ,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?
M.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%0U9!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4
M140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A
M=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#4R+#DV,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S-RPY-3$L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A
M<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N(&1I<W!O
M<V%L(&]F(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C(L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PP.#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS-C0L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!I
M;G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S<Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!M;V1I9FEC871I;VX@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8S+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI
M86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R86YT(&%N9"!O=&AE<B!R96-E:79A8FQE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-3,L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%N9"!N;VYC=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#0R+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.30Y+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U
M,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Y-S`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3@W+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C
M87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0R+#,U,RPP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDL,SDY+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^26YV97-T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&%N9"!S86QE
M<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S<L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S
M(&]F(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U."PX-#<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(R+#DV,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!S
M86QE(&%N9"!M871U<FET:65S(&]F(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,"PU,S0L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L.30U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H("AU<V5D(&EN*2!P<F]V:61E9"!B>2!I;G9E<W1I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PS,C4L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#@T-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6YG(&%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O9B!O
M9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<L-S4T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V+#$R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@27-S=6%N8V4@
M;V8@3&]N9RUT97)M($1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#8Y.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O;B!N;W1E<R!P87EA8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0V-"PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!3=&]C:R!/<'1I;VYS(&%N9"!787)R86YT<R!%>&5R8VES
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@4W1O8VL@3W!T:6]N<R!%>&5R8VES960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P
M<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`L,#0T+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#$X-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M9&5C<F5A<V4@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C,T+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-S`L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4R
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@8V%S:"!F;&]W(&EN9F]R
M;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PY,S$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-#,L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3;6%L;"!"=7-I
M;F5S<R!);FYO=F%T:79E(%)E<V5A<F-H/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@8V%S:"!F;&]W
M(&EN9F]R;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5D=6-T:6]N(&]F(&5Q=6EP;65N="!C;W-T(&)A<VES
M('!U<F-H87-E9"!W:71H(&=R86YT(&9U;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<F=A;FEZ871I;VX@86YD(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^3W)G86YI>F%T:6]N
M(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P
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M=6YL;V-K:6YG(&YE=R!'('!R;W1E:6XM8V]U<&QE9"!R96-E<'1O<B`H1U!#
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M=7`@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[;&EN92UH96EG:'0Z,3(P
M)3MF;VYT+7-I>F4Z-W!T/B8C.#0X,CL\+W-U<#X\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@*'!H
M96YY;&5P:')I;F4@86YD(&ME=&]R;VQA8R!I;FIE8W1I;VXI(#$E+S`N,R4@
M=V%S(&%P<')O=F5D(&)Y('1H92!5+E,N($9O;V0@86YD($1R=6<@061M:6YI
M<W1R871I;VX@*$9$02D@;VX@36%Y(#,P+"`R,#$T(&9O<B!U<V4@9'5R:6YG
M(&-A=&%R86-T('-U<F=E<GD@;W(@:6YT<F%O8W5L87(@;&5N<R!R97!L86-E
M;65N="`H24Q2*2!T;R!M86EN=&%I;B!P=7!I;"!S:7IE(&)Y('!R979E;G1I
M;F<@:6YT<F%O<&5R871I=F4@;6EO<VES("AP=7!I;"!C;VYS=')I8W1I;VXI
M(&%N9"!T;R!R961U8V4@<&]S=&]P97)A=&EV92!O8W5L87(@<&%I;BX@5V4@
M8F5G86X@8V%L;&EN9R!O;B!O<&AT:&%L;6EC('-U<F=E;VYS(&%N9"!T:&5I
M<B!S=&%F9B!I;B!T:&4@52Y3+B!I;B!!=6=U<W0@,C`Q-"!R96=A<F1I;F<@
M3VUI9')I82X@26X@3V-T;V)E<B`R,#$T+"!W92!W97)E(&=R86YT960@=')A
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M<F5E('EE87)S(&9R;VT@=&AE($IA;G5A<GD@,2P@,C`Q-2!E9F9E8W1I=F4@
M9&%T92P@869T97(@=VAI8V@@=&EM92!#35,@=VEL;"!M86ME(&$@;F5W(')E
M:6UB=7)S96UE;G0@9&5T97)M:6YA=&EO;BX@5V4@:&%V92!S=6)M:71T960@
M9F]R($]M:61R:6$@82!W:&]L97-A;&4@86-Q=6ES:71I;VX@8V]S="!O9B`D
M-#8U('!E<B!S:6YG;&4M=7-E('9I86PN(%=E(&5X<&5C="!T;R!B96=I;B!S
M96QL:6YG($]M:61R:6$@:6X@=&AE(%4N4RX@:6X@96%R;'D@,C`Q-2X\+V9O
M;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN
M9RUT;W`Z-G!X.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS,G!X.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/DEN(%-E<'1E;6)E<B`R,#$S+"!W92!S=6)M
M:71T960@82!-87)K971I;F<@075T:&]R:7-A=&EO;B!!<'!L:6-A=&EO;B`H
M34%!*2!T;R!T:&4@175R;W!E86X@365D:6-I;F5S($%G96YC>2`H14U!*2!F
M;W(@3VUI9')I82X@36%R:V5T:6YG(&%N9"!S86QE<R!O9B!/;6ED<FEA(&EN
M('1H92!%=7)O<&5A;B!5;FEO;B`H154I(&%R92!S=6)J96-T('1O(&%P<')O
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M=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M
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M9R!O=7(@<W5B<VED:6%R:65S(&AA=F4@8F5E;B!E;&EM:6YA=&5D+B`@5&AE
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M(%)U;&4@,3`M,#$@;V8@4F5G=6QA=&EO;B!3+5@N(%1H92!I;F9O<FUA=&EO
M;B!A<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T
M:6]N.FYO;F4[/E-E<'1E;6)E<B8C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M(&%N9"!F;W(@=&AE(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E
M8V]R871I;VXZ;F]N93L^=&AR964@86YD(&YI;F4\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;6]N
M=&AS(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!I;F-L=61E<R!A;&P@861J=7-T
M;65N=',L('=H:6-H(&EN8VQU9&4@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M
M96YT<RP@;F5C97-S87)Y('1O('!R97-E;G0@9F%I<FQY(&]U<B!I;G1E<FEM
M(&9I;F%N8VEA;"!I;F9O<FUA=&EO;BX@(%1H92!#;VYS;VQI9&%T960@0F%L
M86YC92!3:&5E="!A="`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[9F]N="US='EL93IN;W)M86P[9F]N="UW96EG:'0Z;F]R;6%L.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.R<^1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N
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M9&EN9RUT;W`Z,3)P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T
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M="!A<F4@:6YC;'5D960@:6X@;W5R($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q
M,"U+(&9O<B!T:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@9FEL960@=VET:"!T:&4@4V5C=7)I=&EE<R!A;F0@
M17AC:&%N9V4@0V]M;6ES<VEO;B`H4T5#*2!O;B!-87)C:"`Q,RP@,C`Q-"X\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D
M9&EN9RUT;W`Z,3AP>#MT97AT+6EN9&5N=#HQ-G!X.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93II=&%L:6,[/E5S92!O9B!%<W1I;6%T97,\+V9O
M;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN
M9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE.C$P<'0[/CQF
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M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY!<R!O9B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/E-E<'1E;6)E<B8C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!W92!H860@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
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M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3AP>#MT97AT+6EN9&5N
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M96=U;&%T;W)Y(&%P<')O=F%L(&]N($UA>2`S,"P@,C`Q-"X\+V9O;G0^/"]D
M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
M,3AP>#MT97AT+6EN9&5N=#HQ-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N
M="US='EL93II=&%L:6,[/E-E9VUE;G1S/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN
M9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E=E(&]P97)A=&4@:6X@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SYO;F4\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX@<V5G;65N="X@36%N86=E;65N="!U<V5S(&-A
M<V@@9FQO=R!A<R!T:&4@<')I;6%R>2!M96%S=7)E('1O(&UA;F%G92!O=7(@
M8G5S:6YE<W,@86YD(&1O97,@;F]T('-E9VUE;G0@;W5R(&)U<VEN97-S(&9O
M<B!I;G1E<FYA;"!R97!O<G1I;F<@;W(@9&5C:7-I;VXM;6%K:6YG+CPO9F]N
M=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG
M+71O<#HQ.'!X.W1E>'0M:6YD96YT.C$V<'@[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7-T>6QE.FET86QI8SL^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=',\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT
M.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C,R<'@[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^26X@075G=7-T(#(P,30L('1H92!&:6YA;F-I86P@
M06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D($%C8V]U;G1I;F<@
M4W1A;F1A<F1S(%5P9&%T92P@;W(@05-5+"!.;RX@,C`Q-"TQ-2!R96QA=&5D
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M<B!$96-E;6)E<B8C,38P.S$U+"`R,#$V+B!792!D;R!N;W0@97AP96-T('1H
M92!A9&]P=&EO;B!O9B!T:&ES(&=U:61A;F-E('1O(&AA=F4@86YY(&EM<&%C
M="!O;B!O=7(@9FEN86YC:6%L('!O<VET:6]N+"!R97-U;'1S(&]F(&]P97)A
M=&EO;G,@;W(@8V%S:"!F;&]W<RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT
M.C,R<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@36%Y(#(P,30L('1H92!&
M:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D($%3
M52!.;RX@,C`Q-"TP.2!R96QA=&5D('1O('1H92!R96-O9VYI=&EO;B!O9B!R
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M;6)E<B`Q-2P@,C`Q-B!A;F0@8V%N;F]T(&)E(&%D;W!T960@8F5F;W)E('1H
M870@969F96-T:79E(&1A=&4N(%=E(&%R92!C=7)R96YT;'D@979A;'5A=&EN
M9R!T:&4@:6UP86-T('1H:7,@<W1A;F1A<F0@;6%Y(&AA=F4@;VX@;W5R(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&]N8V4@:70@:7,@861O<'1E9"X\+V9O;G0^
M/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYE="!,;W-S
M(%!E<B!3:&%R93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M3&]S<R!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^3F5T($QO
M<W,@4&5R(%-H87)E/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE
M:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/D)A<VEC(&YE="!L;W-S('!E<B!S:&%R92!I
M<R!C86QC=6QA=&5D(&)Y(&1I=FED:6YG('1H92!N970@;&]S<R!B>2!T:&4@
M=V5I9VAT960M879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O=71S
M=&%N9&EN9R!F;W(@=&AE('!E<FEO9"X@1&EL=71E9"!N970@;&]S<R!P97(@
M<VAA<F4@:7,@8V]M<'5T960@8GD@9&EV:61I;F<@=&AE(&YE="!L;W-S(&)Y
M('1H92!W96EG:'1E9"UA=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S
M(&%N9"!D:6QU=&EV92!C;VUM;VX@<VAA<F4@97%U:79A;&5N=',@;W5T<W1A
M;F1I;F<@9F]R('1H92!P97)I;V0L(&1E=&5R;6EN960@=7-I;F<@=&AE('1R
M96%S=7)Y+7-T;V-K(&UE=&AO9"X@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N
M=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E1H92!B87-I8R!A;F0@9&EL
M=71E9"!N970@;&]S<R!P97(@<VAA<F4@86UO=6YT<R!F;W(@=&AE(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^=&AR
M964@86YD(&YI;F4\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;6]N=&AS(&5N9&5D(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N
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M,T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG
M:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0U('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H
M=#IB;VQD.SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.FUI9&1L93MB;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
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M;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^-C`T+#,R-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
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M97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXW+#,X-"PS,C4\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/C<L-3$X+#,T.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X
M9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H
M965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V%S:"P@0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T;65N
M=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@L
M($-A<V@@17%U:79A;&5N=',@86YD($EN=F5S=&UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
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M,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/D%S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT
M97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT
M+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N
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M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E
M8V]R871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX@;W(@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A
M=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M+B!);G9E<W1M96YT(&EN8V]M92!C;VYS:7-T<R!P<FEM87)I;'D@;V8@:6YT
M97)E<W0@:6YC;VUE+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q
M-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R
M:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1F%I<BU686QU92!-96%S=7)E;65N=',\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(M5F%L=64@1&ES8VQO<W5R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^1F%I<BU686QU92!-96%S=7)E
M;65N=',\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R
M,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE
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M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT
M+6EN9&5N=#HV-7!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DQE=F5L)B,Q-C`[
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M<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/D]U<B!F86ER+79A;'5E(&AI97)A<F-H>2!F;W(@;W5R(&9I
M;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A
M:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@87)E(&%S(&9O;&QO=W,Z
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
M;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT
M97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P
M.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT
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M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z
M.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SY397!T96UB97(@,S`L(#(P,30\
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N
M="UW96EG:'0Z8F]L9#L^3&5V96PF(S$V,#LR/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/DQE=F5L)B,Q-C`[,SPO9F]N
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C$L,#,P
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M
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M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U
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M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXR,2PP,S`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[
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M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
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M<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L
M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(Q
M+#<P.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
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M.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE
M:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L
M.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SY$96-E;6)E
M<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A
M9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT
M.F)O;&0[/E1O=&%L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT
M+7=E:6=H=#IB;VQD.SXH26X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I=CX\+W1D
M/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D%S<V5T<SH\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP
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M;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^,3(L-S$W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
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M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
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M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R
M,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
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M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$S+#8P
M.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI
M9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,3,L-C`Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C
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M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MF;VYT
M+7-T>6QE.FYO<FUA;#MF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UD96-O<F%T
M:6]N.FYO;F4[)SXD-S4P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
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M>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY3
M97!T96UB97(F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E
M;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
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M<G0M=&5R;2!I;G9E<W1M96YT<R!A<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/E-E<'1E;6)E<B8C,38P.S,P
M+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^(&]R(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F
M-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B930V
M,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!A>6%B;&5S(&%N9"!!8V-R=6%L<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
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M,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE
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M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T
M.V9O;G0M=V5I9VAT.F)O;&0[/E-E<'1E;6)E<B8C,38P.S,P+"`\8G(@8VQE
M87(],T1N;VYE+SXR,#$T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O
M;G0M=V5I9VAT.F)O;&0[/D1E8V5M8F5R)B,Q-C`[,S$L(#QB<B!C;&5A<CTS
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M<W5L=&EN9R`F86UP.R!P<F]F97-S:6]N86P@9F5E<SPO9F]N=#X\+V1I=CX\
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[5&]T86P@86-C<G5E9"!L:6%B:6QI=&EE<SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C8L,C4P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,L
M.30T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^
M/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&5S(%!A>6%B;&4\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($1I<V-L;W-U
M<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]T97,@4&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
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M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@
M36%R8V@@,C`Q-"P@=V4@96YT97)E9"!I;G1O(&$@;F5W($QO86X@86YD(%-E
M8W5R:71Y($%G<F5E;65N="`H=&AE($]X9F]R9"]-:61#87`@3&]A;B!!9W)E
M96UE;G0I('=I=&@@3WAF;W)D($9I;F%N8V4@3$Q#("A/>&9O<F0I(&%N9"!-
M:61#87`@1FEN86YC:6%L(%-"24,L($Q0("A-:61#87`I('!U<G-U86YT('1O
M('=H:6-H('=E(&)O<G)O=V5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0S,BXP(&UI;&QI;VX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXN(%=E('5S960@87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O
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M;F-L=61I;F<@82`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD,38P+#`P,#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!U
M<&9R;VYT(&QO86X@:6YI=&EA=&EO;B!F964@86YD(&QE;F1E<G,F(S@R,3<[
M(&QE9V%L(&-O<W1S+"!W92!R96-E:79E9"`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD,3(N-R!M
M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&YE="!P<F]C965D<RX@5&AE($]X9F]R
M9"]-:61#87`@3&]A;B!!9W)E96UE;G0@<')O=FED97,@9F]R(&UO;G1H;'D@
M:6YT97)E<W0M;VYL>2!P87EM96YT<R!A="!A;B!A;FYU86P@<F%T92!O9B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXY+C(U)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!T:')O=6=H(#PO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MF;VYT+7-T>6QE.FYO<FUA;#MF
M;VYT+7=E:6=H=#IN;W)M86P[=&5X="UD96-O<F%T:6]N.FYO;F4[)SY-87)C
M:"8C,38P.S$L(#(P,34\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN($)E9VEN;FEN9R`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SY!<')I;"8C,38P.S$L(#(P,34\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(&UO;G1H;'D@
M<')I;F-I<&%L(&%N9"!I;G1E<F5S="!P87EM96YT<R!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXD,2XP(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@87)E(&1U92!T:')O=6=H('1H
M92!M871U<FET>2!D871E(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DUA<F-H)B,Q-C`[,2P@
M,C`Q.#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
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M:6YD96)T961N97-S('=I=&@@3WAF;W)D(&%N9"!-:61#87`@86YD('!A>2!T
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M/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
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M($]X9F]R9"]-:61#87`@3&]A;B!!9W)E96UE;G0@:6YC;'5D97,@979E;G1S
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M<F%T92!B>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXU+C`E/"]F;VYT/CQF;VYT('-T>6QE/3-$
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M92!E9F9E8W0@=7!O;B`H:2DF(S$V,#MO=7(@8G5S:6YE<W,@;W!E<F%T:6]N
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M,3<[('-E8W5R:71Y(&EN=&5R97-T(&EN('1H92!C;VQL871E<F%L+"`H:6EI
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M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[=&5X="UA
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M;W-T<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[9F]N
M="US='EL93IN;W)M86P[9F]N="UW96EG:'0Z;F]R;6%L.W1E>'0M9&5C;W)A
M=&EO;CIN;VYE.R<^)#$P,RPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@87-S;V-I871E9"!W
M:71H('1H92!T:&5N(&]U='-T86YD:6YG(&QO86X@=VET:"!/>&9O<F0@86YD
M('1H92!D96)T(&ES<W5A;F-E(&-O<W1S(&]F(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0R-#0L
M,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^(&%S<V]C:6%T960@=VET:"!T:&4@3WAF;W)D+TUI
M9$-A<"!,;V%N($%G<F5E;65N="!A<F4@8F5I;F<@86UO<G1I>F5D('1O(&EN
M=&5R97-T(&5X<&5N<V4@=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S="!M
M971H;V0@=&AR;W5G:"!T:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.V9O;G0M<W1Y;&4Z;F]R;6%L.V9O;G0M=V5I9VAT.FYO<FUA;#MT
M97AT+61E8V]R871I;VXZ;F]N93LG/DUA<F-H)B,Q-C`[,2P@,C`Q.#PO9F]N
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M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DUA<F-H)B,Q-C`[,2P@,C`Q
M.#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M
M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,S)P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY!<R!O9B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/E-E<'1E;6)E<B8C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@<F5M
M86EN:6YG('5N86UO<G1I>F5D(&1I<V-O=6YT(&%N9"!D96)T(&ES<W5A;F-E
M(&-O<W1S(&%S<V]C:6%T960@=VET:"!T:&4@9&5B="!W97)E(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#$N.2!M
M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0R.#0L,#`P/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M+"!R97-P96-T:79E;'DN/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T
M,C$T7SAF9#1?8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7
M;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY2979E;G5E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
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M;W`Z-G!X.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/E)E=F5N=64@<F5C;V=N:7IE9"!F<F]M(&=R86YT
M<R!A;F0@;W1H97(@<V]U<F-E<R!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+V1I
M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN
M9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US
M:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^5&AR964@36]N=&AS($5N
M9&5D("8C,38P.SQB<B!C;&5A<CTS1&YO;F4O/B8C,38P.U-E<'1E;6)E<B`S
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US
M:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^3FEN92!-;VYT:',@16YD
M960F(S$V,#L\8G(@8VQE87(],T1N;VYE+SXF(S$V,#M397!T96UB97(@,S`L
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N
M="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O
M=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SXH26X@=&AO=7-A
M;F1S*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/E-M86QL($)U<VEN97-S($EN;F]V871I=F4@4F5S96%R8V@@
M1W)A;G1S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
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M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(Q-#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
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M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
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M,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P
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M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/C,U.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$L-#,Q/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/E=E(&AA=F4@<&5R:6]D:6-A;&QY(')E
M8V5I=F5D(%-M86QL($)U<VEN97-S($EN;F]V871I=F4@4F5S96%R8V@@*%-"
M25(I(&=R86YT<R!F<F]M('1H92!.871I;VYA;"!);G-T:71U=&5S(&]F($AE
M86QT:"`H3DE(*2P@=VAI8V@@87)E('5S960@=&\@<W5P<&]R="!T:&4@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&]F(&]U<B!P<F]D=6-T(&-A;F1I9&%T
M97,N(%=E(')E8V]R9&5D(')E=F5N=64@<F5L871E9"!T;R!T:&5S92!G<F%N
M=',@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)#(Q-"PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^
M)#$Y-BPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@9F]R('1H92`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/G1H<F5E(&UO;G1H<R!E
M;F1E9"!397!T96UB97(@,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q
M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/BP@<F5S<&5C=&EV96QY+"!A;F0@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#,U.2PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0T-C$L,#`P
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^(&9O<B!T:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C(P
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M="US:7IE.C$P<'0[/B0T,"PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
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M<'0[/FYI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
M;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN
M($%S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL
M(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^)#<X-2PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;V8@<&]T96YT:6%L(')E=F5N=64@
M<F5M86EN960@879A:6QA8FQE('5N9&5R('1H97-E(&=R86YT<RP@:68@<75A
M;&EF>6EN9R!R97-E87)C:"!I<R!P97)F;W)M960N/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[
M=&5X="UI;F1E;G0Z,S)P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!/8W1O
M8F5R(#(P,3`L('=E(&5N=&5R960@:6YT;R!A('!L871F;W)M(&1E=F5L;W!M
M96YT(&9U;F1I;F<@86=R965M96YT('=I=&@@5G5L8V%N($EN8RX@86YD(&ET
M<R!A9F9I;&EA=&4@*&-O;&QE8W1I=F5L>2P@5G5L8V%N*2!P=7)S=6%N="!T
M;R!W:&EC:"!W92!R96-E:79E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD,C`N,"!M:6QL:6]N
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
M;W)A=&EO;CIN;VYE.SXD.3<P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!W87,@<F5C;V=N
M:7IE9"!A<R!R979E;G5E(&1U<FEN9R!T:&4@9FER<W0@<75A<G1E<B!O9B`R
M,#$S+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E
M-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R
M9C8P-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3
M:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
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M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$V
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M:6%L('1E<FT@;V8@=&AE(&QE87-E(&5N9',@:6X@3F]V96UB97(@,C`R-R!A
M;F0@=V4@:&%V92`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
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M;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F
M(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE(')E;6%I;FEN9R!A9V=R
M96=A=&4@;F]N+6-A;F-E;&%B;&4@<F5N="!P87EA8FQE('5N9&5R('1H92!I
M;FET:6%L('1E<FT@;V8@=&AE(&QE87-E(&ES(&%P<')O>&EM871E;'D@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD
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M,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HQ-G!X.V9O;G0M<VEZ
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M<'1E;6)E<B8C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!W92!H860@82!M
M;VYT:&QY(&9E92!O9B!A<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0S,#`L
M,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^+"!W:&EC:"!B96=A;B!I;B!!=6=U<W0@,C`Q-"X@
M5V4@8V%N('1E<FUI;F%T92!T:&4@86=R965M96YT('5P;VX@,S`@9&%Y<R!W
M<FET=&5N(&YO=&EC92!I9B!/;6ED<FEA(&ES('=I=&AD<F%W;B!F<F]M('1H
M92!M87)K970@9F]R(&%N>2!R96%S;VX@;W(@82!R96=U;&%T;W)Y(&%G96YC
M>2!A8W1S('1O('!R979E;G0@;W(@;6%T97)I86QL>2!R97-T<FEC="!T:&4@
M<V%L92!O9B!/;6ED<FEA+"!O<B!U<&]N(#DP(&1A>7,@=W)I='1E;B!N;W1I
M8V4@86YY('1I;64@<W5B<V5Q=65N="!T;R`\+V9O;G0^/&9O;G0@<W1Y;&4]
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M87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD-C,P+#`P,#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!U<&]N(&EN5F5N=&EV('!R;W9I9&EN9R!A9&1I=&EO;F%L('-A;&5S(')E
M<')E<V5N=&%T:79E<RP@=VAI8V@@:7,@97AP96-T960@:6X@/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^2F%N=6%R>2`R,#$U/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A;F0@=VEL;"!C;VYT:6YU
M92!T:')O=6=H(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/DIA;G5A<GD@,C`Q-CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/BX@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
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M($1E8V5M8F5R(#,Q+"`R,#$U+B!0=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@
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M;W5L9"!O=V4@82!C86YC96QL871I;VX@9F5E+B!!<R!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SY397!T96UB97(F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=V4@:&%D
M(&$@9FER;2!P=7)C:&%S92!C;VUM:71M96YT(')E<75I<FEN9R!P87EM96YT
M(&]F(&%P<')O>&EM871E;'D@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#4Q.2PP,#`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W!A9&1I;F<M=&]P.C$R<'@[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SY);B!/8W1O8F5R(#(P,30L('=E(&5N=&5R960@:6YT
M;R!A(&YO;BUE>&-L=7-I=F4@86=R965M96YT('=I=&@@2&]S<&ER82!3+G`N
M02!A;F0@2&]S<&ER82!7;W)L9'=I9&4L($EN8RX@*'1O9V5T:&5R+"`F(S@R
M,C`[2&]S<&ER828C.#(R,3LI(&9O<B!C;VUM97)C:6%L('-U<'!L>2!O9B!/
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M9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C$V<'@[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^1&5V96QO<&UE
M;G0@36EL97-T;VYE<R!A;F0@4')O9'5C="!2;WEA;'1I97,\+V9O;G0^/"]D
M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M9&5S8W)I8F5D(&EN(&]U<B`R,#$S($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q
M,"U+(&9I;&5D('=I=&@@=&AE(%-%0R!O;B!-87)C:"`Q,RP@,C`Q-"X\+V9O
M;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN
M9RUT;W`Z,3)P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/D1U<FEN9R!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$T+"!W92!I;F-U
M<G)E9"!A(&UI;&5S=&]N92!P87EM96YT(&]F(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0R,#`L
M,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^('1O($AE;&EO;B!":6]T96-H($%P4R`H2&5L:6]N
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M<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!T:&4@9FER<W0@<75A<G1E<B!O9B`R
M,#$S+"!W92!R96-O<F1E9"`D/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.3`P+#`P,#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B!A<R!S96QL:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E
M>'!E;G-E(&EN(&-O;FYE8W1I;VX@=VET:"!P<F5V:6]U<VQY(&%W87)D960@
M3DE((&=R86YT<RX\+V9O;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-H87)E:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
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M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT
M97AT+6EN9&5N=#HQ-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93II=&%L:6,[/D-O;6UO;B!3=&]C:R`\+V9O;G0^/"]D:78^/&1I=B!S='EL
M93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M86QI
M9VXZ;&5F=#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M=&5X="UD96-O<F%T:6]N.G5N9&5R;&EN93L^4'5B;&EC($]F9F5R:6YG/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^("T@26X@36%R8V@@,C`Q-"P@=V4@<V]L9"`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M)SXS+C4@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!S:&%R97,@;V8@;W5R(&-O;6UO
M;B!S=&]C:R!A="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC92!O9B`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO
M;F4[)SXD,3$N-3`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@<&5R('-H87)E+B!!9G1E<B!D961U
M8W1I;F<@;V9F97)I;F<@97AP96YS97,@86YD('5N9&5R=W)I=&5R(&1I<V-O
M=6YT<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
M="UD96-O<F%T:6]N.FYO;F4[)SXD,BXU(&UI;&QI;VX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL
M('=E(')E8V5I=F5D(&YE="!P<F]C965D<R!F<F]M('1H92!T<F%N<V%C=&EO
M;B!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
M96-O<F%T:6]N.FYO;F4[)SXD,S<N."!M:6QL:6]N/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D
M9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C$V<'@[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^5V%R<F%N=',\+V9O;G0^/"]D:78^
M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X
M.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!O=7(@
M=&]T86P@;W5T<W1A;F1I;F<@=V%R<F%N=',@87,@;V8@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
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M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN
M92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E
M.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT+6%L:6=N.FQE9G0[)SX\
M='(^/'1D(&-O;'-P86X],T0U(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^
M/'1D('=I9'1H/3-$,S`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
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M97!T96UB97(@,S`L(#(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3DR
M+#<X.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A
M9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DUA<F-H)B,Q
M-C`[,CDL(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
M9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD
M,3(N,C4\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3,S+#,S,SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D]C=&]B97(F
M(S$V,#LR,2P@,C`Q-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO
M=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C(P+C`P/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY/8W1O8F5R)B,Q-C`[
M,C$L(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C,P+C`P/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.SY/8W1O8F5R)B,Q-C`[,C$L(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXT,"XP,#PO9F]N=#X\+V1I=CX\+W1D/CPO
M='(^/'1R/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
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M,C`Q-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;G0M<VEZ93HQ,'!T.SY/;B!-87)C:"`R."P@,C`Q-"P@=V4@97AT96YD960@
M=&\@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^4V5P=&5M8F5R)B,Q-C`[,CDL(#(P,30\+V9O;G0^
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M;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD,3(N,C4\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@<&5R('-H87)E('1H870@
M:&%D(&)E96X@9'5E('1O(&5X<&ER92!O;B!-87)C:"`R.2P@,C`Q-"X@5V4@
M979A;'5A=&5D('1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!B969O
M<F4@86YD(&%F=&5R('1H92!M;V1I9FEC871I;VYS(&%N9"!R96-O<F1E9"!T
M:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)#0U,BPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@8VAA;F=E(&EN
M(&9A:7(@=F%L=64@87,@;W1H97(@97AP96YS92!I;B!T:&4@86-C;VUP86YY
M:6YG($-O;G-O;&ED871E9"!3=&%T96UE;G0@;V8@3W!E<F%T:6]N<R!A;F0@
M0V]M<')E:&5N<VEV92!,;W-S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H(#,Q+"`R,#$T+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN
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M(&]U<B!C;VUM;VX@<W1O8VLN($]F('1H870@86UO=6YT+"`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXS+#`X.#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!S:&%R97,@=V5R92!I<W-U960@=7!O;B!C
M87-H(&5X97)C:7-E(&]F('=A<G)A;G1S+"!P=7)S=6%N="!T;R!W:&EC:"!W
M92!R96-E:79E9"!P<F]C965D<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
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M:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/D]N(%-E<'1E;6)E<B`R."P@,C`Q-"P@=V4@
M97AT96YD960@=&\@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^36%R8V@F(S$V,#LR.2P@,C`Q-3PO
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M)B,Q-C`[,CDL(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN(%=E(&5V86QU871E9"!T:&4@
M9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@8F5F;W)E(&%N9"!A9G1E<B!T
M:&4@;6]D:69I8V%T:6]N<R!A;F0@<F5C;W)D960@=&AE(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0T,3$L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
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M97!T96UB97(@,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
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M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!W87,@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)#@V,RPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT
M97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DEN($]C=&]B
M97(@,C`Q,"P@:6X@8V]N;F5C=&EO;B!W:71H('1H92!6=6QC86X@86=R965M
M96YT+"!W92!I<W-U960@=&\@5G5L8V%N(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/G1H<F5E/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^('=A<G)A;G1S('1O('!U<F-H87-E(&]U<B!C;VUM;VX@<W1O
M8VLL(&5A8V@@97AE<F-I<V%B;&4@9F]R(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$S,RPS,S,\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SX@<VAA<F5S+"!W:71H(&5X97)C:7-E('!R:6-E<R!O9B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD,C`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W
M7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B930V,&,U
M8S<T,F$O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<RP@
M4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
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M96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HT<'@[<&%D9&EN9RUT;W`Z-G!X
M.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W5R(#(P
M,#@@17%U:71Y($EN8V5N=&EV92!0;&%N("AT:&4@,C`P."!0;&%N*2!P<F]V
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M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^,3`@>65A<G,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(&]P=&EO;G,@
M9V5N97)A;&QY('9E<W0@;W9E<B!A(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#MT97AT+61E8V]R871I;VXZ;F]N93L^9F]U<CPO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BUY96%R
M('!E<FEO9"X@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.W!A9&1I;F<M8F]T=&]M.C1P>#MP861D:6YG+71O<#HV<'@[=&5X
M="UI;F1E;G0Z,S)P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY/;B!*86YU87)Y
M(#$L(#(P,30L(&EN(&%C8V]R9&%N8V4@=VET:"!P<F]V:7-I;VYS(&]F('1H
M92`R,#`X(%!L86XL('1H92!A=71H;W)I>F5D('-H87)E<R!A=F%I;&%B;&4@
M9F]R(&=R86YT('5N9&5R('1H92`R,#`X(%!L86X@=V5R92!I;F-R96%S960@
M8GD@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^,2PU,3<L.3<U/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E<RX@
M07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@
M82!T;W1A;"!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
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M9&5R('1H92`R,#`X(%!L86XN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M8F]T=&]M.C1P>#MP861D:6YG+71O
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`\+V9O;G0^/"]D:78^
M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P
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M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[9F]N="US:7IE.C$P
M<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT
M.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W=I
M9'1H.C$P,"4[8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W1E>'0M86QI9VXZ
M;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V(')O=W-P86X],T0Q/CPO=&0^
M/"]T<CX\='(^/'1D('=I9'1H/3-$-3`E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0X)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,R4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M+W1D/CQT9"!W:61T:#TS1#@E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0T)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$."4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#,E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@
M=VED=&@],T0X)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M
M=V5I9VAT.F)O;&0[/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\8G(@
M8VQE87(],T1N;VYE+SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I
M9VAT.F)O;&0[/DYI;F4@36]N=&AS)B,Q-C`[16YD960\8G(@8VQE87(],T1N
M;VYE+SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW
M96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D
M9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$T/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z
M,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
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M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXX+C,Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV+C<S/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXE/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,2XY-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
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M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2XY,#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXE/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\
M9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[
M;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ
M,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT+6%L:6=N.FQE9G0[
M)SX\='(^/'1D(&-O;'-P86X],T0Q-B!R;W=S<&%N/3-$,3X\+W1D/CPO='(^
M/'1R/CQT9"!W:61T:#TS1#0V)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@
M=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I
M9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I
M9VAT.F)O;&0[/E1H<F5E($UO;G1H<R!%;F1E9"`F(S$V,#L\8G(@8VQE87(]
M,T1N;VYE+SXF(S$V,#M397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I
M9VAT.F)O;&0[/DYI;F4@36]N=&AS($5N9&5D)B,Q-C`[/&)R(&-L96%R/3-$
M;F]N92\^)B,Q-C`[4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX\+W1D/CPO
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R
M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N
M="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$S/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L
M9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN
M:7-T<F%T:79E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C<X
M-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@
M8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L
M;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PX
M-#8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[)R!R
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M9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CLG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R
M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
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M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C4L,#@S/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC
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M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT
M+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E-T;V-K(&]P=&EO
M;B!A8W1I=FET>2!F;W(@86QL('-T;V-K('!L86YS(&%N9"!R96QA=&5D(&EN
M9F]R;6%T:6]N(&ES(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[
M9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X
M.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT
M;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
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M(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT
M+7=E:6=H=#IB;VQD.SY796EG:'1E9"T\+V9O;G0^/"]D:78^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M
M=V5I9VAT.F)O;&0[/D%V97)A9V4\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I
M9VAT.F)O;&0[/D5X97)C:7-E/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H
M=#IB;VQD.SY0<FEC92!P97(\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT
M.F)O;&0[/E-H87)E/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
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M:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SY"86QA;F-E(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C8L.38Y+#,P,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C
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M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-BXS
M.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY'<F%N=&5D/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$R+C`P/"]F;VYT/CPO
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^-BXS.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$
M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY&;W)F
M96ET960\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
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M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D
M9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/CDN.#(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
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M+7-I>F4Z,3!P=#L^0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,30\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
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M(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV+C0R/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL
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M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P
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M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT
M/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SY697-T960@86YD(&5X<&5C=&5D('1O('9E<W0@
M870@4V5P=&5M8F5R(#,P+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
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M(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
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M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^-BXS,CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0R+#$T,3PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M:7-A8FQE(&%T(%-E<'1E;6)E<B`S,"P@,C`Q-#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0L
M-S4U+#DY,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,V
M+#$T-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
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M9&EN9RUT;W`Z,3)P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/D%T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXL('1H97)E('=E<F4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXR+#`R-"PP,#4\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@=6YV97-T
M960@;W!T:6]N<R!O=71S=&%N9&EN9R!T:&%T('=I;&P@=F5S="!O=F5R(&$@
M=V5I9VAT960M879E<F%G92!P97)I;V0@;V8@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR+C`\+V9O;G0^/&9O;G0@
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M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^)#$Q+C$@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D:78^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P13)$04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N
M(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G
M86YI>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D
M:6YG+71O<#HV<'@[=&5X="UI;F1E;G0Z,39P>#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z:71A;&EC.SY/<F=A;FEZ871I;VX\+V9O;G0^/"]D
M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M:6=N.G1O<#ML:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HW<'0^)B,Q-S0[
M/"]S=7`^/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
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M=61E<R!A(&1I=F5R<V4@9W)O=7`@;V8@<')E8VQI;FEC86P@<')O9W)A;7,@
M87,@=V5L;"!A<R!T=V\@861D:71I;VYA;"!P;&%T9F]R;7,Z(&]N92!C87!A
M8FQE(&]F('5N;&]C:VEN9R!N97<@1R!P<F]T96EN+6-O=7!L960@<F5C97!T
M;W(@*$=00U(I(&1R=6<@=&%R9V5T<R!A;F0@=&AE(&]T:&5R('5S960@=&\@
M9V5N97)A=&4@86YT:6)O9&EE<RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M86QI9VXZ
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M9VAT.C$R,"4[9F]N="US:7IE.C=P=#XF(S@T.#([/"]S=7`^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^("AP:&5N>6QE<&AR:6YE(&%N9"!K971O<F]L86,@:6YJ96-T:6]N*2`Q
M)2\P+C,E('=A<R!A<'!R;W9E9"!B>2!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G
M($%D;6EN:7-T<F%T:6]N("A&1$$I(&]N($UA>2`S,"P@,C`Q-"!F;W(@=7-E
M(&1U<FEN9R!C871A<F%C="!S=7)G97)Y(&]R(&EN=')A;V-U;&%R(&QE;G,@
M<F5P;&%C96UE;G0@*$E,4BD@=&\@;6%I;G1A:6X@<'5P:6P@<VEZ92!B>2!P
M<F5V96YT:6YG(&EN=')A;W!E<F%T:79E(&UI;W-I<R`H<'5P:6P@8V]N<W1R
M:6-T:6]N*2!A;F0@=&\@<F5D=6-E('!O<W1O<&5R871I=F4@;V-U;&%R('!A
M:6XN(%=E(&)E9V%N(&-A;&QI;F<@;VX@;W!H=&AA;&UI8R!S=7)G96]N<R!A
M;F0@=&AE:7(@<W1A9F8@:6X@=&AE(%4N4RX@:6X@075G=7-T(#(P,30@<F5G
M87)D:6YG($]M:61R:6$N($EN($]C=&]B97(@,C`Q-"P@=V4@=V5R92!G<F%N
M=&5D('1R86YS:71I;VYA;"!P87-S+71H<F]U9V@@<F5I;6)U<G-E;65N="!S
M=&%T=7,@9G)O;2!T:&4@0V5N=&5R<R!F;W(@365D:6-A<F4@86YD($UE9&EC
M86ED(%-E<G9I8V5S("A#35,I(&9O<B!/;6ED<FEA+"!E9F9E8W1I=F4@2F%N
M=6%R>2`Q+"`R,#$U+B!087-S+71H<F]U9V@@<W1A='5S(&%L;&]W<R!F;W(@
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M,34N/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.W!A9&1I;F<M=&]P.C9P>#MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,S)P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!397!T96UB97(@,C`Q,RP@
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M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
M-G!X.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B`\+V9O;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0
M<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A
M9&1I;F<M=&]P.C$X<'@[=&5X="UI;F1E;G0Z,39P>#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z:71A;&EC.SY"87-I<R!O9B!0<F5S96YT871I
M;VX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[
M<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD96YT.C,R<'@[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^3W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!I;F-L=61E('1H92!F:6YA;F-I86P@<&]S:71I;VX@86YD(')E<W5L=',@
M;V8@;W!E<F%T:6]N<R!O9B!/;65R;W,@0V]R<&]R871I;VX@*$]M97)O<RD@
M86YD(&]U<B!W:&]L;'D@;W=N960@<W5B<VED:6%R:65S+B`@06QL(&EN=&5R
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M*$=!05`I(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!A;F0@
M=VET:"!T:&4@:6YS=')U8W1I;VYS('1O($9O<FT@,3`M42!A;F0@4G5L92`Q
M,"TP,2!O9B!296=U;&%T:6]N(%,M6"X@5&AE(&EN9F]R;6%T:6]N(&%S(&]F
M(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(&9O
M<B!T:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SYT:')E92!A;F0@;FEN93PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!M;VYT:',@96YD
M960@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^(&EN8VQU9&5S(&%L;"!A9&IU<W1M96YT<RP@
M=VAI8V@@:6YC;'5D92!N;W)M86P@<F5C=7)R:6YG(&%D:G5S=&UE;G1S+"!N
M96-E<W-A<GD@=&\@<')E<V5N="!F86ER;'D@;W5R(&EN=&5R:6T@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N+B`@5&AE($-O;G-O;&ED871E9"!"86QA;F-E(%-H
M965T(&%T(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MF;VYT
M+7-T>6QE.FYO<FUA;#MF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UD96-O<F%T
M:6]N.FYO;F4[)SY$96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT
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M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT
M+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B!F:6QE9"!W:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG
M92!#;VUM:7-S:6]N("A314,I(&]N($UA<F-H(#$S+"`R,#$T+CPO9F]N=#X\
M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$X<'@[=&5X="UI;F1E;G0Z
M,39P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z:71A;&EC.SY5
M<V4@;V8@17-T:6UA=&5S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI
M<75I9&ET>2!$:7-C;&]S=7)E(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M
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M.V9O;G0M<VEZ93HQ,'!T.SY!<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/E-E<'1E;6)E<B8C,38P.S,P+"`R
M,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^+"!W92!H860@/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P
M,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,C$N."!M:6QL:6]N/"]F;VYT
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M+V9O;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GDL(%!O;&EC>2!;4&]L:6-Y
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P
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M;VX@36%Y(#,P+"`R,#$T+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E9VUE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O<#HQ
M.'!X.W1E>'0M:6YD96YT.C$V<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FET86QI8SL^4V5G;65N=',\+V9O;G0^/"]D:78^/&1I=B!S='EL
M93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M:6YD
M96YT.C,R<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5V4@;W!E<F%T92!I;B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
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M/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5W($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',@
M86YD($-H86YG97,@:6X@06-C;W5N=&EN9R!0<FEN8VEP;&5S(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT
M;W`Z,3AP>#MT97AT+6EN9&5N=#HQ-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M9F]N="US='EL93II=&%L:6,[/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC
M96UE;G1S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/DEN($%U9W5S="`R,#$T+"!T:&4@1FEN86YC:6%L($%C
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M1&5C96UB97(F(S$V,#LQ-2P@,C`Q-BX@5V4@9&\@;F]T(&5X<&5C="!T:&4@
M861O<'1I;VX@;V8@=&AI<R!G=6ED86YC92!T;R!H879E(&%N>2!I;7!A8W0@
M;VX@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;BP@<F5S=6QT<R!O9B!O<&5R871I
M;VYS(&]R(&-A<V@@9FQO=W,N/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6EN9&5N=#HS
M,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DEN($UA>2`R,#$T+"!T:&4@1FEN
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M9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?969E,F8V,#=?-6)D-U\T,C$T7SAF9#1?8F4T-C!C-6,W-#)A#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F93)F-C`W7S5B9#=?-#(Q
M-%\X9F0T7V)E-#8P8S5C-S0R82]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@3&]S<R!0
M97(@4VAA<F4@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!097(@4VAA<F4@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%L8W5L871I;VX@;V8@2&ES=&]R:6-A;"!/=71S=&%N9&EN9R!$:6QU
M=&EV92!396-U<FET:65S($YO="!);F-L=61E9"!I;B!$:6QU=&5D($QO<W,@
M<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
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M+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R
M;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0U('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD
M.SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.FUI9&1L93MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/C(P,3,\+V9O;G0^/"]D:78^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^-C`T+#,R-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
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M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXW+#,X-"PS,C4\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
M;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C<L-3$X+#,T.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T
M86)L93X\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E
M-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R
M9C8P-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3
M:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^1F%I<BU686QU92!-96%S=7)E;65N=',@*%1A8FQE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!!<W-E=',@86YD
M($QI86)I;&ET:65S($UE87-U<F5D(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R
M:6YG($)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
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M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P
M>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W=I9'1H.C$P,"4[8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W1E>'0M
M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V(')O=W-P86X],T0Q
M/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$-#4E(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q,24@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q,24@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0Q,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HX<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,34@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M.'!T.V9O;G0M=V5I9VAT.F)O;&0[/E-E<'1E;6)E<B`S,"P@,C`Q-#PO9F]N
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/E1O=&%L/"]F
M;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI
M9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
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M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,2PP,S`\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q
M,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(Q
M+#`S,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB
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M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/C(Q+#<P.3PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP
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M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P
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M;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C-P>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C$L-S`Y
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HY<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT
M.C$R,"4[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D
M9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/D1E8V5M8F5R(#,Q
M+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT
M+7=E:6=H=#IB;VQD.SY,979E;"`Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M.'!T.V9O;G0M=V5I9VAT.F)O;&0[/DQE=F5L)B,Q-C`[,CPO9F]N=#X\+V1I
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
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M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXQ,BPW,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C$R+#<Q-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3,L-C`Y/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R
M,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
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M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T
M,C$T7SAF9#1?8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7
M;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY!8V-R=65D($QI86)I;&ET:65S("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4&%Y86)L97,@86YD($%C8W)U86QS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@3&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
M=&]P.C9P>#MT97AT+6EN9&5N=#HS,G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/D%C8W)U960@;&EA8FEL:71I97,@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I
M;F<Z/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M
M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H
M=#IB;VQD.SY397!T96UB97(F(S$V,#LS,"P@/&)R(&-L96%R/3-$;F]N92\^
M,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB
M;VQD.SY$96-E;6)E<B8C,38P.S,Q+"`\8G(@8VQE87(],T1N;VYE+SXR,#$S
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV
M+#(U,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXS+#DT-#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T,C$T7SAF9#1?
M8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F
M93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7;W)K<VAE971S
M+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY2979E;G5E(%)E=F5N=64@8GD@06=R965M96YT("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5V96YU92!296-O9VYI=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET
M:6]N+"!-=6QT:7!L92UD96QI=F5R86)L92!!<G)A;F=E;65N=',L($1E<V-R
M:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'@[=&5X="UI;F1E;G0Z,'!X.VQI;F4M:&5I9VAT.FYO<FUA;#MP861D
M:6YG+71O<#HQ,'!X.SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=VED=&@Z,3`P)3MB;W)D97(M8V]L;&%P<V4Z8V]L
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SY4:')E92!-;VYT:',@
M16YD960@)B,Q-C`[/&)R(&-L96%R/3-$;F]N92\^)B,Q-C`[4V5P=&5M8F5R
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SY.:6YE($UO;G1H<R!%
M;F1E9"8C,38P.SQB<B!C;&5A<CTS1&YO;F4O/B8C,38P.U-E<'1E;6)E<B`S
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW
M96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z-'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C1P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0W('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@8V]L<W!A;CTS1#<@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C
M;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO
M=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C$T/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
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M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C$Y-CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
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M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P
M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PT,S$\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE
M+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-H87)E:&]L9&5R<R<@
M17%U:71Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F
M(%-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4L(%=A<G)A;G1S(&]R(%)I9VAT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M=#L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4]
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M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\
M9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[
M;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ
M,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT+6%L:6=N.FQE9G0[
M)SX\='(^/'1D(&-O;'-P86X],T0U(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\
M='(^/'1D('=I9'1H/3-$,S`E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M+SY397!T96UB97(@,S`L(#(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/D5X97)C:7-E
M(%!R:6-E/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DUA<F-H
M)B,Q-C`[,CDL(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D]C=&]B
M97(F(S$V,#LR,2P@,C`Q-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C(P+C`P/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
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M-C`[,C$L(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C,P+C`P/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M,'!T.SY/8W1O8F5R)B,Q-C`[,C$L(#(P,34\+V9O;G0^/"]D:78^/"]T9#X\
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O
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M-BP@,C`Q-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F
M-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B930V
M,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T@^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T
M:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L
M871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H
M961U;&4@;V8@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@4W1O8VL@3W!T
M:6]N<RP@5F%L=6%T:6]N($%S<W5M<'1I;VYS(%M486)L92!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M,T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[9F]N="US:7IE
M.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD
M96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W=I9'1H.C$P,"4[8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W1E>'0M86QI
M9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V(')O=W-P86X],T0Q/CPO
M=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$-3`E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/"]T9#X\=&0@=VED=&@],T0X)2!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,R4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\+W1D/CQT9"!W:61T:#TS1#@E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0T)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/'1D('=I9'1H/3-$."4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#,E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0X)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O
M;G0M=V5I9VAT.F)O;&0[/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\
M8G(@8VQE87(],T1N;VYE+SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M
M=V5I9VAT.F)O;&0[/DYI;F4@36]N=&AS)B,Q-C`[16YD960\8G(@8VQE87(]
M,T1N;VYE+SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N
M="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O
M=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$T/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L
M<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG
M:'0Z,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE
M.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
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M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXX+C,Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV+C<S
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^.#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)3PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z
M,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E
M<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXE/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^,2XY-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C$N-C8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)3PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z
M:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2XY
M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M;&EG;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXE/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@
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M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
M;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT
M97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P
M.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT
M97AT+6%L:6=N.FQE9G0[)SX\='(^/'1D(&-O;'-P86X],T0Q-B!R;W=S<&%N
M/3-$,3X\+W1D/CPO='(^/'1R/CQT9"!W:61T:#TS1#0V)2!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/"]T9#X\=&0@=VED=&@],T0R)2!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X]
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M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/E1H<F5E($UO;G1H<R!%;F1E9"`F
M(S$V,#L\8G(@8VQE87(],T1N;VYE+SXF(S$V,#M397!T96UB97(@,S`L/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/DYI;F4@36]N=&AS($5N9&5D)B,Q
M-C`[/&)R(&-L96%R/3-$;F]N92\^)B,Q-C`[4V5P=&5M8F5R(#,P+#PO9F]N
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L
M9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D
M96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[
M9F]N="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0W('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D
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M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C<X-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.#0P/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
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M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR+#(Y
M,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB
M<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#8V-3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
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M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C4L,#@S
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VX@
M06-T:79I='D@86YD(%)E;&%T960@26YF;W)M871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[=&5X="UI;F1E
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M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M
M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT
M+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P
M<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT
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M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`E(')O=W-P86X],T0Q(&-O;'-P86X]
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M.F)O;&0[/D-O;G1R86-T=6%L)B,Q-C`[($QI9F4\+V9O;G0^/"]D:78^/&1I
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M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M0F%L86YC92!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV
M+#DV.2PS,#,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C8N,S@\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\
M8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
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M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$X-"PR-3`\+V9O;G0^
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,BXP,#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O
M=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L
M;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/C8N,SD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O
M/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I
M;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A
M9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^1F]R9F5I=&5D
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@R,30L,C(S/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXY
M+C@R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE
M+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.C$P<'0[/D)A;&%N8V4@870@4V5P=&5M8F5R(#,P+"`R,#$T/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O
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M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N
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M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-BXT,CPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C8N-#8\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
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M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C
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M<'1E;6)E<B`S,"P@,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^-BPU-S<L-C`S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/C8N,S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X
M(&1O=6)L92`C,#`P,#`P.V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXT,BPQ-#$\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY%>&5R8VES86)L
M92!A="!397!T96UB97(@,S`L(#(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ
M,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
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M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C4N
M,3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
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M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?-6)D-U\T,C$T7SAF
M9#1?8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R82]7;W)K<VAE
M971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$541SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/G-E9VUE;G0\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN
M9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H+"!#87-H($5Q=6EV86QE;G1S+"!A
M;F0@4VAO<G0M=&5R;2!);G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R,2XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!E<F%T:6YG('-E9VUE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)"044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3F5T($QO<W,@4&5R(%-H87)E("T@0V%L8W5L
M871I;VX@;V8@2&ES=&]R:6-A;"!/=71S=&%N9&EN9R!$:6QU=&EV92!396-U
M<FET:65S($YO="!);F-L=61E9"!I;B!$:6QU=&5D($QO<W,@4&5R(%-H87)E
M("A$971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E
M9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=71S=&%N9&EN9R!D:6QU=&EV92!S96-U<FET:65S(&YO="!I
M;F-L=61E9"!I;B!D:6QU=&5D(&QO<W,@<&5R('-H87)E(&-A;&-U;&%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,X-"PS,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4Q
M."PS-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]U='-T86YD:6YG(&]P=&EO;G,@=&\@<'5R8VAA<V4@8V]M;6]N
M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O
M;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=71S=&%N9&EN9R!D:6QU=&EV92!S96-U<FET:65S(&YO="!I;F-L=61E9"!I
M;B!D:6QU=&5D(&QO<W,@<&5R('-H87)E(&-A;&-U;&%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<W.2PY.3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DP.2PS,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E
M8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG
M<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@9&EL=71I=F4@
M<V5C=7)I=&EE<R!N;W0@:6YC;'5D960@:6X@9&EL=71E9"!L;W-S('!E<B!S
M:&%R92!C86QC=6QA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C`T+#,R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8P.2PP,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C
M-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U
M8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#(U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%2$-!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&
M86ER+59A;'5E($UE87-U<F5M96YT<R`M($9I;F%N8VEA;"!!<W-E=',@86YD
M($QI86)I;&ET:65S($UE87-U<F5D(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R
M:6YG($)A<VES("A$971A:6PI("A&86ER(%9A;'5E+"!-96%S=7)E;65N=',L
M(%)E8W5R<FEN9RP@55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S
M(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@0F%S:7,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C$L-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q,RPV,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y($UA<FME="!&=6YD<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!6
M86QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U
M<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]N97DM;6%R:V5T(&9U;F1S(&-L
M87-S:69I960@87,@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36]N97DM;6%R:V5T(&9U;F1S(&-L87-S
M:69I960@87,@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$L,#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S$W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VX@0W5R<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I
M<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!2
M96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]N97DM;6%R:V5T(&9U;F1S
M(&-L87-S:69I960@87,@<F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64L($EN<'5T<RP@
M3&5V96P@,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S
M=7)E9"!O;B!296-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#<P.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8P.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!686QU92P@26YP=71S+"!,979E;"`Q('P@36]N97D@36%R:V5T($9U;F1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&
M86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N
M(%)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2UM87)K970@9G5N
M9',@8VQA<W-I9FEE9"!A<R!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2UM87)K970@9G5N9',@
M8VQA<W-I9FEE9"!A<R!S:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PP,S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW,3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L
M=64L($EN<'5T<RP@3&5V96P@,2!\($YO;B!#=7)R96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!
M<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!"
M87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2UM87)K970@9G5N9',@8VQA<W-I9FEE
M9"!A<R!R97-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C
M-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U
M8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#(V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%24)!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&
M86ER+59A;'5E($UE87-U<F5M96YT<R`M($YA<G)A=&EV92`H1&5T86EL*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD
M($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C
M=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@97AC;'5D960@9G)O;2!F
M86ER('9A;'5E(&AI97)A<F-H>2!D:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L
M:7IE9"!'86EN("A,;W-S*2!O;B!);G9E<W1M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P139)04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<R`M($%C8W)U960@3&EA8FEL:71I
M97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!A>6%B;&5S(&%N9"!!8V-R
M=6%L<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=')A8W0@<F5S96%R8V@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW-#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@U.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W5L=&EN9R`F
M86UP.R!P<F]F97-S:6]N86P@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PU,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC
M86P@=')I86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R(&%C8W)U86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!A8V-R=65D(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,C4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#DT-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969E,F8V,#=?
M-6)D-U\T,C$T7SAF9#1?8F4T-C!C-6,W-#)A#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C
M-S0R82]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%3D%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&5S(%!A>6%B;&4@*$1E=&%I;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XR($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CY/>&9O<F0@36ED8V%P($QO86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY/>&9O<F0@36ED
M8V%P($QO86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`P-"P@,C`Q-#QB<CY/>&9O<F0@36ED8V%P($QO86X@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`P
M-"P@,C`Q-#QB<CY/>&9O<F0@3&]A;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B
M="!);G-T<G5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N(&%N9"!S96-U<FET
M>2!A9W)E96UE;G0L(&5X:7-T:6YG(&]U='-T86YD:6YG(&EN9&5B=&5D;F5S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<&%Y;65N=',@;V8@1&5B=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O9B!$96)T
M(%)E<W1R=6-T=7)I;F<@0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,38P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!)<W-U86YC92!O
M9B!,;VYG+71E<FT@1&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(L-CDY+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BPV.3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T
M(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDN,C4E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E8G0@26YS=')U;65N="P@1&%T92!O9B!&:7)S="!297%U:7)E9"!0
M87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!<'(@
M,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L(%!E<FEO9&EC(%!A>6UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(Q+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96)T($EN<W1R=6UE;G0L($9E92!!;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(%!R97!A
M>6UE;G0@4&5N86QT>2!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L($1E9F%U;'0@26YT97)E<W0@
M4F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5B="!)<W-U86YC92!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO<G1I>F5D(&)A;&%N
M8V4@;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PX-3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO<G1I>F5D(&)A;&%N8V4@;V8@
M9&5B="!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P
M8S5C-S0R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P
M-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E
M=#(Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%24A!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY2979E;G5E("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY2979E;G5E(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,U.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L-#,Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VUA;&P@0G5S:6YE<W,@26YN
M;W9A=&EV92!297-E87)C:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E
M;G5E(&9R;VT@1W)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Y-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8Q+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D=6-T:6]N(&]F
M(&5Q=6EP;65N="!C;W-T(&)A<VES('!U<F-H87-E9"!W:71H(&=R86YT(&9U
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5M86EN:6YG(&%V86EL86)L92!A;6]U;G0@=6YD97(@9W)A
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#4L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#8Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5G5L8V%N($EN8V]R<&]R871E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V
M96YU92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=',@<F5C96EV960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!2979E;G5E+"!2979E;G5E(%)E8V]G;FEZ
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#DW,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V5F93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?
M.&9D-%]B930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%5E1!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,30\8G(^3&5A<V5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I
M;VYS('1O(&5X=&5N9"!T:&4@;&5A<V4@=&5R;3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!T;R!E>'1E;F0@=&AE(&QE
M87-E('1E<FTL(&YU;6)E<B!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5M86EN:6YG(&%G9W)E9V%T
M92!R96YT('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-3DL-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4Y+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L-S<R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDL-#(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#$Y-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPQ,3$L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;E9E;G1I=B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE
M<R!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;W)D960@56YC;VYD:71I
M;VYA;"!0=7)C:&%S92!/8FQI9V%T:6]N+"!$=64@:6X@4F5M86EN9&5R(&]F
M($9I<V-A;"!996%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]R9&5D(%5N8V]N9&ET:6]N86P@4'5R
M8VAA<V4@3V)L:6=A=&EO;BP@0VAA;F=E(&]F($%M;W5N="!A<R!297-U;'0@
M;V8@5F%R:6%B;&4@0V]M<&]N96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1%--(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5;G)E8V]R9&5D(%5N8V]N9&ET:6]N86P@4'5R8VAA<V4@3V)L:6=A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$Y+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^2&5L:6]N($)I;W1E8V@@07!3/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#
M;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5L;&EN9RP@1V5N97)A;"!A;F0@
M061M:6YI<W1R871I=F4@17AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@
M1W)A;G1S(%5N9&5R(%)E=FEE=SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15HS0DD^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4VAA<F5H;VQD97)S)R!%<75I='D@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$P/&)R/G=A<G)A;G0\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R.2P@,C`P
M-SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/D]X9F]R9#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/E=A<G)A;G0M4V5R:65S($4\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY397)I
M97,@12!-;V0@,5$Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/E-E<FEE<R!%($UO9"`S43$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^5V%R
M<F%N="!/;F4\8G(^5G5L8V%N($EN8V]R<&]R871E9#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$P/&)R/E=A<G)A;G0@
M3VYE/&)R/E9U;&-A;B!);F-O<G!O<F%T960\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY787)R86YT(%1W;SQB
M<CY6=6QC86X@26YC;W)P;W)A=&5D/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,S$L(#(P,3`\8G(^5V%R<F%N="!4=V\\8G(^5G5L
M8V%N($EN8V]R<&]R871E9#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$T/&)R/E=A<G)A;G0@5&AR964\8G(^5G5L8V%N
M($EN8V]R<&]R871E9#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y/8W0N(#,Q+"`R,#$P/&)R/E=A<G)A;G0@5&AR964\8G(^5G5L8V%N($EN
M8V]R<&]R871E9#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R:6]D+"!3:&%R97,L($YE
M=R!)<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@4')I8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!A>6UE;G1S(&]F(%-T;V-K($ES<W5A;F-E($-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VLL(&YE="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S<L-S4T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#$R,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!P=7)C:&%S92!B>2!W87)R
M86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3(L-S@Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y
M,BPW.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.3(L-S@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Y-RPT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PU,SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S,L,S,S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S+#,S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M,RPS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,S+#,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S,RPS,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@97AP:7)A=&EO
M;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!
M<'(@,C8L#0H)"3(P,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^4V5P(#(Y+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#(Y+`T*"0DR,#$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M3V-T(#(Q+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/D]C="`R,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W0@,C$L#0H)"3(P
M,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BXR-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C(U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BXR-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y+C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&%S<R!O
M9B!787)R86YT(&]R(%)I9VAT+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C`T+#,R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#0L,S(W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`T+#,R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!686QU92!!9&IU<W1M96YT(&]F(%=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-C,L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M-3(L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0Q,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&%S<R!O9B!787)R86YT(&]R(%)I
M9VAT+"!%>&5R8VES960@1'5R:6YG(%!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PV.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES
M<W5E9"!$=7)I;F<@4&5R:6]D+"!3:&%R97,L($]T:&5R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#,P-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#@X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@5V%R<F%N="!%>&5R8VES97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-RPX,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;&%S<R!O9B!787)R86YT(&]R(%)I9VAT+"!%>&5R8VES92!0<FEC92!O9B!7
M87)R86YT<R!O<B!2:6=H=',L(%=E:6=H=&5D($%V97)A9V4@4')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+CDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+CDT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,N.30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!W87)R86YT<R!I<W-U960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,U%!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I
M;VX@+2!.87)R871I=F4@*$1E=&%I;"D@*%531"`D*3QB<CY);B!-:6QL:6]N
M<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,30\8G(^17%U:71Y($EN8V5N=&EV92!0;&%N(#(P,#@\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB<CY%
M<75I='D@26YC96YT:79E(%!L86X@,C`P.#QB<CY3=&]C:R!/<'1I;VX\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB
M<CY%<75I='D@26YC96YT:79E(%!L86X@,C`P.#QB<CY-87AI;75M/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,30\8G(^
M4W5B<V5Q=65N="!%=F5N=#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS+"!M87AI;75M('1E<FT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#`@;6]N=&AS(#(U
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-2!Y96%R<R`Y(&UO;G1H<R`Q-R!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,@,3$@;6]N
M=&AS(#@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<U('EE87)S(#D@;6]N=&AS(#$W(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;G,L(&%V97)A9V4@=F5S=&EN9R!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC<F5A<V4@:6X@875T:&]R:7IE9"!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,3<L.3<U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO
M;G,L(&YU;6)E<B!O9B!S:&%R97,@<F5S97)V960@9F]R(&ES<W5A;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PW-#$L,C<V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA
M<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3G5M8F5R(&]F(%-H87)E<R!!=F%I
M;&%B;&4@9F]R($=R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PY-C$L,C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;G9E<W1E9"!O<'1I;VYS(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`R-"PP,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPP,C0L,#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N=F5S=&5D(&]P=&EO;G,@;W5T<W1A;F1I;F<L
M('9E<W1I;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<R('EE87)S(#`@;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96-O9VYI
M>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$Q+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@:6X@<&5R
M:6]D("AS:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X-"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D(&EN('!E<FEO9"`H55-$
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$Q+C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15!&044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N("T@1F%I<B!686QU92!O9B!%;7!L;WEE
M92!/<'1I;VX@1W)A;G0@17-T:6UA=&5D(&]N($1A=&4@;V8@1W)A;G0@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@
M;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A
M>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I
M;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!796EG:'1E9"!!=F5R86=E($=R86YT
M($1A=&4@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,"XQ.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BXW-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@."XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXW,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"P@1F%I<B!686QU92!!<W-U;7!T:6]N<R!A;F0@365T
M:&]D;VQO9WD@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#<N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>'!E8W1E9"!T97)M+"!I;B!Y96%R<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,@,"!M;VYT:',@,C4@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U
M('EE87)S(#D@;6]N=&AS(#$W(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Q,2!M;VYT:',@."!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S4@>65A<G,@.2!M;VYT:',@,3<@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R
M97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N.34E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XV-B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$N-C4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F
M93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B
M930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#,T+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M6D]!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP
M96YS871I;VX@+2!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H
M1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC
M92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C
M;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8V-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPR,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L
M,#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T+#,V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L
M;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3$X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M96QL:6YG+"!'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%
M;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL
M;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<X-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#0P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PX
M-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F
M93)F-C`W7S5B9#=?-#(Q-%\X9F0T7V)E-#8P8S5C-S0R80T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9F4R9C8P-U\U8F0W7S0R,31?.&9D-%]B
M930V,&,U8S<T,F$O5V]R:W-H965T<R]3:&5E=#,U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M6$Y!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP
M96YS871I;VX@+2!3=6UM87)Y(&]F(%-T;V-K($]P=&EO;B!!8W1I=FET>2!A
M;F0@4F5L871E9"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<'1I;VYS($]U='-T86YD:6YG/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC
M92`H<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY
M-CDL,S`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'<F%N=&5D("AS:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#0L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960@*'-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U.2PS,S(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960@
M*'-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-"PR
M,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;F1I;F<@8F%L86YC92`H<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPW-SDL.3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960@86YD(&5X<&5C=&5D
M('1O('9E<W0@*'-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L-3<W+#8P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V%B;&4@*'-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S4U+#DY,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG
M:'1E9"U!=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3:&%R93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG
M(&)A;&%N8V4@*%531"!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8N,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@*%531"!P97(@<VAA<F4I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960@
M*%531"!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8N,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9O<F9E:71E9"`H55-$('!E<B!S:&%R92D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2XX,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4@
M*%531"!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8N-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="`H55-$('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXS
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V%B;&4@*%531"!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4N,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960M($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('EE
M87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,@
M-2!M;VYT:',@,34@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T
M("AI;B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V
M('EE87)S(#0@;6]N=&AS(#(R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE("AI;B!Y96%R
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#8@
M;6]N=&AS(#$T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06=G<F5G871E($EN=')I;G-I8R!6
M86QU93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M,BPW.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L,30Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-BPQ-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F93)F-C`W7S5B9#=?
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M:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,U+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]E9F4R9C8P
A-U\U8F0W7S0R,31?.&9D-%]B930V,&,U8S<T,F$M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2010</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 214,000<span></span></td>
        <td class="nump">$ 196,000<span></span></td>
        <td class="nump">$ 359,000<span></span></td>
        <td class="nump">$ 1,431,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Small Business Innovative Research</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from Grants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">214,000<span></span></td>
        <td class="nump">196,000<span></span></td>
        <td class="nump">359,000<span></span></td>
        <td class="nump">461,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding', window );">Reduction of equipment cost basis purchased with grant funding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RemainingGrantFunding', window );">Remaining available amount under grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">785,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">785,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">359,000<span></span></td>
        <td class="nump">461,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vulcan Incorporated</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromGrantors', window );">Grants received</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">8,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred Revenue, Revenue Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 970,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction of equipment cost basis purchased with grant funding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_Reductionofequipmentcostbasispurchasedwithgrantfunding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_RemainingGrantFunding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total available remaining grant funding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_RemainingGrantFunding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_RevenueLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_RevenueLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromGrantors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromGrantors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EENAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">2 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Oxford Midcap Loan [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Oxford Midcap Loan [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 04, 2014

</div>
          <div>Oxford Midcap Loan [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 04, 2014

</div>
          <div>Oxford Loan Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan and security agreement, existing outstanding indebtedness</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 32,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Payments of Debt Restructuring Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">160,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
        <td class="nump">12,699,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">12,699,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.25%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Debt Instrument, Date of First Required Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Apr.
				01,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,021,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_DebtPrepaymentPenaltyRate', window );">Debt Prepayment Penalty Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_AdditionalDefaultInterestRate', window );">Additional Default Interest Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt Issuance Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">244,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized balance of debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,851,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized balance of debt issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 284,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_AdditionalDefaultInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional Default Interest Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_AdditionalDefaultInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_DebtPrepaymentPenaltyRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Prepayment Penalty Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_DebtPrepaymentPenaltyRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the fee that accompanies borrowing money under the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFeeAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments including both interest and principal payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfDebtRestructuringCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Leases</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_OperatingLeaseNumberOfAdditionalRenewalOption', window );">Number of Options to extend the lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_LeaseExtensionPeriod', window );">Options to extend the lease term, number of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Remaining aggregate rent payable</a></td>
        <td class="nump">$ 59,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 59,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
        <td class="nump">11,772,000<span></span></td>
        <td class="nump">9,420,000<span></span></td>
        <td class="nump">36,196,000<span></span></td>
        <td class="nump">26,111,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">InVentiv [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear', window );">Recorded Unconditional Purchase Obligation, Due in Remainder of Fiscal Year</a></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents', window );">Unrecorded Unconditional Purchase Obligation, Change of Amount as Result of Variable Components</a></td>
        <td class="nump">630,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">630,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">DSM [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unrecorded Unconditional Purchase Obligation</a></td>
        <td class="nump">519,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">519,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Helion Biotech ApS</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling, General and Administrative Expenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_GovernmentGrantsUnderReview', window );">Government Grants Under Review</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 900,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_CommitmentsAndContingenciesDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_CommitmentsAndContingenciesDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_GovernmentGrantsUnderReview">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants received by entity between 2004 and 2007 under administrative review.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_GovernmentGrantsUnderReview</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_LeaseExtensionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease Extension Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_LeaseExtensionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_OperatingLeaseNumberOfAdditionalRenewalOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating Lease Number Of Additional Renewal Option</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_OperatingLeaseNumberOfAdditionalRenewalOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the recorded unconditional purchase obligation maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25336-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of change that payments under a contractual obligation might vary as facts and circumstances change.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecordedUnconditionalPurchaseObligationChangeOfAmountAsResultOfVariableComponents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZ3BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>warrant</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 29, 2007</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Oxford</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrant-Series E</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Series E Mod 1Q14</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Series E Mod 3Q14</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrant One

</div>
          <div>Vulcan Incorporated</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Warrant One

</div>
          <div>Vulcan Incorporated</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrant Two

</div>
          <div>Vulcan Incorporated</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Warrant Two

</div>
          <div>Vulcan Incorporated</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrant Three

</div>
          <div>Vulcan Incorporated</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Warrant Three

</div>
          <div>Vulcan Incorporated</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
        <td class="nump">$ 11.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 11.50<span></span></td>
        <td class="nump">$ 11.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">37,754,000<span></span></td>
        <td class="nump">16,120,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock to purchase by warrant</a></td>
        <td class="nump">192,789<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">192,789<span></span></td>
        <td class="nump">192,789<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">197,478<span></span></td>
        <td class="nump">11,539<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">133,333<span></span></td>
        <td class="nump">133,333<span></span></td>
        <td class="nump">133,333<span></span></td>
        <td class="nump">133,333<span></span></td>
        <td class="nump">133,333<span></span></td>
        <td class="nump">133,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_WarrantExpirationDate', window );">Warrant expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Apr. 26,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep. 29,
				 2014<span></span></td>
        <td class="text">Mar. 29,
				 2015<span></span></td>
        <td class="text">Oct. 21,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 21,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 21,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
        <td class="nump">$ 12.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.25<span></span></td>
        <td class="nump">$ 12.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.25<span></span></td>
        <td class="nump">$ 9.13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20.00<span></span></td>
        <td class="nump">$ 20.00<span></span></td>
        <td class="nump">$ 30.00<span></span></td>
        <td class="nump">$ 30.00<span></span></td>
        <td class="nump">$ 40.00<span></span></td>
        <td class="nump">$ 40.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
        <td class="nump">604,327<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">604,327<span></span></td>
        <td class="nump">604,327<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(863,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(452,000)<span></span></td>
        <td class="num">(411,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ClassofWarrantorRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period</a></td>
        <td class="nump">4,689<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
        <td class="nump">3,305<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,088<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 37,828<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights, Weighted Average Price</a></td>
        <td class="nump">23.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23.94<span></span></td>
        <td class="nump">23.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ClassofWarrantorRightNumberofWarrantsIssued', window );">Number of warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ClassofWarrantorRightExercisedDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Exercised During Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ClassofWarrantorRightExercisedDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Weighted Average Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ClassofWarrantorRightNumberofWarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Number of Warrants Issued</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ClassofWarrantorRightNumberofWarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_WarrantExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant expiration date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_WarrantExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, Cash Equivalents and Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, all investments are classified as short-term and available-for-sale on the accompanying Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. Investment income consists primarily of interest income.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3QAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Equity Incentive Plan 2008</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Equity Incentive Plan 2008

</div>
          <div>Stock Option</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Equity Incentive Plan 2008

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014

</div>
          <div>Subsequent Event</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Stock options, maximum term</a></td>
        <td class="text">6 years 0 months 25 days<span></span></td>
        <td class="text">5 years 9 months 17 days<span></span></td>
        <td class="text">5 years 11 months 8 days<span></span></td>
        <td class="text">5 years 9 months 17 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, average vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized', window );">Increase in authorized shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,517,975<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock options, number of shares reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,741,276<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,961,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber', window );">Unvested options outstanding</a></td>
        <td class="nump">2,024,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,024,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested options outstanding, vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 0 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
        <td class="nump">$ 11.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 11.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted in period (shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">184,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted in period (USD per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 11.58<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested employee stock options as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation, Arrangement Share Based Payment Award, Additional Shares Authorized</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ShareBasedCompensationArrangementShareBasedPaymentAwardAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 750<span></span></td>
        <td class="nump">$ 1,384<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">Short-term investments</a></td>
        <td class="nump">21,030<span></span></td>
        <td class="nump">12,717<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grant and other receivables</a></td>
        <td class="nump">381<span></span></td>
        <td class="nump">379<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">1,052<span></span></td>
        <td class="nump">251<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">148<span></span></td>
        <td class="nump">86<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">23,361<span></span></td>
        <td class="nump">14,817<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">846<span></span></td>
        <td class="nump">939<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
        <td class="nump">679<span></span></td>
        <td class="nump">679<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">408<span></span></td>
        <td class="nump">100<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">25,294<span></span></td>
        <td class="nump">16,535<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">4,156<span></span></td>
        <td class="nump">2,329<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">6,250<span></span></td>
        <td class="nump">3,944<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable, net of discount</a></td>
        <td class="nump">3,991<span></span></td>
        <td class="nump">5,600<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">14,397<span></span></td>
        <td class="nump">11,873<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion and discount</a></td>
        <td class="nump">28,551<span></span></td>
        <td class="nump">14,898<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump">8,935<span></span></td>
        <td class="nump">8,148<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.01 per share: Authorized shares - 20,000,000 at September 30, 2014 (unaudited) and December 31, 2013; Issued and outstanding shares&#x2014;none</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01 per share: Authorized shares - 150,000,000 at September 30, 2014 (unaudited) and December 31, 2013; Issued and outstanding shares&#x2014;34,022,145 and 30,359,508 at September 30, 2014 (unaudited) and December 31, 2013, respectively</a></td>
        <td class="nump">340<span></span></td>
        <td class="nump">304<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">280,404<span></span></td>
        <td class="nump">235,685<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(307,333)<span></span></td>
        <td class="num">(254,373)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#x2019; deficit</a></td>
        <td class="num">(26,589)<span></span></td>
        <td class="num">(18,384)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#x2019; equity</a></td>
        <td class="nump">$ 25,294<span></span></td>
        <td class="nump">$ 16,535<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in equity securities and other forms of securities that provide ownership interests classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derived from our proprietary PharmacoSurgery platform, our first drug product Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;"> (phenylephrine and ketorolac injection) 1%/0.3% was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2014 for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. We began calling on ophthalmic surgeons and their staff in the U.S. in August 2014 regarding Omidria. In October 2014, we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria. Marketing and sales of Omidria in the European Union (EU) are subject to approval of our MAA and, most likely, entering into a partnership for European marketing and distribution. In addition to the EU, we plan to enter into one or more partnerships for the marketing and distribution of Omidria in other international territories.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> For Omidria and each of our product candidates and our programs, we have retained all manufacturing, marketing and distribution rights.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries.  All inter-company transactions between and among our subsidiaries have been eliminated.  The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information.  The Consolidated Balance Sheet at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> has been derived from audited financial statements but does not include all of the information and footnotes required by GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> filed with the Securities and Exchange Commission (SEC) on March 13, 2014.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future sales from Omidria and capital that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost or market. Capitalization of costs as inventory begins when the product has received regulatory approval in the U.S. or the EU. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. For Omidria, capitalization of costs as inventory began upon U.S. regulatory approval on May 30, 2014.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.</font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update, or ASU, No. 2014-15 related to disclosure of an entity&#8217;s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity&#8217;s ability to continue as a going concern at each reporting period for a period of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December&#160;15, 2016. We do not expect the adoption of this guidance to have any impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented, or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. This standard is effective for interim and annual periods beginning after December 15, 2016 and cannot be adopted before that effective date. We are currently evaluating the impact this standard may have on our financial statements once it is adopted.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (shares)</a></td>
        <td class="nump">6,969,303<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
        <td class="nump">184,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
        <td class="num">(159,332)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (shares)</a></td>
        <td class="num">(214,223)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (shares)</a></td>
        <td class="nump">6,779,998<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (shares)</a></td>
        <td class="nump">6,577,603<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
        <td class="nump">4,755,993<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (USD per share)</a></td>
        <td class="nump">$ 6.38<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
        <td class="nump">$ 12.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
        <td class="nump">$ 6.39<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited (USD per share)</a></td>
        <td class="nump">$ 9.82<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (USD per share)</a></td>
        <td class="nump">$ 6.42<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (USD per share)</a></td>
        <td class="nump">$ 6.32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (USD per share)</a></td>
        <td class="nump">$ 5.12<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance (in years)</a></td>
        <td class="text">6 years 5 months 15 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in years)</a></td>
        <td class="text">6 years 4 months 22 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
        <td class="text">5 years 6 months 14 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance</a></td>
        <td class="nump">$ 42,797<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
        <td class="nump">42,141<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
        <td class="nump">$ 36,147<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to stock option grants during the periods ended:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three&#160;Months&#160;Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average assumptions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense has been reported in our Consolidated Statements of Operations and Comprehensive Loss as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Stock Option Activity and Related Information</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity for all stock plans and related information is as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160; Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,969,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,577,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,755,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding dilutive securities not included in diluted loss per share calculation</a></td>
        <td class="nump">7,384,325<span></span></td>
        <td class="nump">7,518,348<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Outstanding options to purchase common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding dilutive securities not included in diluted loss per share calculation</a></td>
        <td class="nump">6,779,998<span></span></td>
        <td class="nump">6,909,332<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants to purchase common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding dilutive securities not included in diluted loss per share calculation</a></td>
        <td class="nump">604,327<span></span></td>
        <td class="nump">609,016<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basic and diluted net loss per share amounts for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,909,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,384,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,518,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, Issued shares</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Issued shares</a></td>
        <td class="nump">34,022,145<span></span></td>
        <td class="nump">30,359,508<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="nump">34,022,145<span></span></td>
        <td class="nump">30,359,508<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,909,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,384,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,518,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Nov. 06, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">OMER<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">OMEROS CORP<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001285819<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,075,924<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair-Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>36
<FILENAME>0001285819-14-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001285819-14-000012-xbrl.zip
M4$L#!!0````(`+"`:D6!IB^FM9@``$-8"``1`!P`;VUE<BTR,#$T,#DS,"YX
M;6Q55`D``YLH852;*&%4=7@+``$$)0X```0Y`0``[%WI<]LXEO^^5?L_<#RU
M7=U5D0T0X`'GF.+9XYVDG<3I8_=+BB8AB]T4J2$I'_O7[P,E4@<I67(D2W38
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MI(L#`QXVCX&&AN[\WA\T]Q<M#0/"^)9G>?.025L#-V&64!EKU:B[N[O38F22
MWD!W1,ZF/<H!L#Y_K>DMFJ^]C)?=8R_TLV::BB9!$EXD*4[B>#QL?D:0IV?Y
MPXB?0:<>].)IZ%?C'A^T.""!OQ9&B`^2[-1/AH5X$2.H[)OR_DJNU3-H+3MF
MH=_,+C0T,)OEHW1%?VAI&##.>C>>-ZK&]+WLNB!DVM``#&A)DXAGC6.*EN9!
M0F;-@XJ6ID%YRF]6RHF=07O9530$2PI1R7/2N-`U;^RJ3+KF\UW#=6".L]R+
M_0J>]S4XWY&B-V:,G16M5=<L:.H(T^*S/SZ\O_('?.C-.H>/=^Y5U(!]DJ0W
MXFGG6='TF?>EXNGG@P)Y`IF]$I.G0,K)M%FLQ-N3+!R.(F#J;#+1Q-3Y29SS
M^UP*@6X;QJ)/]-+/$<X3^`%K5O2M>H.I#O.'Z6?5IV$@/N^'/)4*PO@"5R54
MK8M_G;Q#P)NL*SIF;\Z6!Y>/.FMXUO1)(]#,)%A^/L@GS6WP'^\$`SWX'^%R
MEEG;TB`>!PM#")X].)@;4'XZ]^CRHZGLMA#G5[#B7]_S&R]R"NZ,^S#[*I;M
MZV_CR/?B"_"7Z2A)A2_\P(?7/#W``LSDRF^$<ZX^GC8$0,;]*`K],)_0*`4A
M])NX?6#P?(G!DW>"P_-5'+XY:YQT1LQ9$S4O"B7T$_YO+Q8H@1^`DJF5_OK!
M^S-)OP@S>MFW^75NQ('S[S'P>\4AA`CSD&<%@LK^5WGB_W4YRF$E)D*L6CY&
M7OR+-^0SP$TF@N40$KSEHL.7._C]X7_!O3GAS2!O)P"G')]O*+N3=^6`FO`>
M`^8VU,S+?ZH/FR[`0?2C<-G;Z<?4R^])/R[O(0,(WB=>7&%:K.H%.,>T2"%F
MR)YU-6Y2SD5CNZ%<9W0*H96<M@@SD&K0_6"&7/&1@"1J7Q`#<F';BY(!KWL6
M9:5\5N1E8%E_]]+4B_/+]+,P6#,=O!IX*<]$"N][V8#?\]0/,Y[T[R;]LW8K
MY$KFIWJY&?>'4M*C0M8D/.[-!3U7X^N,_WL,_#FW\(]PX8M!SF)[NY&T@MFY
MJ*2)VP,A9^N0F>XG9'8%=,@G\NF+W3[3#OY.VU*,9#\*."?&U7GIU="+(G.<
MA3'/LHLX3FX]$:U^YAGW4G_03NU;G:1NQ.Y!U*]EN.GJ&1TZ*I<MA#3D5SG,
M+UA^G_B>2+,7W'JI8I"GV_R61\E(='7N1[`2O)W8*7WX&O9GCGX#_CMD/0E9
M5SP2^X4_\YBG7@3R-8)A&(>03Q>V?2KBEJ<D&V%L*TET:"O0]C\M#3*W+<7L
M7XQ=D-F&(+--N.F"S`X=E9LW@*D@C,9"E69[/,Z]'XT#'KAI,K22X6B<%W[Q
MLN]X:2Q.$7WD:5&N,Q^:)U@()9SA*$H>.*_M%;4-<65$L$>AS<*.E5+K4'P0
M%$_KUAUR'T7N@J0ZM-;0VB7VK4[L6XZL+K%O56)_7&BCWT]BC^5];<+13WB^
M&O?8H0!X"+CH#TF`/V':;K5\]`A``Z^M.I7S/(A9?X;K0QCXWDB<;VHW6!XY
MP+7,9H>3XLQ1*[?WZ?8%[#V=KYD38U=Y/?K*:\MPTU5>.W1L'_:1*A1J)UJV
M#_Z6.>[04T-/5T-J;PVI_<CJ:DCMJ2$=']I:64-Z6J:W9S&N#C7_R2/`JADF
M.0<#.+IJIRJN#C2;^6M1#>!@R)A63UX8'N:YZE#P.`JZ$L;QE##:A)NNA-&A
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M7N0*"_Z@ZG,1C\9Y5G3`JZ?\P+ULG!9!HYL6;TCU'YKGF^N9?185DQ1BR7:[
MG95+,O5!RVNR2U^SV;+.'-&:==T36:N@T4#3&FP\E\]LIT9WZG=X]>MP_F2<
M5TE($O.'#U[Z%\_=<1QDG0L[`AVJ4IC&Q>E\6:?C>]+Q3B&/2"$[Y&^._,XY
M[4T7.K_0>NWHH-QA9B5F:/OJH'2/=5`0Q^K#MO;5AW8JP^I3LA5+!X#UP=;Q
M(OZMV)QZ:8NYR-?WM*+=5=B7M)K=E=;#76D]AO7O+A^VX%++LU\^?$'(["X1
MOKA+A"\)G=UEP'UB\[DO`SXC,KL+)D=PP>0`Z]T=D3HZ<![)&8UN^^"[U>A.
M_0ZO?AW.GXSS[HC4$>M0=T2JT_&#Z'BGD$>DD!WR-T=^YYRZ(U*==JS2C@[*
M'68VPDSW*H$C?)7`_G$`,$#:)_Q!6'>9M>S`G/C6"-*3V1Z$@M$G>NGG!'?O
MF3[<>Z;GX(]Z\/_N3XI^VTIWQS:.:/OQD,<V7@(ZNZ,;+_GHQHM`:'=\8Y_X
M/.#QC3VBDT)P&P86@*P[PW%T9SA(#]']+#HIWJJ;78YS,6L`&7S+<AL0#\8]
MI.Y"/.,XG,CF/?<RGBU)8CBI=TS0,>E1SE4VS<\O)FN</,P2*F/MZZ]7]E>@
MZVMA9Y:>%82W(*5EKL44OP!.P0`F-1LWHV+Z@'-X0!.!\W)IGG'N<3:/DV$8
MKW]@(9&"C4V>5Y^R;)WC^E$IQN,&JU,^=KKH\.N35FBJO.O6?]KE:=,7*K>6
M]$F7)\T^SH(54S^"BTUF+E_#W6JX/B;B_0#V;A(^K`/5M,MFBU,Z,,/WDW&<
M9Q^]!^\ZXM-#)=+4O'WF_;E[GE+`_7#H1=G;DQ[\510X/3_O69HM$\RP8LDZ
M4G6L(@,C5]9<0W:)K*`323RWF*N`%\6*"G;]S=EZ(IY&J'@3W4I"%=UV,=5-
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M^_WN])7&@($K4V5')=1`MJ8H*M$F:,6NC6QK64::OF0+-F)X9T+:Q_=#K!*-
M3$SDN(ZJ$W!"2#5,4S%*^T[!Q-<466.X3;+9#8!D"K[:M#15P:;*3*J)H&<*
M(,TP:P"2928?3$ID>S7[%@09CN+:%C,L4"S3L6V-FD8I&\-5W)JG)=KA$/0$
MV>P&0088':3*%K8(ADB#:)JN5U+2=;WF<2@ZI)H])X`LJF*7&3K3L643T#(=
MXU(T$&.RFF@T=DC\/*=UMBD#0VPR4\&.I<I8=Y%66F?P[;6L45:PWB;9[$:W
MJ&T:!C4,W8*0V4:."=Z^TBT%V34+I-,=^/?XF[YES1B*)/E1%_?\7WHW)^2+
M7]PY*6/FJA8R-0W+BBM31='U*ME&U)FW\V7Y3464R-J<G'<ALV=9!G*TRT"0
M:S#(;1U$-0L,IR/;M(SW+8KEQF5@"*MM7(9Z&K<D#!&-J2J%@-U67*1@V:F*
M56`-2(,P-*(#*)4V2N,`H%S]M:XKUT1!KHDAJS`,B`E=P[$!HN6::++1:"<8
M8H3([5V3U=)0;:(9+E%<3$TDJB468V6AQ+#=)G75P(D3JK=1&D?UQ<,KU\2`
MB)/J&J8,6X;JV*JN*"5";=.E30C5-,;8GM=$W/?)MBP:(H(UVQ1^P*'8!">`
MRS*G\!.U`!&K"EFJ&19/W8R2=15!!_R/K2*=80>;FD+A,6X9A&%0@'JH*C.Z
M(25/JERK!+L6L1Q;TTW;!C_AR%5EPX"(L28:JF.M@:#FBN]ZNM96IEU;UPA1
M*+)DHBB$VE;EP!U9KPN*$!5O1U=U@<`.,S]*Q!97H^SV=TUC%?.F8<L@>\M4
M;3#YCJX[AEYM@QF&6B\6B."ESGP#A[L6Q-'>YEHE6^Q`',0@_Z-$-P%EF%&C
M!!9R2:U(]1RR;=M-N94;!M31B*T81&-@2QRBNHI6[8I:9JU&(8,I.9!L]RP(
ME]F686JJ82+9U`@DA$JEP#:J5T*?+(A;+XS$!K+8AO"B.2>[L0:_W+<-K#0!
M%F4*Q>#LD*/9V&'4,:LZM676PP%96_9Y*\5^?,NS7UE:EBN[CF[H#A'G(13%
MTO0R<@>77*]K/XLLO[L7:ZP\3,%<)B-550UJ:+*LP:]&:9$-D];V/66,"&KM
M\NQ7EBI8;T=1D6-`5&J+/?#I]A9SL*73>DBZ!UE.+CS._G[BX25#9J"P(K?`
M5+.8ILK5:154W\W<1F=7$+AS_M;E#B96J4-5I+G$M51+5W37+4,\:KG?!/J-
M^#.]+,PN^],S7H"LCTD4^@^3?[\`'V8$:?CJ0MX,<LRD6-:Q0D221AFA9G4>
MSK4M^^3=#U'^.@AOI2Q_B/C;DSY,V>M[PS!Z./\2#D'Y?N%WTN=DZ,6OB[8L
M_#]^CM$H?WWRPTW^>FEX%,:\-^#B!.TYEM%_O1YY@3B+W<N3T3G61_>O!<&]
M,!8GI\^Q"A^LFE5\WD15&`\XB&YYW.1/T?U<G&\)_<E,A22EI"]]3'D&SRP*
M!6+Z,S&@?-89L+`M-^H2,T3>'3/%N,MQ*E8X@T4/Q*Z)U`]C+_9#+X*9IML]
MF13&12U$R@=\KL,HR8I3/Y(7!Q)P/H[R0@K)2!PYA8;BK\LA3Y-,LJ9W443_
M'R>?_50,3(""NT$210]2<A<#!=GX.@N#T$L!N*>29$01/#_G:<]/AB,O?I#R
MU(LS`%[QA&N>WW$^H<$;)O%-,>'\'-+`N^70#SKQ*"R.IO(`)OX"S'C^=%(0
M..B;-PY"(83')3*;<Y3RD9="OS`NIDL#Z,VENS`?2+^>7IU*-Y,=,>`/FOE(
M3.E5.@?#0;CA*`(Z?_S9,#[^)/63=,)P.)Q[=AC#YT.ODG<QOUB/L+B.,95&
MGDA@#(821KU/1;?/XXB+OQ`6:_&9WXRCR1Q7O3]."Q$L3%RL6`VY6P++3Z(D
M/?\[*OZ;P!=LX'3QSV-PE!/L70EA"&?V@S<<O?X[5M%K@EY)PL1\*PG%_(4`
MA#2%F)Z+J5Q<R"N>'(-B[X8/@'4^R"0.-B!X6:OS7,R(6&,W5$]-82:!1DM>
M=>(N>P5&+/0'E:F,A5)%8!:G8=MBWYC[/,N\]$%H[&CB-:0^Q'W""HX?T?^I
M[;+FC93I1879N1IPGDM>OKED'W'`BQ*><X`3!B>?W$W<U_2CU<M@`]M+D,(%
MI':T.`,OFQCE`/K<"MN=)D.IM.J-AOQZG$M!`A*(D[Q:/+&V8`CS9?-8V),D
MAZXP0,3NH3#\UP^2L-RG._'X6-ZWR_\FOU<8MH)]`.[CW;-!,HY`0ARDY14N
M$L;\.8X+=S7S8=L]/^51T6%*!W#*@9A\`*@'1UPN8O$TH4M&'(]ADL\<XH]<
M@L>6'O)?E7-XX%[ZS.9UWZK0#R,^%R7,);I"A,Z]/_#B&V%$AL.P.!,O_7CE
M6#\)^12O;9$PF1C[];`N?Y]E)9NE%8NIB.5E@\>S0V5^W\]T=<B37-UFV(%4
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M%,>U`8J:B9E2%>E54ZGI?$\EFUC@9NIVR=<CEZYD6\.*9NJ,J.+XOD8L7)T[
M5-3ZA:(>T3:Q99ORM6P"X^!J`''J%YX.+^);/LT8'W?Y\\&1:T,,Y"HV9;9J
MJRZ@BSFEEZ&N2NKPTQNBH\TH>RI'VQ289<52F$9,A6);LPTBRY24(8PJ,V7O
M!>9=EH^GN?)U$@63B82\7DE%]#DGMB),GY-7.\K)QLLK(+Z0A/!54=0(YTR*
MR)5]X97%RV4"4?O-A)[V<E#423F]W%_J09[<RP"7(CO,E\L'J^M0V:GT.Y>"
ML$C5175?$N7[;):*%NGI.`;3&`&U@01.+:NV%;*75HY.TI<"IM,YRR3J+<FP
M\+N0^`.N1BGXI#04E<S^I)`)/:>]MBTF/,&?+#FDIM>4.?<\]<.,?TQ#G\_N
M2D];,[S@DI;>93OG<^7Y(PR6@YBN.+9N&LQ4B&;;")PMHN!]D8Z6LNS9BV&P
M?#I_@>%)Y.Z!XT.\?F^%9!W'=@W3="W5M!59AU#-I=4Y`$=#JR1+T.E"1//=
M27;V8M@5DF4F8-/67*P24U<4!^M.=2K*,=A*S,K?NV3G7VKZ_^Q=6W/;2*[^
M*ZS4;%52)7MXOV1J'GBMS=9,DLV</7FF14KA&9G4(2D[_O<+H"^B1$JV;,J1
M'>4EEL0+&HT&T.@/P`[>Z@$R-(@M5S,<3*#1=4.XX)[A.KMX:YX@;W](G]\=
M?`6.)I9K&H9NPL;-U1S-UF1EE<0QSWQ]C(Y5-<OP?-UU?`VV5G84NWX@*T=X
MV]'5T]:Q]W.5UZK<RQ'3<U3#LST-=IR::22N&\JJ,K;AZ+LXXEUJQHMCR',9
M'-=5==N/@M!V52=T8SMP9'*W8VV7ZCEM@S,4A.F.U0X#U=!!>@Q-Q_PT+7`T
M69;(29(?[!!^I(*0GV8=C"#L#_,LN-M^VKVCWDS(BSPCB2(M!*\W@6OC&)2T
MF.,0?.*!A#S-TQW7NV?,#R?X>*/?O178Y($3QF$"=BGTC0#%W')"C+QI`8B!
M:YO^(`\<TW%?!@]^L`N[R6O8"YB1KX6>EQA1Z*M.;(3"='E>%`WQVL!_+X#7
MCS=EFSQ*DLATM-@U;-=(3"<QC+7>M34G'N(1>@2O@D7']4TW&:W[CA_H260G
MGF]%ANUYIL1T&[$Q5,/@%0GC,;W533['INUZGNM:3F0D>HSVU!2[`,_2!XW,
MF<^'*U<WLD+-"F(OL2W7,.(X\66E*PML^TOF\X^/<JG=;)?`U"S34&-7]W3P
M&/W`"C#SSW9#`T$[9TX_34]W>:T%F+:OA8[EA3$6%PY!PCFO?=_S3H+7G1X#
M!WK@7A!H>FAYAA/!SE4U-95#XWPC#KSADAA;Q9WNHVB+?L00LB@\GH-7A/K+
MR^FN!-*NIQRX2>2'KJ<%<:C!'CNQI,'4-PO,X$FU\KTIWI?%XO<W;;W*WRB_
M/H$0XF$W&\M0'3W$O;WAQ(X9&++TJN7TJD(^GI`U=N.@$W!5-9TH!);$EAG%
MP"DS%(I8UWSSA9^`K]E%!X\;#!L'5;U]\OT,66%?\G2AQ(1=5CY=+8HYRXEZ
M(2CQK[FR(#P-0JBKV:R8LJR617I544.!.Z59IE.$6U,V`D_S"E;%(F.@\BRO
ME90_))V#5J;30CKR#?[\`B*M*?%B451MJ_@W>;G*E3_^")6W\-L[D9D$2A1X
M2`?2'([/'I>7&2:E*1^K&]:J!I2XP]*B<I::-<HQ9WM;C73RNY3I63!G0'UG
M+#BZB9*GTV^82##*^V;%#<.T]X7M<:>]KPO6,2'NU_EU6I24F3,'Z9SC,@4:
M+J:(7R#8@T))O4O6^X`+=+M7+@O07\ME77T'P]SFBZ=/YT-9]HOE79H*/&DQ
ME'GZN$G')9CEL[S&'!=BQ14'=[`$#!)G^IY=!:Z(TA3X.V,2YCIB7@%FA((.
M(0Y=*M'&$PO,UZ$YN*[JEC`@]%!69I56=+8NM$J?&U9G="+R*AE49:/6*"PR
M5M<4<W84_!:UZ`5J5!@#YNJVW^IJ-6>I$;UI'">1YP=8'+2;-;@+QP&+F>[(
M)N9#J?QK!5.""WN"FCLGL`@F[H`0I.6VU?C?'/LG4\H*QK]AZD5-^PDS'47)
M+F$YM+,B7X"XI`O*U5K*U.R;?#.-B%TADY9!P'CY?I$=1%F\T_5;%^FJ!.&D
MW.8BJXMT+`7Y3-J/;"2L&997"EIJEN=(_KBJB^DE0U4GH+K&HIQ2+*]`69=H
M_OW5?-6T+$L)D6:@NFDU4XHW`ZI)"5HM86H-5<G2NT:YA5>`&498&OHUA9Q)
M5$@H:UF=WI8L>Q`?<TTH=1((1+`AE!<5&_HW-4NI1G\H18\5L[S;AJ=UWN";
MX3)D*3P=<\`1#%47TY:>RS!U\NT3O)8(]88)I>QW\.8IOYU0ZRV^:13N_BLM
M5YB0"MRT1[(@+T8-?9JV%7,C=VDBD*'LFK-[4[!(-0G-PT1$=D/9H7V*<JU7
M_B/="I3<1A@B^<()&<^VPK8NW?5Z6Q"<DX/>D<HCK%[8$X^V>IE@2T8!L3=%
MQA*C][-+9E8W9->G+4OM'%OHK;%@ME2<8<&:\!2XK1'.QJM>IKT=Z>CK]"O?
MVJ7DIN=8GK5!9V]K*7Y.8?U0%FNYFH$N7E'VO>S)0XX"OX;Y"1W+WJR62X9;
M%?9`S)T`U"H<1VM=*I]7=;-*URIA8_U.N2M&V@21UC);G"P#RGZ^ML`3&M)5
MP<)]\'/&"GH@??DT;;"TT$U.`]GV6,6+0)/@^@+#(/)Y^052:?!'@80JF`G=
MN42^Y2I'D"ZX1^`\P2N6*W#"64Z-"-`@\I?N8;8-!I=5A.Z6U^*/_X]\81#O
M;C8V*Q\S_&!BU"UEBU?(,H7MPWBU$M!X+]7)VC5@+A$TX>D=?7,D'\S2O-&T
M^)&*'/P`H[Y?B_RS:I9%G2I_72XO?=+IXINO5;W(;F'Y3F`I3"^5MVTUS[$(
MP41APN3JNOH;OUI^H_UVO[(A'Y947%GM%)M&!B(PV+!V;V&]+2:\P$*9;]57
MH+?"<A)2UJ'B>D--=C1?VHHA$_.$SA+JI*YH&RYU1\,*,)#EN\J55<-4W31=
M3-$_9G'$W5IE/?)64IL=2"=.TX35@T"J)D(U35GU,R":V0]PH@_C[HL-"'2:
MU"A_%N!;M57)=[^?F9%1OE1WZ:(=*\[>2S`;<8P;3D"=MVF!U<)NQ7+L"DO-
M#B%!_J248)"(575!0>0F%HU,1IE+C:@6,H7Q%5,>5@(_5'Z&6^9U>LURFI95
MBVYLRJJ6P;OS&NG9"%9=;S*<^;97V)`&%@]G.D:HNBJ!A2)F\GD#=.*BYK0N
MBV6.TT&QNH;Y&8OJ%GA6SA?Y15;,B[;S+O9N>&,)>UG^JIH^\!2>M('E#<^8
MK7!<6=Y,Z^)J74@%3^_V5E/9*CD2AX=6$SF=XX]H);TMT!7@&H%+4X/YP,F1
M!@78MJ)89KJ>[*XQ'\=\ZR.&4'!)_#/'(+$2%"##,#/^\B_E+?ONG8R)<9<6
M9I1K6]@#LV0K?HP%(H`'BE&]FL,3EJ!Q>&F_#Q^C=VL92"*?S!Z*#VCP,EU[
MN0LT4N5%VC05R#X%XM##)4O3XJ;V0E?>_NG_]?E"?R<6WY%""L^@B3^A61J%
M^.WZEJ.+_H=RI]@;)/8UGD"@2__+*#+IC2G?F,5ZP`'!@+^$8;NB6C58K_$V
MI7%^_/!/94X`CH/S%P\"`O1!!%5)O5`^I_6GFMJO950`0L#%#T2&)%ZB^YYI
M&6:@ZY:%7<'7#6P2>R?^7KU4M<TQW4/7"`/9*@:TA4NS,/?']VU#M713->S(
M"V4)_]C>F04TWD#HU\9?M=^JFHZM#AN`$SFA[@2NJB>VY5B)H1DR]2Z,-WHN
M2PB2Q4X!U<$!;-/S!,+WBE#@^*8!G`^C),*4ALAR55F4QG./3OB'IED=3'0$
M%`16D@2&%MA^%/I^L&YW%T1#<%'#5&'39EI[:&:D/)+>O=+A64$2.X$7)HFF
MQ4"Y%=L"[>,ZKCI$KVI8GJ6Z3Z7W\;`SP[!-[`_A)5;DAK&G89]V4:3#2X90
M=0]@\E[0V<,IW[\8?<<QW-"P$M\U]"1TW$#(=)(X^B#E][/[(90_HIQ;!&R.
ML0U'Y*J&[VMJX$DD6&B$SG9M%\/<N?2&BFS=2]O>DNUZ[`$C+=.P@P`(#'U+
M-A2)':=/VU8;^7MI`]O\#>PV6'#6D?1CWGZ:_4_Z_>!B1I38IT:^8^FJ'UE&
M%'N6U+]`;:_HCZ5[=H^1N\AY`MVLJ?'N(DR1ZX2Q:NJZ&>F^%3BPS"0@V]_.
M*@.ZP:YLERLZ%MW[^!U&FF/%;A)HFN^Z1J`YB30;AJ[U:IE=&(YG:<]`M[F?
MW[!_,>,X<K5(=_7(34QUK1IBW>])](4&&L1Y'-U1?M4^#AT:!+"._-!)8.F!
M),1!:(MT"#7!AM0O&AWZD<J\?F8PK)'#![!!FY?O%_FL/?J>BL5!=@:C@?]_
M5"FK,<P!Y'>*+^.[;W%+QK*]?OVSR,)TR2Z75_!--[M$2:AV+D=4LN]8M7U^
M;R)KZ_X5?`@GRA^?8:]-/[W#L*@\UV(GKT#N5577U>T(]7$Y+$2_5$>&JWWE
M0>=CG*!HWJ4V*KD2;X9S"/1.\SSC>+IE>M>M/YU2=\E&(>9?W<$8>8B:8`&@
M5N"/M>-#SR/8"A<$"HFG,]S"PTX63Q7QQ!T>3U<R)"/M?:=5(QL]T#5CL<X>
M%4(`8X/[MHF?\9+["ZSA7#?BU$5S?H.OYNF"C4X$+W(J#3[2\/1+9US)*%A\
M5@@%PV'N6_GB:(8!UL3YC"B\=%&5\(D')1L\+2$E0T'<FLYE1HI3>I>Z]8^1
M@I2'`B:>LX8]Z?'UL3&'`XRDQ()\7I0$2A[E@?ZR+A;'H74B)8UW,.&!-EGP
M2XK<:(%P;62;0><E60>@PZ!^+;.]V9B+8U!HW)&$!IP+@:%BT/:]VH(#49K1
M-+Q^J8\[+:3=Y3R@;B?H&)Y*,?LHSE>$!27C?YW>L5X\=_1]URJN)50@V$')
M%BUV5&F!%?`24HL<6UG,Z+P;S7#9!:<A(<`[!/Z/!+D$@1Y)8W)FH#]PL7?D
M`DRW7#.2T(2B3<-M2L:1\:#.9]R/9(C^#'8H>5;F3;/A;';\2CHTY3/0FT9"
M\#3"MUWG4^P35[+9%'L'JMB%$PSR@TK'DRH*[\]I%!RLS5T`1#G)5W6*$!)R
MMDW%V6WG2#BE7J83A2`AQ#R\;8''5"MV_+O,Z_;N6'"YH[3YV*L(<%^9%F5#
MV+(23S<8A`-[9!%J64*5B3U7Q0)Y";)/QYX;XC!A4P2WPC87+$->SW.EVN@L
M-E&RHEE6#4.:<UY?IW_GW9JD_)MT"BJ*%P&=L)T2VR>)8_&-#F`DBND,SRKQ
M@'Q"`@CS`"X1IHD1_/IO+$.*H[E:\:<N%WDVSV6SG=X\,P9(B$B#02D08*D.
M$+1WKZZ5S8((+4>F,,MGZ6J!:GB>UB1FB$/B:Q$!/.D4N)M."1C41<)2053$
MEK*DW`)'*F9.N:HQ@6RB5%,&=IDR-DO@.>BQ&U@5H,!F,Q@H'JS&M(XR7.*X
ML\@7U>T[>&*-)5@%D<!R^83-^;Y*R[_KU;*=$J,*G.8;1+]/UC?\WRJ;7_/T
MH)1ZP]%!G,([CQ`,J6SK:L%<W"W22XXP[+!L2DJ*-9H3<$)LJ;80F1M<"^Z=
M$MH0,=TCI&E:U-/5-6J%*6,JOD9"JV4[)E0@Y#&/E:9GC:;^EYAJ"3[]-;@S
M$K>PI`KD'0:.C;UXKN`)R"J"OX6HILT>P29/X6WQ;NUKX?Q=K9J"S-:Z->%$
MK'1:2$(A[>AB6'>:$8'0,AVP;FX(F@`T3,DHPUZ&O/T?/`WQZKB,D(J;@BO1
M"5.T+(TDO0([).VO1+BS-#@NZ4P&.RJ8APG`9=F"\J+1;89:$?80RONM[MNB
MRT.\_@:F.R/B@3$S=F(^P6]7I.K!TZC(V,I,NMY6?-`>,WBB,.;TXNTWY]B"
M:YJ+X9-VN%M+`&U_FX>N?U+K#.0B\7T-)=Z\+6ZV7MQY8V=(E,7+2,*OBUK`
MS5A2V76>(=CJ8>[-,#DO=:%^S45GRWS=>'&_-L85@W8%=I-9,1,H(A:U(@E&
M*-O==L;NJESGB]+=18,ARVG.PUB';-N>,W;PBZ8:8V)=)'1JO<0'(X+;WGI+
MJ;U/X]O^/:%I'G><^Z6JSH?2BJ7:$>@?M`K,5C+K@<@@>=%UWGZKLHW8P$G*
MU!%#"_NYO!$I&7*-3S2\T-V2=G++6C#'K7`O:''`CH&4V61'FOI#Y.EBESR=
M?%CIA=J@UUVJ8L/P<?'D51+ZVGQ(;])UMR"1SU>:0KOT1@[;/F-7EE]T=SQ+
M-A$[`E`,B[M#L:0[\`%]$,$'Z@B..EJTT_/I$+%7E,W\M\94NZRQMGE[K\YH
MD4W3)9J!@?YG&PVH-"O&?@V>ZAM1I`>&;NNB_UELF[WNG(:^C1#<-XY](XY`
MW#_-$L0N?^$9EY]9;$7;!:1X].#7T+<X=A(M<'S7=0,OAG%:CL!?N*;J8`5K
MS;I0S8LN_/3!A.\;;Y+G`Y,K:TB./:^^9_E)E&BN'SNA9[F^GXC2<GJHF=OS
MJF]W7=U!_+X1?N`&]`LPB"%T/^>P]2K;=#X,G1MAT%LEAC609=6WO-B+$L^T
M0CT18%W52XQN;;B22@`2T-CKEO%^^)#VL8+UE"NF7#!&%^A=#+#"V+426+I8
MLEUW0S/10XF64\-^NT]5U_9,^]8P]HWX/VM[%PES=RQ!WR@'J,,,!ZX>A+[M
M6Y%M.H'HO9GHD=T?L6OM&_'`,`9&S:UW2,9[8&ZU?X\RM]U2F#;,G^.X862Y
M00"K.XYBT=0Q40U-ZRUHT^P/LTOW(</BHV(4(ZT/'!Q>*K<A^\?GVF80&Z$>
M^CJ\+0Y<.Y:(5,UR^VVB5>.P\;%B5AQN15=\S)])1),X-`Q3LT'Q1K9C^K8C
M^U:ZFMK7Q>[VU`W2/CS`+VB$X?^B_5B5/)_V0-RRZMBZ%ZN19206J,W$,63[
M4*S>O$VNZQG6(+U#I#R%Z'V`9NS4[+N)I1FN%L6F8ZFQ+"YOVGH/_NEJIOMD
MHEDMQ/$*Z.ZTYH&F&=A)VU%5.S3=2+-40_;2L8+^E/2M^0;->P<D_YM6\[*?
M>++&$#]Q@!MM>/U`#6,K<=18U;P@TAQOW33<ZC>)]YR]X^L-X:D#9N#C$0<<
MVBJ8+`M;BR=69/BV%5K"/[."?M_AYQWKN)-KV[87!I[A1CXH03<)P0F7)7'[
MI8.?<ZS&V//J:YZC>;J9&'9D>`;,;QB)L09JW#/33Q@KIKPS5*5?9C[S6@1"
M]##,O^>8IF_%>N!JGNT&FAJ[LD@_#*8W03KM%KJ4[Z3E"43?DQCB6VZLN8[O
M.[;JQX%E6($A5E!L:CW'3S?M1Q(M=_*?9I@BD)<-7?6%G0:1.:9$H@"S]KFK
M?%#79"=P#=6)_<0TS-@!#6A'EMB$VR%L6UYT5@!E"5T0<Y0N_YX<MKRJVK:Z
M?F\NOS]OZ^1/5&%!=:D)='N'Q66H4EJN?%ZD)4L`H-_QX[M-T"_^QA`XU')5
MW(B!,D278`WJ%2O9C%P3Y8@G$N&#R??XRX1?@!AZ(<7\=),=^^)A!`88<1&P
M`\_NMRP[CLY'KY>+ZB['H_6L@$?!R]GEB`A:+=I4E/I&.%:1%5C13&A#*I+=
M.3:6S]I^P*7RB==5Q@,?`1*C4&?..V3AL316_9*X/3INAG5'I6O2HA:E'?DY
M-H."32D/33"+G5$+.*AD-4.MR"-U4>(988A8=";_CO#M9XM3:NJ(!9^)T6)`
M/(M^<:<@3$O!.F0C0$<?.JX9S,<H8[I`]G!,S`@8OA^F)4I%5`!DISWF9`CM
M(3$1$NXA50<[4DC7">!\U<INWZ11F#99@QCD[>SP0*"CLM'`4-K$TIR)YXR#
M3N>#>GV5RU->"G2LDWIWXIC:1'?&J24I9(ED!)&+]0U'@LBCJ77R$E.O2Y`I
MQ-_,^$GL2,+DV3BJD8[!:3B;ZV.V:E?"Z#1#Z^3IYZ<_2L7T2N<-%$DA1#!+
M(A+F6<&Z*>`O4N)2TVP`M]'Z%K,"_EH;\TY/!(FR/4+NGC8V?("+^)"KP)#(
MY9;W,6("C'9IC94T\H)0[.2G20>-.F4PX>%6"@L#-RU)3;;MKG$[)H$9P2*%
M;<-?4P1I"AF\P&G""ZZK+.=HY%FU6%2W!/D`S77-994I`BQWQ1`@77=:Z((>
M`A?33+(\>S\>QQ^P&1/W(.#BO;HU2_BY^Q:.,=IX#UXC']R2WL-RK/P:BK+C
M9^P!(SX?OHV\+;+V&_P)@[S"DE+U!4%!ETW^7OS10X^LB:KE7[@M0%+*W]]@
M5*^N;OD'>?&O;;;^LQY\!!'S^QM+_<?&$SJ/'GK:^D;MD?>YS_P^XY6/SWSE
MXWN=\[=K57*E<H-(_6FZX)J`^4:_;6@Y?<M1ZG[FOE3W*PIKT#?WDMG1J]O:
M:$Q;M]XT[$<&;3!;DNN\V<\KKF`Y)[3E=X52LQ2QJWD,+P=5[3"WII3&U1FW
M^SAVN3LC@M3Y<<W#/^&B;\WZ<XQ&&-]UA45>\[3^_0UNW-[\NK%Q4V"_=@#W
M3TPZ,3@S`[_E_;<B`TM_EL[3D<Z/6-KT^#)Y5J-/%%3C!PAJGY?\+>2)]UYQ
M4G(]&-LZ*\RS'#Z_'!IG.3S+X0G(X5D?GN7P%.3PP?KP44[C53K]>UY7JS*[
MX,=CTVF>SV:OS)N,9629L3C/+E)@""8?K./2/W+![YR'A\OJ#V1OOX7`(UEW
MKSCN8^$1.$62/"JK-/5R(+=S;':]"*G9M65^-F'ZB2WR\RFP4Y&VD]!1)Z.&
M[$O'.3I#3F7JSXKF9U`T+\+FG806>AF>DGMI>&='Z:R_SOKKA$3QK+\.<;%&
MBV6_;*%YJO[ZN8]#AR.#7[?C6!V$XS$BLT=@YT^I_E^9>3S+SUE^SO)SEI^S
M_)P@?\XG@GM.!$6)[IMJD;94(?HQ8J??=Z`]5K#XN7<O3K]8XLN)EX\N+?T*
M_^=0R_%T^9,7U9'PQ4>(<1[_*+@O).=U=UYW/Y<Q<_6S,3LOJA>ZJ%Z.,3L^
MHN#G,&8_=[Q[<WN&I9FH>,5P8:01%N"+6V?VI3;60CN5Z<;[CGG"?39(KW@]
M6)>C[:+.Z^&\'E[!>A@--W5>#^?U\`K6P]D^C+'#.*'M_C%Y^Z5H_KZ8U7F^
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M8N'$X[(`DI?$I71`*9'X/8?_RD*EHO;.Y8PMRCF6!05%E<Z43>!RHC;EIR2#
MK[-%H9WL\.HXJ^8XAWG!V9-D=C/F<9^LG?.(;+`RSQZ5>0RKX<HG:M.E@#1L
M(#90Q@:V?L?P#?K*%4Q`3[[Z25F;9U'^A)153\ACC[XX=WHX`LOS8'F>QLKS
MS/%9.SR14CM0#T`J#&/IB2Z7GI`-:EAM!Z&&K(90ZQ;4ZJV9@].W71<<K5]0
M_/)1%*)/BHS&8?9/)+#FUZPG"J']B`E\(5.B;:UO9[$,5O#!I'P8%;(;%B4S
M\:SJF+$I?0$4*53;I1%F[]OUUY60I>=?W?9J"A`G/,8ASYPVSZ@]W:Y,J4?Z
MOD>F0:9!ICD.TV@]VT&F0:9!ID&FJ9MIS`;*%\O2]V]EFOUW<;JU6?.=11%8
MUB/7+&8IC<I-&QI.><RS7&05W]0CJW/</)<:BC'TJU,!V>(;6:!3]R"/8_D)
MQU/?J$[L`^,)X^G4XTGK:4YU)18PHC"B3CVBU%[?P#E?[<NM';=Z^FU?B/U(
M<AK5`R<=X!0FA7B!\2W1)OU>0'7[0-O<UXF-(K5G5:CT=;#+9$%/W9,%W+-&
M,D,RJW%]HU;W?`W)#,D,R0S)[$AD9O:4?F6O?2&9(9DAF2&9'8O,C)YN5?9B
M(9(9*JN]DL@@E-5(,BO5U&B0\QN>WY-QDA(:17`Q\>LLH@N-M)1%="ZN-A;*
M7^5)''723DLG33^:3MK!*E2HEE5Q`P\]L:,>;<G;UM)-DX_Z&%3RM_TORS%Y
M<V'PH]E6Y%D.$P)P7U535(P&U+[8@+A_EU^P\%S*>'"AG^CUYI3?8]DVNF-I
MP#,YC?N2\H"1&4NEM.[[A*;[Y'$CP56V1]$(J>V^GU$_UKZQ*>7QM@'U6-9Y
M\&U*@[R@T:KGR2<^EI-6A#3)/:,I*MO@]*29"<#U=<JNMQ73/I9U'R%X>9SQ
M0$KK_J!1(:??@$96D8)21Y71SX!&-(9Y'\W)D`6E-/'*S[K:(U7J=U;JTP6U
ME1NX564;5__LR.HYEM/3E?I]6(<_I'MVA`_":YKR5_J<NQ50E.*=^Y:0V(5>
M__OXK0`-\I>D_%6SXRH#)WJU*W#<?0TN"S2E]^JI2YG\*Z6PCMZGM'SE<SII
MYAQJW^AI9F42"K)T<=T3""3F#A?S5;4+!2,"(^+H*W_TSTGY9^>I;C./D^3R
M#SY:>,65RVR7RN:SE?I-FHGN+ZKI]'2].FFC;5Y:(:4^-U4.ILJR!R0*/KEX
M;*\<X-HB\0A;VUBH`V,+]UG1<5USG"P;U%V?SG=KUNXGZ9CQ"G>A:Y=-/.KD
M75.-GJ;5)'7QNK-.>PZ/Y'["JJ7.11]E@'&/'/>`T3\R^0?WR'&/_$WI]]_9
M+"_S[XFNE&GW$D@.M7IN;O5LV^DY3G6IJR<OW83;,77M8S6J0]>*5.MVB-2U
M)8'?J&G-M(\[6P$[I,BV4J1$GJT[F*NKVB*/SSJ&QDH';%G(L1UCLC21:HB:
MV?;Q?28+?-XZMI[ZL[D_6"8D7X7\*[N;L4!\R!-R`U\?>0>AY1L%IFWWK`K?
MT=_F+ED`A<\5NCB+6"VS)(9><U.)8[FLEF3%!I?QK8`1,E@'&4SJQ7=U^<*(
MK?;,.KL]_DD37K!B5HWFJN#)`H;F%\82;?PU\`Y:6=(#G['741K)-LV>XV"M
M-WR`=)+3">GAB%OV>[G+O%`E>%(N"WB0R]K*91)YMN9X-:N;P\GCLXZA$4=6
M'%EU"Y;V^#"\CC4_EE%=.\_-R3-+][S.`C`+))76ABQ(TK+*ZCOAD?FM'K83
MUB3S7]M7.*0I/9+#CXS<BG^::I364S2CIRAF)4T@17PSSUJ8%[;-2+(J6`?-
MHSFYY5$TSV$0HQZAY'998(S.:WF)HE0\@2N,FW/"Q7.=O8.:7Y:^N2"CNR`J
MRB;#/<[9=!8E]XR1;*WD;U;V-LF3G$8$O,&G97W?()G.6)S-"_R*K(\X$P>1
M*T92L/PZAAN**L!P8!RSH#SLEN<3<3$X<NEUGC7FNW^HZH5*X$H1?%^)%R\V
M<^+B[]]^+;+S:TIG[X8\"Z(D*U)V.?;6_/=M7C/92[(\*PN*#6C&PB_T?@I,
ME/V`%@TBZ)`//_]$R&_+BXUH*FI!95]8NCR'!VX<#GE4S#LH%K[XQL;OS_RA
MB/VO^M<?PS,"SH$^C++R'5T>PJ\TR,\M;Z@8JM=W1H9I^89F^7I?\37;=Q7?
MU]W^&40,GU^MR,+E3<\^G"LPTUTU<8M5;VR"_E7_\_4F&(;>-S5#43QKJ)F^
M8?2'?MD$QU<\QQN\V@3U0K>::H*QL0FJ,;#[KC*P^IYGC-S!:#0:SGM!\X>*
MHFUH@J4VV`L;@-1W1T-G8/L`(F.H60/3U$;+)IBF[FP`DE%5+SR$S.O^7]GK
M&:;MFIIG6/V1[?A]RS>7P/=TVSK[\&0>L<X.6VIKOS1WV[F2^)Z,5'Y\5I_H
M=Y:33TF6$7`-V5ZL<-?IDE7W;*GL;A*#]9&P'D9:D@GKQ8`!D^Z@F%>9O[HG
M8#)?#-IL=0+\(#X_&[+CHGS,`D,V#&!3&)/*JSX>_45I>W'R?'B_(,M`>,4:
M(/*B4EM$'F4H[LEOV*.?"/N[X#<T$J/"!HM[$)DY2Z?0@2$ILJ4]><HHC#WW
MY_/1?<KRB6A=._#P`QIP56+BP3LO]PB=PMH*W+-T25.SBWR2PL1)&`=,]#S(
M#IJD0<?GDXPP\&G8F<5#Z:/&YLLO50D[R.IRK;.*=3%!(Q"7`F)+"EG%\7SZ
MO!:@89$NPQ`.%2G2(K;GX0K3\"])#E'#:13=KR(_8P&<E7.X-"NGZ7#'<9I,
MRZLL(^`)^I?4*&;;932(0(BBY#9[=W"<[S"F/=I'4YYP@?B\?M$X26'6\'CU
M+8YYN'"Y:T`"%D6+8]Z?*6?EYVQ&@^7G_4?C6Q[F$_@3VK38I@$81726L7?+
M/_[[Z<[*RJCU_(6'W1GK1;V#'3(@2EO>G]G&?VW=]WF\^[0X454//?'`\S2Y
M#=TOT^1HB6ZO;]R]H3+EX;OG#\::<JLU-5#'>ST#YX"M3@3=_J![52)LRL,P
M8J=8)+C*U"]\.HA0VPRUG;/C,(_S%51>KLWQEUO:>4)F11I,8(GP:$%0V2/&
M3F9L5J^*U/4'K9@V4E?:2$<#S%&:*>C1E0`[]=?Z_TU34?BQ_A&MW7&E&#U=
MJRR!2);.KWMTPD&HTS'A]!2U,C6HKL1$;<NH?MN'FA\BNZBRB4FC2>CM4%JT
M>WI?C%//L^=0;A$79RT:%S&X7PIN4^WW=$,"1>F3".Z=4MPWIX*^FK'V)+%M
MD9&[R!#]Q.D5C\J<`*](4P9-?Y3@]K',SC/64_/.];5<-U/K:ZJE^9KB]=5!
M?^`[^D.&I.^YYN/<O+,/JFY8T'%K9F^SY\WF&U_U5\U75=\<^OV!-5`]?6`/
M!@//7:3J*9X[&CPSWU#T*LS_SM(;'K!5:NYZ\N[OR2*3W+VE:9B5,YGUWT56
M[^])_B<#PQ[RHK<VVWS4;->W!@/#5T=NO^_KEJ<XRV:[GO6\V:I:QMOS=E?>
MD(;\]:5,E/&3=/&5.$[=(;?3<3Q+<37;4"Q-&:E]9:C,`>.,5*T_,,\^?-'^
M5#ZK_6$#OGJQ$8\=Z%.>_D&C@KGA_Q99+M*_+\</VS"O9'3_M3C[+R^B6?9P
M_&7Z30PT[AW/_DJF+/T+&@1`'WU.0OVK:GPNGW;/_UU'GK*>$S[RC+ZJ&IZI
M.9IG^(/!"*A#L3W=<7S-&#X%WKE1(F_ERXWM>6O3GZ11/S+<MW55LX?Z:&1H
M?<48Z9JG*:9K64`(WO`9SYWW+;TQP]6#^DQ]Z+/7&NTJ(T_Q+4L?]%7+'JE#
MTUW2A*^ZKO:\MTSM[8W.,I9GG\O,4A9>QM]$TIK(=1,)O*M7%W:(U8%E>(:K
M^[8V\OO#@=;WW06YJ[XQ4OJUYV$W^SK899&2,7CQ_$:XD4PX2VD:3.[+Q-5$
M_,AC&@><1H26/B[S)J/5B$6F"Z<+`1EQ)3*_DLC\$Z_@S+NA3)K-,!>P@5Q`
M]:W)@(;9<$Y?XTF$C9_7&D.Q@9@^VMY,/A7S1P]6<$/HU5M$_/0R^SZQ&Q:1
MRM0J<4<:T;8-;2NO5I9>A+!#V.T.N\J$/A%V"+L-L-LK40&G=O6N*EJ_:OCE
MHWB#."DR&H?9/^N!U0F]C3'?C-Z\NWDHU37HP3:,$=(XJ[N#*R(.$8>(0\0A
MXDX#<:?^NM'G)&;WYU.:_H?E9`R8R$@@LB/XF(N'W%DI41DL\L92EN4I+RN-
M!C2;''/U+XO_*M-];M6;)G9E9<]DZ4=Q'KYY=;R1'3F@91PPAT!?4[7*,"!+
M?R(7(!<@%R`7(!<@%R`7X-K@K1R`CXX.W7S()DF:GPM9;<++=W_*V@R';(J]
MJD6WXU/U^N2)F@Y03>TI^O.")I6\M+J'WV3!8-T#O$2A+-W(C]'9Q%0:0Q1#
M%$,40Q1#%$/T1$(4Y[BHR5FA_YH52L,MKWV\U(8],:`C6ZEL6VRK:V0!0]V3
M`AS[D6F0:9I=FR#=(-TT23>MD#:4BHO:H9YY#*)J!9:0Q3K(8K*`2RJBDH:+
M<'G6C"#O6KLV:-PYA[7+V9,2=C,&!?>>;C*CX)Y\Y[7&4&P@"NZ]9="37!JC
M\X)[0Q8L]/;44F^OIEJFB+PGR$--(-3;:RZ/`-&&>GL(.PEAAWI["#O4V^O6
MU`[U]O"EJ;W8#O7V)'E0)`_<I',<(@X1AXAKA>.D<18B[A00=^JO$FQ]Y5T(
MZQ'V=\%O:+3GR^[U+B.ZD+;2KJR4RK9[9.E'<1[FMAUO.$<.:!D'H+`6<@%R
M`7(!<@%R`7(!<@&N#?!Y4>4[#M4H_.^N0M(9E9$*I2X[+R&".\T5[#2?3FC5
M\7HHAAB&&(88AAB&&(883A!E"RU\,-P:+?36Q:&J]6S5KBP4M[A'%D3AKJI$
M8UK70NH((L@85QA7&%<85QA7&%<X!91T42;1#LAI*X)+OV'0G!;=5DRVX9&_
MJO>L!D7JI(</;N5*FDR$;(9L=OQE#E(:4AI2&E(:4AI2&E(:4AI2&JXYC\YF
M>RNF+__^[=<B.[^F=/;.ISS]@T8%F\L`?68T*U(67L;?F,CA!B0-:,:S'^"%
M090$__GP\T^$_/;2V<5TEO,DSD9W,R82OH?\A@-OA=]HSL#'L7#D-S9^?^8/
MA=+K5_W/'\,S$K*`3VF4O3_[^+M_1G@(O],@/X=C#,WU'7=DZ.IP8&FJHRF^
M9ONNY@]LUSPC1<SGUXL+(2%[]D%YN56;[*JJ-<:6UO@F&#\<>2--51S;&+B*
M-IJW1E$\VQW*U1KHFZ^;6N.,5,UU!P,-.FAHN(;A#=5E:_2^;\O5&F-+:\R1
MZWGZR!Z90]O0^J9FVMJR-8:B:[6V9LBS($I$R*U"['5X/=@\L`QGY&F:Y^NZ
M#C/$@:/J<YOUD:?ZZMF')RRVSDA;-/Y?(L&=*QKLR8+EQV<";\([YZ5[R(*/
MMJ<F;3)V?8BT9H]+*^AB@*R2TR]C0DFZ)$]R)=BS1VX9F<Z;0@(8S"B/R9C'
M-`XXC0@MJ9?0G(RAY>1&M/R"^`]_$YX!>N'X>>)6/F&$W043&E\S,DMYP.`K
M./DV*:*07#%Q=\9OX.!QDA(:SZ]/X.\9Y2')$Y*G-,[&#'XD$:=7/.+Y?4\<
MR>YX/K]DC_"XO!-\`BMG8"9<8)ID.:'A#8US>LV2(B/+!#/X41S]<*N'ZXKK
MP)7+L3JZG]\:(`QQ`J;FMXS%RVO,J!CEX5;0UR29WWVZZG\20AA=D!_B+D$`
MHWHN_)OE-`YI&A*6B1&09Q/`-EUS))EPEM(TF-S/O90*+914'`3-A6N`A>"1
M*;WC4^C(\J9%QD@R)LE5QM*;LI(&CV=%+KH1^AUN?T-Y)+Z?6S-.(IBFE\84
M4V@+7&;>2?DD98Q$0G,U$Q><7V5I0;A9<N]00%MFQ8!^HAFKKJU++Y]ZJ,2!
MX+QRNK8$]AH<.`,O9D4P$4#^NTC$BV$EWK(2)X"+&[;`0[9Y&B2K?[0U_WR<
M.R4!,(CP`,1M:?(<HA0PQGAY4@A`"7*(&^'7>/7IP?%K2SD(A,H\]FBU9EGU
MNDQ?<]G_Q,_"3KCI=L(!,P"@'+X&7\3)DC6`%:C@K4S$I_`9`PPRX$NX13(#
M7Q>9"$V@!QC]\S+N!8L^#-9K1U[=P\&]Q;W@.A$X6RB-9@N"I2\PU8)U@3(N
M*G&^JM4^0!5I28_G3^E1Q&XB?GPV,(''U@)X2<KAXQ%+4/:SD:_$,LT6'+E%
M9?20"<?:.8\PBR64L(12]POP8`/;WD!4.\<22CNZZ^7%\G<VRQ<UE)2RAI)Q
MP.XA0F]_Z&&=!ZRAU%R"-:(-:R@A["2$'=900MAA#:5N3>VPAA*^OK,7VV$-
M)4FRT.2!FW2.0\0AXA!QK7"<-,Y"Q)T"XE`JJQ%%XWI7%%W(@F]3+GN%6GRR
M]*,X#P53CC>R(P>TC`.PA`IR`7(!<@%R`7(!<@%R`:X-\-%1Y9L/\NAT=T=(
M7U-[BJY4MB-[J-]DP6#=`[Q$H2S=R(_1V;SR#88HABB&*(8HABB&:&=#%.>X
M1U[`=FN=*K]"N2R>:DX4KDU[8D!'=H/:;[*`H>Y)`8[]R#3(-,VN39!ND&X:
ME<&=7[34J)&V-)!47%2'Q[I!5*W`$K)8!UE,%G!)1532<!$NSYI1X%YKUP:-
M.^>P=CE[4L)NQJ#@WM--9A3<D^^\UAB*#43!O;<,>I)+8W1><&_(@H7>GEKJ
M[>TL`(3(0TV@&J2H4&^OCCP"1!OJ[2'L)(0=ZNTA[%!OKUM3.]3;PY>F]F([
MU-N3Y$&1/'"3SG&(.$0<(JX5CI/&68BX4T#<J;]*L/65=R&L1T25S!L:[?FR
M>[W+B"ZDK;0K*Z6R[1Y9^E&<A[EMQQO.D0-:Q@$HK(5<@%R`7(!<@%R`7(!<
M@&L#?%Y4^8Y#-0K_NZN0=$9EI$*IR\Y+B.!.<P4[S:<36G6\'HHAAB&&(88A
MAB&&(8831-E""Q\,MT8+O75QJ&H]6[4K"\4M[I$%4;BK*M&8UK60.H((,L85
MQA7&%<85QA7&%4X!)5V42;0#<MJ*X-)O&#2G1;<5DVUXY*_J/:M!D3KIX8-;
MN9(F$R&;(9L=?YF#E(:4AI2&E(:4AI2&E(:4AI2&:\ZCL]E.BNF-&;;FM&<*
MZ.LH504FU^7-=?%%E7[UQ#OO$Q:%A,<D9%,:A_#?+,EX3F@0`"+RC"1C\JPY
MK]ULBRSZ`ET+V,U_%!=9"K67W]P^TFXOVQ^R($EISI/XG?#Q@E-L4^G!=78V
M;I,GB&AZ)5?ZAWJA$3@J`FNK,8UGA-T%41&RD(S39$J2(B5CRM/S&QH5C$PX
M2VD:3.Y)R+,@2K(B92)Q99^.>\6`QQWV>E]\9[.\%"A>TTQ42J5B0Y[NV;4Q
M2['EM;:\IKI\2%MZXF6/&0MR?L.B^POR`PYEY%;\4\GUXZ0:EQ=QRH#/_P]0
M=TUYG)5]`.C*(,)IEB4!I^)UE5N>3TI$OIPGU34@)FE7<%@BCP0T3>]AQ"%T
M.J?[%/@_%1W+A7H@*\>!*0S[Y4%>$I</W,J>']"(Q@$CWR>,P8EC<,UU2L$0
M`90$SDWA8@'C-V+$S7JK$65&[\NZ&ZOCEJ]!3:'Q.4WO!<#$-4O(<7K%(YYS
M@;O9+$WN^!3N7S(@F3/@%0MHD3$!-&$RGTY9*-`I>FL-EG!:`=ZX7QP')XQY
M#$W@-(+69GE:E)"]V#RM6/S]VZ]%=GY-Z>R=#X;\(>P8/M!O]@-Z=1`EP7\^
M_/P3(;\M#_T7!-(G"*'+&(XMQUGH\LOQ7%H0)EBQ0,,W-GY_Y@]%1W_5__PQ
M/(,Q.8`V1]G[LW/]C/`0?J9!?FZ.M('1]SS7TLRA;=K#@>TJOF;[SDCUG(%[
M!C',YY<KLO#L@[*R>:,A;[+9V&SST-8,RS/<H6D--4>#$VROM-E5%-\S!T]M
M=B!&#C.;Q3`L1FX<NN&4QQRZEPK*'=W-6`Q=OZ_AICOT',O1%,<U^ZYC6=K2
M<-4?:/HSPU5#=:S'QF^VZ.WF?]U@OF+V%=?RW:'F&Y[O.H9OCN98\17'&PZ?
MFF^:MM&@]5N0/C1,P[$&IF'9:G^@&+YF:4OK3<LVGSE?=?2&S=_D?&]HJ;ZB
MN2-3<_^?O:?M;11I\J^@T_-(,U*2`QKHYDXZB>9E-7<[.[G),]K[BFT<LX\-
M/C#)9G_]554W&)O8CATG-S/RA]U)'$Q75==[55>'L>FQ(#0UTR>F]`?$=VS+
M/!WZ3\48+'>=@?V@?S\5@=:\MTKQXFO&XZK))K_V=.NQ`F$'@1M8IB=#T#XA
M,[F(@W9/I&GZVT@QW]D4YM/@?!M<#_"?%YLLB:3M!)YIN3:'K;3:#72",!EL
MH,O>`=4HFV9@-R=?LX>L:$Y0:9R95A1+TV4\3.S`0G;4*BT,++''?AP$YM6P
M']@1Q_,LQTLB)J0T;1Y%H`5:V!GW!B)U[7/SP)8<B<$7]%Q^*POMN[Q&E$+I
MF9%K199@5A0Y#FCD;B/<0-K;R'#!#^"R&[ASHG5@CQ+FAI&0<<*9&\4LD=*6
M'7^)>("6[;\A7K?@V*;YI-UDK3E![NB5)WHS,4>E`+(CN.]QVXU#RV\Q]%W3
MV\90./8!!%\"YMN@>F`S+2L.8B_T&3=#X:+>L^T65=L.V$#@F/4.J'Y=!QA'
M;UXB.$L"+P:]9WD1F#&>="HDX:XU8,\#^/1@>178!S;"#V*1!+'C"4\&L2E!
M8?BM!VV&UL`675OF06NT!W2(G""6/]7MC$T[#%SP.T5L!;&=>*+5;#:H:2L<
MN/N.LP7JQOI'`G>`DL+S`V&9//*!H3WP[:/`;JTZ1%/FP*ODGC@C=`?8TP2.
M='P9F9;)K#AR(L9EN\_`IWS`GJ[KGI=V>UW:T`\])F/;3V02RE!&5B<\02`&
MWI_K;XO/"X"[!?5P--T\4+(1N&M<@%=C@]?&[;AE.0^X;["K_D!3K5<_!JY#
M,8P;LQ"V$O84'!<1"H=U00"/^4"!6K:S+;:[X0*/95563[?E/!\_=<F'W;1;
M<YDM72%98KE.!!#)T!):!EAL1TGP+_^Q5;(X(MW_7)EH?\5#;%4\+.]\%8]>
MN2%?I4`G]::.=F>IV7AO7;+IP,6R0+VB1%RZHK37O'S,*LQMC<MZA:DO=:CU
MQ@C3)6'\%V48VR<H-9MWKQME]YCD?9QE*N^WK,I),UX9L[36:3Q8J<KNFWE*
MSU,J[H$R9_3\MYN[&UP4?XZ_W1B_9T:F=<MZ$;5NE<T)[E79K3).BPFE%0DJ
MX/(,*QJ&*D@]9/-RB:FY]HTU?"_'M<I]$*W3[`8(#A`4'KHQ$OC>ET4^J?+T
M"I9]&672PFB6\``A^=R2\+?/Z9/1YIJ/32'N$N"AF*NT.ECP<I']EJV.U]O2
M<YPP!G/L"R>P91B8;ANUAPD_Z/0,(#@-Q'V*D@><V]R,P+KXTN1N;+/.J18\
M'"9[M@.[<\!XR,@X)@(EO,25GNLG#D*LE3DHT$'X^58P[O6]?`'NEK2Y;_(D
M\9S08EW*+PJ]@>^U;6T.@-B+O<!GOUL!N\[*^22KZOA_&\RR;\#[B?;=V4W0
MQ!*N</P(P/0LEL12='EA9-D!03V7;;H[A^!Y+?1`[=VYL`A<H"0(!43N@1<*
M@%NTT$=^/+#MMFO[SGF@#W7IY"AXN<>M@`'71KX;!'Y@,NFUK!$DPRR\Y3"?
M[X)70W`\A/OXP8G!BQ-6S%T>`I@QL`1K*0I!3CS,^$(T=R2$0-@)D'9=MCG&
M<9(R2H`Q@\B*$XP;(E-TTL5M6[RIX\2=7:TBO0Z<#4>*O[DCU=&3K+;V.8RO
M65TVU3C;/S#CNW&O@I^J6GUE/&;@P+U?Z\3?;.M&G+G[I:")F%>#"SJ(S9YO
M.B#O<Y3-\PQ]OQGXQ]B@D/V9URNL8A_]OBOP-.\SJE13NT-:K/)QOB0G=MJL
ML-^F3C&70^TYVKND]VD'4P$!F[%(T9\TJ/R-WFN:UPAA53;W,W`BJ6*]*"N,
MQZLETA<<\;1:%6`'9OD2`,F4=2JG4R!9<0^?3++1JBUDTP>P6?-TI#<'?@<)
M!:>9:OQ5E1;WF6K,@)6HRJY`!U:!74/8ZF8Z!>Q08P.$.!&'J-?'N5QF^'9X
M8^N0=ZZT^@34`%;!B02Y#EOI%_#;"WS+')L`-!P%O;]L5A#.%"CJ1E%B((`-
M!4"U>9;6*L`I@.\,R\8N@=4,-CG<0:-E,P*<$4%8[@'_KJFF,46%@K0!*)XA
M7OO.#3+J3H07$)*V&!"@;7Y(\SGM-;P!F:I6C)!6U%<!TM\R0@-+YU-$-YW/
MKVBUM'@"ZE?$=1K^#E#CL6SF$!KE\V:5$6W*1XT_ZJ\-;J]GL)SV)6Z,3U-D
M0P2@*3:YL-W`5&T;!8)%EDVRR17P!`1C4T`&65VM/4M!ME*C!G.3`[]@WT<!
M@1*%6_EB"2:RW=EUDP58547Y8^.C?;9ZRZJ7Q?T_@-(1;.Q)CD?,`@^,N64G
M;B2D<&R1>%WZ"**A06++,S=]^V<@.`'$?=Z;YT5V$'DQ^#MN8+NAG:RK#A`?
M#>IVS/>MTT%<5UN.(V3H6[$3^)$(O<AR'.D+V85(5N@.\UV.\,5.,-=0G`;I
M7GJ&`M8.&;AM`=;HA6]U6QX'PUJB+5QW-T%W0?H;=A]E7Z9?E/($U?P"+S-D
MOB=][L06E^"Q!Y8ENV2FB$SVKNFY;>_K';)S7ZK[M-#IF1_#@_Q=:=?4&.7E
M$E3O(AUG#77E&[J1#O]=Y"N=`<.>73S"`@!>M;DN,C'H/<"#686J,_^+5#DP
M[_QZ4<ZS<:/[YY85V$J5\*K2):VD+.<\K>ZS=JX=Z/3';$ZZ'>S;+"W`*D\`
M)L6&*WR4;$5>3.?I8D&?HRU,[QL`)UW-<FW,`5HZ35"WO79XC7$%N('U>2B;
MVJB?:G!I;XPOH/AO%?KE70/O?R;!>FK'?=TL]TS"&&S_^C5\N>H?Z^&.8B-X
MW[--^R?YJ\MYN@+Z+W`ST3BJ70:+6,$N&V.`CG@!W!W,JA`=@<`Y>1+@:V75
M?8D[`;P#KL(<]KJ\QR^`3U"AGPC,LLS'5T93M7_IM5&"750?P6+C;((NV!7F
MB4=IC5Y;@2GBZTE)Y9[%",RRVG\``4+8:Y7,1'C7O&2D]P39!)QIH'6&'%!E
MX]7\";%"!NC6K/-5Y\H"=O1'`*'+K.JDLH*+:%+,\E&^@@^S;+%4[=`;'-C#
M#+X(SLH"K^EK$)?1TWIAX+]FH=QME5%^R"<]2H^R(IOF@,,(7H40M=*53E>:
M9ADFAG_/E$]3YW]V7P:-!`382$'#^^^K=($)8O)NEODR0Y8#!WJ68\IZ7B-J
MU*\/,@/T`KH!Q?&`#3EG@&X'6_>RGH"N'LN^A]KR4_UO%!^`EZ8<RBEP"[H_
MY"^#BO^E50778UAH3LEZ]#!!%7SXY3;\^M&85,V]EG4ES.0W$GF)ID"\>^HS
M6V7D[8_*"8C]?E?M:+6[(S]Q=C4<P5\>^@<F@#H0#:CNXBW%U)-9Y:]6$'`0
MM=KRA`[IOC<-!FZ+_08J[,,2?'_XRG(&LJ+,#!B1$C1..@;6_@.+*F7QT;#^
M_J_F#?N[\9CJSNP')9E=.2@IRPE]/4)B]EL70;@_@,[YN%TX(=.%K=Q:3L%$
MI17&$EI,,=C*T>*48`%3L'(0D&'+.D!&T9CQX=.OP.K`RHL4GH/_(!I<YJB=
M_LH0-I`^++4H8X?O4=X8R/TB+VO0E1_4\^":J1LY"%.M6T#_-6/08F6]6G]/
M0[*$M73>`<M%L*-STN-%I\I!FQ(69=&)7UYA#6\ZW2BBP<]!<]\`#Q)%*GA?
M16&QYD((X@KCRWA5CD!R\1%*\]`!$NJ_1U&&?^M.@T!T>MWF&*HL7XP:4$A$
M+2P@-CIM@>N'&0;KRH'XG*&'4*G]5[_D$^,.[#R$P4"G\//=1WJPJZ9ETZFN
MM_UG6C0H:.J\@GMCW/9AT*L"A<I'M5:=002O`GG*"M"'J-50"NN>'5@0'*#S
ML_&L(`N8Z9AZD6$$O@0/'Z+1M0)7!P24,U7C/2L02%;9.DN$Z0I@KPT:T4XC
M_^!6**14,L*`3<^!I=&:@98F"PC&RWC*TJI'Q2WL>W3!"N>5-CS*7*S`1S>`
ME"K]LDC_B:XC8KZY49,,TP?:8O=L53/2GF1O(^`%CQ#O9YB.,-(Q(*Q80=>%
MI\;?',]%5`S,9<RS:Y2W!W`R^P0!W*@B#%NC&+E]^1:G`N9@M6F3?TQ#`;+4
MI6'I<`U)TYJP*>@G]*&1!D&SFI557BL%%BR7<^U#&Q\^!\''UB6*P3E;9J`$
M2&H`V]H(P+*.GXP/\>=@0VAN>F^G_".ED&"/MLC=O?);0<O%WSY2F`%P_J&W
M:UV+5@D@@`A?>64L<-OG^3_!O0(910'7VJ]$CEYGS@BN;J'%!EP3U-OYJ%'L
M!S1K/90.YV]$-U#$]!$MH];H9S7[>3I:#K^Z>Z4M0B@50/E$)0BD"%1E_\?U
M5(;)^?VYL&$>82O/D*WP7.^M\H,G\ND;.'>?BJ3-'0:HBD[K4V8AD]ST+3<,
M$^YY82S#N"W*V<\<WG%-<ZN?[^7`G0^I0Z>HF!2NM``?T[.C((J".&F1<DQW
MT$]I>99X4Z14Y?UU2`F;2VXGH>-&9A(QSIR0KZN3;%@^M87CO@2I9X`['U*'
MNJV=0#BVSX0,8B]R8C-V>=NKQMUD<-[M6C#[39'ZTM9!7K%38<*DY;L1]I'8
MTF&`6=<ZX,*'`Z2``+[_$JR>@>Y\6!W8*LMA,A:VY?E!9/%`.HD7=ZW_IASP
MW[5CLZTNY5=@I3I6\*#@\><3;<_Q'%MXTI:!)^*0>5&7_G?=0=?MM6O3,;]-
MP-<`'`7;(5;Q7=^*_(#Y/`J$BP=VK*XQ*APV4U\S[F\EJE\%V[YF(V:Z0>+$
MD1<XPG(D$T%B=CET+QRRL<4$/Q?=#C1",1;'TK>$GS@B8IZT0K?MF$\\'@SU
MA@6*@[\<MD=]F`N8$KBU@!]5,(J=/.$,"X5U=^"+GJ$:Z+QW2O@%E0`/I2-A
M%@NE(Q-A,M?SVLUW;)G\](VZ>$8!WK.FH[%)[!^C//!I([B_(@<XZ0JD/>3N
ML!@.@7]MR!+^,?*Z;B`<>?:);TL56()#'=R!(_Y;>4.OOX;@L]=LVQL/`HXU
M..J8"%D]=0/4^+]#J$T]4Y3=19[,\6P>IG<,E9:&S\;@?>/L`-5_3!"T8346
MOXM4U<4I"L#H&\/ZQUFF$]0C_,X*<<4A1"M5IJY[20XDR,EP80$]2\<S/<4`
M_Z)#]NWX':,2#-MU,$[)ZE37TM<%:VJPUG,L@&IZ#_!5766?`F7]%S52H:,*
M^!3P2%[/T(!F%66C-*4FO<VHL?*_BS+;E%X@ZV!K`0:?&=5_UL-$5+]%W4LX
M3$L=,.4+W510-)@2(CK4*L0O*/0B,@Q'3E@N)3$\R@U,2NIL:%,$.!UB4B[7
M"7Y8^K[))S05`NBB6@2*IYW]`.T)?AJ)TLS5L*%R71\%X*E+!\>[G3N\>T,!
MQX3FB=)]]VTMO*;?%U[5T3XN[XN\)7BES\Y2_JMNEEAGP*)#U_K1;L8V$XWG
M:87W6]6Z*-/:(V(7O0@5'-L5(!K7)<@4MN\A`_6<+54UIS[(HE6VJLJT95%4
M"RBAJH-_(*=+[/W''"9I,_IJC[^I^XK*CLT">_"1Q76"#C4:+/C4ZI">;E+X
MK$>:Z*6(=Y70]L$_A_P8K=CH)K"B;0A22\*/4TR'T,9M9@=)SE#7Z!X"0%IK
MT18Q+4RK39H#RY&X#62LI\)01QKY"C%L<3\V]W`&7V?+>VJ07ETVH[B_R^X5
MM"_PW#_]EO2;FN/8YL*2KAMX/`3W729.ZR'%B>B[[K5:!.+>'FZ[(-D$N/MS
MW)Y%.3;$$`FX<:X?^\ST/!G%MA/:K:L<2'O@*KLFVSH\-X#A:!`/1!HL3"+3
MD7;$(M..XB@V'=:!F"2#1`\3YE;ZX"P@[G/J'7"`G9C9EA^%\+^82[.C(H28
M@V#(8N1!GQ7$`W&'8P%+^A#/![X;^Z:#H5O7I^4\T\/.F>.=!.(K`C<('.,P
M$B(2,1<NA.V6&;9TY-(:'+R`P,W9FJWR#!BGP;DW,&?"\2(6VAX>#!)^B$>%
M-9QV;#YS_APG1+P!G`<VW9<!BV0((5D<6+X;"NEV!UG"R!J<7KJVN,5VB/=K
MX=P[0",*.9#4,2$>MB6>2VU'FMB)]/E@.,,UR#=C)\+Y*QXSKQ-JE?Z<%_FB
M6=SJ_M]H>_C'<]UZ[L8@`L&E'286%X$$%<H=[K71O.T,ITJX=-+F6;CW@[6%
M2Z\3;3T&#7Z1:9W77Z:WRG%1'S4U5GWJ**O'54X.LAKPTEI%/.67'Q?_NSR4
ML1WZ%A@W!\_#@$)9'_LW_3>/_\\9W>L9GZ-R/AGV^9'/=-?K*^Z'_)IR;Q(+
M7/H9+_V,EW[&2S_CI9_QTL_XO74)7/H9+_V,EW[&2S_CI9_QTL]XZ6>\]#-^
MOPS8G[!$%*!RC][$Y^8]Z0/FK>^HAQ8\8+D+#1[R+*F2HIF"Y6Q49+F'R'0?
MSYFH]__1Z$`))218/Z7T8R0+,$H>]^\(>+8.I:.)K5I[6PRF#=U1#T;QR2!H
M[([^D_)0GWWL.`FM!2AQ/!(_H<)Z/LE3DBC#".9S)7'7;?:"?(MTK%889:O'
M+%,PI(L2'9ZFVGB'8LT1/@1Q$IDPK"%2Y7_CKH2F2!O0*=GD!119OW.)0U$K
M5:O$UU6JFDZ%3[)1*J1!_-0$`12/=7ZL5\O]\$L0W'[<J&#VKSO`^&`=E7:%
M574/@J8&:#L0YH5AF=?_38]]Q30-_&9:N!=?U2`T?,?=]?^HYH>-%_]4PU2(
M`*V.?R^DE#^&*Q<@V.?!0XW/`).&%PK]5+OS7LB<[0Z67F(%DR63/YINXHQR
MIUM5J6[#PA1(4ZF$3__9(L,^#'31*6%$5H/N1T$MV!R0?ZV[=E_M@DU5+\;V
M/6\`>^,+<FCT)2GE23_YTFKU9Q4YN"#&I`0*8,-'NWFXM^W5-%MZ=UJ6*S7M
MIFL,@Z`>-?>9_)<WOT/N57:/%!NAK_KZ#CQ>SVCTS`A=PY1,)'SGCZ8@<[6V
M8<>MW_98:3CP-BZ*`?2<'KV)DS8_&J@.H*_4N(3ID-9"_E=G'*BO\'W5ZUN+
MPC2?9STOX0[UD+Z2"4@8_SFFUA]0(HM%7M?DE=W%H4Z'X217C$,/3T;]GMWR
M;^J"J;A>T?U3/TB_\3^H2J'243H"W>&3H[B@<L(N6]IHU$*[.GLIL9.UI%#N
M<ETWBZ5V'$EZ5*:))'+'Y6([A7)#HY!DWFR4A$&^%W4_6T`3JM8`M:JW;6#L
M=4Y>J9O#="51Y=/*Z>:XMQKG;UZK,A,"DA4Z1]*.--8P5J`*5.#?E4`@#L7/
M5(:.G/*L&%/L@;G4%)D(IW-UD,)+9Q"]0L0_UM/3(,I`VTO13`$`5CD6(E6R
M`"/@LJJ[>7+MD#O45#C+OU1#O:CPINJ9>35N%M@G""X"F+3R$1ZO\#*V54,.
MA8JSQGJ>&(Z5ZQ)_=6^+3Y/;RYS*RYS*RYS*RYS*RYS*RYS*GV].Y??LK5ZN
MM;A<:_'.UUI\S^+0GN7X,:0!F$R9+F2R=W.*RG,EF/7I&JP%=S%C0P<HVL-\
MU!>FCIXM,&VY`-NIN^A4G$D*>:3;J)6\M%DU_?;-)[HJ1T%!37NH##[%+G),
M2%Q#R`H?_;@L?#G_?#G_?#G_?#G__/T+^.7\\^7\\\]Y_OE-#X%MG3>C2W`'
M=X*?=*>!&7I^F`C'Y+;/F>=+SU]?4^R)P5E9Q]\ZS+L7EM?!O6\PO[!#*1TI
M@AC'LKE>PI-P?8.9-3A`ZUG>*^&F2X=/@C4V0SL,;>X`8#(*/#MD[1ROQ&71
MX$)4RQ'/P-I?_WCX]O&`ZP:!)UUF,M.3G.%,IN["5C.)!^=\Q7.D?!%XIU[#
MX/MV$EM>G'#/"21/1,*Z2\G\R!R,WG+,G13<=0?#"Z'<1T<)&RU]+J+(3$S.
MA)]8ZYO_K&0X+G#[\.D+H80_EIOG:T^]@UG&KNO%GH@3B<,-8RY$=\);V,YP
M%IOM.D.0=\+S.M@/778=XNTF8>1(QKV(6\SW><NUS(H'@P@<VWHWT`\<L)9<
M,!=`YX)[B1=(FUOK,0]Q.+A5Y)H)^SW)OH]E;"<)_X^]*^MQ&TG2?X4P9H!9
M0*YFWDPO>@">L\:V75Z7MQO[9-`2RR6,2M*0*K=K?OUF4A)U4+=(*4G%@VU)
MUA$9&7=&?N%[RHA%*`I"UU.VP"N,F0A+JHC.D!@]SOC]\+]5/#H?<'PTJR5V
M!*:NC$+;D\I/8)<5P'CJ:0G@C:U=N"^3<#R)^[#[D-I]I,191@Y3+/3]T"G`
M24)9(I$(="2)TV.*^T<]@^9S,NWBS)NE_;SVMX&G2(G`U]D7?-4?>Y\W?^KO
M<54(_57M6/KU_J<*U7H?^KUN//YM%`\_Y`'>=I@&*MQ08NISPH((*5FG!?`H
M1?X&-%5[;9V[U[%MU?G$S/<JB]#Q_M85E[9H&5C`X:ZRY]RW)1:NCXE-9W`=
M>BBF&Y5P67)LT<VTEZG93/>7D=O-\V%WGD]'H_0A'B1+#39'VQT[DHIFAIFO
M%A2&`7&C!5"@6[([S'&HV+B.`ZBK<%E[%,B5G$C?<["R3,*Q)0M%.`=_930H
M[PZ6G-2TK$_Z3DDZ>?TTB)6J#'MZ1.NTDG_L9ME1@%20&Q!)?"P#(B0I@';0
M)G59-UR'4E;=BO8A#Q/B^3;V44"0BCLBSYZC&Z'(]S:,_2)[A._0):7)8Z*"
MJ>GLW$]Q>I\^Y.=(O^L.GT])^O"4IY5[(M)52"DO<)0'MY5#4<Z9$NU4"M`9
M[CIKP^#F/_+F[_:=O80L=1AIU2QG+71=70X.:2"HJ_)RS)1RX(!&N(BPZ;I;
MKV\Y^1NRV>VS?T\[-8_8%:2L&$*NM`./N)0PC+QHO@RLEK8,])7_TG2,^9JQ
MWDG1>=3OW`2EXXKW(;5]%A"NDA@1%1/841"&%Z'^_;3>=J3XJ'Q,4D$%"@,L
ME3"1,)A#T(0L"C90OH?D*1FGD[M33`)*;)^R"#D(*1?A('<^)M&V943\^LB]
M7^H1.8YFKN(,AWB(,H9]PI1MG,-/VY'KA"?0O$3+F83OE`WEJWSF^%R%N12Y
M@2"^\`ML:@^)V@C/C<X6+B_8ZH3,)]1GA$5*(#1^.IJS57*^#LIE_<SZ[X;]
MP:]O5/29O+%^.8&`G%L+]JB`,O0IMTD0^D*#;=$""@X1MEY]V4_`6.4#LW3J
MI'(5DU$DO-`1BB$:)9P06LQ7]U3H7BYC,+QN@<HTG$3FKFH+08A*1G0,$2HS
M*95^3'58ALCQG5(BBM?PS@^B<M1-DEX6I:/G?VB\`=U?NTRD#GKL_Z'WW8F-
M)B/U#T%?>TG_ZV_)]W@0YD=UBW3I]Y=!-Q[J='?6G]7;D#`M9QU8*+L4\=#Q
M50BHV,_PO"ZG1#,LA^N;?$%Y`=N7.,]*[A]UL_YHF,OPT7$K5W&J2EQ)X'$1
M">%&RI<5ZJ[H+J>S8JU$L)>FLY>P+U"-0B]@GDK,F1=&OK"970#@$<I*.'*(
MY\%WU4M8'AU[]#9$$:<R"H6>8!NH3,@OQL/:$>->68LQ7YL=L9^H\Q>Q;P!+
MA!CG(0M<S_&QBDZQ5U3.*<4EQ,0+4U]/G01'`?$P#FT:4#U\ADJ?SPU;2+S2
MHJO=.9WMWC]6F)W[NN06")F?V-BNH_XMZK2"EASLWPF3:X"QQY!7Y<+VE19]
METNFPG0;2Q82WQ-"%#"SH@R3R6Q&MANZ,Q:F[<G]]'I-^%.#Z&7K`?$!V\2Q
MI_(./\#*B[I,6>30YD41A6!4.E#;L91-!&VG_X^\%7DR?^=!N*KVRD`9''C8
M#XA*Q9DNDG@A8H0K<Z<R/O5WV>$XV-E,^3HI):(WEQL^)L</0.>>)P(B*?6<
M@(8.)HM8WB_%+I*4%'PK)>?0O//$U;-]CR&EL<J+.]Q')"HF?`4J_"J=$JX!
M%A].\^>\^59K0:8G_9QT8(B$<)`3AA1Y$</(]0):9-*,E:29.*O!X4823J)R
MEQAH=%_ANTK&_1!Q2IU`N',J50A;-HU"GD"E1K'L_>^PZ%R/!Y]>TNY3G"7W
MWP;][WE'0O"2O!]^SI&@>AKI/.IGW7CP?[H+;!/?MP>Y[X>_ZQ:U'WM\7"B5
M]13$\7VF0:5#C5L[%R97R5EIY6N![=G+6N?2>.5PH4Y7OP)8[-A.&+E2A_,1
M\;BG4J_B(!#S,@RX7#\S7J=\^[H^ZALIG^+7O#7O6%_G<VZ'?N#Z(9<JFG1U
MR\7<8`F5TI=;&-;\PS9*3J5WW^&P$W`<*G<<XI`PY1%<:1?E3(9*\G4"I=.&
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MW7IV12TZ;`VHKX)K/_"1PP.;%?/\"`YK7,\4\RV,4]U7FKG=6:MKHK96W_<\
M<AW2]Q$BW!$<A13[A'-1M+T%ZM&FYB<BR-I:]M%T_AIVR982*\[\(*`<1XHZ
MY3R"HKU%B=:&3B);$'+N&O+.YZ*FN#5AVVX#'C2Z^[P+]OUP./J1-RS/E75O
M\.A3/R)*FUQ)(L\/[*`X>F5V.57%:#T665O`T>LCM:[/MD441I[-'11R5ZU1
MA'@>'#LB<,I1X;I#K6!].VWX>>M3$0"34D4\H8@\%F$J16$0,2<EOTOYNM<]
M=WW[?-29\AFR@$?4YSYS50QDZXK6O("'H["T/O7_)ZSO\^+&PX>7P43?4@@'
M>3N[NWRU>__X$&7/,0E5[N$1(K`R(2A8ZN@C[D7'AUX<D_3S*@S,O^=87M^G
MHK,T<6`*`I)?$=#707)(YW<GW[Q97^0!C)OS2;__G;UV6T<_7_Z1&43:RM5$
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M%9;]^D;C%;SY997G"\![8G>.V`##Q%./S=)7?=\]]7O*W5<:`8&`GB6@'_7@
MF&7YK%T\&V)2S959<@69W</+:TOQ1L`^,(\@:K6(6AEZ&$0-1`VL6EM$K9VB
M=+#5:DB`MCWGI:=QCUXFI6A\RO"W]QIM9_22Q<->]A]@H"Z?E9["JYG_S"OI
M)>?9`ODZR6I]B[O_U/-^A[VW,S#);C=)'A^-,F?G2V-^(&C-3P2MQ9&@-3\3
MM*9'===4YJU[80H7_U(5=_9*W:&>X'!FY#)9*3=P=;&I\3N_M1)V*8&X8:<(
M=N:V[0R2'.P,V!FP,V!G:K4SA$FP,V!GP,Z`G:G5SE".P,[<2B7Z?!9.85>L
M]\/N'DCOS95$?-UB=/7J4\R.P)4975.VNFZO#,[W<+VX<M]7(_1F'X]`KT"O
M0*]`KT"OZM>KQNF-%#;$;Q5D.P:56G9=?,1T7.W%QR^C23X0,;_^6(_E)<KR
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MAQ4SK6S$2_C26R`HCV1/78"%V/-\0@AVJ&-+/:4C"JD="9DC4;,RM/\60,8C
M9:^NU7@!]U`0"BI=EX>!HWCO2P_Y>BJ1H&$9^_\@T7WH/B6]EWQ&1VEJ_!=M
M9KZH)7J#G1.3%O/G;(]ZKI(:B5WDV7[D!7(N/IXKZ74@%^N"6)PQS!HL.*9Y
ME/6SB7IU]&A-GI(9H**BZ71(Q0,8L1+&W1*$HG,F@J*@[82G`_P]:!S8R&R`
M5=E^O[Q`+5MPEM@=:UOD#B@L()D7DLP@Z:X+)MHIF+>#Z6(VCFG-[5>`N=&\
MBQN^>BU5V9*5SO*^:_H0XX\6X([8:L%54+CU#L=*5SY6`DO3>DOC,`?LS*W$
MT)4$-9D^2QI^G\+8ZS_6.!T])EF6#S&U'I/D&!2Q]EYP0!U&*O/AINQ_W:X:
M/'*+-8+3RGJIVJ(/D$!OYVWX/!Z,7A,]H_59SSO-1V+7H4B5\O/*/H?:E8'3
MMSZ>:Y">-==+M4FY"!1E(%DZ(ED:](=ZC=8D[<<#R(KTYR3$@)`304Y4?(Y5
M=U6N+?H`.=%VWM[GLYQCW9%8DT=I3[S&$41KD`H9Y)S:HUI4,E`M2(1.4*LS
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M)D_JZW1GR&^ZZ:/:U@YY&A?DD88>^DQ.ZS-!YS::4-Y.#._6@Y3#`IN^0.@2
MJ14>N?6M25^>TB2Q/JC_>\JL<*C;0%<YNC&4+=YQ4F>3>>)I7)8*`CH7T(\J
MZ%J1S]K%$TPJ3$>`QKLF&$<0M;,:[T#40-3`JH&H-4+48&"0&1EQXQ.*TP8&
MF2=`YAHP$"&XYW",M,WG"^>'4;WD1S(8C?59U35UT_C^8Y@&L_PY1U2&SFK\
MSF\M>UU*(&[8QX&=N6T[@SI$(+`T8&G`TH"EJ=72X(Z08&G`TH"E`4M3MZ5A
M""[&UU?%:5>QYB$9#!1E'>M[,DQ2C6L\[%EQ[[D_[&<3W57\(SFE9K@7@ORZ
M?2XU7*MPJ@/YW\,;4T2G;B</OOR&]<FA-8%:@SZ!/MV@/N$.EM6AN8!&@4;=
MND:ACE/A&,X;T2A`M3`#U0+J0&>QKQ6%(M3AW`"(#U.DI^Y@`6K68,S`F-68
MWZ#JSM?`F($Q`V,&QNQ*QHQU;*>R:U]@S,"8@3$#8W8M8T8[A%]PP)_ITE-A
M!>U\/+F*\=ZVP<IM^=[NI/^C/WE=G2=X`&:<[=B(1S+R*`I"9C/UG$WG_:'(
M9B)L(V;<;&*(%<^89CV.4BL>#*P<7-T:#^(9^EN:#.(I;-RCQC3+/]0'!+C;
M0H`C5T.`:\RH0;-QP"I8X*D?;"E'&W*/W+@$X*H'O(;C&-Q/IW@=ZL,N2]MB
MVEA5P3=H`Z!Z[)"X/_(7DMY;(_7!5?L4?]_=S'PMVL*?2=KM9V82]RE5F:$>
M&VXD=7EJ"0;N&O6^BQBUPRLU]<O:Y^0Y[@_W.=1K4>>K5].X.WF)!XN=MW[K
M/YII5C3HRFL2IX#9`^')90*`[]_3Y'L\,5,=WBOE[0^S?M=(ZGZ/!R]F\DV9
MD86F`(A39>;'BP?Q4,5]\<0*DFX.NKS@,T$=JTIDTAL<P\0[DLL.L>OGX4U,
M68(C_II"_DI/\!LABD:@"33$B-V1^I$&&B$T8+\,M5\U,ZXRX02NMD4<#\_!
M31%-X[EZZR`M_TACE4?WKAG3&1-S((=V,*L,',*4+:X[@`##?'@G0_.NHN,[
M&S0"-.+JF3_PYZ;X<W"H>YGC)+/X`T<+6U@Y[W:I+)ZME&_&!+I_0TQV"*D.
MM&D?EQ:24A^;*A>FRKH'#%(^L^S843W`M6GB%4K;,(($=`OJK,"XMC'.E`)U
MV\/Y=D7MT2A]3/H55J%K!X2\:O".$>U@7!.(QW9FW78,#\;]AO%8Y9T#`,=0
M(X<:,/#')/Y`C1QJY&>UWS\DXTG>?V\1.V^[-P!,J=&Q.>\((3M25M>Z>O.@
M5%".J:N.=5&$O4:T6C<#?J\I#?RTIISI&'8V0NS`1#;51!K$V;J5N;IY-.;P
MK&726*G#-L4X-L,G&Z.I5$\#%]?GF2GB<ZYOO?6SN=^33$.^:OC7Y.<XZ>HG
MDY'U0[U\Y0I"PPL%3(@.K_"._CYVF2)0<*[0QBABD689+'J7"R6NQ;):FA4O
MF,8W0HS`@K70@AF=?%?7+PRRU9RHL]W^SQCU4ADSHI>;[V>*,%P^,3:H\'>!
M.VCY2`\X8Z]CZ)-@K",E3+&#`Z2;#">,%T<HV1_%+G:'##@I-T5XP)8UU989
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M2>]MK!@2?U^N2U]3X9N--P!C*`\??V/?(9A#"8TY)K="0*=#73;*&#/$[T1U
M;0RF;ST8FELP-(WP>498H69$2LXEIIHT0FC`?H'],D04P7X=$V)5=Z.LT4)S
MKOVZ[>/0S97!/];K6$L=CG549FM@YTV:_Y:Y1Y`?D!^0'Y`?D!\#^0,G@KM`
M-6;8DS]&@WC2'_0GKZ>(W=E#9DV=4"5L$S(]4Z3EKU!JN:`MOYW)S4[]1\%E
M(0&]`[V[+6=6X;!%<&:@5.#,-FM9_1T%M^',;KO>O9J>39+TN6/UA]9K$J<G
M5;;W*6#C](S?508N:LIVZ\\!`K89#JEQ^L#N*LNB0!]`'UJ@#Y7U38$^@#ZT
M0!_`/U2181B4[M?)V\_][)]O'],D45F'RC[T7+(TGAQS.ZS]!35T)QF4U*"D
M9J:':D])#=WQRXW);7=1#33/!,TS5]$D-#R`6C55K9KDT"X7.+;;H<$IT>*4
M2/U>7ZETSWKM)X,>5#T*B^1@A"NODK5;K\Q3H>8Z+M`:T!K0&M`:T!K0&M`:
MT)K*,Y\JIP:=/O%GZS0A_2U/HT$O2;/P7R_]R>O'T23Y(T[S(3/WZ6>]3=DQ
M@X/LT!6AL`5U91"P`*$(^7:$1>3:$8VP=]'!07S\LS38I?XY0L5,G^D\&[4E
MSW&JWI=9HY?4FHPF\4`]FF23>*@IM?Z<L=N*,SU+J"1DIQ!2H+HO3-K68<RG
M?'_'^O.IWWVRGN(?B147H)76_+)_,AT)G5AZZ%%2V;+^@LF=K&8%[\H4'3HI
MZ0"Q7+'UMS08B9TY%XF<.A?IU'D\Y-(#@([\P=,Z(2X"4WRB7ZX?E?A^R;JZ
M$_VM>R=?5#JG'J)B$,\=XAG^'/?3/&"S@N,:=T#J0.I.E[I92/9)AV0GI#+&
M-.+5@2E6XG\%1XD2=X13/T0DZ#U(XWZ^?HC3[M."N5CF(<_ESKI!.D$Z=R3V
M"-_A@X6Q>9T%=;@70CJ$P#2J"^EIV\3GOCL9K=0',:K6(X!`F<:?>@4*VW?V
MP2VJ)J85YK"R8M-N$-^:I:(&,:[ASL`@3H((&BF"I';WT3:._3][U]:<-K*M
M_PJ5FH=SJAQ7WR^S:Z>JNR5-N6H<YS:3FO/BDD'$.H/!&T$R.;_^K&XA#%A@
MP,+!CA[&XQ@0:WV]KE*OK]L&H*W7CCGFMP9U;/@<UJ#8X1N`!Y[@_#3)$N,3
M_@2'3[4>_&R`.ZR]F=MQ/EC(%*+M#EH#?$H#U*>'/F=\*;502"V]T=3ONCO.
MW0&/1U0@=D))8XRHK:>V^+3XM/@<"I]F1RIV&WM8F9[(OO@IC`_9[0@6:OCE
M';0@W>_ESUTF)6(;662Y1<1IS*TUE.IR4H(D5!CWI),26-TN[U''?G:BH24O
M_^G?_FL^`:ON5C,*`<C-G,D[CWH<:K3C<]89W6:>:,V3/=^3><=+SJJU66T1
M!.]EW5&Y*_17OT>Y_%;XY;%?%:[3*4JP3SOGZ3#]DOG?.],";*B;%M<=[^=^
M_&1R'28V;M+Q]\Y-EA;3<=:9C#HWX3-A?.5J6L`R%$4G'?:@1((+#$>3ZNK+
M[^B/QB5#W3`==,:5NW3@KZ!J7H"BKV_2O^%/IYN#P'U'WL8#5YQV/D3E1C>W
MV;`HM]^N]5(OX4TZ*/[]ZC5=\%DA3"PCI8BADB8\B9@QP6=U@C!&[%5G.LS+
MRTV+WJLW'"D*"[P@>JT<^\E*-\L*0JG$4FPD<EQ(;/!,5H,3BGFR*BNC@AU,
M5L#U_099HX@0985"#"*B<493)JNI,<J3>[AB(?@A<=TDJU-,.Y`/)T+[GT[A
MJ,(UKL&5$+",9F0U/D&5SFN_U\\%AA]_9D7P"P@'HQY>9^67LR^[?#=(AV_3
MF\S\DQ>7HYML?%DFQ;.A[SORKYE_PZ=O\/OW_\G&H]A'X/,P.;$X^,<3'5FC
M$D84BF-+C9G#@A/%7KUYQ_YZ"(3]%&P(NB3-QWZ4,EL8HZP(7/Z<'\+VP6>`
M+>(&6309%RLE,<'6(.NX$S2>88,0HXXLF,QP&G!]@TX5:0"M[74Z#A#?KP<1
M"64E&)C#+E*8,H/CN`)11[@>1/F@W[TT$.]'KR40J9""Q5@J89W!CBF9E`DL
MQMCH-9:H?D(0-[ASK!&UCE(5*60<,TQ@654!&L6R'D3Y4D#T_,/).,O.9NS#
MVT9$MFB'4<QY9*B.$AP9A3#X=N7,BCI;"R'"^E#N7*?3#X?POBLO0L@0%[&6
M2@OF>&(L1]!/S_I'(>-H#81"_&00;K!"SDBD79386&MC56R($)4CQU',UD'(
M?R8([V?E10B5CJ"U()0BAR2%'D,[43FR@X9CG2,_0PC?!OEGA!R%F4ZN1Y[6
MH;<,V5D)62/%]1WD9V^3Q384$XH3DB1,(*TY$8PF%>@1K,`"Z$40]M4;)1DF
ML@G?7P?#85#^FN8#?[LO&8U_\W?G?@38+"+:,N7MVPD._5Y2!8DDX75@8PTK
M))NHFAY`HR',+ZI*(DR(^B\HO[<6[/5(<0U-/.%6$8-HY+A0!,W#J2&D!BDF
M.=>:-H#4.AT.!M'G&>>)*2E/JO':,%W[('"+Y60D)9,">D,P,A,+KJG254V>
M4*:6;RA`SQLD?/6&G^(F6L3=-&L63K#C?I9/IMZVA[V[N?CB;%CV]MO4E2M&
MR(5$A#`NH3P21"!)YL4Y<HFJ,4*"&2$-VN"#6CTQB-M;ZL.W,@A&B:911!A"
MPG"F[%WA;BVCZXQ5-W,_HPF5FT4_Q.%'V&L228-YI%420V/N9"S-_+:&XC:N
M2R^*$=Y$)U2KPI/!4Z+#+KH3A%]3/$_B'Z=71?:?*5PH_@H_/GV_+?/YFM<?
MRM^8&:EB[B#5Q#9&SA)_]\-(;1'B8+-U`)/P7.8Y(KQB^.%%3S(RKY5WO=F1
M*.X+>8.AW,16,8%C,V\S1;(V.XE3V6!(W5')(T-X\XU-#3":A"**9:Q%3"SB
MM,I8W!BY#F&,3G$3->9+@7B#$7-)C`&+=<S&&(4;H/.L)3%%ZR!6IU2W"&]S
M8UEI"*TNX<Q:>&_$*;&J*F*EL'Q#F&CBQN@Q(+S`.G8VG(SS89%W:["LZ0:6
MG]M2L%4C4`1])R81]/,,50&76"SN/;<E4LM&L]5:10Z&UU[M)H6JW<8J(32)
ML+.),#.J41\W56V[*:346C<8-._I\.00T?=L0S,D&3%1C"Q7&IIR;N*[NW,*
M:U0'D18:<M%SA*BQCEP89"E%,?4/^1E2#IJ>:CN"X]JN#V:LP29G2\V.!,X5
M.UR$TT#-;:BRL?%](_:[)^8[W6)EH_5PTL.XZM/!Z3<JP/>$'C4\I?LT\G]:
MD,5\^3+.OD!6>DS.<`E#<<R<,!&TXRYQ5,]+2'?O%I+/&9AMLRGE"11]:KSW
M2C4DHH9`+HZEBR-+F),ZKBPXXD;7Q5$NI6@RCFZKVE,#VEC4Y80A01+HU"UE
MD>"`X/SVL75.;P@3#4;=QRF\(_C%=C=ELX/<RH.8(0D2$#.8CJ`!Y<3)^5X0
M,/8->._2%#6J8\/X;NP7'@4N4TH:HB!P*!$Q'@M]MQV.$V+6-O7D=*>PW)R&
MQP'MP6X*+BZ.Y`(*/*F1P]Q!B8<9=*O"2)>0A!H6KUT<?,IWJ4@.NCB[!UC-
ML:;4.1))L$M+'(WM?.(`^J)-:J_:Y#JIKAZ.O%>[[&KZE(UOZG>POE^>ID#:
M(JLP18I*PRD3;-X,4L+-JS?OQ%_HG/!H19&#"/SC@*&K8R9:&$L1B[GBB<:1
M[PA%%8A$$CD`AO^ES[%\^<`L6PP8BZ08*Q,)C5W,D8MDY0TZ$O9G`>;>8)+3
M,;?<((4CJ'89Y#!%JN[7)$@'8#`^5S\%,`WL+9E?XH.7<BEMG:?_Y#?3FWN[
MZ6$!!->8<"&)Q4ASDT25<9HD]L:)T>IV^F/&__XN@^4V$._6\"*IN3(RX8)&
M%,G(<C=W7A$AN]KP4LCQ-3=)#Z+)P1!;*1`^9#=I/H2&Q`%R8T!EF@ZV]G'&
M,4=$<NFHM3A12+$J*UB7H.#CXARS)GQ\?TV:A7)]#[=.`+(%E$SJ6&EIL';2
M8:C[*8GGX1+^'BH/?HX;J3SVUZ19*'?NDA]CK$I!^T\DT2Q&S$$H!)0K9U=.
MZ(`P.R>D082;4W`%>#]Z?`:Q-NM%T_%\ABG(4KS-OH67BJT&$_GBLQ#PXQ@9
M$1-E-57@TBZN_%D;8VIN4%&^NLEA*]%V4.=B<KURIVVFR<?LUG=W:)X&W2`M
MBHO^;`)[-H!]EVC+R_7'HQL_K5J=+3;J5R>GW>_VT&*WQZ#T=311)HXQ#9N]
MB<"&)A+RJW9U#T&@BU!;`A.4;!*4=6HP3F(JE+$)$X)08YQC!'$;,1H1PNHV
MME&*^('46#Q_L.I4]]C])$3D.'88RF]-=!Q;*Y)YG0.]2MWF'`Y-+-E2K5HQ
M:]1<(@-X\.'&4BE"'*,NBL#*"%8Q%,V:\"K^:Z3OW7M_C155[+[G+8FPNXB;
MJB6M1<P8I0I[F2*;4&.KQX`TEOB>B$1PI1\IHJ=4B/*B.QCY,?)=F!&,D)8A
M#8G514HF4-A%,Z.@L5"Q.#@S0I.\!_?.X0F&.4-J?L*J_%>G1.T@9`A/0.8`
M6?9F-.P$,]C_9,5:)9[@\,Y5`H8I?,782U=>\=WT"A3M7/3[F0\PS3`RO.Z<
M#3OA5)9P]MQ)YUOFZ0Q[VW-+/&#JVW),T%/>@>L-X*\-<4V$T.L/_?1\$-W2
M,HI@&>FDDW9N2SA',SCW.".T(<U_"7<VFU'Z%K)Z4/RT8_J3S)-<]*;=DO&B
M4C3[QU>B64F>$6SL&US/OQ?BY&CJSX#]$2B0A@T@F/(XZV;Y5Z@)AMD$5GC4
MS;)>T?$U7&`9@1(9:O*N%^6'Z$SEJ6I4Z=.&H][3A>Z*]^C91>WPN?;(Y?;(
MY?"9)8:T]LCE]LCE]LCE]LCEGX8?L37/]LCEUNJ.SNK:(Y=WP+\]<OG%^'UK
MC5_:(Y=;ZSQFZVR/7&Y/7#MN/WUIYM.>N-8:5*,(M4<N'VMH/R+<GI>+'A%P
MSSP9'!&2K0D>I0FV1RZW#<!1>^)+,Y^V`6@-JE&$VB.7VR.7?RX//B+@VB.7
M6P-\P0;8'KG<'KG\K#VUQ:?%I\7GP$<N[R7*H'YWZ$;!CN8@X(OYU)8ZN9O<
M@F_,X`M[_KC<>WKL\S4UXP2S#23-;,8/4SC9W;;(7CHI9[;FLQ&@R>T4%$V+
MK!F5L)8G3*IFQ']@R&QXL'F(^FT3>^DPGQF#Q0"AK]->YRK+8"VFX=CEL#H@
M^=S@9NM_VOD,2_<U'4Q3/P#B%[*?YN/.UT`<"HKZO\R7\2KKC^`J?N0L#8-I
M_M6;42_O0\@+@]'AM;$?D^K-+M<,4HR3$U1S?V(OK,`.AU_"V=L+NOKQG3!/
M/YNL\R][^=,N&`3$V>\0%3H.5/3W+`)8'R?P/T_VX'&Z"`=ZSR'P3!'C[!HN
ME'_-.K^/9F=8AW&UZW'F41M.KHM.Z>CEFE`\6Y/G$;S*"?G.W3[\60"[FX<J
M1MT\(/4MGUQWTFIXJB'O82>B9GOF8P+`MVQ\-_L$_O-]T?H[LSEKL.YB.@C#
MF#,+R8MBF@X;C`OTA**&PL+ZT';:N>B7L2*]\?.B)TW)CE2S83FL2AY(&3K3
M6W_*MC]F?AZ2%]+,B4\R?BTF/N25(VZ+XZ/ST='&`CB5)XHTH^Y)B!O>GL:!
M_@5L;4GU1=4\`H,,8HH?B%U(3J.O>1%"T,PR*V">242!<F@AFART)-IV/VU3
MY5"52L<5M<]!:Z/ZG>M-UT8/%!K/HG1]-O4/QB^E_FE$AYHB:HN!P/TLQ"N=
M]TK:A=*U)UXOK^I=/:V"VG7A*]1\9>6SA._<2F9`'PVV$)Z>!EIPK*(A_U""
M-N8?SR1;G@T[LTT`?D5@7<".NJ/A,"N9,$+-[6WBS^F@"SUL^@4\QEM42*BS
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MP>])&1S6D'KYR]<]P6P9;5K+?"++C++NJF'BC89YV,U</W2O5B@+&L&Z`5N5
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M%O6/X3@#7/XOZ_V6YD//17`Q/!M^S8J)OUJQ?ORTEW7SFW10_/O5V=MD:1I5
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M5P$3%.T'V/9ZK@`)%^G'Q01DGV0;O'>N$:;8"FF<C4&O)+&QBF?N2KUIV(,/
MCR_-&:N5V60LFAO*+O_IW_YK#F$R[Y97^J.D()MCMC%J'\UP^:=KSSZ1W:8S
MBBK0H)\/P<=RZ'6+BGNFF%&*]$?C&[#VDKWB-V/>=<;9?Z:YYX6"94N_E$0U
MDQ'\Z^^LD\W-)_`D%<7TYK8DKRG9YOK]K#LIJ86"=7I&O=O1>'+'A%,K2KC8
M(A?1<`3?<=KY"$DY\"^!"#F\N>@4TZO_#5\Q@E\]/<A<H'S8'4Q[GGKG:S:<
MEA0\\&DOW4G)A723CO_.)G?T3_E=&#[I!,Z1UU>I)P=<W!TTI_29R1CND@<F
MDN[RL]CP!N]4('\&&GKY/V>=JXK;Y$Y2N.AU#M\W#I_VUQ_GF><8]%>`%[^"
M(X^F%653'UQQ-)X!_`TNF`UR4+'CZ4`AM100)'Q9-`VD<A[A;C[N3F\`7;AD
M\:_.]>@;O'U\`L)/0/89Q:'W_^F@U^GEL&3P)>/1C?]PL;#$NS)>+,>7Y=CS
M.3A#UC,@"=C4VZF/I!?]CYYGXV(Z\<)Z![%ID7?-L!?E@^DDZ]4EZM4*8S$$
MQPB;A#'#N1.:(<(4U55]882B"R&X)&UY]89`1<(PI7=J["?J8=2]7U`MJNM8
M`CDYMC+!D<-Q;)VA%;F'E+9.74HTXU#,'*>ZL+KOUZM+D4":269)C*FTR.K$
MS=1%/$E$W>K"XC*.Y'&JRS:JZY"A@I/$&:>-LL1!\1G4U0FB0LNZU66`A&"D
M&75][?/KC*FDVG?RR8<Z-RKJ:B@HHA=U>4T7E)$$*GR16".B&!Q4,\Q-Y9G:
M+"E35I-:A.)HLPS[R0FPKY736&A,<(*<XC&-(&8HBRJ7LL)&JW)JIO>3<U1.
M<GZ8#7+N(6J,&7&193%1E+)(8@J]U<P=-$9F550L60VF=7+L+>XF"R`)^&&B
M$.,LB2)E:!*;2EPJ.5D55W&UN[2]JFJ.LGX*6>[,SSA#0OO@63K71-?+F:]<
M1MD5?*"8C*>^)+@K_R_^@6S?.\][W?3V]U$ZO-\&+#>+FAB(4`F"VAG1"$$;
MH'5E0PPKM*#I,/@C](NGB%>J;M)A05<W\!S,_<\EE=IH_,$[>CQC'WOGR<?F
M+Q:S5XN5:!#>]:#1D075P`483ZA1OOQGVEGPEWD?3.SB(N;%B!$L+__X&%U"
M@7,9)("(3$\UFZG:E`K;HM(K6:W?0;DU6@[',VOXF-TB#'EFPQT,*RA!)-9(
M8J8P301U!'%KJ(5X;>MR$!-*;Z/PDG0/J50&\CMXSDK*OU6=T'MVT9T@/!G!
M_RA>EVJ,(U)%"8H@KS!NL2,LF1<27"QJ-:/N@URS2:=Z\?Z_O6MK3EM)PG]%
MY=J'I,J.-1=),ZES4B6-9A+O)K'C>,_6V3<"LL,N1AP$<=A?O]VC"\*`C1UA
M0Z*7Q"`QT]W3UQFIOQI3:&MG6*/,T-;.$E#WR>Q)K90::@(50,(8AR$#AQ3%
MI%1E)3VQVDI)P?5:^FL\OL6M_B%>?VN%\$_,T,^3;WVHB=<DMA67)T.H09*J
M4>C[-&]!:]DM[_F<#"#27+U-AF`*`XC>8>\:(@^(IH,MZW1>MV1W[UH(*G4`
MDA`T"%0,B0:4^V5@#C172P'/=>=N^0X.:W)X#T4*4%/T55UA?:MW'WC$J93,
MA%Q[C$0BBLL]-]>X&DSMS9GW9T'(JBEJ%!0]5H=7]KXR"9I[VG,0X4UG<&I+
MV4=L:QH9F\`UL23"4.E3$?.24JU(?:O,$H"):4'X@RBK<716=#O'NLUV&LSO
MP%8;I<U5?F43AA9"M1=RJK$[H,N%(#X4##0N38-RLA2JB>MY<Z5X"&DUCLZ3
MWM0V-TTO<?]AA%K5A?@.]7,_*YN$]G"7X@K'N)S:Q'6MNUB[F?<9&!Y$TZP_
M3++L9#A,OUEK*5.*96M9S&.EC#2-#8MT:%PB/183C\82/H'_-/*V:'C-6A['
MX19$Q+8J(HWYO!'H3!6'I"!F'I0Q<2@"$)[A2_N@.R>>O"QK4#P+V^JQ[Q,0
MB!`&:G7-?7"]'O-]QK06PHWV18&V)R$FP>U(;I@',9D)SU."H(1\5P6>7DBQ
MFM:?HGV_#69F%?/W'A7\F.E(H8WTB62<04AA`LIE/M^_<I>.F4!UZMJQ@OP%
M]B`SZ'<A=U:=[*OI],=_X$;H_!AP93U791O5#Z)9F&7)Q.9]<\8_ID,U'8]!
MYCF/JWY7_?FN#U$/Q#%[GWQ+!@M)377/R7`TG63V!K)^R`\0-H%T7&N#^];)
ML#M;/5[MSNP\Z0*M()Y[UB.,E-):>S&/E=!<2Q;0,K!++9?.*_U`UM?C'GGO
MU-IL5Y!$JH`'$`!B0BC7/@_B,I=S0U<MA<VG%"3:\]X(4AHJC#$N"\-8$VWP
M=+84)-%BZ51VCP6Y=]Y"4:6%)Z-(R9ABT`J5*--F/Z"DP;6Q)USG\P.NA[0$
MCT(5"L.-D)2J".)L1*LM3ND9O=\MP0O9-'M26WLX:*LGM^>+1Y?_@]K-'LQ=
M%:!K>#QHSP2S%/(9//-$)+:B47CV^#;AFSX!U;8-__V`^#_8-YS[/V=;[9^^
M;WC+X+XSN/?OS>QVQ^)M=-?>J8[&%Q:8[$-JT;.T1<]:E.C*1WVK.Q:0MMHW
M&)I_6_*75]"/B.Y6U\^MJ^>>N-3=U=D6LF!)BUMTC%;5GD[5&FMNUZI:JVJM
M5]LY5?LY5>G70>GACY,>?YJ28N]+AL>A].R>`NVN@]J&"FW^\O-^ZE?;L&V]
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MMA<5Q'[XN?VH6\DA9\T]M-!6KAMN`JZ'[WLRPA[<]VQ;?<[^E3A?.]\29V0;
M=:-6#6;8]"SI?TMZS@;OM[SX')V<ORS[HI7@1<['3MXUV\$&\?W)U((M73KO
MDLY@`C_Z>/+NY:%S\[4/(R!ZTA2;8UL@J1%B5-DAQN44V&RMA_T$4]M)%L=!
M%*?1.,4VLTX7@5-Z%B8)49Y*Z+8:^M2@,\F'SV&5"EIAF*4U>I1'I(0?@JDT
M,IAE]D='*LR[L&"K/SV4BEV3UZBB!>504#9'.0)QX;H]%?43VP+H.K4M5A+;
M`FBA;XJS\C7OG5^4E6\4/X;J0[2@4=)%>QW,#AMA(E<;2-YW2^%SLKA/=D^;
M[6A#;`;4:NIFFKKHQ;%O.'PJ&HIGZ,7!\4.XFLPLLU6#<:<'OAZN=K#);>9\
M22"&.E6S\1Q4T7I^IVRFWE@`X.XNFD/#AI"[V\;(:TWB0281-I*O;,I&M13S
MDKK1-3E\NA0G$%YSQ@E+,$HGB$`\/R.'_[';/RAPYUNG/UA$`*VRS4.G?^G\
M-87BZ-*BJE;);3_#W!NA7Y/>W4\B;UHS$+KMHN%DZ)QV)RF:*B);'2(6JNU>
M8+%ET0<[(\BYD:F%Q+UTO)TK<"7V&^N5:X]B6V/M8X/ER\O^H(\H5"^P/?`\
MB\EO?HF>/9MV<CS<O(ZX2>:%2T.)O?O*=>"V`>A4<\X4:Y>W&,0F$**@%)^.
M!K9:Z8+1P>47;\\4%%1P'33G^I5S>IF#]8+LLHK!'S>@G$/QBC;+X$TGF\=N
M^+N77";C\;P:>^5<?"U-!E7A]O6G]')_DT&#@;ODO.@6;C_E+/4LFEP!N3R&
M=`;\P!BL!7G%@+$INN]]'>=K?>DMJFB$B8^J`2B'B/F4PTC/;SC+@=/"F\ZX
M%_9*M"M[/0NGDZ_IV/*SC-%'_MX9(IX=_,=(U;?_0^<_Z?AB-DJRTTN$9@N'
M/0TIVF3V&7OWP^A)M@B=-L>ENH46<#;H##]VKI,Y5D$^$/@)BP&?X`T7-_#W
M[-_).-7H#>^#FHNCF$H9^(@1%41"25$`UTI-W&`!-;$$#20>"6108D(V+MC;
MB_;ECK&CV?R6^N@%K-?'U*)H)[T<O.Q>.,E%T03<CR-N/*$5-=SS(RE4A<)G
ME%Z%Z>M2A+FMBZ8Y\FN"*<#*]/=1/S?B>!T\X:<:<)\%NC@M@0]/<SC$&CX0
M0GUG^D/:8Y\(SQ6G5)\YR`?C'E$J"B756C/%0EH!B"KE,90!\8Y<=D1+9,F5
MQ#Z&&?(H9DC%3!UHPD5HM%A*$8:1(E*[BKA&1"Q4Q@V,9]G@1Z[<`AMW`YSE
MX1PQ%L<C]-!)[Y87N(?Q\OMALKQVPJ/$]P4AQ'.I\8PP%=*-JT2Y=L0]HF0O
MF;ZX29>8)B3RF7)Y#.JI/!F[^*E06":HO_],8QFZO-;:IU[(B%">$M1CH4^#
M"B=1T_CYV"[`4)<LTN,AX2+@8(!N2+7G!A5@O,NCH'0L_(CZ]Q,,L[\.P9_V
M+)[.H+,6C'$!:58%,@3+4`C:3F5(@@I\Q@L%/7AS"5$B^>UX:?#YG`5RD.EG
MW<[@3RAH]+!WEYCJ`B!^Z',CW4C%@OF^UL(O5RQT:7CPYNB(T"-&<@+6S32G
M)4Z[%H<VOR4''C7P7;8!,4$0"JX]$$=$@82(4*8KU-U8P6I\8CD=:V=91PC2
MNBD9-#:"2Q[*T`V$%MH0P4J<>>X%;NZF5Q%2S;),1D[CY@O#7-0,3RKN&R5"
M/_8)*Q>&Q$+.8P5S%TE9F&F9$$P*-YB?Q,;SA&*4F1@RD,`-187=Q(D7(<CI
MT:?%F7'H^82Y":H$$<H')U`#?_]',MM@YEAP$X6QXJ'VN?14S&3E.P/&P7="
MX"!4>(+(?/Z5,RT1DEY?IT.;Y^;)W^ETDDTZRYB&18JV=-/ZG"WT?2("Z0LO
M%C$#^PED7%(<Z4BMR-D8=V%Q*5]@X`X*;W-C^H-DK&"!K]+Q)D(%:IB*7.ZJ
M"%;0#[C1E4Z'00#J%':[R2"Q$<&QH]=)6YCN-BWGR97%6!Y.L$[8@!A7DHC'
M@9+$CY1'7,_5ID1UC"#+/7AS^D&?GWYVU.GY69V,Q9GF=%R,.RBDS[/K+^E@
M`P)TS#@HL?`#Q05EL4^Y*`DP$+5R`O*9%\;.IQSTA_]]?9FFDV$Z2=[#!^>[
M_6J<8JGZ=3(9O3X^OKFY>?7]RWCP*AU?'5/79<=X^1AO/"CNGX"]_'Z0($HS
MU.D'SC$,_]LQ_JC_&O^%C_\'4$L#!!0````(`+"`:D4^O-G'`Q(``%:H```5
M`!P`;VUE<BTR,#$T,#DS,%]C86PN>&UL550)``.;*&%4FRAA5'5X"P`!!"4.
M```$.0$``.5=6W/;N))^WZK]#]Z<U\48-P+@U&1/.;=S4IN)4LF<G?/&PJ5A
M<T<2O225Q/OKMR'+L6/+$DV1M#.;*D<VA08:7S<:W4`#_.6O7Q?SH\]0-V6U
M?/Z,_42?'<'25Z%<GCY_]H]/Y.33R[=OG_WU/_[U7W[Y-T+^^>+CNZ-7E5\M
M8-D>O:S!MA".OI3MV='O`9H_CF)=+8Y^K^H_RL_VWX]B52^@GE\<_0[N33G'
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M@QE[:9NS]//Z?U8XCN8XUIJ397B[_`Q-FT;>7@X[5W`XJ]5B45[6B2V\K)8M
MCG*T(!W4L@/IF.QU4\O.%0S`ZK*IYF5()O6%G2?K\.D,H(.P]Q&.Q]H'6R,R
M9]"6WG:`\B&U#,KTIQ;_7PMQ%M.X>#.OOCP(UYT5C,;J[!SJ]51XJ7N+\QK.
M8-F4G^%=U?3FOUNM!W?JRDW`1E[CJ&DOWBZ3/[!N>1_K76@/9O"-+>O_LO,5
M_`JV6=70R;+N)!J'I3?E$L=*:><G30-K,W1CYMD4#"?M-]K9\B/X55VCH7IA
MF[*CH9N@Z7'@>6_KI,Z?X8!^WE/'.`QW<S(ZD![,WGMHTY#_`/6G,[3!^UBZ
MI_C0;+RT<[^:K\?Z+/Z];-JJ3A/#;-4FGSE%)J_*^2I)ZU-2MK4NOJ_:MTL_
M7P5`+V?]-?IG-^KLIAN3,S(T=-U4:R?1X2Q5+>"4?I%JW<O)EK*#,M!1[O=2
M',S,K#ZUR_)_UTJ$YO-3>;HL(VH1SFW>5ZNU._D!9^DN#G.?NB;M0#>T^]<X
M:6?&D,K@TOD(GV&YVCO.;A4;JMEN\MY:>"@6-A\O+DY.:UA/DMUL8$?R@]E<
M6]BS:AZ@;E(TWE[LX^Q^BA&8Z2;!?70C,-9-BOOH#F>LK?P?Z,K".E#"**E3
M^+*;:B2FKIWP^!JKKBX`9N?IB[_5:(M>-VVY2)'@;/D*/V9Q_?12C/MA'JO!
MD:!X8$CPH$I&8GG[T]=?TZ\'=>,!%8_5M=5B8>N+65Q_?:DB)QZ1Q>&*$^9'
MF"<UN1'A']3=PQH;"8*.UJP#[58&_76@\@X+;8HF?GKN)%RV`E];6&(@,WP[
MW9;VO[6_;AW;GU?^.P@W;:[W;J)MW'JG9=604VO/CQ.TQS!OFZLG:[`)99M=
MH+]L'A=WF7FYJM.*Y!4W<^M@_OP9ME[LI2E8,$(*SDENI"<"@!,K+24\^)PZ
M2K56XOMNSM-^5U5?H;REGW=5)3VY8B(M2M?6MQ^A`5O[LY=5<[TD=8/WO30%
MEA6Y8#GQ4FN2"6\(-3$2;[VTS`EK\VP?[S=TY*3V1U6-<_/S9^S9T1<H3\_:
M]:^7-6"[=U3G^VVX38GC)@WJ5",I6UA<T:>]QE&D4HV'%]+ND/.@^ORAKB(T
M:5_7SM_``Y3Z'L*"&Z^X\IKDE`L"@D;"06*7HPR!L2SDC/?3#OX#:L=HH$VA
M(E?^VF8Z?)#IVTM;!)7[S/N,1*\I-FTU\=PQDG,)3BCA=.;Z*8KX@15E#-QV
MZ\J>:0-+IN7,W^K2SCO-&7<("NN!<VI0N[V/)`JP)#*;;PR@S3ESK)^DY0\H
MZ<'!FL(4S-HSJ/NX0+L)"ZE\!HP*DAGIB%,4L3,9)S+Q(5#->1[[J4;V`ZK&
M:*#=4)%?CF_YYP,[[=L"D:%"A`<FK`S6;-<4E`D:W!D!'=QLIQ21J0*N]6;R
M+D=T7:!P&=-61D9DEFOB:"X)5]00G=FH%!7<P-[99<P>=/"H;Y8KE(XR!X,5
M9C$0Z:@C%C)+(,^9<+GV8'LZT!.%5SW$<MM;/A"0*6;$9(?2X+QECMJ7MJXO
M<+BNUSQW"+T3?9'C/T6C(4I33J*&G!@3T"_PSE#.=,;<#Z`,O21938/7)+'V
M9[39:5Y\4]6?D/'K1(#+[8CKOSL8BX?653B7<1F#)\8S32+EBH2`J'N.THB*
M&QKTDX[(!].A*;";0I\^@@<<`<G1>@_M?IW96KY@EFF98DAG01.;"^QEKH`(
MYZW(9.`^Z[F.-U$`/IA>#(7/%++_4,.Y+<-F:V:_[+>6+X*!:+.8DZ!R2S)I
M/8'H%5&@@8K`F)+T28?D@\E^*'RFB\([>I5W"Q=,1I$Q&8@S1F-,BM8,I$*[
MQFT>\B@BRZ&?U">*M@>3^B#@3#/<JW.HVXL/<WN9Z(P3U7F*#-%0[1SU]Y,5
MEH&UT48$+G/822Z(R2`2*7&N<QRB!/GT'8*#(HR!\9EFTF_:NO08FV]WA=]7
M2]_!$^A:28&#2%'F,^(<NM)YU)$P91`*[4*TC'MO>VK)E.[!05HR*EH33QB=
MU&-K^0*1RST7EC`6*9%<:P)6I)5-HP)7T>B\9Q`ZI;-PD"8,!<P40K^90;$,
MZW21K8F"6^2_C[2PD,>0H3MLM&0D1!<(EPP(DXJ"5UX;M=>#&+W7^WVC;>OU
M4J-KQW'Z5\$0$2)._YIEQ`@E(P0/*N1/>:5E6-%5(^`U459#2J:^2M/OE,VP
MA:!P03LEHB4TMP@1HQ3->02264^YYM1DTOP@VM!+8'?3%X9!:<+,EB>4J?68
MSO+PFC`84)-,AM7R]#>H%Z_`=5@HVU*ZH.C7!84>`\N$)EYX1SR&!ZCN3#+K
M<^Y$SXEA&C]X8`48!J*I1=_)^]U.4)C<&6$S36)TGD0O#6&:!A*-XUE@2D#V
MI,/E<3V#H3";0B->003D+WQ$%E_B9]E-+W:1%5DF<N&9Q4YR22#3.?89!*$2
MO`&@$>.*'\0\#*\=`R,WA8X\*%[:`A=7D"$H%D&RCH!1.3'H'A&:T=Q[AP_Z
MQA'3!,NCZL,@>$VTRW*IN6N.]^WE;RE=($@ZX`_)TIZ1]#H2B3X0L<Y%PP0-
M+.NYZSI-!'&HJ.YNLPP`T22)'=5BL3D0M3>'XU;1(L9`\]SD:4W)$*F9(`X<
M^L`,/YS(%+I)3]E5&%CH`^`S2<`8<&):Y^1_L&5XNWQIS\OV^HZA;>'B=HHB
M>!?0O9$$IS!%:(J%(?,,`R$&T4-06O7,=)[&&1A8_L/!-,T&2VO+)837MEZF
M2P@QU%TM5NLT?/1C2E_NWEC91UQ(22T3D!.0`7UB@?&2#.@3<QVL]4%*:7JN
M)$SC&0RL'*,@-M4$L2<=^)ZYXAZJPFKG<I8%`DIFV"Q.B=IQ((H++9C,9)0]
M,W&FV9<?U6<<%KC1,N'[W%LW1N)VASOH)DK@WKYG^@'JLL*YP-=@T]'RR\\'
M)\INKZ:0RID\<YR8&#.2@]`D2"](YG2F9.Z==_9Q]J=28AEVX4-=?2X1^Q<7
M_VC2"?/--7O+T\WQ\]U&I'LEA5,N\SQJPJU#EYHK252@BC"6AV`SKI7Q3SG^
M&$_LU8283C$?_0VGT713UVSYJFS.JZ:\O(IL[_F)G70%]V!L.H(&.)43B):1
M')UWDCN>LXCSL<UZNK(W](>,J$!CR;4:%\5IUD'/:_#EU654)XNJ;C=W4^U<
M!KV7JM"9YM8*(-$I35CNDV_/*`G&"W3H(4CHZ<%,$_A.I"S#0CC)<FBZ.^G>
M2XJV+8EN)2BLU98ZGQ&C,.1C`L-_@6$>2<<UG`V&4MWSH.<TD?%$"C(8>I,L
MDJZ#^O\LTQ',%FIH=F:DWBE<*!\`E*"$<YD3)0TGU&J/D#'@1E.?9SU7RZ8)
MB"?2B4&0FV8=[;]7EP=Q9_'W="\6.FSK^[P@I`,W4'\N_4[WMEL%!5#KT%@"
MQGJ9P(Y[1\"FJ,\AKI'FH$S/I?5IPN6)]&8T-*?0I=LN_MOEC4,Z.U1H)UWA
MM),NW9CA#"*9*46)D<H0SKR6-(\`>4^+H_Y43NW0*#Z.QFR.]EQM0F^.^*#?
M=2.;]T&JU*7"@NJ@!05+G.".H"'V1&D-Q$>,1H47QKB>1ZOTGUS'1H+W<93O
M5LID\O;OO4BOD_)UJ;"PT00?N2&9<XYXT(PP")Q(IDPN>>9]7P-G_DQ3XV3H
M/H[N7:?=?'>A<R<UNT5;9%(+B3$HT38R`DY%HB%3),LEC0$0_+Z7-^5_;HTZ
M',C'49ZUL;U.T^IKKNZOIK#:9,`S2J0*`6-8(4@.SA,P3.O`M6:\[U$+^N?6
MJ4%!G4*]$"GL1;7X[J5!VS<VKLL5T8+WDAHB'4[T"I@@1KA`-'/2\Q"BDGWW
M+J;9O)A(00Y%;2(-V`;%Y:5=!^Y[;:FDB(XR$;)D7*DGS$I*,BO3Y6@NK:1:
M%OKN6TRS$OW8^U[#8#K-\N/%Y>N.JA./2-5P[Z'NG<N272LIA&:&V716(E,<
MO;_H2>1.8>R;8SS"O0#:\QS`X^Z('2SQ.^N5(T+Z*(IU_[U!#]&L^VM!''+K
ME<!PPC%(EPLA#C(S!`,*K_/,9,KTW!WA?V[5&A33B>[S\`"A>8,0)H9GL9]R
M/:":PE+*<YHQDH',"-5.$&LYN@C:4J:CR9AXTD=4IE*N<3%]1&=K\X+&PYRM
M+944*FBG!1IL&M!YY0+=6)$6XR1"8$WT!GC/G9AI-.NQG:UA,)W:;KUMFE7*
M;YS%&PG^'8W55MK"!?!"&TJ,B8*@U98$AU`@W@GEG%48QCSI:R['$N\."S44
MD(^G/#>/CCY8>VX2%UJCW3>Y)`9R0XSU&/0&DQ,:,PX84:=KPIYRS/>HZG,@
MDM.<S#C?.'ZSN.UEH%O/8VPG*7+P44A@)"KLIK<Y1Q0Y8(>I!K`>O.^Y/2<>
MU=4>6ED&!'!RO_KZI5[-ZZ]0^[)).?;=G.EMM`7/@U99$"1W:%95;BGV7EN2
M+CC1'K]R^DD?ZGT$`S,4D+N5YYZ7EUPQ$F\Q8I?A*A-FEV(\N(Y"<^2="T.4
M,)(P!I)8(7/"45S4,C",]G1@'C4E:2@%F0+024[VW#Q=LUG-QV_7YY(6YS6<
MP;(I/W^WV3'MD9N;7%QN#:!D9_$W^W6'_=M!50B=`0U,$VF8P3!:Y"@'33'8
M#98ZY:V!O6]I^G^RM31-Q#J4K'[`K:1OVV>=Y+ZE-%H5QWUNTCW.S!(7`A#O
M-4;T*6LHQ$QQ]Z0O^3M`2K<OM!P$G6F<_W7^Q"Y17Q4II-(N@[29FFYA50J[
M(4"BJZIS=!&TR`U[TO(]6"IWG/C>P$PZH#>I?IV&\U79`H"[(%0@+*.6:$$%
M$<9+`DYG&7:,<]8SDIMHTV1H:0\!T30C^O+UJ.@VO4(%G5?KS<`-TSN'^0ZZ
M0@?F/,T"$0(0-$IS(C,AB-,4@%HM@_\QQGX_Z=V]NGI0K"8YR`I+A&"><B_#
MHER637OY:O7]FK&'LM!>!<9Q+`%@#&%B2A^V0A$>I?3>F6"?]HWWP^K&\&A-
MDZEX]9J_;V[OSH3$.Z4+B);RJ!7"E>%_)MTU%S0ZR90KII7EJF^0/MDR\4#>
MWS#H3"/URR-O^VW`K9*%APA,ZW0\3KNT@@"$&YL3KB4-1J'Y4X>_7WCDA=[!
MQ'TH-)-X@YODUNI[MVB_Y'<3%EP[+6,&Q'FFB`G4$1Z,(]%$I[6-F8M/_9CI
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M3FM8F\@QA^1ZS&^]('OL=L:$\FYKHV*8MC_OO55GBK:N_8CX>G$^KRX`+K=C
MUS=$O&[:<I'V.V?+5_@QB^NGE_A/"LDD3L;VIK<_W?C*C\!.BA;JBUF\L76^
MV96_0"OZ$=8WI]YPDZ=G<?^(^>4X?>60$/_X/U!+`P04````"`"P@&I%Z(+C
MG:8X``!9@0(`%0`<`&]M97(M,C`Q-#`Y,S!?9&5F+GAM;%54"0`#FRAA5)LH
M851U>`L``00E#@``!#D!``#D75MSVSB6?M^J_0_>S.NZC?NEJ[-3``'TN"8=
MI^+NZ=DG%B/!-K<ETD-*3MR_?D%95.Q$%XHB*7FW4HD="0#/^<[AN>#@\M-?
MOTPG9P^^*-,\>_L&_@#>G/ELE(_3[/;MF]^NS]5U='GYYJ__]>__]M-_G)__
M4W]\=V;RT7SJL]E95/ADYL=GG]/9W=GO8U_^<793Y-.SW_/BC_0A^<^SF[R8
M^F+R>/:[_^3221BS/#]?#G7V]%OX\(]/2>G/OI3IC^7HSD^3=_DHF2W(N9O-
M[G^\N/C\^?,/7SX5DQ_RXO8"`8`O5KTVMJC^=UXW.Z\^.H?H',,?OI3C-V>!
MZ:QL,/ZRY8_5M^/9JL/SQO3BZ<M5TZKOBZ$_XT5;**6\6'R[:EJFZQJ&0>'%
M/W]Y=[U`XSS-REF2C?R;`-?9V4]%/O$?_<U9]?.WCY<O!L@#VGGYPRB?7E1?
M7ZC1J)C[\;LT^130GZ6^#(^N*/CQKO`W;]]4[0,VD`")087,7S;WF#W>^[=O
MRG1Z/PFP7'1!S/>?&#]+TLG^1.X:J0?B?TT^3=K@^;+?P81%27E7_;7_FH=7
M;A)>RU)EX\OLP9>SZB7=26'C`0XG-9].TZ<QPQ.B/)L%@Q",30.U;-"U3_*:
MJ67C`3H@-2OS23JNK*].)I5UN+[SOH&P=W7LC[0/21&0N?.S=)0T@'*?43HE
M^GH6_ET(\>JF>B_<)/^\%ZY;!^B-U*M[7RR\YI/N3>\+?^>S,GWP[_*R-?W-
M1CV8J3JB"`^QX:V9/5YF5>BP>/(NTIOT/9A`EZ3%/Y+)W/_BDW)>^$:6=6NG
M?DAR:1;>E329J++T"S/TS/,L&X[5;-7W*OOH1_.B"(9*)V7:T-`-\.A^X'F?
M%)4Z/_@#^-PP1C\$-PLR&G0]F+SW?E:]\A]\<7T7;/`NDC8T[YJ,*)F,YI/%
MNWYU\[>TG.5%Y1BNYK,J9JZ2&)-.YI6TKBME6^CB^WQVF8TF\[$/4<[BZQ"?
M/1NSF6X,3DC7T#53K:V=#B<IG_G@TA^K47=2LJ9MIP0TE/O&'@<3<U7<)EGZ
MYT*)@OF\3F^S]"9H4?!MHU$^7X23'X*7;A(PMQEK4`::H=U^Q$&9Z4,JG4OG
MHW_PV7SG>_9-LZX>VTS>:QMW1<+RAWY4MX5?.,EF-K!A]X/)7%C8NWPR]D59
M9>.SQUV4;>[1`S'-)+BK7P^$-9/BKGZ'$S;+1W^$4-8O$J60)35*7[;WZHFH
MKT'XC0U#YX_>7]U77_Q<!%MDRUDZK3+!J\R$'U<WBT^?Q+@;YKX>V!,4>Z8$
M>PW2$\GK/[5?JE\/8F./@?MB;3Z=)L7CU<WBZR<54:.`;'A=@\/\Z">5FCS+
M\`]B]["']01!0VO6H.]:`I-B5-.X_/4YF:O"1IK-+L;I]&+9YB*9?`/RAM))
M70VI*BYT0>FSGET2%'ZO)J+R['SL;Y+Y9-:2O(WC]$1L/DW2['!:7PS3*:F+
MD<^G?OK)%VWI7#=&ET3>A;&*T?R3/U]!TI+4+2.M)3@H29JEU;OV+K19MJQH
M:EF'>WJ(_S+SV=B/.W],L[I8;X]?9X\Z>MB>9:NNGMJT#M7_\[8*<O',\-1)
M/MKA2*I/XFV/2<O1)*]F%0/=_G+FIRM.)\DG/WG[)CPC;C%*;!7'S"GGA&:1
MPA&70DL5*4.%9`#;EZQ-JD4!>5'CV3%OOSZ?56K%UV*$&`A,G:/0*`(I((PB
MS6J>M!9H%T]?M405H[.\",G*VS>P[K4T?WMYZVI!Q@`RRH?`*[`7/EA8\!^K
M8?SX[9M9L9BK6'X8GA7>`3M9I.?!>/O;ZI<M2O,<R9ND_+2`<UZ>WR;)_46E
M3!=^,BOK3Q;J=0[@<AW)7Y8?QY=9>&/]JG!6+V!17])U+TN#7C&'2FD(E.("
M0F`U4Y+6P``6[7PY.E*D+>ZQC6+M*?2\+[P6BG0<G3`O(K?F6O'4+[9("6.E
M=8Q!@R!&3-B:3\<0C-=&L;WIQ\;H^:MV="J]9AIQ$%;_=W5C>)UXP<]K4(GA
M5>':3\*8MS_[S!?)))A.-9X&*92SIPFEY>1+^<N+7&J-:NPU3BPLLX9BQF$$
M'.4N8E2N3#`D8BA569<H-M:3?66:#X=8<\TI_>B'V_SA8NS3)Z4)OWRK*^&C
M^)V_329/"UPVA!5K6L52**H$4I9::['0.I*DIEH&H%K)&;W.,.)P?+J7ZA,I
M&^W^MTUBI9!`#`,C.`,."D.)J.D-[-/3<_\'H9YW"L/IB^]D//11I+:/M#8D
M^Y?9/X+I2!\VNLLUK6(08@R'@":20&8=%<'"UW112LAI.,/V<.9=L=Y*).;Z
ME^W26#6('9#!L[*($R.AE<(QOM(P!7`[0>SOK0811%NN6\G@;WX20-%I/O.C
M.W5_O5T@ZUO'U"E-(7?.&<=DA'448O(EG5:#=M+!IRF=3B!H):KEBNOL]IU/
M2O]^7CWWZD:-QPODDLG'$*Y^3B9/U<I-$MQKD!A$1$:06RHU4@X9B_7*"%@+
M3R09&&SZLD_P6JG$@@Y;3>U7/ON#+])\O$GRZ]K&A&LDM=`0,R$%P@2H58:$
M"&.G85<'$W`'&`TQ,_!2#TLWGP76?PF"F,ZG'Y+'!49FOJYJL><(,>7,1`XK
M$Z(X+H`+\1VH><=8N=.P[$/H1[_(#:$U'_VH$L#XMVR49[7)^C`O1G>!D:M/
MD_3V:>YD[B^SC[X"?%R9-Q?`2R;_[9-M<TP'CQTCI*H4@@IGJ0HI.X5TY8R5
M)NWJ8^0U:]K0F`ZA@[]E13.NHKLD8!J<Z[1:_*S*C[X,6?O5S3^2(JWF>*JU
M37GVO)J_1BM[>%JL(FT(QIQB;47P\$YA4V-J#)&M])2^9CT]/LHGI;G/-Z4^
M<=J%AGX_:FPMIAQ9:`F3P!FD->52`QF2&8DA:J>)[/^%)AZ,YC#^N@Q&/"29
MV=CX!S_)[RL`E\6'K;YX2[^8:RQ`R'2I`<0"R(5P<)65!"?12FOX:]::+O%J
ME<7]G#_X(JL>NEC=7OY6.?*/_B'UGS<E<UNZQ$!`2+F)$.1``LX%$2N*C5*F
ME83%:Y1PQU`]$^Y/%R]7[1VVDJ_1R0L[5_!U5'5>U5*W+.K;W#B.G./<1II#
M*5BD900MDTIB&7)H@LC.I08]<[5I.=_ZAC'44F#'(510`HH,,SJJN0&$M<M_
M.UJUUX40OBU\'\)]SVOP^BV'TTB&+$F`2%)@D+&:*E.S:D]L5=VATMI2]=X/
MAN.738&T%CG"&8R84$1*1%?T$H7=ZZAZ-T9]4_VT'0RG+[Z3KGKW+K7A4X[E
M`2V?JI5.HVUYZ\N&L36*&.&,TII'*(J<QF[%B;3MDHK>%HUUZ#`/PF$XB4;S
MHCH<J[%@OVD?2X,YCC`D#D;&,05,5&MJI%UT8O)M*Y2ULCT,BB%$7.UUJK*G
M;[8\S:*D*!Y#/K787;U%Y(WZQPXY*"1!("1=W#D%&`1+O@U3<JC]*WNI0&O9
MY?TC-,C+_Y"DDRHV='EQ'8C^>L#0TS$'7_^_1&J;8=AWK%A6JVTQPT+!""'+
M0K)-:SRP$.HT:LO]:$S?:`U4+_1!UZM]FN_];+>&K&T?1P9K;`@R@3&#&7,N
M@C5?A,!VKJ/S"G(_6M`%(D-(^D/A[Y-TO)SRW"WIM>VKU?82*NL8P4HQ!"2$
M*[X,H>V"^<XKN/U(N@M$!EDY,KOSQ0O6MRT2^:YQ'%"Q"`8+983!-&*2<;:R
M4A*U6^G7>?6S'QD?#,?@\7[3.#_&SEB")*\*K0)P0@E?A2XA8&XGULY+B3VY
MZ@.0&,8XY_>^F#U^F"1/1]F&`&)1H0HN9:N-WMPM)I(!QI0VC`(0PHR`&JFY
M1$3A4PS-#L[G.D1DH/+OK$A',S]>GWZ\S[-1@YBLZ2`Q-!I;2@VD&FC)M;/X
MJ[-RT8DLXNY8)WK#9V!GWD@9UK:/E50B)![!=UF-!3/*.+/BB[=<T-1SV':P
MW+N`8CAWOM./QYI#QB(@+'&&B,@26>U!75!N(]MR+5#/<5E'$W1[\CZ$U)X?
MLY2-%P>RO3A>LL$\;-,A8A4"%!"222.D!E1;[51=];,4"WU:KKS#J?>>$!I8
M/YK/S&_N%!MM<*0B0("11"`)K*OGCJPC)CJMN=GN!;=9,PY#:A`+_W2\<WUP
M>(/,;6V'6#L)20A@0RH**5&!M:^<<=MR7=\0.M!:1-]Z@RYP&4CBWQR&UTCH
MZ_O$2%!&+$>26A<!367$ZYC%,MMRUJTW^]^/W#N!9A##GV>WO_IB:ORG!A/J
M:UK'KCK.PFFNH*&*,L@XK/-4BXC@K<3=6Y;6@[@/!^4X'GXOSQXC)@%P4"M$
M%(=<8?.5(XAYNS6\O25E?8CY4$R&?IT;9>#K.\1:66NAQ9@BJQ"E$;,K0T6M
M:)>]#6'#>XK?ND!I"/D;?^,#;>./@;PH_$R;:<&V;H%++!RR0=$QM%0*H`Q8
MV3+(VKWY0QCX?G2A0ZP&68NS^Q3@=2MP-O>*@>2:(VAXY`AA&FD0K68WE,+M
M'/X0GJ`??>@.JB'4H=74SQ;4-&18,@2A`0)*Q)2@:C75A6R[15B]3?/UK@R=
M(370(HLG4[:@>M>BO#6M8X$9"/A@@Y"PC(:H)WB]FB=@3VR:IPOA?+_*XD!0
MAO(!RQM3=BZ]_*9IS)QBAEI)'(^X5%B&D+?FAH2(][0BP1Y$?"`B@\S?K,[[
M^9"DX\LL2N[3V=<KA]?-WJSO$5-$+8'`6D!##$,)Y[HN?%AA3VUM7`_2[@:8
M8:KQLX"1']NDR$+$45V?,9_.%]<`A1`U':7;J_"[.L<AMZF.VC.`8:H`9(R"
M5>P2P#RQ,*\'5>@<H^/$=WO%=3&2$'!*,#68(P0#4@;5'!E)VDF]MWBN!ZD?
MC,DIE',/*./&D#/"M6$<11@:R2B6?#6IY0`XK95W0Y;NNL!KZ!W['Y)J7N+.
MSZH;GE^2\EJV[X<X2PG&>*0X0`1'0`K@$'?5@AAB=ZX,[)FK/;?O.X4HT\@Z
MZBRWRG$#;<T-1.9DM^\W%<+V[?O[<?^JM^];2&448L:0\85?M"!"FYI5C%2[
MO4;#;M]O+*TMV_?W@^'X^[^98$HSJPQRC&J&F>2JIC?"2+Z.[?N-4=^T$;P=
M#*<OON'%ML?V_=ZE=NPIQA",7!4+(S->3*5\\,7BINO&LXZ;!H@MEB+$7E`[
M0X%@E@)&:LZ-!H-=)]1^S6%+!]L+/L-KQH+*4LUG=WF1_NG7'1G=K&-<E558
M9*4D((IX!"(:K3B-@OLZM?G*GC3A0%R.I0&793G?6_I/G6+'"5,0$F*@@P0#
MB\G*?'+@VB6N/<Y=]BKY5I@<2^I7\UDY2[)QFMWN*?IG/6.G"5;48L`$IL!:
M%BE9\TH1:A=Q]SAAV:O\VP,S<$&J14S0H'>L(;"$.H0D=D)*BQ%F-<]61NW<
M0(_SF)TI0_?@#*P0>X0"6WK%D>$A`*[VRD)*E;9*N)72(V7;*4!OTYC]*,"!
MH!Q%\#LC@`T]8@<P1]0&K0;(*"<51'@U6X%1N[4(G1\C/(3`6P%R%&$W<_S;
MNL4""F<XBB0VFDH(M..NYA)PV&X!4N=G"P\A]O:H#%"46#%>7MU4.YK=)/_\
M.H\3UB&@QD*%D`HBB@1`4!K.%1&61DR[G8[EM.H1UA'NF%$A+,0@`I1!0FMN
ML.)#W?*X;SVBL1"VUR/VX_Y5UR.`#$D@B:#B4%&$J=/(UJQJXH82]"'UB,;2
MVE*/V`^&XT]HAVQ-*6T$-`"("`2:N:OIM4B@UU&/:(SZIIGM=C"<OOA.NA[1
MN]3VD=:&FRJNI\%UZ'D9/$-97F99_K"X$+V^06/[Y:&-.L<`*L0YA40BC"`.
M@!!=<P'8R5ZYVQC\O&=$AL@LJL,,0U3YH<@?TA!"ZL??@G>^S%97XZE18.-I
M$<_N[0[[#Q9CK0Q7BG&$58A`H`8L6B)BM'#MELT-67]J&U#UCM5`VG.9A;3%
MO\O+;=G`BW9Q2*&5$-)Q$E$9R)=,U'Q8:=1@M>9F,N]34-_K1&N8AEDN_S_S
M\FG'UJ]Y=:=A-DHG_@75O^;=F9,^'A<;BA$A400$5(!BBX);K%'5`)Y8F7-`
MY3L!M(?0X9\#[!4O5YE)R_N\7(CRZF;GZ5Q;^\5:4189R'%X6[$@U<UBJN;3
MBNC4CE0_JJCS_H`=9J?X?>%'Z>+R096-U30O9NF?R8:;VAOTBH6+6"2JR68$
M!")61YRMD(.ZG?+T=X3G*2E/=[`.LL>DFF[624"CNA\U)):[M&9]AU@)B"EB
M!@:#3BTBD$:BY@S:J-U!<?V=[WE*"M,)HH,L]UCLHOM[FH5_9[[PY=83@K]K
M'#MN<0"'`&NDHQ)38E:&LSK9^K06=9R4CAR,YK"Q^-7-[TFQN`]S<2NF'U<7
M5?CB(1UM/:FBV0"Q,-I"9Z!ET"$F`!016;T9BI_:,?&GI$>](#R$;@6P"A]L
MI/%//Y_!L]S6VR![:SY(+""#"&*)(8^"K];<0+IZNX!HMU6^OS/K3TG'>D/Y
M.'KV[)J5O53K6;_J#.*(<@V(T8X!&9'J=5KRZ0`_L;,U^A#@3AUI#]=QU&)Y
M)TM]@M3R;I80\#\[_'LO?6DR8,P$%JHZP9@*[1`%#MBZC&.IE.U<7V]YV5$4
MJ0<<CZ-AWQPY6^62WQU&NI>&-1DP%I)B;I!@P?$CQ97#7P6A#&EW>4=OB=Q1
M-*P''(^C85^/OWOPV=:CA';VC4,28ABV5%A9E0VY@G85+2#4\FRAWI*[H^C-
M89`=*<JNC.;70Q';FI[-P\2*8P,P<)`S'@RQ%CBJ47""H79;?7K+YHZB.)VA
M=UKE^T[*]K$)^2A`"$%')4,1(@K5\V3!LW][J?RQ'=:PI=M^,#RB%EUF#[[L
M:A'(EL%BA+D$E%NG-2'($$94/;OFH#3MM&K(K:<=+P+I#JMA9JH?EY,A:O2O
M>5KXC;>S;9W!;CI([`1UF,*((VV14-42_945YDR<6'[?IXB_F[?N"<.C:-'F
M>Y?W4:/-H\08&"+"'RR%@"IR5J,5!N'/B5F=8^I19R`.LT\Z'WD_+EV`L"+V
MZJ:=)NTQ3$P(9A2&URADH%`$3#BLUW4Z!\R)Y?%#JE)_*)Y68-1)0!3C_V7O
MVIK<QG'U7^+]\LCK;FJ3="J9J:WSI/*XU1W7.G:/+]GT_OI#VI;Z:EFF)%J>
MW7Y(4FE2(CY`(`B``/32V``OT@@Z[0AS5<J"!RBQ)<Q@Y_J,<C08AA>4(C];
M3!;3GLSKAH<5`DD"8K,L!@4-)U@F8970[@WA8ES::7CSNC^L<N]G\8)R+%%Y
M<_?L$FO+3>S=N85B0`<U2SP)/XIA1RC:T\L`P#A76<5N&J<7AC;L7'U`=SE1
M>=Z#YVQ9>3ZY4%(+YSS2&""DO#,"LHIB*TV:]S"WQ9Q/6#I@ET-:OI8/!T/_
MYN[S<E-6(98&&3DVI;!8,15^!*8286H0TZZBSALQLA)2&26C)\22KOA54AD!
MV*FLFX>(\'JRN*W2D=RO<C6=K=^M&W+V,PIGI15&$*.)T-@R+:RL:)(0C"SG
M,(,4#`UA]O/TL^4WB4[KN87&.E;:,(QA(@2U5E%?T<N02^N;,5A`ZD);2A_0
MC>N@T\L!I[">"B"H-!ACZ[6G&M8?"]`L[;@\6-Y@1N$9#,,<4A17'AO"A;^B
MP_KG9!ZWSR_E:K:\?1VN;9"C<QY30(&=]X92KRT+YIDB%%0H$*#38@HY2R"F
M'I$'1.ERLJ*"]*]6CT'03W;M:C._@%0+%2B5#B+O@J)5_$G3"I]V83EG3<1^
MI:,;/%DN6FT?'O:UA";SJFC6A\7=<O5C?U.L1>?&=D\H"#8,(VYA-,^B%2^J
MB@X,,H73KF+E+)Z77!!J$(#RY%WM+_7$:SZ->55/PPHFK1-&(245#GH/NJ#[
M*BH$=",K6=`[;]XD325#DW20_5K>;J=QY<N[L@IA3Y?KS1^3]6S]L%U-O\<+
M??^>;;[?Q^/4W?988<0.3XMY\HPZ!ZF(WPNT5NC*@0.-86EUP(9+4AE(!/(A
M^$Q2<M16/&1JA=_NFA'_>%B5WV/IIY\O:IM<5<%%%5->/<34P/`E<L^(DU('
M.\T2:2@ZF>`P,%7G-H#2X7F<,DJ(M(9*:2FJJ&%2CK4!5&LFG&@`=1;UDVLN
MN"@M\N&XJQP'&IM@CT@B*E(I3ZQ'G+D!5%MN-11</`^&]H;34!7[%(3!DG3Q
M7K3Q`MH(0+5>![V[CH*+K5$_5KHO#8;QLR\_V\XHN#@XURX1G=O=6VG:\JLA
M!7=AN48S+#P``&$.14V^\C;M.E#.(GJIFV0B`CGX5V?^'^Y$MLGM.3JG(!`%
MTI"@%FCMD`7"XHH^#U5:F"1GAGPJA_N"),\GNR_V&0X0-@CF?+D[&!T6WO@=
M-\PKL*'84XT`)MI:'/LILP.=RC@\DBJJ/?+KS3?>'SHYI.!OY2)`,(\756]_
M!.0C^;$4[&DY.#&SX-9Z&78H*#0-Y!)GL:YH#8?XM#R^P91`_Y+0+SX7V03.
M4?Z%1AP@XS57T:-.!`885O0$,D>65-,_O[LBDI7#K>K@OC.ZH%YKB4PP4R7R
MV"B/B3W0I(E*K)*=,SNW\]:>#$:>:$%,,8\4[Y?YN6PN>O1F=,"'2Z.0AI0K
M"@EA4%:VJ1:6I;58S1E;3F5P=S!RAH-.[\^O1A84A>U&8F4"-LPH!XDA%2U4
MJ[2ZG3G#PNF,[0)$%K5\N,2_?*EC3O.X>6(1MA\(O9':A1^M!(.@%E_M5)IO
M,F=SO&1EW2<NF7+1$DK3(\@ED,[R<'I@UL.X^U1T.,G2O&`YP_FI_.T"0Y9$
MG^<1N7H[N;G[;?*K*;WG^*S"DG!&X)!!CV/`&3&O546C0BC-:9:S_UTJJ_L#
M)0?CW62U".IF7?5@U9/U;!I]`;/Y=M.8?'QB9J&"E"LHPU&$:BD5(O!)R*F4
M:0%]>04"T"\P.83@G^7L_GM8FOH9=I_[\O,V8G5SMUO]L^Z-[64C[8$%Q-Q`
M)ZTS%$BJ!6*L_CRHEXEI0.`*9"8+8`.E?-CE=!M1B!4P=D&?9XDP'1([VD;B
MJM<_>^O'AH2.4U,*!*CT4$-L$5<\IF\'WFD,O`$827#2+=1;='%6KH_E<+P9
M4X2U*A33?;SBQE%`,?;5JJU7N>*+[Z9O]`?YZ_AB(OE7G;]!J:/:8>XA,TY0
M86RP)0^D4B#2;H$-E+_1@5$-J1OG(7#YV+]D$B`MN.3$0BFH08[7XLV$N([4
MC=:H'TL"2(-A_.P;=>K&X%P;FEO5QO%;>/Z)[3P.*1`5F&+AD()4..`=1*A:
M+_:)S5L&Z8K9^Y;8`8?^^:;"2F[C:OQ\\EZN^)LQA:*<$,!EV`>(DLH3+G"U
M8A40&$?\=1#.=0%BN$]N?TW-A>-&..><^/9>C"V4LD1!#B@"SF`I&84U!4&?
MC*0DSJ`?81=`AF.IGZVGD_G_E9.5#_]SZGST:G3!&?36LK`+:$:M(X9065'A
M*1O)-<Y!V=H-DJ$9NQ>Z]JQ]-KYP"CEF#(44&*2#[C&T%E&"Q]*)*`-STT'I
MG[V_K2;1[_/M\<<?R_D1EKX84VB+F-$6*A9]S4$X&675B@V2(VGV,P@;NP`Q
MU#'C:WF_2Z1:;#Y/?C2Z<EX-#0:<Q<%P1\!K":'0G@-7;QG>I#&R]UC9<+Z=
M;G@,Q4\3Z%Q-YA\6M^6O?Y2/C0Q]-;90L;0]T5A3:Q%%G-(8_3F<Q3A(2VCH
M/20V($>[`=(_2\V^!\'3GMYLZQX;7GC%%<84!3,]7O=46GA:&P$0IF42]A[J
M&H2Q/6$RU.?J9_-R9<)Z[I>KYH_UQ<C""^ZYD)8IH06+IV?VI&R82*LXW'\D
M:L!OM0L>@RG?I_*0N\C8^EEHK%D3-TPLF-6.>"TLA8X2Y8&/MYLJ%QE)#)U<
MA\NH=W@&BC'ZR6RUJX;RJ9RLMZO]K?(CP<7J]3V^Z5#9:3+?MUQ3B^?ML0X#
M;]6FGGL36P`&S7@(V:YMN9G,YD?6>V:UAOHE36MYO8"/#1'1'IY:"(B!@99;
MHPD$T@+#(/"(>XT$T^#LN_!]TGXLB-KQB85$WAN.A,->8^,5B$F9!YJU<HE[
M1#\AUZP\75X"SZN.X0I%)`I@8BMX^)N2@&=%*A<P[20P4`PW&UL;(K[GX77Y
MD"'@W%%G,8)>(4>X-*)>K]`:7D?$MS7JQV*':3",GWVCCO@.SK54;J7G)];:
M1S\^L\K\JOQS6RZFQQ3O&;.+>*T"40F9=U(9B9V7LJ*94IZFD,^//8Y2(0^'
M8U;9>6_-1U7"&;,+2*2BFB'I,'58.PF=J&@.Y-/Q*?M!.'I,6GI'[K]#:D:S
MQUR+L(Q#2-:UQOWTPH_34DI>3R^<I\(Y*JP,QR]B"/&,5E03GJ]N4+N,^%[Y
MV$)&.L*5V7:I__GW6;D*[_[^^#%6W&AOOC0\H(#6.J.TCYLZM<XZB)YV=6/3
MBK6?GW)S+19,?U!>3-.\)2%I8SKZG`)B2#!RWH3O$DAE,8;U04`&R*_"L.F%
MT6U44<\P_O>*U9@MG_%+TP6EZ,/B8;M9[P"![:V?M[.*>(/-46NE00YSK(P5
MM1D)8#;W:`>CIP?^'9.2SGAEMGIVV[N93];K]H;.RSF%8\!!3-&NEREFQ#);
M1R*L3;SR='[>Z;78-IW0RRH=>WB.`?+[8OG'NES]C+CLI#[\>KF8!AAWD>_G
MA+;?HGI^92'#>899"F-;7"0)4X2YFE_2R:LPDE(EYI@,C@/D_XERORB/V3"[
M=@G.+[F?EHOR\=-D]:]RX[>+V_5)B^W]"850D$`&F5&`.<B"!<)LG29`1FNL
M78S!RP%0;9:7(\DTGY>+0_;F4=:_.ZX`0!D"(=<HV)F>$H%0[60+YYZ1]2D>
M#<?[`#.'8GB_*UD-HYVM8[Y-P+!!5[1^1F$UTR3&J0$$T@"*F*CM7:?Q2-3'
M)?*IAL8R26E\+=>;U6RZ*7?K:2<4[2860"ANE?2,6^H@%$'+U2=CX'5:J*-W
MM7*QS+J^`<RA2M3/R6P>-:I?KKX%N?T6`3G5H?;XI$):%0!RB#L9:QPA+GU-
MH84R+>6R]WO%EU06O8&713QVT)RWLQR=4TBMH71(4V2HL6'S]+3>CZ4&:<>7
MWF\G7U0X>L(N9Y+_Y]C#/9:A3\JA'^20?Y)=84"P\U:M,_`'>4]!PM%!"D>0
M$Y@;Y30#9L]3+(ABG0J971;+4ZWM>GM'85PPY36$VB+JC08<:5MC*!(OX?;<
M%>]"4M/L.<F&^57?`R">&03"R5$HH7%`%S)>DPI>=X>_[#V`"S*ZX6;`>0A>
M/K5<0&-`,-0A(\IZAQ55NEHOU_I*VOBU1OU8CGD:#.-GWVA<Y!?AVF5\52?<
M4`7!%B$.!%+,*V.\LK&(Q'[5!HJQIE!>=#=/`"X'NW\/A$[FL_^4MW\+6,9:
M^C>+IS8H3:;UB9F%ITQ0B3T(ARK!&"+4UM\&IHE)2;E\VA<2DGXQS7FHW-D?
MP]P?_UQN(A)5\?<<[S"3^70[WX4I;N[^/EL'R9Q-)_-GE_AW]<+#&?K)&_1Y
M&1M2S+=A,1\6AW+BSY]YP=.V"EO.[9L%NU_[U?KP,<06"]O-@>#7Y?;;'+3[
M>D6AC`!"DO#A4&^M1W)7:S.(N.'`P=/-IX9!\-OT>WF[G9<W=QT)/=E#OM<7
M%0A(BY2EC#E(!0T[CU1/:/)<K<D;3]OY1>=UY_I+8C[P:?MB2D,_OO^`$RF+
M`[ZUP,P[`HV#5H3M4T!D8N&=/6.8P:.J\WYIV7SMYQX-6[)$4=Y=;*R9=S*5
M[-34@@?RD`?4,T4!T4107%-+H!IAZ?I1R4`KN>P,]U]=R$;C5/E+RU9^F7(_
M'N;+Q[+<%1Z[>8A@G4Q"/#JG@(@ZP3PT"&A$D-<&\8H^)6BVHAWM3O#]L>MU
M][&>`,HA`/^,L=V&],-WQQ48:.S"M^"]P8`AIJ`7%1V"DI&Y:@9C=!=0+K=C
MM%:2ZL=RNVCJ!=W+\PMI@=/(`@29(9HY9'G]47#"_35HC8R'STN`/I!C\)43
M;4B7X')3KK],'I\[4P9[P04==[;\8_-AL=ZLMB^:(C9\PT=F%(1Q#KUR7A`+
M%27>T3HIV@ES=CG)(>@[Y1M[9W0!@8*4,F`DM]9*9K6O$[>DPZ-()^G,DV7?
M.(S6Z?22M!.^HK>#B[#K.XN$99)0I8DA#N*ZTIHPN4S6LUP\G=C9*!H)D.2P
M8UXNLM6)]]B4(L;#E/5<8J>9M1`(A^K:?-SQ\;I3NK"JD>N=T?FKR<#HO!UC
M8/TY+#]R<^7FUUT`Z]/L=CIY^+B<''<U-(PN.`20,X:%-P$!;BDU]28H.$QK
MDC38<:$[W,N^(>G`NOA.=;\J=YM\&^Z],Z$@7!MG(.-:"(LHDT%PZ^IC1*59
M8(,Y#X9@8'=4\FM<,UFM'F,>RRFG0-.T`@4SE5+%(";04<=T;#)37X_SV31O
M"N_[ML,[09-#`+Z6#Y/'7;+.S5U<>@/37P\M`')0606U=LP3+R@F]?9$66+1
MQ$P?>7=&=X0C!W._O%C@[F;C=KK9QMPTLUPW)O*=FEHPY0&1,BA$BB"F&B-2
MPX:%33M4]7Y'<"CF]PQ/%F%8+:=E>;N.WL,/Z_5VLIB6-W<?EXO[W\K5CQ/?
M_NG)A3)*82@\0@XP)R$+UFI%L<&)?85[OQ<XF$#T#5#^W?_#8E.N@B1_G6S*
M;YOPQ^V7<C4-OYC<MW?`-3VD$,YPP@FQ3E)N$#+0UA?G"3=I48#>>Y_FL0QZ
M!"J_J,36<S=W?K8*ZR__W,Y68?5[C0A;2TK#,PIKN(`:,$`98LP2I8BOZ(?2
MIE6KZ+V[:AY!Z0^G_'*R[_$[FQX6W%HV7LTK$++2,6,%=@A:@9Q4M=TLI$K+
M6.V]26L>>>B&37X9\.7I(/.1&8575`C!C*9:($P\5:[6@][C-".S]U:N>?B>
MBDJ2*RB^^LNJ.N%\*1>3^>;QZ_L]6YLG%)0(*03Q8:%*4(XQ0;4/A7J5ILM[
M[]K:-P][!26)A>KV=H?:9&[W_OSG%L<Q-C9.*KA%RE@CK#!:"F6IU;6J@98G
M-M/HO5WK(+SL$YEL2OAP$#EUV'\S-G88@=8A*9G26"LIN:CKXA'!Q]*L=5#-
MVP&0_+OL[XO)C^5J$V\)QGHS9^VW[\PM@+;``6`!<<`1JQ1_4E`2XD0!N!KG
M7M\`Y1&(NW(53@?[+KI[N?U<-HO!NS,*CETX1RC@,;>*:Z[8X4)(W)TP2$R8
MN!KG7C^P#)1/=[.ZGRQF_]EE_JG%[;?9_6)V-YM.%ALUW4GF;''_93F?36='
MT^P&OA49G1EM,]/>#BY8V#DM=,08X*TWTGB*J^O,2/F33J*!J3IY5_/%P"(6
M1E9!.03Y"Z8!]]AR4%%C*<MUZ:(Q%:T+$U[?FNQ"_577&,+,T6`<.&-B&(AA
MY:2O2-6,YDI9..\>82*W&@H%G0?#Y2O-`"`I#Z=I"#"BG#N"1;U>)+T=7ZI8
M)]2/-J--@F'\[!M-EM=%N);?!GUNG9CE8AT,D=M]8>]8"^7F[DLX,<<8Q^Z_
MMNNPWZS7MEQ/5[.'@T'SUHKY+:A\'9;[KX9==]#W%EPI["RSTA@*A*`@U@,]
MX`P4SW5'O*4YW.-V/B981V!/7_#21U>K&D@'`9/:X*`7I%*$:<T0EM@9Y\*Y
MZ+JLZJCH'))(4^:9=MPI90(U@A$$*)6YJMF?:U6W9D*S57T>]:.]UO%A$3["
M\@FFR*7(D>;['0VS"@$TH$9CABG&82>$6`5\D:2:!X,V,6R<UP9OS=OE4+#D
M,!..K/9DMG_CO`()1KT4%")EM%;<(``J.KD7(^X1U@OWVDE$)ZS^NK(QFH/"
M>$4BORA\#=9E>$]LRV)C(\[E0URV^_40,"Q/EC-H,;N@#@?KDVDL.2)4$`"9
MJVAF#(S,LN^)?V\2F?O&:02F^E6[P*DD\9N&A&@G"4<*VT.E4,))./-?E[$.
M&+&><$HII\;'>@B(5=0H*=+ZF`UOK+=F0K.Q?A[U5^T"MYY2Q"T&E#.IA`Q6
MJZI)]=E:%'8QOUMSJ\$%?AX,E_>A>BI\V#J`@IY0@*#6A%3KQ8[B\9G-G5`_
MYDQ-@V'\[!N-97L1KN4W6C]/-MM5>7-W$[30SE1IVOS?#BZ0ALH0;!B7"N&@
M@ACR%47&GM[\+^YL3MTX.V.1@[L'Q_<K@_-Q_V>;2$6[!Q16&.(-9,9Z3HB!
M"&!848ZX2Y."P=*O>I2"0?#)(1F_KX/LNO5F]B-@T=@CX<7``D$3%%T`2$#.
M(0.:R1HHQUS:$72P7*L>.=T)AQP<_3C[<SN[C7M-W<&OS1?>-*V0B`-LD/G_
M\JZMMVT="?^DY?T"[`NO!P7.:7;;XBQV7P@W4=H<.%;7=GKY]TO*EM*FL653
ME*QT6Z!.8U+D?#,BA\.Y6&,4=#"=G3LJC89Y%]:C14D6Y'9!5*:Q0GZ.9-?K
M,U;V0UU"NM=/MA/+A=6$&H=LMXM1*O.BET8+>RS(\T*(3,'OM[MS])OJ4W+T
M/7];/ZE_$!92:;GGGGEIF1.J3>(2Z08N[^T?+:ZQI%%D!'@F4>:K+]]I(NMZ
M%7^\WA6W2;7"/RY6'ZK-J]7W;>Y6UW>?EJ>YK91X?/!6(IT*@P$>WR>$C+&V
M10W&M31+J$8+CBQY8)@>O9$LVV^JN%`^C).U=/_L+-^5@]7IFT<>LVX_VRX@
MPXTS5""@E3:"`X*AU-`0J[36_4E#SIO?(3OU3VT"9Y(PC[T"&@KFM6,<[.>E
MD/$7]=(>B&1=AN87;9B&D".DN?<(,IA43165C#VIPOFI;B!.,DP/8-01F_1Y
M",S`J,D)9XI;0F34!(PP3N)VO@"`&19$&83Z0>MF%@SS9]^L;=*C<^T<;AW8
MX=[>Q[VB];A]M5K5GQ<I5WQ[E7\\;>-)G4/*,QQA@-9B2R3CEE'>[C#2JLD\
M9HZKE?G@UR,CDL77/Q^6UXM5\O-8QY-2R@ITG)6'V@>C,5;<&<D,XXI0"&FG
M'T"8&<)9W'Y<AGN%0)C&HZG9V%.6L-]269%C=N*?V@;'B)22V`@2UC29RFR+
MCE9TLCKV/4PMH["60B'K-7Q3W3Q<)YSJVY1RJ7&(NJXWV_?I<N+30UP2%E$#
M_G*W_?@AS>GVH2G_>OBHD?.TP+&-9U+$/(IT::&X)*ZETXG,B\#BKW#1X\D$
M.&7*0\(@#M:(H.]C]S.-`\+)7PXCR;2@WA,/'&MG:3#/.X,4O^8IRLWA,$RQ
M)'^?N;&9:KT^FACUF>9!46BH0@1!AX!R*:I#M511PO*"?XO?ZI1=F`L`,05[
MVV0.3TQL1[)A[%L&%M<5K'!<4BQEU@M&3*?N(4_R[*K%KVW*,G48!A?@9_=Q
M77]8I00MIS/XIZY!*`L9\A1[PJ."J*'CJ*46<)ZG7Q6_GAF5XT-!F5")/D%W
MW@2"'%'*"R2L(PPKP$VG+'J0F::Z^.7(*"KSN<2/>[>Q_]#?NJ(((Y:":TK-
M?:R7D5L;%U7)[;>)AKE@A+!9+C:;J]NF(.FQFYFC[0,`5`A%'9$60@29@H))
M992E/)[$3:\WTDBW\UW!\V:Z^ELS^=XXA,.]@I(^O@[.P50=D6'BF<<MG0JH
MO.JFA8,2!G+HZ15\,31F&U&\!VQ?LO5J_>;NP\>^>G$'^P3N#$2(41T5($`0
MIP""%A0*P50B<EXX0PDFU^,@-(5J\.Q<>T-'C_0*5C#G,%=2>H<\YI3%37A/
M(Y.>SN\FJB#?3I&$03C]FC(QF^NM>8I"B?NOI'EM$J'7B\W'ZFM<(>\V57W[
M93>?3<\%V$F]`X)>TKBG.F*Q99YRJTQ+![%^9J7NBW"D'ANE/&Y7ZU3^^H_Z
M!OX3DA[>/M,V.*`%XU(+RX4RPB)(?#M'AWB>?6ZT:(KRG!R.R4"^X6[<4[GW
MM$?@UAJ","4XG8<1XX"2=KXB3G@>!O0)>#@0F2Q.MG2L#J==>+9=L,9&8I&E
MU$LM+05QJNW<@"=Y,<&CQ3L4Y]I`/(;PZMV7^B1>=>T"ML@;0)6S6!EM!;8"
M=2=+"F9B\!Z;5[EX#.)5;'3:F_5=RX"T-51ZAHPW5GIHOI,E"FA>7,EHT02C
M\2L;D?)^<GGNJ5'19@A$TE,N..:1@*#3H)#34UWT7\S0,!R3RWL\QLG&14%$
MHDV<JG5`>=[.UT"(YF<F&(3Z(=?'/!CFS[[9G.@OPK4"&UTQQT;*$24H%4=,
MAN\T8=$M\99E+I;CNZ6>#/%)CHWG@9#%L'T9^A/JO[?G2<1Q/$QZ*IQ-5Y:1
MWDY;,DCD:2/C>YQF,68`X9,$LZ8M.=4OJFYL4Y-X5S-P9]!Y77UIOCJ>D^R4
M!P2AK8?:.ZHEHAQ*QX3M3`C0S,0?=:3KM#$@FD0XT@S_L;Z[/GIUVC4*U$8*
MN`.&<8X1YD9AV0'D7%X<P-BVLU),SH5A$L?%K@9Y)XNG%'L[UBTHI+&QP+AD
M30)8*X(ZHZ#Q;&95W<LRNR`P4_NM/E8<-_7]?;UJ"#@F`WU]0X2,42,`C]I%
MBKS`%KN.7@/SU*RQ[7:E!*$P.A>[Y'S]D&"+N%37<8O:WE4;LU@NJQO];=]N
MLV]XMH/$Z4\.\65!&$(FC=""8>*4ZW9`1'5>+.#85L5"DC0M=D,LD.[KI[M=
MUC5[I#SLLXT#I0@83;0'PFKF0-PCN[51"Y2G(8QMAQS(X6)P7&QQ</L+W4:]
MZ;[L9`^>NR3T/2\8(Q%`C$,J),7$XI24NA5F*/,258Z6IV2"A:`P8A>3I*N'
M[6:[.!03=6K7X*"/D"+G4A(8*H6!\O$2`(/>PH_3%GN?0#[RP9E"%/SB;OWG
M8OE0J9N_'C;;I#H_RO`1.3C:+^"H3$O'I208&D84C^]`=Y>M,DT*HU6++RL$
M)9')T@4:<NIVR/K'5>H',\<A!>'T)P0/%`046"0LQY(98]6C#5.KO-=]O&+R
M!=6&T4"ZN&WQ:OOQ:$F._LX!1$(I\#">KQD51#*H.GNLD#(S[<2O8%3,P6=J
M0T2G$>^$^=1`VJ?=`HE#21!U'L<1TP8BJSH=6@F1F=3\A5@="R)3?AMHE-7N
MR\W^V\V_JO11W:C/U7KQX:!]N>CS@V8LDD_C&3F>K'C\PU2G'Z?TT'E2,G-S
MY24A+"=..R/(XR1WB]Y9$O/\(P)"D02'.*#0$F<,$Y9V%.'<(H`S-UV.C-)(
MH:$_QT^.&1/:^"FE#"*FOD^UK1J+S81#=>K]U:V[_[2LOU7555,FM\F>T"9"
MO[EJK$A7M\UO=_&D4P+R.LE)2GYUR6*W22Y^FIE*`ORA"2G4WQZ;[*]MU)?%
M^N;W$^)>AS\\..T%9M1Z#SU5@C*(J(CO$Z-,>0%ZPPE&0NW1):^/Q,TA&L\(
MJ1TV1L".4@"UTU)"FL)&O"(MAM*QS./?V:OT\:I@$XK*X6C=28&>;6SOVX?W
MF^J_#ZDR84HJ_R[.MB>R]T"/8"P1A,2=CAK!D,.(.Y4`D1!@`=A4'F2Y[K93
MB<-3@2R"YB06BI]GVAOM>;!/X,AYX`'&R?[&'(=2H88^!!SU0LW/L;<8Q_HE
M8!!&OYXLS,9+>'XB<''6]Y8+?K9]H(1"&9&R@#-CC`2&I1IU0D/OI8%YD:/C
M56,;SI_C',]"91(CY'(1CR[W?3K!]\V"E9PX!BE6`#-.D:5>M5LAXS@OWFVZ
MN)L+*0(#()Q2$'J7^1\;!DZ`<%)3YC#5QG./`6PI$=[K^>[S>0PYP-5!:+QD
M_LYN[[X$6PM8>W=VO%>KZ[C:W'VNT@3>?8D_?_M/M:Y=LD@>CRDYM7_P4&O.
M@$2(>&B]TQAUZY>%<F;!![F,J,>'9HJW]DW:E'KVYJY-X%)H:Z6+,DY)LDYS
M:MOY:X[SWM7SKW5>V,:<B]]D_.]5P;]K%;S@"#D)B0(,*YS*P?F6!NK=#`-J
M!_#A.4X.PN%E\G1V>_"TK)R>A7\LOM[=/]SW,O&'=H$K1"50/&4RX5P9R&EG
MT\9\+F4H!G&@+D?_-'S\JUZGT_[FZM96[[=J=;-3%AYC#'HVWQ.?$"*A0F('
M*3*249X*(N&6=D?,5/6+7]C6/`ZZ,Y&LWI/8R<\(RAM%$$<.(00`DUJ:COZH
M*O/Y;OK%.7R^!`W"\/]/EF:G;+P<$;J0U_'.6Z;?D/^T;=`0*`&I-"9MV`X0
M9%Q+#S+3V7Y.4UA&X--S;L8#$)HL3<'[?M^+]T]WZL<HBLWFX;XA<N.^?JJN
MM]7-NVI]?RRP;;Q!@Z.2`V\T=(8:0[6+IXC.)F/55#5H3[U(NJ#GRUQX,)F4
MY^#<_/-GM=EV00*]<EUHF(!9_$L!Y@10C0DS6'>K#E$Z;S4=S37_TI)\&=2S
M3/>]\STPVYN;AIN+Y2Y.13UL/];K`[68QADHI1R4R!GNF]@X0IE&8H^.5@S.
MI+K>!65R%KC/>D7MTC+T"_%H8P4DK`!)J\=&4DH!XK@U,VID5)Z'T6BQ"R]Q
M;2T$_4L2Y<^+NV4R7_EZW0053"#13X<,#$<BL6986.@8%0J+UO*J'<W,(C9:
M%IA?0+`'<B!?@<A1W7=GT<WK>O4Y:CW5GI:CZD.Y80+D4EOK4W(O+I@Q#*5L
M.SMD!(=Y"NUH^6LNJCQ<#/4IUMLV*NMMM?Y\=UT]#W1'1D/;YEV]72R__SZE
MBWM=;_]=;1]K:.YT^/@F[G^5VAT[KDT[D>"E%U8;+8`G-MUD*-G>:FA"V,P2
M\UQP;9XU7U[T&W*)ER%P9QW0P,?U!\8S=#Q1.]GBBP6:6<*A7U'NSV3!K)7N
M_3;WVR[*>G4P3\XX`P5(D.;"$Z\@!U!'U<R:A"2GD#`#\TZ.HR5.>HD*=@G<
M9R'!!YT<GJ7P2=J('Y),#!'O<K,((![:,8PR8!7C.L(B=M[1G&H"",C,%C-:
M*JDY"__%N#)6BHEGDQP\_]MT6;3:7#+QP4D;K5HV$AQ_NKI]JD(VR:I_/R$+
M0N&10E10)0<:$0JPA519!N*)#C&#-$'&]-IW1EH*.\^O,O2>GAZAX'@!<&VI
M$3XYFUE``=&TPY9P,U4=TJ.I$BXF3P?S)ER.`[/-H9`JR=Q7;[>+;3/P[WO2
M>UQ#C_0*W@"(F7&61`4(`P&%1"TP$&;>NTV62^$B(E*/A>X4NN6!V?:Z[1WM
M%SQ4BDC)<:J.R2GGUL&63B<DF:_;9Q'NG281@[#Z=65C=FZ<\Q.)"X0&59LJ
MCO-1K6YL];E:UI_2M/?Z=7_(4'_OP+3'`EEMI/50I)LL1%J:A?:9:6+'.O$5
MXM_3V*+B.$UBGJB6\9D??JM6\<RXC'-7-_>1%9OM+NW<?OJ;?C??<YX3:#R`
M6BYL/"%K)@CTQKH6!PEL7MS*:$YKX\C+F(A-(3E[3:RZ>5Y1V\__B,B<]H!@
M&!'44PP]5]()[I3'+>4:F$QSTEBR,I>3URC@7LY>>K9I,R@(+#;"T!2$H1R5
M@,B6,DM%WG72:$O,7,2F")C3&@\?[N\7ZV_[G+T[NZBZCBMHJL>[NGE3+=-;
M\&IU6Z_O=\OV,8/B&#E<^[/H_OUOZ:ODJA'_\S]02P,$%`````@`L(!J16)=
M>`@'<0``!AX&`!4`'`!O;65R+3(P,30P.3,P7VQA8BYX;6Q55`D``YLH852;
M*&%4=7@+``$$)0X```0Y`0``U%U=;^,XEGU?8/^#MN9A7Y(.J6\VIF=`B>1.
M@%2EM](]/<!@$3BVDA+*L3*2G$KVUR_U93N.[9`4*6G[H9-*'-US#\G#RZM+
M\L]_?7E<6L])7J39ZI=/\"?PR4I6\VR1KAY^^?3[S3F^B2\O/_WU+__^;W_^
MC_/S?T1?KRR2S=>/R:JTXCR9E<G"^I&6WZP_%DGQW;K/LT?KCRS_GC[/SJS[
M+'],\N6K]4=RQ](E?V9Q?MX^RFJ^XS_\_G/UO[M9D5@O1?IS,?^6/,ZNLOFL
MK#%]*\NGGR\N?OSX\=/+7;[\*<L?+FP`G(O-7QW]1/6O\^YCY]6/SJ%][L"?
M7HK%)XM[OBIJVP)&NH^_O/O\#Z?^-$0(7=2_W7RT2`]]D#\67OSC\]5-[>=Y
MNBK*V6J>?.)L6%;#1YXMDZ_)O55]_?WKY5%XZ*+ZQ,4J>:C:X=<D3[/%33G+
MRZO97;+D..JG?<N3^\./6.;YFR=4%*&*(NA7%/WI@P>7KT_)+Y^*]/%IR?FY
MZ..``N+R/5IC\&H:OJB@/,7K_@-U`_Z-#^M$+^3WC]0-NNEL=+4PT8?W'ZL;
MO%[,9CM'5LZ6FCO'NT<>![VL/G;%OVL_63W^A`S7UEMQW7ER\E(FJT6R:,3S
MS;.M=/'+)_[=[;HX?YC-GF[I+%]5,Q#O"3??9GF"[XHRG\W+6S=B/@L1##TW
M!B`,`HH18';`(B_PF`-NZ^?=)JOSWV\Z\_6/-#W_DPP%[]G-DR);Y_-FAN+`
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MN[?^EA:\`Z?SV=*Z7I=5O%C%YQ9I/;6VKEI?LM*Z7#7^6NFJ^0S_]BHK"NNI
MDX'C8W\R[2\FNA-O>CFY[IRIFGS7G=WV[1QJ5EH[+E5_=$CO?YO=\2=6[EFU
M?T/KOOX6.C%CC-@=)C+7C,E`-IFQ*3F_L5F:_WVV7"<D+>;+K%CS0;J94ST7
M1Q$$$0T8#*#-0!RT<ZH=PAAA0:7J9<.<YE2PK!J7M0-LO##Q%$TG!KX6=B<R
MA/7XDAGH?H+#*GM,\JU!7!1)66"^\DYG=^FR'OJ?DUF%8'&]^EK)0<Y'>S0K
MTJ*>K&Z1S5@<V"%U6.3$#`,711V<"%-')#8TC<%P`+@=EF=6`][B09^U`]_J
M\%M\[M]X8-4NM+/^B;$[;'N=5L@I-96R>+:-A(\UTO7D&VG1IO7K2?C_16.]
M03R9H;4W+5:$U9,=0`ZHI[J>%!Z8!8=JE)$GR,'<S(;MZX+3ZB));Z^2A]F2
M\G"Z?,4O:7$;8A?9$#"'A`'_ZKE^!#H300AMD:E2Y;F&I[\:CM7@X;$H1R0J
MDTHDG9Z?3/,C-^=(47,B1"^2^4\/V?,%]ZZ)SODW^T'Y`<\/J$\??D96E%[0
ML_[=0V+D-T\GV>,L7?%U<$`]2AP;,FQ3-T!QN'E^R$-YT6$O]5##8[[KT@T:
MF?$N1\W'@]T8*Y)O;T0)T3#*=UT^,L256)G`^%;#G?7L#JH9J.BUC2FJP);E
MR;_6R6K>B(H?8VI["/J,(APCAS*T6:5[7B`TU^NT9U@/=G!9&V!RP8!6=B73
M?`,1*R<I:IR:3?0=)THDWZ>!YJFE_72X="S[IXTN>64[9+@55>@B[$6^C:CC
M42>B"-*P,\U1>$K*UL/>@,F](R-2+@C2RK6DS@U$LVIB3IUALZIWG#81U=-`
M^M143X=+QU1/&UV]5*_8Y(@^)X]W27Y+F1=2ZH4$@=AW8]=EW=M,.W0#1OO*
MGK3!<72O.-LF634(GCS-ZHIGE&$MDK=+KO7/!N441&^?.4G54R9^PK*G[I.`
M[O4D3&4AN_GV;VF2\P=\>[U*GCF_5;`)":$QCEB5&?<()13:V]1X3`+%M6P?
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MGW@0,JZ3R/6QZ]/-8AA1I"1:0X,<+""S[EZM-V.YY^IT\-:4E-`I-V0/!1YY
MJ:N951$)'ZLAIS8#C,;#L0EDW(81GG\^9ZOD]?,L_YZ4;+U:%&V,'6+H0A_Z
M,08^A3X/M'W26?-=N16YH@G3U8<5*JN!9=6X)+5>E3DQI1Z`-#F=?<_76`ON
MP]2<$,N>7$Y$ZOIZD6GM8#([A;]DJYAK7[(J6R,`X-B%,(ALOG1GGAO:]N;5
M-*$$".__E7ZR85'A>*P6D,RN3WF"3HN(>6[DM&.'%@'1T,&/Q%Y7HSRI[6"5
MXTML/^J^FP?TLA\=4]@[J@X^T]$CC!^?<)6NDLLR>2QN0^B`&)*`Q)$+`2(@
M]C?I"#\"0J6%0^`8\)6*RE[ORA&K]L3\-GV)QA.0]PFUF_)+:I4S%2;:8J8/
M5S#3<N,<L"#4A`9/6=AP>6P.'*B%IC!C#N5J[Q,75.D5SH3$L^(;AU)]H?]:
MI\^SY9LRB>VQ2K<D\B.WVO4-N/D8>+8?;NK,:.1()4?T61TB7W+^V*S_[^OU
M_[Q*3Z7W*1_F,_XO[H*5;'V03*=HI%\LPS(.\W)S906NUM;ZFQV8;XKJME`'
MSL0(4W@B.:._&2:2KS'@6&:Z!\LL8+XF19FG\S*I`1RR"D(<$(R8'Q"/0ABZ
MT-Y4D@$6B:]1^IL:6QSSC0>U3LI$KAIX%EA.#$NQG`INL34Z*"E]1BB5B/>'
MI58MI-^CN._T<B1:_Y")8P&Y/@JG$'-K]"8STL\D(V?\/$N7U9M,EN4W?!+:
MG@!\BPCF,3FU`XJBF+AV@-C&(H%(Z*1/#6;&EO_B6Y:7Y_S)CU:Z>N;M]*@0
M(?>A62PD'HAAR0*/#M3Y?9:?%QS6SG'I`P>\QPDZ$>%J8'4B(:T.3S+M74Y6
MK>JDPR%Y1%$$$;4CSXZ]F(2$,F]38H$B(%4RIV[%L%;5=_C(*H\Z98+",PA;
MDKI38YK&0OLH/Z=DIS>G4U&=_H[LBXXF:H0UY_B%!Y`Q%B-&(T)H1!GQ8QHT
M!@&*")0*D-2MF"Z+X&%1?3_-KXKWT_3@3TR`AJ%.3H`.7O8RVC4O*K>U]&=U
M(A*DP9$/;OA2I498@K8B=WU?7<:2K(HZ1?`U6597^\59418UDNHRU,6OL]=Z
MB;*Y08(ZH4\Q@\RWF0_=&,0A]&W;C^W(!8X3"XXSPRC,#<8M\.H>IEWH5HO=
MJL&?-2/UO,9O=0Z,=]U*/\)/C.V!6G(B`C"4M]DHPT7YMD#Z^+3,7A.^:LN?
MTWE20XDJ*+M@\7+9WO5\?5^5N3^LTO_M[FNM/6@.TP=!1+PX9`R[(0$><",O
M[L"Z02QTY/6X"`U'4;NWQW5N6:U?;U1GU[4S:^M<]8=;]ZS&OT:V).\J&;DG
MB,TUT^\$<E/0N.UO^.Y`C4UT8M(:MTM,9"X;F82CEPB.UR3",]_E:IX])C<E
MGWRKF?:JA5)O$&8Q@`X/UHGK,NR`$(;([DQ""(4V->BP8W@6:J!9&VQ6!T[M
MU(!>C(K-`T.1*:?FZCP:4>(3))W04QW43D05M;B2Z>]Y>A2JW43*(,8N0H%#
M8N('7A`0NED0T!"Y&C1*T-)X*J6VL[\GK[V4R@"EVK1JG!WW)XF2URM)@J>M
M6++.B&F6$D7"JO4U*9+J##J\6I#JJ*?LJ;)-7ZJP+VDW8?D1<T*;1#$B#(8A
M"WW;[4R'$9-Z.ZO#GF$%ZR#6Y;\[(*T6I:1^:6%83,6&)E=.RS[B=:Q=[0*L
MG1`VG9Q/1-ZTNI29ZZ*RR=-DR7_[\%_)*LEG2PX`+Q[355IE;,OT.6DQ=-OQ
MO<@&)`A)Z'N1'[J0Q81V(!`@1"HIJM6RZ61G`_;,:N'6P_4MX&[$RM;1:6X!
MP63D:.1+)ADE>!]+*J6X/)4---(F$Y%/0\[M9^\,4BA>7:,E<7BUV6#H$@\%
M(+)=#S@$>ICX8),\M.-8*M(<&IMA6=;_WN%*>C_W:,TN6$HTX1:7G`N.M*V%
M\YQ_KDD%W+T>JGBP\(]9OCA[^V>58VJ[OS65,.EMF5.%3R/U@8G,/:.YOU]D
M-6HSB%>D-PB2Q6&`[21Z&_MNZ#'/@2S`B(8!Q<SIK$<@EMM+H\>DZ45`F<V_
MM\(RWU621"D'HHMGL7E@!(KEY'T#\.@D_G&NR4RUNQ!SITK?]5(_$575[=5^
M4;P)TL33(@>-WF((B!.'L4?=F&#J(>"BSAKQ0G;[G.1WF7`&1,V(S!#<Q2,\
M$E7VY*@2)IBN,,^4GEATZ-3#05Y.Y1CZ$3D1Z>GKQ7[60`<I^BO?H]TBVIV"
M?)\$CANX.'1]"##!,8)!M1G1AZ$'/*ET@&DL@P1DD<0H'*=%Q$1N2HTAIX9]
M=R.,MXVH)^<Z-B3T;,V)2/)@[JIN2=!"<\_3VS8[(0#`01Q#VPU]#[FVY[FL
M.0`I]D%$8M%2PIY6S`G"T8/"QMMY=)JK$P-9$\D3&:>ZO!$Z^TN1)*E1MF]R
MQ1>,65[^EN2/E]NS3;8#WF<Q1#:/[.P0Q;X=>@2S#HKKQK[L:8FZ[1L.F9KC
ME-X-RVJL7BH?!6.D'<0E<,PFD-?%]^R?U?3?;`_EV4$]9G"DP.T'.FJJI28D
MKL9</*"X9ND4?V$PGV?K59FN'G[-END\3;;"'T`/5MM>``400I=Y08Q]2(GO
MN['CNJ*5R#TL&$Q8;T!9':KQPIOC#)U*3/>G=2(C3X<G^PEH7>2()YV[*N=F
MTYCKA(S:R(X\G_D1#2C&?-`ZH>_:P/.0U+G.DH\VGK?I*O<5]_E*$B689#;'
MD61R69P>,UGE-T2<RB:K,381S5!%OY\][D."O#9<;5[_`T0A\%$4.X@1A+'K
M1Q&WA!P:4TH]3TD?Q!\_G$9<*==DJ;`F*19F"%,6#"&NS*K&E4!%4@_ZIJ8>
M"AX<4Q!5,@PD3&[M$/L$(!(@C&!UD;WG.EV,8Y-`:F^F1K.CI$=.+="-I4H^
M;@'=&1*MY)M.C$PV%Z(E!2+<%!-10Q.>*2<\),D35L\OZVK;P/7]]5-2[2=8
M/=PD#XU!9F,G(`RYF$`2`>0Q+]H89'*UD.I6#&MC`ZQZPYMUT*RBQ2:I@CV8
M%!.]84B4T[@M?QM4ULV'_!E1LZ/TG!"O_I1.1*LT.)+I[FV22G3@K."=-"^+
M**`A#@,2>QC$&"#<OFT+`/^1U"[-?I8,*U(%[GS_+&Q9+>K)I9@>#4>CG"8=
M/$U\U)=.)YDZ(4]Z&)Z(1&ER)C/1"65W0_)PK7S=ILX9_P]2+P@I\L(P(@%K
M;TN$"+-(>%>;W%/-#:`&R'CO?=X2<6)\*#(VD0&ABGY_!U8?$A0.I*T+5+]E
M2\Y.T=C^DI7)'[-JPV)97.=?TX=ONR]H`QA`AGV*7$1]#'U2#;X6$`QLN?,5
MC*$PG?G=.5AT%_I_6NU@J]"?61U^WOFLQ@/ETV*U-Y-@#GD2+229:E9MG/9=
MEC5>9*%,]ZD\MO$FG(@`#^#HT9-8S5*K(NO[!<7U]O(:YO5357U<5&%6LYVW
M*-:/S<_J_K]3>8Q)B#P7.8'M^]@),81V77D<V!X*0Z:H]4-`&W(".+Z9OW;*
M:KTZLS9^63N.2:G.)%I=>NJ86H/WF$\&;&O3,XR&5A&;=H9L_NG-18-Z?WR"
M&KX1QKL=8P,X#'V&(Y]`-XIM+^:@4;@!;.-Q;\@01FF\C.7P%D7%<S-';$W9
MB6G*#:D^1QFZZ6(2DY;F%A.:O\;J)9.;RD8CPO0%&(I-TVM9]@;AO$R?^9IQ
M;[IU(R\BD0T\GU"[FG,9<SHT+J"JJ3:=$(:8FMJ8VNH@UA4WW:;MR]5]EC^J
M;*DWU2CJJZ.!VT//*FAO0NG::$)SA@S!D@L:C2TV.;4WXZ7``D4[J<(ZS9=&
ME9VJ:`O/Y_EZMMQNJ/%@$(?$YF8C2%Q$8H8V]QS'CB=ZG6<?$^8&=X>J.;NX
MQ37>&\,3))T8H#JHG<@HU.)*IK_G*<<]M<5D<97.[M)E6J;)?FJ!V`[`V'$!
M"T(WB-W0[1+B=@AA)+7G7:-9P_%-B\_:`:@<Q?2G6#9R&91=]6CE`,E3"D\^
M8E$H)-'6%!,10!.>'0T]-).G6H01O<;+6=%>QX@1PR"@%`(;^K[C,I\Y",>8
M>`'"`$<]RBRD[`Q=2%&=CEW#ZWV_K@*G2C41QNCL6?4@P>00M0R[-(E7*RB1
M.SD-Z^'*Z8J#'O2(;\BK+%S?M[4,;2E#?2%C0&-HV[X7.=@!KAUX`(+.H`>!
ME$:I6S&L4,T0XH.JA;8I%U*[O;4'FV+J-`R1<MJDSJ&9C7+'*#JA2_UIG8@J
M:7!D?]>;)FKZ*5)[W2()?4J=`"/$J,V<P/,=V)GT$9,Z<:"/G?%42>VVUEZ<
M]E`F`W1JTZ9Q;FH]09.L/DF2.V6%DG5%1*.4Z/E0I;+')&_.ZRXJW^:SXEOR
MDN3SM$BR^Q]M16A[O9<-&?*0@ZA+'.(S+Z@.=VU-NX0)U:?HM&=8M5KZSV^2
MO$K"4$&-TLKH::T:BTS)M5X-T*H06A5$J\-8Z5B'4N"N07,L+[+YNJHR:XZI
MGQK;;]`-SOK>K%&14,\%`#F@G@DD:#DP(Y@@=>29P8A+F;D^*#53U%I(/V<+
M^-_0;0U1$(5^@**0!"&NWLQ`EW6&J"UVLHWZTTWG_%KUMS@JJX(E)5!*=(F(
MOFFF)"5^GR0U.5=B2T:\3;.F*-4*[`G*\@&'CXIP'W(F(;F]',AT]1,U.74V
MAEIS`2&Q:SN>Z]@@PK8?`,_MS(7<GH*H2ML84EH=96F5ITY*8(VRUD-FG5VA
MZ*FW\A0JJ:Y1*C5HKRRELB*\[__'4JS,V+0$6=V-P[+<DQ8Q<>[2+ZND-4)B
MXE-J$\]C*$+$`]QF9P0P5^C\:+4G#Y/IL#@@&?V0)TA`>(UR(R>W.[0HZ:L\
M/Q*J:I0G-2WM^(+:I'/?R6."J4S&%&12'7RFHS\H2.)O/[+6B$-L%@,/4^+@
M."*A0T*[,^)X0*@04NW)`TDB!Z0PY"4($I=$,]RH22+'TD<2)?B1ET0S//63
M1%NW)&Z<_$`2Y<F8D"0J@#\@B:H4R$DB;[1.>>V(Q!YBOAVSF"`&XQWE]8`7
M2XNBQ+.'DL4*DLK`EZ%)0AH-,:0HCA6:7O(HPY*"0!IBJY]$.MHE<NOF1R*I
M0,B49%(%_B&A5*9!3"K_OE[.9ZO+U3S+G[*\VA#;&O.JC7"V&[@NAJ$/XQ"&
M&V/$CX3*H/I9,"R;#2YK%YB,+*@3)R"A@W`F)Z0'Z%*24W7>)$1U$/[4I%6-
M1S&1/>;V,:GM3=,4!+>_$YG.GB,COM<O]YR;[EV6'3A12)@74AX"@P@$:!,(
MQW8H'J%*/=6PR#989/1!CA,!+35&AYQ^-C"4)%..$@F9-$:-FC0*4R2FAKO>
M'5-`)0:FH'IJP+.^C:]69U_O-+K:WOL%O##$'G41@="&?B6HFR4_BK%"A;VD
M!<.JMZD(;[;1];C;3Y'`T[(X''=R$JE$F\D*^K?,'-`0/4Q.JVI>U8G#]?*]
M*)&X.)1;N2R*=;(@Z[RZS;@^FZLIROR2_*A_5=R&$6$P8M2+D.T%$%$_))MR
M(1@+U>]H-FFZG*<>20U,J\'9GLQWUIS!5)Q9'&SS">F3(S2Q+J96(Q`N)U^Z
MN#9T<:D(>R<D3C/]$]$\W5Z]N_34`&GBJEB9^35/Y\FM1[B%@(+X_Z@[NR8W
M<6T-_Q4N9ZHZIY`$0IP[(:2IU)F:3B79YUS,A8O8=,(I-_0V[IZ=_>LWP@:[
MO[`^,9-437<Z$Z]7K^!!6EI(.$D01`FC*!VYRWFJ13[UC_5--ZDDZ*7HHDO#
M&D4\^7%%$T$JAOCAR]C\*8;H>[043A@H?\D"T\;K;#[7'\AW''5)N!1=Z_H=
M2E<49HCE(>.R("]$&8W@6"K-!-;:R-HJD&<F#-I.\XA!WF$O8DU0V'FJAH[9
M[-2#B;F3OK;T>]>E">8X,7<A%'+3EM>[^KDR2)U4NV9=EIM6=$T<`M[>L>;^
MOJE[%:MN6HAC1L($`T;#SJL<\3$P`UJ[,-A'\\VLH\##FZ'5<)=U]]VZ%QFT
M4N5-4)?[_F3BN[NRGUVL38!F;[TBU69U71-MSPS_>&;X0=^!=W,#[I)A4Y1S
M9O924.>N02]YY]@JNTUGAE.5OY3K;H(H=PYDQ79;;K*?+X_^6G7XA0@`G#*2
M$8PB3ODX2X1Q1JPWIG&H98Z)7_L2D,&^"1ZZ?_&C:$NY=]WQW6L7^]BX[":M
MY/PB>L@PC?]R/YR;X'0Z_*D%P:$)LL-T3KN<;^<<==,OKQ!X[\Z%X'NVYJKL
MTN/-9JUJ9/ZOAVK7+XCGQ;Y<Q3$,619E(B1YAGD8,CR.K#,"E3)R%A_O&=##
MK5^.JH)-)\N@[E;7MFFZSN28'C`'LTZ"@GP>L_3KE#V:9E>JK'RE:=4K/V_N
M>U4D=MXLH9S$L@5O%"Y;F6$WIN;'W7?Z9.OXER/DP8JQ%(80)R`F:8RB'"6"
MC)0'*;(>25LK\(SG05_P(`6>[S[E8K!L[[_%$'E6ZYT-C,<.^31TR#+'PI?<
MU1T!.^NM)8][W3529;3KV%([%-\^[MM]46^J^ON*`P$@@)SS-$KBE#"0GG;)
M1*'66>#6P>:J`'Q]JY^I=`%;+8<MN.K+7&<(5?)U/E*>R=&%HHG52^:?47M4
M4&=NE#+51%'MY+G6)=W\_V.[E_.3$U-7B`F<\B1-(P08CFC2L77<XH;J%13:
M1?+,,RFN/Y"^#$[RSH<IFBBSM%6-8_,YJ@<Q"S.]\&O2IPEXN?%W(>1RU)C&
MQR6HDVWL0=D,,9KG8\)G58@K$5(0QF$.29Z@%#.6T],K;1E5&I"YCGF]<=FH
M]WGMKDX6SJ7W"GG,*]GN?-*[$,<UDJ%7<MXL0^JR!]22I^KVO)=1]6#P$M*L
M/IK5^+TN7;Z)<[O_T8D,NX!Q*$`$!8Y)E&)`D_&IEZ9ZM>CVX7R7*BB\%=(+
M=?GRC:+1:L/HF3W6>[PXL'?^]VUZ01,#:X>.+V1T[;)%.N_8F)AE5,4ZKGH=
M6-NNHNZZ2,,813R!.&,`YG1<\**$:*TQ606:M7;UM)1]E&=1G:IOJ1K/9G-3
MCV3&1GHO1GUIDF(=JK&W"V&6F[9,5)]:&N0@']"O$8U_V1[_MOV_4GXI-_2I
MW!7?CR\M91AW>N(,HB3-DNX7IN.R$8N$^OXTLRFZ?BYA:CGW)A@:%1Q;I?4F
MX\R=:YN.N%:_SKI"__?J4E?YCFMUK;=LB-LN=I`RT7#8**'BHP<7GV[QTFCE
M9(P_RRV&!8="Z9.JPZQJ!6$7D,,DC$$><<8PR>,Q/LK5S]AP&=3SP_WTIL)0
M&=>_EZ>W1ZA3DTV?P#/XZ^PA>W)])._'Z[IN^Y"<P7WGST&#7K!XR+WMD-9S
MS-+DQ3ZJ;-MU\6GDQ#CE?-GM[GM15__NKU/6U&VSK3;]'[*BK=K;NT_=Y3I<
MQ]EC6]5EV^9EN]Y5#_)'M-[0];IYK/<RR=?]XW55ME_+?^VSK7QK,Z$4\1SG
M*6-Q2$@<9A$(!4Q$ADA($ZU=!:^KU/.C[;QQ05%O@B_5][JZJ]:2`B?=P2!<
M,X5WY5Y6RP'^?3I8[]EZWJZ;X%G+;H*^;1+KYZWK?GQL7W#6P/ZZ>.-:"/Z4
MK0SZ9LZ]*:/7/IO(:2[C6EE(4G0A9C1+O)VUE\J+?7FH"&-%^T-LF[]:^JW=
M[XKU?@6B!&4I9F'.0D1C#+'(DX1&A,<,H?S2@=1.8OA<M3W*ZK?<Z(0%O;+@
MST';W&R9\FERH=:!O0NYL]VTY=7BK#.#%$]OOB^VV^$6_UC7S5-WTS^5G[O[
MO_N`'\?MKD-`89+$($HA@@!%#$39$#G$4:1^D+.3<+Y+4*3(TV/^)#,8=&J=
M4.S&885TQOSF:E+LHJ]F1T"[,5CG-.C9C38\&-J%X8H'1*M8\EZ2PJV?2TA/
M.&Y1X^WBTQR#_5'NY7/ITZYYJC9R1Y!_M.7F8WW[4,IWU^OO=-UIZ;<,&9]:
M**-Y-R+$">R>60R#+,3LJ"3/B-!ZY\=#>-_)@T%:4(S:_ELS0^##=+7A\)7]
MUGN\=&(/8^-!KMPBZ1>I.*CJ7X-33YQ47V\`K>_LQ+#:8S<M9+#MLX7-;->\
M/FSEP5KWY>]-VZX09)205"01B]/NLU-,AB`\S:E6&;C>)_M>.NSNVVVG0Y^*
M.NXH`\^3,?HL.P@)?I%2?@WH?K^KOCWNBV_;4F[<]ZG8E5-[]?FBULF>:2`9
MV+@<UIB(?XT18PN4"7%Z2[+]VGPN90.K;?DL]-=&EV9YC&`4,1820,,8<=B-
M]`>M60BT]IVXBD#/O#IKD[P1=T.K^NV&)<CD3^7W:SD8>3R,/X+&P4#P.MVM
M1L[%][0>@%]T\MB@X#69N[_^VPP[??32Q'/@JA?%0AXGU_6@6=!=JOEP^ZVH
M:BGHMLZK]J%I*YG[NKVC;5ONVU5&8\QRD*#NF8I(1(@`=`C*"8.KNOPNCZ/]
MJOZPL@NHQ*+TP*)7VI2Y)#4&<L_&7F&QE0M"12]0\UEBZ:[:0V$&1XWHWKMX
MQ+?</?0D[K#<+Q_6^Y_!IVW_2M$_'ZL'><O(BN?U]E%NGQ/<5MM^S?^WHCW]
M__('7ZN^&&SXV<Q\GS1\`M1N.FHAQ'74F,;'M:S)P+Q\Z,:753&LNM\WN_UQ
MW7Y%!,.,P!#F,"0PXAE+\(A=D"F5&;N(XWFX?2ZMO\.*,W&:T+.R4PUY<SFI
M![QS53=!]Z=M>2I;.I-X$_S1U`^[9O.XGK;7"[TFO)M@EPO'%T(N)TUIW%^0
M)@<I9D4W<&3-_4-9MX=HE``40YR#/",QAQ&(&1FB`<XR[4,5]4/XKAR0[]9_
M^"9ER9,V1EURM^WN^ZL<,OC*I*GZ'#M7%W(7V;;BK8,(;4W1.)2PZJ9;_U/5
MW7^[*[!L]RN1<-3-K:*0YZF(4Q1'^3BV2'"J5:EM\/&^T_]-_:'/E%5'09=O
M%F?&J3W2/7NF]R278CY4]0<I)QCTS'ZTX$M#)IABX=Y">&+3@E>'!UJ:8;`T
M<-I`\3?YWW(CFMV7<O=4K>51RGG&@<@!QT!`3$)`6#12C"9*E7V.0WKFS?#^
MUGVSZ5_B4'L^>_58-\,^F[VF.?-G[\(=-09WS2X85%XM[3UEG5(BVXGW"P&;
MZU:]FVQV:)HR`#_6ZUW9C=KR\O#U+(?-BH=J7VS'!#8!&$"`4@02UDV$LB0'
M\8C@D.0Z$'08UC,(V8_N3V7[8G&R3V?U>8%M57RKMD8+E2Z]5X/CE6S7`^0@
M,OAED/FK=/^T1'B4>KWU074;)V#IH2\6`DP?+6N\7\C6X/Q<KLOJ258>M2N>
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M8`$QI`D5Z#3:I7FDM4&T)PF^"X^/&H.'@\A#-<1!YDAO:RJ[Z0Q3*L_>#TZH
M//;,I[.>.0H/SI1?G<XJ]FK1V6E_+9;.;EMYD<X>3+6@\_"0^%P^E?5CN<I3
MD6/$8\)3^29Q0@$?RWTA1);94MUHWJO/#G*ZJ7^OQQJOVFZ:DM2GD4Z@.5K[
M^9*U,\'QA6-:'#1U>['(,V[01;K9666S_B/'MG^,T]ASF-($Y2$*!4APT@UT
M,X+8H$$0#$/+%2#SP//A;>IETAD,-E[FF<=;-PL]_43])'910\/WC=1;ZK'O
MC\4RT47;+B_WN#+0PZ8NJYPF40@A!").,60PHG`H>A0P9GRU;_;%5HV3#L-J
M47)4J%ZBJ/(RK[=-72Z;KL;.*_FM1TZ#35P6NW/+!#<]],5"J.FC9<8[M&B:
M9TO,C_53V;[SDJP\C"*,$RZR+(I@'N&(#F6>`J0Y=[`-EDUXS^/,49K[;;"L
M3+<BYUQ^.R7HJ2>6L!^!OK/Z4'713<N&JY,6JD'6G9D:;\3\/&Y80-?_?*QV
MY?!N=?]Z-JTWXPO:*T%B@6+`$IAQ2&B8B60<(">8:!8G.0SL?Q&_^_F/8EB]
M;XMMV>]<_W#^:GIY>I&]+G5G^RY[08VZ<]MO^#K.SW&3F*/,\=W_F\,&`C>]
M^:/8V=_5475Q@JP>NF(A1/71LE?O_'@RSYR@]*FHMG)I2=;A=ZSX4JX?=X<1
M,PKSB'2_44H(H$QP>8S:44+WFULBU"+RC`SMR%GU#[I>O"TI;=PV1*5OFYVQ
M<A3ZX:[9?9#/K>"D]=JH?-]%'58ZZ(NEPM)%TR[1TIE]1N?4RXBW=Q,:H@CA
M&'2H)E@`TBE*P+#1MA!A;GQNO75@SS/ZY\>O[W^4_:"S'^K<%_NC2$N0.NT'
M19)>JPLT4?K,?2E+6KTHF&H8.453'_VQ%)QZ:=M+GOHST$.Z=(6`2%F>1QAF
M$/",1Y@/.]*($)+$P0*32=BY%IA^>1SR=`]GV;OJC>RIM^3IY2YPG31UZK[W
M9.EB,Z1.,J/*?;$0AOIHF7$F5-,\6WZ*JB[J]=NY6`+3*$Q#$6-`8I2'.`5B
M4,*BA#A8;K()[WEP.DISO]QD9;H5.>?RVRE!3SVQX.6F"6?UH>JBFY8-5R<M
M5(.L.S.-9O_R?.\N?C=H_KVIOW\M=_=Y^6V_HFE&.!<P0R&$5'!&P!'S.,Q3
MIE4MZB#<K#/]0:.<;TJ5'[I/O`^D3HO9O:G/^G/Z&2RVF<F;N.M]^OZV9XJ3
M=DO#%T)"ERV:F*`[,4N9=)_+AV.R]?;NCV9?#N\;K7)$,>U^$12G$,4,XHP/
M\00CH=X:D'$8_PL^PX)$4P>U5#:\6:F),G,CU0#FUT$C;)TD253UHH:7'V<F
MU7OF3/#)VL^%4,F^'8WC"TWGZ.D!?+)=_<;)M_WA\FU1;X;=XOB_RMVZZD:"
M*YZG.6$D8EE$,I3CC.3I("`%H=(>N.ZCSCKRZM4&1[G]0LNXQ>*H6.?<9+?^
M3Y/LNM9;K:TLVG6-0ZNOYK[9V=4N>T'M"&L=@]YXN/@S>0D'6OMI6./[^K19
M^3_3<`J<H2Y<%C.,441(G.<T%D-@##DV7NXWBG;%YX\N_!Q:;+"2[]U==X\8
M?9YY6+!_RR_557HKKQ<RLG;8H*GU>`=6>5A$6N4B)B&)4X80RD4FX@R,=`TS
M[&(1WB3L7(OPYTOO=V^L)'E;2+ILO.L%)*>>>U\X6NQJD9-5(N6^6`@C?;3,
M>%5(TSQE:LKPM-[(+[),_ZG8RNS(IW)7-9N7[^ZO`$%<"!;'(LLQI()&<3AH
MB,*,Z7#3:>`9R+DY:I&OQ_<4E9.T_IOR)%^3G&[-5V/GU7S7HR<;+.Z_.5-Z
M$QRT!F_L03(S/W6LG""HEQY9"$/]M*V9X9)VPE':X7VW^]F1_'^+[6,7/,X(
M[<*E'$#!NY$O34Y#7R+2U4,O^LN^V.UM,*H;5^<^?BE1_Y9^2<V@V`??RN]5
M7<OAD'RKLP_A!*;:/6!#49^V.\-G(8>E!Y5!+W,1U'QAG38N3:U?-">-&Z4$
M2#O+7),QY2%')(DPX0GG'#',CL%!&!)T)".O%1?EW435Y^(@T`T52[E3_64>
M_IWO4\4>^'O=IZJ-,KM/M2Q3/]3X\>%A6_8+65NI0&R;OS[6=\WN_G"T\E"6
M&'7Q$$QR(%<BY$HYB;(A/*9([Y1C1S$]KQ.<RSS<IW>=T&XF."K5'*LX\UIM
MM'(-F_7&*\\<[I$H-09G(J]75*WHW@0*7?N_$!@Z;];+@ZF]V*:QP>[A!%MY
MINT*ISDGC$*:4M1-&@'O)HY##`)XJK>!KL8'>T9;?Z_U)Z[(XTNKB^<M.W!*
MC5G>3-(#TR`CD#IFW\/V9,$$78R<6@A"S+2_VF/6V`"U2K[/Y>9Q+9'3W(U[
M3*V;=O^M:*OVX;BKRN:O:O_CNZSCN'NL-]UH31X&AF/.04P`(A3D.<F&LF;`
M&(Z5:_H\Q?>,EE&UG,*,N@,I/.B5!Z/T0&H/>O'!4;U.S9FO_IDFU5*Z1@]H
M?_]>T:@)7$#OF%4'^NHEM4I!,]O>JQGTW`E+J![TW<1FOFM:-VO07=CEX0CT
MXZIUL?W4M-6S`;H(<0Y)QJ&(A6!AA#$AH8")R!#)XQRH3F-=Q/(XAQWDR7MV
M%!@,"J\X@57P;6KVZM+VA8P[W;;IY;S5O6$:%;['$T_ZVKM/Q>YVU\O9]+G#
M3^7NRX]B5ZXX2DF>8I")/`X)YG&(HS%Z%@*],E\G(;W7^@Y'P;12YDTWZ=T%
M3U)A\,L_ON0RQQZT4NA$%8%7Q]48>`6S]2AX\OG+P>=.8W<_!P>5AQ5'6<(1
M]$)GKP%6<6^R$-BI_0NAH>M6O2H)]F":(1'[4"U]W/]H=M6_R\V*4I1@QM,T
M"AE+6,AB-D9E/!3F)-0.-3<!BU':@7SZ^Q?:.6M"/*^F6I+NH"TXB;LJW5XZ
MI4PU8XL723/SUDQ2S-(D*WK)712ZB"*),`4@BG(@0(1"CJ)\B)B$0G.7%N,P
M<U/K(,L=L53=-*>5!R/=D.H@;`&4.@C1))2FK0NFDVY+%,AD9(X5E6X?]^V^
M."2;1!8A&G,48H+BD'/,:#J$C2%4VLW`5:RY^=2<M+F#E):YYJ3RY:L;7)VI
M6P"SSM1H@LO$Y073RZ@Y"@@SMTF]-K6YOV_JZ6EI!D(>Q0+"%`F2IAQ!A(?0
M/&5:$T07\7P7A/0272?)G!BMQK6Y/=9CV]'>!>;&%'R;JO9UZ/I"6.>T22\K
M?9W;9<*\5Y-8EB<8X2B1=70QS3@E8L0LI-R4==IQ9F6<;1K,RE!MIGGUTH9E
MU\Y^37BDQBUC9Y?'*_.FO,\I2WO,^31,94.4P)AW/`QA3D5*`41#.(`@LV*3
M8HQ9N623Z#(VT9!''ORS9]'-=1)<[YBC`R%-.Y<*(-UF7(*/D2WFX#F?@!)`
M1)Y`ELJMBU(@3ZX40\PP`="*/CJ!9D60=2[+SE-#&/FRTP61KI?#FK))ATTF
M[BX54$9MN40I<X-4WT9X*NO'\G.Y;K[7?5'9MY]4;B#YO2\Z&RO,`!(Q3_(D
M`2#-*>2L^YIF@$4Y)5&<1&KE[6YB^;O-C@J#,XERHZTSD4J%EQYMUJI7G]]N
MTP)U)[:KUJ,KV?(&Q;RXNHR*<\=M:CQ>A@9T^]IORY[@-,(""1IF@&"1<=S-
M-@\!*&1"Z90O_4_U/,0:;IT_>S4F3%(T1YWO[GTQ@[AW2_19[-X:.^!>M$@+
MJ5_?.4G"W($%P5%3^!L$-&FZ%N9^K^KRX[Z\;U>0)8RSF,`PHQDC21@A<`R2
M95FN5)%O]LESX4XJ"GI))C>XAE/JW/-CDB'[9O-''X)^?+($H9)?6C0<FWF!
MB/IV+(B*!N+?(*.I!1J'=_5QY#;BO_6'(ZPXCM(TC?(D2E`6,PIXCH9`-):[
M=JNGX/0_?29*]AOF'R1I']*E;9A:?LVO5V:P5++)TW%<+]R8R)V9.[>0A)E%
M`UZ=O&5GA>JHZKZHY"ZB?0QQ?/49(BR+*&"*,Q(+$8F0XR$20XE2H;S%QWLG
MQU%44#P5U5:.6(/BOGFL]T$GL-P=M@;0&U$8N:@T[/)MH"Y.!N]Z08$PV>7"
MR"RM,9AOT\P&8E_E1NIG%]UN-//99A3_93\X>Z/][X_0;,Q:QC#-J@6-LRO'
MXFRI/EZS:U<T!BRF,(*`PY#R+,.0#K'B"$>FQTDI!_`,W\.SK+OTUV7U9'56
ME+IE:J,V[V[ID?;YB5"#H"L>`35(F!B^65FXD!&<71LFSG8R-$09)_GQA8#C
MP'&%41XBBFA&\ACG@N"()4,8*"*M@^ET/]LS1`8Y'49Z/9H4T79*#2`^3=)C
MQ^C/YTO^>*'&"R,F@&%JV4)882R_<7/EV!'B^:*E+%`E-`<8BAB)*,D`R`!/
MX!`W3!*MA)%UL+D8<E1V,WP3G#3:<<7`7R/0^+76CCQZKLY!HU=NJ>/)W.AE
M\LJB/=,`LS5*-^?=KB+((TH%@23G$48T3-B8&Q.AVF*@]H?.D^$VRVHK6**5
MS';KAE$.^TJ):X5\M;HY"P&!ONZWL].Z#5=+2N?'[-KPM:@WO-Y7^Y__H>Y\
M>QNWM33^500LL-L+I'<ED93$NZ\H4NP6.YT))FT7%WUA.(DF,:YCS=K.=/+M
MEY(L.4YLF8=_9+5OF@EF=![^)#X\AZ+(8WO9JW!I(A/!$6)9R)D0(J,Y"B4/
M42;DN3'5?4"/@^M.7O!*9]`*!1_\X)LZ8+KV8O3-9G%=W@6]^5P(H%/3O%X@
M3V'VUT_#*M_/IZ8?WI>+61-L46[:M55QREA<;T0L6<H+$A*$9!=`2%;H9#KP
MJWI.=3HQP/6,!G2&1P._8&!NK\]D(/O9E'=_?ZB^_:=J6)OXJ!_>YCOO&GW$
M0\S!7-@C+(17ML\$H(]WWO+*4C[L%PR%A$I5,R&A(J?UL=8"=_%B&FJ]CK<.
MXGLZIAM5#X;0#^`5?O8PSSO$:!P-TT,X0@<.,@3EA*$XX3@!?W'3CLKQ`V;@
M/K^J?S*+288(RHJ8120K0EE$<=Q='TFN=5PA^*)CN4LMQL!)],#H.X=S)H9.
M,8S#H2O4@<ZX`(C)A'H]3/>17F[0<*U>S=3%[^L`<CE_F#&28ARF5&4HF%$F
M<9JA+@!3+J+;K6%7]=RO>S%!K0;0L8%LSO=L?UA@75N7B(.^?=#D$YW;#,L$
M>K>A\,KVB3`8M:^[<[3%?%O.&!.816E(XK#@B-*$1'V@A(;:_=SLZF.-XZVJ
M0,D*:ET&0SJ0FO[8[@^8X2"OS<KA>'\`X<S`;P9L`AYAV8`CJ8`-"I!GR,7F
M;K[\9SE?2_6;S2Q-(BE$0C.2)T04F&-"NU"2)%I[A=E<?RS?:'4%M;"@46;@
M'&!V^M[A$YNA>P"(.?2/-R#..(@IM@EYB'$3CKB('0X#'VEMJPU6L+A(."<1
M"7F<JW2'D]ZT,$JU%K#;11C92W;#JYV;@`A"_<07/#M'T>/FW%->P=!R%1-X
MD_,5HT:<=!9S)%K>\NMZ7G]V<_/R=%LM9[F($YZ+B"48X5P964*2+@"/J=#U
M$]A5/7O(3DS0J@&X!I#->:?PAP7F#KI$'/C!09-/>(`9E@GT>T/AE>T3`5W/
M\/*Y?%C4:R96VX_SIWK^4Z`"I7$H<QI%62[3L.AK'<FUN[G1Q<=8W?`2[$4%
MM2KH&@<PL?.=WSLLF`=`.;E:]_"&P-#R!U-8$W`&._UO%T/8@0#X!%=IQWJ^
M_'EU7W[_G_)EQD(9I3A'.1$B)G%*2,ZZ0"0-M?85-K_Z.$ZQ4Q4TL@*E"^P5
M8&JZ9N$3F)%;`%@Y\XLW$`8-PQ389!S#N`'O+,,.A99G\.?U^F`&I)M+E2QE
M")$X0Y0G*&9Y)DD_!Q)%VFNHC`-X=HZ=KH/I.H.W(^;\SAO(*.A@'F)&S8&/
MG&)QPDJLT4W`3>S;4#E\EL!YB%PLRS57(1ZJ]<M,9JE,,RH2EN594B_72/;I
M3I(A6!8"N_8X.4BC*>A$@1,0("[=],,?*:/D0Q>2L\SCH/V#>8<9J0GXA)7\
M=SF'#09(E3)TID$B\@++^F/^J""8R5#B_IL0$F+8)QMVH4:J7XZ=<Z9UD(<7
MO-JUS5ADS0H=8ZCNZA[8B2B.R4[&F]RTYGUYY`X28$N0VZU02=2RVCROR_XK
MMB+F(14Q(ZE4?LD+4811>PH+2>.(ZIYZ9GAUC^\@E:!@K\CD&TU7FU(<(W.D
M#SE".9'OSFU;\6[;"0=0#/O*K^7W;:[:]J\90XRGA&:<(UR$+,DXDUVXD!#0
M.8NF,3R/ZQ^KK1ILKN<O]?=OX%UQ#+&9>(P?8I8F4XL*&E67M9D>CK;/P'%.
MTF@,FC'H-*980"<K+K;UBHL-6]WS2N4'JX=R=;<H-T?\3H:<RA#G$1>84Q')
M*"&MB(@6(F2`8P'=!?4X:;?7&=1[+QPHG<3H#B(YT!G]W)&)=%%/C3MRV*`O
MA&Z[\RM3B2-)",GS&)%("L1#'G8J(IZ"#Y5W&-KW6XRAKFUPDJI+Z`Y-U`]O
M7RYZN?0%!M/62.%WY:_DI`:M,[%24XC0+?]>';78NS=-,U8PAE4JAA,>\[R0
MHHV(TR3'NA6%101_W?78\:$7RV].$QKH@PZP3J2_N6C)\?WT[.%8]*-?GI?;
MQ==E62S;0TOWYY=N9J%@:9I%,8H%8I00&66T$T$+#IKC<!O9<T9RI-]=!9W>
M'^_+Y>);N6Y.\WBM^BH0Y>9NO?A:_WVS#3Q=W1A3SQOKGEC;(/1V!']<5\O%
MW4MPN;P&1!MDJ2[NVF1=UDGCSAJO.X3:7OSSZJYZ*F^V\^WA<=$J<R)9F">T
M*!#G(DG#,*%YF'.!:(31N3>;MI?WUXU;14$OZ7*IS`DV`YW.EN9$NI=U,RJW
M#QFPRWSZJGR^+D"*[U_+U:;<]`&QZIZ9C#,BPCPO8A%F]3%Y=4!,9<1`YYZ8
M1_&<EO3"@G*G[!_`-,,"H)[KC,,.YCM[;)VHRSG/23X#WF//="+NXZ`AE>O'
M#5Q`;4KUEQ_9ZEZH)&)9?:U];Q=]ACA!DN1QB'`N!$H)1CO;PXP7"'2.FUTD
M[P52*ZZ91+S?RP-7/58T=:N<L4!"JYI7#%\IZUQJ]/)D`--@.>("[T0<RE%C
MWI4;[A!I.]5/Y4IYXU+%9/=/BU7SV=Y6%<I=V%0(255A$V4Y49%Q(5#>A4U0
MK+5EF*M8GMWJIERJO_AP%3RT.IL>-S]0"C0N:[AZUC4F5YAY_?2*Y*&V"]G7
M&50#!N8*\D0LS%ES*C_/HFW)-\OC-(RYS%/&6"IQAD(4=8%4_'"VK4]<-BSU
MSEX=9%6]$.U^U9X67;TK]&SKO//4#.L[I\!LZ[I+%W.0(DX;W$1\Q:(!YXHV
M(`JX=[335!^JS69&9)[3F),TIK%$G$F$Q2Y4CAG&1NX!N+YG_Z@UM(='[SRD
M6AE[!X0:T#T\`3/UC]W,]`^UH+]=RD3V3'1LQ(#@U(S$I`FGK,08!^!US;=R
MLVT/:*AC?2RW,T93REF<1R1E),(XB6C6A<I$`CJ`TN3ZGNNFO:1@T6@".HD1
M,MVW6WYI0=]L]:!:.5>!$C3Z2ZUW2`9?:)D#G(B16#7AW8LL6QP`(U%=407K
M"B<2J[J)(L9EA!+.B@ASW(4A.8MGJ_)AOBWO=6T$=G6M3D';3O%:"*!OM(*Z
M4@;L(4!:NO[A`9.A=^SX7&;>Y`V(0<<P0S89MS"4_\XI;##HUR[;QW+]L5I5
MAQE./]L2QE$D.<T+]5_.LB0*>V_*"P9:FF<9RO=+[UK=+O\(?MB9R-^N@M70
M`.L%J6:-,QY-8+G3@'RMK*][=N)&+WT&40U506X83\297+7F;6WD$I*V;ZG$
MZ54M%D<I#6DA4LQX(F145V)=D((F!62V!79ES_,L2DRP5#I&[C$'#`8ZB!FK
MB?0'0_&5B\<%_HW?UW7YJ#K4XEO95PZ?OOPZ_SX3]=[):91$$M6'>\>)K#<Z
M;$.R.!:09]\FCN>><"#M3)]PSU!O3!X+'VQ`/B1W,`?9S!\$U9=`*;P*V':[
M7MP^;YLE[MLJN)ZO!]?:^/HL[Q3#`2-R07XBMN2D*>^_KG.$1]NRBOEZI9*!
MS76Y;C8<RN>;Q5V],F6Q?%;%??T%7\HBBJBJ7BAE,8[V3DDH)9#*PC:6Y]*B
MD=,N86L%U45%8V&!RIF"32TY^.&W&['_XT"*[(>VGL&-"1IF<IVR^N27=O^R
MJV#/?:=O9"L[0VO`SEQQGHBE.6M.Y>=Q!%K;_Y:+AT=U?59_#O90?GQ^NBW7
MG[XT$EYMJ_963812'A54%)R$E.19G"2]T1))*<3Q/$GP;(2=ZA_GK>S6ZS;!
M\T9YHDHXU+CT5>D,;K4,L_W'4*?T=?/T#'0"]PWFJYW@8*<X:"77.>/[72(O
M;[EF?`><V/,-FXA!^VYE-6HOT+1SE02O-?>=J"NB69@A(B6)!,,1"7%"XCRA
MC#-!,IHK-3K^[3JF9\,&[.-2RQWXRLDO^6'SO21T<*G>\V83YGV_.[*O6?@U
M2>X'"B_PO+\9W6H4S9@54A0V(Q80SI$ARA?>"X])WII5^7TJ(:/.SZO?5>C%
MMU_*>N2;A2S-9!SFF.(H*23)>"B[$(1@K>_Y3*[K?5U7JR;XH]4#LBLH(HTA
MP",=Z%J,$<$`O-HC(#,_!H#2,]S#%IXR54,.4S!.4^F5_6,`,4!Q\\ONZE*E
M\JE,>(H%5<E])I,4=U=GH=ZWS,!+>K8])<2H8P.8:)B='QPPGQN!!,#=_!`Q
M,S8],GJ>UK?KE)W!&SX%)S-075G=;8A__7>Y5+<[7U3;\NZ1?;W9A2*2Y21*
MI91")I2CG">L"U7DH;Z9&5[?L[.UJH*=K$#I@O1J4V8:9C<"+ICSO2,5W!@Y
MH2DS@"V.P,[,(]\_;<XL\WB;3_FG):$IF*EM$RIW#XSSV=D/BU7Y\[9\VLP*
MEJ)$,BFS/.$,\91F>2<A"9'666@^XDYFEK:6'#2:W4\=`FZ#J^E:/W?`UY3M
M1."[GKOU<Q-\S]]JW0R'D[@]):N)7#CK*0P^OIH&GM`UQ:<W6/4?"7\HYYO^
MI2:[OV]V?ITO/Y>K\L_Y\E.S4?`LY)CR*"T(S6,F8U&@O)]5*8I(:U\D#V$]
M#U7[U0.MGDV][*/\OBU59]T^EL&R;D.@+OP$L4C'Y#6&I\M!AXU.^[T'&J'=
MZHU/7X*]UF`G=G=++@@>,#1=[@:8C4Q.;X3>N`1"=&I8\L-Y"J.2IY95WA]2
MR)C4!"YJ?]VH$-?E>E'=SW":QS3/\@@E&<UBA$-6=(%BG&AM8FQ^=<\CS+EQ
MY2I8]6-0]16R<8T%4(T1Q3M+V,#1NE2O)V@%^2<%&`*\$S-S>B@Y/3,_UMA3
MGFT%9@K6;->`RM4S8KH-6!-T(Y^WJN3X9;%:/#T_7<]?FMI$/)<SDB:"2\1$
MG&1I%LJB*,(N/$(,=`*?JYB>3?ES^31?U$OU@_G#P[K9WB.HORT+OAJ=^NN,
M]+`O7Q*R59J_N0I:D<%.9=#)#)3.2VT\-DSOB)GYXC^11=?.FW5JTS*GV`!;
MV-_5".]_6RD>7<9[K1[@1Z7FT^UR\=",JTK!SZO6'^[K[%@N-G?SY3_+^7H6
MQXQE,2.9+`C#"2%1_<9V]^(VQUH+KL=3X]U"VP8$!RT(NB8$^S9<U9T\6*R"
MOAUUKMNV)*B;`MX]W_N-U//A:=U#F$./<OL\;=AO27W`V<>[HQ/Q_!$;_.YP
M@'%1:X\3OZW6>M+X8WU6VJ<O[*EZ7FW9YG.Y>5YN/WWY?;Y>U$ED_9%[M6J.
M4F,\%QBAE*"\R#BFDB'1214"@SZUO(0^SV/)ODDZ=M2VJS:AMF7!?!.T;:M_
MU[4NV#</.+Y<Y`'0&W&F?N]A8]#%;KN7<<G#O1D8J2[Y)$QD[+HH@FHZ'=/7
M^);/56^]*V\>RW+;RIT5!2)I7$0%3F@H19SG)*5Y2-,DI"B*_8QC!CHF-%[Y
M&GQ,[H[C0<;SC?$WF$QU9'@/U,4(8'&;_FI.;]-44T>WQNOH$,8T1UDH""8B
MQ$48I5DFH_YUK:J/9M_*]6WEYAC&<[$@W?RU+,#TQ?&#&,_OMOT7.D10E_)$
M>JFCQH`.$80ATENC\%.E'LE5'>6G]5PE8K_5,P^?RV^+\L]9F$41206/HS2D
M89IF..OC"<:$]E(%FR">LYN]M*#5%C3B@E8=Y)6[%4F--0IC081E(A/A!UBY
M,!9'LP4,.XAJ."X7WU1Z=_L2U)\#;U^"VW+[9UFN`A4!-R.!^B$-GAO:A^=<
MJG]=M^;OMLL>!DB=6OW@`NX4%D$X:4?E^*D#9E!LLRFW^\.R"\&PR*1@>9[R
MF'.9H^90`QK3'--":^&9X:4]>WBK!EA[0NGHE9,>P<!\N142_-%)T?_0PDV2
M>`AB("LT)#:1--!4?>7DL3$R!/Z\KE?_],&H0"GB*,(RXD(F+!1<[(+Q7'(#
M7X!&\&P/.SG!O!'W#R.?`$.#V(5/7B:N<15TR"YL'V_`G'414Y"3,A/C1ASU
M%#LD^F<DS#=UT5K_K_B_Y\6W^;+Y&&S+Y^OURV+U\/M\^5S.9"RCC.(X3&F6
M2LG")`IWP47"*&A-D9N(OJU'J6MR];OZAW*O<^Q]_75@#70OM[`GTMT<-^KM
MKO\>D.F/]-_FBV7]ADU6ZQL5^::\>UXOMHMR4VO9ONS_O/.'&4VR@J($92SB
M<5PDJB8AG1"490R4!3B/[KF;WCQ6Z^V/]0<JP:(_(Q)<4+AGKIE$7!0W,,'H
MM/[XI5K_N%%J@[V\JZ`5?/"KG>:Q\P\HTZ'<Q-O]F8B1>FS@VYS&,TK(^NI2
M>;I2LOE8;KM@7*`<"1P+%4V@))&21UTPC"-0*646P?=L>3UWU20T57/0X'HO
M$KZNV02@GB/Z9P=SO5=ZFD.?+N5J1[D,KQ"VX#@1=[)LQ/N5O-9(M%WF>EU^
MG2_N=^__NF!%S&C$"IE@Q%@2AS2*^F`"$]`G;&81/+O,3E3W>AMJ+8;4]*S%
M/S"8M72L=H(NY2Q'L0PXBQW&B3B+92,JET^6R<G3!S-$LXB+(HY4EB0R@0A/
M:)(F?:9$8ZWM,RTN[]E3VH.1[PZF@DV.E@8RTS,5S[A@CM*2>C,3?(E#HP^`
M#'B)!;V)&(E-"XX="&T#P^QMT@Q)4>"8IO7*[2Q,,<%I/Y'%N<20@W!A5P89
M!_SHVU_K?V)G'$!2!J^.G$*R>F5TR?=$NN^'M&E-Q!X,Q0^]#P(B`%0L]4GT
MVY=K]8QLV>J^GI9IUC"J8FF&:1(F"<M%0L*04(8BC+N8,68(5KA8!/)>O[3:
MFHF2LA-V59^C""YE;'#J5C0CD806-JVLJZ`1UK`L]BP_#K'T5.*<YC18Z3C`
M.Q$C<M.6=W6/,T"0CPNVZ\7=MKP__IKNH^+194\B1P4A(B)YF-,TEP7:%V"2
M@\HBAV$]6]A>:?/J&CRYZPZO[HSO1<A"IX%[J/W"@.:'5T*5L_52Q_^N0Y/A
MX)2Q\QLQ$?/ST;+WGW_X@6<R+_0J&*,LHRA1E6.1HRP13$C1!TMA.SJ811AE
M=LAV5@A"##PQY`F6S=S0Q9SJ*!:]&2(#C!/Q'\M&G)XG,D8"G"J:Y6F4)#S,
M"BP%SGB!*:&[JQ>\J#^HA\X1G;WD*)-#%I-"YYE`9H.<XC"9!KK([,_9:1]M
M+!/IZ5#51R=Z@(W6[LL?%O/;Q;)98Z,2E)MM=?>OQVJIB.R6X/0KC1E.PQ#'
M0F0T#TE>Y)+Q+CY!60Y)&IP%]9Q'O-+99/>;Q_FZW"G]]W_+XBC]KV9":/L"
M=`MWU/7\Y"+`88[SEO5N[>#%/EG0139@5\ZI3\30W+>K\ORXFIOBVP\N1"X0
M9SS$H:`XBVE8R&X!8B&QX(8V"`WCV?BZ#X:6>X70#ZUL&()-S2<^8QN;P'=7
MIQ'IV98IU^D9E7%+3EN3'1S]:NONKMZ89W/=;N_>O?'+)8UPPO)89!'!3(7;
M1TL+#/O.TRR$9Q/J5!EN;&_*3;-"\X\,6+%UM':*+O8*_RB8H:+.CN1$K,:V
M%6^+/A=0(!:S?B[OWWO;+,Y(@HLTIJ20/,P)Y6DW@U0D!6QQLGD4_T93"S-=
MH&Q!3]MK1@`'MIN&V;%\9WS'.8YGV'0LD4['=VP;\MYZG*#1K[:JU<.OY?I)
ME+?]%Q@RQ`F1><HB01A)HB2-NH4"18RS%%1F&5Q_I/KJ:[6NMY.J-X%>5=NR
M3W6:Q47U;^\7FV8@@!9?)D@UJR[/-('EEE+3?NE;Z]E77+_,M[LO!\>NN-[C
M&2JU+&!.Q("LFO"VN++&83'%,XL3&H8RREF,61JE#(E]I`BE`O(^R^#RH[S;
MZA8^OYK8L9[7.0_.=#['*3/[>9R+3]Z`)FVTX4W%2"Q:<':2!@C#*'=Y]>(]
M9T511`5")"Y83`A/BCY3(D4&6F%C&,)S!O/Q:+IR]R:O:78XMD]A(&3A68PG
MJ':)3/'];OE\7Y]".*F41FM]CB7<J?B192L&<AMC*-J^),HOI0IP_UG%X.K_
MB\.8*)-QH>P0106A6<A$V*=44:*U$;230)X]JM,6#`_>'@#JF=!H[&!6U&.K
M=06ML`NN#ARB-&!"3N!.Q(K<M*7R\/1!]Q6LGIX6[79<]7+H:E4?J5JN[M2@
M-@MIFJ=Q)%(N,4[R.`]YO\"),02:\K&)XWOJ9R^MW4KPM;C@ASJO"K*_`=W*
MBJN>68V%%.95;VD>Z!I[5\;3A`9\R@77B=B4DZ:\W7?1&1YMDQI8;Y1'":))
M'$4BS"(:)RPCK%^$&1>@'4\MPGBVJ)N3RQRABX!L4.K9TD@48:[T6M1_="L9
MV7:[7MP^;YN3'K=5<#V_[-H@HR6-#G!/Q*Q<M*1R_BS"=Q1KD[@F=+L';8:2
M,`\)$G&<%0FAJKK,^E!A`5JA:')]S^;42PK^G[RK:VX;Q[)_A0];6[U5SA1!
M`@2X\P3B8RI5F78JZ9YYR(-*D>B$-;;HD>2>N'_]DI1(R8Y-`R``PMZ'3J<2
M13CWW.MS<8$+8-=BNHANE]OHCQ99]%_Q7V(0W9;;0Z/V_T;T;O^]WE9_EL?6
M[5WT+DKBBSCN_HN6^^AS$RGES=?FGZ3Q1=3^I$2_W&V6=\ULN%S_3S>EX.7J
M^`G0?2+]:_1^MVOWOKN+$^_VNWWSFW:EYC!&IYC)7S?U1K=CR<B;:C+IVI%Z
M^GCRX>>##SM`%T=>_=]U]IB:$0&<0F0@RC?)A)]O.9M(AU;M6&_.QLDDS3@2
M.928X9RF>1X/-2JDJ=8REO:7>Z@2ZXVAQ`'D2>-2>!$GR06`J/M<\_4IRB]0
M3$R'O8B:+[\M5^VS5]>ZAVKT`T2]\G46&_KE;A,6`:CF8U)>J'"-^`M$+\WQ
M/U'+3B!"O9US/;SXNJS6[S=L>5OME]<+E"`!02Q$C&()$,2XZ-\A$D3HW6=M
M.H;K5LX!5M3>OOFNVD2K`S+=IDY3#M4TQ0=]>M)RQEP+*6J88R\QYZ:=\VEJ
MQIHY)Y(9B,Y,-N-Q(Z<56C0N8=HOJTVY%LOMIIDI[.AJ=7=S=[ULLCTOKZI5
MM5]0(0J80QYG*:(QR#(4#PMV34&LM<1O83C76G1"%*T/D+0O7II.J9H>>693
M3YIZ<%&/+OKEG-LCP)$]$T?W*[U$V8AD6>0[$/6R:=%/]RA9)FO"5L`BR4&,
M$4P13W&2`$1SGO0C\1QBG2Y1@Z_WTB7ZU#T'9@IF0J#IPK]5[IPM^,^^RJ^U
MNJ_,:2`J-,6"%U?S-<FP=@?+`N`,XH)G.&$IX'F&TAP/S:LRC@T[T\T&\Z)`
M9_WI?F]>>9EK-7GR2K.>6#U]TTI@UZN,M9?:HC80S;)GC^8U*II$O:AG]4VY
M[8\/MIT:[<[GIW)7-O_P.ZMW^]V"-M,R5'"90B'3%*0R1P*E2,1Q$N,LBU4*
MP.FC.%^[/X!JU[([5(H298&^<6WRRYSF\M/Q//%`7@\LZI#YHW!=-\5%,T];
MMDLG@5#Y`),VI;?;<M7\BVK5Y-4^)`\G,\H_RNNZNYR[:T/L>%^UZ/^BG`U:
M(CJ-C_,T[A3^16J>D'9[=,ZLZ18-J6U'FMFE$!^W]56YVW7KB+(\.U`E)4Y0
M\VO"):`RE0+A?E2!$#&X&<)T*/=ZOKN[;OL.H_]>WMS^M?F!.N&,KDK3"R.,
MF57<8O!'JIG4GR.+6F@S7R#Q#%-C&P]V*`YD'FK+FJ?OD[!#DK)ZB9O;Z_J^
M+#^5W3KA$R="D22Q+"B0E!`.8B&%Y/W`20JU!&SZ:(XUK`?8I/>;]I*;;B:A
M*5L6*%53+K]LZHE7C^W=]@`NA`MP7N1K1,+L<1V(BEDTJ'85EB;U]'$&_]NV
M6EX?YGV8X4QD.0"4"`@PEQP.\SZ0,?UB6G\(US.OOFS9MY",BD`#VC2*:+>,
M&5;0/6D=*O/RV8`Y@]K9+8/3"N?5@_"S7!G_9/A+9;$Y4R'5Q!.L>*H@GDJ*
MYDLZSUZ-1HN,,`DRF$())48H+899;`&!UJ&+B4,YUN3CVSHM/'5)ML6BVOS1
M(X%Z$GU\;R><JQ/'F1J9-EJB.)`YHRUKGGR4QQ))%BYS+0K!4H`PR61,>:.2
M,*7]@%F!B=:#/<:C>-D_7AY_QI3N.7L%MY*JDAK(#Y0%0Y1O)=6C1KWUJ^TX
M*):[=M7]M&1"M]LFV,IV3EG<GS[R<7G?_A']SW*[OKQM/[B[/!V:^51?7\MZ
MV_[E`F0TXP60'#".$YB"+(Y)>QP4"I$G7&O5:2:(KB<8!W#1&3K=IK.97*<V
M.WD%7M.;U71HWWUMX4;G)D5G-D5?[Z/SSQWMBCK#+J*C:1?G3H^^M.9%1_N\
MGXYWXJ6QWKMYPR*0Q#$W"X][`$-PRAPIZ]>[]ESF`@$I8)-)F90YA`E%"4F.
M0"5`34%V6VZK>OUYO]SNO><L18PZPO?8'&4-+,IOU:9M3H^^+IN_6)71+X>3
MLKHW.<W@0^]IRX'C@LA8%]'!LM>;J@[X_60IS2AX>PE*EP!WN<G(%=[2TM^:
M#^YW[S<?.W%><(B@9`R"&%($`,6P0#U*Q%/ALX+2A.:X<NK0-%(U4^K1]9.?
MO./01?,EG8-1[1GM@UE-YCE<P-W,,*_*:G^W];[>9==/#E.084"\D?QC:KWE
MY#/)"7K'-P_7H_"[;9/H#L-UR';=7Q[AB!_E=E4U4!<P3Y.4\B2'7!*`4@HR
MUB,1"0*+3?FMZ_Y0$R_[`)0$*C\(U#E6]0ZG'HIQ'G'`NF*NF(GNV?-!;\]9
M2ICCG*D6]6,2[\Z/H<BX0PN?.L?JDDQOA<#9Y(9NUN+';;7MON&41YJ\`1+"
M!(8,<,9ESK.\!\Z$B#75>W:\SL7^"'&^HL&"3_W4$9Z<.7LJ.;/S<#KX9.E\
MR<6U[QR6&_;B)I34%0XAEHL2VZZ:<>,F)00!F#&<``Q0PD0LAZ4\E!)QW+@1
M&T^I4!^A_K9-;XQZI7/89U;?L0E2W.9=OE=UXQL1KPD$.%^^UW.%-W'Z1[EK
MYI<'02U7S6]_J]L_^AD_!"G.($44L[P`.<H`2'O\'`FO"_O60#M>\C_@["9J
MY1%I>]74'\T?SS6CM^=O/Q/[65P]W_S^+&+$6<2T?_P6-K-5O>DP25H/J#>2
M.^WS8CFE.G*<MTQ[7,!K[QL\`LT8RC+,4H9RG`LA4IG"'F@!1>$SI>JC<YP[
MSP#-E2L-/.8G*;IUUNP;)8='JU]E@OO),PXSF7D4O)&4-8$`R[EIJBOF6(OZ
M9UE]^]YFU#_*[?);V>\O?=Q6J[)MA[XZMD,3B`3FA0`\EH10C'+>MT-+F!*O
M6<H!?,=IK(?Y[HASV`R..J3=8T&=R?-U(EL+!.^MRG/$0""]S+WIT3-Q-=_#
ME=[=ZV=%U7:LO9$<[)(A=VNR;IP96A9?R%A*S!C#,`%$"LA@7/3P21QGLQX0
MFH1\KF-#OW_FI_?]9CP]-,WM025JJ[Y^'=GY;:;D^?.P<BC]_TJ^ZK3,DW$U
MW68OS>ZT^N!'32!29@(3"DD*J!0@CP$=FC)98??F"(^X?1V*<IM8?3K:4G(-
MU,?V$^S._%C5*TNS]EPZ)=7.$%BO)=W.08UNRIW-??[2[G!>1LD*F&14`)BR
M(D--4!0%8KBW`G.!O&9>N]#];+'.GWXM.]Q3!I[/US,FX2?.LKVY/*SE6)>I
MV$V$O95L[(@=VPG9I1/#.=PW:I3((,\362``0<)R1@4[330`5KH+_W58XCAC
MGQT(G'4EVG$X^%F?#B<2YENU5CI/^.H2O$O'SWD8T4I`OI;T'P99O@\Q6G1Q
M<-O1>8$DAI0RD,>T*+"DF1SF-A""&8\]3L(]PV%(U>P?I/Z^GOU$5<^_$4VU
M3LM,^XEZ;@OHK.6H58`2"BG*>,X21F)&<3*<("UBGH1U`G.2*7.>RYRUL'(=
M(GXJJX"B8[[22OTHY]NJKJ8Y?]:3GU:B\HW,!7RQY?V4J$4GSW%V=!0^3](8
MIS07A&0)@9(#<2P09<R8WJO)H6#V><YTUMQOS<E^DOP<_ITOFS\XFOJV$K:B
M(_V<9+422F\D!5NGQ=VI5XMN4WMX>RKV1X`_E3?+JCWJP>I-=VSN;GG]6[F]
MZ4_1+6*!4I+R-.$\!SFE("%I;X.D2.D4;)#`?9U_';1R0!R=08X^5%>J1V"#
MI%'E7?+0,#O.O%$QGGF+8^8]?NY!YNT3[\^I]NGP:>U6.O/Z"B))XYWVT+#K
M1)39Z^\VYW2V8TOMB7G//GMBVA9TZ,P\=PN;F_H5_.R;+(U\?=F,K]I[0L]9
ME"Q2C*0`+"8)%A(P"&2">U,H+[#V,DE@^!W/Z8I^%[K:1/?E<FMV,5=@G.FL
MF@0&_76LH(QO>3R?>N=83?'KX)=65@(-MY!664*EZ*D5EU"Q^LW;VALUSUD(
M%B1#&4RS-,D8D"RC2=;?M29C@I!^8\3K,&O.)HFY,K_/J/$S(0@T8%YEW\2;
MF438"PJ'<XL9(O>-3#GF8,[R3&0VYWN;H#R_N_6\*0S`C,H\E@6)"<`XI_%I
MK@4I\#D3<8'?9R_&7%,,)W[W,Y>8V^6AMF>\F7F!@8,=3@!<AML;R?1.*;*<
MTMV[TT]K!_WV;=N]MOJ^`5MM=M7J'\OKNW+8R``%ID5<D!P#+C@L,,1HP`Q0
MYJV58RI0Q]EX@!<-^*(.H,_=]<G.]-"7X=./<_5A/!L,,W5=3(X+CUT6/N-C
M_JZ*:9'BIX?B!8^XZIFP%0AOH4?"&A<V>R+L.FB.`_@/@2^X@#E@B4P%9"P&
M.0*<](`A(G2FQULT4?KI9YCO-G==I_DYX.''7X$T)"A/<8,\PO&LJ_S<H6`8
M'B'5^/,2X>Z>A$FN">AFA&<R\R(!D!9"$I%)D.0%HX2`(2,7>6#/4IM:,=]6
M?W#W'Q@'@I^D&48,O(;=>X/EI2!SK[''9[WJ8&H4OI'<[8$H[Q<<V''M'/OL
M#P&#!2MH0F-!,TPE3Z%`*1V.'"1QIE^]S@/3WZ[Y?%OEVJ[SOB/NTFN!;'P'
MD$B=^,K/'K9I@(24"F=FPMV.]#3G*"<S7G[=O]_L]MMN$^6W=N0%:)=V41:S
M''/.\XP7$L0RP;)(2"Y2KI.%3+[?<?KXO/I>KN^NRZB^BC[4FV_O]NUYUQ9H
M=$*ZB[YT8%7W^";QJ98:7%.IJ>F66'2BS$]0-2*I4X@-1`LGF5#;B[-)ZD-_
M5+N%C)'@">%9#A$M((,"I/U(A#"MCE*#KW>L/8]^/J(O+:AI&J/&FHG$6"=,
M3V%TN?*@)"T"92'1HB]('=&S8%1&#,@P5)%?ES<EK]O^O45&4$ZYQ'DJBHQS
M$!.1].-A++2.O1L/XE=1+J(66O3E`&Z:LN@P::(OCDB<I#+*_'E0FQ,_RIIC
M0&F0RF-BQZC^&!.CUL)[^>.J8>COU7JUO/U0+S=_+V^^-G^,00QPEJ5$LD;Y
M,$>(H4'P,(#*G;>&W^]8>PZHH@.LJ,45?3D@TVJ--"5O7'-\\:8G-S-3IM$$
MZH$ZL]Y-(PK5VBR?MOFY[LB)#(70U#C5A-I>P.C+;3L(_;8MNY6UXV@0%TPP
MD.&"$)Z@+&]FF/UH$E*EM:N)0_@1W2[N!V@31,2(167I=4V@D?K.RYVV!KOF
MT$R&M4G4D>`G3!Y7X2D<A2/$DZSX68NGDV)8@W^H-N7[?7FS6\`,8R"ID`1R
M0!&4`@WJ+PC3:E<S'</WFEZ++.J@3:N_-5@T*;_=$#AQC4^).P^U]T".<NFM
M3V>0E;>!&:.%MRDMALK#EMOM?=L3=%/?;?:+I/EBA&@&4@@$$EF1(CR,6<@)
M*X":`SG6H"X9MSV(NW)UMZWV]]&RU_V+J/Q1[?;M90#UJ6<JJC;KQIYRO2EW
MNTDJI<NXB50Y)%M/KQ[N=%Y$?]O68_1Y$*J'U"BKE2&C04J6J2VCNC6)(&7Q
M^E3>'KI`=I=7[?B+.!&`<@J*0F022H)2.&R1H$QJS9>TO]RQ2)WPM$T#+2)-
MX=%G2TULG!*E)S`Z'#E1E\=<C"B*,6V!J(@Y_MI2_&BJQ<<'HWPJ6ZU:[9M\
MWUY4LMOO%AF5,<QS(A*4@!05:0*'*59*N%;SQ.3!'*O)QT<_)]$#B%&'45-?
MIO.KIC=>J=73GVFL.E&DE]@:42AK1`>B6/;LJ1U%Y*3B[?VFT8%F[$_+??EY
MW_RR_E@V8;K9+[^5"R(8AAA"+G*$69(PP(L>`<1,FI=RDX9UK')TM=K>E>NF
M7#M@C+8-ODGUVC223:HW;_Q.6GOJ3A,<.&Z!7D0'J-$)ZZQUWAB)RE6?%4\$
MHH4N+!NM""V29ZB/O!GT\DI6VP9$^>^[:CL<(@`+SC`!19S%*$NRC$-*VV=J
M#@!`SK7NA+<WJN_FMQ9K.W7IT$8]W/XPT23=G$2^B6SZXGVB:II2[D$S1QA4
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M/ONC4D^C`V)10ZO]L6FFU^:LJFGVJ/W/Z;8=TD+0;DN6U-8CRJ26W^WNVNO5
MCQOGC`(NDCS/:)$6-,\QX</&$,'Z!R"TOMU+_7Y$U#6'F)3M>GQI%.S.J#(I
MU=58<E>AGY/Q4FUN1%Q(5;F9`4_5XQ.H,%P!_'VSO*FW^^K/<LVKW:I;`H@+
M'HLXYC$4L8"<4GR:<N8@G7",RF0TQZIR!BGZ>GBJHMU@;,\K1.LCQDG+@T8,
MFRP4NB9WXI+A.='\16(]+!X^P9?R,N(4KD.2+CL&C2XM3J=*0]JNRNVV7,MJ
M,\CHK^5^@5/1WL(<RQ1SB@M,LYP.-70::VYNF(TQHXQ5_6Q@9="F;,RIJH2Y
MIU-7N`Z(HB.D0QOR1=2@\BY73W(S*E+3V`Q&FB::\9,@V:!%689^7>[OMN7E
MU>5MN>T*_]TB*0!E,&49SFF2QB3/DF,'"L2,YTIK:A.^WK'X7&Z_+3?5GQT8
M37DQX4I-61S3I"<J!S"M(I_@1%]^*W_LHZ*)_'_Y/G_^,SDCJC*!R4`$98H%
MM;6PTI218KFK=I=7=-7-F:K-MX_U=;6Z/_S:ADX7.0M.&)0,9(Q+#"$#29R"
M?O0$"RUIL32D8[GI4+8_2Q^;#_6+JYJZ8XM<-2V:@5<]?1HH/4&\B`[PHB_'
M_\^G5FKTC2B89?X#437;5M5.@U93_7[?-2(K=OOJ9KDO&XT%3(($)Y0`C$$6
M%UG.^E%$)K0>J]'\:M>5VZZ;%PQX-(5,ER<UP7)(D9XP/68G(%5ZR-&(^AB2
M&8C*F**OK424IFI\J/Y]5ZVK_7V[U'1=[YJIVDFI\@3'*4L89XP"`;(LIL.8
MK`!:3XU,&LBQH@S8HA,XO9\7!]RJZ8XW6O54:#JC3A1HC*T1/;)"<B#J9,>6
MVD$4:BK7^\T?32E3;W^:7U&12Y85*<>$%Q`QD?"AND0HUSI'9#R(8\4:<)FE
M=\N$JDF5%R[U9&HBC4XTZCF:1O1I,K.!:--T.VK+(:?[^&CYK=W!^U3>MEM+
MSQ6`A`.4<RRQS&3.,T%H?^=V,W@LM*95=D9TK%9'D+J5FB4VU=3)/Y%Z4G7$
M%PT``Y(L)>Y&],LN]X&(F66C'K]EZ8`R]?VZ\C]GBUS;>M/\=M5=9[JCFS7[
MWKZGN7N_.?],M5E5M]?E[H1-\CPI""Z*&#<JG"2,<=YC`\TL46N'SP<@QR+9
MV'"VF!P]M**[/?9H1U1M'GZP-T5Q?VQ&ERIN1(;F3<VM2U^.=+/1:8'\L:U1
MG[X-)!/XM?GQ]JM_PM6GR\=7:B^O:#/TNKJ^VU=_E)\/EV17Y4[\6%W?K<NU
M;"AMGVR^.^Q<7EZ)Y7;30-U]++?=B\V'9U"3..<)Y2C+!$`$Q20Y=J<P'`N`
MM0I_S]!<3\#/G@,^MR<Z&13U%D5M`$=G-G7;"4>KVMLU#@_!&[[`[-OEBI/_
M<+VM627,X6@W-855EXP5'_/X/I#<-)?UC\N9.9V@G*\F8BONG_Z"[O7=-),"
M`B8`)YP1`A)&LAYRQE*M_?HY<3K.9,^)FM%3W;/Z4RTSO197ZJ4I4R\ZR30.
M*1Y).R$X-I`<%`05=7@_=U:RT]G3RK@9*)$QDAE%,2P@0>DP+@243$\Q&H/-
MDR>F/<`^G>$IHN^(7"O*/>_#["_QI2W#!E0'K:4F]B@)HC%1RJHF;FZOZ_NR
M_+RO5_^ZO&WE]OA6)DB0()D$+(F+!":R8`GN!Z0$:1U2-!_%L8Y=GCT*5]\>
MCL'LZ^BV^?CWY:X]H7ASTU3NNQ:WIII-8%9-QOR0JJ=?/::H`Q4=4.D_CVM'
MMYXE:$2PII,:B%)9,*2V'6^:VO3/Y7:['-[N3>,B%<T$3DJ6QEF242!)/PA!
ML-#1([UO=JQ!1S#6A$>3-C6Q<<>8GL`<<<PE*0]H&)$1,[H"D0Y#\+6-B/&[
M9/AA>)^7,A*3'`J2(LFY3')$Q&E),].:[7@#-=-BH/8.QP?C-\']^=?+>J$;
MU]I9''3CU1"7%#\H/&_NW=&!:+]_N^VN#)H2[ROC'&\USWDLBH3'"?B_]JZU
MQVT;B_X5?ML6F"[T($7I(T6118#)`VG:8K<?#(^MS&CKD5+)GF;VUZ^HESV)
MQT-*(L4$B\4&T\1CGGLN>2XO=<4;4!@'S$OPL&/&$"OU\S.#R&`B/JA3=52G
MO-B#+.\4*LO;S]0_[HJJ`I]J4:H:4=JL=YO#;LP+^(;\:B3,:'#I(C'F:IF>
M#K.PKR^V*'KW^P@LJD;/&U5&42Y?I]<\TJJS_JT`D>95@X*(].FV*26,'X\?
MZ?KQD+_7Y;8]A*E^;HX/7N5MRY[?T^SVKI9&\I"6Z]NT^4?1C(ROL_*W]>Z0
MK@)($<2)SQ*8)#[Q'(IBC"/NX(02Y"AU2[0-N^Y*/V'+3S?"&'!J,#BQ&-P\
M@M//=5:#QNRK[DRTN@*MZ2*8M<9?@=Y\T-G??J1M,B@H``T'JB6!EGE(MF;0
M,M@:BPJMGE-ZJ@_-.O=2>:*ET\R2J&TM/5\6.-J*T]!.8$!&JNIPW]I$\NWK
M=']7;(M=<?M(;JI]N=[L5YS&/(E8).X-P!R2D'N\APX9C'3K\XQ0K=;DH[B"
M$TN;%Y1.;`5_]-8:KP#7[T`=NJMA^GSK6JN#DKGT59N[EM%4]OE3NJDCPV^%
M.&3:95U3+!=1R.M\,/0P3E"2L(BZ/71.U4K_;,"K.8OJ48&'`9:II&9.IRX0
M*`WXTY)`>06&67(T5JW;E(5Q\KS_3,7)B;/G>XR34RG1&2=G<9=:G+QY&?J-
M"O0/:7GOKE#H1F[BLHA[">3(@9`&'>($1E#I:=>",$U%Q?IW[Z_$&<YCNBZ5
M;_59T(T*`=%^#]H7!X6-2P0_+;YZ*>8M.T%L"G4+,W$NPMG@G&42P/=9]2<O
MT_1I/TW,>8)P1,6=XUZ,'41H#SP@CMJ-<XNCU1SF!*:?/M:@Z@C7]9`MY3OS
MVD/3$NF?=G]:$_2$I4"8.K+3L(6YWSGGF<K\)DT<FX*A'83HS/IF<)5T:+P4
MDY/L(=NF^;89GXFW#6D4$EB/CXD+&<3]^#3F2DU]9AO45#ZV[4"!QRS=;14#
MU7P4R\6;1=A5"QLO)CH]SB4D7Y:_"\H]NPLL$>#Y[2HTS]T)<I@V%_A=9^L;
M<?*6I=7K="TNWM^^S=^+`L(RRV_K#[PI\K+_SZ9!47M#$F5A',6N&R<>XC1V
M:LWN;O3S0QA2I8S`'"K-@GJR[CO8S3V)]6:OQ]H\'3\%/_(:/(..5%=E>WPX
M6K;G<Y]V#9_$MJ3(F_&HA5'`D.$7PH1)ZHW&D>OA129(G"`*&?18Z&-*6%R'
MO@$D"1S3L40>F;%X<@5:>QH!.K&H%ZHM*/)+,M6VFYSPGJIACYL+.GJ</3;P
MF/2SM9'I6N+UU65<_QU%J!'&:XA28UT@':GHNKI;03_Q/.R$'@DXH923!'O]
M=U,W9"H!1NH+-<<%@0&D3UXU_"@DY*'9N]YE:5GS<_<(MD,W-46UEV--3J1G
M)TQ-6\7PAC50#'E!NI0(L41QU#`7$V:`:M?B6E#6N^R_Z?;G=99?%U7U-A==
MNZI]D[NM.`I"%/E-[5`8!!Y$">Z']5&D=*G2U+$TJ\(1'A#XP`\"X8]BPW`"
M4K79\51ZY33")+-J\C&15#U]D"^S=4%ZYN+9$E6:S9PO6R?/2I-\'<?ATZ==
M<^:TWL7K>AINTE_NTG1_;(I:G78@]#F'CL.PBR$AD-4$MA@01ESM/J=9!]:L
M<F2S*0_ID^1(M;)B5IHEBR268EBQWN$$)NAP@@;H21_F1=M+J1!YJ?9`AS\L
M444]MGU9$:"/0&F]'`88WK#"K@=CQB+?)=1OKJW@PW$G0CZ47*WJ7ZQO21Z7
MVG)O4G[%QX65-9X[2Y;/!`.*N::1Y$(H[M-R]3Y]2/-#^C[=%+=Y)AXI'Q=>
M@FGH$^9!'Y$PB3U(831L5(@CE?U,'D1WN64+37(3,)VRRQ)BE"TU)>E0@1-8
M8SI^3F=P6VP.3>00OV<'DT\@R6OS70KJ7\K*].2H#7PL2E!V7)='X/^4%FUA
M>2/%3N0[C1"_Q,49/9Z-OH5E>3X[BIGGU>AFE2]64U;/E5.V#W5]AI#CQBR.
M(A<%'&%.8!B0,$`!B5B@]K:9,52:P\!IYT*9LNWJ8MWVY.Z4VGTLF7=:Z5[%
MI-2P9S6WHYSHB$M)K7%G6[)E7\#P9_M/FJ5>X6SQIDK_.M1CL3KR[3_4O]WT
M$J,)#"$D"4(T##Q6)R6,B.$BU_%#)U"J>Q\[AN[(,,`"#2X@@(UK^#B:1=E3
M0OT$JAX(CN%.T\G?67(N'O)-H],6=9MJQE='=W/0,D5YAHY?C#O<\7V?\B!@
MV(V(UPSH.0SQ4*EE[?A1EE&?<0T$)W`Y6H$TT#B+!BW3*O!9@M1T2)%4>Y5(
MU9"7M6@4-6/5J&O>@R!RHUKZ$@<'E-+(H8$O!HM=SB/JP@E*)#F"816:ICNR
MK(W2'`V$3=2;A5IQG>5%7F84>;138E2-N"POHRB1EI9W]2P2_4R;S5028<@"
M%_G$\0.,O`1QTJ=Q`?8#%451^F+-0B*P=+UZQR10:AS)Z8<V>M1D0YX9+6IQ
MRL(%D1A%EB7:,`Y[,<-L&:D$_58&.B&+8A0P'\648^X[;C]*R+E2#:KB5YM3
M@W$)C2I3:HJ@@:31FK!,NO*4"0E=4*3,,F501?^,-HPB0:Y:@_UUR/:/KVJK
M<M&J1XSXX>_ZY\=_IV7!Q*W\W2:%NW&,`R?R/,C=A+/8]X9SX,2-L'3IQFPC
M:M:2%B<8@()F\=1?&:H4)LS'[V6I68Y:-04ZSVJ+$@B8H,$ID>/HY%JA(F01
MSL>5A\S'O5R!B"PUSU6+S$ZM#:4C\QM5Z)R-BCO-]^*I8K.5Q5$8)TG$Z@TL
M@I!1BE'2#Q!C7VF3*?^MNFO[!)!QF:8",W*;2CVDJ*FY'!]:=I*#^1<VD>H4
M6;)_'`&\F#H[QJST7DQ"['DL<L4[TS[QHR1@O!\"<:;4WU#E>\VL]G&9I!(_
M"BM>`S6CUOPR^>,)!2^M>T6B;%KYJM#/K?U1YDNO_M?KS]G]X;X;!!,/10[!
M]9<SC`EU,4+](#X.I'+#<=^L60$Z,(I+7Y$<N<6OCQ>UY=_A6.HAU!,:+DC`
M.+HL$8&1X(LY9HRR$/RG*,5C\NKMQR2]V9-\V^8@QZ;/S2ZD'BN,?.8BCT8!
MPB1DW.^'9U#M?L:YQM0N'C7,ICBD$J7"`FES05*7AI]T:1^54,S&O*S^F"==
M59GFXEN3<DD1>%'3YG6!-6HWLUE?Z:`.VN94R.Y\GW!*H(<]YGDUCT$41W0`
M$#!?<1LUUZCVJ.2X1&Q&_F=32@W4:]/*91(]:1*GZ:6B([X=Q50U3%TS1U$G
M7Q>Y+S9_MKW"NPUL[#HD=%%$J=C`,@=ZE/4#>52M:D']VS6K8`,(M(A4:R'5
MF9+3,;TDC7ILV*)9K`#R2T(N:,]X\BS1F`D&?%GT.)$*_7W'KH=;/UG,0S]`
M"><N1R1$@>L-63(/';7":_UP=*O2U'934VYX-N%-22&TRY%JRFG*AW:U`[N6
MN++9H%MMT72#%L_5L6LLV3:T868HP@ZGL<LHHA3%#,(ASB4)<58/:7E36-"(
M^26@*O)T:I/B_K?H&U/==P\9]O]OP&O*M39)U,),F&O`J^8<_1OAYH_?TFJ?
MY;?OTC(KMN[*#^K_(<?'T$&Q#P/JQT."#TFLEG>;!&8D91\D:UWKWOHV!0\M
M2/"I06EJSSO*<9IWO[I]9G@??-5MASN+P+L7'&S7AOB,,W1LC:?XW*8(9-SV
MN;;+TQT@]][(BP"?@;?=-K?;K7?-OU?DL+\K2G&S^8I$//(8Q=QW:0`A"F(O
M[%#&)'"ENFXM!$USI'F5;\JTA@NR'*P'5*!J8*J\(+&`TR['F&_`7R.B#(@O
M1YG3#ST]:CG:U'ZH`D>K+'>TPBLS=CM\W+LUSSG^2L[S5R-=+_<BSNR$G]DZ
M+.Q9&U[M6=#ZPHKE92I-?7,0CY&ZNPU/@7IA$CJB>,>G$4+(\;#?O^L0>Y2H
MW>!E')W9A#5O8(KJCW8C`>K_I^6#:.!6E""KJH-HHF`J@1WO4LU9K!%O&D]E
MWPS.'Q]L%LYHGW.,CK1V\B3XUG/;Z03,E>#.Y`KC0>IAG>W$A;J\*'^N?W>_
M"OQZ1?AQX(>)RP(4$C_LW\R)&6+1$K%*&:3M!0CGE*XWLHESC9D+!3GU*6$V
MUFF=#1:$/)6)8'7L^])1!D+@Z+GQG47"\3QH"H@3':-P^COFD6A;!EB]*9KN
ME6D'?N7B*$X2[E#FXS"@-/#"N,<88E>^+Y1I8)KCWZ\=FCYK`\5A7^W7^3;+
M;Y7/`TWZ2_;8UU)7C0A.+\2FN(M-YPKL.H/`8%$7JZSVL.IYKZ6>'M]HZWA^
MDA?Y3YWCTOM/N^(Q34%U>M@"ULU;-OOZMVZZ)J95T\1TN]ZGD_MPS4SOQ;/=
M!;QHS<GN$K9_=:Z[F`.D$V;6+8%?TO(A$UU8S^UK!BP-P.I#L5_O3O^=%M7^
M3;'_5[KO6J+5&7[[.+O>UYQT27-7/.)A$M,X=#A,1$\:$O476<40!KY*&FT9
M]`4W%U?3ZI@L(U(R;[8,M<:WJ?HHU5GZ;!NSJY,]26OOU=,MCK"V_LP>/-;1
M[&CP55<=U636)T8;SJ_-.O1"UFWIS+(D%[>5G>*;D`=;PO,*LX0YL</KW81+
M(*%^S*(>L!]Z2FU`ET.I/>B6`Q:P.972]+/X6?6!ZX+N7#BHSNI)R^+G]Q(G
MEPB)TO/B>X]^\D28"G2*KM'_C+;+C)N#\NI5W@;BE0N]&(<<<N)BQXU=Z"14
MH,3(A0%UR8C7]LR!T_ZJ7H.GUK,L[W)#\$-;0/3CM_+T["RQ.IZ93?.@)?JT
ME/5S/1^;PPGS*=&SW9;/POP]%5>VUQK;OES&/J?E)JO2=V4MRRL'8=]W28@2
M$N"X7B1AVRP(HQ@ZT/%GEBF#R)?0L%]_2<3/;3&D=5(V'_E3=&Z!*?"MB.`2
MU*@JY&+N4[OUZZ[8U=ZLVBN?ZBUDFF359E=4AS+]D'[>Q[5?_EQ%;NB&D'D\
MYDY8_\%BGSC<PSR&.'8CIGP;V"RCFBB'ZX#^H[NK;\QM8?,P+%F,M@BYB@_P
M3S#VO(JL/`5'G.`/@10T4!>Y>$R&PTOB/KL?;)'F^0T[=X&9!NJD9?'T(HET
M7[U.UV+8[=O\O;B-L<SRVUK2L^J((_&YG\2QYR,2$!1R%'KA@(-BI3L;9A]<
MLTCR+%_GFVR]`RW@YE[3ZVQ]D^W:&TU["\!Z#X1QH+$.%#D8+`*-28K2.K^7
MY!1V40>I">V1[JO>.X,WON:_EMRF/'<YX56E]H+^:O.2)3*LS[["T'3_2I1/
M)]MU_5/]E_U?U7^(T_[Z;_X'4$L#!!0````(`+"`:D41VPK_\T8```9T`P`5
M`!P`;VUE<BTR,#$T,#DS,%]P<F4N>&UL550)``.;*&%4FRAA5'5X"P`!!"4.
M```$.0$``.Q=6W/;.)9^WZK]#][,Z[J-^Z6KLU.X]K@JW7;9?9E]8C$2;;-:
M%CVDY"3SZQ>41,6Q=:$HDI*=?4AL2P!XSG<^'!P`!^!/?_]\/SIY3/(BS<;O
MW\$?P+N39#S(ANGX]OV[WZ]/U;4Y/W_W]__YS__XZ;].3_^IKSZ<V&PPO4_&
MDQ.3)_$D&9Y\2B=W)W\.D^*ODYL\NS_Y,\O_2A_C_SZYR?+[)!]].?DS^>C3
M46BS.#U=-'4R_RU\^-?'N$A./A?IC\7@+KF//V2#>#(3YVXR>?CQ[.S3IT\_
M?/Z8CW[(\MLS!``^6]9:6Z+\Z[0J=EI^=`K1*88_?"Z&[TZ"TN.B1ON+DC]^
M+C_XIOPG/"L-I91GLV^718MT5<'0+#S[YR\?KF<JGJ;C8A*/!\F[@,')R4]Y
M-DJNDIN3\N?O5^??-)`%"+/BAT%V?U9^?:8&@WR:##^D\<<`Z21-BO#H4H(?
M[_+DYOV[LGQ0&!(@,2C5_=OZ&I,O#\G[=T5Z_S`*NIZU(<S+3VPRB=/1[D)N
M:ZD#X7^+/XZ:X/EMO;T%,W%Q5_YS_YJ&?C0*?:U0X^'Y^#$I)F7/VRIA[0;V
M%S6[OT_G;88GF&P\";T\>)`:M*Q1M4OQZM&R=@,MB#HNLE$Z+%VJCD>E=[B^
M2Y(:QMY6L3O1+N,\('.73-)!7`/*75II5>CK2?A_9L2+F[)?^%'V:2=<-S;0
MF:@7#TD^&PKGW+M_R).[9%RDC\F'K&@L?[U6]U:J"A/"0USH-9,OY^,R'I@]
M>9OH=>KN+:"/T_R/>#1-?DGB8IHGM3SKQDK=B.33<>@K:3Q219',W-"3D6=1
M<*@FR[H7XZMD,,WSX*AT7*0U'5T/C^X&GE_CO*3S8[*'GFO:Z$;@>D%&C:I[
MB_=K,BF[_&627]\%'[Q-I#7%VQ;#Q*/!=#3KZQ<W_TB+29:7`\/%=%+&S.7,
MQ*:C:6FMZY)L,R[^FDW.QX/1=)B$*&?V=8C/GK19CQN]"](V=/6HM;'2_B)E
MDR0,Z5_*5K=*LJ)LJP+4M/O:&GL+<Y'?QN/TWS,2!?=YG=Z.TYO`HC"V#0;9
M=!9.7H91ND[`W*2M7A6HAW;S%GM5I@NKM&Z=J^0Q&4^W]K-GQ=IZ;#U[KRS<
ME@B+'_J+NLV3V2!9SP?6K+ZWF#,/>Y>-ADE>E+/QR9=MDJVOT8$P]2RXK5X'
M@M6SXK9Z^PLVR09_A5`VF4V4PBRIUO1E<ZV.A/H:A-^XT'3V)4DN'LHO?LZ#
M+W+%)+TO9X(78QM^7-S,/IV;<3O,73VP(RAVG!+LU$A'(J_^U'TN?]U+C1T:
M[DJUZ?U]G'^YN)E]/:>(&@1D0W<-`^95,BII\F2&OY>Z^SVL(PAJ>K,:=7<6
M\.G&AIS+.$YN2Q`^Q!^39RBOJC?*\V^JE9LILMQ,@6PF]:K66I2RG*RT*NCS
M!EN4-<RHTFSHQBU#N[K9UN6^GL1YRUBO:[A%V7\+0W_2KM0OFVQ3WFP2CUJ6
M]T63[<C;@`R3ER+6L/Q#GA0A])ZYNP^AU*)LV6;#K=#Y8Y+/DV0\3(;S7=;P
MH%$V6*7-3).;N/@X4V=:G-[&\<-9Z9O/DM&DJ#Z9>>M3`!?;R'];?!PM5@[*
MY=&91/&H4!^+21X/)I4\HQ*#]^_"\Z,:M2+/.'$`:2(,5Y(YS+@''G&O*>>:
M^V_5')4;YEE>P=F9GM?3AV"U<I(4CYYNX-BT&(RR<I&R^"U`KL/3_]J@^"[-
M1,IA[PD`CD-.E"(N\*M"@GH&MR'QE%HJ'YQD>9@KO'\7ZH5O;I(\7XQ<&Y(!
M9E2;//$)#\&IY2&>>/\.58^/\\$+MG[;RJ+$V<-LL^MT<)>.AE7M,FNB`W)D
MO>$>E%MVYK/GO;GM/EXO+^#5]GUG(7986\P5=Y8)`C2GF#H`@@D"_+OV_9=Q
M9OE)M$"QW-$N'WL5K!.L>&>RXNM^UA/)M]:)%`62:NLQ<1YCB+VDKI*;,P:^
MPYY:VY19-R`_Z9:==8"%N)=Y=I,49199//))4IAI7J*WH0]LKA@A[SFBX7]D
M/50>>T>7V#E*14,ZH7WH=/P,Z@3</FA4K2`M)NA/G/MV)FVM&U$O`EH*>B6$
MA<!YYVVE+\*D*9GP=^2;N@)[,[FV#%ZA9+DC^UN>QJ-:(]>+"A$WG#DF(53"
M$<BMMV3I42$S38<M\AU1HU6$^W`V%Y.[)'\91F[W-)LK1DHS83QD!!-//*<4
M?P5.$V@:<HE^1USJ!.D>XZ"=Z+1>/ZV=P9!RP3Q0-G0?@E6E'].\Z8#%=F;2
MDZ6E5\JDMD#N=8Z[:M'_U<YH*>1&6*2MUM`2:8V7;KZ6@(3!=*M;[&@U:W"7
M#*>CY.)F#?RUUK)J-Q)9A(%2F`#/!>&&"&)XA0*$FGV'\^/:Q'B^DM45ZAWV
M\1V/9/34V4N)RBSP9X)M[^^;*T8`*&X,1$0P*@FBE'@]@]TPH.WVJ+H[;5_:
MX/HNRR>_)?G]$V/4Z?L-6HN8-U`B8#$2TC`DJ%6^PH40\U:=0%MLR?JV0)<.
MH>[QI[Y<P8:33LL=@CJ>89=V(@^,](!H:"PQTL(0T].Y?X;26:`.Y"CJZ%#+
M1^S44*00])12K1&FT%ML@`$5&M!LW_=[K>ZA&\H\]Q9=VN(PCN*`&U^'<1>,
M.F,P88)J[*GA6G$HE5&6"@D5X"UMCM6CRM-3"\\7'.NW$`&!J?<46D4@!811
MI%FED]8"_7^GW\7P61]&Z&-!Z7P</$"R/+A9W8J@/J>K5KEKU(HX5$K#,!WB
M8>H#G&9*TDI'P(P[!-':Y59G5L^Z0OF`3++9?9R.=^?2O%[DD!+62><9@Q9!
MC)APE9Z>H8-DYG3CJ5JQ=CT&-<*V#PY=)Z/0YNW/R3C)XU&YF#.\3\=IZ9W+
M'/E%/GGQ2W+_,<DW+9CMTDXD''.68L:A`9Z6<S0JE_T3-MZW?3T<VY4/SQ?*
M.D2[/NN*9/##;?9X-DS2.>'"+\]Y%CZ*/B2W\6A^WG_-*+>B5"2%HDH@Y:AS
M#@NMC225U#(`=8A$D0[#IZZ'N/TA;I\8<U'6CE?/BT1*(8$8!E9P!CP4EA)1
MR1O4WYI"]\HBZKU,EK6"8:,LCO/Q'T&K]''MH+&B5`3"2.O+35Y)('.>BN"K
M*KDH)>3U#PG-39&U!5LC<]KK7S9;<ED@\D"&\8493JR$3HHRI;F21@'<U(A'
ME-S7CA&;(M;(?O](1@%.G6:39'"G'JXW&W-UZ8AZI2GDWGOKF318FQ`1+^1T
M&C2U[+%FVK5CYE:P;&3S6H'$AW2<G(>X=&UVW6ZM1$YQS+SR7FAF%#9<"EWI
MQ0!NN@YQK!SI.F+KW@2-J+6X9FQ\^R&)B^37:4GIBQLU'*:363[R59B4?(I'
M\R.ZZYBU4R,1,$0:R!V5&BF/K,-Z.<@Y!P\R73P*8C4P?-:3%1IQ:R:'*S<Z
MRMSV^2G3=11:538B7".IA8:8"2D0)D`M)]2(L*;[\*]_TK@G4UH`NY<$X&\(
M7?CI)*C^2SI.[Z?WE_&7&49VNFIS9\<6(LJ9-1XK&^9<7``?9F.@TAUCU71'
M]_6/=<V)UJT)^J#?53(H[3C\?3S(QI43O9SF@[N@R,7'47H[7_R;)N?CJZ2,
M*X>EP_4!O'CTOTF\:8%U[[8CA%2Y<D"%=U2%\(-"N@QAE29-]R/W.A'Q>EG:
MMSWZX._OX[R>5N8N#IB&4.&^O`A-%5=),1U-+F[^B/.TC'7+>TZR\=/LQQ6,
M[N!ID3+:$HPYQ=J)$*]XA6V%J;5$'N*DQNOE^.$M=%2L?WJX?JYI&^Q^V6KD
M'*8<.>@(D\!;I#7E4@/)60B7(6K*XMU/B7Q?+-[;$OW$&/-SXP$QFSPFH^RA
M!'"QX[<Q?MA0+^(:"V`IH180!R`7PB_3<%P8G!HRCN_*N,<D_YB]M8"V3>@;
M3:M_S@*NX_*AL\OZBM_+6.0J>4R33^MFUQNJ1$!`2+DU"'(@`>>"B*7$5BG;
MD"SB^W)/+</<::)JK1=1])2@NLRE*(/IQ37VEUDQ\^HU\E+K5(^L1MH(`QD.
M/8D[QK1U4DDLD=24H$.=;*M$7Y>ANKI@!+44V',(%92`(LNL-I4V@+"WFGW>
MKJ6?9^#L`_&QI-A0(\/D4P`C*;#(.DV5K:1V!TH<[9,8.]IN0R;-;D@>/I,&
M2.>0)YQ!PX0B4B*ZE)<H_-9<PEXF6Y=)LQN&O21S+M,,-^SLKB\<&>\Y=T9S
M*`4S6AKHV%(C1)JF_A[K[DE+_J`U0'NYSF+^PI_M<=*W!2-G%;'"6Z4U-\@8
MK[%?:B+=6SW@NH]-G]]7L0^@_5%C<8E&;88\*Q])BSDV&!(/C?5,`6LJKVBT
M?[,GH9M:=R5)]L.T#ZZL.?@],7&>?PG3Y-G[`S9PIU;]R",/A20(A+DT]UX!
M!L%";\N4?*LGZ/8DP8K#]&U#W8L[>HS343D@^RR_#D)_?1?7_(T@7_^N<2'3
MKFU%LCR)@1D6"AJ$'`,"T@H/+,36\^NO-!1JEWI=P][3GGX2.DUYU<VOR60[
MU5:6CXS%&EN";%#,8L9\>5O%0B]"8--1\5C31;JA4QO0]D&9RSQYB-/A8H%_
M.V56EB_/ADFHG"]O+U,,`0GA4B]+:-,I^A&E:W3#DC;0["57;783XE/5-Z6E
MO2@<!50<@L%-6F$Q-4PRSI:N4J*F&?E'E.K0#3_VAK+WN5C=.5B$O74$25YF
M50C`"25\&<2%.4A32AS[[9(M!RU[0-K/Z)(])/GDR^4HGK](.X12LPWE,"9N
M'&365XN(9(`QI2VC`(2`*Z!&*BT14?A-1[M[3]I;A+:G#)))G@XFR7#UU/#7
M;#RH$>;6;22"5F-'J854`RVY]@Y_'7J]>6M'QUHF5V=`]QSCU&+5RO*1DDJ$
M26$8EIW&@EEEO5WJQ1LG=1[[5>XM$:@-3/L+>;;&.I'FD#$#A"/>$F$<D>5M
M%C/)G7&-DR-WCWL/$>2TM,"\(XA]F/_IBZ#&P]DK,[]Y`7"-#8FZ340J!'&`
M(&N%U(!JI[VJ=O@<Q4*_T7"GQ<VLCJ#NF6CU][K65XJLMM@H`PBPD@@D@?/5
MDJ7SQ#9].<2Q;U*TSX#U%-L/\EX&K\&@S!<O%K>BUWI%Q(H*D?82DC!;0%9`
M2E10[:MFW#7.PWY%9&ILZY>OA]@?X)ZHT^(+1I"@C#B.)'7>`$VEX55<YYAK
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M=00"YP`-<1XEG.MJD]$)]V:SECN@33L(]Y,=-(G3<3)T<3X.45FA!H/I_714
MWOT0Y@/I(-V<%;2M<A1FI.5EY18P3!6`C%&PC.\"F&\UINZ`4ZV#?9A@>J<@
M.D(2`DX)IA9SA&!`RJ)*(RM)4_H<>_9'!_39&]QCR`K9(QLD@IP1KBWCR&!H
M):-8\N4JJP=;WV7\2K.E^]RX;P/X0UQL=#E#\BZ9I(.O@=.;N^7(`V:1T`YY
MZKT!A#$AYF]"Q<)2N_6ZAXXUW_&6(Z\091JYH(SC3GENH:NT@<B^M2M-NK'T
MYEN.=H/X6&XY<I!*$\+L,&T/OVA!A+:5U!BIID=Y7PTQ=K3=AEN.=D/R\+<<
M,<&49DY9Y!G5##/)526OP8U3A8_5\GN9;-TM1[MA^"IN.2*>*\$8-XH#1+`!
M<ND,&7%O];#3GOZ@-4#[7UT/T=Q%/I-[.%NSNTSRZ[N`6>T%]W4-1`Y+$0)8
MJ+VE0#!'`2/+<56#@[PK]T")Y'4YL''MO26@^Z?83,I"32=W`?M_)ZM>6E.O
M8E3N<3+CI"3`&&Z`H6:IJ0D]]*U[I[8IM2?`AZ+2>5%,=Z;1O%+D.6$*0D(L
M])!@X#!9COD<^*8+&\>_;-\IA1J!>RCZ7$PGQ20>#]/Q[8X<>E(S\II@11T&
M3&`*G&-&R4I7BE#3F=/QK]5W2J3F"/>\S=P@;JI1.](0.$(]0A)[(:7#"+-*
M9R=-TQ'NV/-?6F15^RCWS*P=PJ4-M2)C>9B0EC=R0$J5=DKX9>]!RC5ETE[O
M27FU3-H3W8,P:&N4M*9&Y`'FB+K0/0"RRDL%$5[.?O'V"_[;>M_)&V).(V0/
MPIIZP=&F:I&`PEN.C,164PF!]MQ76@(.F^9P[O4*E%?.G^;P]K1#N%2^N+@I
M+V'QH^S3P5^!LA1DMTW!%]4B2#C6DAE@#0@A*4,L6(`K(APU&-NMM_0<UV:@
M\X1[9E4(J3$P@#)(Z%(;Q6G#_OEJ%N;VLO#F3<#=H#V634`@PXR=&*@X5!1A
MZC5RE=2:^#=/B!UMMV$3<#<D#[\)&";52FDKH`5`&!!DYKZ2UR'QUBX1W\MD
MZS8!=\-PL\W7O*/N^CX>C?2T"(%%49R/Q]EC0/PQJ=Z=]TM2OIQ^A;WK5XX`
M5(AS"HE$&$$<`"&ZT@(PTO0BNKV8T+[QFQDNZQC-U[`QK)F"6"B"PYR%(@$0
ME,L!DFG_YK=>FHT1K0':!T7*>\-#8'299X]IB-/UE]^+9'@^7KYR7@T"T^>I
MB]OCZ=T;B[!6EBO%.`H1F&%0`V86B%@M?-/TY6,=C/Z/O&MM;AM'MG\)[\='
M/&=3.Q-/9;(U=3^A-#:=:*\B924[=[*__@*R2#NV15$0"=),4A7/)``(G#[H
MQJ/1W0<W-H5!+T3#=^NXR:Q^W>S:E-0/Y0)&1@DA/2>&RMA]R40]#B>MFIL[
M4PF)OR17-MYEGG;]^W[W\'#ZX^9#=;U97R]7U0^]_KCI3\$-\;E@*4:$&`,$
M5(!BA^(ZL$95`SA7*UN0Q1,06XG)\$M<X*:Q7*WM<O?UX/)\=7LRCFQKO:`5
M9<9"CN.TQX*D;-RJ'J<39OCMHGR@YSKNX>ZJFX_#9U<8E2V;X613)IQ-E.KU
M\D':ZQOU9;.]6_YW_[\M#&RI%80WS(AT>8*`0,1IPUF#'-2Y_)NZ>IP4"_N3
M3Y%M;[H^T8N(AME\24EO3M'O]0I!"8@I8A9&XT(=(I`:48\,.I,;%7GJ;F.3
M8EXOHBGB=+9_QO[/Y3K^&056[5ISC[PH'#QW.()#@+/24XDIL8TJ3\EW9NI:
M-BFR72R6LEN>J]L_%]OM(D+W2_JSNDE9!:OMM^5U:X"O;@T$8;6#WD+'H$=,
M`"@,:::8XJ.DT_K9"#F(J$J0-(*UK:+6MM7#SR?P'")]=-AM=V\D",@@@EAB
MR$U<AFAN(6VF*1"Y\7RF[O@V*;(.)JYQ"/LDN>99''U2+R4E,91K0*SV#$A#
MTKP\C-,#/GQ(LA_WSN6(.0073M(M'_EQ&'9(S%E'%3TDZ(S[JR<9BLZB7I<&
M`Q-8J)34A`KM$04>N/KNVU$I<^UZ]_WT3\7)`40R#EF?I8](IP`O\@&<1=8N
M#08A*>86"1;7-4AQY?&C()0EN4^3I[X%'X6J`PAD'*H^AFG^5JU;XT*>K!OB
MKL\R[*AP,OEP<`5=LQA"*#M0Y-2WY:,0\#+L1]K6)#7^&`4\5QD>;R8HCBW`
MP$/.>#0-6F!3H^`%0[F/5R>8UGH4TO6&_+2\=7KQT@E6<0(00M!3R9!!1*'Z
MF#6N4XPK9G[+1H0KZV`QC#!&I..[];=JUY?S6$MC`6$N`>7.:TT(LH0151_.
M>BAM+CVG?C4XO/-8?Z"7N7KY?C@"4]?_N5]NJZ/YQUNO9+HV$KR@'E-H.-(.
M"94>8S5V@3,QWU.=(=GRXBIF('&,0DCU;;%<I4U5.K5?K*H_JKC<.&6GSV@E
M8&")B+^Q%`(JXYU&#0;Q]_":\&>D9&_R*!,497-=53<['R%,G;VZS2/E&<T$
M0C"C,,Y(P3P4$1,.ZQ<1W@,[U].;DIP<3AS36D#VLG`,&'II;(07:02==H2Y
MVE?)`Y2=U'/J21H+$G(P88Q(QT,8X7[V,RV-!8$D`2D!,X."8@N8A/7C-&\(
M%S/5E\/O9_H#O;2I3D%$4ACVJ]LG\2$ZVN=7ZP;%@(Z*GW@2?RF&':'H8;PL
MB@Z/$A:\J-KKA0PM=K@/V,>CV=/$J6?S[&GEH*06SGFD,4!(>6<$9/6(K32Y
M!]<7G<[,E&@7X%Z":1^JKX>]T]7M^\U=55\QMO#K6)5@L6(J_A*82H2I04R[
M>G3>B.%C>4YLISL$R7H"/ROL04WP!,!><UY]3:+:+=8WM0>D^[O:7B]WK\8Y
M.[N-X*RTP@AB-!$:6Z:%E?68)`2C.%Z_608-#7_QDY(GW6^C7>>Z06.=8G@9
MQC`1@EJKJ*_'RY#+32$XP>O<D:QB'[!/:[/9RR8S6$\%$%0:C+'UVE,-FXD&
M-,L]^YAZ=J^"+!Q,&"7HF'J><H_''^EJY=MBE>S_[U64T,USKXD60I[33(`"
M.^\-I5Y;%I>JBE!0HT"`SKU(F_IQ7(_G'0/"/1[I5)Q&V^WW.&-.YG7N4C]`
MJH6*(Y4.(N^BZE?\4?<+GQLFY&R3^W4OEBC][=V,R'89VC-BF73`8<$)$XX[
MY["I/8`8!$#D7G:=;5\?6.;6!;>FY3EV%M9%WIS??_VZVF.P6-611M^M;S?;
M+XNN&2J[M1!('"Q&W,*T/TI;<%&'F6.0*9S[*OT-1NK.Y=@P2)?Q/WYXEIP>
M*K?Z%S\6"TQ:)XQ"2BH<;3YTT>[7HQ#0S35(5N]"?N%)G(UQUKG8A^KF_CKU
M?'-;U:Y/UYO=W5^+W7+W]7Y[_3D%2?B_Y=WG3^F$Y?;^6#CW"UI+K^H8=0Y2
MD28>M%;H^F@9&L-R@P9/\$A_*/J40_\)RTH%@3]X+<=_329\\R6V_[E:[Y;?
M?@CK5S0R_,-#Z*:3W5Z=OU8C($SCGETSF98;QC(.`),Z;ILLEI#@DRYV`ZT[
M<I-#Z]@>IXP2(JVA4EJ*'D9#))-RKLFA+Q;NB7S09Z':?<4P;"AX:9&'@BK'
M@<8FKJ(D$76O*<_._3)U+N3*KB44_'E(]B]_=V8H>`5A7$*[%-+&>`%M`J#N
MKX,^UVUXJI*_2&3'0L&?AV&1O>B%8;]5>G?I(:8&QM4K]XPX68_(4#3[9S5Y
M^J`W0,MX9.R?V+81HRX2N(LP&,VP\```A#D4S0Q1WN8^@9ZJDNA#CB_\*;*@
M+$&$YJ'A(3)%%\_6HW4"@2@.#0EJ@=8.62#B^NDP/@]5[N7VF]$<EU.E+VS+
M*)&'_!=QLV<CPU>;_4;VT/%6S=)2+V!#L:<:`4RTM9A3@@]+<:*,PZ,D)2G`
MH1X$_T+K]`=S"3K]4JTC!*L4=^3FRW*]3,-/:59.$^I$S<"M]3*NSZ#0-`Z7
M.(MU/5:&4:Y?_=354O^4ZA?H4>S;.78M:,0!,EYSE6XQB<``PWH\<9CE$L>7
M=5#HGSB70EN4*ITRD;Q2.E"OM40F;ALE\M@HCXD]C$D3E9U/:^IT&6+YDXUJ
MF6NX])HMC?BAF^^K]@/E%Z4C/EP:A32D7%%("(.RW@AH81D<P^GX;3'E<E1+
M7MB>7L,\*QDHBI948F4B-LPH!XDA]5BH5KEI#[H[+8WUSJ%7CER":1&;<X@^
MM?E1[YVF2WO%$&TKA-Y([>(OK02#H)D)VJG<(_VIQT/NTQ+U"7`A?_*,%&H(
M<@FDLSSN^ICU,)G6>AQ.LMRSWO.]B=[LDN42/(MX/SZ]AV]LY=7MQ\7?;3Z/
MQVL%2^+>CD,&/4YN*HAYK>HQ*H1R#X3%S\.9_M`MP2"WV*ZC`DQNY74ZEN5U
M.E5:KN[O6I]#G:@95)PN"LJXA:1:2H4(?)PM5,I<?R+Y\YBI?A$NP:8_J^6G
MS[%KZELTK)^J]_<I>?+5[;[W5_=WN[O%WMNI.\GR&@P0<P.=M,Y0(*D6B+%F
MGE$OL_TBP<]#OB+(#^C'9C?7]WLWH/7-PY7^$P^_,[W5CGAMUE^H?RY>^5++
MC=O9;02#)6>>68.Q$L`H:VU<EV+@#<#"GLZGW)L7RK+:'7-)>U$F(*X42KZ,
M7G'C**`8^[K7UJNY^:$,*-;G7BJ9$$_%-8U21[7#W$-FG*#"V+BZ/O2:`I'[
M.'^JQ+A`;"U>:>>!.+Y7FF02("VXY,1"*:A!CM?]14SD7M=-6>C9(COFE78>
MAOW+O-9J3Y39KRW>:*>J!`2H]%!#;..,X.GU=%R;U..18)1@0I-7!#TB.AQ#
M/L;V3S`B%0F("DRQ<$A!*ASP#B)4]Q?[[&RL4]8*_<CO%4)D`-H_`53LR4WJ
MC5\M7GNH]*),4)03`KB,A"=**D^XP'6/541@ADJ@=PI<@NAP2N#W^M&RC9O3
M$]K@A[)!*4L4Y(`BX.(J63(*FQ%$&SBWF)F#JH5+D!V.&WZYNUZL_J=:;'W\
MFU.KAV>E`V?06\OB$D@S:ATQA,IZ%)ZR<C%&9L"/R[`=FB$/[.W.D2?E@U/(
M,6,HI,`@';6AH0W7"9Y=LN,"+,E'MW^>?-PNTCGD']^__+59'>'&#V6"MH@9
M;:%BZ38FLIQ15O?8(#FW?,*#\.$21(<ZA/A0?=H[K:[OWB^^M)Y-/BL:5\L6
MQPTY`EY+"(7V'+C&&GJ3RXBIAMT8A!$]`#L4,4P<YW:Q>K>^J?[^9_6]E1G/
MR@:54L01C36U%E'$*4TWMH?#&@YR7;7.OP]_\]2X#-G^N6$>D@(^KGO:=RC'
MB@>ON,*8HKBY2N$BE!:>-@LE"'-/KZ9ZSST(0WH"=R@%XI>K:FMB?SYMMNWJ
MXX>2P0ONN9"6*:$%2Z<P[%']L>RP89.]AAY0>UP"[&!VY3$%P/Y:?/?D7KS=
MR+14#,QJ1[P6ED)'B?+`D^8ZD`*2?5_Z4QV&]H[S@)X*?K'<[D/?_58M=O?;
MAX`[9[HH]..^T_3$1D6\VJ3.='DSW%8MF#A5I2!`$A[GK"$*80(\XMYP(#FZ
MR&FAWY%^C"CK57L*EM9ZP6L'G%""6T,5,`I(I>NQQK^:ZVOZ?N2_&0[ITI/W
M$!5ZL5*[7767`F8]23U]*'BC[IJZ5^L/*9/;]N!/M;/5W6*YFHT*B-I5:PBT
MXW'%#Y$'ALN]L#02T,B3CAX=_;&:/K2A_ASJ8WY,%[88)/*1BT@X[#4V7H'T
M&.4P9JU<]M+O+:N"SCS8C"&#J;A%"44D@L!C*WC\20G3H.XU%S#WQ&&JS"DF
MY!8GJO,@']^)"G#NJ+,80:^0(UP:T?17Q"DV,XI<)+)C3E3G85C">;Z9!/K[
MD\6$WU;_N:_6U\=4R!FU0WH7B:B$S#NIC,3.RT8!4\IS5<M4?2Q*JY;A1%&4
M?J_U^:AN.J-V@$0JJAF2#E.'M9/0B7K,/O]%T%35UB!T.$:UWF`?BVJ[9@;^
M5J6G)F=R[7GUX#P5SE%A)3",&$(\H_6H"9]=^,M!"-&!;!?B7MBN-O_YCV6U
MC=_^_/W7%#VKNVEM:2!`:YU1VB=K0:VS#J)'<V%L;A*NJ7JK3<"Z]B>-T;3>
MRR%DF=JC[02((<'(>1.G-I#*8@R;=:Z,D,]=#_;$DBZJL"<9%.7BN_77^[O=
M'A#8W?"^K!72&T]'K94&.<RQ,E8T*Q@`9W=L,3`1CM'M8N`+&]R]63"KQ6[7
MW<;^6"<X!AS$%*F4#@,S8IF%]?BLS7XF.%4GWPF8U8L$4)1@#_`<`^1?Z\U?
MNVK[+>&RGSCQGS?KZPCCG@Q/!]K=Z/;\R2#C:IQ9"J&/$U@2I@ASC;SD;%,X
M]4"W8P0>5T(E^/_;9EU]_VVQ_=_JSM^O;W8G#??K%8)0D$`&F5&`.<BB_6"V
M'ADC\[?9HS%E,X!XVHEWY,[T_69]\+T[RJ%7RP4`E"$0<HWB<L-3(A!JMOEQ
M'3VW-[N3HTX?4LEB3-;2Y->6Y^$]M!H$Q,!`RZW1!`)I@6&-S6`:Y![V3?6)
M3^DU8GD1E;"BKZ>C?<6#H<6P=FXC6,TT23>5(([>`(J8:#!W&L_-UA:E3*<\
MPY<+)4M??JAV=]OE]5VU[T\W=G6K&(!0W"KI&;?402CBDJ`Y30!>SRV7TQB4
M&D02)92;^K98KI*R]YOM'W$"_)$`V8/4HLV.5PK2J@B00]S)%,L-<>F;$5HH
M<_W9YG>Y<;GZZDT*17BVA^8\HWFT3I!:0^F0ILA08^.2U=-F%1R7*+F'(?,[
MZ^N!93T)H;1O]?O%]B$OS<R<I#F/4!LN#&0I2C#R%A_DB(5P_FPGZ4%.6D^2
M,Q:(F])M)Q?KWK\1C(M[90VAMHAZHP%'VM88$I']CGNJ:^Q^>=5^G%I,*E-Q
MPR:>&028(D()C14#D/&FUX#E>G.\&2Z5$WN+8_9Y0AC?,5M`8T#<#$!&E/4.
M*WIXEA3[RW7VCFRJI+E(9,<<L\_#<(3KQJPYT78".LAW`E&`2>$(<@)SHYQF
MP#2"B'*9V>G`^`IL"F(L=6YZXD@T$&P1XD`@Q;PRQBN;@L`\]-I`,3=%.++H
M7SG_/%,")7CSKSC0Q6KYW^KFEZCG4T:=J_5CIK<VQ7BB9O"4"2JQ!W$7+!A#
MA-K&YF":[>-XD:J;,\'ZE4?I$X2]=I]/@`5!`?&(*D:`P8`!S.%AHA-N/#A)
M_E%=M,Z*N="QJ6"QQU9KA",HB@I/!1(U(MKPV;L\7\22/*^J7/`'G/OOJ[ND
MF>KD2:/,]^<9G#K,]6-5@O46(V09-0I;)A2&Y+`O`M)R>O("N<P(NTSHHW4"
M]-X;Z9VVUFGG+3..UV/4%LXU:L+E,C^1.2P7X7+3TRQ6U_>K?2M7M_]8[J)<
ME]>+U9.`3?L,4\MO3Z[#WF]2=L;5?9S'[]:'!%1/VQSQAJ#/B2^U,XI@:J2#
MD$/'`)5UK!L6U_+C3/P_KC]7-_>KZNI6K>^6-R^$X_Y^D(R/;$\I$>_O#L)]
MP<T3UP/]?BB@.'.0LI0Q!VFTB@))5:/I(,^-&?YF54QG=FTF))8B-]N7#4M_
M?[V!$^]@!OQJP,P[`HV#Z49("(A,BIUX$+7!<TNX-393GU^X3T:RX\V>%!3Z
MY%.;4U4#C\-#'E`?-QB`:"(H;D9+H)I;#K%)$:@3J;-E58*9[LO7U>9[5>W#
M@EY]36"=?#]SM$Z`B#K!/#0(:$20UP;Q>GQ*T+F%8NI?[L]W+CTA78))?R97
MI):7,Z^6"QAH[.*DBOLP#!AB"GI1CT-0,LIA]5MFS"7HOH%U9)>+X[X^$901
M0$CB!*;>6H_D/GE<O;9AN=ILZMR<QPHQ5XQO8!*H+YO[==OA22_M!VF!T\@"
M!)DAFCED>6-B..'^IS+F0_*N7^)G2:_<T>:(]XU]'D,2[9D7$D8KFORS.'?J
M$&>$<NKQ27^BJ1]#=KBXZ/]C`7`1^:H]`=99)#2B=;@TRA5V;*8JYW*6#78<
MF2F:(?7)YJ[:_;[X_O2@O*@:L=5?=X^7RAV4R.L5@D-FOS2BW'LNC+,.P!I1
M!.7)L_<2H^NB!X[4"`HKPZD4QF#B@&+"I+0B#^,#E,[U;N%2:6^&0+?0?!SQ
MCK&O60D=,5Y09Z2+?R*N+"--[%DPE@-1ZNR[=>SB0U+S$Y>$KY0.$"A(*0-&
M<FNM9%;[YF6<='BNKX$NE?(KL_$R9$OL+W_LY8D[MI>%@P<TV7C+)*%*$T,<
MQ$TT^`YW[$-P93AZ9,NSE1L90):G1J<;J&-50G)K5=9SB9UFUD(@'&JR#G`W
MRJ.P$C0Y3[2M+,E&,ROZQM7?MQ'CWY8WUXNOOVX6QV]Z6DH'#@'DC&'A342`
MV[C6:*(J"0YS$XA/7NHYHMKT#><%8D_?5)^VU=[MNXOD7ZD0DM>J,Y!Q+82-
M6T`92=\$2R<J=Q4QP;<%0PC_<D3+FX@N-RY':@3".(=>.2^(A8H2[VC#;1?W
M0#.]0!EN49$+;7G:F,5V^ST]N?E_]JZTN8T;V_XE[,M'K*]<Y41^=B93];Z@
M:+(E<X8B%2ZV-;_^`22[K8UD$[VPQ4RJ(CM1HQOWW(/EXBXXY:LXUBR@*`JE
MBD%,H*..Z707=E61RE]KVGECI1\E42.,^V#2Y^)A]+A-3KJY35T_PIZ7CP:`
M'%160:T=\R2:>)A4VS+*LB\Z&?P"U9PD#:'L@QB?GG5P6XAL,UYO4MZ-6:R.
M)DV>:AJ8\H!(&1=SBB"F&B-2P8:%S;5Y&Y7T>A_$:1G:7HBT7(R+8K)*_H\/
MJ]5F-!\7-[<?%_.[/XKE_8DYYW3CH(Q2&`J/D`/,2<BB=5A*;##-C<EL5+GK
MG9"I;7#[W_I\F$?8XRCX/%H77Z(.B\FG8CE.ZKRK?VA[["5!.,,))\0Z2;E!
MR$!;%>I,"8R9]!IJ@=]^MD4M(MX_YVSL[\VMGRYC_XN_-M.HP?VT#&M3[L@[
M0JJ9!35@@#+$F"5*$5_*#Z7-K=?+KG]"ZPKC_CD6A\-T,9F.]QVNS:L7[0)"
M5CIFK,`.02N0DZHR.(14N7YA_G?C4C-<^^>/+TY'+AYH$;RB0@AF--4"8>*I
M<M7\ZSW.W9V+OQMG<A'-.G=.G_ZT+,W*3\5\-%L_IN7UT+GSP0:!$B&%(#YV
M5`G*,2:H.G2E7N6N/_)Z]=\JH%GJ5Y/)-.$]FMGB=K29/=MA':+`T4:!6Z2,
M-<(*HZ50EEI=37'0\NP[D\&5\Z!-5'M;./;6WZF3G5?/INNCH75(2J8TUDI*
M+JJ;@HC@V>76!N^B;&FU:`!F_[N*?\Q']XOE.I7?2G$^9^TOWF@;@+;``6`!
M<<`1JQ3_-3%*B+/)\[Z<5FWO.YHCW0^S=OKQTWDU`'XOCO/IS1:!8Q>--P4\
MYE9QS17;)SVEY16#[`BJH=X0T1V+VL"WP^C7F^7=:#[]STY1\\F7Z=U\>CL=
MC^9K-=[2?#J_^[283<?3"R6]O.Y&C=C8PXT"`AP:J@B3$EKFL<$:E]4,M;M8
MXDLZL*L3&OO\P9!NU51QYHF<C)L?[K'EH)3&4G:UQ1-:T._+E),FP-:?W+LM
M<X^9HW&CXXQ)OD^&E9.^$I[1B\2V]9'QFZF[([7JST.R??V[,VO5`R`I%T)`
M@!'EW!$LJOXBZ:\M/+Z1R@[5JC\/PSXV=!6Q/]:(8GO]<&#1$+8I5\``;[V1
MQM-J,D3*YSK:AFX+-)P/6@.T#XH\W<"9Q7P5U\/)[EK:5,GUYO;3$Q7JS2I*
MLEK98C5>3A_V>[[7BVF=K+E.OQNX4MA99J4Q%`A!0;H.:X\S4/QJBYLU8-QB
MN/H9B/URP>R^MJT8#BD4WBO@`(20>,J-8C!JA!&#"3FYT1N6%9,66H<DTI1Y
MIAUW2AF&L&`$`4KE16[3[=UPJ:W2XX;+>5CVL4)]F,?16OR:VI+ZDJ*.I_4=
M:14TP$`RR5/J,!+6&HM0"144.O<RG`'R)5>YBZ[`O"!A3B;Z'6T7I).8<\.$
M$_&OW#M*1"FGD/HBY8"Z(4TKVJ['H"QL^XG!7Q7Q.^GF<%M\+V:+A]1M]_.A
MF*^*DS7^:K0.P$JJ@==>:$E5G*LQ(Z7,6N"+U'KIE4_GZOY5O'[;&+\'BQQ(
M!P&3VF#IK52*,*WC#"ZQ,\XYFAL!,,#\CI:6KL88]L&*=$=7^M?]M9E^'\U2
M-D$R1KXMENL4]EWO7JSZ+PE(*&;3I1%222CB?I$27(X+9'GN.>\`6=3!AKDS
MG/M@VN^;-#'>W-X\%.GB[/G=E^+N%+$.M@D>*<RMET39%!`NJ:>ZDL^;W!M:
M!I@TU`&/VH)U(*<C5^7EY=0J%I<5#S4&2'/!H2KOK9+^]'6IPSH?`8Q83SBE
ME%/C4U%.Q$IIE!07L7<OZ^6MK=_CAR7G`3L4+Z_UE")N,:"<225DW$15PBL/
M+W)<UK]7I[;NCGAYST/R\EY>3X47C`(%/:$`0:T)*?N+';VV&]4:J>R0E_<\
M#-^#34DE\1`K2(AVDO"X^;"FE(C$W<??P\M[[GS0&J"];/M'Z\VRJ/::B_G1
M_?ZKAP/24!F"#8N6#,(1'(9\=6&HS:;(4">.-G3[<K??%-0^:++W[;[8.#WN
M?M;QZM=[0;#"$&\@,]9S0@Q$`,-2<L3=U<\XS>G4"=!]4.P?JS@(W&H]O8]8
M'+WF_=F#`4$35^<(D("<0P8TDQ50CKG<B(ZA!Y2W2)E&@/9!C8_3OS;32=II
MG55_^UBS(!$'V"!CC5'00<:`JJ0T&N;&-0ZP$DF+3&D1T7[\O=^CV(OE&>O4
MH28A!7T:IK'EPFI"C4.V6I,I/5V4OHO2(H/G2TMH]F(K[<Y8/Q</*1WK_`U.
MK?9!6$BEY9Y[YJ5E3JBRJ&F4&[C<6:=1N9#WM5AU@7,OAE;QX\F>;+F8Q[^.
MMY@D)Y'Y-IK?%:L/\Z?/3.?CZ<.L7M1L&Z\/WDJD!=<:\#@P$3+&VA(U&"?T
M3'8.L`!)F_9;_\AWZ-CY7,09>W.9^V,J.&JX:%X]&SA$47-.XF@[X^UU7MZ6
MD<.4XK,C5P\4;]@#]+D8+^[FV]H!QX;GJ2;!<B.P<HA@JN)2B(@ALNPU5J=O
MU7BGYR<-U+?H!-GNAU16D'AM$GY]5.E^T[OMQ'-D_)S3/$#LJ8L34IR"I%7(
MF?BGU-`0JP2AIZ-!SI/FD._RU3.!,TF8QSYJ$0KFM6,<[/NED/'7EIS:C<[>
M&$<YZ`[%=PDA1TAS[Q%D,%FB*MH1^UX+YZ_-E=U`;4?<EN>!.`"W)2><*6X)
MD7&;;X2)ZT?97P#`M4T$C51VT&UY%H99!:^^W(]FLS(7[,-\OO@^2M<NEH&Z
MQ^_<J-4XI`L$(@S06FR)9-PRRO=2Z#@/RBMD0IX6%QU#FT60/S>S\6B>PL&7
MT:Q/)6:/<^+0\\%HC!5W1C+#N"(40@K+OD*875YFJ/ZC=FC0$II9FM\O8<<"
M%-Y\+B##C3-4(*"5-H(#@JN^:9U=EGZHFFZ^WK<!8S\)-MLNICKG_Q.WMT<#
MD%\]&QPC4DIBXSC`FB9'A"T'@%:47=O%*`V5^BISIAF<F3/`9#-.<"]N4^'G
M;;+.>+%:?TV.[(=-7(=&JV+R8[K^=I?Z=+N93Z;SN\/S1,[;`L<6<(N81U$N
M+127Q)5R.G&92*<A,J4_C#.YE%;!^+$M??TIJKSQ<$"8(20QDDP+ZCWQP+&R
MEP;S7#MRJ.$$K=*B.9Y]+#!/;]+8=G6Q/'I!SAN/!T53+3!$$'0(*)?2Q%0I
M%24L-T^J4?3`X%G2(J)]\*0LL?C")7*DV.7^R<#B3(<5CI.<I<QZP8BI+";D
M2:X?;:C7D+3+CF9@7H`8ST]F_U-,ZC/E5=,@E(4,>8H]X='&TM!Q5$H+.,_=
MOP[H/I%.V=(4T!X-G!IVS2H0Y(A27B!A'6%8`6ZJ_;<'V5;N@#SRG5@PYP+7
MO?=O_X=^K*ZYW5KQETF*?.U+JN%Q/]PH2"Z44XI@$K$VR&CGJ^@%ILG)V+B^
MI/QM,UNGP`LWV_G,?KG/:@S&>N\)P"K.!4086:PDI1X*6240.I,;)SC`ZAUM
M$.+MX=L)U!V.\2_?(F#?%K.HJ55*_E\_7F18[SY=8R@_?S!`CE(^.DH5C5,0
M+P?8E3AR<+IT2$<!F>O%^-_/0/U]L2[.BP"O_8X@H8""..3CZB#B#Z=QE?VG
MH<R^W6"@6_:F3'B5ZM8-SKV.V0M6<<P=N<@99AP%4@@MT\RJ$)+**$NY](J?
M-#0[&KGC;\5D,RMN;K>\T(]F-EJM3I8F.-PJJ"@-X,Y!@"!CF'CF<2FG`NI:
MH^1RM?UR=+:&;"\ECU+G;F[_.4I+_?IF^7EZ]VU]HJ;CP3:!.P,18C1.,Q@0
MQ"F`H)2/PLO$5W9#EE:T_+*B44NX7HPW)TL['FD5K&#.8:ZD]''!PIRR:(3N
M96327R2WN1ONM*#G.LS)PC4OXBBM[JLDZ'BT^E;\+);CZ:I8W/[8]6=U(N2H
M5NN`H)=48NF(Q99YRJTRI1S$^NR[C-X)/\[5YJ)KA/.84BRGQ<K]MIC`_X7D
M!"_>>#8XH`7C4@L;C5XC+(+$EWUTZ)I*YK7/@N9X-M0YKKY;5_,O6P1NK2$(
M4X+3825BT4XB97]%[/`E',;O3O\-4<UB02G'_'#9WC>?"];8*"RRE'JII:4@
M=K7L&_`DMTS6`%/'6]=X0RR;Z/F/'XM:>JZ>"]@B;P!5SF)EM!78BLK>PA1<
MQ(W[OO2<BV4C/<>'ZHWH)T\&I*VATC-DO+'20_.$AQ30W&/[`?E=.]=U-II#
M22&*!@U#((J>:CXSCP0$U6X3.7VUQ8=:/#AH#NOEDXIB9^.<)*+0)G;5.J`\
M+_MKX-55P6RDLD-)1>=A>-F<$<H1)8AP0A04+'585).59=G#?D!F?+YZ:J6)
MG`=@EK)O?MY&6(\K^.DS(9H(.)J0G@IG4Q1)E+?:;Q@D<M?S`5GE[2BU`6@]
M'NIN%Z:/-8J8OOE\`(`*H:@CTD8<($LTK3:?TEQMB;CN/`*-`.Z#.-L.?EBM
M-L7$;I:IZDH1`9_LSAU_+WYL?W6\'&Z=%P2AK8?:.ZHEHAQ*QX2M3JN@N4B^
M4:=V0Z[FWXH8:!O>7HB5>OAI.1T?]657#P5JHP3<`<,XQPASH["L`'(N-S%Y
M0`M11P3)A;"7%)+1XS8$;2]M(NMH/B[,8G4TDO!8LZ"0QL8"X]*A)\!:$52=
M>QO/<KU)PSU';HDH+8+:=_91V=>;6[.XOU_,MP(<X\^IMB%"QJ@1@,=M>$KX
MQA:[2EX#<VV9X1Y-MT6BEI&]6,!#>7?0EV(<E]7UM%B9T6Q63/3C_KG5_L&S
MPVGJOSG$@88PA$P:H47<7#KEJE4;49U;EF6H^4_=4+)?)30Y<7<_'Z:[TO5V
MM#Y8P>O-AP.E"!A-4C2HU<R!N,A7$[06*'=[-/2"J.U0I35<+S9=N7WDQW:C
M5_VR(C$\=Y(Z];Y@C$0`,0ZID!03B[D7U:B`,O>BFT8)5>^&;WU"?S%*WFS6
MJ_7H4.6`NDV#@SY"BIQ+Q62I%`;*7ZXT#')OA1;7OA-K&=@^:.1'T^6?H]FF
M4)-_;78W?/[B_Q$.'6T7<+1/I.-2$@P-(XK'\5-%P*CLDR5Y[01J$]6L7=%6
MG$7YR<7SV?'9:=>AK5+]-P0/%`046"0LQY(98]4OWXM6V9?/@VNE2;<`7_QH
M^V;][>@%]*<;!Q`%I<!#@CRC@D@&5>5'$E)FEU+\>Y]IYV#;]WE494KL!D+=
MJC@OFP42/R5!W.,YCI@V$%E5&1]*B.S;)*_^T+M%5-M?NK8;^^J7J_UO5_\L
MTA_%1'TOEJ.[@ZZ15M\?-&-1?*H1CN8LC_\P5=D2Z6*S7(9=[6GY)>%OCXJ[
MXZ]?G=Q-MF>Q[>U7!(2B"`YQ0*$ESA@F+*TDPC8[Z.MJ3\X[1KC7S.\+EF+)
MS?SF/OX#'>7"R:@X;;G?W]\8C6&O3V[2.MJ:/H\X>541X.6A4*T:#KGO#!QR
MZ!5SDD@7^<RL-[S$"'*4>]G6`/>QN>0XGBC>&=1=#NYMI%.J/VH6]P_%?+5]
MPT6&]J_R%UM/8M69S\4L!4]N'=3;N>AKZF[IQJXQ%31[<=`2($BX2K?J6(.]
M%4!P+CU@,/X\'6AP8;3T4Z'J3"`-WQPBFSDFG"A!&`0JI:#"/5Z"`GIM5POT
MS;*7!?UZU5;O,U%U.GESZ^X?9HO'HKAY2+_8%D(M+^&=W&R]>#>WV_^[*TQS
MF?W)4"<QIC654@$=5QW$A7'6R*V:N=58J9/[]0Z#`U_I_$G1,OWXBKOJQV@Y
MV7%@M:NZ_F&^.SAZ87KMN!#!J3AT*@*QOYX$1@PEW&)GB;58(6"HWNO#*`HN
MDC0SR'FQ-G'?BH<<K$)[B[S-0>"71RA:HO<[.-1\\ENQ_K:8+&:+NSKV5P]?
M#]YH;Z63V])K/BYA'OD2<Q(M\_Q8X?\.A4Y5\>[H[WX^%..HHC\745/36=Q)
M?GX[=*O'KP=(#?',(8$XM]1:)PTL,?=&7>0VMVX&SJ`8W.7H:D73O8VNKZ>E
M_GJ.U'\4R_MC(6S=?310`26TT$F/+/$4$)*R)[8(6R));ES``#UP@Q]+0U#P
MNUN@/D]7__;+HO@PCPPJ5NL^EZ>WOATX]WX7ZV\]1YH#JDR)-U,@]S!Y@`['
MP0^H`>FYW_#"UW.!G7Z?3HKYY,3PJ/N*X"A.UWT*1:+T7,&H"UY*'U5V1?E#
M0V9Y1^KJ_;#S]^0O2C?*7K"T]E`/,)4%5J4ZZ,G93H$'\;\%4X+1^(.<3D3H
MW(%[:GRL#@V0,PI]-_M&P(Y2`+734D*:RH-Z14H,I6/9P:_7[9FIS;S#WN%>
M]=;+WG7S=57\M8G==-_CCS_BAT^4'#_0(AA+!"'*4FH$0PXC[E2234*`!6!7
M4$WH@GQXR<A6='`A?ITL37ZP3>#(^3AN,4[9#,QQ*!7:RH>`HU[DUK,9(L>:
M:O@T8[(PO0!G#A:_.OI\H(1"&9&R@#-CC`2&X227AMY+`W/+4[\/KIRKV^-L
MR4*TEQC^V2CNM>]/+5E/'PM6<N(8I%@!S#A%EGI5SKF,X]SBMN^HV.6%%JT&
M6NB32R>7I^</!DZ`<%)3YC#5QG./`:QVE=Y?ZQ4]>=H\0(DL*+.BZW<QG1_F
MXRABM,]3!_[X$?_^^'_1KG<I-N!XK<6Z[8.'6G,&)$+$0YNN^T+5*+%07J0^
M6H^T.%>CB^XQ[F,2^9SFT!.K4?5,X%)H:Z6+@X62E!K`:660:HYSIXYW5)[Q
M0DM1K@IZH]#)/>^3IX(7'"$G(5&`886E9<Z7,E#OKJUN<P,EOD6#+!#[(,)O
MHY_3^\W]22H\>RYPA:@$BJ?;)3A7!G)*2SDP9]>Z[F2I<M$>D/T0XE^+9;+N
M5C>WMOBZ5O/);JG\513KQ-)3\PTA"BHD=I`B(QGE2CB/2]D=,;D^WT;>L+_%
MPM2-@@9"SI.65>UW!.6-(H@CAU#4,Y-:FDK^N->\UEFN=7J<3[\L!?16'607
M\WWZQ/#ELT%#H`2DTI@TVSM`D'&E/,A<K17?@<+?J@W2`.I!!W!]K%&9O_G+
M@]->8$:M]]#3N,=E$%5;$2]`[E'VT,N*7GXY[EUW_XWX/3\@U%')@3<:NO]O
M[]IZ&[EU\$^JJ+N`\R)14K%`T0+;HD"?A.S&FP9U[(6=!#WGUQ^-[7&3-,[8
MX[EHG"!`D/@RHDA^$BF*)`I$X4)V`?>G0-Z2H9;NQ]GJRW)0?`RHG</=[SU-
MG$5O#YM?O\_6]_N26(T0Z6B8Q&3^$80I3H1C7")S^^V:6]?6GBD^RC4R),81
M7ZM(2".]!ZB]OKZM/G@UWY9WLP_W?V:I_N]P-:+.!ZIZ^!@:4,5-*4LNI*-Z
MQQUG);1=\8L_-Q]>N8L08-%K_+XP?3,:>ALK4>TUJ3Q]AD9D4Y<J5A^`.XJV
M[;VHXL_K)KC:=R3#*6'B\>IV7KEA<;G:Y-L/`(V70R;)\B29DTQ["%)HRW0=
M$W!!M.Y&56!+ZPL`Q9G2:V\.M?%H=F4F?EXN'K,--]O-Y4UCJ+MA$BCCO(]5
MHR>E):*D5=.3+6>T@K9V?NEM1$8UA483WQ"+?EV<Z=?9ZO'VZ^QU1N^GL9G;
M^K?E_=7\Z?M5)L;/R_L_9O>?9U^7-XMJ@]NZ-AG2NY>JS[WE#@]+2(HF:N_0
M:1*YKXX%K:F/"!WG\E+[HXRX6Q0MX$E#;0Q4)15\(([$O)"!Y1:9"Z;F+]-T
ME+XO'P`:0I9%^R*O5@'KPP-Y=:`$G#JE(X\6%`&7K4Z/%2>5`"X1VGKF)S>S
M>1Z<N#@HC"JU(O3_8`3TF#)XSTKAGP..[JA(1"C&(.N`MU*YS!:]S2E0PG'"
M2>M>&B<W^'GOT!E-IH.7;7C]U2H\N5A_E'+X=T)]8%H&F_5-TBB!(T$-DE*)
M-(N3L<9F)'V7<CC*0++S#6'YKU^^O?0A-@PXOJQ#A^,EHIP7J&-U4\430;@3
M6/.6*VS;%;WT"VE#:>3!$@_CR7`(,^+3(B^!LU^S6FR6]I]VLVBX-O[&MU)$
M`DQB\#Q;2XQHT(;6<P1H'8LM74]'5IAE7P(:40D;KX>_^;T4P5INC&(>O51"
M*1_VT`_:C)+O/X`B=B+ZX]2I%:,'29G+DLOC_&D7UW[V.)LOOU=D[^RVYE2Z
MYF\GZ2+3U#LT/H*N@D^4UW/6+EYJ*XR.%.%EVEWG#!_$`Y_-\S-O?IPMLF,S
MS[3;Z[O;Q6UE>%19RCORU\VY!Z<\)XGL)7FE?7;CG-0<(OI0\\$0WS83J_1[
M?/TH7I^L+R9@T&AJ_'1$TD+'(R7NJUN]CG)!F`=AO21[PX8BGE'@OV@U+LM*
M'%>H0P!D1_SL^O6Y[0#^AMX?]X"$DFL1!8.HK`E:99>3U3-W!%N?31:NSJ,I
MT'(`*8UWBG_R@7NR0#Q#C:)*YK1!&,)-/3,O]&!%[@=/>2E%`SN1R_#GVP]W
M=U>K_^ZZ7&Z/[^W7;/I4/307U[LSMD^+;\O5W=;>^CCS?GG"J(%81TQ$2@P$
ME7UKM0FS"!Z\\RJ,=.9]9OSSEX?[]?W5XCI;QY^7\WE<KJHW>PR3OSY@`FFE
M=Q`]H%>4,Y"$[+@;#/6C=,(I_]3[:)WL.&K>B1"+B)X?/]&#UWM[&RL)B($'
M0C!&PSFU@FJZXV<$`8UAMJY`\7VS@V:G?'4_@?M5'>EH?Y!I)=TIH&6LNU:>
M"QX1.1!N!8!5V3&N.2D\:]R:IWK(<%D(.4NH@Q6:^;1>/\RN_<-JG[2[S5UY
M8EFOZ[LO;T+@Y(<E;AAEUE/#?=15S5606',D4-'V9L#QV:]FJ^:+V4UEG+Q?
M1>];=%-8ZS,3O\UN[Q^JM*W%=?C[^^UJ\X0AEO_&L5->+(!J#(HC>/31>&EJ
M?F,(;2\G')\7^P&5(B4]!62-ZW,PK3=WG14%5961"R3NK5+!=%M;ZN1\V:W/
M$18?V!E+ME/`RN_;#)?-TK`M);2L7AH20L>2D#@P);,M:Q4:!T9(`%9SWXO0
M%ED7F[%;)JIZ$O<4P+8S9ZM0=.^H^M=82:*04B%#890)(;#(>,U/QT/;A/>+
MS=,M$S[GRG4*.'G"\K>28BIQ?!LRWG(D,4ES$91W`3R)6ELEC*]U(W*F+[6$
MW/1C,?T(^((@-S[.4B0Q*D14G(*.@2,GKN:])J1M%[)W%]/I7-?'@>6)^E`$
M%B\NXUC'*(/2EFL&-@8P!.S^=!9=V\L'I6]XEX3&T;1A$HBL)S@Z*$\B)'$J
M;0#.T$F1U=LY@:J6A/*A;6?IBRWW.D%<]JD014#SW`#'2.;L672E(+DW-#H!
M'"@:M`'_64)!]1]^^P!NS^;MD/HQ!1Q/QP$U3D3%K<5LV%CG5+0R[M=0SMO>
M(GEG`;[2\=F/-DP!B<T!FI$`>AYA*3LAEELAO4&*FJ!5=!^\=<2W;?;ZCL*'
MI6-V4`69`I2?!(M&PNR1%"1/&5&L2C;4DFH>/82=01,)(F][@O2.@I.E@[,?
M36A?L?Z,J;R@__.LJJV018#+Q2:4]7`UKSIRO9%2-P89B03!-/.,>F_`6`M4
MLYJST8JV8<G23X,&#DM.0+2#;5U?FCGPY>25[1`S:-,V-BPUB2F1?7$DFJH0
M`3E$JFJ96.\NK=-RV7K?51?&P?1A"A@]V=X^Q)Q>^I]V3F2J*@)S)AF5"!&E
MI;*^:16)%J*M!UEJF/-=(7HT-9D"T`_;[F,@N@4U"8%+&PV)3A,-2AE+_EE\
MN>T_]>\#NKU!MW]]&,7+M#<WJTWVVZ=,^^UB??MUV_ZY9Z^R8=@$3F5_R&FC
MP&=GR*F]/Y0Y!Z+M_;O20Y-3]"*[%>44#CR?;-?/YSQ,W/#YF,D';@!I9($C
M$C`"O*[YRX5NV\+FHCW`SG2VOWC@65*>`HJ:;>$#4AHU^'>`ID2!6Q>B#C("
M-0ZMUK#7&&<NK;C)1:-P*"V8F%/V?*X#^5XO!DWH++4D6*EL](QG9\#NS7]*
M9-O=[J)=K%YQ5H*8!Z_4N2GTO'Y.Q#LOO&D0P?(0694I`\X8QC![O)$HRIUC
MC?T]>EK^]A6^7T?(TSI`E>IM-7B]?KC;OK81]&]9M"[3]]=;2UZG`R6P7AO!
M#5-4RJSZ%H#NN"F,;EU!^"RCODB7]VBU.]A1:@1Y#;+Q=UW;_B00=#QFRKY.
MM$YZX`ZIP,QCH_?\I:U/5DLUKXL!Q[AR'!8G!R:W*\!]UD[0_,#$G7#>42*D
M#[1:1F)D-6<X"6T[R91JV!:CX3T*J<DL_<\/U8>KB>5__@]02P,$%`````@`
ML(!J1<DY6"2)#```BG0``!$`'`!O;65R+3(P,30P.3,P+GAS9%54"0`#FRAA
M5)LH851U>`L``00E#@``!#D!``#M76UO(CD2_G[2_0<?7VY76@*$R6@FFNR*
M!+*#E``'S,SJOJQ,MP%K&INUW4G87W^VN]UT@_L-R(032#M+8U>5GZJRR^47
M.I]^>UEXX`DQCBFYJ30NZA6`B$-=3&8WE2^C:FMTU^U6?OOUG__X]*]J]8_;
MX0-H4\=?("+`'4-0(!<\8S$'WUS$OX,IHPOPC;+O^`G^`J:4+1#S5N`;FMQC
M3\KDU6HH"@1/+]R]YLX<+2"`0C`\\06ZEVQM-(6^)VXJ/OG+AQZ>8N1*:!Y2
M+2<(8M4"LAD2/;A`?`D==%.9"[&\KM6>GY\OJ$1"^85#%[7+>N-=_6-3JBJ5
M)_Q:`ON>H'V9,.^"LIFDK#=KJGH".3+DA!+B+^P,KF`UL5JBFB2J2BK$L!/Q
MY3,E&13DHCKXO*I$\(A^"OE$2S<UFJ5:;U2;#<.D$+@B8HFK?54+*N.D.,-(
MF'`!B1,9Z67+J,]-3=WX^/%C3==&I-RU$4JQC=H?CP\CW3LJLK,`H+L+7BPI
M$X!LN3FN\@S"94+CH),]4`<*W=7C.EL9:\@3W)14UZ(N)(8*J)7$PZBWX8+=
M`6E9>R/:[A2[(]*R=D*4U9-2\&RSJ&]5PU=51=7&Y9XPUJ.^'`S#=Q`8'VN0
M.<K=TG..J**7I0<)%)2M[N7W8M`\QA)2.FLA"N-'A;'Q?A^,6C1!,S49%,<4
MYSHLD!*&,1S[`[!'_B(XXIR]@/&0<':#L@<.^S12<!09!M7R5<DV.7(N9O2I
MYE"?"+92(:I9)+;9^,R7ZEK(KFA\QF1*M2H<:JV,T;>=HFQ"KHMP:2R&1SWL
MCP"].//2$"(F_;0_"$R>$!>E.TF,+7S>OXL0B!T]%3?*(%ES!8_5M8`=<7#L
ME$9A>-3#`1"()2L/P3#IIRP0D!`JM"1=9DJ72TRF-"R2A6H.OS83^1!-@<Y7
MK\-9-#NKK2T972(FL$RN8BL'+6#.T/2FHK+XJLG?_W2@=R'S8$.RU4`RQ=#S
ME61Q?$^K\;`&:22H^'U3X=+>'C+*_W"M7#0MJY5DP00?LU(>G)152K(@[UCU
M63)45A_)PN4"?+>^IR2,)07`<L'7<ASF(_<!PPGVL,)<`8K@R[";MN;5""Q\
M43.FH757^O6R4?_0J-=!%;0Q=SS*?8;DEU`*B(GY5-ODW13K<^3VR:_Z>=,0
M(7=(DL6Y,7J+,R8'B)TO+#66+N>`[9(V$A![NSHF55ZFP][5/[RK7Q9P6$KI
M3T$C/Y_].883;_=A%7)G^JI9_]"L-XKXZJ=`W,EYY0[RN?K7^<O'3]"3RO`6
M<;LZ<51;F07=DR\F)PB^LP1!)?`7_7\0DPL@<4%,\LEYC"X6.%!=FOB.$H')
M3*Z\"L]060*RO=2XM'EI+4Z[)B'P[)S(%&7FJGPQV5-40\Y26V$OTU$G.RU)
M*W#J85=M\]U"3^W0CN8(%0Y\J>Q9'I+#2/ZGAM)(VDZ?&2D']7NC_D.WW1IW
MVN"V]=#JW77`Z'.G,QZ=O1*:=0"9U&R.!)90]W114E:>OZ[TB"KH+_!30OA)
MCZK(9+P_59/YO4>?=QA==C$Y7FOFC++16'X\=GK28_U[<-<:?0;W#_UO)SW>
MXH;NR_6Z1A?,0PNIZ1P1CI_0`^5[.C%'=HYG+TMYMC_H#%OCKB0`K5Y;4CX.
MAIW/G=ZH^[4#'OJCDW.XN20A3=^1:8!8=8FZ#:&!%7-KIH0LY]6CR2^ZJ1%[
M5)E)(`_$!)Z:>^XA9E^AYZ-'!%7Z5F(I9F?-67Z]MR3V2E!52P)Q46=72"/<
M8R+S"`R]%N=()^FQS820T&V)B+=/ADB=D,E\^Q9R7&HQ\)H`<G:ZWEMVNE*Z
MA:HQF$``2H_E^":+P06@T&)`((82$($#&MW)KD:LONY!IB;*)[1WK]F4E._^
M9G'W1\+/WHM;ILPN9Y:`G(W.]Y:-SC1?G>IF9P\)E5H.$!O-Y?*LF$\VF7)F
M4ML6F10!E`P@A0`MY<0M?[>&U9]^QEQ0II;)?5^H.W+J<F\;>[Z*)2,U,>C9
MHT=%ESB>[R*W2W0U<N,RRP3''P<G)\)>6B;8[=ZB]\(CB(!.P1HDB*$$!B98
MXP02*#!(`28@Q+K9Q*G&[(VN4"9:VUESXO2E)4Y;/'ZR(9H*Q`=PI;0OZ(4X
M1\[Y1=T6G!4_"`6<LKE+!=!MOIP3B;KE1")A^I.-0'TV@P3_K8'(==P(SPB>
MRM!.1,O1MSQE9!]0#Q<_X2LE,2>?:5B&3%R^7N3%6@#K)H!IX^S1=/N7&74[
MR,W)/QJ6_*.L=\\#MX`[7F\`%QO(E_7&Y78`+N]J\W1RSAZB)T3\@CF)(<Y)
M1VRQ-60]4?.6B89)EISTPQ;H0@$G&[]"_<./VU5KQI#>(2JS",H3DKT<:C0L
MRR'C%_,Y68%(ZLDNC/2R<$X]%S&N;L.)53'_6/ARHE+3$I7B4OX-`CEG#Y2)
M5JG<.8&K:0E<-F^<;!3;-FR9\)7*G1.WFI:X97?+J<8K09WOMU#RJZL=B/`2
M5PM2>'/BUI4M;BE)52T*Q&6=O:%$KT^'IYW%TJ,KA/I+5?$[DPN`#A=XH2[M
M]$E;?O2GNC2(,D5'U\&;S8F65Y83R[0^$!Z0F4/H*3!@0(`&Z(9!A$>=4RM$
MBC2H"D/N>7`'!MWIG+J8J'RW;T^2Z6X_GU3;K6XO[;RHQP,XM8CX?$>_*^'H
MU*JPT;/_DP[R%PO(5OVIK@ZB8,N1`T4F,BWB#I&GXF#L6MX!^L2.3>;WDZLR
M_21`H2*[IC(S@$&B]\9"+/%KB>?^DW!FJ<0[2T).\GUE2[[3O'L""?BGVN9K
M`L*2Y.L$],L$PE>4:2\JG_P9_AKR3@I6]PG&#$/OCG)UW52]#"'ZX::5`'N>
MLNY-13"U-\K]B<R6A!\D<]1?WE3TB[FNL4"+"@A^?AV4+"B10X>MNK)&J5(!
M0?DD^(7&3<5AR,7"%"\1P]0=:P'!FY1$XLT)J6I1(AATQ%"Z$S)G;M4LA>:(
ME7-=W5&@%[YFKDL$DCU6#&6$BK3+(=I%/>(O%%I'HMG4+:Z$Z[-PN9>EQ9T'
M.:?3;RH;(X*R(9[-1>=%BL<<#1AV4%3)PUK^#:D/Y+:>$(.S@,HH?$!YN]C&
MO&=,6>*+',A9!BKDY4Q]W+:O[LL.M-!"%MCDV+U[<[71P5^I`_3\Q41.%9&G
MNIS[*%O#5);=5<1RK,P0VUE'*%M2,<4TO=8YXZ>=T7PF)P"DFHXB56FN/9PK
M5"]Y(\7'P;V?$DH;CF(*N^)ZOE(!S)]H4_T8U=NCQT>DNJC1+%ZP4QC6K_B\
M=ND"8K+_.&RCB1@PM(0K53Y`<LH0J_A4DD7P5M-(NK7#GQ*93VCY@5(K9(X4
M+,=S?*,KV&WN$F52_(0&,L\8/\OGU7]E8.RH()GL@27HWZZ#IFH;[2!F_?IE
M\R<O6T%U;RG'UPUV4BD1=/>2<`1!.#+%[U2F=$25Z<U:_H6XB`W1$T;/1M=L
MDC=)_W=S^V?D29Y;3`5RYJWE*#G64VN/<&1WR5<=D9(:;)4>P:3Y(,<"ZKP(
M]9-E2I)Y>$K=[CW*0#J\P7N4W.E7=VY,$);R(S!Z^)MQ,M,6#O+^_G2]TATB
M@IZA%VS?&57*,AWAJJ'_(M,0]X%"$MV$2;HKB^`(AWD`UZ;"_P%J[#IPJ4QM
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MSL%?0_#;G_MI4)/\+C))Z2(]JE__B]Q@+9\PUD'%OJ:I=DKZ`G>J%9DC,U@4
M+K_H]#E<D&U,!D6ICW%B6$#/N_6Y3&,Y[Q)"G_2-37-'8T/1@L1'J.=7WW,@
MZ1*'LB5EZH)94K6,^B/85P@W`CHO2QR0MV.GAFF5>VR#JAGXX"X(<?8)2IK>
M4GZ$'2A$.9XS9,>?K#EB#9ZI'7^L_`>B#Z[0!7_?1W[]'U!+`0(>`Q0````(
M`+"`:D6!IB^FM9@``$-8"``1`!@```````$```"D@0````!O;65R+3(P,30P
M.3,P+GAM;%54!0`#FRAA5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+"`
M:D4^O-G'`Q(``%:H```5`!@```````$```"D@0"9``!O;65R+3(P,30P.3,P
M7V-A;"YX;6Q55`4``YLH851U>`L``00E#@``!#D!``!02P$"'@,4````"`"P
M@&I%Z(+CG:8X``!9@0(`%0`8```````!````I(%2JP``;VUE<BTR,#$T,#DS
M,%]D968N>&UL550%``.;*&%4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
ML(!J16)=>`@'<0``!AX&`!4`&````````0```*2!1^0``&]M97(M,C`Q-#`Y
M,S!?;&%B+GAM;%54!0`#FRAA5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`+"`:D41VPK_\T8```9T`P`5`!@```````$```"D@9U5`0!O;65R+3(P,30P
M.3,P7W!R92YX;6Q55`4``YLH851U>`L``00E#@``!#D!``!02P$"'@,4````
M"`"P@&I%R3E8)(D,``"*=```$0`8```````!````I('?G`$`;VUE<BTR,#$T
M,#DS,"YX<V155`4``YLH851U>`L``00E#@``!#D!``!02P4&``````8`!@`:
)`@``LZD!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="nump">$ 214<span></span></td>
        <td class="nump">$ 196<span></span></td>
        <td class="nump">$ 359<span></span></td>
        <td class="nump">$ 1,431<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">11,772<span></span></td>
        <td class="nump">9,420<span></span></td>
        <td class="nump">36,196<span></span></td>
        <td class="nump">26,111<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">5,574<span></span></td>
        <td class="nump">4,210<span></span></td>
        <td class="nump">14,196<span></span></td>
        <td class="nump">11,934<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">17,346<span></span></td>
        <td class="nump">13,630<span></span></td>
        <td class="nump">50,392<span></span></td>
        <td class="nump">38,045<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(17,132)<span></span></td>
        <td class="num">(13,434)<span></span></td>
        <td class="num">(50,033)<span></span></td>
        <td class="num">(36,614)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(944)<span></span></td>
        <td class="num">(592)<span></span></td>
        <td class="num">(2,555)<span></span></td>
        <td class="num">(1,768)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
        <td class="num">(254)<span></span></td>
        <td class="nump">154<span></span></td>
        <td class="num">(382)<span></span></td>
        <td class="nump">421<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(18,327)<span></span></td>
        <td class="num">(13,870)<span></span></td>
        <td class="num">(52,960)<span></span></td>
        <td class="num">(37,951)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (18,327)<span></span></td>
        <td class="num">$ (13,870)<span></span></td>
        <td class="num">$ (52,960)<span></span></td>
        <td class="num">$ (37,951)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (USD per share)</a></td>
        <td class="num">$ (0.54)<span></span></td>
        <td class="num">$ (0.46)<span></span></td>
        <td class="num">$ (1.61)<span></span></td>
        <td class="num">$ (1.36)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share (shares)</a></td>
        <td class="nump">34,005,642<span></span></td>
        <td class="nump">29,844,507<span></span></td>
        <td class="nump">32,945,346<span></span></td>
        <td class="nump">27,984,133<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(a),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_RevenueRecognitionTextBlock', window );">Revenue</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from grants and other sources is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business Innovative Research Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vulcan Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have periodically received Small Business Innovative Research (SBIR) grants from the National Institutes of Health (NIH), which are used to support the research and development of our product candidates. We recorded revenue related to these grants of </font><font style="font-family:inherit;font-size:10pt;">$214,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$196,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$359,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$461,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. We recorded cost reductions to property and equipment due to assets being purchased with grant funding of </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$785,000</font><font style="font-family:inherit;font-size:10pt;"> of potential revenue remained available under these grants, if qualifying research is performed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, we entered into a platform development funding agreement with Vulcan Inc. and its affiliate (collectively, Vulcan) pursuant to which we received </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> for our G protein-coupled receptor (GPCR) program. Of the funds received, </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded as deferred revenue. The remaining deferred revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$970,000</font><font style="font-family:inherit;font-size:10pt;"> was recognized as revenue during the first quarter of 2013.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_RevenueRecognitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for revenue recognition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_RevenueRecognitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes Payable</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we entered into a new Loan and Security Agreement (the Oxford/MidCap Loan Agreement) with Oxford Finance LLC (Oxford) and MidCap Financial SBIC, LP (MidCap) pursuant to which we borrowed </font><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;">. We used approximately </font><font style="font-family:inherit;font-size:10pt;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;"> of the loan proceeds to repay all of the amounts owed by us under our then outstanding loan from Oxford and, after deducting all loan initiation costs including a </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;"> upfront loan initiation fee and lenders&#8217; legal costs, we received </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds. The Oxford/MidCap Loan Agreement provides for monthly interest-only payments at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">9.25%</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. Beginning </font><font style="font-family:inherit;font-size:10pt;">April&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, monthly principal and interest payments of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> are due through the maturity date of </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Oxford/MidCap Loan Agreement requires a </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> loan maturity fee upon full repayment of the loan. We may prepay the outstanding principal balance in its entirety at any time if we pay an additional fee equal to </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> of the then-outstanding principal balance, which prepayment fee would be waived if we refinance the indebtedness with Oxford and MidCap and pay the loan maturity fee. As security under the Oxford/MidCap Loan Agreement, we granted Oxford, as collateral agent for the lenders, a security interest in substantially all of our assets, excluding intellectual property. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Oxford/MidCap Loan Agreement contains covenants that limit or restrict our ability to incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, pledge our intellectual property or repurchase stock. Additionally, the Oxford/MidCap Loan Agreement includes events of default regarding non-payment, inaccuracy of representations and warranties, covenant breach, occurrence of a material adverse effect (MAE, as defined below), cross default to material indebtedness, bankruptcy or insolvency, material judgment defaults and a change of control. The occurrence of an event of default could result in the acceleration of the Oxford/MidCap Loan Agreement and, under certain circumstances, could increase our interest rate by </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the period of default.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MAE is defined as a material adverse effect upon (i)&#160;our business operations, properties, assets, results of operations or financial condition of Omeros, taken as a whole with respect to our viability, that reasonably would be expected to result in our inability to repay any portion of the loans in accordance with the terms of the Oxford/MidCap Loan Agreement, (ii)&#160;the validity, perfection, value or priority of the lenders&#8217; security interest in the collateral, (iii)&#160;the enforceability of any material provision of the Oxford/MidCap Loan Agreement or related agreements, or (iv)&#160;the ability of the lenders to enforce their rights and remedies under the Oxford/MidCap Loan Agreement or related agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We accounted for the Oxford/MidCap Loan Agreement as a debt modification and, accordingly, the remaining unamortized debt issuance costs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$103,000</font><font style="font-family:inherit;font-size:10pt;"> associated with the then outstanding loan with Oxford and the debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$244,000</font><font style="font-family:inherit;font-size:10pt;"> associated with the Oxford/MidCap Loan Agreement are being amortized to interest expense using the effective interest method through the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;"> Oxford/MidCap Loan Agreement maturity date. Additionally, the </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> maturity fee, which is treated as a debt discount, is being amortized to interest expense using the effective-interest method through </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining unamortized discount and debt issuance costs associated with the debt were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$284,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>segment</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments</a></td>
        <td class="nump">$ 21.8<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump">1<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashCashEquivalentsAndShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NumberOfOperatingSegments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract research</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting &amp; professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2008 Equity Incentive Plan (the 2008 Plan) provides for the grant of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units and performance shares to employees, directors and consultants and subsidiary corporations&#8217; employees and consultants. Options are granted with exercise prices equal to the closing fair market value of our common stock on the date of the grant. The terms of options may not exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10 years</font><font style="font-family:inherit;font-size:10pt;"> and options generally vest over a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;">-year period. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2014, in accordance with provisions of the 2008 Plan, the authorized shares available for grant under the 2008 Plan were increased by </font><font style="font-family:inherit;font-size:10pt;">1,517,975</font><font style="font-family:inherit;font-size:10pt;"> shares. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, a total of </font><font style="font-family:inherit;font-size:10pt;">8,741,276</font><font style="font-family:inherit;font-size:10pt;"> shares were reserved for issuance under our stock plans, of which </font><font style="font-family:inherit;font-size:10pt;">1,961,278</font><font style="font-family:inherit;font-size:10pt;"> were available for future grants under the 2008 Plan.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, in connection with our annual employee review process, we granted qualified employees options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$11.58</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to stock option grants during the periods ended:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three&#160;Months&#160;Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average assumptions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense has been reported in our Consolidated Statements of Operations and Comprehensive Loss as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity for all stock plans and related information is as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160; Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,969,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,779,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,577,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,755,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,024,005</font><font style="font-family:inherit;font-size:10pt;"> unvested options outstanding that will vest over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.0</font><font style="font-family:inherit;font-size:10pt;"> years. Excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with these options is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Obligations</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease our office and laboratory space in The Omeros Building under a lease agreement with BMR-201 Elliott Avenue LLC (BMR). The initial term of the lease ends in November 2027 and we have </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> options to extend the lease term, each by </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining aggregate non-cancelable rent payable under the initial term of the lease is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$59.4 million</font><font style="font-family:inherit;font-size:10pt;">. The deferred rent balance relates to rent deferrals since the inception of our lease. Deferred rent is being amortized to research and development and selling, general and administrative expense on a straight-line basis through the term of the lease.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we entered into an agreement with Ventiv Commercial Services, LLC (inVentiv) for field sales representatives and related sales operation services for the U.S. commercial launch of Omidria. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had a monthly fee of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, which began in August 2014. We can terminate the agreement upon 30 days written notice if Omidria is withdrawn from the market for any reason or a regulatory agency acts to prevent or materially restrict the sale of Omidria, or upon 90 days written notice any time subsequent to </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into an amendment to the agreement with inVentiv for additional sales representatives in the U.S. Under the terms of the amendment, our total monthly fee will increase to approximately </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;"> upon inVentiv providing additional sales representatives, which is expected in </font><font style="font-family:inherit;font-size:10pt;">January 2015</font><font style="font-family:inherit;font-size:10pt;">, and will continue through </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a non-exclusive agreement with Patheon Manufacturing Services LLC (Patheon) for commercial supply of Omidria through December 31, 2015. Pursuant to the terms of the contract, we are required to provide a monthly, non-binding production forecast covering the term of the contract. Upon submission of the monthly forecast, a portion of the forecast becomes a firm purchase commitment. In the event we do not purchase the quantities included in the firm purchase commitment, we would owe a cancellation fee. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had a firm purchase commitment requiring payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$519,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into a non-exclusive agreement with Hospira S.p.A and Hospira Worldwide, Inc. (together, &#8220;Hospira&#8221;) for commercial supply of Omidria. We have no firm purchase commitments under this agreement until, in connection with the commencement of commercial manufacturing of Omidria at Hospira, we provide monthly rolling forecasts that will be used to calculate our firm purchase commitment. We have not commenced commercial manufacturing of Omidria at Hospira and, therefore, do not currently have any firm purchase commitments under this agreement.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Development Milestones and Product Royalties</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have retained worldwide commercial rights to Omidria and all of our product candidates in our clinical and preclinical programs. We potentially owe certain development milestones and sales based royalties on commercial sales of certain product candidates within our pipeline. These are low-single-digit royalties based on net sales or net income as more fully described in our 2013 Annual Report on Form 10-K filed with the SEC on March 13, 2014.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2014, we incurred a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to Helion Biotech ApS (Helion) related to the filing of an Investigational New Drug Application (IND) with the FDA for our mannan-binding lectin-associated serine protease-2 (MASP-2) program. </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2013, we recorded $</font><font style="font-family:inherit;font-size:10pt;">900,000</font><font style="font-family:inherit;font-size:10pt;"> as selling, general and administrative expense in connection with previously awarded NIH grants.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Public Offering</font><font style="font-family:inherit;font-size:10pt;"> - In March 2014, we sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">3.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a public offering price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$11.50</font><font style="font-family:inherit;font-size:10pt;"> per share. After deducting offering expenses and underwriter discounts of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, we received net proceeds from the transaction of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our total outstanding warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, which have a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$23.94</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="30%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding At<br clear="none"/>September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;29, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.00</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April&#160;26, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 28, 2014, we extended to </font><font style="font-family:inherit;font-size:10pt;">September&#160;29, 2014</font><font style="font-family:inherit;font-size:10pt;"> the expiration dates of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">197,478</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.25</font><font style="font-family:inherit;font-size:10pt;"> per share that had been due to expire on March 29, 2014. We evaluated the fair value of the warrants before and after the modifications and recorded the </font><font style="font-family:inherit;font-size:10pt;">$452,000</font><font style="font-family:inherit;font-size:10pt;"> change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2014.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During September 2014, warrants associated with a total of </font><font style="font-family:inherit;font-size:10pt;">4,689</font><font style="font-family:inherit;font-size:10pt;"> shares were exercised by the warrant holders resulting in the issuance of </font><font style="font-family:inherit;font-size:10pt;">3,305</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Of that amount, </font><font style="font-family:inherit;font-size:10pt;">3,088</font><font style="font-family:inherit;font-size:10pt;"> shares were issued upon cash exercise of warrants, pursuant to which we received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37,828</font><font style="font-family:inherit;font-size:10pt;">, and the remainder were issued pursuant to cashless net exercise provisions in the warrants.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 28, 2014, we extended to </font><font style="font-family:inherit;font-size:10pt;">March&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;"> the expiration date of the remaining warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">192,789</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock that had been due to expire on </font><font style="font-family:inherit;font-size:10pt;">September&#160;29, 2014</font><font style="font-family:inherit;font-size:10pt;">. We evaluated the fair value of the warrants before and after the modifications and recorded the </font><font style="font-family:inherit;font-size:10pt;">$411,000</font><font style="font-family:inherit;font-size:10pt;"> change in fair value as other expense in the accompanying Consolidated Statement of Operations and Comprehensive Loss for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Considering the extensions on March 28 and September 28, 2014, the total other expense recorded in the Consolidated Statement of Operations and Comprehensive Loss for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$863,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, in connection with the Vulcan agreement, we issued to Vulcan </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> warrants to purchase our common stock, each exercisable for </font><font style="font-family:inherit;font-size:10pt;">133,333</font><font style="font-family:inherit;font-size:10pt;"> shares, with exercise prices of </font><font style="font-family:inherit;font-size:10pt;">$20</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$30</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$40</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform, designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derived from our proprietary PharmacoSurgery platform, our first drug product Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;"> (phenylephrine and ketorolac injection) 1%/0.3% was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2014 for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. We began calling on ophthalmic surgeons and their staff in the U.S. in August 2014 regarding Omidria. In October 2014, we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. We expect pass-through to remain in effect for a period of two to three years from the January 1, 2015 effective date, after which time CMS will make a new reimbursement determination. We have submitted for Omidria a wholesale acquisition cost of $465 per single-use vial. We expect to begin selling Omidria in the U.S. in early 2015.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria. Marketing and sales of Omidria in the European Union (EU) are subject to approval of our MAA and, most likely, entering into a partnership for European marketing and distribution. In addition to the EU, we plan to enter into one or more partnerships for the marketing and distribution of Omidria in other international territories.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries.  All inter-company transactions between and among our subsidiaries have been eliminated.  The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information.  The Consolidated Balance Sheet at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> has been derived from audited financial statements but does not include all of the information and footnotes required by GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> filed with the Securities and Exchange Commission (SEC) on March 13, 2014.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Policy Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and short-term investments. We believe that our existing cash, cash equivalents and short-term investments, together with anticipated future sales from Omidria and capital that we may be able to raise through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales, will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes for at least the next 12 months. Corporate partnerships, public or private equity sales, additional debt financings, corporate collaboration and licensing arrangements or asset sales may not be available on terms that are acceptable to us, if at all, and any further equity financing would dilute the ownership of our existing shareholders. If we are unable to raise capital as and when needed, such failure would have a significant negative impact on our financial condition.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost or market. Capitalization of costs as inventory begins when the product has received regulatory approval in the U.S. or the EU. We expense inventory costs related to product candidates as research and development expenses prior to regulatory approval in the respective territory. For Omidria, capitalization of costs as inventory began upon U.S. regulatory approval on May 30, 2014.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update, or ASU, No. 2014-15 related to disclosure of an entity&#8217;s ability to continue as a going concern. This standard requires management to evaluate whether substantial doubt exists regarding the entity&#8217;s ability to continue as a going concern at each reporting period for a period of one year after the date the financial statements are issued or available to be issued. The standard establishes certain required disclosures if substantial doubt exists. This standard must be applied prospectively and is effective for interim and annual periods beginning after December&#160;15, 2016. We do not expect the adoption of this guidance to have any impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09 related to the recognition of revenue that supersedes existing guidance. This standard clarifies the principles for recognizing revenue utilizing a five-step process. This standard must be applied retroactively to each prior reporting period presented, or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. This standard is effective for interim and annual periods beginning after December 15, 2016 and cannot be adopted before that effective date. We are currently evaluating the impact this standard may have on our financial statements once it is adopted.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 01<br><br> -Paragraph b<br><br> -Subparagraph 6<br><br> -Article 10<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22499-107794<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22580-107794<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Direct Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510796<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Indirect Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Accounting Change<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.10-01.(b)(6))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Retrospective Application<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22583-107794<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
        <td class="nump">$ 1,665<span></span></td>
        <td class="nump">$ 2,211<span></span></td>
        <td class="nump">$ 5,083<span></span></td>
        <td class="nump">$ 4,364<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">879<span></span></td>
        <td class="nump">1,371<span></span></td>
        <td class="nump">2,791<span></span></td>
        <td class="nump">2,518<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling, General and Administrative Expenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 786<span></span></td>
        <td class="nump">$ 840<span></span></td>
        <td class="nump">$ 2,292<span></span></td>
        <td class="nump">$ 1,846<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our total outstanding warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, which have a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$23.94</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="30%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding At<br clear="none"/>September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;29, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,333</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.00</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April&#160;26, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604,327</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair-Value Measurements - Narrative (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash excluded from fair value hierarchy disclosure</a></td>
        <td class="nump">$ 750,000<span></span></td>
        <td class="nump">$ 1,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECVAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (52,960,000)<span></span></td>
        <td class="num">$ (37,951,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of assets</a></td>
        <td class="num">(9,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">246,000<span></span></td>
        <td class="nump">222,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">5,083,000<span></span></td>
        <td class="nump">4,364,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
        <td class="nump">532,000<span></span></td>
        <td class="nump">371,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant modification expense</a></td>
        <td class="nump">863,000<span></span></td>
        <td class="nump">41,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grant and other receivables</a></td>
        <td class="num">(2,000)<span></span></td>
        <td class="nump">1,053,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and noncurrent assets</a></td>
        <td class="num">(842,000)<span></span></td>
        <td class="nump">31,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">3,949,000<span></span></td>
        <td class="nump">453,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(970,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Deferred rent</a></td>
        <td class="nump">787,000<span></span></td>
        <td class="nump">2,987,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(42,353,000)<span></span></td>
        <td class="num">(29,399,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases and sales of property and equipment, net</a></td>
        <td class="num">(12,000)<span></span></td>
        <td class="num">(137,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of investments</a></td>
        <td class="num">(58,847,000)<span></span></td>
        <td class="num">(22,963,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from the sale and maturities of investments</a></td>
        <td class="nump">50,534,000<span></span></td>
        <td class="nump">35,945,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
        <td class="num">(8,325,000)<span></span></td>
        <td class="nump">12,845,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="nump">37,754,000<span></span></td>
        <td class="nump">16,120,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
        <td class="nump">12,699,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
        <td class="num">(1,464,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_ProceedsfromStockOptionsandWarrantsExercised', window );">Proceeds from Stock Options and Warrants Exercised</a></td>
        <td class="nump">1,055,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">50,044,000<span></span></td>
        <td class="nump">16,184,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
        <td class="num">(634,000)<span></span></td>
        <td class="num">(370,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">1,384,000<span></span></td>
        <td class="nump">1,520,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">1,150,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">1,931,000<span></span></td>
        <td class="nump">1,243,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Small Business Innovative Research</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding', window );">Reduction of equipment cost basis purchased with grant funding</a></td>
        <td class="nump">$ 40,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_ProceedsfromStockOptionsandWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from Stock Options and Warrants Exercised</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_ProceedsfromStockOptionsandWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_Reductionofequipmentcostbasispurchasedwithgrantfunding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction of equipment cost basis purchased with grant funding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_Reductionofequipmentcostbasispurchasedwithgrantfunding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment for noncash service expenses paid for by granting of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentOfWarrantsGrantedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract research</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting &amp; professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,536</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accrued Liabilities - Accrued Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_AccruedContractResearchCosts', window );">Contract research</a></td>
        <td class="nump">$ 1,746<span></span></td>
        <td class="nump">$ 858<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting &amp; professional fees</a></td>
        <td class="nump">1,536<span></span></td>
        <td class="nump">649<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
        <td class="nump">1,403<span></span></td>
        <td class="nump">1,346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_AccruedClinicalTrialCosts', window );">Clinical trials</a></td>
        <td class="nump">949<span></span></td>
        <td class="nump">596<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accruals</a></td>
        <td class="nump">616<span></span></td>
        <td class="nump">495<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
        <td class="nump">$ 6,250<span></span></td>
        <td class="nump">$ 3,944<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_AccruedClinicalTrialCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued clinical trial costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_AccruedClinicalTrialCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_AccruedContractResearchCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued preclinical research and development contract costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>omer_AccruedContractResearchCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>omer_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>185</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/CashCashEquivalentsAndInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair-Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/FairValueMeasurements</Role>
      <ShortName>Fair-Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.omeros.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair-Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair-Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Revenue Revenue by Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/RevenueRevenueByAgreementTables</Role>
      <ShortName>Revenue Revenue by Agreement (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Significant Accounting Policies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail</Role>
      <ShortName>Organization and Significant Accounting Policies (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair-Value Measurements - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail</Role>
      <ShortName>Fair-Value Measurements - Narrative (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Accrued Liabilities - Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail</Role>
      <ShortName>Accrued Liabilities - Accrued Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Notes Payable (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.omeros.com/role/NotesPayableDetail</Role>
      <ShortName>Notes Payable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/RevenueDetail</Role>
      <ShortName>Revenue (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/CommitmentsAndContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Shareholders' Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/ShareholdersEquityDetail</Role>
      <ShortName>Shareholders' Equity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Stock-Based Compensation - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensationNarrativeDetail</Role>
      <ShortName>Stock-Based Compensation - Narrative (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element omer_Reductionofequipmentcostbasispurchasedwithgrantfunding had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_Cash had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ResearchAndDevelopmentExpense had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2406403 - Disclosure - Fair-Value Measurements - Narrative (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2410401 - Disclosure - Notes Payable (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2411402 - Disclosure - Revenue (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2412401 - Disclosure - Commitments and Contingencies (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Shares' elements on report '2413402 - Disclosure - Shareholders' Equity (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2413402 - Disclosure - Shareholders' Equity (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 1001000 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>omer-20140930.xml</File>
    <File>omer-20140930.xsd</File>
    <File>omer-20140930_cal.xml</File>
    <File>omer-20140930_def.xml</File>
    <File>omer-20140930_lab.xml</File>
    <File>omer-20140930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue Revenue by Agreement (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleElementArrangements', window );">Revenue Recognition, Multiple-deliverable Arrangements, Description</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from grants and other sources is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Small Business Innovative Research Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vulcan Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleElementArrangements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition for multiple-deliverable arrangements including, at a minimum (as applicable): (1) the nature of such arrangements, (2) the significant deliverables within the arrangements, (3) the general timing of delivery or performance of service for the deliverables within the arrangements, (4) performance-, cancellation-, termination- or refund-type provisions, (5) a discussion of the significant factors, inputs, assumptions, and methods used to determine selling price (whether vendor-specific objective evidence, third-party evidence, or estimated selling price) for the significant deliverables, (6) whether the significant deliverables in the arrangements qualify as separate units of accounting and the reasons that they do not qualify as separate units of accounting, if applicable, and (7) the general timing of revenue recognition for significant units of accounting. This element is applicable to all multiple-deliverable arrangements, including software arrangements (for example, software products, upgrades or enhancements, postcontract customer support, or services).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771336&amp;loc=SL6750900-111635<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771336&amp;loc=d3e50766-111635<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMultipleElementArrangements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
